

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
WO 02/00690 A2

- |   |                           |                |                          |    |
|---|---------------------------|----------------|--------------------------|----|
| (51) International Patent Classification <sup>7</sup> : | C07K 14/00                | 09/854,208     | 10 May 2001 (10.05.2001) | US |
| (21) International Application Number:                  | PCT/US01/19692            | 09/854,280     | 10 May 2001 (10.05.2001) | US |
| (22) International Filing Date:                         | 20 June 2001 (20.06.2001) | 09/866,028     | 25 May 2001 (25.05.2001) | US |
| (25) Filing Language:                                   | English                   | 09/866,034     | 25 May 2001 (25.05.2001) | US |
| (26) Publication Language:                              | English                   | PCT/US01/17092 | 25 May 2001 (25.05.2001) | US |
|   |                           | 09/870,574     | 30 May 2001 (30.05.2001) | US |
|   |                           | PCT/US01/17443 | 30 May 2001 (30.05.2001) | US |
|   |                           | PCT/US01/17800 | 1 June 2001 (01.06.2001) | US |
- (30) Priority Data:
- |                |                                |    |
|----------------|--------------------------------|----|
| 60/213,637     | 23 June 2000 (23.06.2000)      | US |
| 60/219,556     | 20 July 2000 (20.07.2000)      | US |
| 60/220,624     | 25 July 2000 (25.07.2000)      | US |
| 60/220,664     | 25 July 2000 (25.07.2000)      | US |
| PCT/US00/20710 | 28 July 2000 (28.07.2000)      | US |
| 60/222,695     | 2 August 2000 (02.08.2000)     | US |
| 09/643,657     | 17 August 2000 (17.08.2000)    | US |
| PCT/US00/23522 | 23 August 2000 (23.08.2000)    | US |
| PCT/US00/23328 | 24 August 2000 (24.08.2000)    | US |
| 60/230,978     | 7 September 2000 (07.09.2000)  | US |
| 60/000,000     | 15 September 2000 (15.09.2000) | US |
| 09/664,610     | 18 September 2000 (18.09.2000) | US |
| 09/665,350     | 18 September 2000 (18.09.2000) | US |
| 60/242,922     | 24 October 2000 (24.10.2000)   | US |
| 09/709,238     | 8 November 2000 (08.11.2000)   | US |
| PCT/US00/30952 | 8 November 2000 (08.11.2000)   | US |
| PCT/US00/30873 | 10 November 2000 (10.11.2000)  | US |
| PCT/US00/32678 | 1 December 2000 (01.12.2000)   | US |
| 09/747,259     | 20 December 2000 (20.12.2000)  | US |
| PCT/US00/34956 | 20 December 2000 (20.12.2000)  | US |
| 09/767,609     | 22 January 2001 (22.01.2001)   | US |
| 09/796,498     | 28 February 2001 (28.02.2001)  | US |
| PCT/US01/06520 | 28 February 2001 (28.02.2001)  | US |
| PCT/US01/06666 | 1 March 2001 (01.03.2001)      | US |
| 09/802,706     | 9 March 2001 (09.03.2001)      | US |
| 09/808,689     | 14 March 2001 (14.03.2001)     | US |
| 09/816,744     | 22 March 2001 (22.03.2001)     | US |
| 09/828,366     | 5 April 2001 (05.04.2001)      | US |
- (71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BAKER, Kevin, P. [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). FERRARA, Napoleone [US/US]; #704, 2090 Pacific Avenue, San Francisco, CA 94109 (US). GERBER, Hanspeter [CH/US]; #5, 1121 Tennessee Street, San Francisco, CA 94107 (US). GERRITSEN, Mary, E. [CA/US]; 541 Parrott Drive, San Mateo, CA 94402 (US). GODDARD, Audrey [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). GODOWSKI, Paul, J. [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). GURNEY, Austin, L. [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). HILLAN, Kenneth, J. [GB/US]; 64 Seward Street, San Francisco, CA 94114 (US). MARSTERS, Scot, A. [US/US]; 990 Cherry Street, San Carlos, CA 94070 (US). PAN, James [CA/US]; 2705 Coronet Boulevard, Belmont, CA 94002 (US). PAONI, Nicholas, F. [US/US]; 1756 Terrace Drive, Belmont, CA 94002 (US). STEPHAN, Jean-Philippe, F. [FR/US]; 320 C Lansdale Avenue, Millbrae, CA 94030 (US). WATANABE, Colin, K. [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). WILLIAMS, P., Mickey [US/US]; 509 Alto Avenue, Half Moon Bay, CA 94019 (US). WOOD, William, I. [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US). YE, Weilan [CN/US]; 119 Barkentine Street, Foster City, CA 94404 (US).
- (74) Agents: AGARWAL, Atulya, R. et al.; c/o GENENTECH, INC., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISORDERS INVOLVING ANGIOGENESIS

(57) Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

WO 02/00690 A2



(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



## COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISORDERS INVOLVING ANGIOGENESIS

### 1. Field of the Invention

The present invention relates to compositions and methods useful for the modulation (e.g., promotion or inhibition) of angiogenesis and/or cardiovascularization in mammals in need of such biological effect. The present invention further relates to the diagnosis and treatment of disorders involving angiogenesis (e.g., cardiovascular as well as oncological disorders).

### 2. Background of the Invention

#### 2.1. Angiogenesis

Angiogenesis, defined as the growth or sprouting of new blood vessels from existing vessels, is a complex process that primarily occurs during embryonic development. Under normal physiological conditions in adults, angiogenesis takes place only in very restricted situations such as hair growth and wounding healing (Auerbach, W. and Auerbach, R., 1994, *Pharmacol Ther* 63(3):265-3 11; Ribatti et al., 1991, *Haematologica* 76(4):3 11-20; Risau, 1997, *Nature* 386(6626):67 1-4). Unregulated angiogenesis has gradually been recognized to be responsible for a wide range of disorders, including, but not limited to cardiovascular disease, cancer, rheumatoid arthritis, psoriasis and diabetic retinopathy (Folkman, 1995, *Nat Med* 1(1):27-31; Isner, 1999, *Circulation* 99(13): 1653-5; Koch, 1998, *Arthritis Rheum* 41(6):951-62; Walsh, 1999, *Rheumatology (Oxford)* 38(2):103-12; Ware and Simons, 1997, *Nat Med* 3(2): 158-64).

#### 2.2. Cardiac Disorders and Factors

Heart failure affects approximately five million Americans, and new cases of heart failure number about 400,000 each year. It is the single most frequent cause of hospitalization for people age 65 and older in the United States. Recent advances in the management of acute cardiac diseases, including acute myocardial infarction, are resulting in an expanding patient population that will eventually develop chronic heart failure. From 1979 to 1995, hospitalizations for congestive heart failure (CHF) rose from 377,000 to 872,000 (a 130 percent increase) and CHF deaths increased 116 percent.

CHF is a syndrome characterized by left ventricular dysfunction, reduced exercise tolerance, impaired quality of life, and markedly shortened life expectancy. The sine qua non of heart failure is an inability of the heart to pump blood at a rate sufficient to meet the metabolic needs of the body's tissues (in other words, there is insufficient cardiac output).

At least four major compensatory mechanisms are activated in the setting of heart failure to boost cardiac output, including peripheral vasoconstriction, increased heart rate, increased cardiac contractility, and increased plasma volume. These effects are mediated primarily by the sympathetic nervous system and the renin-angiotensin system. See, Eichhorn, American Journal of Medicine, 104: 163-169 (1998). Increased output from the

sympathetic nervous system increases vascular tone, heart rate, and contractility. Angiotensin II elevates blood pressure by 1) directly stimulating vascular smooth muscle contraction, 2) promoting plasma volume expansion by stimulating aldosterone and antidiuretic hormone secretion, 3) stimulating sympathetic-mediated vascular tone, and 4) catalyzing the degradation of bradykinin, which has vasodilatory and natriuretic activity. See, review by Brown and Vaughan, Circulation, 97: 1411-1420 (1998). As noted below, angiotensin II may also have directly deleterious effects on the heart by promoting myocyte necrosis (impairing systolic function) and intracardiac fibrosis (impairing diastolic and in some cases systolic function). See, Weber, Circulation, 96: 4065-4082 (1998).

A consistent feature of congestive heart failure (CHF) is cardiac hypertrophy, an enlargement of the heart that is activated by both mechanical and hormonal stimuli and enables the heart to adapt to demands for increased cardiac output. Morgan and Baker, Circulation, 83: 13-25 (1991). This hypertrophic response is frequently associated with a variety of distinct pathological conditions such as hypertension, aortic stenosis, myocardial infarction, cardiomyopathy, valvular regurgitation, and intracardiac shunt, all of which result in chronic hemodynamic overload.

Hypertrophy is generally defined as an increase in size of an organ or structure independent of natural growth that does not involve tumor formation. Hypertrophy of the heart is due either to an increase in the mass of the individual cells (myocytes), or to an increase in the number of cells making up the tissue (hyperplasia), or both. While the enlargement of an embryonic heart is largely dependent on an increase in myocyte number (which continues until shortly after birth), post-natal cardiac myocytes lose their proliferative capacity. Further growth occurs through hypertrophy of the individual cells.

Adult myocyte hypertrophy is initially beneficial as a short term response to impaired cardiac function by permitting a decrease in the load on individual muscle fibers. With severe, long-standing overload, however, the hypertrophied cells begin to deteriorate and die. Katz, "Heart Failure", in: Katz A.M. ed., Physiology of the Heart (New York: Raven Press, 1992) pp. 638-668. Cardiac hypertrophy is a significant risk factor for both mortality and morbidity in the clinical course of heart failure. Katz, Trends Cardiovasc. Med., 5: 37-44 (1995). For further details of the causes and pathology of cardiac hypertrophy see, e.g., Heart Disease. A Textbook of Cardiovascular Medicine, Braunwald, E. ed. (W.B. Saunders Co., 1988), Chapter 14, "Pathophysiology of Heart Failure."

On a cellular level, the heart is composed of myocytes and surrounding support cells, generically called non-myocytes. While non-myocytes are primarily fibroblast/mesenchymal cells, they also include endothelial and smooth muscle cells. Indeed, although myocytes make up most of the adult myocardial mass, they represent only about 30% of the total cell numbers present in heart. In response to hormonal, physiological, hemodynamic, and pathological stimuli, adult ventricular muscle cells can adapt to increased workloads through the activation of a hypertrophic process. This response is characterized by an increase in myocyte cell size and contractile protein content of individual cardiac muscle cells, without concomitant cell division and activation of embryonic genes, including the gene for atrial natriuretic peptide (ANP). Chien *et al.*, FASEB J., 5: 3037-3046 (1991); Chien *et al.*, Annu. Rev. Physiol., 55: 77-95 (1993). An increment in myocardial mass as a result of an increase in myocyte size that is associated with an accumulation of interstitial collagen within the extracellular matrix and around intramyocardial coronary arteries has been described in left ventricular hypertrophy secondary to pressure overload

in humans. Caspari *et al.*, Cardiovasc. Res., **11**: 554-558 (1977); Schwarz *et al.*, Am. J. Cardiol., **42**: 895-903 (1978); Hess *et al.*, Circulation, **63**: 360-371 (1981); Pearlman *et al.*, Lab. Invest., **46**: 158-164 (1982).

It has also been suggested that paracrine factors produced by non-myocyte supporting cells may additionally be involved in the development of cardiac hypertrophy, and various non-myocyte derived hypertrophic factors, such as, leukocyte inhibitory factor (LIF) and endothelin, have been identified. Metcalf, Growth Factors, **7**: 169-173 (1992); Kurzrock *et al.*, Endocrine Reviews, **12**: 208-217 (1991); Inoue *et al.*, Proc. Natl. Acad. Sci. USA, **86**: 2863-2867 (1989); Yanagisawa and Masaki, Trends Pharm. Sci., **10**: 374-378 (1989); U.S. Patent No. 5,573,762 (issued November 12, 1996). Further exemplary factors that have been identified as potential mediators of cardiac hypertrophy include cardiotrophin-1 (CT-1) (Pennica *et al.*, Proc. Nat. Acad. Sci. USA, **92**: 1142-1146 (1995)), catecholamines, adrenocorticosteroids, angiotensin, and prostaglandins.

At present, the treatment of cardiac hypertrophy varies depending on the underlying cardiac disease. Catecholamines, adrenocorticosteroids, angiotensin, prostaglandins, LIF, endothelin (including endothelin-1, -2, and -3 and big endothelin), and CT-1 are among the factors identified as potential mediators of hypertrophy. For example, beta-adrenergic receptor blocking drugs (beta-blockers, *e.g.*, propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, carvedilol, etc.) and verapamil have been used extensively in the treatment of hypertrophic cardiomyopathy. The beneficial effects of beta-blockers on symptoms (*e.g.*, chest pain) and exercise tolerance are largely due to a decrease in the heart rate with a consequent prolongation of diastole and increased passive ventricular filling. Thompson *et al.*, Br. Heart J., **44**: 488-98 (1980); Harrison *et al.*, Circulation, **29**: 84-98 (1964). Verapamil has been described to improve ventricular filling and probably reducing myocardial ischemia. Bonow *et al.*, Circulation, **72**: 853-64 (1985).

Nifedipine and diltiazem have also been used occasionally in the treatment of hypertrophic cardiomyopathy. Lorell *et al.*, Circulation, **65**: 499-507 (1982); Betocchi *et al.*, Am. J. Cardiol., **78**: 451-457 (1996). However, because of its potent vasodilating properties, nifedipine may be harmful, especially in patients with outflow obstruction. Disopyramide has been used to relieve symptoms by virtue of its negative inotropic properties. Pollick, N. Engl. J. Med., **307**: 997-999 (1982). In many patients, however, the initial benefits decrease with time. Wigle *et al.*, Circulation, **92**: 1680-1692 (1995). Antihypertensive drug therapy has been reported to have beneficial effects on cardiac hypertrophy associated with elevated blood pressure. Examples of drugs used in antihypertensive therapy, alone or in combination, are calcium antagonists, *e.g.*, nitrendipine; adrenergic receptor blocking agents, *e.g.*, those listed above; angiotensin converting enzyme (ACE) inhibitors such as quinapril, captopril, enalapril, ramipril, benazepril, fosinopril, and lisinopril; diuretics, *e.g.*, chlorothiazide, hydrochlorothiazide, hydroflumethazide, methylclothiazide, benzthiazide, dichlorphenamide, acetazolamide, and indapamide; and calcium channel blockers, *e.g.*, diltiazem, nifedipine, verapamil, and nifedipine.

For example, treatment of hypertension with diltiazem and captopril showed a decrease in left ventricular muscle mass, but the Doppler indices of diastolic function did not normalize. Szlachet *et al.*, Am. J. Cardiol., **63**: 198-201 (1989); Shahi *et al.*, Lancet, **336**: 458-461 (1990). These findings were interpreted to indicate that excessive amounts of interstitial collagen may remain after regression of left ventricular hypertrophy. Rossi *et al.*, Am. Heart J., **124**: 700-709 (1992). Rossi *et al.*, *supra*, investigated the effect of captopril on the prevention and

regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy, in experimental rats.

Agents that increase cardiac contractility directly (ionotropic agents) were initially thought to benefit patients with heart failure because they improved cardiac output in the short term. However, all positive inotropic agents except digoxigenin have been found to result in increased long-term mortality, in spite of short-term improvements in cardiac performance. Massie, Curr. Op. in Cardiology, 12: 209-217 (1997); Reddy *et al.*, Curr. Opin. Cardiol., 12: 233-241 (1997). Beta-adrenergic receptor blockers have recently been advocated for use in heart failure. Evidence from clinical trials suggests that improvements in cardiac function can be achieved without increased mortality, though documented improvements of patient survival have not yet been demonstrated. See also, U.S. Pat. Nos. 5,935,924, 5,624,806; 5,661,122; and 5,610,134 and WO 95/28173 regarding the use of cardiotropin-1 or antagonists thereof, or growth hormone and/or insulin-like growth factor-I in the treatment of CHF. Another treatment modality is heart transplantation, but this is limited by the availability of donor hearts.

Endothelin is a vasoconstricting peptide comprising 21 amino acids, isolated from swine arterial endothelial culture supernatant and structurally determined. Yanagisawa *et al.*, Nature, 332: 411-415 (1988). Endothelin was later found to exhibit various actions, and endothelin antibodies as endothelin antagonists have proven effective in the treatment of myocardial infarction, renal failure, and other diseases. Since endothelin is present in live bodies and exhibits vasoconstricting action, it is expected to be an endogenous factor involved in the regulation of the circulatory system, and may be associated with hypertension, cardiovascular diseases such as myocardial infarction, and renal diseases such as acute renal failure. Endothelin antagonists are described, for example, in U.S. Pat. No. 5,773,414; JP Pat. Publ. 3130299/1991, EP 457,195; EP 460,679; and EP 552,489. A new endothelin B receptor for identifying endothelin receptor antagonists is described in U.S. Pat. No. 5,773,223.

Current therapy for heart failure is primarily directed to using angiotensin-converting enzyme (ACE) inhibitors, such as captopril, and diuretics. These drugs improve hemodynamic profile and exercise tolerance and reduce the incidence of morbidity and mortality in patients with CHF. Kramer *et al.*, Circulation, 67(4): 807-816 (1983); Captopril Multicenter Research Group, J.A.C.C., 2(4): 755-763 (1983); The CONSENSUS Trial Study Group, N. Engl. J. Med., 316(23): 1429-1435 (1987); The SOLVD Investigators, N. Engl. J. Med., 325(5): 293-302 (1991). Further, they are useful in treating hypertension, left ventricular dysfunction, atherosclerotic vascular disease, and diabetic nephropathy. Brown and Vaughan, *supra*. However, despite proven efficacy, response to ACE inhibitors has been limited. For example, while prolonging survival in the setting of heart failure, ACE inhibitors appear to slow the progression towards end-stage heart failure, and substantial numbers of patients on ACE inhibitors have functional class III heart failure.

Moreover, improvement of functional capacity and exercise time is only small and mortality, although reduced, continues to be high. The CONSENSUS Trial Study Group, N. Engl. J. Med., 316(23): 1429-1453 (1987); The SOLVD Investigators, N. Engl. J. Med., 325(5): 293-302 (1991); Cohn *et al.*, N. Engl. J. Med., 325(5): 303-310 (1991); The Captopril-Digoxin Multicenter Research Group, JAMA, 259(4): 539-544 (1988). Hence, ACE inhibitors consistently appear unable to relieve symptoms in more than 60% of heart failure patients and reduce mortality of heart failure only by approximately 15-20%. For further adverse effects, see Brown and Vaughan,

*supra*.

An alternative to ACE inhibitors is represented by specific AT1 receptor antagonists. Clinical studies are planned to compare the efficacy of these two modalities in the treatment of cardiovascular and renal disease. However, animal model data suggests that the ACE/Ang II pathway, while clearly involved in cardiac hypertrophy, is not the only, or even the primary pathway active in this role. Mouse genetic "knockout" models have been made to test individual components of the pathway. In one such model, the primary cardiac receptor for Ang II, AT sub 1A, has been genetically deleted; these mice do not develop hypertrophy when Ang II is given experimentally (confirming the basic success of the model in eliminating hypertrophy secondary to Ang II). However, when the aorta is constricted in these animals (a model of hypertensive cardiac stress), the hearts still become hypertrophic. This suggests that alternative signaling pathways, not depending on this receptor (AT sub 1A), are activated in hypertension. ACE inhibitors would presumably not be able to inhibit these pathways. See, Harada *et al.*, Circulation, 97: 1952-1959 (1998). See also, Homcy, Circulation, 97: 1890-1892 (1998) regarding the enigma associated with the process and mechanism of cardiac hypertrophy.

About 750,000 patients suffer from acute myocardial infarction (AMI) annually, and approximately one-fourth of all deaths in the United States are due to AMI. In recent years, thrombolytic agents, *e.g.*, streptokinase, urokinase, and in particular tissue plasminogen activator (t-PA) have significantly increased the survival of patients who suffered myocardial infarction. When administered as a continuous intravenous infusion over 1.5 to 4 hours, t-PA produces coronary patency at 90 minutes in 69% to 90% of the treated patients. Topol *et al.*, Am. J. Cardiol., 61: 723-728 (1988); Neuhaus *et al.*, J. Am. Coll. Cardiol., 12: 581-587 (1988); Neuhaus *et al.*, J. Am. Coll. Cardiol., 14: 1566-1569 (1989). The highest patency rates have been reported with high dose or accelerated dosing regimens. Topol, J. Am. Coll. Cardiol., 15: 922-924 (1990). t-PA may also be administered as a single bolus, although due to its relatively short half-life, it is better suited for infusion therapy. Tebbe *et al.*, Am. J. Cardiol., 64: 448-453 (1989). A t-PA variant, specifically designed to have longer half-life and very high fibrin specificity, TNK t-PA (a T103N, N117Q, KHRR(296-299)AAAA t-PA variant, Keyt *et al.*, Proc. Natl. Acad. Sci. USA, 91: 3670-3674 (1994)) is particularly suitable for bolus administration. However, despite all these advances, the long-term prognosis of patient survival depends greatly on the post-infarction monitoring and treatment of the patients, which should include monitoring and treatment of cardiac hypertrophy.

### 2.3. Growth Factors

Various naturally occurring polypeptides reportedly induce the proliferation of endothelial cells. Among those polypeptides are the basic and acidic fibroblast growth factors (FGF) (Burgess and Maciag, Annual Rev. Biochem., 58: 575 (1989)), platelet-derived endothelial cell growth factor (PD-ECGF) (Ishikawa *et al.*, Nature, 338: 557 (1989)), and vascular endothelial growth factor (VEGF). Leung *et al.*, Science, 246: 1306 (1989); Ferrara and Henzel, Biochem. Biophys. Res. Commun., 161: 851 (1989); Tischer *et al.*, Biochem. Biophys. Res. Commun., 165: 1198 (1989); EP 471,754B granted July 31, 1996.

Media conditioned by cells transfected with the human VEGF (hVEGF) cDNA promoted the proliferation of capillary endothelial cells, whereas control cells did not. Leung *et al.*, Science, 246: 1306 (1989). Several

additional cDNAs were identified in human cDNA libraries that encode 121-, 189-, and 206-amino acid isoforms of hVEGF (also collectively referred to as hVEGF-related proteins). The 121-amino acid protein differs from hVEGF by virtue of the deletion of the 44 amino acids between residues 116 and 159 in hVEGF. The 189-amino acid protein differs from hVEGF by virtue of the insertion of 24 amino acids at residue 116 in hVEGF, and  
5 apparently is identical to human vascular permeability factor (hVPF). The 206-amino acid protein differs from hVEGF by virtue of an insertion of 41 amino acids at residue 116 in hVEGF. Houck *et al.*, Mol. Endocrin., **5**: 1806 (1991); Ferrara *et al.*, J. Cell. Biochem., **47**: 211 (1991); Ferrara *et al.*, Endocrine Reviews, **13**: 18 (1992); Keck *et al.*, Science, **246**: 1309 (1989); Connolly *et al.*, J. Biol. Chem., **264**: 20017 (1989); EP 370,989 published May 30, 1990.

10 It is now well established that angiogenesis, which involves the formation of new blood vessels from preexisting endothelium, is implicated in the pathogenesis of a variety of disorders. These include solid tumors and metastasis, atherosclerosis, retrolental fibroplasia, hemangiomas, chronic inflammation, intraocular neovascular syndromes such as proliferative retinopathies, *e.g.*, diabetic retinopathy, age-related macular degeneration (AMD), neovascular glaucoma, immune rejection of transplanted corneal tissue and other tissues, rheumatoid arthritis, and  
15 psoriasis. Folkman *et al.*, J. Biol. Chem., **267**: 10931-10934 (1992); Klagsbrun *et al.*, Annu. Rev. Physiol., **53**: 217-239 (1991); and Garner A., "Vascular diseases", In: Pathobiology of Ocular Disease. A Dynamic Approach, Garner A., Klintworth GK, eds., 2nd Edition (Marcel Dekker, NY, 1994), pp 1625-1710.

In the case of tumor growth, angiogenesis appears to be crucial for the transition from hyperplasia to neoplasia, and for providing nourishment for the growth and metastasis of the tumor. Folkman *et al.*, Nature, **339**:  
20 58 (1989). The neovascularization allows the tumor cells to acquire a growth advantage and proliferative autonomy compared to the normal cells. A tumor usually begins as a single aberrant cell which can proliferate only to a size of a few cubic millimeters due to the distance from available capillary beds, and it can stay 'dormant' without further growth and dissemination for a long period of time. Some tumor cells then switch to the angiogenic phenotype to activate endothelial cells, which proliferate and mature into new capillary blood vessels. These newly formed blood  
25 vessels not only allow for continued growth of the primary tumor, but also for the dissemination and recolonization of metastatic tumor cells. Accordingly, a correlation has been observed between density of microvessels in tumor sections and patient survival in breast cancer as well as in several other tumors. Weidner *et al.*, N. Engl. J. Med., **324**: 1-6 (1991); Horak *et al.*, Lancet, **340**: 1120-1124 (1992); Macchiarini *et al.*, Lancet, **340**: 145-146 (1992). The precise mechanisms that control the angiogenic switch is not well understood, but it is believed that  
30 neovascularization of tumor mass results from the net balance of a multitude of angiogenesis stimulators and inhibitors (Folkman, 1995, Nat Med **1**(1):27-31).

The search for positive regulators of angiogenesis has yielded many candidates, including aFGF, bFGF, TGF- $\alpha$ , TGF- $\beta$ , HGF, TNF- $\alpha$ , angiogenin, IL-8, etc. Folkman *et al.*, J.B.C., *supra*, and Klagsbrun *et al.*, *supra*. The negative regulators so far identified include thrombospondin (Good *et al.*, Proc. Natl. Acad. Sci. USA, **87**: 6624-  
35 6628 (1990)), the 16-kilodalton N-terminal fragment of prolactin (Clapp *et al.*, Endocrinology, **133**: 1292-1299 (1993)), angiostatin (O'Reilly *et al.*, Cell, **79**: 315-328 (1994)), and endostatin. O'Reilly *et al.*, Cell, **88**: 277-285 (1996).

Work done over the last several years has established the key role of VEGF, not only in stimulating vascular endothelial cell proliferation, but also in inducing vascular permeability and angiogenesis. Ferrara *et al.*, Endocr. Rev., **18**: 4-25 (1997). The finding that the loss of even a single VEGF allele results in embryonic lethality points to an irreplaceable role played by this factor in the development and differentiation of the vascular system. Furthermore, VEGF has been shown to be a key mediator of neovascularization associated with tumors and intraocular disorders. Ferrara *et al.*, Endocr. Rev., *supra*. The VEGF mRNA is overexpressed by the majority of human tumors examined. Berkman *et al.*, J. Clin. Invest., **91**: 153-159 (1993); Brown *et al.*, Human Pathol., **26**: 86-91 (1995); Brown *et al.*, Cancer Res., **53**: 4727-4735 (1993); Mattern *et al.*, Brit. J. Cancer, **73**: 931-934 (1996); Dvorak *et al.*, Am. J. Pathol., **146**: 1029-1039 (1995).

Also, the concentration levels of VEGF in eye fluids are highly correlated to the presence of active proliferation of blood vessels in patients with diabetic and other ischemia-related retinopathies. Aiello *et al.*, N. Engl. J. Med., **331**: 1480-1487 (1994). Furthermore, recent studies have demonstrated the localization of VEGF in choroidal neovascular membranes in patients affected by AMD. Lopez *et al.*, Invest. Ophthalmol. Vis. Sci., **37**: 855-868 (1996).

Anti-VEGF neutralizing antibodies suppress the growth of a variety of human tumor cell lines in nude mice (Kim *et al.*, Nature, **362**: 841-844 (1993); Warren *et al.*, J. Clin. Invest., **95**: 1789-1797 (1995); Borgström *et al.*, Cancer Res., **56**: 4032-4039 (1996); Melnyk *et al.*, Cancer Res., **56**: 921-924 (1996)) and also inhibit intraocular angiogenesis in models of ischemic retinal disorders. Adamis *et al.*, Arch. Ophthalmol., **114**: 66-71 (1996). Therefore, anti-VEGF monoclonal antibodies or other inhibitors of VEGF action are promising candidates for the treatment of solid tumors and various intraocular neovascular disorders. Such antibodies are described, for example, in EP 817,648 published January 14, 1998 and in WO98/45331 and WO98/45332 both published October 15, 1998.

There exist several other growth factors and mitogens, including transforming oncogenes, that are capable of rapidly inducing a complex set of genes to be expressed by certain cells. Lau and Nathans, Molecular Aspects of Cellular Regulation, **6**: 165-202 (1991). These genes, which have been named immediate-early- or early-response genes, are transcriptionally activated within minutes after contact with a growth factor or mitogen, independent of *de novo* protein synthesis. A group of these intermediate-early genes encodes secreted, extracellular proteins that are needed for coordination of complex biological processes such as differentiation and proliferation, regeneration, and wound healing. Ryseck *et al.*, Cell Growth Differ., **2**: 235-233 (1991).

Highly-related proteins that belong to this group include *cef 10* (Simmons *et al.*, Proc. Natl. Acad. Sci. USA, **86**: 1178-1182 (1989)), *cyr 61*, which is rapidly activated by serum- or platelet-derived growth factor (PDGF) (O'Brien *et al.*, Mol. Cell Biol., **10**: 3569-3577 (1990), human connective tissue growth factor (CTGF) (Bradham *et al.*, J. Cell. Biol., **114**: 1285-1294 (1991)), which is secreted by human vascular endothelial cells in high levels after activation with transforming growth factor beta (TGF- $\beta$ ), exhibits PDGF-like biological and immunological activities, and competes with PDGF for a particular cell surface receptor, *fisp-12* (Ryseck *et al.*, Cell Growth Differ., **2**: 235-233 (1991)), human vascular IBP-like growth factor (VIGF) (WO 96/17931), and *nov*, normally arrested in adult kidney cells, which was found to be overexpressed in myeloblastosis-associated-virus-type-1-induced nephroblastomas. Joliet *et al.*, Mol. Cell. Biol., **12**: 10-21 (1992).

The expression of these immediate-early genes acts as "third messengers" in the cascade of events triggered by growth factors. It is also thought that they are needed to integrate and coordinate complex biological processes, such as differentiation and wound healing in which cell proliferation is a common event.

As additional mitogens, insulin-like growth factor binding proteins (IGFBPs) have been shown, in complex with insulin-like growth factor (IGF), to stimulate increased binding of IGF to fibroblast and smooth muscle cell surface receptors. Clemmons *et al.*, *J. Clin. Invest.*, **77**: 1548 (1986). Inhibitory effects of IGFBP on various IGF actions *in vitro* include stimulation of glucose transport by adipocytes, sulfate incorporation by chondrocytes, and thymidine incorporation in fibroblast. Zapf *et al.*, *J. Clin. Invest.*, **63**: 1077 (1979). In addition, inhibitory effects of IGFBPs on growth factor-mediated mitogen activity in normal cells have been shown.

#### 2.4. Need for Further Treatments

In view of the role of vascular endothelial cell growth and angiogenesis in many diseases and disorders, it is desirable to have a means of reducing or inhibiting one or more of the biological effects causing these processes. It is also desirable to have a means of assaying for the presence of pathogenic polypeptides in normal and diseased conditions, and especially cancer. Further, in a specific aspect, as there is no generally applicable therapy for the treatment of cardiac hypertrophy, the identification of factors that can prevent or reduce cardiac myocyte hypertrophy is of primary importance in the development of new therapeutic strategies to inhibit pathophysiological cardiac growth. While there are several treatment modalities for various cardiovascular and oncologic disorders, there is still a need for additional therapeutic approaches.

#### 3. Summary of the Invention

The present invention provides compositions and methods for modulating (*e.g.*, promoting or inhibiting) angiogenesis and/or cardiovascularization in mammals. The present invention is based on the identification of compounds (*i.e.*, proteins) that test positive in various cardiovascular assays that test modulation (*e.g.*, promotion or inhibition) of certain biological activities. Accordingly, the compounds are believed to be useful drugs and/or drug components for the diagnosis and/or treatment (including prevention and amelioration) of disorders where such effects are desired, such as the promotion or inhibition of angiogenesis, inhibition or stimulation of vascular endothelial cell growth, stimulation of growth or proliferation of vascular endothelial cells, inhibition of tumor growth, inhibition of angiogenesis-dependent tissue growth, stimulation of angiogenesis-dependent tissue growth, inhibition of cardiac hypertrophy and stimulation of cardiac hypertrophy, *e.g.*, for the treatment of congestive heart failure. In addition, the compositions and methods of the invention provide for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of angiogenesis-related disorders, for monitoring the efficacy of compounds in clinical trials and for identifying subjects who may be predisposed to such angiogenic-related disorders.

In one embodiment, the present invention provides a composition comprising a PRO polypeptide, an agonist or antagonist thereof, or an anti-PRO antibody in admixture with a pharmaceutically acceptable carrier. In one aspect, the composition comprises a therapeutically effective amount of the polypeptide, agonist, antagonist



or antibody. In another aspect, the composition comprises a further active ingredient, namely, a cardiovascular, endothelial or angiogenic agent or an angiostatic agent, preferably an angiogenic or angiostatic agent. Preferably, the composition is sterile. The PRO polypeptide, agonist, antagonist or antibody may be administered in the form of a liquid pharmaceutical formulation, which may be preserved to achieve extended storage stability. Preserved liquid pharmaceutical formulations might contain multiple doses of PRO polypeptide, agonist, antagonist or antibody, and might, therefore, be suitable for repeated use. In a preferred embodiment, where the composition comprises an antibody, the antibody is a monoclonal antibody, an antibody fragment, a humanized antibody, or a single-chain antibody.

In a further embodiment, the present invention provides a method for preparing such a composition useful for the treatment of a cardiovascular, endothelial or angiogenic disorder comprising admixing a therapeutically effective amount of a PRO polypeptide, agonist, antagonist or antibody with a pharmaceutically acceptable carrier.

In a still further aspect, the present invention provides an article of manufacture comprising:

- (a) a composition of matter comprising a PRO polypeptide or agonist or antagonist thereof;
- (b) a container containing said composition; and
- (c) a label affixed to said container, or a package insert included in said container referring to the use of said PRO polypeptide or agonist or antagonist thereof in the treatment of a cardiovascular, endothelial or angiogenic disorder, wherein the agonist or antagonist may be an antibody which binds to the PRO polypeptide. The composition may comprise a therapeutically effective amount of the PRO polypeptide or the agonist or antagonist thereof.

In another embodiment, the present invention provides a method for identifying an agonist of a PRO polypeptide comprising:

- (a) contacting cells and a test compound to be screened under conditions suitable for the induction of a cellular response normally induced by a PRO polypeptide; and
- (b) determining the induction of said cellular response to determine if the test compound is an effective agonist, wherein the induction of said cellular response is indicative of said test compound being an effective agonist.

In another embodiment, the present invention provides a method for identifying an agonist of a PRO polypeptide comprising:

- (a) contacting cells and a test compound to be screened under conditions suitable for the stimulation of cell proliferation by a PRO polypeptide; and
- (b) measuring the proliferation of said cells to determine if the test compound is an effective agonist, wherein the stimulation of cell proliferation is indicative of said test compound being an effective agonist.

In another embodiment, the invention provides a method for identifying a compound that inhibits the activity of a PRO polypeptide comprising contacting a test compound with a PRO polypeptide under conditions and for a time sufficient to allow the test compound and polypeptide to interact and determining whether the activity of the PRO polypeptide is inhibited. In a specific preferred aspect, either the test compound or the PRO polypeptide is immobilized on a solid support. In another preferred aspect, the non-immobilized component carries a detectable

label. In a preferred aspect, this method comprises the steps of:

(a) contacting cells and a test compound to be screened in the presence of a PRO polypeptide under conditions suitable for the induction of a cellular response normally induced by a PRO polypeptide; and

5 (b) determining the induction of said cellular response to determine if the test compound is an effective antagonist.

In another preferred aspect, this process comprises the steps of:

(a) contacting cells and a test compound to be screened in the presence of a PRO polypeptide under conditions suitable for the stimulation of cell proliferation by a PRO polypeptide; and

(b) measuring the proliferation of the cells to determine if the test compound is an effective antagonist.

10 In another embodiment, the invention provides a method for identifying a compound that inhibits the expression of a PRO polypeptide in cells that normally expresses the polypeptide, wherein the method comprises contacting the cells with a test compound and determining whether the expression of the PRO polypeptide is inhibited. In a preferred aspect, this method comprises the steps of:

15 (a) contacting cells and a test compound to be screened under conditions suitable for allowing expression of the PRO polypeptide; and

(b) determining the inhibition of expression of said polypeptide.

In a still further embodiment, the invention provides a compound that inhibits the expression of a PRO polypeptide, such as a compound that is identified by the methods set forth above.

20 Another aspect of the present invention is directed to an agonist or an antagonist of a PRO polypeptide which may optionally be identified by the methods described above.

One type of antagonist of a PRO polypeptide that inhibits one or more of the functions or activities of the PRO polypeptide is an antibody. Hence, in another aspect, the invention provides an isolated antibody that binds a PRO polypeptide. In a preferred aspect, the antibody is a monoclonal antibody, which preferably has non-human complementarity-determining-region (CDR) residues and human framework-region (FR) residues. The antibody  
25 may be labeled and may be immobilized on a solid support. In a further aspect, the antibody is an antibody fragment, a single-chain antibody, or a humanized antibody. Preferably, the antibody specifically binds to the polypeptide.

30 In a still further aspect, the present invention provides a method for diagnosing a disease or susceptibility to a disease which is related to a mutation in a PRO polypeptide-encoding nucleic acid sequence comprising determining the presence or absence of said mutation in the PRO polypeptide nucleic acid sequence, wherein the presence or absence of said mutation is indicative of the presence of said disease or susceptibility to said disease.

35 In a still further aspect, the invention provides a method of diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal which comprises analyzing the level of expression of a gene encoding a PRO polypeptide (a) in a test sample of tissue cells obtained from said mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample as compared to the control sample is indicative of the presence of a cardiovascular, endothelial or angiogenic disorder in said mammal. The expression of a gene encoding a PRO polypeptide may optionally be accomplished by measuring

the level of mRNA or the polypeptide in the test sample as compared to the control sample.

In a still further aspect, the present invention provides a method of diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal which comprises detecting the presence or absence of a PRO polypeptide in a test sample of tissue cells obtained from said mammal, wherein the presence or absence of said PRO polypeptide in said test sample is indicative of the presence of a cardiovascular, endothelial or angiogenic disorder in said mammal.

In a still further embodiment, the invention provides a method of diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal comprising (a) contacting an anti-PRO antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the antibody and the PRO polypeptide in the test sample, wherein the formation of said complex is indicative of the presence of a cardiovascular, endothelial or angiogenic disorder in the mammal. The detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type. A larger or smaller quantity of complexes formed in the test sample indicates the presence of a cardiovascular, endothelial or angiogenic dysfunction in the mammal from which the test tissue cells were obtained. The antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. The test sample is usually obtained from an individual suspected to have a cardiovascular, endothelial or angiogenic disorder.

In another embodiment, the invention provides a method for determining the presence of a PRO polypeptide in a sample comprising exposing a sample suspected of containing the PRO polypeptide to an anti-PRO antibody and determining binding of said antibody to a component of said sample. In a specific aspect, the sample comprises a cell suspected of containing the PRO polypeptide and the antibody binds to the cell. The antibody is preferably detectably labeled and/or bound to a solid support.

In further aspects, the invention provides a cardiovascular, endothelial or angiogenic disorder diagnostic kit comprising an anti-PRO antibody and a carrier in suitable packaging. Preferably, such kit further comprises instructions for using said antibody to detect the presence of the PRO polypeptide. Preferably, the carrier is a buffer, for example. Preferably, the cardiovascular, endothelial or angiogenic disorder is cancer.

In yet another embodiment, the present invention provides a method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal comprising administering to the mammal an effective amount of a PRO polypeptide. Preferably, the disorder is cardiac hypertrophy, trauma such as wounds or burns, or a type of cancer. In a further aspect, the mammal is further exposed to angioplasty or a drug that treats cardiovascular, endothelial or angiogenic disorders such as ACE inhibitors or chemotherapeutic agents if the cardiovascular, endothelial or angiogenic disorder is a type of cancer. Preferably, the mammal is human, preferably one who is at risk of developing cardiac hypertrophy and more preferably has suffered myocardial infarction.

In another preferred aspect, the cardiac hypertrophy is characterized by the presence of an elevated level of PGF<sub>2α</sub>. Alternatively, the cardiac hypertrophy may be induced by myocardial infarction, wherein preferably the administration of the PRO polypeptide is initiated within 48 hours, more preferably within 24 hours, following myocardial infarction.

In another preferred embodiment, the cardiovascular, endothelial or angiogenic disorder is cardiac hypertrophy and said PRO polypeptide is administered together with a cardiovascular, endothelial or angiogenic agent. The preferred cardiovascular, endothelial or angiogenic agent for this purpose is selected from the group consisting of an antihypertensive drug, an ACE inhibitor, an endothelin receptor antagonist and a thrombolytic agent. If a thrombolytic agent is administered, preferably the PRO polypeptide is administered following administration of such agent. More preferably, the thrombolytic agent is recombinant human tissue plasminogen activator.

In another preferred aspect, the cardiovascular, endothelial or angiogenic disorder is cardiac hypertrophy and the PRO polypeptide is administered following primary angioplasty for the treatment of acute myocardial infarction, preferably wherein the mammal is further exposed to angioplasty or a cardiovascular, endothelial, or angiogenic agent.

In another preferred embodiment, the cardiovascular, endothelial or angiogenic disorder is a cancer and the PRO polypeptide is administered in combination with a chemotherapeutic agent, a growth inhibitory agent or a cytotoxic agent.

In a further embodiment, the invention provides a method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal comprising administering to the mammal an effective amount of a PRO polypeptide agonist, antagonist or anti-PRO antibody. Preferably, the cardiovascular, endothelial or angiogenic disorder is cardiac hypertrophy, trauma, a cancer, or age-related macular degeneration. Also preferred is where the mammal is human, and where an effective amount of an angiogenic or angiostatic agent is administered in conjunction with the agonist, antagonist or anti-PRO antibody.

In still further embodiments, the invention provides a method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal that suffers therefrom comprising administering to the mammal a nucleic acid molecule that codes for either (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide or (c) an antagonist of a PRO polypeptide, wherein said agonist or antagonist may be an anti-PRO antibody. In a preferred embodiment, the mammal is human. In another preferred embodiment, the gene is administered via *ex vivo* gene therapy. In a further preferred embodiment, the gene is comprised within a vector, more preferably an adenoviral, adeno-associated viral, lentiviral, or retroviral vector.

In yet another aspect, the invention provides a recombinant retroviral particle comprising a retroviral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide, or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein the retroviral vector is in association with retroviral structural proteins. Preferably, the signal sequence is from a mammal, such as from a native PRO polypeptide.

In a still further embodiment, the invention supplies an *ex vivo* producer cell comprising a nucleic acid construct that expresses retroviral structural proteins and also comprises a retroviral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein said producer cell packages the retroviral vector in association with the structural proteins to produce

recombinant retroviral particles.

In yet another embodiment, the invention provides a method for inhibiting endothelial cell growth in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein endothelial cell growth in said mammal is inhibited, and wherein said agonist or antagonist may be an anti-PRO antibody. Preferably, the mammal is human and the endothelial cell growth is associated with a tumor or a retinal disorder.

In yet another embodiment, the invention provides a method for stimulating endothelial cell growth in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein endothelial cell growth in said mammal is stimulated, and wherein said agonist or antagonist may be an anti-PRO antibody. Preferably, the mammal is human.

In yet another embodiment, the invention provides a method for inhibiting cardiac hypertrophy in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein cardiac hypertrophy in said mammal is inhibited, and wherein said agonist or antagonist may be an anti-PRO antibody. Preferably, the mammal is human and the cardiac hypertrophy has been induced by myocardial infarction.

In yet another embodiment, the invention provides a method for stimulating cardiac hypertrophy in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein cardiac hypertrophy in said mammal is stimulated, and wherein said agonist or antagonist may be an anti-PRO antibody. Preferably, the mammal is human who suffers from congestive heart failure.

In yet another embodiment, the invention provides a method for inhibiting angiogenesis induced by a PRO polypeptide in a mammal comprising administering a therapeutically effective amount of an anti-PRO antibody to the mammal. Preferably, the mammal is a human, and more preferably the mammal has a tumor or a retinal disorder.

In yet another embodiment, the invention provides a method for stimulating angiogenesis induced by a PRO polypeptide in a mammal comprising administering a therapeutically effective amount of a PRO polypeptide to the mammal. Preferably, the mammal is a human, and more preferably angiogenesis would promote tissue regeneration or wound healing.

In yet another embodiment, the invention provides a method for modulating (*e.g.*, inhibiting or stimulating) endothelial cell growth in a mammal comprising administering to the mammal a PRO21, PRO181, PRO205, PRO214, PRO221, PRO229, PRO231, PRO238, PRO241, PRO247, PRO256, PRO258, PRO263, PRO265, PRO295, PRO321, PRO322, PRO337, PRO363, PRO365, PRO444, PRO533, PRO697, PRO720, PRO725, PRO771, PRO788, PRO791, PRO819, PRO827, PRO828, PRO836, PRO846, PRO865, PRO1005, PRO1006, PRO1007, PRO1025, PRO1029, PRO1054, PRO1071, PRO1075, PRO1079, PRO1080, PRO1114, PRO1131, PRO1155, PRO1160, PRO1184, PRO1186, PRO1190, PRO1192, PRO1195, PRO1244, PRO1272, PRO1273, PRO1274, PRO1279, PRO1283, PRO1286, PRO1306, PRO1309, PRO1325, PRO1329, PRO1347, PRO1356, PRO1376, PRO1382, PRO1411, PRO1412, PRO1419, PRO1474, PRO1477, PRO1488, PRO1508, PRO1550,

PRO1556, PRO1760, PRO1782, PRO1787, PRO1801, PRO1868, PRO1887, PRO1890, PRO3438, PRO3444, PRO4302, PRO4324, PRO4333, PRO4341, PRO4342, PRO4353, PRO4354, PRO4356, PRO4371, PRO4405, PRO4408, PRO4422, PRO4425, PRO4499, PRO5723, PRO5725, PRO5737, PRO5776, PRO6006, PRO6029, PRO6071, PRO7436, PRO9771, PRO9821, PRO9873, PRO10008, PRO10096, PRO19670, PRO20040, PRO20044, PRO21055, PRO21384 or PRO28631 polypeptide, agonist or antagonist thereof, wherein endothelial cell growth in said mammal is modulated.

In yet another embodiment, the invention provides a method for modulating (e.g., inhibiting or stimulating) smooth muscle cell growth in a mammal comprising administering to the mammal a PRO162, PRO181, PRO182, PRO195, PRO204, PRO221, PRO230, PRO256, PRO258, PRO533, PRO697, PRO725, PRO738, PRO826, PRO836, PRO840, PRO846, PRO865, PRO982, PRO1025, PRO1029, PRO1071, PRO1080, PRO1083, PRO1134, PRO1160, PRO1182, PRO1184, PRO1186, PRO1192, PRO1265, PRO1274, PRO1279, PRO1283, PRO1306, PRO1308, PRO1309, PRO1325, PRO1337, PRO1338, PRO1343, PRO1376, PRO1387, PRO1411, PRO1412, PRO1415, PRO1434, PRO1474, PRO1488, PRO1550, PRO1556, PRO1567, PRO1600, PRO1754, PRO1758, PRO1760, PRO1787, PRO1865, PRO1868, PRO1917, PRO1928, PRO3438, PRO3562, PRO4302, PRO4333, PRO4345, PRO4353, PRO4354, PRO4405, PRO4408, PRO4430, PRO4503, PRO5725, PRO6714, PRO9771, PRO9820, PRO9940, PRO10096, PRO21055, PRO21184 or PRO21366 polypeptide, agonist or antagonist thereof, wherein endothelial cell growth in said mammal is modulated.

In yet another embodiment, the invention provides a method for modulating (e.g., inducing or reducing) cardiac hypertrophy in a mammal comprising administering to the mammal a PRO21 polypeptide, agonist or antagonist thereof, wherein cardiac hypertrophy in said mammal is modulated.

In yet another embodiment, the invention provides a method for modulating (e.g., inducing or reducing) endothelial cell apoptosis in a mammal comprising administering to the mammal a PRO4302 polypeptide, agonist or antagonist thereof, wherein cardiac hypertrophy in said mammal is modulated.

In yet another embodiment, the invention provides a method for modulating (e.g., stimulating or inhibiting) angiogenesis in a mammal comprising administering a therapeutically effective amount of a PRO1376 or PRO1449 polypeptide, agonist or antagonist thereof to the mammal, wherein said angiogenesis is modulated.

In yet another embodiment, the invention provides a method for modulating (e.g., inducing or reducing) angiogenesis by modulating (e.g., inducing or reducing) endothelial cell tube formation in a mammal comprising administering to the mammal a PRO178, PRO195, PRO228, PRO301, PRO302, PRO532, PRO724, PRO730, PRO734, PRO793, PRO871, PRO938, PRO1012, PRO1120, PRO1139, PRO1198, PRO1287, PRO1361, PRO1864, PRO1873, PRO2010, PRO3579, PRO4313, PRO4527, PRO4538, PRO4553, PRO4995, PRO5730, PRO6008, PRO7223, PRO7248 or PRO7261 polypeptide, agonist or antagonist thereof, wherein endothelial cell tube formation in said mammal is modulated.

In other embodiments of the present invention, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.

In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98%

nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In a further aspect, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.

Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 600, 700 or 800 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO antibody.

In another embodiment, the invention provides an isolated PRO polypeptide encoded by any of the isolated

nucleic acid sequences hereinabove identified.

5 In a certain aspect, the invention provides an isolated PRO polypeptide comprising an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.

10 In a further aspect, the invention provides an isolated PRO polypeptide comprising an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein.

15 In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and that is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

20 Another aspect of the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

25 In yet another embodiment, the invention provides agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.

30 In a further embodiment, the invention provides a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native PRO polypeptide.

In a still further embodiment, the invention provides a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

35 Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.



In additional embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cells comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, yeast, or Baculovirus-infected insect cells. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.

In yet another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.

In yet other embodiments, the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.

#### 4. Brief Description of the Drawings

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO181 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA23330-1390".

Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO178 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA23339-1130".

Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO444 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA26846-1397".

Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.

Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO195 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA26847-1395".

Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PRO182 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA27865-1091".

Figure 10 shows the amino acid sequence (SEQ ID NO:10) derived from the coding sequence of SEQ ID

NO:9 shown in Figure 9.

Figure 11 shows a nucleotide sequence (SEQ ID NO:11) of a native sequence PRO205 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA30868-1156".

5 Figure 12 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 11.

Figure 13 shows a nucleotide sequence (SEQ ID NO:13) of a native sequence PRO204 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA30871-1157".

Figure 14 shows the amino acid sequence (SEQ ID NO:14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.

10 Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a native sequence PRO1873 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA30880".

Figure 16 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

15 Figure 17 shows a nucleotide sequence (SEQ ID NO:17) of a native sequence PRO214 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA32286-1191".

Figure 18 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 17.

Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a native sequence PRO221 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA33089-1132".

20 Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:19 shown in Figure 19.

Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PRO228 cDNA, wherein SEQ ID NO:21 is a clone designated herein as "DNA33092-1202".

25 Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PRO229 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA33100-1159".

Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

30 Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a native sequence PRO230 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA33223-1136".

Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.

35 Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PRO7223 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA34385".

Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.

Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PRO241 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA34392-1170".

Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

5        Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a native sequence PRO263 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA34431-1177".

Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.

10       Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PRO321 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA34433-1308".

Figure 34 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PRO231 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA34434-1139".

15       Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a native sequence PRO238 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA35600-1162".

20       Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.

Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PRO247 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA35673-1201".

Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39.

25       Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PRO256 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA35880-1160".

Figure 42 shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.

30       Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PRO258 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA35918-1174".

Figure 44 shows the amino acid sequence (SEQ ID NO:44) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.

Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PRO265 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA36350-1158".

35       Figure 46 shows the amino acid sequence (SEQ ID NO:46) derived from the coding sequence of SEQ ID NO:45 shown in Figure 45.

Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PRO21 cDNA, wherein SEQ

ID NO:47 is a clone designated herein as "DNA36638-1056".

Figure 48 shows the amino acid sequence (SEQ ID NO:48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.

5 Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PRO295 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA38268-1188".

Figure 50 shows the amino acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.

Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PRO302 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA40370-1217".

10 Figure 52 shows the amino acid sequence (SEQ ID NO:52) derived from the coding sequence of SEQ ID NO:51 shown in Figure 51.

Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PRO301 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA40628-1216".

15 Figure 54 shows the amino acid sequence (SEQ ID NO:54) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.

Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PRO337 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA43316-1237".

Figure 56 shows the amino acid sequence (SEQ ID NO:56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.

20 Figure 57 shows a nucleotide sequence (SEQ ID NO:57) of a native sequence PRO7248 cDNA, wherein SEQ ID NO:57 is a clone designated herein as "DNA44195".

Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.

25 Figure 59 shows a nucleotide sequence (SEQ ID NO:59) of a native sequence PRO846 cDNA, wherein SEQ ID NO:59 is a clone designated herein as "DNA44196-1353".

Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59.

Figure 61 shows a nucleotide sequence (SEQ ID NO:61) of a native sequence PRO1864 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA45409-2511".

30 Figure 62 shows the amino acid sequence (SEQ ID NO:62) derived from the coding sequence of SEQ ID NO:61 shown in Figure 61.

Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PRO363 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA45419-1252".

35 Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:63 shown in Figure 63.

Figure 65 shows a nucleotide sequence (SEQ ID NO:65) of a native sequence PRO730 cDNA, wherein SEQ ID NO:65 is a clone designated herein as "DNA45624-1400".

Figure 66 shows the amino acid sequence (SEQ ID NO:66) derived from the coding sequence of SEQ ID NO:65 shown in Figure 65.

Figure 67 shows a nucleotide sequence (SEQ ID NO:67) of a native sequence PRO365 cDNA, wherein SEQ ID NO:67 is a clone designated herein as "DNA46777-1253".

5 Figure 68 shows the amino acid sequence (SEQ ID NO:68) derived from the coding sequence of SEQ ID NO:67 shown in Figure 67.

Figure 69 shows a nucleotide sequence (SEQ ID NO:69) of a native sequence PRO532 cDNA, wherein SEQ ID NO:69 is a clone designated herein as "DNA48335".

10 Figure 70 shows the amino acid sequence (SEQ ID NO:70) derived from the coding sequence of SEQ ID NO:69 shown in Figure 69.

Figure 71 shows a nucleotide sequence (SEQ ID NO:71) of a native sequence PRO322 cDNA, wherein SEQ ID NO:71 is a clone designated herein as "DNA48336-1309".

Figure 72 shows the amino acid sequence (SEQ ID NO:72) derived from the coding sequence of SEQ ID NO:71 shown in Figure 71.

15 Figure 73 shows a nucleotide sequence (SEQ ID NO:73) of a native sequence PRO1120 cDNA, wherein SEQ ID NO:73 is a clone designated herein as "DNA48606-1479".

Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:73 shown in Figure 73.

20 Figure 75 shows a nucleotide sequence (SEQ ID NO:75) of a native sequence PRO7261 cDNA, wherein SEQ ID NO:75 is a clone designated herein as "DNA49149".

Figure 76 shows the amino acid sequence (SEQ ID NO:76) derived from the coding sequence of SEQ ID NO:75 shown in Figure 75.

Figure 77 shows a nucleotide sequence (SEQ ID NO:77) of a native sequence PRO533 cDNA, wherein SEQ ID NO:77 is a clone designated herein as "DNA49435-1219".

25 Figure 78 shows the amino acid sequence (SEQ ID NO:78) derived from the coding sequence of SEQ ID NO:77 shown in Figure 77.

Figure 79 shows a nucleotide sequence (SEQ ID NO:79) of a native sequence PRO724 cDNA, wherein SEQ ID NO:79 is a clone designated herein as "DNA49631-1328".

30 Figure 80 shows the amino acid sequence (SEQ ID NO:80) derived from the coding sequence of SEQ ID NO:79 shown in Figure 79.

Figure 81 shows a nucleotide sequence (SEQ ID NO:81) of a native sequence PRO734 cDNA, wherein SEQ ID NO:81 is a clone designated herein as "DNA49817".

Figure 82 shows the amino acid sequence (SEQ ID NO:82) derived from the coding sequence of SEQ ID NO:81 shown in Figure 81.

35 Figure 83 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PRO771 cDNA, wherein SEQ ID NO:83 is a clone designated herein as "DNA49829-1346".

Figure 84 shows the amino acid sequence (SEQ ID NO:84) derived from the coding sequence of SEQ ID

NO:83 shown in Figure 83.

Figure 85 shows a nucleotide sequence (SEQ ID NO:85) of a native sequence PRO2010 cDNA, wherein SEQ ID NO:85 is a clone designated herein as "DNA50792".

5 Figure 86 shows the amino acid sequence (SEQ ID NO:86) derived from the coding sequence of SEQ ID NO:85 shown in Figure 85.

Figure 87 shows a nucleotide sequence (SEQ ID NO:87) of a native sequence PRO871 cDNA, wherein SEQ ID NO:87 is a clone designated herein as "DNA50919-1361".

Figure 88 shows the amino acid sequence (SEQ ID NO:88) derived from the coding sequence of SEQ ID NO:87 shown in Figure 87.

10 Figure 89 shows a nucleotide sequence (SEQ ID NO:89) of a native sequence PRO697 cDNA, wherein SEQ ID NO:89 is a clone designated herein as "DNA50920-1325".

Figure 90 shows the amino acid sequence (SEQ ID NO:90) derived from the coding sequence of SEQ ID NO:89 shown in Figure 89.

15 Figure 91 shows a nucleotide sequence (SEQ ID NO:91) of a native sequence PRO1083 cDNA, wherein SEQ ID NO:91 is a clone designated herein as "DNA50921-1458".

Figure 92 shows the amino acid sequence (SEQ ID NO:92) derived from the coding sequence of SEQ ID NO:91 shown in Figure 91.

Figure 93 shows a nucleotide sequence (SEQ ID NO:93) of a native sequence PRO725 cDNA, wherein SEQ ID NO:93 is a clone designated herein as "DNA52758-1399".

20 Figure 94 shows the amino acid sequence (SEQ ID NO:94) derived from the coding sequence of SEQ ID NO:93 shown in Figure 93.

Figure 95 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO720 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "DNA53517-1366-1".

25 Figure 96 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 95.

Figure 97 shows a nucleotide sequence (SEQ ID NO:97) of a native sequence PRO738 cDNA, wherein SEQ ID NO:97 is a clone designated herein as "DNA53915-1258".

Figure 98 shows the amino acid sequence (SEQ ID NO:98) derived from the coding sequence of SEQ ID NO:97 shown in Figure 97.

30 Figure 99 shows a nucleotide sequence (SEQ ID NO:99) of a native sequence PRO865 cDNA, wherein SEQ ID NO:99 is a clone designated herein as "DNA53974-1401".

Figure 100 shows the amino acid sequence (SEQ ID NO:100) derived from the coding sequence of SEQ ID NO:99 shown in Figure 99.

35 Figure 101 shows a nucleotide sequence (SEQ ID NO:101) of a native sequence PRO840 cDNA, wherein SEQ ID NO:101 is a clone designated herein as "DNA53987-1438".

Figure 102 shows the amino acid sequence (SEQ ID NO:102) derived from the coding sequence of SEQ ID NO:101 shown in Figure 101.

Figure 103 shows a nucleotide sequence (SEQ ID NO:103) of a native sequence PRO1080 cDNA, wherein SEQ ID NO:103 is a clone designated herein as "DNA56047-1456".

Figure 104 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO:103 shown in Figure 103.

5        Figure 105 shows a nucleotide sequence (SEQ ID NO:105) of a native sequence PRO1079 cDNA, wherein SEQ ID NO:105 is a clone designated herein as "DNA56050-1455".

Figure 106 shows the amino acid sequence (SEQ ID NO:106) derived from the coding sequence of SEQ ID NO:105 shown in Figure 105.

10       Figure 107 shows a nucleotide sequence (SEQ ID NO:107) of a native sequence PRO793 cDNA, wherein SEQ ID NO:107 is a clone designated herein as "DNA56110-1437".

Figure 108 shows the amino acid sequence (SEQ ID NO:108) derived from the coding sequence of SEQ ID NO:107 shown in Figure 107.

Figure 109 shows a nucleotide sequence (SEQ ID NO:109) of a native sequence PRO788 cDNA, wherein SEQ ID NO:109 is a clone designated herein as "DNA56405-1357".

15       Figure 110 shows the amino acid sequence (SEQ ID NO:110) derived from the coding sequence of SEQ ID NO:109 shown in Figure 109.

Figure 111 shows a nucleotide sequence (SEQ ID NO:111) of a native sequence PRO938 cDNA, wherein SEQ ID NO:111 is a clone designated herein as "DNA56433-1406".

20       Figure 112 shows the amino acid sequence (SEQ ID NO:112) derived from the coding sequence of SEQ ID NO:111 shown in Figure 111.

Figure 113 shows a nucleotide sequence (SEQ ID NO:113) of a native sequence PRO1012 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "DNA56439-1376".

Figure 114 shows the amino acid sequence (SEQ ID NO:114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 113.

25       Figure 115 shows a nucleotide sequence (SEQ ID NO:115) of a native sequence PRO1477 cDNA, wherein SEQ ID NO:115 is a clone designated herein as "DNA56529-1647".

Figure 116 shows the amino acid sequence (SEQ ID NO:116) derived from the coding sequence of SEQ ID NO:115 shown in Figure 115.

30       Figure 117 shows a nucleotide sequence (SEQ ID NO:117) of a native sequence PRO1134 cDNA, wherein SEQ ID NO:117 is a clone designated herein as "DNA56865-1491".

Figure 118 shows the amino acid sequence (SEQ ID NO:118) derived from the coding sequence of SEQ ID NO:117 shown in Figure 117.

Figure 119 shows a nucleotide sequence (SEQ ID NO:119) of a native sequence PRO162 cDNA, wherein SEQ ID NO:119 is a clone designated herein as "DNA56965-1356".

35       Figure 120 shows the amino acid sequence (SEQ ID NO:120) derived from the coding sequence of SEQ ID NO:119 shown in Figure 119.

Figure 121 shows a nucleotide sequence (SEQ ID NO:121) of a native sequence PRO1114 cDNA, wherein

SEQ ID NO:121 is a clone designated herein as "DNA57033-1403-1".

Figure 122 shows the amino acid sequence (SEQ ID NO:122) derived from the coding sequence of SEQ ID NO:121 shown in Figure 121.

5 Figure 123 shows a nucleotide sequence (SEQ ID NO:123) of a native sequence PRO828 cDNA, wherein SEQ ID NO:123 is a clone designated herein as "DNA57037-1444".

Figure 124 shows the amino acid sequence (SEQ ID NO:124) derived from the coding sequence of SEQ ID NO:123 shown in Figure 123.

Figure 125 shows a nucleotide sequence (SEQ ID NO:125) of a native sequence PRO827 cDNA, wherein SEQ ID NO:125 is a clone designated herein as "DNA57039-1402".

10 Figure 126 shows the amino acid sequence (SEQ ID NO:126) derived from the coding sequence of SEQ ID NO:125 shown in Figure 125.

Figure 127 shows a nucleotide sequence (SEQ ID NO:127) of a native sequence PRO1075 cDNA, wherein SEQ ID NO:127 is a clone designated herein as "DNA57689-1385".

15 Figure 128 shows the amino acid sequence (SEQ ID NO:128) derived from the coding sequence of SEQ ID NO:127 shown in Figure 127.

Figure 129 shows a nucleotide sequence (SEQ ID NO:129) of a native sequence PRO1007 cDNA, wherein SEQ ID NO:129 is a clone designated herein as "DNA57690-1374".

Figure 130 shows the amino acid sequence (SEQ ID NO:130) derived from the coding sequence of SEQ ID NO:129 shown in Figure 129.

20 Figure 131 shows a nucleotide sequence (SEQ ID NO:131) of a native sequence PRO826 cDNA, wherein SEQ ID NO:131 is a clone designated herein as "DNA57694-1341".

Figure 132 shows the amino acid sequence (SEQ ID NO:132) derived from the coding sequence of SEQ ID NO:131 shown in Figure 131.

25 Figure 133 shows a nucleotide sequence (SEQ ID NO:133) of a native sequence PRO819 cDNA, wherein SEQ ID NO:132 is a clone designated herein as "DNA57695-1340".

Figure 134 shows the amino acid sequence (SEQ ID NO:134) derived from the coding sequence of SEQ ID NO:133 shown in Figure 133.

Figure 135 shows a nucleotide sequence (SEQ ID NO:135) of a native sequence PRO1006 cDNA, wherein SEQ ID NO:135 is a clone designated herein as "DNA57699-1412".

30 Figure 136 shows the amino acid sequence (SEQ ID NO:136) derived from the coding sequence of SEQ ID NO:135 shown in Figure 135.

Figure 137 shows a nucleotide sequence (SEQ ID NO:137) of a native sequence PRO982 cDNA, wherein SEQ ID NO:137 is a clone designated herein as "DNA57700-1408".

35 Figure 138 shows the amino acid sequence (SEQ ID NO:138) derived from the coding sequence of SEQ ID NO:137 shown in Figure 137.

Figure 139 shows a nucleotide sequence (SEQ ID NO:139) of a native sequence PRO1005 cDNA, wherein SEQ ID NO:139 is a clone designated herein as "DNA57708-1411".



Figure 140 shows the amino acid sequence (SEQ ID NO:140) derived from the coding sequence of SEQ ID NO:139 shown in Figure 139.

Figure 141 shows a nucleotide sequence (SEQ ID NO:141) of a native sequence PRO791 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "DNA57838-1337".

5       Figure 142 shows the amino acid sequence (SEQ ID NO:142) derived from the coding sequence of SEQ ID NO:141 shown in Figure 141.

Figure 143 shows a nucleotide sequence (SEQ ID NO:143) of a native sequence PRO1071 cDNA, wherein SEQ ID NO:143 is a clone designated herein as "DNA58847-1383".

10       Figure 144 shows the amino acid sequence (SEQ ID NO:144) derived from the coding sequence of SEQ ID NO:143 shown in Figure 43.

Figure 145 shows a nucleotide sequence (SEQ ID NO:145) of a native sequence PRO1415 cDNA, wherein SEQ ID NO:145 is a clone designated herein as "DNA58852-1637".

Figure 146 shows the amino acid sequence (SEQ ID NO:146) derived from the coding sequence of SEQ ID NO:145 shown in Figure 145.

15       Figure 147 shows a nucleotide sequence (SEQ ID NO:147) of a native sequence PRO1054 cDNA, wherein SEQ ID NO:147 is a clone designated herein as "DNA58853-1423".

Figure 148 shows the amino acid sequence (SEQ ID NO:148) derived from the coding sequence of SEQ ID NO:147 shown in Figure 147.

20       Figure 149 shows a nucleotide sequence (SEQ ID NO:149) of a native sequence PRO1411 cDNA, wherein SEQ ID NO:149 is a clone designated herein as "DNA59212-1627".

Figure 150 shows the amino acid sequence (SEQ ID NO:150) derived from the coding sequence of SEQ ID NO:149 shown in Figure 149.

Figure 151 shows a nucleotide sequence (SEQ ID NO:151) of a native sequence PRO1184 cDNA, wherein SEQ ID NO:151 is a clone designated herein as "DNA59220-1514".

25       Figure 152 shows the amino acid sequence (SEQ ID NO:152) derived from the coding sequence of SEQ ID NO:151 shown in Figure 151.

Figure 153 shows a nucleotide sequence (SEQ ID NO:153) of a native sequence PRO1029 cDNA, wherein SEQ ID NO:153 is a clone designated herein as "DNA59493-1420".

30       Figure 154 shows the amino acid sequence (SEQ ID NO:154) derived from the coding sequence of SEQ ID NO:153 shown in Figure 153.

Figure 155 shows a nucleotide sequence (SEQ ID NO:155) of a native sequence PRO1139 cDNA, wherein SEQ ID NO:155 is a clone designated herein as "DNA59497-1496".

Figure 156 shows the amino acid sequence (SEQ ID NO:156) derived from the coding sequence of SEQ ID NO:155 shown in Figure 155.

35       Figure 157 shows a nucleotide sequence (SEQ ID NO:157) of a native sequence PRO1190 cDNA, wherein SEQ ID NO:157 is a clone designated herein as "DNA59586-1520".

Figure 158 shows the amino acid sequence (SEQ ID NO:158) derived from the coding sequence of SEQ

ID NO:157 shown in Figure 157.

Figure 159 shows a nucleotide sequence (SEQ ID NO:159) of a native sequence PRO1309 cDNA, wherein SEQ ID NO:159 is a clone designated herein as "DNA59588-1571".

5 Figure 160 shows the amino acid sequence (SEQ ID NO:160) derived from the coding sequence of SEQ ID NO:159 shown in Figure 159.

Figure 161 shows a nucleotide sequence (SEQ ID NO:161) of a native sequence PRO836 cDNA, wherein SEQ ID NO:161 is a clone designated herein as "DNA59620-1463".

Figure 162 shows the amino acid sequence (SEQ ID NO:162) derived from the coding sequence of SEQ ID NO:161 shown in Figure 161.

10 Figure 163 shows a nucleotide sequence (SEQ ID NO:163) of a native sequence PRO1025 cDNA, wherein SEQ ID NO:163 is a clone designated herein as "DNA59622-1334".

Figure 164 shows the amino acid sequence (SEQ ID NO:164) derived from the coding sequence of SEQ ID NO:163 shown in Figure 163.

15 Figure 165 shows a nucleotide sequence (SEQ ID NO:165) of a native sequence PRO1131 cDNA, wherein SEQ ID NO:165 is a clone designated herein as "DNA59777-1480".

Figure 166 shows the amino acid sequence (SEQ ID NO:166) derived from the coding sequence of SEQ ID NO:165 shown in Figure 165.

Figure 167 shows a nucleotide sequence (SEQ ID NO:167) of a native sequence PRO1182 cDNA, wherein SEQ ID NO:167 is a clone designated herein as "DNA59848-1512".

20 Figure 168 shows the amino acid sequence (SEQ ID NO:168) derived from the coding sequence of SEQ ID NO:167 shown in Figure 167.

Figure 169 shows a nucleotide sequence (SEQ ID NO:169) of a native sequence PRO1155 cDNA, wherein SEQ ID NO:169 is a clone designated herein as "DNA59849-1504".

25 Figure 170 shows the amino acid sequence (SEQ ID NO:170) derived from the coding sequence of SEQ ID NO:169 shown in Figure 169.

Figure 171 shows a nucleotide sequence (SEQ ID NO:171) of a native sequence PRO1186 cDNA, wherein SEQ ID NO:171 is a clone designated herein as "DNA60621-1516".

Figure 172 shows the amino acid sequence (SEQ ID NO:172) derived from the coding sequence of SEQ ID NO:171 shown in Figure 171.

30 Figure 173 shows a nucleotide sequence (SEQ ID NO:173) of a native sequence PRO1198 cDNA, wherein SEQ ID NO:173 is a clone designated herein as "DNA60622-1525".

Figure 174 shows the amino acid sequence (SEQ ID NO:174) derived from the coding sequence of SEQ ID NO:173 shown in Figure 173.

35 Figure 175 shows a nucleotide sequence (SEQ ID NO:175) of a native sequence PRO1265 cDNA, wherein SEQ ID NO:175 is a clone designated herein as "DNA60764-1533".

Figure 176 shows the amino acid sequence (SEQ ID NO:176) derived from the coding sequence of SEQ ID NO:175 shown in Figure 175.

Figure 177 shows a nucleotide sequence (SEQ ID NO:177) of a native sequence PRO1361 cDNA, wherein SEQ ID NO:177 is a clone designated herein as "DNA60783-1611".

Figure 178 shows the amino acid sequence (SEQ ID NO:178) derived from the coding sequence of SEQ ID NO:177 shown in Figure 177.

5        Figure 179 shows a nucleotide sequence (SEQ ID NO:179) of a native sequence PRO1287 cDNA, wherein SEQ ID NO:179 is a clone designated herein as "DNA61755-1554".

Figure 180 shows the amino acid sequence (SEQ ID NO:180) derived from the coding sequence of SEQ ID NO:179 shown in Figure 179.

10       Figure 181 shows a nucleotide sequence (SEQ ID NO:181) of a native sequence PRO1308 cDNA, wherein SEQ ID NO:181 is a clone designated herein as "DNA62306-1570".

Figure 182 shows the amino acid sequence (SEQ ID NO:182) derived from the coding sequence of SEQ ID NO:181 shown in Figure 181.

Figure 183 shows a nucleotide sequence (SEQ ID NO:183) of a native sequence PRO4313 cDNA, wherein SEQ ID NO:183 is a clone designated herein as "DNA62312-2558".

15       Figure 184 shows the amino acid sequence (SEQ ID NO:184) derived from the coding sequence of SEQ ID NO:183 shown in Figure 183.

Figure 185 shows a nucleotide sequence (SEQ ID NO:185) of a native sequence PRO1192 cDNA, wherein SEQ ID NO:185 is a clone designated herein as "DNA62814-1521".

20       Figure 186 shows the amino acid sequence (SEQ ID NO:186) derived from the coding sequence of SEQ ID NO:185 shown in Figure 185.

Figure 187 shows a nucleotide sequence (SEQ ID NO:187) of a native sequence PRO1160 cDNA, wherein SEQ ID NO:187 is a clone designated herein as "DNA62872-1509".

Figure 188 shows the amino acid sequence (SEQ ID NO:188) derived from the coding sequence of SEQ ID NO:187 shown in Figure 187.

25       Figure 189 shows a nucleotide sequence (SEQ ID NO:189) of a native sequence PRO1244 cDNA, wherein SEQ ID NO:189 is a clone designated herein as "DNA64883-1526".

Figure 190 shows the amino acid sequence (SEQ ID NO:190) derived from the coding sequence of SEQ ID NO:189 shown in Figure 189.

30       Figure 191 shows a nucleotide sequence (SEQ ID NO:191) of a native sequence PRO1356 cDNA, wherein SEQ ID NO:191 is a clone designated herein as "DNA64886-1601".

Figure 192 shows the amino acid sequence (SEQ ID NO:192) derived from the coding sequence of SEQ ID NO:191 shown in Figure 191.

Figure 193 shows a nucleotide sequence (SEQ ID NO:193) of a native sequence PRO1274 cDNA, wherein SEQ ID NO:193 is a clone designated herein as "DNA64889-1541".

35       Figure 194 shows the amino acid sequence (SEQ ID NO:194) derived from the coding sequence of SEQ ID NO:193 shown in Figure 193.

Figure 195 shows a nucleotide sequence (SEQ ID NO:195) of a native sequence PRO1272 cDNA, wherein

SEQ ID NO:195 is a clone designated herein as "DNA64896-1539".

Figure 196 shows the amino acid sequence (SEQ ID NO:196) derived from the coding sequence of SEQ ID NO:195 shown in Figure 195.

5 Figure 197 shows a nucleotide sequence (SEQ ID NO:197) of a native sequence PRO1412 cDNA, wherein SEQ ID NO:197 is a clone designated herein as "DNA64897-1628".

Figure 198 shows the amino acid sequence (SEQ ID NO:198) derived from the coding sequence of SEQ ID NO:197 shown in Figure 197.

Figure 199 shows a nucleotide sequence (SEQ ID NO:199) of a native sequence PRO1286 cDNA, wherein SEQ ID NO:199 is a clone designated herein as "DNA64903-1553".

10 Figure 200 shows the amino acid sequence (SEQ ID NO:200) derived from the coding sequence of SEQ ID NO:199 shown in Figure 199.

Figure 201 shows a nucleotide sequence (SEQ ID NO:201) of a native sequence PRO1347 cDNA, wherein SEQ ID NO:201 is a clone designated herein as "DNA64950-1590".

15 Figure 202 shows the amino acid sequence (SEQ ID NO:202) derived from the coding sequence of SEQ ID NO:201 shown in Figure 201.

Figure 203 shows a nucleotide sequence (SEQ ID NO:203) of a native sequence PRO1273 cDNA, wherein SEQ ID NO:203 is a clone designated herein as "DNA65402-1540".

Figure 204 shows the amino acid sequence (SEQ ID NO:204) derived from the coding sequence of SEQ ID NO:203 shown in Figure 203.

20 Figure 205 shows a nucleotide sequence (SEQ ID NO:205) of a native sequence PRO1283 cDNA, wherein SEQ ID NO:205 is a clone designated herein as "DNA65404-1551".

Figure 206 shows the amino acid sequence (SEQ ID NO:206) derived from the coding sequence of SEQ ID NO:205 shown in Figure 205.

25 Figure 207 shows a nucleotide sequence (SEQ ID NO:207) of a native sequence PRO1279 cDNA, wherein SEQ ID NO:207 is a clone designated herein as "DNA65405-1547".

Figure 208 shows the amino acid sequence (SEQ ID NO:208) derived from the coding sequence of SEQ ID NO:207 shown in Figure 207.

Figure 209 shows a nucleotide sequence (SEQ ID NO:209) of a native sequence PRO1306 cDNA, wherein SEQ ID NO:209 is a clone designated herein as "DNA65410-1569".

30 Figure 210 shows the amino acid sequence (SEQ ID NO:210) derived from the coding sequence of SEQ ID NO:209 shown in Figure 209.

Figure 211 shows a nucleotide sequence (SEQ ID NO:211) of a native sequence PRO1195 cDNA, wherein SEQ ID NO:211 is a clone designated herein as "DNA65412-1523".

35 Figure 212 shows the amino acid sequence (SEQ ID NO:212) derived from the coding sequence of SEQ ID NO:211 shown in Figure 211.

Figure 213 shows a nucleotide sequence (SEQ ID NO:213) of a native sequence PRO4995 cDNA, wherein SEQ ID NO:213 is a clone designated herein as "DNA66307-2661".

Figure 214 shows the amino acid sequence (SEQ ID NO:214) derived from the coding sequence of SEQ ID NO:213 shown in Figure 213.

Figure 215 shows a nucleotide sequence (SEQ ID NO:215) of a native sequence PRO1382 cDNA, wherein SEQ ID NO:215 is a clone designated herein as "DNA66526-1616".

5        Figure 216 shows the amino acid sequence (SEQ ID NO:216) derived from the coding sequence of SEQ ID NO:215 shown in Figure 215.

Figure 217 shows a nucleotide sequence (SEQ ID NO:217) of a native sequence PRO1325 cDNA, wherein SEQ ID NO:217 is a clone designated herein as "DNA66659-1593".

10       Figure 218 shows the amino acid sequence (SEQ ID NO:218) derived from the coding sequence of SEQ ID NO:217 shown in Figure 217.

Figure 219 shows a nucleotide sequence (SEQ ID NO:219) of a native sequence PRO1329 cDNA, wherein SEQ ID NO:219 is a clone designated herein as "DNA66660-1585".

Figure 220 shows the amino acid sequence (SEQ ID NO:220) derived from the coding sequence of SEQ ID NO:219 shown in Figure 219.

15       Figure 221 shows a nucleotide sequence (SEQ ID NO:221) of a native sequence PRO1338 cDNA, wherein SEQ ID NO:221 is a clone designated herein as "DNA66667-1596".

Figure 222 shows the amino acid sequence (SEQ ID NO:222) derived from the coding sequence of SEQ ID NO:221 shown in Figure 221.

20       Figure 223 shows a nucleotide sequence (SEQ ID NO:223) of a native sequence PRO1337 cDNA, wherein SEQ ID NO:223 is a clone designated herein as "DNA66672-1586".

Figure 224 shows the amino acid sequence (SEQ ID NO:224) derived from the coding sequence of SEQ ID NO:223 shown in Figure 223.

Figure 225 shows a nucleotide sequence (SEQ ID NO:225) of a native sequence PRO1343 cDNA, wherein SEQ ID NO:225 is a clone designated herein as "DNA66675-1587".

25       Figure 226 shows the amino acid sequence (SEQ ID NO:226) derived from the coding sequence of SEQ ID NO:225 shown in Figure 225.

Figure 227 shows a nucleotide sequence (SEQ ID NO:227) of a native sequence PRO1376 cDNA, wherein SEQ ID NO:227 is a clone designated herein as "DNA67300-1605".

30       Figure 228 shows the amino acid sequence (SEQ ID NO:228) derived from the coding sequence of SEQ ID NO:227 shown in Figure 227.

Figure 229 shows a nucleotide sequence (SEQ ID NO:229) of a native sequence PRO1434 cDNA, wherein SEQ ID NO:229 is a clone designated herein as "DNA68818-2536".

Figure 230 shows the amino acid sequence (SEQ ID NO:230) derived from the coding sequence of SEQ ID NO:229 shown in Figure 229.

35       Figure 231 shows a nucleotide sequence (SEQ ID NO:231) of a native sequence PRO3579 cDNA, wherein SEQ ID NO:231 is a clone designated herein as "DNA68862-2546".

Figure 232 shows the amino acid sequence (SEQ ID NO:232) derived from the coding sequence of SEQ

ID NO:231 shown in Figure 231.

Figure 233 shows a nucleotide sequence (SEQ ID NO:233) of a native sequence PRO1387 cDNA, wherein SEQ ID NO:233 is a clone designated herein as "DNA68872-1620".

5 Figure 234 shows the amino acid sequence (SEQ ID NO:234) derived from the coding sequence of SEQ ID NO:233 shown in Figure 233.

Figure 235 shows a nucleotide sequence (SEQ ID NO:235) of a native sequence PRO1419 cDNA, wherein SEQ ID NO:235 is a clone designated herein as "DNA71290-1630".

Figure 236 shows the amino acid sequence (SEQ ID NO:236) derived from the coding sequence of SEQ ID NO:235 shown in Figure 235.

10 Figure 237 shows a nucleotide sequence (SEQ ID NO:237) of a native sequence PRO1488 cDNA, wherein SEQ ID NO:237 is a clone designated herein as "DNA73736-1657".

Figure 238 shows the amino acid sequence (SEQ ID NO:238) derived from the coding sequence of SEQ ID NO:237 shown in Figure 237.

15 Figure 239 shows a nucleotide sequence (SEQ ID NO:239) of a native sequence PRO1474 cDNA, wherein SEQ ID NO:239 is a clone designated herein as "DNA73739-1645".

Figure 240 shows the amino acid sequence (SEQ ID NO:240) derived from the coding sequence of SEQ ID NO:239 shown in Figure 239.

Figure 241 shows a nucleotide sequence (SEQ ID NO:241) of a native sequence PRO1508 cDNA, wherein SEQ ID NO:241 is a clone designated herein as "DNA73742-1662".

20 Figure 242 shows the amino acid sequence (SEQ ID NO:242) derived from the coding sequence of SEQ ID NO:241 shown in Figure 241.

Figure 243 shows a nucleotide sequence (SEQ ID NO:243) of a native sequence PRO1754 cDNA, wherein SEQ ID NO:243 is a clone designated herein as "DNA76385-1692".

25 Figure 244 shows the amino acid sequence (SEQ ID NO:244) derived from the coding sequence of SEQ ID NO:243 shown in Figure 243.

Figure 245 shows a nucleotide sequence (SEQ ID NO:245) of a native sequence PRO1550 cDNA, wherein SEQ ID NO:245 is a clone designated herein as "DNA76393-1664".

Figure 246 shows the amino acid sequence (SEQ ID NO:246) derived from the coding sequence of SEQ ID NO:245 shown in Figure 245.

30 Figure 247 shows a nucleotide sequence (SEQ ID NO:247) of a native sequence PRO1758 cDNA, wherein SEQ ID NO:247 is a clone designated herein as "DNA76399-1700".

Figure 248 shows the amino acid sequence (SEQ ID NO:248) derived from the coding sequence of SEQ ID NO:247 shown in Figure 247.

35 Figure 249 shows a nucleotide sequence (SEQ ID NO:249) of a native sequence PRO1917 cDNA, wherein SEQ ID NO:249 is a clone designated herein as "DNA76400-2528".

Figure 250 shows the amino acid sequence (SEQ ID NO:250) derived from the coding sequence of SEQ ID NO:249 shown in Figure 249.

Figure 251 shows a nucleotide sequence (SEQ ID NO:251) of a native sequence PRO1787 cDNA, wherein SEQ ID NO:251 is a clone designated herein as "DNA76510-2504".

Figure 252 shows the amino acid sequence (SEQ ID NO:252) derived from the coding sequence of SEQ ID NO:251 shown in Figure 251.

5        Figure 253 shows a nucleotide sequence (SEQ ID NO:253) of a native sequence PRO1556 cDNA, wherein SEQ ID NO:253 is a clone designated herein as "DNA76529-1666".

Figure 254 shows the amino acid sequence (SEQ ID NO:254) derived from the coding sequence of SEQ ID NO:253 shown in Figure 253.

10       Figure 255 shows a nucleotide sequence (SEQ ID NO:255) of a native sequence PRO1760 cDNA, wherein SEQ ID NO:255 is a clone designated herein as "DNA76532-1702".

Figure 256 shows the amino acid sequence (SEQ ID NO:256) derived from the coding sequence of SEQ ID NO:255 shown in Figure 255.

Figure 257 shows a nucleotide sequence (SEQ ID NO:257) of a native sequence PRO1567 cDNA, wherein SEQ ID NO:257 is a clone designated herein as "DNA76541-1675".

15       Figure 258 shows the amino acid sequence (SEQ ID NO:258) derived from the coding sequence of SEQ ID NO:257 shown in Figure 257.

Figure 259 shows a nucleotide sequence (SEQ ID NO:259) of a native sequence PRO1600 cDNA, wherein SEQ ID NO:259 is a clone designated herein as "DNA77503-1686".

20       Figure 260 shows the amino acid sequence (SEQ ID NO:260) derived from the coding sequence of SEQ ID NO:259 shown in Figure 259.

Figure 261 shows a nucleotide sequence (SEQ ID NO:261) of a native sequence PRO1868 cDNA, wherein SEQ ID NO:261 is a clone designated herein as "DNA77624-2515".

Figure 262 shows the amino acid sequence (SEQ ID NO:262) derived from the coding sequence of SEQ ID NO:261 shown in Figure 261.

25       Figure 263 shows a nucleotide sequence (SEQ ID NO:263) of a native sequence PRO1890 cDNA, wherein SEQ ID NO:263 is a clone designated herein as "DNA79230-2525".

Figure 264 shows the amino acid sequence (SEQ ID NO:264) derived from the coding sequence of SEQ ID NO:263 shown in Figure 263.

30       Figure 265 shows a nucleotide sequence (SEQ ID NO:265) of a native sequence PRO1887 cDNA, wherein SEQ ID NO:265 is a clone designated herein as "DNA79862-2522".

Figure 266 shows the amino acid sequence (SEQ ID NO:265) derived from the coding sequence of SEQ ID NO:265 shown in Figure 265.

Figure 267 shows a nucleotide sequence (SEQ ID NO:267) of a native sequence PRO4353 cDNA, wherein SEQ ID NO:267 is a clone designated herein as "DNA80145-2594".

35       Figure 268 shows the amino acid sequence (SEQ ID NO:268) derived from the coding sequence of SEQ ID NO:267 shown in Figure 267.

Figure 269 shows a nucleotide sequence (SEQ ID NO:269) of a native sequence PRO1782 cDNA, wherein

SEQ ID NO:269 is a clone designated herein as "DNA80899-2501".

Figure 270 shows the amino acid sequence (SEQ ID NO:270) derived from the coding sequence of SEQ ID NO:269 shown in Figure 269.

5 Figure 271 shows a nucleotide sequence (SEQ ID NO:271) of a native sequence PRO1928 cDNA, wherein SEQ ID NO:271 is a clone designated herein as "DNA81754-2532".

Figure 272 shows the amino acid sequence (SEQ ID NO:272) derived from the coding sequence of SEQ ID NO:271 shown in Figure 271.

Figure 273 shows a nucleotide sequence (SEQ ID NO:273) of a native sequence PRO1865 cDNA, wherein SEQ ID NO:273 is a clone designated herein as "DNA81757-2512".

10 Figure 274 shows the amino acid sequence (SEQ ID NO:274) derived from the coding sequence of SEQ ID NO:273 shown in Figure 273.

Figure 275 shows a nucleotide sequence (SEQ ID NO:275) of a native sequence PRO4341 cDNA, wherein SEQ ID NO:275 is a clone designated herein as "DNA81761-2583".

15 Figure 276 shows the amino acid sequence (SEQ ID NO:276) derived from the coding sequence of SEQ ID NO:275 shown in Figure 275.

Figure 277 shows a nucleotide sequence (SEQ ID NO:277) of a native sequence PRO6714 cDNA, wherein SEQ ID NO:277 is a clone designated herein as "DNA82358-2738".

Figure 278 shows the amino acid sequence (SEQ ID NO:278) derived from the coding sequence of SEQ ID NO:277 shown in Figure 277.

20 Figure 279 shows a nucleotide sequence (SEQ ID NO:279) of a native sequence PRO5723 cDNA, wherein SEQ ID NO:279 is a clone designated herein as "DNA82361".

Figure 280 shows the amino acid sequence (SEQ ID NO:280) derived from the coding sequence of SEQ ID NO:279 shown in Figure 279.

25 Figure 281 shows a nucleotide sequence (SEQ ID NO:281) of a native sequence PRO3438 cDNA, wherein SEQ ID NO:281 is a clone designated herein as "DNA82364-2538".

Figure 282 shows the amino acid sequence (SEQ ID NO:282) derived from the coding sequence of SEQ ID NO:281 shown in Figure 281.

Figure 283 shows a nucleotide sequence (SEQ ID NO:283) of a native sequence PRO6071 cDNA, wherein SEQ ID NO:283 is a clone designated herein as "DNA82403-2959".

30 Figure 284 shows the amino acid sequence (SEQ ID NO:284) derived from the coding sequence of SEQ ID NO:283 shown in Figure 283.

Figure 285 shows a nucleotide sequence (SEQ ID NO:285) of a native sequence PRO1801 cDNA, wherein SEQ ID NO:285 is a clone designated herein as "DNA83500-2506".

35 Figure 286 shows the amino acid sequence (SEQ ID NO:286) derived from the coding sequence of SEQ ID NO:285 shown in Figure 285.

Figure 287 shows a nucleotide sequence (SEQ ID NO:287) of a native sequence PRO4324 cDNA, wherein SEQ ID NO:287 is a clone designated herein as "DNA83560-2569".



Figure 288 shows the amino acid sequence (SEQ ID NO:288) derived from the coding sequence of SEQ ID NO:287 shown in Figure 287.

Figure 289 shows a nucleotide sequence (SEQ ID NO:289) of a native sequence PRO4333 cDNA, wherein SEQ ID NO:289 is a clone designated herein as "DNA84210-2576".

5        Figure 290 shows the amino acid sequence (SEQ ID NO:290) derived from the coding sequence of SEQ ID NO:289 shown in Figure 289.

Figure 291 shows a nucleotide sequence (SEQ ID NO:291) of a native sequence PRO4405 cDNA, wherein SEQ ID NO:291 is a clone designated herein as "DNA84920-2614".

10       Figure 292 shows the amino acid sequence (SEQ ID NO:292) derived from the coding sequence of SEQ ID NO:291 shown in Figure 291.

Figure 293 shows a nucleotide sequence (SEQ ID NO:293) of a native sequence PRO4356 cDNA, wherein SEQ ID NO:293 is a clone designated herein as "DNA86576-2595".

Figure 294 shows the amino acid sequence (SEQ ID NO:294) derived from the coding sequence of SEQ ID NO:293 shown in Figure 293.

15       Figure 295 shows a nucleotide sequence (SEQ ID NO:295) of a native sequence PRO3444 cDNA, wherein SEQ ID NO:295 is a clone designated herein as "DNA87997".

Figure 296 shows the amino acid sequence (SEQ ID NO:296) derived from the coding sequence of SEQ ID NO:295 shown in Figure 295.

20       Figure 297 shows a nucleotide sequence (SEQ ID NO:297) of a native sequence PRO4302 cDNA, wherein SEQ ID NO:297 is a clone designated herein as "DNA92218-2554".

Figure 298 shows the amino acid sequence (SEQ ID NO:298) derived from the coding sequence of SEQ ID NO:297 shown in Figure 297.

Figure 299 shows a nucleotide sequence (SEQ ID NO:299) of a native sequence PRO4371 cDNA, wherein SEQ ID NO:299 is a clone designated herein as "DNA92233-2599".

25       Figure 300 shows the amino acid sequence (SEQ ID NO:300) derived from the coding sequence of SEQ ID NO:299 shown in Figure 299.

Figure 301 shows a nucleotide sequence (SEQ ID NO:301) of a native sequence PRO4354 cDNA, wherein SEQ ID NO:301 is a clone designated herein as "DNA92256-2596".

30       Figure 302 shows the amino acid sequence (SEQ ID NO:302) derived from the coding sequence of SEQ ID NO:301 shown in Figure 301.

Figure 303 shows a nucleotide sequence (SEQ ID NO:303) of a native sequence PRO5725 cDNA, wherein SEQ ID NO:303 is a clone designated herein as "DNA92265-2669".

Figure 304 shows the amino acid sequence (SEQ ID NO:304) derived from the coding sequence of SEQ ID NO:303 shown in Figure 303.

35       Figure 305 shows a nucleotide sequence (SEQ ID NO:305) of a native sequence PRO4408 cDNA, wherein SEQ ID NO:305 is a clone designated herein as "DNA92274-2617".

Figure 306 shows the amino acid sequence (SEQ ID NO:306) derived from the coding sequence of SEQ

ID NO:305 shown in Figure 305.

Figure 307 shows a nucleotide sequence (SEQ ID NO:307) of a native sequence PRO9940 cDNA, wherein SEQ ID NO:307 is a clone designated herein as "DNA92282".

5 Figure 308 shows the amino acid sequence (SEQ ID NO:308) derived from the coding sequence of SEQ ID NO:307 shown in Figure 307.

Figure 309 shows a nucleotide sequence (SEQ ID NO:309) of a native sequence PRO5737 cDNA, wherein SEQ ID NO:309 is a clone designated herein as "DNA92929-2534-1".

Figure 310 shows the amino acid sequence (SEQ ID NO:310) derived from the coding sequence of SEQ ID NO:309 shown in Figure 309.

10 Figure 311 shows a nucleotide sequence (SEQ ID NO:311) of a native sequence PRO4425 cDNA, wherein SEQ ID NO:311 is a clone designated herein as "DNA93011-2637".

Figure 312 shows the amino acid sequence (SEQ ID NO:312) derived from the coding sequence of SEQ ID NO:311 shown in Figure 311.

15 Figure 313 shows a nucleotide sequence (SEQ ID NO:313) of a native sequence PRO4345 cDNA, wherein SEQ ID NO:313 is a clone designated herein as "DNA94854-2586".

Figure 314 shows the amino acid sequence (SEQ ID NO:314) derived from the coding sequence of SEQ ID NO:313 shown in Figure 313.

Figure 315 shows a nucleotide sequence (SEQ ID NO:315) of a native sequence PRO4342 cDNA, wherein SEQ ID NO:315 is a clone designated herein as "DNA96787-2534-1".

20 Figure 316 shows the amino acid sequence (SEQ ID NO:316) derived from the coding sequence of SEQ ID NO:315 shown in Figure 315.

Figure 317 shows a nucleotide sequence (SEQ ID NO:317) of a native sequence PRO3562 cDNA, wherein SEQ ID NO:317 is a clone designated herein as "DNA96791".

25 Figure 318 shows the amino acid sequence (SEQ ID NO:318) derived from the coding sequence of SEQ ID NO:317 shown in Figure 317.

Figure 319 shows a nucleotide sequence (SEQ ID NO:319) of a native sequence PRO4422 cDNA, wherein SEQ ID NO:319 is a clone designated herein as "DNA96867-2620".

Figure 320 shows the amino acid sequence (SEQ ID NO:320) derived from the coding sequence of SEQ ID NO:319 shown in Figure 319.

30 Figure 321 shows a nucleotide sequence (SEQ ID NO:321) of a native sequence PRO5776 cDNA, wherein SEQ ID NO:321 is a clone designated herein as "DNA96872-2674".

Figure 322 shows the amino acid sequence (SEQ ID NO:322) derived from the coding sequence of SEQ ID NO:321 shown in Figure 321.

35 Figure 323 shows a nucleotide sequence (SEQ ID NO:323) of a native sequence PRO4430 cDNA, wherein SEQ ID NO:323 is a clone designated herein as "DNA96878-2626".

Figure 324 shows the amino acid sequence (SEQ ID NO:324) derived from the coding sequence of SEQ ID NO:323 shown in Figure 323.

Figure 325 shows a nucleotide sequence (SEQ ID NO:325) of a native sequence PRO4499 cDNA, wherein SEQ ID NO:325 is a clone designated herein as "DNA96889-2641".

Figure 326 shows the amino acid sequence (SEQ ID NO:326) derived from the coding sequence of SEQ ID NO:325 shown in Figure 325.

5        Figure 327 shows a nucleotide sequence (SEQ ID NO:327) of a native sequence PRO4503 cDNA, wherein SEQ ID NO:327 is a clone designated herein as "DNA100312-2645".

Figure 328 shows the amino acid sequence (SEQ ID NO:328) derived from the coding sequence of SEQ ID NO:327 shown in Figure 327.

10       Figure 329 shows a nucleotide sequence (SEQ ID NO:329) of a native sequence PRO10008 cDNA, wherein SEQ ID NO:329 is a clone designated herein as "DNA101921".

Figure 330 shows the amino acid sequence (SEQ ID NO:330) derived from the coding sequence of SEQ ID NO:329 shown in Figure 329.

Figure 331 shows a nucleotide sequence (SEQ ID NO:331) of a native sequence PRO5730 cDNA, wherein SEQ ID NO:331 is a clone designated herein as "DNA101926".

15       Figure 332 shows the amino acid sequence (SEQ ID NO:332) derived from the coding sequence of SEQ ID NO:331 shown in Figure 331.

Figure 333 shows a nucleotide sequence (SEQ ID NO:333) of a native sequence PRO6008 cDNA, wherein SEQ ID NO:333 is a clone designated herein as "DNA102844".

20       Figure 334 shows the amino acid sequence (SEQ ID NO:334) derived from the coding sequence of SEQ ID NO:333 shown in Figure 333.

Figure 335 shows a nucleotide sequence (SEQ ID NO:335) of a native sequence PRO4527 cDNA, wherein SEQ ID NO:335 is a clone designated herein as "DNA103197".

Figure 336 shows the amino acid sequence (SEQ ID NO:336) derived from the coding sequence of SEQ ID NO:335 shown in Figure 335.

25       Figure 337 shows a nucleotide sequence (SEQ ID NO:337) of a native sequence PRO4538 cDNA, wherein SEQ ID NO:337 is a clone designated herein as "DNA103208".

Figure 338 shows the amino acid sequence (SEQ ID NO:338) derived from the coding sequence of SEQ ID NO:337 shown in Figure 337.

30       Figure 339 shows a nucleotide sequence (SEQ ID NO:339) of a native sequence PRO4553 cDNA, wherein SEQ ID NO:339 is a clone designated herein as "DNA103223".

Figure 340 shows the amino acid sequence (SEQ ID NO:340) derived from the coding sequence of SEQ ID NO:339 shown in Figure 339.

Figure 341 shows a nucleotide sequence (SEQ ID NO:341) of a native sequence PRO6006 cDNA, wherein SEQ ID NO:341 is a clone designated herein as "DNA105782-2693".

35       Figure 342 shows the amino acid sequence (SEQ ID NO:342) derived from the coding sequence of SEQ ID NO:341 shown in Figure 341.

Figure 343 shows a nucleotide sequence (SEQ ID NO:343) of a native sequence PRO6029 cDNA, wherein

SEQ ID NO:343 is a clone designated herein as "DNA105849-2704".

Figure 344 shows the amino acid sequence (SEQ ID NO:344) derived from the coding sequence of SEQ ID NO:343 shown in Figure 343.

5 Figure 345 shows a nucleotide sequence (SEQ ID NO:345) of a native sequence PRO9821 cDNA, wherein SEQ ID NO:345 is a clone designated herein as "DNA108725-2766".

Figure 346 shows the amino acid sequence (SEQ ID NO:346) derived from the coding sequence of SEQ ID NO:345 shown in Figure 345.

Figure 347 shows a nucleotide sequence (SEQ ID NO:347) of a native sequence PRO9820 cDNA, wherein SEQ ID NO:347 is a clone designated herein as "DNA108769-2765".

10 Figure 348 shows the amino acid sequence (SEQ ID NO:348) derived from the coding sequence of SEQ ID NO:347 shown in Figure 347.

Figure 349 shows a nucleotide sequence (SEQ ID NO:349) of a native sequence PRO9771 cDNA, wherein SEQ ID NO:349 is a clone designated herein as "DNA119498-2965".

15 Figure 350 shows the amino acid sequence (SEQ ID NO:350) derived from the coding sequence of SEQ ID NO:349 shown in Figure 349.

Figure 351 shows a nucleotide sequence (SEQ ID NO:351) of a native sequence PRO7436 cDNA, wherein SEQ ID NO:351 is a clone designated herein as "DNA119535-2756".

Figure 352 shows the amino acid sequence (SEQ ID NO:352) derived from the coding sequence of SEQ ID NO:351 shown in Figure 351.

20 Figure 353 shows a nucleotide sequence (SEQ ID NO:353) of a native sequence PRO10096 cDNA, wherein SEQ ID NO:353 is a clone designated herein as "DNA125185-2806".

Figure 354 shows the amino acid sequence (SEQ ID NO:354) derived from the coding sequence of SEQ ID NO:353 shown in Figure 353.

25 Figure 355 shows a nucleotide sequence (SEQ ID NO:355) of a native sequence PRO19670 cDNA, wherein SEQ ID NO:355 is a clone designated herein as "DNA131639-2874".

Figure 356 shows the amino acid sequence (SEQ ID NO:356) derived from the coding sequence of SEQ ID NO:355 shown in Figure 355.

Figure 357 shows a nucleotide sequence (SEQ ID NO:357) of a native sequence PRO20044 cDNA, wherein SEQ ID NO:357 is a clone designated herein as "DNA139623-2893".

30 Figure 358 shows the amino acid sequence (SEQ ID NO:358) derived from the coding sequence of SEQ ID NO:357 shown in Figure 357.

Figure 359 shows a nucleotide sequence (SEQ ID NO:359) of a native sequence PRO9873 cDNA, wherein SEQ ID NO:359 is a clone designated herein as "DNA143076-2787".

35 Figure 360 shows the amino acid sequence (SEQ ID NO:360) derived from the coding sequence of SEQ ID NO:359 shown in Figure 359.

Figure 361 shows a nucleotide sequence (SEQ ID NO:361) of a native sequence PRO21366 cDNA, wherein SEQ ID NO:361 is a clone designated herein as "DNA143276-2975".

Figure 362 shows the amino acid sequence (SEQ ID NO:362) derived from the coding sequence of SEQ ID NO:361 shown in Figure 361.

Figure 363 shows a nucleotide sequence (SEQ ID NO:363) of a native sequence PRO20040 cDNA, wherein SEQ ID NO:363 is a clone designated herein as "DNA164625-2890".

5        Figure 364 shows the amino acid sequence (SEQ ID NO:364) derived from the coding sequence of SEQ ID NO:363 shown in Figure 363.

Figure 365 shows a nucleotide sequence (SEQ ID NO:365) of a native sequence PRO21184 cDNA, wherein SEQ ID NO:365 is a clone designated herein as "DNA167678-2963".

10       Figure 366 shows the amino acid sequence (SEQ ID NO:366) derived from the coding sequence of SEQ ID NO:365 shown in Figure 365.

Figure 367 shows a nucleotide sequence (SEQ ID NO:367) of a native sequence PRO21055 cDNA, wherein SEQ ID NO:367 is a clone designated herein as "DNA170021-2923".

Figure 368 shows the amino acid sequence (SEQ ID NO:368) derived from the coding sequence of SEQ ID NO:367 shown in Figure 367.

15       Figure 369 shows a nucleotide sequence (SEQ ID NO:369) of a native sequence PRO28631 cDNA, wherein SEQ ID NO:369 is a clone designated herein as "DNA170212-3000".

Figure 370 shows the amino acid sequence (SEQ ID NO:370) derived from the coding sequence of SEQ ID NO:369 shown in Figure 369.

20       Figure 371 shows a nucleotide sequence (SEQ ID NO:371) of a native sequence PRO21384 cDNA, wherein SEQ ID NO:371 is a clone designated herein as "DNA177313-2982".

Figure 372 shows the amino acid sequence (SEQ ID NO:372) derived from the coding sequence of SEQ ID NO:371 shown in Figure 371.

Figure 373 shows a nucleotide sequence (SEQ ID NO:373) of a native sequence PRO1449 cDNA, wherein SEQ ID NO:373 is a clone designated herein as "DNA64908-1163-1".

25       Figure 374 shows the amino acid sequence (SEQ ID NO:374) derived from the coding sequence of SEQ ID NO:373 shown in Figure 373.

30       Figure 375 shows wholemount in situ hybridization results on mouse embryos using a mouse orthologue of PRO1449 which has about 78% amino acid identity with PRO1449. The results show that PRO1449 orthologue is expressed in the developing vasculature. The cross-section further shows expression in endothelial cells and progenitors of endothelial cells.

Figure 376 shows that a PRO1449 orthologue having about 78% amino acid identity with PRO1449 is expressed in vasculature of many inflamed and diseased tissues, but is very low, or lacking, in normal adult vessels.

Figure 377 shows that a PRO1449 orthologue having about 78% amino acid identity with PRO1449 induces ectopic vessels in the eyes of chicken embryos.

35

## 5. Detailed Description of the Invention

### 5.1. Definitions

The phrases "cardiovascular, endothelial and angiogenic disorder", "cardiovascular, endothelial and angiogenic dysfunction", "cardiovascular, endothelial or angiogenic disorder" and "cardiovascular, endothelial or angiogenic dysfunction" are used interchangeably and refer in part to systemic disorders that affect vessels, such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins, and/or lymphatics. This would include indications that stimulate angiogenesis and/or cardiovascularization, and those that inhibit angiogenesis and/or cardiovascularization. Such disorders include, for example, arterial disease, such as atherosclerosis, hypertension, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon, aneurysms, and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular disorders such as peripheral vascular disease, cancer such as vascular tumors, e.g., hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's sarcoma, lymphangioma, and lymphangiosarcoma, tumor angiogenesis, trauma such as wounds, burns, and other injured tissue, implant fixation, scarring, ischemia reperfusion injury, rheumatoid arthritis, cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis. This would also include angina, myocardial infarctions such as acute myocardial infarctions, cardiac hypertrophy, and heart failure such as CHF.

"Hypertrophy", as used herein, is defined as an increase in mass of an organ or structure independent of natural growth that does not involve tumor formation. Hypertrophy of an organ or tissue is due either to an increase in the mass of the individual cells (true hypertrophy), or to an increase in the number of cells making up the tissue (hyperplasia), or both. Certain organs, such as the heart, lose the ability to divide shortly after birth. Accordingly, "cardiac hypertrophy" is defined as an increase in mass of the heart, which, in adults, is characterized by an increase in myocyte cell size and contractile protein content without concomitant cell division. The character of the stress responsible for inciting the hypertrophy, (e.g., increased preload, increased afterload, loss of myocytes, as in myocardial infarction, or primary depression of contractility), appears to play a critical role in determining the nature of the response. The early stage of cardiac hypertrophy is usually characterized morphologically by increases in the size of myofibrils and mitochondria, as well as by enlargement of mitochondria and nuclei. At this stage, while muscle cells are larger than normal, cellular organization is largely preserved. At a more advanced stage of cardiac hypertrophy, there are preferential increases in the size or number of specific organelles, such as mitochondria, and new contractile elements are added in localized areas of the cells, in an irregular manner. Cells subjected to long-standing hypertrophy show more obvious disruptions in cellular organization, including markedly enlarged nuclei with highly lobulated membranes, which displace adjacent myofibrils and cause breakdown of normal Z-band registration. The phrase "cardiac hypertrophy" is used to include all stages of the progression of this condition, characterized by various degrees of structural damage of the heart muscle, regardless of the underlying cardiac disorder. Hence, the term also includes physiological conditions instrumental in the development of cardiac hypertrophy, such as elevated blood pressure, aortic stenosis, or myocardial infarction.

"Heart failure" refers to an abnormality of cardiac function where the heart does not pump blood at the rate

needed for the requirements of metabolizing tissues. The heart failure can be caused by a number of factors, including ischemic, congenital, rheumatic, or idiopathic forms.

“Congestive heart failure” (CHF) is a progressive pathologic state where the heart is increasingly unable to supply adequate cardiac output (the volume of blood pumped by the heart over time) to deliver the oxygenated blood to peripheral tissues. As CHF progresses, structural and hemodynamic damages occur. While these damages have a variety of manifestations, one characteristic symptom is ventricular hypertrophy. CHF is a common end result of a number of various cardiac disorders.

“Myocardial infarction” generally results from atherosclerosis of the coronary arteries, often with superimposed coronary thrombosis. It may be divided into two major types: transmural infarcts, in which myocardial necrosis involves the full thickness of the ventricular wall, and subendocardial (nontransmural) infarcts, in which the necrosis involves the subendocardium, the intramural myocardium, or both, without extending all the way through the ventricular wall to the epicardium. Myocardial infarction is known to cause both a change in hemodynamic effects and an alteration in structure in the damaged and healthy zones of the heart. Thus, for example, myocardial infarction reduces the maximum cardiac output and the stroke volume of the heart. Also associated with myocardial infarction is a stimulation of the DNA synthesis occurring in the interstice as well as an increase in the formation of collagen in the areas of the heart not affected.

As a result of the increased stress or strain placed on the heart in prolonged hypertension due, for example, to the increased total peripheral resistance, cardiac hypertrophy has long been associated with “hypertension”. A characteristic of the ventricle that becomes hypertrophic as a result of chronic pressure overload is an impaired diastolic performance. Fouad *et al.*, J. Am. Coll. Cardiol., 4: 1500-1506 (1984); Smith *et al.*, J. Am. Coll. Cardiol., 5: 869-874 (1985). A prolonged left ventricular relaxation has been detected in early essential hypertension, in spite of normal or supranormal systolic function. Hartford *et al.*, Hypertension, 6: 329-338 (1984). However, there is no close parallelism between blood pressure levels and cardiac hypertrophy. Although improvement in left ventricular function in response to antihypertensive therapy has been reported in humans, patients variously treated with a diuretic (hydrochlorothiazide), a  $\beta$ -blocker (propranolol), or a calcium channel blocker (diltiazem), have shown reversal of left ventricular hypertrophy, without improvement in diastolic function. Inouye *et al.*, Am. J. Cardiol., 53: 1583-7 (1984).

Another complex cardiac disease associated with cardiac hypertrophy is “hypertrophic cardiomyopathy”. This condition is characterized by a great diversity of morphologic, functional, and clinical features (Maron *et al.*, N. Engl. J. Med., 316: 780-789 (1987); Spirito *et al.*, N. Engl. J. Med., 320: 749-755 (1989); Louie and Edwards, Prog. Cardiovasc. Dis., 36: 275-308 (1994); Wigle *et al.*, Circulation, 92: 1680-1692 (1995)), the heterogeneity of which is accentuated by the fact that it afflicts patients of all ages. Spirito *et al.*, N. Engl. J. Med., 336: 775-785 (1997). The causative factors of hypertrophic cardiomyopathy are also diverse and little understood. In general, mutations in genes encoding sarcomeric proteins are associated with hypertrophic cardiomyopathy. Recent data suggest that  $\beta$ -myosin heavy chain mutations may account for approximately 30 to 40 percent of cases of familial hypertrophic cardiomyopathy. Watkins *et al.*, N. Engl. J. Med., 326: 1108-1114 (1992); Schwartz *et al.*, Circulation, 91: 532-540 (1995); Marian and Roberts, Circulation, 92: 1336-1347 (1995); Thierfelder *et al.*, Cell, 77: 701-712

(1994); Watkins *et al.*, Nat. Gen., 11: 434-437 (1995). Besides  $\beta$ -myosin heavy chain, other locations of genetic mutations include cardiac troponin T, alpha topomyosin, cardiac myosin binding protein C, essential myosin light chain, and regulatory myosin light chain. See, Malik and Watkins, Curr. Opin. Cardiol., 12: 295-302 (1997).

Supravalvular "aortic stenosis" is an inherited vascular disorder characterized by narrowing of the ascending aorta, but other arteries, including the pulmonary arteries, may also be affected. Untreated aortic stenosis may lead to increased intracardiac pressure resulting in myocardial hypertrophy and eventually heart failure and death. The pathogenesis of this disorder is not fully understood, but hypertrophy and possibly hyperplasia of medial smooth muscle are prominent features of this disorder. It has been reported that molecular variants of the elastin gene are involved in the development and pathogenesis of aortic stenosis. U.S. Patent No. 5,650,282 issued July 22, 1997.

"Valvular regurgitation" occurs as a result of heart diseases resulting in disorders of the cardiac valves. Various diseases, like rheumatic fever, can cause the shrinking or pulling apart of the valve orifice, while other diseases may result in endocarditis, an inflammation of the endocardium or lining membrane of the atrioventricular orifices and operation of the heart. Defects such as the narrowing of the valve stenosis or the defective closing of the valve result in an accumulation of blood in the heart cavity or regurgitation of blood past the valve. If uncorrected, prolonged valvular stenosis or insufficiency may result in cardiac hypertrophy and associated damage to the heart muscle, which may eventually necessitate valve replacement.

The treatment of all these, and other cardiovascular, endothelial and angiogenic disorders, which may or may not be accompanied by cardiac hypertrophy, is encompassed by the present invention.

The terms "cancer", "cancerous", and "malignant" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma including adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer. The preferred cancers for treatment herein are breast, colon, lung, melanoma, ovarian, and others involving vascular tumors as noted above.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g.,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ ), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents, folic acid antagonists, anti-metabolites of nucleic acid metabolism, antibiotics, pyrimidine analogs, 5-fluorouracil, cisplatin, purine nucleosides, amines, amino acids, triazol nucleosides, or corticosteroids. Specific examples include Adriamycin, Doxorubicin, 5-Fluorouracil,



Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytosin, Taxol, Toxotere, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan, and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors, such as tamoxifen and onapristone.

A "growth-inhibitory agent" when used herein refers to a compound or composition that inhibits growth of a cell, such as an Wnt-overexpressing cancer cell, either *in vitro* or *in vivo*. Thus, the growth-inhibitory agent is one which significantly reduces the percentage of malignant cells in S phase. Examples of growth-inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13. Additional examples include tumor necrosis factor (TNF), an antibody capable of inhibiting or neutralizing the angiogenic activity of acidic or basic FGF or hepatocyte growth factor (HGF), an antibody capable of inhibiting or neutralizing the coagulant activities of tissue factor, protein C, or protein S (see, WO 91/01753, published 21 February 1991), or an antibody capable of binding to HER2 receptor (WO 89/06692), such as the 4D5 antibody (and functional equivalents thereof) (e.g., WO 92/22653).

"Treatment" is an intervention performed with the intention of preventing the development or altering the pathology of a cardiovascular, endothelial, and angiogenic disorder. The concept of treatment is used in the broadest sense, and specifically includes the prevention (prophylaxis), moderation, reduction, and curing of cardiovascular, endothelial, and angiogenic disorders of any stage. Accordingly, "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) or ameliorate a cardiovascular, endothelial, and angiogenic disorder such as hypertrophy. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. The disorder may result from any cause, including idiopathic, cardiopathic, or myotrophic causes, or ischemia or ischemic insults, such as myocardial infarction.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial effect, such as an anti-hypertrophic effect, for an extended period of time.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, pigs, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

The phrase "cardiovascular, endothelial or angiogenic agents" refers generically to any drug that acts in treating cardiovascular, endothelial, and angiogenic disorders. Examples of cardiovascular agents are those that promote vascular homeostasis by modulating blood pressure, heart rate, heart contractility, and endothelial and smooth muscle biology, all of which factors have a role in cardiovascular disease. Specific examples of these include angiotensin-II receptor antagonists; endothelin receptor antagonists such as, for example, BOSENTAN™ and MOXONODIN™; interferon-gamma (IFN-γ); des-aspartate-angiotensin I; thrombolytic agents, *e.g.*, streptokinase, urokinase, t-PA, and a t-PA variant specifically designed to have longer half-life and very high fibrin specificity, TNK t-PA (a T103N, N117Q, KHRR(296-299)AAAA t-PA variant, Keyt *et al.*, Proc. Natl. Acad. Sci. USA, 91: 3670-3674 (1994)); inotropic or hypertensive agents such as digoxigenin and β-adrenergic receptor blocking agents, *e.g.*, propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, and carvedilol; angiotensin converting enzyme (ACE) inhibitors, *e.g.*, quinapril, captopril, enalapril, ramipril, benazepril, fosinopril, and lisinopril; diuretics, *e.g.*, chlorothiazide, hydrochlorothiazide, hydroflumethazide, methylchlorothiazide, benzthiazide, dichlorphenamide, acetazolamide, and indapamide; and calcium channel blockers, *e.g.*, diltiazem, nifedipine, verapamil, nicardipine. One preferred category of this type is a therapeutic agent used for the treatment of cardiac hypertrophy or of a physiological condition instrumental in the development of cardiac hypertrophy, such as elevated blood pressure, aortic stenosis, or myocardial infarction.

"Angiogenic agents" and "endothelial agents" are active agents that promote angiogenesis and/or endothelial cell growth, or, if applicable, vasculogenesis. This would include factors that accelerate wound healing, such as growth hormone, insulin-like growth factor-I (IGF-I), VEGF, VIGF, PDGF, epidermal growth factor (EGF), CTGF and members of its family, FGF, and TGF-α and TGF-β.

"Angiostatic agents" are active agents that inhibit angiogenesis or vasculogenesis or otherwise inhibit or prevent growth of cancer cells. Examples include antibodies or other antagonists to angiogenic agents as defined above, such as antibodies to VEGF. They additionally include cytotherapeutic agents such as cytotoxic agents, chemotherapeutic agents, growth-inhibitory agents, apoptotic agents, and other agents to treat cancer, such as anti-HER-2, anti-CD20, and other bioactive and organic chemical agents.

In a pharmacological sense, in the context of the present invention, a "therapeutically effective amount" of an active agent such as a PRO polypeptide or agonist or antagonist thereto or an anti-PRO antibody, refers to an amount effective in the treatment of a cardiovascular, endothelial or angiogenic disorder in a mammal and can be determined empirically.

As used herein, an "effective amount" of an active agent such as a PRO polypeptide or agonist or antagonist thereto or an anti-PRO antibody, refers to an amount effective for carrying out a stated purpose, wherein such amounts may be determined empirically for the desired effect.

The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (*i.e.*, PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein

may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods.

5 A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.

15 The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

25 The approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen *et al.*, Prot. Eng., 10:1-6 (1997) and von Heinje *et al.*, Nucl. Acids Res., 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

35 "PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed

herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO variant polypeptides are at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150 or 200 amino acids in length and alternatively at least about 300 amino acids in length, or more.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a PRO sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program

ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations, Tables 2-3 demonstrate how to calculate the  
5 % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO".

Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program. However, % amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul *et al.*, Nucleic  
10 Acids Res., 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov>, or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix =  
15 BLOSUM62.

In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues  
25 in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

In addition, % amino acid sequence identity may also be determined using the WU-BLAST-2 computer program (Altschul *et al.*, Methods in Enzymology, 266:460-480 (1996)). Most of the WU-BLAST-2 search  
30 parameters are set to the default values. Those not set to default values, *i.e.*, the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. For purposes herein, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acids residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (*i.e.*, the sequence against which the PRO polypeptide of interest is being compared which may be a PRO  
35 variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an amino acid sequence A which

has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

5 "PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, a PRO variant  
10 polynucleotide will have at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or  
15 any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

Ordinarily, PRO variant polynucleotides are at least about 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 450, or 600 nucleotides in length and alternatively at least about 900 nucleotides in length, or more.

"Percent (%) nucleic acid sequence identity" with respect to the PRO polypeptide-encoding nucleic acid  
20 sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a PRO polypeptide-encoding nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign  
25 (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % nucleic acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1. The ALIGN-2 sequence comparison computer program was authored by  
30 Genentech, Inc., and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2  
35 program and do not vary.

For purposes herein, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that

has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4-5 demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA".

Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program. However, % nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul *et al.*, Nucleic Acids Res., 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.

In addition, % nucleic acid sequence identity values may also be generated using the WU-BLAST-2 computer program (Altschul *et al.*, Methods in Enzymology, 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, *i.e.*, the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. For purposes herein, a % nucleic acid sequence identity value is determined by dividing (a)

the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (*i.e.*, the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80% nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.

In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding the full-length PRO polypeptide as shown in the specification herein and accompanying figures. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.

"Isolated", when used to describe the various polypeptides disclosed herein, means a polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Preferably, the isolated polypeptide is free of association with all components with which it is naturally associated. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" nucleic acid molecule encoding a PRO polypeptide or an "isolated" nucleic acid molecule encoding an anti-PRO antibody is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the PRO-encoding nucleic acid or the natural source of the anti-PRO-encoding nucleic acid. Preferably, the isolated nucleic acid is free of association with all components with which it is naturally associated. An isolated PRO-encoding nucleic acid molecule or an isolated anti-PRO-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the PRO-encoding nucleic acid molecule or from the anti-PRO-encoding nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule encoding a PRO polypeptide or an isolated nucleic acid molecule encoding an anti-PRO antibody includes PRO-nucleic acid molecules or anti-PRO-nucleic acid molecules contained in cells that ordinarily express PRO polypeptides or anti-PRO antibodies where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked



coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize, for example, promoters, polyadenylation signals, and enhancers.

5 Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a PRO polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, 10 contiguous and in the same reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. 15 In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower 20 temperatures less so. For additional details and explanation of stringency of hybridization reactions, *see*, Ausubel *et al.*, Current Protocols in Molecular Biology (Wiley Interscience Publishers, 1995).

"Stringent conditions" or "high-stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as 25 formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA 30 at 55°C.

"Moderately-stringent conditions" may be identified as described by Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Press, 1989), and include the use of washing solution and hybridization conditions (*e.g.*, temperature, ionic strength, and % SDS) less stringent than those described above. 35 An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters

in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The modifier "epitope-tagged" when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

"Active" or "activity" in the context of PRO variants refers to form(s) of PRO proteins that retain the biologic and/or immunologic activities of a native or naturally-occurring PRO polypeptide.

"Biological activity" in the context of a molecule that antagonizes a PRO polypeptide that can be identified by the screening assays disclosed herein (*e.g.*, an organic or inorganic small molecule, peptide, etc.) is used to refer to the ability of such molecules to bind or complex with the PRO polypeptide identified herein, or otherwise interfere with the interaction of the PRO polypeptide with other cellular proteins or otherwise inhibits the transcription or translation of the PRO polypeptide. Particularly preferred biological activity includes cardiac hypertrophy, activity that acts on systemic disorders that affect vessels, such as diabetes mellitus, as well as diseases of the arteries, capillaries, veins, and/or lymphatics, and cancer.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes one or more of the biological activities of a native PRO polypeptide disclosed herein, for example, if applicable, its mitogenic or angiogenic activity. Antagonists of a PRO polypeptide may act by interfering with the binding of a PRO polypeptide to a cellular receptor, by incapacitating or killing cells that have been activated by a PRO polypeptide, or by interfering with vascular endothelial cell activation after binding of a PRO polypeptide to a cellular receptor. All such points of intervention by a PRO polypeptide antagonist shall be considered equivalent for purposes of this invention. The antagonists inhibit the mitogenic, angiogenic, or other biological activity of PRO polypeptides, and thus are useful for the treatment of diseases or disorders characterized by undesirable excessive neovascularization, including by way of example tumors, and especially solid malignant tumors, rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, and chronic inflammation. The antagonists also are useful for the treatment of diseases or disorders characterized by undesirable excessive vascular permeability, such as edema associated with brain tumors, ascites associated with malignancies, Meigs' syndrome, lung inflammation, nephrotic syndrome, pericardial effusion (such as that associated with pericarditis), and pleural effusion. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments, or amino acid sequence variants of native PRO polypeptides, peptides, small organic molecules, etc.

A "small molecule" is defined herein to have a molecular weight below about 500 daltons.

The term "PRO polypeptide receptor" as used herein refers to a cellular receptor for a PRO polypeptide, ordinarily a cell-surface receptor found on vascular endothelial cells, as well as variants thereof that retain the ability to bind a PRO polypeptide.

5 "Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules that lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas. The term "antibody" is used in the broadest sense and specifically covers, without limitation, intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (*e.g.*, bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.

10 "Native antibodies" and "native immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain ( $V_H$ ) followed by a number of constant domains. Each light chain has a variable domain at one end ( $V_L$ ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.

20 The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody to and for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a  $\beta$ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the  $\beta$ -sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies. *See, Kabat et al., NIH Publ. No.91-3242, Vol. I, pages 647-669 (1991).* The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

25 "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen-binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (*Zapata et al., Protein Eng., 8(10): 1057-1062 (1995)*); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

35 Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize

readily. Pepsin treatment yields an  $F(ab')_2$  fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the  $V_H$ - $V_L$  dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.  $F(ab')_2$  antibody fragments originally were produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( $\kappa$ ) and lambda ( $\lambda$ ), based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM; and several of these may be further divided into subclasses (isotypes), *e.g.*, IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called  $\alpha$ ,  $\delta$ ,  $\epsilon$ ,  $\gamma$ , and  $\mu$ , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler *et al.*, Nature, 256: 495 (1975), or may be made by recombinant DNA methods (*see, e.g.*, U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.*, Nature, 352: 624-628 (1991) and Marks *et al.*, J. Mol. Biol., 222: 581-597 (1991), for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. U.S. Patent No. 4,816,567; Morrison *et al.*, Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984).

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub>, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv FR residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody preferably also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, Nature, 321: 522-525 (1986); Reichmann *et al.*, Nature, 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992). The humanized antibody includes a PRIMATIZED™ antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.

"Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of an antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains that enables the sFv to form the desired structure for antigen binding. For a review of sFv see, Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenberg and Moore, eds. (Springer-Verlag: New York, 1994), pp. 269-315.

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) in the same polypeptide chain (V<sub>H</sub> - V<sub>L</sub>). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993).

An "isolated" antibody is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere

with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody *in situ* within recombinant cells, since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

An antibody that "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

The word "label" when used herein refers to a detectable compound or other composition that is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition that is detectable. Radionuclides that can serve as detectable labels include, for example, I-131, I-123, I-125, Y-90, Re-188, At-211, Cu-67, Bi-212, and Pd-109. The label may also be a non-detectable entity such as a toxin.

By "solid phase" is meant a non-aqueous matrix to which an antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant that is useful for delivery of a drug (such as the PRO polypeptide or antibodies thereto disclosed herein) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

As used herein, the term "immunoadhesin" designates antibody-like molecules that combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity that is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD, or IgM.

As shown below, Table 1 provides the complete source code for the ALIGN-2 sequence comparison computer program. This source code may be routinely compiled for use on a UNIX operating system to provide

the ALIGN-2 sequence comparison computer program.

5 In addition, Tables 2-5 show hypothetical exemplifications for using the below described method to determine % amino acid sequence identity (Tables 2-3) and % nucleic acid sequence identity (Tables 4-5) using the ALIGN-2 sequence comparison computer program, wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, "PRO-DNA" represents a hypothetical PRO-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA" nucleic acid molecule of interest is being compared, "X", "Y", and "Z" each represent different hypothetical amino acid residues and "N", "L" and "V" each  
10 represent different hypothetical nucleotides.

Table 1

```

/*
 *
 * C-C increased from 12 to 15
 * Z is average of EQ
 * B is average of ND
 * match with stop is _M; stop-stop = 0; J (joker) match = 0
 */
#define _M      -8      /* value of a match with a stop */

int      day[26][26] = {
/*      A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
/* A */      { 2, 0, -2, 0, 0, -4, 1, -1, -1, 0, -1, -2, -1, 0, _M, 1, 0, -2, 1, 1, 0, 0, -6, 0, -3, 0},
/* B */      { 0, 3, -4, 3, 2, -5, 0, 1, -2, 0, 0, -3, -2, 2, _M, -1, 1, 0, 0, 0, 0, -2, -5, 0, -3, 1},
/* C */      { -2, -4, 15, -5, -5, -4, -3, -3, -2, 0, -5, -6, -5, -4, _M, -3, -5, -4, 0, -2, 0, -2, -8, 0, 0, -5},
/* D */      { 0, 3, -5, 4, 3, -6, 1, 1, -2, 0, 0, -4, -3, 2, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 2},
/* E */      { 0, 2, -5, 3, 4, -5, 0, 1, -2, 0, 0, -3, -2, 1, _M, -1, 2, -1, 0, 0, 0, -2, -7, 0, -4, 3},
/* F */      { -4, -5, -4, -6, -5, 9, -5, -2, 1, 0, -5, 2, 0, -4, _M, -5, -5, -4, -3, -3, 0, -1, 0, 0, 7, -5},
/* G */      { 1, 0, -3, 1, 0, -5, 5, -2, -3, 0, -2, -4, -3, 0, _M, -1, -1, -3, 1, 0, 0, -1, -7, 0, -5, 0},
/* H */      { -1, 1, -3, 1, 1, -2, -2, 6, -2, 0, 0, -2, -2, 2, _M, 0, 3, 2, -1, -1, 0, -2, -3, 0, 0, 2},
/* I */      { -1, -2, -2, -2, -2, 1, -3, -2, 5, 0, -2, 2, 2, -2, _M, -2, -2, -2, -1, 0, 0, 4, -5, 0, -1, -2},
/* J */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* K */      { -1, 0, -5, 0, 0, -5, -2, 0, -2, 0, 5, -3, 0, 1, _M, -1, 1, 3, 0, 0, 0, -2, -3, 0, -4, 0},
/* L */      { -2, -3, -6, -4, -3, 2, -4, -2, 2, 0, -3, 6, 4, -3, _M, -3, -2, -3, -3, -1, 0, 2, -2, 0, -1, -2},
/* M */      { -1, -2, -5, -3, -2, 0, -3, -2, 2, 0, 0, 4, 6, -2, _M, -2, -1, 0, -2, -1, 0, 2, -4, 0, -2, -1},
/* N */      { 0, 2, -4, 2, 1, -4, 0, 2, -2, 0, 1, -3, -2, 2, _M, -1, 1, 0, 1, 0, 0, -2, -4, 0, -2, 1},
/* O */      { _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, 0, _M, _M, _M, _M, _M, _M, _M, _M, _M},
/* P */      { 1, -1, -3, -1, -1, -5, -1, 0, -2, 0, -1, -3, -2, -1, _M, 6, 0, 0, 1, 0, 0, -1, -6, 0, -5, 0},
/* Q */      { 0, 1, -5, 2, 2, -5, -1, 3, -2, 0, 1, -2, -1, 1, _M, 0, 4, 1, -1, -1, 0, -2, -5, 0, -4, 3},
/* R */      { -2, 0, -4, -1, -1, -4, -3, 2, -2, 0, 3, -3, 0, 0, _M, 0, 1, 6, 0, -1, 0, -2, 2, 0, -4, 0},
/* S */      { 1, 0, 0, 0, 0, -3, 1, -1, -1, 0, 0, -3, -2, 1, _M, 1, -1, 0, 2, 1, 0, -1, -2, 0, -3, 0},
/* T */      { 1, 0, -2, 0, 0, -3, 0, -1, 0, 0, 0, -1, -1, 0, _M, 0, -1, -1, 1, 3, 0, 0, -5, 0, -3, 0},
/* U */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */      { 0, -2, -2, -2, -2, -1, -1, -2, 4, 0, -2, 2, 2, -2, _M, -1, -2, -2, -1, 0, 0, 4, -6, 0, -2, -2},
/* W */      { -6, -5, -8, -7, -7, 0, -7, -3, -5, 0, -3, -2, -4, -4, _M, -6, -5, 2, -2, -5, 0, -6, 17, 0, 0, -6},
/* X */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */      { -3, -3, 0, -4, -4, 7, -5, 0, -1, 0, -4, -1, -2, -2, _M, -5, -4, -4, -3, -3, 0, -2, 0, 0, 10, -4},
/* Z */      { 0, 1, -5, 2, 3, -5, 0, 2, -2, 0, 0, -2, -1, 1, _M, 0, 3, 0, 0, 0, 0, -2, -6, 0, -4, 4}
};

```



**Table 1 (cont')**

```

/*
*/
#include <stdio.h>
#include <ctype.h>

#define MAXJMP      16      /* max jumps in a diag */
#define MAXGAP      24      /* don't continue to penalize gaps larger than this */
#define JMPS        1024    /* max jmps in an path */
#define MX          4       /* save if there's at least MX-1 bases since last jmp */

#define DMAT        3       /* value of matching bases */
#define DMIS        0       /* penalty for mismatched bases */
#define DINS0       8       /* penalty for a gap */
#define DINS1       1       /* penalty per base */
#define PINS0       8       /* penalty for a gap */
#define PINS1       4       /* penalty per residue */

struct jmp {
    short          n[MAXJMP];    /* size of jmp (neg for dely) */
    unsigned short x[MAXJMP];    /* base no. of jmp in seq x */
};
/* limits seq to 2^16-1 */

struct diag {
    int            score;        /* score at last jmp */
    long           offset;       /* offset of prev block */
    short          ijmp;         /* current jmp index */
    struct jmp     jp;          /* list of jmps */
};

struct path {
    int            spc;          /* number of leading spaces */
    short          n[JMPS];      /* size of jmp (gap) */
    int            x[JMPS];      /* loc of jmp (last elem before gap) */
};

char              *ofile;       /* output file name */
char              *namex[2];     /* seq names: getseqs( ) */
char              *prog;        /* prog name for err msgs */
char              *seqx[2];      /* seqs: getseqs( ) */
int               dmax;         /* best diag: nw( ) */
int               dmax0;        /* final diag */
int               dna;          /* set if dna: main( ) */
int               endgaps;       /* set if penalizing end gaps */
int               gapx, gapy;     /* total gaps in seqs */
int               len0, len1;     /* seq lens */
int               ngapx, ngapy;   /* total size of gaps */
int               smax;          /* max score: nw( ) */
int               *xbm;          /* bitmap for matching */
long              offset;        /* current offset in jmp file */
struct            diag          *dx;    /* holds diagonals */
struct            path          pp[2];  /* holds path for seqs */

char              *calloc( ), *malloc( ), *index( ), *strcpy( );
char              *getseq( ), *g_calloc( );

```

Table 1 (cont')

```

/* Needleman-Wunsch alignment program
 *
 * usage: progs file1 file2
 * where file1 and file2 are two dna or two protein sequences.
 * The sequences can be in upper- or lower-case and may contain ambiguity
 * Any lines beginning with ';', '>' or '<' are ignored
 * Max file length is 65535 (limited by unsigned short x in the jmp struct)
 * A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
 * Output is in the file "align.out"
 *
 * The program may create a tmp file in /tmp to hold info about traceback.
 * Original version developed under BSD 4.3 on a vax 8650
 */
#include "nw.h"
#include "day.h"

static _dbval[26] = {
    1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};

static _pbval[26] = {
    1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
    1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
    1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)
    int    ac;
    char   *av[];
{
    prog = av[0];
    if (ac != 3) {
        fprintf(stderr, "usage: %s file1 file2\n", prog);
        fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
        fprintf(stderr, "The sequences can be in upper- or lower-case\n");
        fprintf(stderr, "Any lines beginning with ';', '>' or '<' are ignored\n");
        fprintf(stderr, "Output is in the file \"align.out\"\n");
        exit(1);
    }
    namex[0] = av[1];
    namex[1] = av[2];
    seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
    xbm = (dna)? _dbval : _pbval;

    endgaps = 0;                /* 1 to penalize endgaps */
    ofile = "align.out";        /* output file */

    nw();                       /* fill in the matrix, get the possible jumps */
    readjumps();                /* get the actual jumps */
    print();                     /* print stats, alignment */

    cleanup(0);                 /* unlink any tmp files */
}

```

main

**Table 1 (cont')**

```

/* do the alignment, return best score: main( )
 * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
 * pro: PAM 250 values
 * When scores are equal, we prefer mismatches to any gap, prefer
 * a new gap to extending an ongoing gap, and prefer a gap in seqx
 * to a gap in seq y.
 */
nw( )
{
    char          *px, *py;          /* seqs and ptrs */
    int            *ndely, *dely;     /* keep track of dely */
    int            ndelx, delx;       /* keep track of delx */
    int            *tmp;              /* for swapping row0, row1 */
    int            mis;               /* score for each type */
    int            ins0, ins1;        /* insertion penalties */
    register       id;                /* diagonal index */
    register       ij;               /* jmp index */
    register       *col0, *col1;      /* score for curr, last row */
    register       xx, yy;            /* index into seqs */

    dx = (struct diag *)g_calloc("to get diags", len0+len1+1, sizeof(struct diag));

    ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
    dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
    col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
    col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
    ins0 = (dna)? DINS0 : PINS0;
    ins1 = (dna)? DINS1 : PINS1;

    smax = -10000;
    if (endgaps) {
        for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
            col0[yy] = dely[yy] = col0[yy-1] - ins1;
            ndely[yy] = yy;
        }
        col0[0] = 0; /* Waterman Bull Math Biol 84 */
    }
    else
        for (yy = 1; yy <= len1; yy++)
            dely[yy] = -ins0;

    /* fill in match matrix
     */
    for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
        /* initialize first entry in col
         */
        if (endgaps) {
            if (xx == 1)
                col1[0] = delx = -(ins0+ins1);
            else
                col1[0] = delx = col0[0] - ins1;
            ndelx = xx;
        }
        else {
            col1[0] = 0;
            delx = -ins0;
            ndelx = 0;
        }
    }
}

```

nw

Table 1 (cont')

...NW

```

for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
    mis = col0[yy-1];
    if (dna)
        mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
    else
        mis += _day[*px-'A'][*py-'A'];

    /* update penalty for del in x seq;
     * favor new del over ongong del
     * ignore MAXGAP if weighting endgaps
     */
    if (endgaps || ndely[yy] < MAXGAP) {
        if (col0[yy] - ins0 >= dely[yy]) {
            dely[yy] = col0[yy] - (ins0+ins1);
            ndely[yy] = 1;
        } else {
            dely[yy] -= ins1;
            ndely[yy]++;
        }
    } else {
        if (col0[yy] - (ins0+ins1) >= dely[yy]) {
            dely[yy] = col0[yy] - (ins0+ins1);
            ndely[yy] = 1;
        } else
            ndely[yy]++;
    }

    /* update penalty for del in y seq;
     * favor new del over ongong del
     */
    if (endgaps || ndelx < MAXGAP) {
        if (col1[yy-1] - ins0 >= delx) {
            delx = col1[yy-1] - (ins0+ins1);
            ndelx = 1;
        } else {
            delx -= ins1;
            ndelx++;
        }
    } else {
        if (col1[yy-1] - (ins0+ins1) >= delx) {
            delx = col1[yy-1] - (ins0+ins1);
            ndelx = 1;
        } else
            ndelx++;
    }

    /* pick the maximum score; we're favoring
     * mis over any del and delx over dely
     */

```

**Table 1 (cont')**

...nw

```

id = xx - yy + len1 - 1;
if (mis >= delx && mis >= dely[yy])
    coll[yy] = mis;
else if (delx >= dely[yy]) {
    coll[yy] = delx;
    ij = dx[id].ijmp;
    if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
    && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
        dx[id].ijmp++;
        if (++ij >= MAXJMP) {
            writejumps(id);
            ij = dx[id].ijmp = 0;
            dx[id].offset = offset;
            offset += sizeof(struct jmp) + sizeof(offset);
        }
        dx[id].jp.n[ij] = ndelx;
        dx[id].jp.x[ij] = xx;
        dx[id].score = delx;
    }
    else {
        coll[yy] = dely[yy];
        ij = dx[id].ijmp;
        if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
        && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++;
            if (++ij >= MAXJMP) {
                writejumps(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
            dx[id].jp.n[ij] = -ndely[yy];
            dx[id].jp.x[ij] = xx;
            dx[id].score = dely[yy];
        }
        if (xx == len0 && yy < len1) {
            /* last col
            */
            if (endgaps)
                coll[yy] -= ins0+ins1*(len1-yy);
            if (coll[yy] > smax) {
                smax = coll[yy];
                dmax = id;
            }
        }
    }
    if (endgaps && xx < len0)
        coll[yy-1] -= ins0+ins1*(len0-xx);
    if (coll[yy-1] > smax) {
        smax = coll[yy-1];
        dmax = id;
    }
    tmp = col0; col0 = coll; coll = tmp;
}
(void) free((char *)ndely);
(void) free((char *)dely);
(void) free((char *)col0);
(void) free((char *)coll);
}

```

Table 1 (cont')

```

/*
 *
 * print() -- only routine visible outside this module
 *
 * static:
 * getmat() -- trace back best path, count matches: print()
 * pr_align() -- print alignment of described in array p[]: print()
 * dumpblock() -- dump a block of lines with numbers, stars: pr_align()
 * nums() -- put out a number line: dumpblock()
 * putline() -- put out a line (name, [num], seq, [num]): dumpblock()
 * stars() -- put a line of stars: dumpblock()
 * stripname() -- strip any path and prefix from a seqname
 */

#include "nw.h"

#define SPC      3
#define P_LINE  256    /* maximum output line */
#define P_SPC    3      /* space between name or num and seq */

extern _day[26][26];
int olen;              /* set output line length */
FILE *fx;              /* output file */

print()
{
    int    lx, ly, firstgap, lastgap;    /* overlap */

    if ((fx = fopen(ofile, "w")) == 0) {
        fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1);
    }
    fprintf(fx, "<first sequence: %s (length = %d)\n", namex[0], len0);
    fprintf(fx, "<second sequence: %s (length = %d)\n", namex[1], len1);
    olen = 60;
    lx = len0;
    ly = len1;
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) { /* leading gap in x */
        pp[0].spc = firstgap = len1 - dmax - 1;
        ly -= pp[0].spc;
    }
    else if (dmax > len1 - 1) { /* leading gap in y */
        pp[1].spc = firstgap = dmax - (len1 - 1);
        lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) { /* trailing gap in x */
        lastgap = len0 - dmax0 - 1;
        lx -= lastgap;
    }
    else if (dmax0 > len0 - 1) { /* trailing gap in y */
        lastgap = dmax0 - (len0 - 1);
        ly -= lastgap;
    }
    getmat(lx, ly, firstgap, lastgap);
    pr_align();
}

```

print

Table 1 (cont')

```

/*
 * trace back the best path, count matches
 */
static
getmat(lx, ly, firstgap, lastgap)
    int      lx, ly;
    int      firstgap, lastgap;
/* "core" (minus endgaps) */
/* leading trailing overlap */
{
    int      nm, i0, i1, siz0, siz1;
    char     outx[32];
    double   pct;
    register n0, n1;
    register char *p0, *p1;

    /* get total matches, score
    */
    i0 = i1 = siz0 = siz1 = 0;
    p0 = seqx[0] + pp[1].spc;
    p1 = seqx[1] + pp[0].spc;
    n0 = pp[1].spc + 1;
    n1 = pp[0].spc + 1;

    nm = 0;
    while ( *p0 && *p1 ) {
        if (siz0) {
            p1++;
            n1++;
            siz0--;
        }
        else if (siz1) {
            p0++;
            n0++;
            siz1--;
        }
        else {
            if (xbm[*p0-'A'] & xbm[*p1-'A'])
                nm++;
            if (n0++ == pp[0].x[i0])
                siz0 = pp[0].n[i0++];
            if (n1++ == pp[1].x[i1])
                siz1 = pp[1].n[i1++];
            p0++;
            p1++;
        }
    }

    /* pct homology:
    * if penalizing endgaps, base is the shorter seq
    * else, knock off overhangs and take shorter core
    */
    if (endgaps)
        lx = (len0 < len1)? len0 : len1;
    else
        lx = (lx < ly)? lx : ly;
    pct = 100.*(double)nm/(double)lx;
    fprintf(fx, "\n");
    fprintf(fx, "< %d match%s in an overlap of %d: %.2f percent similarity\n",
        nm, (nm == 1)? "" : "es", lx, pct);
}

```

getmat

**Table 1 (cont')**

```

fprintf(fx, "< gaps in first sequence: %d", gapx);
if (gapx) {
    (void) sprintf(outx, "(%d %s%s)",
        ngapx, (dna)? "base": "residue", (ngapx == 1)? "": "s");
    fprintf(fx, "%s", outx);

    fprintf(fx, ", gaps in second sequence: %d", gapy);
    if (gapy) {
        (void) sprintf(outx, "(%d %s%s)",
            ngapy, (dna)? "base": "residue", (ngapy == 1)? "": "s");
        fprintf(fx, "%s", outx);
    }
    if (dna)
        fprintf(fx,
            "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
            smax, DMAT, DMIS, DINS0, DINS1);
    else
        fprintf(fx,
            "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
            smax, PINS0, PINS1);
    if (endgaps)
        fprintf(fx,
            "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
            firstgap, (dna)? "base": "residue", (firstgap == 1)? "": "s",
            lastgap, (dna)? "base": "residue", (lastgap == 1)? "": "s");
    else
        fprintf(fx, "<endgaps not penalized\n");
}

static      nm;          /* matches in core - for checking */
static      lmax;        /* lengths of stripped file names */
static      ij[2];       /* jmp index for a path */
static      nc[2];       /* number at start of current line */
static      ni[2];       /* current elem number - for gapping */
static      siz[2];
static char  *ps[2];      /* ptr to current element */
static char  *po[2];      /* ptr to next output char slot */
static char  out[2][P_LINE]; /* output line */
static char  star[P_LINE]; /* set by stars() */

/*
 * print alignment of described in struct path pp[]
 */
static
pr_align()
{
    int      nn;          /* char count */
    int      more;
    register i;

    for (i = 0, lmax = 0; i < 2; i++) {
        nn = stripname(name[i]);
        if (nn > lmax)
            lmax = nn;

        nc[i] = 1;
        ni[i] = 1;
        siz[i] = ij[i] = 0;
        ps[i] = seqx[i];
        po[i] = out[i];
    }
}

```

...getmat

pr\_align



**Table 1 (cont')****...pr\_align**

```

for (nn = nm = 0, more = 1; more;) {
    for (i = more = 0; i < 2; i++) {
        /*
         * do we have more of this sequence?
         */
        if (!*ps[i])
            continue;

        more++;

        if (pp[i].spc) { /* leading space */
            *po[i]++ = ' ';
            pp[i].spc--;
        }
        else if (siz[i]) { /* in a gap */
            *po[i]++ = '-';
            siz[i]--;
        }
        else { /* we're putting a seq element
                */
            *po[i] = *ps[i];
            if (islower(*ps[i]))
                *ps[i] = toupper(*ps[i]);
            po[i]++;
            ps[i]++;

            /*
             * are we at next gap for this seq?
             */
            if (ni[i] == pp[i].x[ij[i]]) {
                /*
                 * we need to merge all gaps
                 * at this location
                 */
                siz[i] = pp[i].n[ij[i]++];
                while (ni[i] == pp[i].x[ij[i]])
                    siz[i] += pp[i].n[ij[i]++];
            }
            ni[i]++;
        }
    }
    if (++nn == olen || !more && nn) {
        dumpblock();
        for (i = 0; i < 2; i++)
            po[i] = out[i];
        nn = 0;
    }
}

/*
 * dump a block of lines, including numbers, stars: pr_align()
 */
static
dumpblock()
{
    register i;

    for (i = 0; i < 2; i++)
        *po[i] = '\0';
}

```

**dumpblock**

Table 1 (cont')

...dumpblock

```

(void) putc('\n', fx);
for (i = 0; i < 2; i++) {
    if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' ')) {
        if (i == 0)
            nums(i);
        if (i == 0 && *out[1])
            stars( );
        putline(i);
        if (i == 0 && *out[1])
            fprintf(fx, star);
        if (i == 1)
            nums(i);
    }
}

/*
 * put out a number line: dumpblock( )
 */
static
nums(ix)
int      ix;      /* index in out[] holding seq line */
{
    char      nline[P_LINE];
    register  i, j;
    register char *pn, *px, *py;

    for (pn = nline, i = 0; i < lmax+P_SPC; i++, pn++)
        *pn = ' ';
    for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
        if (*py == ' ' || *py == '-')
            *pn = ' ';
        else {
            if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                j = (i < 0)? -i : i;
                for (px = pn; j /= 10, px--)
                    *px = j%10 + '0';
                if (i < 0)
                    *px = '-';
            }
            else
                *pn = ' ';
            i++;
        }
    }
    *pn = '\0';
    nc[ix] = i;
    for (pn = nline; *pn; pn++)
        (void) putc(*pn, fx);
    (void) putc('\n', fx);
}

/*
 * put out a line (name, [num], seq, [num]): dumpblock( )
 */
static
putline(ix)
int      ix;
{

```

nums

putline

Table 1 (cont')

...putline

```

int          i;
register char *px;

for (px = namex[ix], i = 0; *px && *px != ':'; px++, i++)
    (void) putc(*px, fx);
for (; i < lmax+P_SPC; i++)
    (void) putc(' ', fx);

/* these count from 1:
 * ni[] is current element (from 1)
 * nc[] is number at start of current line
 */
for (px = out[ix]; *px; px++)
    (void) putc(*px&0x7F, fx);
(void) putc('\n', fx);
}

```

```

/*
 * put a line of stars (seqs always in out[0], out[1]): dumpblock()
 */

```

```

static
stars()
{

```

stars

```

    int          i;
    register char *p0, *p1, cx, *px;

    if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
        !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
        return;
    px = star;
    for (i = lmax+P_SPC; i; i--)
        *px++ = ' ';

    for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
        if (isalpha(*p0) && isalpha(*p1)) {
            if (xbm[*p0-'A'] & xbm[*p1-'A']) {
                cx = '*';
                nm++;
            }
            else if (!dna && day[*p0-'A'][*p1-'A'] > 0)
                cx = '.';
            else
                cx = ' ';
        }
        else
            cx = ' ';
        *px++ = cx;
    }
    *px++ = '\n';
    *px = '\0';
}

```

**Table 1 (cont')**

```

/*
 * strip path or prefix from pn, return len: pr_align( )
 */
static
stripname(pn)
char    *pn;    /* file name (may be path) */
{
    register char    *px, *py;

    py = 0;
    for (px = pn; *px; px++)
        if (*px == '/')
            py = px + 1;
    if (py)
        (void) strcpy(pn, py);
    return(strlen(pn));
}

```

**stripname**

Table 1 (cont')

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
 * g_calloc() -- calloc() with error checkin
 * readjumps() -- get the good jumps, from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file: nw()
 */
#include "nw.h"
#include <sys/file.h>

char *jname = "/tmp/homgXXXXXX"; /* tmp file for jumps */
FILE *fj;

int cleanup(); /* cleanup tmp file */
long lseek();

/*
 * remove any tmp file if we blow
 */
cleanup(i)
int i;
{
    if (fj)
        (void) unlink(jname);
    exit(i);
}

/*
 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
char *
getseq(file, len)
char *file; /* file name */
int *len; /* seq len */
{
    char line[1024], *pseq;
    register char *px, *py;
    int natgc, tlen;
    FILE *fp;

    if ((fp = fopen(file, "r")) == 0) {
        fprintf(stderr, "%s: can't read %s\n", prog, file);
        exit(1);
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
        if (*line == ';' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n'; px++)
            if (isupper(*px) || islower(*px))
                tlen++;
    }
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc( ) failed to get %d bytes for %s\n", prog, tlen+6, file);
        exit(1);
    }
    pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';

```

cleanup

getseq

Table 1 (cont')

...getseq

```

py = pseq + 4;
*len = tlen;
rewind(fp);

while (fgets(line, 1024, fp)) {
    if (*line == ';' || *line == '<' || *line == '>')
        continue;
    for (px = line; *px != '\n'; px++) {
        if (isupper(*px))
            *py++ = *px;
        else if (islower(*px))
            *py++ = toupper(*px);
        if (index("ATGCU", *(py-1)))
            natgc++;
    }
    *py++ = '\0';
    *py = '\0';
    (void) fclose(fp);
    dna = natgc > (tlen/3);
    return(pseq+4);
}

```

```

char *
g_calloc(msg, nx, sz)
char *msg;          /* program, calling routine */
int nx, sz;         /* number and size of elements */
{
    char *px, *calloc();

    if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
        if (*msg) {
            fprintf(stderr, "%s: g_calloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
            exit(1);
        }
    }
    return(px);
}

```

g\_calloc

```

/*
 * get final jmps from dx[] or tmp file, set pp[], reset dmax: main( )
 */

```

```

readjmps()
{
    int fd = -1;
    int siz, i0, i1;
    register i, j, xx;

    if (fj) {
        (void) fclose(fj);
        if ((fd = open(jname, O_RDONLY, 0)) < 0) {
            fprintf(stderr, "%s: can't open( ) %s\n", prog, jname);
            cleanup(1);
        }
    }
    for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; i++) {
        while (1) {
            for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)
                ;
        }
    }
}

```

readjmps

**Table 1 (cont')****...readjumps**

```

    if (j < 0 && dx[dmax].offset && fj) {
        (void) lseek(fd, dx[dmax].offset, 0);
        (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
        (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
        dx[dmax].ijmp = MAXJMP-1;
    }
    else
        break;
}
if (i >= JMPS) {
    fprintf(stderr, "%s: too many gaps in alignment\n", prog);
    cleanup(1);
}
if (j >= 0) {
    siz = dx[dmax].jp.n[j];
    xx = dx[dmax].jp.x[j];
    dmax += siz;
    if (siz < 0) { /* gap in second seq */
        pp[1].n[i1] = -siz;
        xx += siz;
        /* id = xx - yy + len1 - 1
        */
        pp[1].x[i1] = xx - dmax + len1 - 1;
        gapy++;
        ngapy -= siz;
        /* ignore MAXGAP when doing endgaps */
        siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
        i1++;
    }
    else if (siz > 0) { /* gap in first seq */
        pp[0].n[i0] = siz;
        pp[0].x[i0] = xx;
        gapx++;
        ngapx += siz;
        /* ignore MAXGAP when doing endgaps */
        siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
        i0++;
    }
}
else
    break;
}

/* reverse the order of jumps
*/
for (j = 0, i0--; j < i0; j++, i0--) {
    i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
    i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
}
for (j = 0, i1--; j < i1; j++, i1--) {
    i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
    i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
}
if (fd >= 0)
    (void) close(fd);
if (fj) {
    (void) unlink(jname);
    fj = 0;
    offset = 0;
}
}

```

**Table 1 (cont')**

```

/*
 * write a filled jmp struct offset of the prev one (if any): nw( )
 */
writejumps(ix)                                writejumps
{
    int ix;
    char *mktemp( );
    if (!fj) {
        if (mktemp(jname) < 0) {
            fprintf(stderr, "%s: can't mktemp( ) %s\n", prog, jname);
            cleanup(1);
        }
        if ((fj = fopen(jname, "w")) == 0) {
            fprintf(stderr, "%s: can't write %s\n", prog, jname);
            exit(1);
        }
    }
    (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
    (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
}

```



Table 2

PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXXXYYYYYY	(Length = 12 amino acids)

5      % amino acid sequence identity =  
 (the number of identically matching amino acid residues between the two polypeptide sequences as determined by  
 ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =  
 5 divided by 15 = 33.3%

Table 3

PRO	XXXXXXXXXX	(Length = 10 amino acids)
Comparison Protein	XXXXXXXXYYYYYYZZYZ	(Length = 15 amino acids)

10      % amino acid sequence identity =  
 (the number of identically matching amino acid residues between the two polypeptide sequences as determined by  
 ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =  
 5 divided by 10 = 50%

Table 4

20      PRO-DNA	NNNNNNNNNNNNNN	(Length = 14 nucleotides)
Comparison DNA	NNNNNNLLLLLLLLLL	(Length = 16 nucleotides)

15      % nucleic acid sequence identity =  
 (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-  
 2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =  
 6 divided by 14 = 42.9%

Table 5

30      PRO-DNA	NNNNNNNNNNNN	(Length = 12 nucleotides)
Comparison DNA	NNNNLLLVV	(Length = 9 nucleotides)

35      % nucleic acid sequence identity =  
 (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-  
 2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =  
 4 divided by 12 = 33.3%

## 5.2. Compositions and Methods of the Invention

### 5.2.1. PRO Variants

5 In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO polypeptide such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

10 Variations in the native full-length sequence PRO polypeptide or in various domains of the PRO polypeptide described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO polypeptide that results in a change in the amino acid sequence of the PRO polypeptide as compared with the native sequence PRO polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO polypeptide. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO polypeptide with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, *i.e.*, conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 15 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

20 In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

	Original Residue	Exemplary Substitutions	Preferred Substitutions
5	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
	Gln (Q)	asn	asn
10	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
15	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala; tyr	leu
20	Pro (P)	ala	ala
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
25	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilic: cys, ser, thr;

(3) acidic: asp, glu;

(4) basic: asn, gln, his, lys, arg;

(5) residues that influence chain orientation: gly, pro; and

(6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter *et al.*, Nucl. Acids Res., 13:4331 (1986); Zoller *et al.*, Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells *et al.*, Gene, 34:315 (1985)], restriction selection mutagenesis [Wells *et al.*, Philos. Trans. R. Soc. London SerA, 317:415

(1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

#### 5.2.2. Modifications of PRO Polypeptides

Covalent modifications of PRO polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking the PRO polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in the native sequence PRO polypeptide (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO polypeptide. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO polypeptide (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino

acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

5 Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, *et al.*, Arch. Biochem. Biophys., 259:52 (1987) and by Edge *et al.*, Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and  
10 exo-glycosidases as described by Thotakura *et al.*, Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of the PRO polypeptide comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

15 The PRO polypeptide of the present invention may also be modified in a way to form a chimeric molecule comprising the PRO polypeptide fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the PRO polypeptide with a protein transduction domain which targets the PRO polypeptide for delivery to various tissues and more particularly across the brain blood barrier, using, for example, the protein transduction domain of human immunodeficiency virus TAT  
20 protein (Schwarze *et al.*, 1999, *Science* 285: 1569-72).

In another embodiment, such a chimeric molecule comprises a fusion of the PRO polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO polypeptide. The presence of such epitope-tagged forms of the PRO polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of  
25 the epitope tag enables the PRO polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-His) or poly-histidine-glycine (poly-His-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field *et al.*, Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan *et al.*, Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky *et al.*, Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp  
30 *et al.*, BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin *et al.*, Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner *et al.*, J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth *et al.*, Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

35 In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions

preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions *see* also, U.S. Patent No. 5,428,130 issued June 27, 1995.

5                                    5.2.3.    Preparation of the PRO Polypeptide

10                                    The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed. However, for sake of simplicity, in the present specification the protein encoded by the PRO DNA as well as all further native homologues and variants included in the foregoing definition of PRO polypeptides, will be referred to as "PRO" regardless of their origin or mode of preparation.

15                                    The description below relates primarily to production of PRO polypeptides by culturing cells transformed or transfected with a vector containing nucleic acid encoding PRO polypeptides. It is, of course, contemplated that alternative methods that are well known in the art may be employed to prepare the PRO polypeptide. For instance, the PRO polypeptide sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques. *See, e.g.,* Stewart *et al.*, Solid-Phase Peptide Synthesis (W.H. Freeman Co.: San Francisco, CA, 1969); Merrifield, *J. Am. Chem. Soc.*, 85: 2149-2154 (1963). *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, with an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO polypeptide.

25                                    5.2.3.1: Isolation of DNA Encoding PRO Polypeptides

25                                    DNA encoding the PRO polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the mRNA encoding the PRO polypeptide and to express it at a detectable level. Accordingly, DNAs encoding the human PRO polypeptide can be conveniently obtained from cDNA libraries prepared from human tissues, such as described in the Examples. The gene encoding the PRO polypeptide may also be obtained from a genomic library or by oligonucleotide synthesis.

30                                    Libraries can be screened with probes (such as antibodies to the PRO polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook *et al.*, *supra*. An alternative means to isolate the gene encoding the PRO polypeptide is to use PCR methodology. Sambrook *et al.*, *supra*; Dieffenbach *et al.*, PCR Primer: A Laboratory Manual (New York: Cold

Spring Harbor Laboratory Press, 1995).

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation, or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook *et al.*, *supra*.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNASTar, and INHERIT, which employ various algorithms to measure homology.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook *et al.*, *supra*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

#### 5.2.3.2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for PRO polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook *et al.*, *supra*.

Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO<sub>4</sub> treatment and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook *et al.*, *supra*, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, Gene, **23**: 315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, **52**:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, J. Bact., **130**: 946 (1977) and Hsiao *et al.*, Proc. Natl. Acad. Sci. (USA), **76**: 3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, *e.g.*, polybrene or polyornithine, may also be used. For various techniques for

transforming mammalian cells, *see*, Keown *et al.*, Methods in Enzymology, 185: 527-537 (1990) and Mansour *et al.*, Nature, 336: 348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325); and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, *e.g.*, *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, *e.g.*, *Salmonella typhimurium*, *Serratia*, *e.g.*, *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (*e.g.*, *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan<sup>r</sup>*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan<sup>r</sup>*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, *e.g.*, PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding the PRO polypeptide. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer *et al.*, Bio/Technology, 9: 968-975 (1991)) such as, *e.g.*, *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt *et al.*, J. Bacteriol., 737 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg *et al.*, Bio/Technology, 8: 135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna *et al.*, J. Basic Microbiol., 28: 265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case *et al.*, Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, *e.g.*, *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, Biochem. Biophys. Res. Commun., 112: 284-289 [1983]; Tilburn *et al.*, Gene, 26: 205-221 [1983]; Yelton *et al.*, Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4: 475-479 [1985]). Methylophilic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*,



*Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylophs, 269 (1982).

Suitable host cells for the expression of nucleic acid encoding glycosylated PRO polypeptides are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, J. Gen. Virol., 36: 59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

#### 5.2.3.3. Selection and Use of a Replicable Vector

The nucleic acid (*e.g.*, cDNA or genomic DNA) encoding the PRO polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence if the sequence is to be secreted, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques that are known to the skilled artisan.

The PRO polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the PRO polypeptide that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, *e.g.*, the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin

is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding the PRO polypeptide such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub *et al.*, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7. Stinchcomb *et al.*, Nature, 282: 39 (1979); Kingsman *et al.*, Gene, 7: 141 (1979); Tschemper *et al.*, Gene, 10: 157 (1980). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977).

Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding the PRO polypeptide to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems (Chang *et al.*, Nature, 275: 615 (1978); Goeddel *et al.*, Nature, 281: 544 (1979)), alkaline phosphatase, a tryptophan (*trp*) promoter system (Goeddel, Nucleic Acids Res., 8: 4057 (1980); EP 36,776), and hybrid promoters such as the *tac* promoter (deBoer *et al.*, Proc. Natl. Acad. Sci. USA, 80: 21-25 (1983)). Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the PRO polypeptide.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, J. Biol. Chem., 255: 2073 (1980)) or other glycolytic enzymes (Hess *et al.*, J. Adv. Enzyme Reg., 7: 149 (1968); Holland, Biochemistry, 17: 4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters that are inducible promoters having the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

PRO nucleic acid transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, and Simian Virus 40 (SV40); by heterologous mammalian promoters, e.g., the actin

promoter or an immunoglobulin promoter; and by heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the PRO polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the sequence coding for PRO polypeptides, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the PRO polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of the PRO polypeptide in recombinant vertebrate cell culture are described in Gething *et al.*, Nature, 293: 620-625 (1981); Mantei *et al.*, Nature, 281: 40-46 (1979); EP 117,060; and EP 117,058.

#### 5.2.3.4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native-sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to DNA encoding the PRO polypeptide and encoding a specific antibody epitope.

#### 5.2.3.5. Purification of PRO Polypeptides

Forms of PRO polypeptides may be recovered from culture medium or from host cell lysates. If

membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., TRITON-X™ 100) or by enzymatic cleavage. Cells employed in expression of nucleic acid encoding the PRO polypeptide can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell-lysing agents. It may be desired to purify the PRO polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO polypeptide. Various methods of protein purification may be employed and such methods are known in the art and described, for example, in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice (Springer-Verlag: New York, 1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO polypeptide produced.

#### 5.2.4. Uses of PRO Polypeptides

##### 5.2.4.1. Assays for Cardiovascular, Endothelial, and Angiogenic Activity

Various assays can be used to test the polypeptide herein for cardiovascular, endothelial, and angiogenic activity. Such assays include those provided in the Examples below.

Assays for testing for endothelin antagonist activity, as disclosed in U.S. Pat. No. 5,773,414, include a rat heart ventricle binding assay where the polypeptide is tested for its ability to inhibit iodinated endothelin-1 binding in a receptor assay, an endothelin receptor binding assay testing for intact cell binding of radiolabeled endothelin-1 using rabbit renal artery vascular smooth muscle cells, an inositol phosphate accumulation assay where functional activity is determined in Rat-1 cells by measuring intra-cellular levels of second messengers, an arachidonic acid release assay that measures the ability of added compounds to reduce endothelin-stimulated arachidonic acid release in cultured vascular smooth muscles, *in vitro* (isolated vessel) studies using endothelium from male New Zealand rabbits, and *in vivo* studies using male Sprague-Dawley rats.

Assays for tissue generation activity include, without limitation, those described in WO 95/16035 (bone, cartilage, tendon); WO 95/05846 (nerve, neuronal), and WO 91/07491 (skin, endothelium).

Assays for wound-healing activity include, for example, those described in Winter, Epidermal Wound Healing, Maibach, HI and Rovee, DT, eds. (Year Book Medical Publishers, Inc., Chicago), pp. 71-112, as modified by the article of Eaglstein and Mertz, J. Invest. Dermatol., 71: 382-384 (1978).

An assay to screen for a test molecule relating to a PRO polypeptide that binds an endothelin B<sub>1</sub> (ETB<sub>1</sub>) receptor polypeptide and modulates signal transduction activity involves providing a host cell transformed with a DNA encoding endothelin B<sub>1</sub> receptor polypeptide, exposing the cells to the test candidate, and measuring endothelin B<sub>1</sub> receptor signal transduction activity, as described, e.g., in U.S. Pat. No. 5,773,223.

There are several cardiac hypertrophy assays. *In vitro* assays include induction of spreading of adult rat cardiac myocytes. In this assay, ventricular myocytes are isolated from a single (male Sprague-Dawley) rat,

essentially following a modification of the procedure described in detail by Piper *et al.*, "Adult ventricular rat heart muscle cells" in Cell Culture Techniques in Heart and Vessel Research, H.M. Piper, ed. (Berlin: Springer-Verlag, 1990), pp. 36-60. This procedure permits the isolation of adult ventricular myocytes and the long-term culture of these cells in the rod-shaped phenotype. Phenylephrine and Prostaglandin  $F_{2\alpha}$  ( $PGF_{2\alpha}$ ) have been shown to induce a spreading response in these adult cells. The inhibition of myocyte spreading induced by  $PGF_{2\alpha}$  or  $PGF_{2\alpha}$  analogs (e.g., fluprostenol) and phenylephrine by various potential inhibitors of cardiac hypertrophy is then tested.

One example of an *in vivo* assay is a test for inhibiting cardiac hypertrophy induced by fluprostenol *in vivo*. This pharmacological model tests the ability of the PRO polypeptide to inhibit cardiac hypertrophy induced in rats (e.g., male Wistar or Sprague-Dawley) by subcutaneous injection of fluprostenol (an agonist analog of  $PGF_{2\alpha}$ ). It is known that rats with pathologic cardiac hypertrophy induced by myocardial infarction have chronically elevated levels of extractable  $PGF_{2\alpha}$  in their myocardium. Lai *et al.*, Am. J. Physiol. (Heart Circ. Physiol.), 271: H2197-H2208 (1996). Accordingly, factors that can inhibit the effects of fluprostenol on myocardial growth *in vivo* are potentially useful for treating cardiac hypertrophy. The effects of the PRO polypeptide on cardiac hypertrophy are determined by measuring the weight of heart, ventricles, and left ventricle (normalized by body weight) relative to fluprostenol-treated rats not receiving the PRO polypeptide.

Another example of an *in vivo* assay is the pressure-overload cardiac hypertrophy assay. For *in vivo* testing it is common to induce pressure-overload cardiac hypertrophy by constriction of the abdominal aorta of test animals. In a typical protocol, rats (e.g., male Wistar or Sprague-Dawley) are treated under anesthesia, and the abdominal aorta of each rat is narrowed down just below the diaphragm. Beznak M., Can. J. Biochem. Physiol., 33: 985-94 (1955). The aorta is exposed through a surgical incision, and a blunted needle is placed next to the vessel. The aorta is constricted with a ligature of silk thread around the needle, which is immediately removed and which reduces the lumen of the aorta to the diameter of the needle. This approach is described, for example, in Rossi *et al.*, Am. Heart J., 124: 700-709 (1992) and O'Rourke and Reibel, P.S.E.M.B., 200: 95-100 (1992).

In yet another *in vivo* assay, the effect on cardiac hypertrophy following experimentally induced myocardial infarction (MI) is measured. Acute MI is induced in rats by left coronary artery ligation and confirmed by electrocardiographic examination. A sham-operated group of animals is also prepared as control animals. Earlier data have shown that cardiac hypertrophy is present in the group of animals with MI, as evidenced by an 18% increase in heart weight-to-body weight ratio. Lai *et al.*, *supra*. Treatment of these animals with candidate blockers of cardiac hypertrophy, e.g., the PRO polypeptide, provides valuable information about the therapeutic potential of the candidates tested. One further such assay test for induction of cardiac hypertrophy is disclosed in U.S. Pat. No. 5,773,415, using Sprague-Dawley rats.

For cancer, a variety of well-known animal models can be used to further understand the role of the genes identified herein in the development and pathogenesis of tumors, and to test the efficacy of candidate therapeutic agents, including antibodies and other antagonists of native PRO polypeptides, such as small-molecule antagonists. The *in vivo* nature of such models makes them particularly predictive of responses in human patients. Animal models of tumors and cancers (e.g., breast cancer, colon cancer, prostate cancer, lung cancer, etc.) include both non-recombinant and recombinant (transgenic) animals. Non-recombinant animal models include, for example,

rodent, *e.g.*, murine models. Such models can be generated by introducing tumor cells into syngeneic mice using standard techniques, *e.g.*, subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under the renal capsule, or orthotopic implantation, *e.g.*, colon cancer cells implanted in colonic tissue. *See, e.g.*, PCT publication No. WO 97/33551, published September 18, 1997. Probably the most  
5 often used animal species in oncological studies are immunodeficient mice and, in particular, nude mice. The observation that the nude mouse with thymic hypo/aplasia could successfully act as a host for human tumor xenografts has led to its widespread use for this purpose. The autosomal recessive *nu* gene has been introduced into a very large number of distinct congenic strains of nude mouse, including, for example, ASW, A/He, AKR, BALB/c, B10.LP, C17, C3H, C57BL, C57, CBA, DBA, DDD, I/st, NC, NFR, NFS, NFS/N, NZB, NZC, NZW,  
10 P, RIII, and SJL. In addition, a wide variety of other animals with inherited immunological defects other than the nude mouse have been bred and used as recipients of tumor xenografts. For further details *see, e.g.*, The Nude Mouse in Oncology Research, E. Boven and B. Winograd, eds. (CRC Press, Inc., 1991).

The cells introduced into such animals can be derived from known tumor/cancer cell lines, such as any of the above-listed tumor cell lines, and, for example, the B104-1-1 cell line (stable NIH-3T3 cell line transfected with the *neu* protooncogene); *ras*-transfected NIH-3T3 cells; Caco-2 (ATCC HTB-37); or a moderately well-differentiated grade II human colon adenocarcinoma cell line, HT-29 (ATCC HTB-38); or from tumors and cancers. Samples of tumor or cancer cells can be obtained from patients undergoing surgery, using standard conditions involving freezing and storing in liquid nitrogen. Karmali *et al.*, Br. J. Cancer, 48: 689-696 (1983).  
15

Tumor cells can be introduced into animals such as nude mice by a variety of procedures. The subcutaneous (s.c.) space in mice is very suitable for tumor implantation. Tumors can be transplanted s.c. as solid blocks, as needle biopsies by use of a trochar, or as cell suspensions. For solid-block or trochar implantation, tumor tissue fragments of suitable size are introduced into the s.c. space. Cell suspensions are freshly prepared from primary tumors or stable tumor cell lines, and injected subcutaneously. Tumor cells can also be injected as subdermal implants. In this location, the inoculum is deposited between the lower part of the dermal connective  
20 tissue and the s.c. tissue.

Animal models of breast cancer can be generated, for example, by implanting rat neuroblastoma cells (from which the *neu* oncogene was initially isolated), or *neu*-transformed NIH-3T3 cells into nude mice, essentially as described by Drebin *et al.* Proc. Nat. Acad. Sci. USA, 83: 9129-9133 (1986).  
25

Similarly, animal models of colon cancer can be generated by passaging colon cancer cells in animals, *e.g.*, nude mice, leading to the appearance of tumors in these animals. An orthotopic transplant model of human colon cancer in nude mice has been described, for example, by Wang *et al.*, Cancer Research, 54: 4726-4728 (1994) and Too *et al.*, Cancer Research, 55: 681-684 (1995). This model is based on the so-called "METAMOUSE<sup>TM</sup>" sold by AntiCancer, Inc., (San Diego, California).  
30

Tumors that arise in animals can be removed and cultured *in vitro*. Cells from the *in vitro* cultures can then be passaged to animals. Such tumors can serve as targets for further testing or drug screening. Alternatively, the tumors resulting from the passage can be isolated and RNA from pre-passage cells and cells isolated after one or more rounds of passage analyzed for differential expression of genes of interest. Such passaging techniques can  
35

be performed with any known tumor or cancer cell lines.

For example, Meth A, CMS4, CMS5, CMS21, and WEHI-164 are chemically induced fibrosarcomas of BALB/c female mice (DeLeo *et al.*, J. Exp. Med., **146**: 720 (1977)), which provide a highly controllable model system for studying the anti-tumor activities of various agents. Palladino *et al.*, J. Immunol., **138**: 4023-4032 (1987). Briefly, tumor cells are propagated *in vitro* in cell culture. Prior to injection into the animals, the cell lines are washed and suspended in buffer, at a cell density of about  $10 \times 10^6$  to  $10 \times 10^7$  cells/ml. The animals are then infected subcutaneously with 10 to 100  $\mu$ l of the cell suspension, allowing one to three weeks for a tumor to appear.

In addition, the Lewis lung (3LL) carcinoma of mice, which is one of the most thoroughly studied experimental tumors, can be used as an investigational tumor model. Efficacy in this tumor model has been correlated with beneficial effects in the treatment of human patients diagnosed with small-cell carcinoma of the lung (SCCL). This tumor can be introduced in normal mice upon injection of tumor fragments from an affected mouse or of cells maintained in culture. Zupi *et al.*, Br. J. Cancer, **41**: suppl. 4, 30 (1980). Evidence indicates that tumors can be started from injection of even a single cell and that a very high proportion of infected tumor cells survive. For further information about this tumor model see, Zacharski, Haemostasis, **16**: 300-320 (1986).

One way of evaluating the efficacy of a test compound in an animal model with an implanted tumor is to measure the size of the tumor before and after treatment. Traditionally, the size of implanted tumors has been measured with a slide caliper in two or three dimensions. The measure limited to two dimensions does not accurately reflect the size of the tumor; therefore, it is usually converted into the corresponding volume by using a mathematical formula. However, the measurement of tumor size is very inaccurate. The therapeutic effects of a drug candidate can be better described as treatment-induced growth delay and specific growth delay. Another important variable in the description of tumor growth is the tumor volume doubling time. Computer programs for the calculation and description of tumor growth are also available, such as the program reported by Rygaard and Spang-Thomsen, Proc. 6th Int. Workshop on Immune-Deficient Animals Wu and Sheng eds. (Basel, 1989), p. 301. It is noted, however, that necrosis and inflammatory responses following treatment may actually result in an increase in tumor size, at least initially. Therefore, these changes need to be carefully monitored, by a combination of a morphometric method and flow cytometric analysis.

Further, recombinant (transgenic) animal models can be engineered by introducing the coding portion of the PRO gene identified herein into the genome of animals of interest, using standard techniques for producing transgenic animals. Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, *e.g.*, baboons, chimpanzees and monkeys. Techniques known in the art to introduce a transgene into such animals include pronucleic microinjection (U.S. Patent No. 4,873,191); retrovirus-mediated gene transfer into germ lines (*e.g.*, Van der Putten *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 6148-615 (1985)); gene targeting in embryonic stem cells (Thompson *et al.*, Cell, **56**: 313-321 (1989)); electroporation of embryos (Lo, Mol. Cell. Biol., **3**: 1803-1814 (1983)); and sperm-mediated gene transfer. Lavitrano *et al.*, Cell, **57**: 717-73 (1989). For a review, see for example, U.S. Patent No. 4,736,866.

For the purpose of the present invention, transgenic animals include those that carry the transgene only in part of their cells ("mosaic animals"). The transgene can be integrated either as a single transgene, or in

concatamers, *e.g.*, head-to-head or head-to-tail tandems. Selective introduction of a transgene into a particular cell type is also possible by following, for example, the technique of Lasko *et al.*, Proc. Natl. Acad. Sci. USA, **89**: 6232-636 (1992). The expression of the transgene in transgenic animals can be monitored by standard techniques. For example, Southern blot analysis or PCR amplification can be used to verify the integration of the transgene. The level of mRNA expression can then be analyzed using techniques such as *in situ* hybridization, Northern blot analysis, PCR, or immunocytochemistry. The animals are further examined for signs of tumor or cancer development.

Alternatively, "knock-out" animals can be constructed that have a defective or altered gene encoding a PRO polypeptide identified herein, as a result of homologous recombination between the endogenous gene encoding the PRO polypeptide and altered genomic DNA encoding the same polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding a particular PRO polypeptide can be used to clone genomic DNA encoding that polypeptide in accordance with established techniques. A portion of the genomic DNA encoding a particular PRO polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector. *See, e.g.*, Thomas and Capecchi, Cell, **51**: 503 (1987) for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected. *See, e.g.*, Li *et al.*, Cell, **69**: 915 (1992). The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse or rat) to form aggregation chimeras. *See, e.g.*, Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL: Oxford, 1987), pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock-out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized, for instance, by their ability to defend against certain pathological conditions and by their development of pathological conditions due to absence of the PRO polypeptide.

The efficacy of antibodies specifically binding the PRO polypeptides identified herein, and other drug candidates, can be tested also in the treatment of spontaneous animal tumors. A suitable target for such studies is the feline oral squamous cell carcinoma (SCC). Feline oral SCC is a highly invasive, malignant tumor that is the most common oral malignancy of cats, accounting for over 60% of the oral tumors reported in this species. It rarely metastasizes to distant sites, although this low incidence of metastasis may merely be a reflection of the short survival times for cats with this tumor. These tumors are usually not amenable to surgery, primarily because of the anatomy of the feline oral cavity. At present, there is no effective treatment for this tumor. Prior to entry into the study, each cat undergoes complete clinical examination and biopsy, and is scanned by computed tomography (CT). Cats diagnosed with sublingual oral squamous cell tumors are excluded from the study. The tongue can become paralyzed as a result of such tumor, and even if the treatment kills the tumor, the animals may not be able to feed themselves. Each cat is treated repeatedly, over a longer period of time. Photographs of the tumors will be taken daily during the treatment period, and at each subsequent recheck. After treatment, each cat undergoes another CT



scan. CT scans and thoracic radiograms are evaluated every 8 weeks thereafter. The data are evaluated for differences in survival, response, and toxicity as compared to control groups. Positive response may require evidence of tumor regression, preferably with improvement of quality of life and/or increased life span.

In addition, other spontaneous animal tumors, such as fibrosarcoma, adenocarcinoma, lymphoma, chondroma, or leiomyosarcoma of dogs, cats, and baboons can also be tested. Of these, mammary adenocarcinoma in dogs and cats is a preferred model as its appearance and behavior are very similar to those in humans. However, the use of this model is limited by the rare occurrence of this type of tumor in animals.

Other *in vitro* and *in vivo* cardiovascular, endothelial, and angiogenic tests known in the art are also suitable herein.

#### 5.2.4.2. Tissue Distribution

The results of the cardiovascular, endothelial, and angiogenic assays herein can be verified by further studies, such as by determining mRNA expression in various human tissues.

As noted before, gene amplification and/or gene expression in various tissues may be measured by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.

Gene expression in various tissues, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native-sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope. General techniques for generating antibodies, and special protocols for *in situ* hybridization are provided hereinbelow.

#### 5.2.4.3. Antibody Binding Studies

The results of the cardiovascular, endothelial, and angiogenic study can be further verified by antibody binding studies, in which the ability of anti-PRO antibodies to inhibit the effect of the PRO polypeptides on endothelial cells or other cells used in the cardiovascular, endothelial, and angiogenic assays is tested. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies, the preparation of which will be described hereinbelow.

Antibody binding studies may be carried out in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques (CRC Press, Inc., 1987), pp.147-158.

Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of target protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte that remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. *See, e.g.,* U.S. Pat. No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

#### 5.2.4.4. Cell-Based Tumor Assays

Cell-based assays and animal models for cardiovascular, endothelial, and angiogenic disorders, such as tumors, can be used to verify the findings of a cardiovascular, endothelial, and angiogenic assay herein, and further to understand the relationship between the genes identified herein and the development and pathogenesis of undesirable cardiovascular, endothelial, and angiogenic cell growth. The role of gene products identified herein in the development and pathology of undesirable cardiovascular, endothelial, and angiogenic cell growth, *e.g.,* tumor cells, can be tested by using cells or cells lines that have been identified as being stimulated or inhibited by the PRO polypeptide herein. Such cells include, for example, those set forth in the Examples below.

In a different approach, cells of a cell type known to be involved in a particular cardiovascular, endothelial, and angiogenic disorder are transfected with the cDNAs herein, and the ability of these cDNAs to induce excessive growth or inhibit growth is analyzed. If the cardiovascular, endothelial, and angiogenic disorder is cancer, suitable tumor cells include, for example, stable tumor cell lines such as the B104-1-1 cell line (stable NIH-3T3 cell line transfected with the *neu* protooncogene) and *ras*-transfected NIH-3T3 cells, which can be transfected with the desired gene and monitored for tumorigenic growth. Such transfected cell lines can then be used to test the ability of poly- or monoclonal antibodies or antibody compositions to inhibit tumorigenic cell growth by exerting cytostatic or cytotoxic activity on the growth of the transformed cells, or by mediating antibody-dependent cellular cytotoxicity (ADCC). Cells transfected with the coding sequences of the genes identified herein can further be used to identify drug candidates for the treatment of cardiovascular, endothelial, and angiogenic disorders such as cancer.

In addition, primary cultures derived from tumors in transgenic animals (as described above) can be used in the cell-based assays herein, although stable cell lines are preferred. Techniques to derive continuous cell lines from transgenic animals are well known in the art. *See, e.g.,* Small *et al.*, Mol. Cell. Biol., 5: 642-648 (1985).

#### 5.2.4.5. Gene Therapy

Described below are methods and compositions whereby disease symptoms may be ameliorated. Certain diseases are brought about, at least in part, by an excessive level of gene product, or by the presence of a gene product exhibiting an abnormal or excessive activity. As such, the reduction in the level and/or activity of such gene products would bring about the amelioration of such disease symptoms.

Alternatively, certain other diseases are brought about, at least in part, by the absence or reduction of the level of gene expression, or a reduction in the level of a gene product's activity. As such, an increase in the level of gene expression and/or the activity of such gene products would bring about the amelioration of such disease symptoms.

In some cases, the up-regulation of a gene in a disease state reflects a protective role for that gene product in responding to the disease condition. Enhancement of such a target gene's expression, or the activity of the target gene product, will reinforce the protective effect it exerts. Some disease states may result from an abnormally low level of activity of such a protective gene. In these cases also, an increase in the level of gene expression and/or the activity of such gene products would bring about the amelioration of such disease symptoms.

The PRO polypeptides described herein and polypeptidyl agonists and antagonists may be employed in accordance with the present invention by expression of such polypeptides *in vivo*, which is often referred to as gene therapy.

There are two major approaches to getting the nucleic acid (optionally contained in a vector) into the patient's cells: *in vivo* and *ex vivo*. For *in vivo* delivery the nucleic acid is injected directly into the patient, usually at the sites where the PRO polypeptide is required, *i.e.*, the site of synthesis of the PRO polypeptide, if known, and the site (*e.g.*, wound) where biological activity of the PRO polypeptide is needed. For *ex vivo* treatment, the patient's cells are removed, the nucleic acid is introduced into these isolated cells, and the modified cells are administered to the patient either directly or, for example, encapsulated within porous membranes that are implanted into the patient (*see, e.g.*, U.S. Pat. Nos. 4,892,538 and 5,283,187). There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or transferred *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, transduction, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. Transduction involves the association of a replication-defective, recombinant viral (preferably retroviral) particle with a cellular receptor, followed by introduction of the nucleic acids contained by the particle into the cell. A commonly used vector for *ex vivo* delivery of the gene is a retrovirus.

The currently preferred *in vivo* nucleic acid transfer techniques include transfection with viral or non-viral vectors (such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV)) and lipid-based systems (useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol; *see, e.g.*, Tonkinson *et al.*, Cancer Investigation, 14(1): 54-65 (1996)). The most preferred vectors for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral vector such as a retroviral vector includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other

elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. In addition, a viral vector such as a retroviral vector includes a nucleic acid molecule that, when transcribed in the presence of a gene encoding the PRO polypeptide, is operably linked thereto and acts as a translation initiation sequence. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used (if these are not already present in the viral vector). In addition, such vector typically includes a signal sequence for secretion of the PRO polypeptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence, most preferably the native signal sequence for the PRO polypeptide. Optionally, the vector construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such vectors will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.

In some situations, it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell-surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins that bind to a cell-surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, *e.g.*, capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins that undergo internalization in cycling, and proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu *et al.*, J. Biol. Chem., 262: 4429-4432 (1987); and Wagner *et al.*, Proc. Natl. Acad. Sci. USA, 87: 3410-3414 (1990). For a review of the currently known gene marking and gene therapy protocols, see, Anderson *et al.*, Science, 256: 808-813 (1992). See also WO 93/25673 and the references cited therein.

Suitable gene therapy and methods for making retroviral particles and structural proteins can be found in, *e.g.*, U.S. Pat. No. 5,681,746.

#### 5.2.4.6. Use of Gene as a Diagnostic

This invention is also related to the use of the gene encoding the PRO polypeptide as a diagnostic. Detection of a mutated form of the PRO polypeptide will allow a diagnosis of a cardiovascular, endothelial, and angiogenic disease or a susceptibility to a cardiovascular, endothelial, and angiogenic disease, such as a tumor, since mutations in the PRO polypeptide may cause tumors.

Individuals carrying mutations in the genes encoding a human PRO polypeptide may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a patient's cells, such as from blood, urine, saliva, tissue biopsy, and autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki *et al.*, Nature, 324: 163-166 (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid encoding the PRO polypeptide can be used to identify and analyze the PRO polypeptide mutations. For example, deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal

genotype. Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA encoding the PRO polypeptide, or alternatively, radiolabeled antisense DNA sequences encoding the PRO polypeptide. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase A digestion or by differences in melting temperatures.

5 Genetic testing based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. DNA fragments of different sequences may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures. See, 10 *e.g.*, Myers *et al.*, Science, 230: 1242 (1985).

Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method, for example, Cotton *et al.*, Proc. Natl. Acad. Sci. USA, 85: 4397-4401 (1985).

15 Thus, the detection of a specific DNA sequence may be achieved by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing, or the use of restriction enzymes, *e.g.*, restriction fragment length polymorphisms (RFLP), and Southern blotting of genomic DNA.

#### 5.2.4.7. Use to Detect PRO Polypeptide Levels

In addition to more conventional gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

20 Expression of nucleic acid encoding the PRO polypeptide may be linked to vascular disease or neovascularization associated with tumor formation. If the PRO polypeptide has a signal sequence and the mRNA is highly expressed in endothelial cells and to a lesser extent in smooth muscle cells, this indicates that the PRO polypeptide is present in serum. Accordingly, an anti-PRO polypeptide antibody could be used to diagnose vascular disease or neovascularization associated with tumor formation, since an altered level of this PRO polypeptide may 25 be indicative of such disorders.

A competition assay may be employed wherein antibodies specific to the PRO polypeptide are attached to a solid support and the labeled PRO polypeptide and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of the PRO polypeptide in the sample.

#### 30 5.2.4.8. Chromosome Mapping

The sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal 35 location. The mapping of DNAs to chromosomes according to the present invention is an important first step in

correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis for the 3'- untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for  
5 PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner.  
10 Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome-specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires use of the clones from which the gene encoding the PRO polypeptide was derived, and the longer the better. For example, 2,000 bp is good, 4,000 bp is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the time. For a review of this technique, see, Verma *et al.*, Human Chromosomes: a Manual of Basic Techniques (Pergamon  
15 Press, New York, 1988).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available online through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region is then identified  
25 through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized  
30 to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).

#### 5.2.4.9. Screening Assays for Drug Candidates

This invention encompasses methods of screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). Screening assays for antagonist  
35 drug candidates are designed to identify compounds that bind or complex with the PRO polypeptide encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other

cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

5 All assays for antagonists are common in that they call for contacting the drug candidate with a PRO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

10 In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the PRO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, *e.g.*, on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PRO polypeptide and drying. Alternatively, an immobilized antibody, *e.g.*, a monoclonal antibody, specific for the PRO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, *e.g.*, the  
15 coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, *e.g.*, by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

20 If the candidate compound interacts with but does not bind to a particular PRO polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, *e.g.*, cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers  
25 (Fields and Song, Nature (London), 340: 245-246 (1989); Chien *et al.*, Proc. Natl. Acad. Sci. USA, 88: 9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage  
30 of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER™) for identifying protein-protein  
35 interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a PRO polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

If the PRO polypeptide has the ability to stimulate the proliferation of endothelial cells in the presence of the co-mitogen ConA, then one example of a screening method takes advantage of this ability. Specifically, in the proliferation assay, human umbilical vein endothelial cells are obtained and cultured in 96-well flat-bottomed culture plates (Costar, Cambridge, MA) and supplemented with a reaction mixture appropriate for facilitating proliferation of the cells, the mixture containing Con-A (Calbiochem, La Jolla, CA). Con-A and the compound to be screened are added and after incubation at 37°C, cultures are pulsed with <sup>3</sup>H-thymidine and harvested onto glass fiber filters (phD; Cambridge Technology, Watertown, MA). Mean <sup>3</sup>H-thymidine incorporation (cpm) of triplicate cultures is determined using a liquid scintillation counter (Beckman Instruments, Irvine, CA). Significant <sup>3</sup>(H)-thymidine incorporation indicates stimulation of endothelial cell proliferation.

To assay for antagonists, the assay described above is performed; however, in this assay the PRO polypeptide is added along with the compound to be screened and the ability of the compound to inhibit <sup>3</sup>(H)thymidine incorporation in the presence of the PRO polypeptide indicates that the compound is an antagonist to the PRO polypeptide. Alternatively, antagonists may be detected by combining the PRO polypeptide and a potential antagonist with membrane-bound PRO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The PRO polypeptide can be labeled, such as by radioactivity, such that the number of PRO polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan *et al.*, Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the PRO polypeptide. Transfected cells that are grown on glass slides are exposed to the labeled PRO polypeptide. The PRO polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled PRO polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is



resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

5 In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with the labeled PRO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

The compositions useful in the treatment of cardiovascular, endothelial, and angiogenic disorders include, without limitation, antibodies, small organic and inorganic molecules, peptides, phosphopeptides, antisense and  
10 ribozyme molecules, triple-helix molecules, etc., that inhibit the expression and/or activity of the target gene product.

More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with a PRO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or  
15 humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the PRO polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO polypeptide.

Another potential PRO polypeptide antagonist is an antisense RNA or DNA construct prepared using  
20 antisense technology, where, *e.g.*, an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature PRO polypeptides herein, is used to design an antisense RNA oligonucleotide  
25 of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - *see*, Lee *et al.*, Nucl. Acids Res., 6:3073 (1979); Cooney *et al.*, Science, 241: 456 (1988); Dervan *et al.*, Science, 251:1360 (1991)), thereby preventing transcription and the production of the PRO polypeptide. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex;  
30 in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex helix formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point  
35 of the hybridized complex. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the PRO polypeptide (antisense - Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988).

The antisense oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre, *et al.*, 1987, *Proc. Natl. Acad. Sci. U.S.A.* 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, e.g., Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents (see, e.g., Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an  $\alpha$ -anomeric oligonucleotide. An  $\alpha$ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gautier, *et al.*, 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue, *et al.*, 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue, *et al.*, 1987, *FEBS Lett.* 215:327-330).

Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein, *et al.* (1988, *Nucl. Acids Res.* 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin, *et al.*, 1988, *Proc. Natl. Acad. Sci. U.S.A.* 85:7448-7451), etc.

The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the PRO polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, *e.g.*, between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

5 Antisense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases in length, about 20 bases in length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases in length, about 55 bases in length, about 60 bases in length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more.

Potential antagonists further include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the PRO polypeptide, thereby blocking the normal biological activity of the PRO polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

15 Additional potential antagonists are ribozymes, which are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details *see, e.g.*, Rossi, Current Biology, 4: 469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

20 While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy target gene mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions which form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Myers, 1995, *Molecular Biology and Biotechnology: A Comprehensive Desk Reference*, VCH Publishers, New York, (see especially Figure 4, page 833) and in Haseloff and Gerlach, 1988, *Nature*, 334:585-591, which is incorporated herein by reference in its entirety.

25 Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the target gene mRNA, *i.e.*, to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

30 The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, *et al.*, 1984, *Science*, 224:574-578; Zaug and Cech, 1986, *Science*, 231:470-475; Zaug, *et al.*, 1986, *Nature*, 324:429-433; published International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, *Cell*, 47:207-216). The Cech-type ribozymes have an eight base pair active site that hybridizes to a target RNA sequence

whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes that target eight base-pair active site sequences that are present in the target gene.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (*e.g.*, for improved stability, targeting, *etc.*) and should be delivered to cells that express the target gene *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous target gene messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details *see, e.g.*, PCT publication No. WO 97/33551, *supra*.

These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

#### 5.2.4.10. Types of Cardiovascular, Endothelial, and Angiogenic Disorders to be Treated

The PRO polypeptides, or agonists or antagonists thereto, that have activity in the cardiovascular, angiogenic, and endothelial assays described herein, and/or whose gene product has been found to be localized to the cardiovascular system, are likely to have therapeutic uses in a variety of cardiovascular, endothelial, and angiogenic disorders, including systemic disorders that affect vessels, such as diabetes mellitus. Their therapeutic utility could include diseases of the arteries, capillaries, veins, and/or lymphatics. Examples of treatments hereunder include treating muscle wasting disease, treating osteoporosis, aiding in implant fixation to stimulate the growth of cells around the implant and therefore facilitate its attachment to its intended site, increasing IGF stability in tissues or in serum, if applicable, and increasing binding to the IGF receptor (since IGF has been shown *in vitro* to enhance human marrow erythroid and granulocytic progenitor cell growth).

The PRO polypeptides or agonists or antagonists thereto may also be employed to stimulate erythropoiesis or granulopoiesis, to stimulate wound healing or tissue regeneration and associated therapies concerned with re-growth of tissue, such as connective tissue, skin, bone, cartilage, muscle, lung, or kidney, to promote angiogenesis, to stimulate or inhibit migration of endothelial cells, and to proliferate the growth of vascular smooth muscle and endothelial cell production. The increase in angiogenesis mediated by the PRO polypeptide or agonist would be beneficial to ischemic tissues and to collateral coronary development in the heart subsequent to coronary stenosis. Antagonists are used to inhibit the action of such polypeptides, for example, to limit the production of excess connective tissue during wound healing or pulmonary fibrosis if the PRO polypeptide promotes such production. This would include treatment of acute myocardial infarction and heart failure.

Moreover, the present invention provides the treatment of cardiac hypertrophy, regardless of the underlying cause, by administering a therapeutically effective dose of the PRO polypeptide, or agonist or antagonist thereto. If the objective is the treatment of human patients, the PRO polypeptide preferably is recombinant human PRO

polypeptide (rhPRO polypeptide). The treatment for cardiac hypertrophy can be performed at any of its various stages, which may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.

The decision of whether to use the molecule itself or an agonist thereof for any particular indication, as opposed to an antagonist to the molecule, would depend mainly on whether the molecule herein promotes cardiovascularization, genesis of endothelial cells, or angiogenesis or inhibits these conditions. For example, if the molecule promotes angiogenesis, an antagonist thereof would be useful for treatment of disorders where it is desired to limit or prevent angiogenesis. Examples of such disorders include vascular tumors such as haemangioma, tumor angiogenesis, neovascularization in the retina, choroid, or cornea, associated with diabetic retinopathy or premature infant retinopathy or macular degeneration and proliferative vitreoretinopathy, rheumatoid arthritis, Crohn's disease, atherosclerosis, ovarian hyperstimulation, psoriasis, endometriosis associated with neovascularization, restenosis subsequent to balloon angioplasty, scar tissue overproduction, for example, that seen in a keloid that forms after surgery, fibrosis after myocardial infarction, or fibrotic lesions associated with pulmonary fibrosis.

If, however, the molecule inhibits angiogenesis, it would be expected to be used directly for treatment of the above conditions.

On the other hand, if the molecule stimulates angiogenesis it would be used itself (or an agonist thereof) for indications where angiogenesis is desired such as peripheral vascular disease, hypertension, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon, aneurysms, arterial restenosis, thrombophlebitis, lymphangitis, lymphedema, wound healing and tissue repair, ischemia reperfusion injury, angina, myocardial infarctions such as acute myocardial infarctions, chronic heart conditions, heart failure such as congestive heart failure, and osteoporosis.

If, however, the molecule inhibits angiogenesis, an antagonist thereof would be used for treatment of those conditions where angiogenesis is desired.

Specific types of diseases are described below, where the PRO polypeptide herein or agonists or antagonists thereof may serve as useful for vascular-related drug targeting or as therapeutic targets for the treatment or prevention of the disorders. Atherosclerosis is a disease characterized by accumulation of plaques of intimal thickening in arteries, due to accumulation of lipids, proliferation of smooth muscle cells, and formation of fibrous tissue within the arterial wall. The disease can affect large, medium, and small arteries in any organ. Changes in endothelial and vascular smooth muscle cell function are known to play an important role in modulating the accumulation and regression of these plaques.

Hypertension is characterized by raised vascular pressure in the systemic arterial, pulmonary arterial, or portal venous systems. Elevated pressure may result from or result in impaired endothelial function and/or vascular disease.

Inflammatory vasculitides include giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa (including the microangiopathic form), Kawasaki's disease, microscopic polyangiitis, Wegener's granulomatosis, and a variety

of infectious-related vascular disorders (including Henoch-Schonlein purpura). Altered endothelial cell function has been shown to be important in these diseases.

Reynaud's disease and Reynaud's phenomenon are characterized by intermittent abnormal impairment of the circulation through the extremities on exposure to cold. Altered endothelial cell function has been shown to be important in this disease.

Aneurysms are saccular or fusiform dilatations of the arterial or venous tree that are associated with altered endothelial cell and/or vascular smooth muscle cells.

Arterial restenosis (restenosis of the arterial wall) may occur following angioplasty as a result of alteration in the function and proliferation of endothelial and vascular smooth muscle cells.

Thrombophlebitis and lymphangitis are inflammatory disorders of veins and lymphatics, respectively, that may result from, and/or in, altered endothelial cell function. Similarly, lymphedema is a condition involving impaired lymphatic vessels resulting from endothelial cell function.

The family of benign and malignant vascular tumors are characterized by abnormal proliferation and growth of cellular elements of the vascular system. For example, lymphangiomas are benign tumors of the lymphatic system that are congenital, often cystic, malformations of the lymphatics that usually occur in newborns. Cystic tumors tend to grow into the adjacent tissue. Cystic tumors usually occur in the cervical and axillary region. They can also occur in the soft tissue of the extremities. The main symptoms are dilated, sometimes reticular, structured lymphatics and lymphocysts surrounded by connective tissue. Lymphangiomas are assumed to be caused by improperly connected embryonic lymphatics or their deficiency. The result is impaired local lymph drainage. Griener *et al.*, Lymphology, 4: 140-144 (1971).

Another use for the PRO polypeptides herein or agonists or antagonists thereto is in the prevention of tumor angiogenesis, which involves vascularization of a tumor to enable it to grow and/or metastasize. This process is dependent on the growth of new blood vessels. Examples of neoplasms and related conditions that involve tumor angiogenesis include breast carcinomas, lung carcinomas, gastric carcinomas, esophageal carcinomas, colorectal carcinomas, liver carcinomas, ovarian carcinomas, thecomas, arrhenoblastomas, cervical carcinomas, endometrial carcinoma, endometrial hyperplasia, endometriosis, fibrosarcomas, choriocarcinoma, head and neck cancer, nasopharyngeal carcinoma, laryngeal carcinomas, hepatoblastoma, Kaposi's sarcoma, melanoma, skin carcinomas, hemangioma, cavernous hemangioma, hemangioblastoma, pancreas carcinomas, retinoblastoma, astrocytoma, glioblastoma, Schwannoma, oligodendroglioma, medulloblastoma, neuroblastomas, rhabdomyosarcoma, osteogenic sarcoma, leiomyosarcomas, urinary tract carcinomas, thyroid carcinomas, Wilm's tumor, renal cell carcinoma, prostate carcinoma, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs' syndrome.

Age-related macular degeneration (AMD) is a leading cause of severe visual loss in the elderly population. The exudative form of AMD is characterized by choroidal neovascularization and retinal pigment epithelial cell detachment. Because choroidal neovascularization is associated with a dramatic worsening in prognosis, the PRO polypeptide or agonist or antagonist thereto is expected to be useful in reducing the severity of AMD.

Healing of trauma such as wound healing and tissue repair is also a targeted use for the PRO polypeptides herein or their agonists or antagonists. Formation and regression of new blood vessels is essential for tissue healing and repair. This category includes bone, cartilage, tendon, ligament, and/or nerve tissue growth or regeneration, as well as wound healing and tissue repair and replacement, and in the treatment of burns, incisions, and ulcers.

5 A PRO polypeptide or agonist or antagonist thereof that induces cartilage and/or bone growth in circumstances where bone is not normally formed has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a PRO polypeptide or agonist or antagonist thereof may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma-  
10 induced, or oncologic, resection-induced craniofacial defects, and also is useful in cosmetic plastic surgery.

PRO polypeptides or agonists or antagonists thereto may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a PRO polypeptide or agonist or antagonist thereto may also exhibit activity for  
15 generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, or endothelium), muscle (smooth, skeletal, or cardiac), and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate.

A PRO polypeptide herein or agonist or antagonist thereto may also be useful for gut protection or  
20 regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage. Also, the PRO polypeptide or agonist or antagonist thereto may be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells, or for inhibiting the growth of tissues described above.

A PRO polypeptide or agonist or antagonist thereto may also be used in the treatment of periodontal  
25 diseases and in other tooth-repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells, or induce differentiation of progenitors of bone-forming cells. A PRO polypeptide herein or an agonist or an antagonist thereto may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes, since blood  
30 vessels play an important role in the regulation of bone turnover and growth.

Another category of tissue regeneration activity that may be attributable to the PRO polypeptide herein or agonist or antagonist thereto is tendon/ligament formation. A protein that induces tendon/ligament-like tissue  
35 or other tissue formation in circumstances where such tissue is not normally formed has application in the healing of tendon or ligament tears, deformities, and other tendon or ligament defects in humans and other animals. Such a preparation may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the PRO polypeptide herein or

agonist or antagonist thereto contributes to the repair of congenital, trauma-induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions herein may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions herein may also be useful in the treatment of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The PRO polypeptide or its agonist or antagonist may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.*, for the treatment of central and peripheral nervous system disease and neuropathies, as well as mechanical and traumatic disorders, that involve degeneration, death, or trauma to neural cells or nerve tissue. More specifically, a PRO polypeptide or its agonist or antagonist may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions that may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma, and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a PRO polypeptide herein or agonist or antagonist thereto.

Ischemia-reperfusion injury is another indication. Endothelial cell dysfunction may be important in both the initiation of, and in regulation of the sequelae of events that occur following ischemia-reperfusion injury.

Rheumatoid arthritis is a further indication. Blood vessel growth and targeting of inflammatory cells through the vasculature is an important component in the pathogenesis of rheumatoid and sero-negative forms of arthritis.

A PRO polypeptide or its agonist or antagonist may also be administered prophylactically to patients with cardiac hypertrophy, to prevent the progression of the condition, and avoid sudden death, including death of asymptomatic patients. Such preventative therapy is particularly warranted in the case of patients diagnosed with massive left ventricular cardiac hypertrophy (a maximal wall thickness of 35 mm or more in adults, or a comparable value in children), or in instances when the hemodynamic burden on the heart is particularly strong.

A PRO polypeptide or its agonist or antagonist may also be useful in the management of atrial fibrillation, which develops in a substantial portion of patients diagnosed with hypertrophic cardiomyopathy.

Further indications include angina, myocardial infarctions such as acute myocardial infarctions, and heart failure such as congestive heart failure. Additional non-neoplastic conditions include psoriasis, diabetic and other proliferative retinopathies including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, chronic inflammation, lung inflammation, nephrotic syndrome, preeclampsia, ascites, pericardial effusion (such as that associated with pericarditis), and pleural effusion.



In view of the above, the PRO polypeptides or agonists or antagonists thereof described herein, which are shown to alter or impact endothelial cell function, proliferation, and/or form, are likely to play an important role in the etiology and pathogenesis of many or all of the disorders noted above, and as such can serve as therapeutic targets to augment or inhibit these processes or for vascular-related drug targeting in these disorders.

5

#### 5.2.4.11. Administration Protocols, Schedules, Doses, and Formulations

The molecules herein and agonists and antagonists thereto are pharmaceutically useful as a prophylactic and therapeutic agent for various disorders and diseases as set forth above.

10

Therapeutic compositions of the PRO polypeptides or agonists or antagonists are prepared for storage by mixing the desired molecule having the appropriate degree of purity with optional pharmaceutically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN<sup>TM</sup>, PLURONICS<sup>TM</sup> or polyethylene glycol (PEG).

15

20

25

Additional examples of such carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and polyethylene glycol. Carriers for topical or gel-based forms of agonist or antagonist include polysaccharides such as sodium carboxymethylcellulose or methylcellulose, polyvinylpyrrolidone, polyacrylates, polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wood wax alcohols. For all administrations, conventional depot forms are suitably used. Such forms include, for example, microcapsules, nano-capsules, liposomes, plasters, inhalation forms, nose sprays, sublingual tablets, and sustained-release preparations. The PRO polypeptides or agonists or antagonists will typically be formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml.

30

35

Another formulation comprises incorporating a PRO polypeptide or agonist or antagonist thereof into formed articles. Such articles can be used in modulating endothelial cell growth and angiogenesis. In addition, tumor invasion and metastasis may be modulated with these articles.

PRO polypeptides or agonists or antagonists to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. PRO polypeptides ordinarily will be stored in lyophilized form or in solution if administered systemically. If in lyophilized form, the PRO polypeptide or agonist or antagonist thereto is typically formulated in combination with other ingredients for reconstitution with an appropriate diluent at the time for use. An example of a liquid formulation of a PRO polypeptide or agonist or antagonist is a sterile, clear, colorless unpreserved solution filled in a single-dose vial for subcutaneous injection. Preserved pharmaceutical compositions suitable for repeated use may contain, for example, depending mainly on the indication and type of polypeptide:

- a) PRO polypeptide or agonist or antagonist thereto;
- b) a buffer capable of maintaining the pH in a range of maximum stability of the polypeptide or other molecule in solution, preferably about 4-8;
- c) a detergent/surfactant primarily to stabilize the polypeptide or molecule against agitation-induced aggregation;
- d) an isotonifier;
- e) a preservative selected from the group of phenol, benzyl alcohol and a benzethonium halide, *e.g.*, chloride; and
- f) water.

If the detergent employed is non-ionic, it may, for example, be polysorbates (*e.g.*, POLYSORBATE™ (TWEEN™) 20, 80, etc.) or poloxamers (*e.g.*, POLOXAMER™ 188). The use of non-ionic surfactants permits the formulation to be exposed to shear surface stresses without causing denaturation of the polypeptide. Further, such surfactant-containing formulations may be employed in aerosol devices such as those used in a pulmonary dosing, and needleless jet injector guns (*see, e.g.*, EP 257,956).

An isotonifier may be present to ensure isotonicity of a liquid composition of the PRO polypeptide or agonist or antagonist thereto, and includes polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol. These sugar alcohols can be used alone or in combination. Alternatively, sodium chloride or other appropriate inorganic salts may be used to render the solutions isotonic.

The buffer may, for example, be an acetate, citrate, succinate, or phosphate buffer depending on the pH desired. The pH of one type of liquid formulation of this invention is buffered in the range of about 4 to 8, preferably about physiological pH.

The preservatives phenol, benzyl alcohol and benzethonium halides, *e.g.*, chloride, are known antimicrobial agents that may be employed.

Therapeutic PRO polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The formulations are preferably administered as repeated intravenous (*i.v.*), subcutaneous (*s.c.*), or intramuscular (*i.m.*) injections, or as aerosol formulations suitable for intranasal or intrapulmonary delivery (for intrapulmonary delivery *see, e.g.*, EP 257,956).

PRO polypeptides can also be administered in the form of sustained-released preparations. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer *et al.*, J. Biomed. Mater. Res., **15**: 167-277 (1981) and Langer, Chem. Tech., **12**: 98-105 (1982) or poly(vinylalcohol)), polylactides (U.S. Patent No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, Biopolymers, **22**: 547-556 (1983)), non-degradable ethylene-vinyl acetate (Langer *et al.*, *supra*), degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Sustained-release PRO polypeptide compositions also include liposomally entrapped PRO polypeptides. Liposomes containing the PRO polypeptide are prepared by methods known *per se*: DE 3,218,121; Epstein *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 3688-3692 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, **77**: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. Patent Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal therapy.

The therapeutically effective dose of a PRO polypeptide or agonist or antagonist thereto will, of course, vary depending on such factors as the pathological condition to be treated (including prevention), the method of administration, the type of compound being used for treatment, any co-therapy involved, the patient's age, weight, general medical condition, medical history, etc., and its determination is well within the skill of a practicing physician. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the maximal therapeutic effect. If the PRO polypeptide has a narrow host range, for the treatment of human patients formulations comprising human PRO polypeptide, more preferably native-sequence human PRO polypeptide, are preferred. The clinician will administer the PRO polypeptide until a dosage is reached that achieves the desired effect for treatment of the condition in question. For example, if the objective is the treatment of CHF, the amount would be one that inhibits the progressive cardiac hypertrophy associated with this condition. The progress of this therapy is easily monitored by echo cardiography. Similarly, in patients with hypertrophic cardiomyopathy, the PRO polypeptide can be administered on an empirical basis.

With the above guidelines, the effective dose generally is within the range of from about 0.001 to about 1.0 mg/kg, more preferably about 0.01-1.0 mg/kg, most preferably about 0.01-0.1 mg/kg.

For non-oral use in treating human adult hypertension, it is advantageous to administer the PRO polypeptide in the form of an injection at about 0.01 to 50 mg, preferably about 0.05 to 20 mg, most preferably 1 to 20 mg, per kg body weight, 1 to 3 times daily by intravenous injection. For oral administration, a molecule based on the PRO polypeptide is preferably administered at about 5 mg to 1 g, preferably about 10 to 100 mg, per kg body weight, 1 to 3 times daily. It should be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein. Moreover, for human administration, the formulations preferably meet sterility, pyrogenicity, general safety, and purity as required by FDA Office and Biologics standards.

The dosage regimen of a pharmaceutical composition containing the PRO polypeptide to be used in tissue regeneration will be determined by the attending physician considering various factors that modify the action of the polypeptides, *e.g.*, amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (*e.g.*, bone), the patient's age, sex, and diet, the severity of any infection, time of administration, and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF-I, to the final composition may also affect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations, and tetracycline labeling.

The route of PRO polypeptide or antagonist or agonist administration is in accord with known methods, *e.g.*, by injection or infusion by intravenous, intramuscular, intracerebral, intraperitoneal, intracerebrospinal, subcutaneous, intraocular, intraarticular, intrasynovial, intrathecal, oral, topical, or inhalation routes, or by sustained-release systems as noted below. The PRO polypeptide or agonist or antagonists thereof also are suitably administered by intratumoral, peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. The intraperitoneal route is expected to be particularly useful, for example, in the treatment of ovarian tumors.

If a peptide or small molecule is employed as an antagonist or agonist, it is preferably administered orally or non-orally in the form of a liquid or solid to mammals.

Examples of pharmacologically acceptable salts of molecules that form salts and are useful hereunder include alkali metal salts (*e.g.*, sodium salt, potassium salt), alkaline earth metal salts (*e.g.*, calcium salt, magnesium salt), ammonium salts, organic base salts (*e.g.*, pyridine salt, triethylamine salt), inorganic acid salts (*e.g.*, hydrochloride, sulfate, nitrate), and salts of organic acid (*e.g.*, acetate, oxalate, p-toluenesulfonate).

For compositions herein that are useful for bone, cartilage, tendon, or ligament regeneration, the therapeutic method includes administering the composition topically, systemically, or locally as an implant or device. When administered, the therapeutic composition for use is in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage, or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Preferably, for bone and/or cartilage formation, the composition would include a matrix capable of delivering the

protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and preferably capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

5 The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance, and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid, and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are  
10 nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above-mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalcium phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

15 One specific embodiment is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the polypeptide compositions from disassociating from the matrix.

20 One suitable family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, one preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt%, based on total formulation weight, which  
25 represents the amount necessary to prevent desorption of the polypeptide (or its antagonist) from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the polypeptide (or its antagonist) the opportunity to assist the osteogenic activity of the progenitor cells.

#### 5.2.4.12. Combination Therapies

30 The effectiveness of the PRO polypeptide or an agonist or antagonist thereof in preventing or treating the disorder in question may be improved by administering the active agent serially or in combination with another agent that is effective for those purposes, either in the same composition or as separate compositions.

For example, for treatment of cardiac hypertrophy, PRO polypeptide therapy can be combined with the administration of inhibitors of known cardiac myocyte hypertrophy factors, *e.g.*, inhibitors of  $\alpha$ -adrenergic agonists  
35 such as phenylephrine; endothelin-1 inhibitors such as BOSENTAN<sup>TM</sup> and MOXONODIN<sup>TM</sup>; inhibitors to CT-1

(U.S. Pat. No. 5,679,545); inhibitors to LIF; ACE inhibitors; des-aspartate-angiotensin I inhibitors (U.S. Pat. No. 5,773,415), and angiotensin II inhibitors.

5 For treatment of cardiac hypertrophy associated with hypertension, the PRO polypeptide can be administered in combination with  $\beta$ -adrenergic receptor blocking agents, *e.g.*, propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, or carvedilol; ACE inhibitors, *e.g.*,  
10 quinapril, captopril, enalapril, ramipril, benazepril, fosinopril, or lisinopril; diuretics, *e.g.*, chlorothiazide, hydrochlorothiazide, hydroflumethazide, methylchlorothiazide, benzthiazide, dichlorphenamide, acetazolamide, or indapamide; and/or calcium channel blockers, *e.g.*, diltiazem, nifedipine, verapamil, or nocardipine. Pharmaceutical compositions comprising the therapeutic agents identified herein by their generic names are commercially available,  
15 and are to be administered following the manufacturers' instructions for dosage, administration, adverse effects, contraindications, etc. *See, e.g., Physicians' Desk Reference* (Medical Economics Data Production Co.: Montvale, N.J., 1997), 51th Edition.

Preferred candidates for combination therapy in the treatment of hypertrophic cardiomyopathy are  $\beta$ -adrenergic-blocking drugs (*e.g.*, propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol,  
15 acetobutolol, atenolol, metoprolol, or carvedilol), verapamil, difedipine, or diltiazem. Treatment of hypertrophy associated with high blood pressure may require the use of antihypertensive drug therapy, using calcium channel blockers, *e.g.*, diltiazem, nifedipine, verapamil, or nocardipine;  $\beta$ -adrenergic blocking agents; diuretics, *e.g.*, chlorothiazide, hydrochlorothiazide, hydroflumethazide, methylchlorothiazide, benzthiazide, dichlorphenamide, acetazolamide, or indapamide; and/or ACE-inhibitors, *e.g.*, quinapril, captopril, enalapril, ramipril, benazepril,  
20 fosinopril, or lisinopril.

For other indications, PRO polypeptides or their agonists or antagonists may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as EGF, PDGF, TGF- $\alpha$  or TGF- $\beta$ , IGF, FGF, and CTGF.

In addition, PRO polypeptides or their agonists or antagonists used to treat cancer may be combined with  
25 cytotoxic, chemotherapeutic, or growth-inhibitory agents as identified above. Also, for cancer treatment, the PRO polypeptide or agonist or antagonist thereof is suitably administered serially or in combination with radiological treatments, whether involving irradiation or administration of radioactive substances.

The effective amounts of the therapeutic agents administered in combination with the PRO polypeptide or agonist or antagonist thereof will be at the physician's or veterinarian's discretion. Dosage administration and  
30 adjustment is done to achieve maximal management of the conditions to be treated. For example, for treating hypertension, these amounts ideally take into account use of diuretics or digitalis, and conditions such as hyper- or hypotension, renal impairment, etc. The dose will additionally depend on such factors as the type of the therapeutic agent to be used and the specific patient being treated. Typically, the amount employed will be the same dose as that used, if the given therapeutic agent is administered without the PRO polypeptide.

#### 5.2.4.13. Articles of Manufacture

An article of manufacture such as a kit containing the PRO polypeptide or agonists or antagonists thereof useful for the diagnosis or treatment of the disorders described above comprises at least a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition that is effective for diagnosing or treating the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the PRO polypeptide or an agonist or antagonist thereto. The label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. The article of manufacture may also comprise a second or third container with another active agent as described above.

#### 5.2.5. Antibodies

Some of the most promising drug candidates according to the present invention are antibodies and antibody fragments that may inhibit the production or the gene product of the genes identified herein and/or reduce the activity of the gene products.

##### 5.2.5.1. Polyclonal Antibodies

Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants that may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A or synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

##### 5.2.5.2. Monoclonal Antibodies

The anti-PRO antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal is typically immunized with an

immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell. Goding, Monoclonal Antibodies: Principles and Practice (New York: Academic Press, 1986), pp. 59-103. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. Kozbor, J. Immunol., 133:3001 (1984); Brodeur *et al.*, Monoclonal Antibody Production Techniques and Applications (Marcel Dekker, Inc.: New York, 1987) pp. 51-63.

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the PRO polypeptide. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods. Goding, *supra*. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the



invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison *et al.*, *supra*) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy-chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known in the art.

#### 5.2.5.3. Human and Humanized Antibodies

The anti-PRO antibodies may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (*e.g.*, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub>, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody preferably also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Jones *et al.*, Nature, 321: 522-525 (1986); Riechmann *et al.*, Nature, 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, Nature, 321: 522-525 (1986); Riechmann *et al.*, Nature, 332: 323-327 (1988); Verhoeven *et al.*, Science, 239: 1534-

1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries. Hoogenboom and Winter, *J. Mol. Biol.*, 227: 381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222: 581 (1991). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies. Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985) and Boerner *et al.*, *J. Immunol.*, 147(1): 86-95 (1991). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed that closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016, and in the following scientific publications: Marks *et al.*, *Bio/Technology*, 10: 779-783 (1992); Lonberg *et al.*, *Nature*, 368: 856-859 (1994); Morrison, *Nature*, 368: 812-813 (1994); Fishwild *et al.*, *Nature Biotechnology*, 14: 845-851 (1996); Neuberger, *Nature Biotechnology*, 14: 826 (1996); Lonberg and Huszar, *Intern. Rev. Immunol.*, 13: 65-93 (1995).

#### 5.2.5.4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO polypeptide, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities. Milstein and Cuello, *Nature*, 305: 537-539 (1983). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10: 3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant-domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further

details of generating bispecific antibodies, *see*, for example, Suresh *et al.*, Methods in Enzymology, **121**: 210 (1986).

#### 5.2.5.5. Heteroconjugate Antibodies

5 Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune-system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection. WO 91/00360; WO 92/200373; EP 03089. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### 5.2.5.6. Effector Function Engineering

15 It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). *See*, Caron *et al.*, J. Exp. Med., **176**: 1191-1195 (1992) and Shopes, J. Immunol., **148**: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.*, Cancer Research, **53**: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. *See*, Stevenson *et al.*, Anti-Cancer Drug Design, **3**: 219-230 (1989).

#### 5.2.5.7. Immunoconjugates

25 The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

30 Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane (IT), bifunctional derivatives

of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, Science, **238**: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyl-diethylene triamine-pentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See, WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is conjugated to a cytotoxic agent (e.g., a radionucleotide).

#### 5.2.5.8. Immunoliposomes

The antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 3688 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, **77**: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, J. Biol. Chem., **257**: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See, Gabizon *et al.*, J. National Cancer Inst., **81**(19): 1484 (1989).

#### 5.2.5.9. Pharmaceutical Compositions of Antibodies

Antibodies specifically binding a PRO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders as noted above and below in the form of pharmaceutical compositions.

If the PRO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco *et al.*, Proc. Natl. Acad. Sci. USA, **90**: 7889-7893 (1993).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, *supra*.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

#### 5.2.5.10. Methods of Treatment using the Antibody

It is contemplated that the antibodies to a PRO polypeptide may be used to treat various cardiovascular, endothelial, and angiogenic conditions as noted above.

The antibodies are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous administration of the antibody is preferred.

Other therapeutic regimens may be combined with the administration of the antibodies of the instant invention as noted above. For example, if the antibodies are to treat cancer, the patient to be treated with such

antibodies may also receive radiation therapy. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, Ed., M.C. Perry (Williams & Wilkins: Baltimore, MD, 1992). The chemotherapeutic agent may precede, or follow administration of the antibody, or may be given simultaneously therewith. The antibody may be combined with an anti-estrogen compound such as tamoxifen or EVISTA<sup>TM</sup> or an anti-progesterone such as onapristone (*see*, EP 616812) in dosages known for such molecules.

If the antibodies are used for treating cancer, it may be desirable also to administer antibodies against other tumor-associated antigens, such as antibodies that bind to one or more of the ErbB2, EGFR, ErbB3, ErbB4, or VEGF receptor(s). These also include the agents set forth above. Also, the antibody is suitably administered serially or in combination with radiological treatments, whether involving irradiation or administration of radioactive substances. Alternatively, or in addition, two or more antibodies binding the same or two or more different antigens disclosed herein may be co-administered to the patient. Sometimes, it may be beneficial also to administer one or more cytokines to the patient. In a preferred embodiment, the antibodies herein are co-administered with a growth-inhibitory agent. For example, the growth-inhibitory agent may be administered first, followed by an antibody of the present invention. However, simultaneous administration or administration of the antibody of the present invention first is also contemplated. Suitable dosages for the growth-inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth-inhibitory agent and the antibody herein.

In one embodiment, vascularization of tumors is attacked in combination therapy. The anti-PRO polypeptide antibody and another antibody (*e.g.*, anti-VEGF) are administered to tumor-bearing patients at therapeutically effective doses as determined, for example, by observing necrosis of the tumor or its metastatic foci, if any. This therapy is continued until such time as no further beneficial effect is observed or clinical examination shows no trace of the tumor or any metastatic foci. Then TNF is administered, alone or in combination with an auxiliary agent such as alpha-, beta-, or gamma-interferon, anti-HER2 antibody, heregulin, anti-heregulin antibody, D-factor, interleukin-1 (IL-1), interleukin-2 (IL-2), granulocyte-macrophage colony stimulating factor (GM-CSF), or agents that promote microvascular coagulation in tumors, such as anti-protein C antibody, anti-protein S antibody, or C4b binding protein (*see*, WO 91/01753, published 21 February 1991), or heat or radiation.

Since the auxiliary agents will vary in their effectiveness, it is desirable to compare their impact on the tumor by matrix screening in conventional fashion. The administration of anti-PRO polypeptide antibody and TNF is repeated until the desired clinical effect is achieved. Alternatively, the anti-PRO polypeptide antibody is administered together with TNF and, optionally, auxiliary agent(s). In instances where solid tumors are found in the limbs or in other locations susceptible to isolation from the general circulation, the therapeutic agents described herein are administered to the isolated tumor or organ. In other embodiments, a FGF or PDGF antagonist, such as an anti-FGF or an anti-PDGF neutralizing antibody, is administered to the patient in conjunction with the anti-PRO

polypeptide antibody. Treatment with anti-PRO polypeptide antibodies preferably may be suspended during periods of wound healing or desirable neovascularization.

For the prevention or treatment of cardiovascular, endothelial, and angiogenic disorder, the appropriate dosage of an antibody herein will depend on the type of disorder to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments.

For example, depending on the type and severity of the disorder, about 1 µg/kg to 50 mg/kg (e.g., 0.1-20 mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily or weekly dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated or sustained until a desired suppression of disorder symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays, including, for example, radiographic tumor imaging.

#### 5.2.5.11. Articles of Manufacture with Antibodies

An article of manufacture containing a container with the antibody and a label is also provided. Such articles are described above, wherein the active agent is an anti-PRO antibody.

#### 5.2.5.12. Diagnosis and Prognosis of Tumors using Antibodies

If the indication for which the antibodies are used is cancer, while cell-surface proteins, such as growth receptors over expressed in certain tumors, are excellent targets for drug candidates or tumor (e.g., cancer) treatment, the same proteins along with PRO polypeptides find additional use in the diagnosis and prognosis of tumors. For example, antibodies directed against the PRO polypeptides may be used as tumor diagnostics or prognostics.

For example, antibodies, including antibody fragments, can be used qualitatively or quantitatively to detect the expression of genes including the gene encoding the PRO polypeptide. The antibody preferably is equipped with a detectable, e.g., fluorescent label, and binding can be monitored by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. Such binding assays are performed essentially as described above.

*In situ* detection of antibody binding to the marker gene products can be performed, for example, by immunofluorescence or immunoelectron microscopy. For this purpose, a histological specimen is removed from the patient, and a labeled antibody is applied to it, preferably by overlaying the antibody on a biological sample. This procedure also allows for determining the distribution of the marker gene product in the tissue examined. It will be apparent to those skilled in the art that a wide variety of histological methods are readily available for *in situ* detection.

The following Examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

The disclosures of all patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

5        6.        EXAMPLES

Commercially available reagents referred to in the Examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following Examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA. Unless otherwise noted, the present invention uses standard procedures of recombinant DNA technology, such as those described hereinabove and in the following textbooks: Sambrook *et al.*, supra; Ausubel *et al.*, Current Protocols in Molecular Biology (Green Publishing Associates and Wiley Interscience, N.Y., 1989); Innis *et al.*, PCR Protocols: A Guide to Methods and Applications (Academic Press, Inc.: N.Y., 1990); Harlow *et al.*, Antibodies: A Laboratory Manual (Cold Spring Harbor Press: Cold Spring Harbor, 1988); Gait, Oligonucleotide Synthesis (IRL Press: Oxford, 1984); Freshney, Animal Cell Culture, 1987; Coligan *et al.*, Current Protocols in Immunology, 1991.

15            6.1.        EXAMPLE 1:    Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding Therefor

The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST databases included public databases (*e.g.*, Dayhoff, GenBank), and proprietary databases (*e.g.* LIFESEQ®, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST-2 (Altschul *et al.*, Methods in Enzymology, 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases, 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA).

25            Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap. In addition, the consensus DNA sequences obtained were often (but not always) extended using repeated cycles of BLAST or BLAST-2 and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above.

30            Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO polypeptide. Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length. The probe sequences are typically 40-55 bp in length. In some cases, additional oligonucleotides are synthesized when the consensus sequence is greater than about 1-1.5 kbp. In order to screen several libraries for a full-length clone, 35        DNA from the libraries was screened by PCR amplification, as per Ausubel *et al.*, Current Protocols in Molecular



Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.

The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; *see*, Holmes *et al.*, Science, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

## 6.2. EXAMPLE 2: Isolation of cDNA Clones by Amylase Screening

### 6.2.1. Preparation of oligo dT primed cDNA library

mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System). In this procedure, the double stranded cDNA was sized to greater than 1000 bp and the SalI/NotI linked cDNA was cloned into XhoI/NotI cleaved vector. pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/NotI cDNA cloning sites.

### 6.2.2. Preparation of random primed cDNA library

A secondary cDNA library was generated in order to preferentially represent the 5' ends of the primary cDNA clones. Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST-AMY.0 using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above). In this procedure the double stranded cDNA was sized to 500-1000 bp, linked with blunt to NotI adaptors, cleaved with SfiI, and cloned into SfiI/NotI cleaved vector. pSST-AMY.0 is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, after the cloning sites. Thus, cDNAs cloned into this vector that are fused in frame with amylase sequence will lead to the secretion of amylase from appropriately transfected yeast colonies.

### 6.2.3. Transformation and Detection

DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DH10B bacteria (Life Technologies, 20 ml). The bacteria and vector mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37°C for 30 minutes. The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37°C). Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, *e.g.*, CsCl-gradient. The purified DNA was then carried on to the yeast protocols below.

The yeast methods were divided into three categories: (1) Transformation of yeast with the plasmid/cDNA combined vector; (2) Detection and isolation of yeast clones secreting amylase; and (3) PCR amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis.

The yeast strain used was HD56-5A (ATCC-90785). This strain has the following genotype: MAT alpha, ura3-52, leu2-3, leu2-112, his3-11, his3-15, MAL<sup>+</sup>, SUC<sup>+</sup>, GAL<sup>+</sup>. Preferably, yeast mutants can be employed that have deficient post-translational pathways. Such mutants may have translocation deficient alleles in *sec71*, *sec72*, *sec62*, with truncated *sec71* being most preferred. Alternatively, antagonists (including antisense nucleotides and/or ligands) which interfere with the normal operation of these genes, other proteins implicated in this post translation pathway (e.g., SEC61p, SEC72p, SEC62p, SEC63p, TDJ1p or SSA1p-4p) or the complex formation of these proteins may also be preferably employed in combination with the amylase-expressing yeast.

Transformation was performed based on the protocol outlined by Gietz *et al.*, *Nucl. Acid. Res.*, 20:1425 (1992). Transformed cells were then inoculated from agar into YEPD complex media broth (100 ml) and grown overnight at 30°C. The YEPD broth was prepared as described in Kaiser *et al.*, *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight culture was then diluted to about 2 x 10<sup>6</sup> cells/ml (approx. OD<sub>600</sub>=0.1) into fresh YEPD broth (500 ml) and regrown to 1 x 10<sup>7</sup> cells/ml (approx. OD<sub>600</sub>=0.4-0.5).

The cells were then harvested and prepared for transformation by transfer into GS3 rotor bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>), and resuspended into LiAc/TE (2.5 ml).

Transformation took place by mixing the prepared cells (100 µl) with freshly denatured single stranded salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1 µg, vol. < 10 µl) in microfuge tubes. The mixture was mixed briefly by vortexing, then 40% PEG/TE (600 µl, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>, pH 7.5) was added. This mixture was gently mixed and incubated at 30°C while agitating for 30 minutes. The cells were then heat shocked at 42°C for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and resuspended into TE (500 µl, 10 mM Tris-HCl, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells were then diluted into TE (1 ml) and aliquots (200 µl) were spread onto the selective media previously prepared in 150 mm growth plates (VWR).

Alternatively, instead of multiple small reactions, the transformation was performed using a single, large scale reaction, wherein reagent amounts were scaled up accordingly.

The selective media used was a synthetic complete dextrose agar lacking uracil (SCD-Ura) prepared as described in Kaiser *et al.*, *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 208-210 (1994). Transformants were grown at 30°C for 2-3 days.

The detection of colonies secreting amylase was performed by including red starch in the selective growth media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the procedure described by Biely *et*

*al.*, Anal. Biochem., 172:176-179 (1988). The coupled starch was incorporated into the SCD-Ura agar plates at a final concentration of 0.15% (w/v), and was buffered with potassium phosphate to a pH of 7.0 (50-100 mM final concentration).

The positive colonies were picked and streaked across fresh selective media (onto 150 mm plates) in order to obtain well isolated and identifiable single colonies. Well isolated single colonies positive for amylase secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly.

#### 6.2.4. Isolation of DNA by PCR Amplification

When a positive colony was isolated, a portion of it was picked by a toothpick and diluted into sterile water (30  $\mu$ l) in a 96 well plate. At this time, the positive colonies were either frozen and stored for subsequent analysis or immediately amplified. An aliquot of cells (5  $\mu$ l) was used as a template for the PCR reaction in a 25  $\mu$ l volume containing: 0.5  $\mu$ l Klentaq (Clontech, Palo Alto, CA); 4.0  $\mu$ l 10 mM dNTP's (Perkin Elmer-Cetus); 2.5  $\mu$ l Kentaq buffer (Clontech); 0.25  $\mu$ l forward oligo 1; 0.25  $\mu$ l reverse oligo 2; 12.5  $\mu$ l distilled water. The sequence of the forward oligonucleotide 1 was:

5'-TGTAACGACGGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID NO:382)

The sequence of reverse oligonucleotide 2 was:

5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID NO:383)

PCR was then performed as follows:

	a.	Denature	92°C, 5 minutes
20	b.	3 cycles of:	92°C, 30 seconds
		Denature	59°C, 30 seconds
		Anneal	72°C, 60 seconds
		Extend	
25	c.	3 cycles of:	92°C, 30 seconds
		Denature	57°C, 30 seconds
		Anneal	72°C, 60 seconds
		Extend	
	d.	25 cycles of:	92°C, 30 seconds
		Denature	55°C, 30 seconds
		Anneal	72°C, 60 seconds
		Extend	
30	e.	Hold	4°C

The underlined regions of the oligonucleotides annealed to the ADH promoter region and the amylase region, respectively, and amplified a 307 bp region from vector pSST-AMY.0 when no insert was present. Typically, the first 18 nucleotides of the 5' end of these oligonucleotides contained annealing sites for the sequencing primers. Thus, the total product of the PCR reaction from an empty vector was 343 bp. However, signal sequence-fused cDNA resulted in considerably longer nucleotide sequences.

Following the PCR, an aliquot of the reaction (5  $\mu$ l) was examined by agarose gel electrophoresis in a 1% agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by Sambrook *et al.*, *supra*. Clones resulting in a single strong PCR product larger than 400 bp were further analyzed by DNA sequencing after purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth, CA).

### 6.3. EXAMPLE 3: Isolation of cDNA Clones Using Signal Algorithm Analysis

Various polypeptide-encoding nucleic acid sequences were identified by applying a proprietary signal sequence finding algorithm developed by Genentech, Inc., (South San Francisco, CA) upon ESTs as well as clustered and assembled EST fragments from public (*e.g.*, GenBank) and/or private (LIFESEQ®, Incyte Pharmaceuticals, Inc., Palo Alto, CA) databases. The signal sequence algorithm computes a secretion signal score based on the character of the DNA nucleotides surrounding the first and optionally the second methionine codon(s) (ATG) at the 5'-end of the sequence or sequence fragment under consideration. The nucleotides following the first ATG must code for at least 35 unambiguous amino acids without any stop codons. If the first ATG has the required amino acids, the second is not examined. If neither meets the requirement, the candidate sequence is not scored. In order to determine whether the EST sequence contains an authentic signal sequence, the DNA and corresponding amino acid sequences surrounding the ATG codon are scored using a set of seven sensors (evaluation parameters) known to be associated with secretion signals. Use of this algorithm resulted in the identification of numerous polypeptide-encoding nucleic acid sequences.

### 6.4. EXAMPLE 4: Isolation of cDNA clones Encoding Human PRO Polypeptides

Using the techniques described in Examples 1 to 3 above, numerous full-length cDNA clones were identified as encoding PRO polypeptides as disclosed herein. These cDNAs were then deposited under the terms of the Budapest Treaty with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC) as shown in Table 7 below.

Table 7

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
25	23330-1390	209775	4/14/1998
	23339-1130	209282	9/18/1997
	26846-1397	203406	10/27/1998
	26847-1395	209772	4/14/1998
	27865-1091	209296	9/23/1997
30	30868-1156	1437-PTA	3/2/2000
	30871-1157	209380	10/16/1997
	32286-1191	209385	10/16/1997
	33089-1132	209262	9/16/1997
	33092-1202	209420	10/28/1997

	33100-1159	209377	10/16/1997
	33223-1136	209264	9/16/1997
	34392-1170	209526	12/10/1997
	34431-1177	209399	10/17/1997
5	34433-1308	209719	3/31/1998
	34434-1139	209252	9/16/1997
	35600-1162	209370	10/16/1997
	35673-1201	209418	10/28/1997
	35880-1160	209379	10/16/1997
10	35918-1174	209402	10/17/1997
	36350-1158	209378	10/16/1997
	36638-1056	209456	11/12/1997
	38268-1188	209421	10/28/1997
	40370-1217	209485	11/21/1997
15	40628-1216	209432	11/7/1997
	43316-1237	209487	11/21/1997
	44196-1353	209847	5/6/1998
	45409-2511	203579	1/12/1999
	45419-1252	209616	2/5/1998
20	46777-1253	209619	2/5/1998
	48336-1309	209669	3/11/1998
	48606-1479	203040	7/1/1998
	49435-1219	209480	11/21/1997
	49631-1328	209806	4/28/1998
25	50919-1361	209848	5/6/1998
	50920-1325	209700	3/26/1998
	50921-1458	209859	5/12/1998
	52758-1399	209773	4/14/1998
	53517-1366-1	209802	4/23/1998
30	53915-1258	209593	1/21/1998
	53974-1401	209774	4/14/1998
	53987-1438	209858	5/12/1998
	56047-1456	209948	6/9/1998
	56050-1455	203011	6/23/1998
35	56110-1437	203113	8/11/1998
	56405-1357	209849	5/6/1998
	56433-1406	209857	5/12/1998

	56439-1376	209864	5/14/1998
	56529-1647	203293	9/29/1998
	56865-1491	203022	6/23/1998
	56965-1356	209842	5/6/1998
5	57033-1403-1	209905	5/27/1998
	57037-1444	209903	5/27/1998
	57039-1402	209777	4/14/1998
	57689-1385	209869	5/14/1998
	57690-1374	209950	6/9/1998
10	57694-1341	203017	6/23/1998
	57695-1340	203006	6/23/1998
	57699-1412	203020	6/23/1998
	57700-1408	203583	1/12/1999
	57708-1411	203021	6/23/1998
15	57838-1337	203014	6/23/1998
	58847-1383	209879	5/20/1998
	58852-1637	203271	9/22/1998
	58853-1423	203016	6/23/1998
	59212-1627	203245	9/9/1998
20	59220-1514	209962	6/9/1998
	59493-1420	203050	7/1/1998
	59497-1496	209941	6/4/1998
	59586-1520	203288	9/29/1998
	59588-1571	203106	8/11/1998
25	59620-1463	209989	6/16/1998
	59622-1334	209984	6/16/1998
	59777-1480	203111	8/11/1998
	59848-1512	203088	8/4/1998
	59849-1504	209986	6/16/1998
30	60621-1516	203091	8/4/1998
	60622-1525	203090	8/4/1998
	60764-1533	203452	11/10/1998
	60783-1611	203130	8/18/1998
	61755-1554	203112	8/11/1998
35	62306-1570	203254	9/9/1998
	62312-2558	203836	3/9/1999
	62814-1521	203093	8/4/1998

	62872-1509	203100	8/4/1998
	64883-1526	203253	9/9/1998
	64886-1601	203241	9/9/1998
	64889-1541	203250	9/9/1998
5	64896-1539	203238	9/9/1998
	64897-1628	203216	9/15/1998
	64903-1553	203223	9/15/1998
	64908-1163-1	203243	9/9/1998
	64950-1590	203224	9/15/1998
10	65402-1540	203252	9/9/1998
	65404-1551	203244	9/9/1998
	65405-1547	203476	11/17/1998
	65410-1569	203231	9/15/1998
	65412-1523	203094	8/4/1998
15	66307-2661	431-PTA	7/27/1999
	66526-1616	203246	9/9/1998
	66659-1593	203269	9/22/1998
	66660-1585	203279	9/22/1998
	66667-1596	203267	9/22/1998
20	66672-1586	203265	9/22/1998
	66675-1587	203282	9/22/1998
	67300-1605	203163	8/25/1998
	68818-2536	203657	2/9/1999
	68862-2546	203652	2/9/1999
25	68872-1620	203160	8/25/1998
	71290-1630	203275	9/22/1998
	73736-1657	203466	11/17/1998
	73739-1645	203270	9/22/1998
	73742-1662	203316	10/6/1998
30	76385-1692	203664	2/9/1999
	76393-1664	203323	10/6/1998
	76399-1700	203472	11/17/1998
	76400-2528	203573	1/12/1999
	76510-2504	203477	11/17/1998
35	76529-1666	203315	10/6/1998
	76532-1702	203473	11/17/1998
	76541-1675	203409	10/27/1998

	77503-1686	203362	10/20/1998
	77624-2515	203553	12/22/1998
	79230-2525	203549	12/22/1998
	79862-2522	203550	12/22/1998
5	80145-2594	204-PTA	6/8/1999
	80899-2501	203539	12/15/1998
	81754-2532	203542	12/15/1998
	81757-2512	203543	12/15/1998
	81761-2583	203862	3/23/1999
10	82358-2738	510-PTA	8/10/1999
	82364-2538	203603	1/20/1999
	82403-2959	2317-PTA	8/1/2000
	83500-2506	203391	10/29/1998
	83560-2569	203816	3/2/1999
15	84210-2576	203818	3/2/1999
	84920-2614	203966	4/27/1999
	86576-2595	203868	3/23/1999
	92218-2554	203834	3/9/1999
	92233-2599	134-PTA	5/25/1999
20	92256-2596	203891	3/30/1999
	92265-2669	256-PTA	6/22/1999
	92274-2617	203971	4/27/1999
	92929-2534-1	203586	1/12/1999
	93011-2637	20-PTA	5/4/1999
25	94854-2586	203864	3/23/1999
	96787-2534-1	203589	1/12/1999
	96867-2620	203972	4/27/1999
	96872-2674	550-PTA	8/17/1999
	96878-2626	23-PTA	5/4/1999
30	96889-2641	119-PTA	5/25/1999
	100312-2645	44-PTA	5/11/1999
	105782-2693	387-PTA	7/20/1999
	105849-2704	473-PTA	8/3/1999
	108725-2766	863-PTA	10/19/1999
35	108769-2765	861-PTA	10/19/1999
	119498-2965	2298-PTA	7/25/2000
	119535-2756	613-PTA	8/31/1999



	125185-2806	1031-PTA	12/7/1999
	131639-2874	1784-PTA	4/25/2000
	139623-2893	1670-PTA	4/11/2000
	143076-2787	1028-PTA	12/7/1999
5	143276-2975	2387-PTA	8/8/2000
	164625-2890	1535-PTA	3/21/2000
	167678-2963	2302-PTA	7/25/2000
	170021-2923	1906-PTA	5/23/2000
	170212-3000	2583-PTA	10/10/2000
10	177313-2982	2251-PTA	7/19/2000

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

**6.5 EXAMPLE 5: Isolation of cDNA clones Encoding Human PRO1873, PRO7223, PRO7248, PRO730, PRO532, PRO7261, PRO734, PRO771, PRO2010, PRO5723, PRO3444, PRO9940, PRO3562, PRO10008, PRO5730, PRO6008, PRO4527, PRO4538 and PRO4553**

DNA molecules encoding the PRO1873, PRO7223, PRO7248, PRO730, PRO532, PRO7261, PRO734, PRO771, PRO2010, PRO5723, PRO3444, PRO9940, PRO3562, PRO10008, PRO5730, PRO6008, PRO4527, PRO4538 and PRO4553 polypeptides shown in the accompanying figures were obtained through GenBank.

**6.6. EXAMPLE 6: Use of PRO as a Hybridization Probe**

The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.

DNA comprising the coding sequence of full-length or mature PRO (as shown in accompanying figures) or a fragment thereof is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries.

5 Hybridization and washing of filters containing either library DNAs is performed under the following high-stringency conditions. Hybridization of radiolabeled probe derived from the gene encoding PRO polypeptide to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

10 DNAs having a desired sequence identity with the DNA encoding full-length native sequence can then be identified using standard techniques known in the art.

#### 6.7. EXAMPLE 7: Expression of PRO in *E. coli*

This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in *E. coli*.

15 The DNA sequence encoding PRO is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see, Bolivar *et al.*, Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a poly-His leader (including the first six STII codons, poly-His sequence, and enterokinase cleavage site),  
20 the PRO coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook *et al.*, *supra*. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA  
25 sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

30 After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

PRO may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and  
35 proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an

expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an OD<sub>600</sub> of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium citrate·2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 ml water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

*E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni<sup>2+</sup>-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A<sub>280</sub> absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### 6.8. EXAMPLE 8: Expression of PRO in mammalian cells

This example illustrates preparation of a potentially glycosylated form of PRO by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO DNA using ligation methods such as described in Sambrook *et al.*, *supra*. The resulting vector is called pRK5-PRO.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-PRO DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya *et al.*, *Cell*, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of the PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Sompanyrac *et al.*, *Proc. Natl. Acad. Sci.*, 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin and 0.1 µg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, PRO can be expressed in CHO cells. The pRK5-PRO can be transfected into CHO cells using known reagents such as CaPO<sub>4</sub> or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as <sup>35</sup>S-methionine. After determining the presence of a PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested.

The medium containing the expressed PRO polypeptide can then be concentrated and purified by any selected method.

Epitope-tagged PRO may also be expressed in host CHO cells. The PRO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-His tag into a Baculovirus expression vector. The poly-His tagged PRO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged PRO can then be concentrated and purified by any selected method, such as by Ni<sup>2+</sup>-chelate affinity chromatography.

PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g., extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or as a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel *et al.*, Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used in expression in CHO cells is as described in Lucas *et al.*, Nucl. Acids Res., 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect® (Qiagen), Dospers® or Fugene® (Boehringer Mannheim). The cells are grown as described in Lucas *et al.*, *supra*. Approximately 3 x 10<sup>7</sup> cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into a water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 ml of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 ml of selective media (0.2 µm filtered PS20 with 5% 0.2 µm diafiltered fetal bovine serum). The cells are then aliquoted into a 100 ml spinner containing 90 ml of selective media. After 1-2 days, the cells are transferred into a 250 ml spinner filled with 150 ml selective growth medium and incubated at 37°C. After another 2-3 days, 250 ml, 500 ml and 2000 ml spinners are seeded with 3 x 10<sup>5</sup> cells/ml. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at 1.2 x 10<sup>6</sup> cells/ml. On day 0, the cell number and pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 ml of 500 g/L

glucose and 0.6 ml of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability drops below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22  $\mu$ m filter. The filtrate is either stored at 4°C or immediately loaded onto columns for purification.

5 For the poly-His tagged constructs, the proteins are purified using a Ni<sup>2+</sup>-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni<sup>2+</sup>-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly  
10 purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which has been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before  
15 elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ l of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### 20 6.9. EXAMPLE 9: Expression of PRO in Yeast

The following method describes recombinant expression of PRO in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can be cloned  
25 into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by  
30 precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.

35 Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

6.10. EXAMPLE 10: Expression of PRO in Baculovirus-Infected Insect Cells

The following method describes recombinant expression in Baculovirus-infected insect cells.

The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-His tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO (such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley *et al.*, Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-His tagged PRO can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert *et al.*, Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 ml Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 µm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 ml, washed with 25 ml of water and equilibrated with 25 ml of loading buffer. The filtered cell extract is loaded onto the column at 0.5 ml per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A<sub>280</sub> baseline again, the column is developed with a 0 to 500 mM imidazole gradient in the secondary wash buffer. One ml fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Following PCR amplification, the respective coding sequences are subcloned into a baculovirus expression vector (pb.PH.IgG for IgG fusions and pb.PH.His.c for poly-His tagged proteins), and the vector and Baculogold® baculovirus DNA (Pharmingen) are co-transfected into 105 *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711), using Lipofectin (Gibco BRL). pb.PH.IgG and pb.PH.His are modifications of the commercially available baculovirus expression vector pVL1393 (Pharmingen), with modified polylinker regions to include the His or Fc tag sequences. The cells are grown in Hink's TNM-FH medium supplemented with 10% FBS (Hyclone). Cells are

incubated for 5 days at 28°C. The supernatant is harvested and subsequently used for the first viral amplification by infecting Sf9 cells in Hink's TNM-FH medium supplemented with 10% FBS at an approximate multiplicity of infection (MOI) of 10. Cells are incubated for 3 days at 28°C. The supernatant is harvested and the expression of the constructs in the baculovirus expression vector is determined by batch binding of 1 ml of supernatant to 25 ml of Ni<sup>2+</sup>-NTA beads (QIAGEN) for histidine tagged proteins or Protein-A Sepharose CL-4B beads (Pharmacia) for IgG tagged proteins followed by SDS-PAGE analysis comparing to a known concentration of protein standard by Coomassie blue staining.

The first viral amplification supernatant is used to infect a spinner culture (500 ml) of Sf9 cells grown in ESF-921 medium (Expression Systems LLC) at an approximate MOI of 0.1. Cells are incubated for 3 days at 28°C. The supernatant is harvested and filtered. Batch binding and SDS-PAGE analysis is repeated, as necessary, until expression of the spinner culture is confirmed.

The conditioned medium from the transfected cells (0.5 to 3 L) is harvested by centrifugation to remove the cells and filtered through 0.22 micron filters. For the poly-His tagged constructs, the protein construct is purified using a Ni<sup>2+</sup>-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni<sup>2+</sup>-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc containing) constructs of proteins are purified from the conditioned media as follows. The conditioned media is pumped onto a 5 ml Protein A column (Pharmacia) which has been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 ml of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity of the proteins is verified by SDS polyacrylamide gel (PAGE) electrophoresis and N-terminal amino acid sequencing by Edman degradation.

Alternatively, a modified baculovirus procedure may be used incorporating high-5 cells. In this procedure, the DNA encoding the desired sequence is amplified with suitable systems, such as Pfu (Stratagene), or fused upstream (5'-of) of an epitope tag contained with a baculovirus expression vector. Such epitope tags include poly-His tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pIE1-1 (Novagen). The pIE1-1 and pIE1-2 vectors are designed for constitutive expression of recombinant proteins from the baculovirus ie1 promoter in stably-transformed insect cells (1). The plasmids differ only in the orientation of the multiple cloning sites and contain all promoter sequences known to be important for ie1-mediated gene expression in uninfected insect cells as well as the hr5 enhancer element. pIE1-1 and pIE1-2 include the translation initiation site and can be used to produce fusion proteins. Briefly, the desired sequence or the desired portion of the sequence (such as the sequence encoding the



extracellular domain of a transmembrane protein) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector. For example, derivatives of pIE1-1 can include the Fc region of human IgG (pb.PH.IgG) or an 8 histidine (pb.PH.His) tag downstream (3'-of) the desired sequence. Preferably, the vector construct is sequenced for confirmation.

High-5 cells are grown to a confluency of 50% under the conditions of, 27°C, no CO<sub>2</sub>, NO pen/strep. For each 150 mm plate, 30 µg of pIE based vector containing the sequence is mixed with 1 ml Ex-Cell medium (Media: Ex-Cell 401 + 1/100 L-Glu JRH Biosciences #14401-78P (note: this media is light sensitive)), and in a separate tube, 100 µl of CellFectin (CellFECTIN (GibcoBRL #10362-010) (vortexed to mix)) is mixed with 1 ml of Ex-Cell medium. The two solutions are combined and allowed to incubate at room temperature for 15 minutes. 8 ml of Ex-Cell media is added to the 2 ml of DNA/CellFECTIN mix and this is layered on high-5 cells that have been washed once with Ex-Cell media. The plate is then incubated in darkness for 1 hour at room temperature. The DNA/CellFECTIN mix is then aspirated, and the cells are washed once with Ex-Cell to remove excess CellFECTIN, 30 ml of fresh Ex-Cell media is added and the cells are incubated for 3 days at 28°C. The supernatant is harvested and the expression of the sequence in the baculovirus expression vector is determined by batch binding of 1 ml of supernatant to 25 ml of Ni<sup>2+</sup>-NTA beads (QIAGEN) for histidine tagged proteins or Protein-A Sepharose CL-4B beads (Pharmacia) for IgG tagged proteins followed by SDS-PAGE analysis comparing to a known concentration of protein standard by Coomassie blue staining.

The conditioned media from the transfected cells (0.5 to 3 L) is harvested by centrifugation to remove the cells and filtered through 0.22 micron filters. For the poly-His tagged constructs, the protein comprising the sequence is purified using a Ni<sup>2+</sup>-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni<sup>2+</sup>-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 48°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is then subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc containing) constructs of proteins are purified from the conditioned media as follows. The conditioned media is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 ml of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity of the sequence is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation and other analytical procedures as desired or necessary.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### 6.11. EXAMPLE 11: Preparation of Antibodies that Bind PRO

This example illustrates preparation of monoclonal antibodies which can specifically bind the PRO polypeptide or an epitope on the PRO polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

5 Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified PRO, fusion proteins containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

10 Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital  
15 bleeding for testing in ELISA assays to detect anti-PRO antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then  
20 be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against PRO. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.

25 The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

#### 6.12. EXAMPLE 12: Purification of PRO Polypeptides Using Specific Antibodies

30 Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

35 Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise,

monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

#### 6.13. EXAMPLE 13: Drug Screening

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such

as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

#### 6.14. EXAMPLE 14: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, Bio/Technology, 9: 19-21 (1991)).

In one approach, the three-dimensional structure of the PRO polypeptide, or of an PRO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, J. Biochem., 113:742-746 (1993).

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

6.15. EXAMPLE 15: Stimulation of Endothelial Cell Proliferation (Assay 8)

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to stimulate adrenal cortical capillary endothelial cell (ACE) growth. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of conditions or disorders where angiogenesis would be beneficial including, for example, wound healing, and the like (as would agonists of these PRO polypeptides). Antagonists of the PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of cancerous tumors.

Bovine adrenal cortical capillary endothelial (ACE) cells (from primary culture, maximum of 12-14 passages) were plated in 96-well plates at 500 cells/well per 100 microliter. Assay media included low glucose DMEM, 10% calf serum, 2 mM glutamine, and 1X penicillin/streptomycin/fungizone. Control wells included the following: (1) no ACE cells added; (2) ACE cells alone; (3) ACE cells plus VEGF (5 ng/ml); and (4) ACE cells plus FGF (5ng/ml). The control or test sample, (in 100 microliter volumes), was then added to the wells (at dilutions of 1%, 0.1% and 0.01%, respectively). The cell cultures were incubated for 6-7 days at 37°C/5% CO<sub>2</sub>. After the incubation, the media in the wells was aspirated, and the cells were washed 1X with PBS. An acid phosphatase reaction mixture (100 microliter; 0.1M sodium acetate, pH 5.5, 0.1% Triton X-100, 10 mM p-nitrophenyl phosphate) was then added to each well. After a 2 hour incubation at 37°C, the reaction was stopped by addition of 10 microliters 1N NaOH. Optical density (OD) was measured on a microplate reader at 405 nm.

The activity of a PRO polypeptide was calculated as the fold increase in proliferation (as determined by the acid phosphatase activity, OD 405 nm) relative to (1) cell only background, and (2) relative to maximum stimulation by VEGF. VEGF (at 3-10 ng/ml) and FGF (at 1-5 ng/ml) were employed as an activity reference for maximum stimulation. Results of the assay were considered "positive" if the observed stimulation was  $\geq$  50% increase over background. VEGF (5 ng/ml) control at 1% dilution gave 1.24 fold stimulation; FGF (5 ng/ml) control at 1% dilution gave 1.46 fold stimulation.

PRO21 tested positive in this assay.

6.16. EXAMPLE 16: Inhibition of Vascular Endothelial Growth Factor (VEGF) Stimulated Proliferation of Endothelial Cell Growth (Assay 9)

The ability of various PRO polypeptides to inhibit VEGF stimulated proliferation of endothelial cells was tested. Polypeptides testing positive in this assay are useful for inhibiting endothelial cell growth in mammals where such an effect would be beneficial, e.g., for inhibiting tumor growth.

Specifically, bovine adrenal cortical capillary endothelial cells (ACE) (from primary culture, maximum of 12-14 passages) were plated in 96-well plates at 500 cells/well per 100 microliter. Assay media included low glucose DMEM, 10% calf serum, 2 mM glutamine, and 1X penicillin/streptomycin/fungizone. Control wells included the following: (1) no ACE cells added; (2) ACE cells alone; (3) ACE cells plus 5 ng/ml FGF; (4) ACE cells plus 3 ng/ml VEGF; (5) ACE cells plus 3 ng/ml VEGF plus 1 ng/ml TGF-beta; and (6) ACE cells plus 3 ng/ml VEGF plus 5 ng/ml LIF. The test samples, poly-his tagged PRO polypeptides (in 100 microliter volumes), were then added to the wells (at dilutions of 1%, 0.1% and 0.01%, respectively). The cell cultures were

incubated for 6-7 days at 37°C/5% CO<sub>2</sub>. After the incubation, the media in the wells was aspirated, and the cells were washed 1X with PBS. An acid phosphatase reaction mixture (100 microliter; 0.1M sodium acetate, pH 5.5, 0.1% Triton X-100, 10 mM p-nitrophenyl phosphate) was then added to each well. After a 2 hour incubation at 37°C, the reaction was stopped by addition of 10 microliters 1N NaOH. Optical density (OD) was measured on a microplate reader at 405 nm.

The activity of PRO polypeptides was calculated as the percent inhibition of VEGF (3 ng/ml) stimulated proliferation (as determined by measuring acid phosphatase activity at OD 405 nm) relative to the cells without stimulation. TGF-beta was employed as an activity reference at 1 ng/ml, since TGF-beta blocks 70-90% of VEGF-stimulated ACE cell proliferation. The results are indicative of the utility of the PRO polypeptides in cancer therapy and specifically in inhibiting tumor angiogenesis. Numerical values (relative inhibition) are determined by calculating the percent inhibition of VEGF stimulated proliferation by the PRO polypeptides relative to cells without stimulation and then dividing that percentage into the percent inhibition obtained by TGF-β at 1 ng/ml which is known to block 70-90% of VEGF stimulated cell proliferation. The results are considered positive if the PRO polypeptide exhibits 30% or greater inhibition of VEGF stimulation of endothelial cell growth (relative inhibition 30% or greater).

PRO247, PRO720 and PRO4302 tested positive in this assay.

6.17. EXAMPLE 17: Enhancement of Heart Neonatal Hypertrophy Induced by LIF+ET-1 (Assay 75)

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to enhance neonatal heart hypertrophy induced by LIF and endothelin-1 (ET-1). A test compound that provides a positive response in the present assay would be useful for the therapeutic treatment of cardiac insufficiency diseases or disorders characterized or associated with an undesired level of hypertrophy of the cardiac muscle.

Cardiac myocytes from 1-day old Harlan Sprague Dawley rats (180 μl at  $7.5 \times 10^4$ /ml, serum <0.1, freshly isolated) are introduced on day 1 to 96-well plates previously coated with DMEM/F12 + 4%FCS. Test PRO polypeptide samples or growth medium alone (negative control) are then added directly to the wells on day 2 in 20 μl volume. LIF + ET-1 are then added to the wells on day 3. The cells are stained after an additional 2 days in culture and are then scored visually the next day. A positive in the assay occurs when the PRO polypeptide treated myocytes obtain a score greater than zero. A score of zero represents non-responsive cells whereas scores of 1 or 2 represent enhancement (*i.e.* they are visually larger on the average or more numerous than the untreated myocytes).

PRO21 polypeptides tested positive in this assay.

6.18. EXAMPLE 18: Detection of Endothelial Cell Apoptosis (FACS) (Assay 96)

The ability of PRO polypeptides of the present invention to induce apoptosis in endothelial cells was tested in human venous umbilical vein endothelial cells (HUVEC, Cell Systems) in gelatinized T175 flasks using HUVEC cells below passage 10. PRO polypeptides testing positive in this assay are expected to be useful for

therapeutically treating conditions where apoptosis of endothelial cells would be beneficial including, for example, the therapeutic treatment of tumors.

On day one, the cells were split [420,000 cells per gelatinized 6 cm dishes - (11 x 10<sup>3</sup> cells/cm<sup>2</sup> Falcon, Primaria)] and grown in media containing serum (CS-C, Cell System) overnight or for 16 hours to 24 hours.

On day 2, the cells were washed 1x with 5 ml PBS ; 3 ml of 0% serum medium was added with VEGF (100 ng/ml); and 30  $\mu$ l of the PRO test compound (final dilution 1%) or 0% serum medium (negative control) was added. The mixtures were incubated for 48 hours before harvesting.

The cells were then harvested for FACS analysis. The medium was aspirated and the cells washed once with PBS. 5 ml of 1 x trypsin was added to the cells in a T-175 flask, and the cells were allowed to stand until they were released from the plate (about 5-10 minutes). Trypsinization was stopped by adding 5 ml of growth media. The cells were spun at 1000 rpm for 5 minutes at 4°C. The media was aspirated and the cells were resuspended in 10 ml of 10% serum complemented medium (Cell Systems), 5  $\mu$ l of Annexin-FITC (BioVision) added and chilled tubes were submitted for FACS. A positive result was determined to be enhanced apoptosis in the PRO polypeptide treated samples as compared to the negative control.

PRO4302 polypeptide tested positive in this assay.

#### 6.19. EXAMPLE 19: Induction of c-fos in HUVEC Cells (Assay 123)

This assay is designed to determine whether PRO polypeptides show the ability to induce c-fos in HUVEC cells. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of conditions or disorders where angiogenesis would be beneficial including, for example, wound healing, and the like (as would agonists of these PRO polypeptides). Antagonists of the PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of cancerous tumors.

Human venous umbilical vein endothelial cells (HUVEC, Cell Systems) in growth media (50% Ham's F12 w/o GHT: low glucose, and 50% DMEM without glycine: with NaHCO<sub>3</sub>, 1% glutamine, 10 mM HEPES, 10% FBS, 10 ng/ml bFGF) were plated on 96-well microtiter plates at a cell density of 5x10<sup>3</sup> cells/well. The day after plating (day 2), the cells were starved for 24 hours by removing the growth media and replacing with serum free media. On day 3, the cells are treated with 100  $\mu$ l/well test samples and controls (positive control = growth media; negative control = Protein 32 buffer = 10 mM HEPES, 140 mM NaCl, 4% (w/v) mannitol, pH 6.8). One plate of cells was incubated for 30 minutes at 37°C, in 5% CO<sub>2</sub>. Another plate of cells was incubated for 60 minutes at 37°C, in 5% CO<sub>2</sub>. The samples were removed, and RNA was harvested using the RNeasy 96 kit (Qiagen). Next, the RNA was assayed for c-fos, egr-1 and GAPDH induction using Taqman.

The measure of activity of the fold increase over the negative control (Protein 32/HEPES buffer described above) value was by obtained by calculating the fold increase of the ratio of c-fos to GAPDH in test samples as compared to the negative control. The results are considered positive if the PRO polypeptide exhibits at least a two-fold value over the negative buffer control.

PRO1376 polypeptide tested positive in this assay.

6.20. EXAMPLE 20: Normal Human Iliac Artery Endothelial Cell Proliferation (Assay 138)

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce proliferation of human iliac artery endothelial cells in culture and, therefore, function as useful growth factors.

5 On day 0, human iliac artery endothelial cells (from cell lines, maximum of 12-14 passages) were plated in 96-well plates at 1000 cells/well per 100 microliter and incubated overnight in complete media [epithelial cell growth media (EGM, Clonetics), plus supplements: human epithelial growth factor (hEGF), bovine brain extract (BBE), hydrocortisone, GA-1000, and fetal bovine serum (FBS, Clonetics)]. On day 1, complete media was replaced by basal media [EGM plus 1% FBS] and addition of PRO polypeptides at 1%, 0.1% and 0.01%. On  
10 day 7, an assessment of cell proliferation was performed by Alamar Blue assay followed by Crystal Violet. Results are expressed as % of the cell growth observed with control buffer.

The following PRO polypeptides tested positive in this assay: PRO214, PRO238, PRO256, PRO363, PRO365, PRO791, PRO836, PRO1025, PRO1029, PRO1186, PRO1192, PRO1272, PRO1274, PRO1279, PRO1306, PRO1325, PRO1329, PRO1376, PRO1411, PRO1419, PRO1508, PRO1787, PRO1868, PRO1890,  
15 PRO4324, PRO4333, PRO4408, PRO4499, PRO5725, PRO6006, PRO9821, PRO9873, PRO10008, PRO10096, PRO19670, PRO20040, PRO20044, PRO21384 and PRO28631.

6.21. EXAMPLE 21: Pooled Human Umbilical Vein Endothelial Cell Proliferation (Assay 139)

20 This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce proliferation of pooled human umbilical vein endothelial cells in culture and, therefore, function as useful growth factors.

On day 0, pooled human umbilical vein endothelial cells (from cell lines, maximum of 12-14 passages) were plated in 96-well plates at 1000 cells/well per 100 microliter and incubated overnight in complete media [epithelial cell growth media (EGM, Clonetics), plus supplements: human epithelial growth factor (hEGF), bovine  
25 brain extract (BBE), hydrocortisone, GA-1000, and fetal bovine serum (FBS, Clonetics)]. On day 1, complete media was replaced by basal media [EGM plus 1% FBS] and addition of PRO polypeptides at 1%, 0.1% and 0.01%. On day 7, an assessment of cell proliferation was performed by Alamar Blue assay followed by Crystal Violet. Results are expressed as % of the cell growth observed with control buffer.

The following PRO polypeptides tested positive in this assay: PRO181, PRO205, PRO221, PRO229, PRO231, PRO238, PRO241, PRO247, PRO256, PRO258, PRO263, PRO265, PRO295, PRO321, PRO322, PRO337, PRO363, PRO444, PRO533, PRO697, PRO725, PRO771, PRO788, PRO819, PRO827, PRO828, PRO846, PRO865, PRO1005, PRO1006, PRO1007, PRO1025, PRO1054, PRO1071, PRO1075, PRO1079, PRO1080, PRO1114, PRO1131, PRO1155, PRO1160, PRO1184, PRO1190, PRO1192, PRO1195, PRO1244, PRO1272, PRO1273, PRO1279, PRO1283, PRO1286, PRO1306, PRO1309, PRO1325, PRO1329, PRO1347,  
30 PRO1356, PRO1376, PRO1382, PRO1412, PRO1419, PRO1474, PRO1477, PRO1488, PRO1550, PRO1556, PRO1760, PRO1782, PRO1787, PRO1801, PRO1868, PRO1887, PRO3438, PRO3444, PRO4302, PRO4324, PRO4341, PRO4342, PRO4353, PRO4354, PRO4356, PRO4371, PRO4405, PRO4422, PRO4425, PRO5723,



PRO5725, PRO5737, PRO5776, PRO6029, PRO6071, PRO7436, PRO9771, PRO10008, PRO10096, PRO21055 and PRO21384.

6.22. EXAMPLE 22: Human Coronary Artery Smooth Muscle Cell Proliferation (Assay 140)

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce proliferation of human coronary artery smooth muscle cells in culture and, therefore, function as useful growth factors.

On day 0, human coronary artery smooth muscle cells (from cell lines, maximum of 12-14 passages) were plated in 96-well plates at 1000 cells/well per 100 microliter and incubated overnight in complete media [smooth muscle growth media (SmGM, Clonetics), plus supplements: insulin, human epithelial growth factor (hEGF), human fibroblast growth factor (hFGF), GA-1000, and fetal bovine serum (FBS, Clonetics)]. On day 1, complete media was replaced by basal media [SmGM plus 1% FBS] and addition of PRO polypeptides at 1%, 0.1% and 0.01%. On day 7, an assessment of cell proliferation was performed by Alamar Blue assay followed by Crystal Violet. Results are expressed as % of the cell growth observed with control buffer.

The following PRO polypeptides tested positive in this assay: PRO162, PRO181, PRO182, PRO195, PRO204, PRO221, PRO230, PRO256, PRO258, PRO533, PRO697, PRO725, PRO738, PRO826, PRO836, PRO840, PRO846, PRO865, PRO982, PRO1025, PRO1029, PRO1071, PRO1080, PRO1083, PRO1134, PRO1160, PRO1182, PRO1184, PRO1186, PRO1192, PRO1265, PRO1274, PRO1279, PRO1283, PRO1306, PRO1308, PRO1309, PRO1325, PRO1337, PRO1338, PRO1343, PRO1376, PRO1387, PRO1411, PRO1412, PRO1415, PRO1434, PRO1474, PRO1488, PRO1550, PRO1556, PRO1567, PRO1600, PRO1754, PRO1758, PRO1760, PRO1787, PRO1865, PRO1868, PRO1917, PRO1928, PRO3438, PRO3562, PRO4302, PRO4333, PRO4345, PRO4353, PRO4354, PRO4405, PRO4408, PRO4430, PRO4503, PRO5725, PRO6714, PRO9771, PRO9820, PRO9940, PRO10096, PRO21055, PRO21184 and PRO21366.

6.23. EXAMPLE 23: Microarray Analysis to Detect Overexpression of PRO Polypeptides in HUVEC Cells Treated with Growth Factors

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce angiogenesis by stimulating endothelial cell tube formation in HUVEC cells.

Nucleic acid microarrays, often containing thousands of gene sequences, are useful for identifying differentially expressed genes in tissues exposed to various stimuli (e.g., growth factors) as compared to their normal, unexposed counterparts. Using nucleic acid microarrays, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The cDNA probes are then hybridized to an array of nucleic acids immobilized on a solid support. The array is configured such that the sequence and position of each member of the array is known. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene. If the hybridization signal of a probe from a test (exposed tissue) sample is greater than hybridization signal of a probe from a control (normal, unexposed tissue) sample, the gene or genes overexpressed in the exposed tissue are identified. The

implication of this result is that an overexpressed protein in an exposed tissue may be involved in the functional changes within the tissue following exposure to the stimuli (e.g., tube formation).

The methodology of hybridization of nucleic acids and microarray technology is well known in the art. In the present example, the specific preparation of nucleic acids for hybridization and probes, slides, and hybridization conditions are all detailed in U.S. Provisional Patent Application Serial No. 60/193,767, filed on March 31, 2000 and which is herein incorporated by reference.

In the present example, HUVEC cells grown in either collagen gels or fibrin gels were induced to form tubes by the addition of various growth factors. Specifically, collagen gels were prepared as described previously in Yang *et al.*, *American J. Pathology*, 1999, 155(3):887-895 and Xin *et al.*, *American J. Pathology*, 2001, 158(3):1111-1120. Following gelation of the HUVEC cells, 1X basal medium containing M199 supplemented with 1% FBS, 1X ITS, 2 mM L-glutamine, 50 µg/ml ascorbic acid, 26.5 mM NaHCO<sub>3</sub>, 100U/ml penicillin and 100 U/ml streptomycin was added. Tube formation was elicited by the inclusion in the culture media of either a mixture of phorbol myristate acetate (50 nM), vascular endothelial cell growth factor (40 ng/ml) and basic fibroblast growth factor (40 ng/ml) ("PMA growth factor mix") or hepatocyte growth factor (40 ng/ml) and vascular endothelial cell growth factor (40 ng/ml) (HGF/VEGF mix) for the indicated period of time. Fibrin Gels were prepared by suspending Huvec (4 x 10<sup>5</sup> cells/ml) in M199 containing 1% fetal bovine serum (Hyclone) and human fibrinogen (2.5mg/ml). Thrombin (50U/ml) was then added to the fibrinogen suspension at a ratio of 1 part thrombin solution:30 parts fibrinogen suspension. The solution was then layered onto 10 cm tissue culture plates (total volume: 15 ml/plate) and allowed to solidify at 37°C for 20 min. Tissue culture media (10 ml of BM containing PMA (50 nM), bFGF (40ng/ml) and VEGF (40 ng/ml)) was then added and the cells incubated at 37°C in 5%CO<sub>2</sub> in air for the indicated period of time.

Total RNA was extracted from the HUVEC cells incubated for 0, 4, 8, 24, 40 and 50 hours in the different matrix and media combinations using a TRIzol extraction followed by a second purification using RNAeasy Mini Kit (Qiagen). The total RNA was used to prepare cRNA which was then hybridized to the microarrays.

In the present experiments, nucleic acid probes derived from the herein described PRO polypeptide-encoding nucleic acid sequences were used in the creation of the microarray and RNA from the HUVEC cells described above were used for the hybridization thereto. Pairwise comparisons were made using time 0 chips as a baseline. Three replicate samples were analyzed for each experimental condition and time. Hence there were 3 time 0 samples for each treatment and 3 replicates of each successive time point. Therefore, a 3 by 3 comparison was performed for each time point compared against each time 0 point. This resulted in 9 comparisons per time point. Only those genes that had increased expression in all three non-time-0 replicates in each of the different matrix and media combinations as compared to any of the three time zero replicates were considered positive. Although this stringent method of data analysis does allow for false negatives, it minimizes false positives.

PRO178, PRO195, PRO228, PRO301, PRO302, PRO532, PRO724, PRO730, PRO734, PRO793, PRO871, PRO938, PRO1012, PRO1120, PRO1139, PRO1198, PRO1287, PRO1361, PRO1864, PRO1873,

PRO2010, PRO3579, PRO4313, PRO4527, PRO4538, PRO4553, PRO4995, PRO5730, PRO6008, PRO7223, PRO7248 and PRO7261 tested positive in this assay.

#### 6.24. EXAMPLE 24: *In situ* Hybridization

*In situ* hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis, and aid in chromosome mapping.

*In situ* hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision, 1: 169-176 (1994), using PCR-generated  $^{33}\text{P}$ -labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinized in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, *supra*. A ( $^{33}\text{P}$ )UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in Kodak NTB2<sup>TM</sup> nuclear track emulsion and exposed for 4 weeks.

##### 6.24.1. $^{33}\text{P}$ -Riboprobe synthesis

6.0  $\mu\text{l}$  (125 mCi) of  $^{33}\text{P}$ -UTP (Amersham BF 1002, SA <2000 Ci/mmol) were speed-vacuum dried. To each tube containing dried  $^{33}\text{P}$ -UTP, the following ingredients were added:

2.0  $\mu\text{l}$  5x transcription buffer

1.0  $\mu\text{l}$  DTT (100 mM)

2.0  $\mu\text{l}$  NTP mix (2.5 mM: 10  $\mu\text{l}$  each of 10 mM GTP, CTP & ATP + 10  $\mu\text{l}$  H<sub>2</sub>O)

1.0  $\mu\text{l}$  UTP (50  $\mu\text{M}$ )

1.0  $\mu\text{l}$  RNAsin

1.0  $\mu\text{l}$  DNA template (1  $\mu\text{g}$ )

1.0  $\mu\text{l}$  H<sub>2</sub>O

1.0  $\mu\text{l}$  RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

The tubes were incubated at 37°C for one hour. A total of 1.0  $\mu\text{l}$  RQ1 DNase was added, followed by incubation at 37°C for 15 minutes. A total of 90  $\mu\text{l}$  TE (10 mM Tris pH 7.6/1 mM EDTA pH 8.0) was added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a MICROCON-50<sup>TM</sup> ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, a total of 100  $\mu\text{l}$  TE was added, then 1  $\mu\text{l}$  of the final product was pipetted on DE81 paper and counted in 6 ml of BIOFLUOR II<sup>TM</sup>.

The probe was run on a TBE/urea gel. A total of 1-3  $\mu\text{l}$  of the probe or 5  $\mu\text{l}$  of RNA Mrk III was added to 3  $\mu\text{l}$  of loading buffer. After heating on a 95°C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, and the sample was loaded and run at 180-250 volts for 45 minutes. The gel was wrapped in plastic wrap (SARAN<sup>TM</sup> brand) and exposed to XAR film with an intensifying screen in a -70°C freezer one hour to overnight.

6.24.2. <sup>33</sup>P-Hybridization6.24.2.1. *Pretreatment of frozen sections*

The slides were removed from the freezer, placed on aluminum trays, and thawed at room temperature for 5 minutes. The trays were placed in a 55°C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml SQ H<sub>2</sub>O). After deproteination in 0.5 µg/ml proteinase K for 10 minutes at 37°C (12.5 µl of 10 mg/ml stock in 250 ml prewarmed RNase-free RNase buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, and 100% ethanol, 2 minutes each.

6.24.2.2. *Pretreatment of paraffin-embedded sections*

The slides were deparaffinized, placed in SQ H<sub>2</sub>O, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinated in 20 µg/ml proteinase K (500 µl of 10 mg/ml in 250 ml RNase-free RNase buffer; 37°C, 15 minutes) for human embryo tissue, or 8 x proteinase K (100 µl in 250 ml RNase buffer, 37°C, 30 minutes) for formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

6.24.2.3. *Prehybridization*

The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) - saturated filter paper. The tissue was covered with 50 µl of hybridization buffer (3.75 g dextran sulfate + 6 ml SQ H<sub>2</sub>O), vortexed, and heated in the microwave for 2 minutes with the cap loosened. After cooling on ice, 18.75 ml formamide, 3.75 ml 20 x SSC, and 9 ml SQ H<sub>2</sub>O were added, and the tissue was vortexed well and incubated at 42°C for 1-4 hours.

6.24.2.4. *Hybridization*

1.0 x 10<sup>6</sup> cpm probe and 1.0 µl tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48 µl hybridization buffer was added per slide. After vortexing, 50 µl <sup>33</sup>P mix was added to 50 µl prehybridization on the slide. The slides were incubated overnight at 55°C.

6.24.2.5. *Washes*

Washing was done for 2x10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25 M EDTA, V<sub>f</sub>=4L), followed by RNaseA treatment at 37°C for 30 minutes (500 µl of 10 mg/ml in 250 ml RNase buffer = 20 µg/ml). The slides were washed 2 x10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA (20 ml 20 x SSC + 16 ml EDTA, V<sub>f</sub>=4L).

6.24.2.6. *Oligonucleotides*

*In situ* analysis was performed on three of the DNA sequences disclosed herein. The primers used to generate the probes and/or the probes employed for these analyses are as follows:

5 DNA33100-p1: 5'GGA TTC TAA TAC GAC TCA CTA TAG GGC CGG GTG GAG GTG GAA CAG AAA  
3' (SEQ ID NO:375)

DNA33100-p2: 5' CTA TGA AAT TAA CCC TCA CTA AAG GGA CAC AGA CAG AGC CCC ATA CGC  
3' (SEQ ID NO:376)

DNA34431-p1: 5'GGA TTC TAA TAC GAC TCA CTA TAG GGC CAG GGA AAT CCG GAT GTC TC  
3' (SEQ ID NO:377)

10 DNA34431-p2: 5' CTA TGA AAT TAA CCC TCA CTA AAG GGA GTA AGG GGA TGC CAC CGA GTA  
3' (SEQ ID NO:378)

DNA38268-p1: 5'GGA TTC TAA TAC GAC TCA CTA TAG GGC CAG CTA CCC GCA GGA GGA GG  
3' (SEQ ID NO:379)

15 DNA38268-p2: 5'CTA TGA AAT TAA CCC TCA CTA AAG GGA TCC CAG GTG ATG AGG TCC AGA  
3' (SEQ ID NO:380)

DNA64908 probe: 5'CCATCTCGGAGACCTTTGTGCAGCGTGTATACCAGCCTTACCTCACCA  
CTTGCGACGGACACAGAGCCTGCAGCACCTACCGAACCATCTACCGGAC  
20 TGCCTATCGCCGTAGCCCTGGGGTGACTCCCGCAAGCCTCGCTATGCTTG  
CTGCCCTGGTTGGAAGAGGACCAAGTGGGCTCCCTGGGGCTTGTGGAGCA  
GCAATATGCCAGCCTCCATGTGGGAATGGAGGGAGTTGCATCCGCCAG  
GACACTGCCGCTGCCCTGTGGGATGGCAGGGAGATACTTGCCAGACAGA  
TGTTGATGAATGCAGTACAGGAGAGGCCAGTTGTCCCCAGCGCTGTGTC  
AATACTGTGGGAAGTTACTGGTGCCAGGGATGGGAGGGACAAAGCCCAT  
25 CTGCAGATGGGACGCGCTGCCTGTCTAAGGAGGGGCCCTCCCGGTGGCC  
CCAACCCACAGCAGGAGTGGACAGCA3' (SEQ ID NO:381)

6.24.2.7. *Results*

*In situ* analysis was performed and the results from these analyses are as follows:

6.24.2.7.1. DNA33100-1159 (PRO229) (Scavenger-R/CD6  
homologTNF motif)

A specific positive signal was observed in mononuclear phagocytes (macrophages) of fetal and adult spleen, liver, lymph node and thymus. All other tissues were negative.

5 6.24.2.7.2. DNA34431-1177 (PRO263) (CD44)

A specific positive signal was observed in human fetal tissues and placenta over mononuclear cells, with strong expression in epithelial cells of the adrenal cortex. All adult tissues were negative.

6.24.2.7.3. DNA38268-1188 (PRO295) (Integrin)

10 A specific positive signal was observed in human fetal ganglion cells, fetal neurons, adult adrenal medulla and adult neurons. All other tissues were negative.

6.24.2.7.4. DNA64908-1163-1 (PRO1449)

15 A specific positive signal was observed in the developing vasculature (from E7-E11), in endothelial cells and in progenitors of endothelial cells in wholemount in situ hybridizations of mouse embryos (Figure 375). Specific expression was also observed in a subset of blood vessels and epidermis from E12 onward. A mouse orthologue of PRO1449 which has about 78% amino acid identity with PRO1449 was used as the probe.

In normal adult tissues, expression was low to absent. When present, expression was confined to the vasculature (Figure 376). Figure 376 further shows that highest expression in adult tissues was observed regionally in vessels running within the white matter of the brain. Elevated expression was also observed in vasculature of many inflamed and diseased tissues, including, but not limited to, tumor vasculature.

20 Following electroporation of the mouse orthologue of PRO1449 into the choroid layer in the eyes of chicken embryos, new vessel formation was observed in the electroporated eye (top right), but not in the control side from the same embryo (top left), or an embryo that was electroporated with a control cDNA (bottom right) (Figure 377).

25 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct(s) deposited, since the deposited embodiment(s) is/are intended as single illustration(s) of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material(s) herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific  
30 illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure

248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) and Figure 374 (SEQ ID NO:374).

2. An isolated nucleic acid molecule having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure 71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figures 75A-75B (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ



5 ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure  
123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID  
NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure  
137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:139), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID  
10 NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure  
151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID  
NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure  
165 (SEQ ID NO:165), Figure 167 (SEQ ID NO:167), Figure 169 (SEQ ID NO:169), Figure 171 (SEQ ID  
NO:171), Figure 173 (SEQ ID NO:173), Figure 175 (SEQ ID NO:175), Figure 177 (SEQ ID NO:177), Figure  
10 179 (SEQ ID NO:179), Figure 181 (SEQ ID NO:181), Figure 183 (SEQ ID NO:183), Figure 185 (SEQ ID  
NO:185), Figure 187 (SEQ ID NO:187), Figure 189 (SEQ ID NO:189), Figure 191 (SEQ ID NO:191), Figure  
193 (SEQ ID NO:193), Figure 195 (SEQ ID NO:195), Figure 197 (SEQ ID NO:197), Figure 199 (SEQ ID  
NO:199), Figure 201 (SEQ ID NO:201), Figure 203 (SEQ ID NO:203), Figure 205 (SEQ ID NO:205), Figure  
207 (SEQ ID NO:207), Figure 209 (SEQ ID NO:209), Figure 211 (SEQ ID NO:211), Figure 213 (SEQ ID  
15 NO:213), Figure 215 (SEQ ID NO:215), Figure 217 (SEQ ID NO:217), Figure 219 (SEQ ID NO:219), Figure  
221 (SEQ ID NO:221), Figure 223 (SEQ ID NO:223), Figure 225 (SEQ ID NO:225), Figure 227 (SEQ ID  
NO:227), Figure 229 (SEQ ID NO:229), Figure 231 (SEQ ID NO:231), Figure 233 (SEQ ID NO:233), Figure  
235 (SEQ ID NO:235), Figure 237 (SEQ ID NO:237), Figure 239 (SEQ ID NO:239), Figure 241 (SEQ ID  
NO:241), Figure 243 (SEQ ID NO:243), Figure 245 (SEQ ID NO:245), Figure 247 (SEQ ID NO:247), Figure  
20 249 (SEQ ID NO:249), Figure 251 (SEQ ID NO:251), Figure 253 (SEQ ID NO:253), Figure 255 (SEQ ID  
NO:255), Figure 257 (SEQ ID NO:257), Figure 259 (SEQ ID NO:259), Figure 261 (SEQ ID NO:261), Figure  
263 (SEQ ID NO:263), Figure 265 (SEQ ID NO:265), Figure 267 (SEQ ID NO:267), Figure 269 (SEQ ID  
NO:269), Figure 271 (SEQ ID NO:271), Figure 273 (SEQ ID NO:273), Figure 275 (SEQ ID NO:275), Figure  
277 (SEQ ID NO:277), Figure 279 (SEQ ID NO:279), Figure 281 (SEQ ID NO:281), Figure 283 (SEQ ID  
25 NO:283), Figure 285 (SEQ ID NO:285), Figure 287 (SEQ ID NO:287), Figures 289A-289B (SEQ ID NO:289),  
Figure 291 (SEQ ID NO:291), Figure 293 (SEQ ID NO:293), Figure 295 (SEQ ID NO:295), Figure 297 (SEQ  
ID NO:297), Figure 299 (SEQ ID NO:299), Figure 301 (SEQ ID NO:301), Figure 303 (SEQ ID NO:303), Figure  
305 (SEQ ID NO:305), Figure 307 (SEQ ID NO:307), Figure 309 (SEQ ID NO:309), Figures 311A-311B (SEQ  
ID NO:311), Figure 313 (SEQ ID NO:313), Figure 315 (SEQ ID NO:315), Figure 317 (SEQ ID NO:317), Figure  
30 319 (SEQ ID NO:319), Figure 321 (SEQ ID NO:321), Figure 323 (SEQ ID NO:323), Figure 325 (SEQ ID  
NO:325), Figure 327 (SEQ ID NO:327), Figure 329 (SEQ ID NO:329), Figure 331 (SEQ ID NO:331), Figure  
333 (SEQ ID NO:333), Figure 335 (SEQ ID NO:335), Figure 337 (SEQ ID NO:337), Figure 339 (SEQ ID  
NO:339), Figure 341 (SEQ ID NO:341), Figure 343 (SEQ ID NO:343), Figure 345 (SEQ ID NO:345), Figure  
347 (SEQ ID NO:347), Figure 349 (SEQ ID NO:349), Figures 351A-351B (SEQ ID NO:351), Figure 353 (SEQ  
35 ID NO:353), Figure 355 (SEQ ID NO:355), Figure 357 (SEQ ID NO:357), Figure 359 (SEQ ID NO:359), Figure  
361 (SEQ ID NO:361), Figure 363 (SEQ ID NO:363), Figure 365 (SEQ ID NO:365), Figure 367 (SEQ ID  
NO:367), Figure 369 (SEQ ID NO:369), Figure 371 (SEQ ID NO:371) and Figure 373 (SEQ ID NO:373).

3. An isolated nucleic acid molecule having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure 71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figures 75A-75B (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure 123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure 137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:139), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure 151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID NO:165), Figure 167 (SEQ ID NO:167), Figure 169 (SEQ ID NO:169), Figure 171 (SEQ ID NO:171), Figure 173 (SEQ ID NO:173), Figure 175 (SEQ ID NO:175), Figure 177 (SEQ ID NO:177), Figure 179 (SEQ ID NO:179), Figure 181 (SEQ ID NO:181), Figure 183 (SEQ ID NO:183), Figure 185 (SEQ ID NO:185), Figure 187 (SEQ ID NO:187), Figure 189 (SEQ ID NO:189), Figure 191 (SEQ ID NO:191), Figure 193 (SEQ ID NO:193), Figure 195 (SEQ ID NO:195), Figure 197 (SEQ ID NO:197), Figure 199 (SEQ ID NO:199), Figure 201 (SEQ ID NO:201), Figure 203 (SEQ ID NO:203), Figure 205 (SEQ ID NO:205), Figure 207 (SEQ ID NO:207), Figure 209 (SEQ ID NO:209), Figure 211 (SEQ ID NO:211), Figure 213 (SEQ ID NO:213), Figure 215 (SEQ ID NO:215), Figure 217 (SEQ ID NO:217), Figure 219 (SEQ ID NO:219), Figure 221 (SEQ ID NO:221), Figure 223 (SEQ ID NO:223), Figure 225 (SEQ ID NO:225), Figure 227 (SEQ ID NO:227), Figure 229 (SEQ ID NO:229), Figure 231 (SEQ ID NO:231), Figure 233 (SEQ ID NO:233), Figure 235 (SEQ ID NO:235), Figure 237 (SEQ ID NO:237), Figure 239 (SEQ ID NO:239), Figure 241 (SEQ ID NO:241), Figure 243 (SEQ ID NO:243), Figure 245 (SEQ ID NO:245), Figure 247 (SEQ ID NO:247), Figure 249 (SEQ ID NO:249), Figure 251 (SEQ ID NO:251), Figure

253 (SEQ ID NO:253), Figure 255 (SEQ ID NO:255), Figure 257 (SEQ ID NO:257), Figure 259 (SEQ ID NO:259), Figure 261 (SEQ ID NO:261), Figure 263 (SEQ ID NO:263), Figure 265 (SEQ ID NO:265), Figure 267 (SEQ ID NO:267), Figure 269 (SEQ ID NO:269), Figure 271 (SEQ ID NO:271), Figure 273 (SEQ ID NO:273), Figure 275 (SEQ ID NO:275), Figure 277 (SEQ ID NO:277), Figure 279 (SEQ ID NO:279), Figure 281 (SEQ ID NO:281), Figure 283 (SEQ ID NO:283), Figure 285 (SEQ ID NO:285), Figure 287 (SEQ ID NO:287), Figures 289A-289B (SEQ ID NO:289), Figure 291 (SEQ ID NO:291), Figure 293 (SEQ ID NO:293), Figure 295 (SEQ ID NO:295), Figure 297 (SEQ ID NO:297), Figure 299 (SEQ ID NO:299), Figure 301 (SEQ ID NO:301), Figure 303 (SEQ ID NO:303), Figure 305 (SEQ ID NO:305), Figure 307 (SEQ ID NO:307), Figure 309 (SEQ ID NO:309), Figures 311A-311B (SEQ ID NO:311), Figure 313 (SEQ ID NO:313), Figure 315 (SEQ ID NO:315), Figure 317 (SEQ ID NO:317), Figure 319 (SEQ ID NO:319), Figure 321 (SEQ ID NO:321), Figure 323 (SEQ ID NO:323), Figure 325 (SEQ ID NO:325), Figure 327 (SEQ ID NO:327), Figure 329 (SEQ ID NO:329), Figure 331 (SEQ ID NO:331), Figure 333 (SEQ ID NO:333), Figure 335 (SEQ ID NO:335), Figure 337 (SEQ ID NO:337), Figure 339 (SEQ ID NO:339), Figure 341 (SEQ ID NO:341), Figure 343 (SEQ ID NO:343), Figure 345 (SEQ ID NO:345), Figure 347 (SEQ ID NO:347), Figure 349 (SEQ ID NO:349), Figures 351A-351B (SEQ ID NO:351), Figure 353 (SEQ ID NO:353), Figure 355 (SEQ ID NO:355), Figure 357 (SEQ ID NO:357), Figure 359 (SEQ ID NO:359), Figure 361 (SEQ ID NO:361), Figure 363 (SEQ ID NO:363), Figure 365 (SEQ ID NO:365), Figure 367 (SEQ ID NO:367), Figure 369 (SEQ ID NO:369), Figure 371 (SEQ ID NO:371) and Figure 373 (SEQ ID NO:373).

4. An isolated nucleic acid molecule having at least 80% nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

5. A vector comprising the nucleic acid of Claim 1.

6. A host cell comprising the vector of Claim 5.

7. The host cell of Claim 6, wherein said cell is a CHO cell.

8. The host cell of Claim 6, wherein said cell is an *E. coli*.

9. The host cell of Claim 6, wherein said cell is a yeast cell.

10. A process for producing a PRO polypeptide comprising culturing the host cell of Claim 6 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

11. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID

NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) and Figure 374 (SEQ ID NO:374).

12. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

13. A chimeric molecule comprising a polypeptide according to Claim 11 fused to a heterologous amino acid sequence.

14. The chimeric molecule of Claim 13, wherein said heterologous amino acid sequence is an epitope tag sequence.

15. The chimeric molecule of Claim 13, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

16. An antibody which specifically binds to a polypeptide according to Claim 11.

17. The antibody of Claim 16, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

18. An isolated nucleic acid molecule having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26),  
5 Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64),  
10 Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102),  
15 Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID

NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure

144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18



(SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure

284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), lacking its associated signal peptide.

19. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) an amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID

NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), lacking its associated signal peptide;

(b) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26

(SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure

292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), with its associated signal peptide; or

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID

NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), lacking its associated signal peptide.

20. A method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal comprising administering to the mammal a therapeutically effective amount of a polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32),

Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure

298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), or agonist or antagonist thereof.

21. The method according to Claim 20, wherein the mammal is human.

22. The method of Claim 21, wherein the human has suffered myocardial infarction.

23. The method of Claim 21, wherein the human has cardiac hypertrophy, trauma, a cancer, or age-related macular degeneration.

24. The method of Claim 23, wherein the cardiac hypertrophy is characterized by the presence of an elevated level of  $\text{PGF}_{2\alpha}$ .

25. The method of Claim 20, wherein the polypeptide is administered together with a cardiovascular, endothelial or angiogenic agent.

26. The method of Claim 23, wherein the polypeptide is administered following primary angioplasty.

27. The method of Claim 20, wherein the cardiovascular, endothelial or angiogenic disorder is cancer.

28. The method of Claim 27, wherein the polypeptide is administered in combination with a chemotherapeutic agent, a growth inhibitory agent or a cytotoxic agent.

29. The method of Claim 20, wherein said agonist is an antibody to said polypeptide.

30. The method of Claim 20, wherein said antagonist is an antibody to said polypeptide.



31. A method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal comprising administering to the mammal a nucleic acid molecule that encodes a polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure

256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372) or Figure 374 (SEQ ID NO:374), or agonist or antagonist thereof.

32. The method of Claim 31, wherein said agonist is an antibody to said polypeptide.
33. The method of Claim 31, wherein said antagonist is an antibody to said polypeptide.
34. The method of Claim 31, wherein the mammal is human.
35. The method of Claim 31, wherein the nucleic acid molecule is administered via *ex vivo* gene therapy.
36. A method for inhibiting endothelial cell growth in a mammal comprising administering to the mammal a PRO247, PRO720 or PRO4302 polypeptide or agonist thereof, wherein endothelial cell growth in said mammal is inhibited.
37. A method for stimulating endothelial cell growth in a mammal comprising administering to the mammal a PRO21, PRO181, PRO205, PRO214, PRO221, PRO229, PRO231, PRO238, PRO241, PRO247, PRO256, PRO258, PRO263, PRO265, PRO295, PRO321, PRO322, PRO337, PRO363, PRO365, PRO444, PRO533, PRO697, PRO725, PRO771, PRO788, PRO791, PRO819, PRO827, PRO828, PRO836, PRO846, PRO865, PRO1005, PRO1006, PRO1007, PRO1025, PRO1029, PRO1054, PRO1071, PRO1075, PRO1079,

PRO1080, PRO1114, PRO1131, PRO1155, PRO1160, PRO1184, PRO1186, PRO1190, PRO1192, PRO1195, PRO1244, PRO1272, PRO1273, PRO1274, PRO1279, PRO1283, PRO1286, PRO1306, PRO1309, PRO1325, PRO1329, PRO1347, PRO1356, PRO1376, PRO1382, PRO1411, PRO1412, PRO1419, PRO1474, PRO1477, PRO1488, PRO1508, PRO1550, PRO1556, PRO1760, PRO1782, PRO1787, PRO1801, PRO1868, PRO1887, PRO1890, PRO3438, PRO3444, PRO4302, PRO4324, PRO4333, PRO4341, PRO4342, PRO4353, PRO4354, PRO4356, PRO4371, PRO4405, PRO4408, PRO4422, PRO4425, PRO4499, PRO5723, PRO5725, PRO5737, PRO5776, PRO6006, PRO6029, PRO6071, PRO7436, PRO9771, PRO9821, PRO9873, PRO10008, PRO10096, PRO19670, PRO20040, PRO20044, PRO21055, PRO21384 or PRO28631 polypeptide, or agonist thereof, wherein endothelial cell growth in said mammal is stimulated.

38. A method for inducing cardiac hypertrophy in a mammal comprising administering to the mammal a PRO21 polypeptide or agonist thereof, wherein cardiac hypertrophy in said mammal is induced.

39. A method for stimulating angiogenesis induced by a PRO1376 or PRO1449 polypeptide in a mammal comprising administering a therapeutically effective amount of said polypeptide to the mammal, wherein said angiogenesis is stimulated.

40. A method for inducing endothelial cell apoptosis comprising administering to the endothelial cell a PRO4302 polypeptide or agonist thereof, wherein apoptosis in said endothelial cell is induced.

41. A method for stimulating smooth muscle cell growth comprising administering to the smooth muscle cell a PRO162, PRO181, PRO182, PRO195, PRO204, PRO221, PRO230, PRO256, PRO258, PRO533, PRO697, PRO725, PRO738, PRO826, PRO836, PRO840, PRO846, PRO865, PRO982, PRO1025, PRO1029, PRO1071, PRO1080, PRO1083, PRO1134, PRO1160, PRO1182, PRO1184, PRO1186, PRO1192, PRO1265, PRO1274, PRO1279, PRO1283, PRO1306, PRO1308, PRO1309, PRO1325, PRO1337, PRO1338, PRO1343, PRO1376, PRO1387, PRO1411, PRO1412, PRO1415, PRO1434, PRO1474, PRO1488, PRO1550, PRO1556, PRO1567, PRO1600, PRO1754, PRO1758, PRO1760, PRO1787, PRO1865, PRO1868, PRO1917, PRO1928, PRO3438, PRO3562, PRO4302, PRO4333, PRO4345, PRO4353, PRO4354, PRO4405, PRO4408, PRO4430, PRO4503, PRO5725, PRO6714, PRO9771, PRO9820, PRO9940, PRO10096, PRO21055, PRO21184 or PRO21366 polypeptide, or agonist thereof, wherein smooth muscle cell growth in said smooth muscle cell is stimulated.

42. A method for inducing endothelial cell tube formation comprising administering to the endothelial cell a PRO178, PRO195, PRO228, PRO301, PRO302, PRO532, PRO724, PRO730, PRO734, PRO793, PRO871, PRO938, PRO1012, PRO1120, PRO1139, PRO1198, PRO1287, PRO1361, PRO1864, PRO1873, PRO2010, PRO3579, PRO4313, PRO4527, PRO4538, PRO4553, PRO4995, PRO5730, PRO6008, PRO7223, PRO7248 or PRO7261 polypeptide, or agonist thereof, wherein tube formation in said endothelial cell is induced.

1/392

**FIGURE 1**

GCCCACGCGTCCGATGGCGTTACGTTTCGCGGCCTTCTGCTACATGCTGGCGCTGCTGCT  
CACTGCCGCGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTGATGAGCTGAAGAC  
TGATTACAAGAATCCTATAGACCAGTGTAATACCCTGAATCCCCTTGTA TCTCCCAGAGTA  
CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGCAGCAGAGTGGCTTACACTGGG  
TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAGTGATGAG  
TGGCCCAGGACTCTATGACCCTACAACCATCATGAATGCAGATATTCTAGCATATTGTCA  
GAAGGAAGGATGGTGCAAATTAGCTTTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG  
CATGATCTATGTTTTGGTGAGCTCTTAGAACAACACACAGAAGAATTGGTCCAGTTAAGT  
GCATGCAAAAAGCCACCAAATGAAGGGATTCTATCCAGCAAGATCCTGTCCAAGAGTAGC  
CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTTTAAATGTTTCCACAT  
TTTTGCTTGTGGAAAGACTGTTTTCATATGTTATACTCAGATAAAAGATTTTAAATGGTAT  
TACGTATAAAATTAATATAAAATGATTACCTCTGGTGTTGACAGGTTTGAACCTTGCACTTC  
TTAAGGAACAGCCATAATCCTCTGAATGATGCATTAATTACTGACTGTCCTAGTACATTG  
GAAGCTTTTGTATAGGAACCTTGTAAGGGCTCATTGTTTGGTTTCATTGAAACAGTATCTAA  
TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAAATGTATATCTGACTAG  
TGGGAAACTTCATGGGTTTCCTCATCTGTGTCATGTCGATGATTATATATGGATACATTTAC  
AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATTATCCCTGTATATTGCATGAAT  
GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATACTTGCTTTAATTCTTAAGCATA  
AGTAAACATGATATAAAAAATATATGCTGAATTACTTGTGAAGAATGCATTTAAAGCTATT  
TTAAATGTGTTTTTATTTGTAAGACATTACTTATTAAGAAATTGGTTATTATGCTTACTG  
TTCTAATCTGGTGGTAAAGGTATTCTTAAGAATTTGCAGGTACTACAGATTTTCAAACT  
GAATGAGAGAAAATTGTATAACCATCCTGCTGTTCCCTTTAGTGCAATACAATAAACTCT  
GAAATTAAGACTC

2/392

**FIGURE 2**

MAFTFAAFCYMLALLLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTLNPLVLPEYLIHA  
FFCVMFLCAAEWLTLGLNMPLLAYHIWRYMSRPVMSGPGLYDPTTIMNADILAYCQKEGW  
CKLAFYLLAFFYYLYGMIYVLVSS

Important features:

Signal peptide:

amino acids 1-20

Type II transmembrane domain:

amino acids 11-31

Other transmembrane domain:

amino acids 57-77 and 123-143

3/392

## FIGURE 3

GGCTCAGAGGCCCCACTGGACCCTCGGCTCTTCCTTGGACTTCTTGTGTGTTCTGTGAGC  
TTCGCTGGATTTCAGGGTCTTGGGCATCAGAGGTGAGAGGGTGGGAAGGTCCGCCGCGATG  
GGGAAGCCCTGGCTGCGTGCGCTACAGCTGCTGCTCCTGCTGGGCGCGTCTGTGGGCGCGG  
GCGGGCGCCCCGCGCTGCACCTACACCTTCGTGCTGCCCCCGCAGAAGTTCACGGGCGCT  
GTGTGCTGGAGCGGCCCCGCATCCACGCGGGCGACGCCCCGAGGCCGCAACGCCAGCGAG  
CTGGCGGCGCTGCGCATGCGCGTCGGCCGCCACGAGGAGCTGTTACGCGAGCTGCAGAGG  
CTGGCGGCGGCCGACGGCGCCGTGGCCGGCGAGGTGCGCGCGCTGCGCAAGGAGAGCCGC  
GGCCTGAGCGCGCGCCTGGGCCAGTTGCGCGCGCAGCTGCAGCACGAGGCGGGGCCCCGGG  
GCGGGCCCCGGGGGCGGATCTGGGGGCGGAGCCTGCCGCGGCGCTGGCGCTGCTCGGGGAG  
CGCGTGCTCAACGCGTCCGCCGAGGCTCAGCGCGCAGCCGCCCGGTTCCACCAGCTGGAC  
GTCAAGTTCGCGAGCTGGCGCAGCTCGTCAACCAGCAGAGCAGTCTCATCGCCCGCCTG  
GAGCGCCTGTGCCCCGGGAGGCGCGGGCGGGCAGCAGCAGGTCCTGCCGCCACCCCCACTG  
GTGCCCTGTGGTTCCGGTCCGTCTTGTGGGTAGCACCAGTGACACCAGTAGGATGCTGGAC  
CCAGCCCCAGAGCCCCAGAGAGACCAGACCCAGAGACAGCAGGAGCCCATGGCTTCTCCC  
ATGCCCTGCAGGTACCCCTGCGGTCCCCACCAAGCCTGTGGGCCCGTGGCAGGATTGTGCA  
GAGGCCCCGCCAGGCAGGCCATGAACAGAGTGGAGTGTATGAACTGCGAGTGGGCCGTAC  
GTAGTGTGAGTATGGTGTGAGCAGCAACTGGAGGGTGGAGGCTGGACTGTGATCCAGCGG  
AGGCAAGATGGTTTCAGTCAACTTCTTCACTACCTGGCAGCACTATAAGGCGGGCTTTGGG  
CGGCCAGACGGAGAATACTGGCTGGGCCTTGAACCCGTGTATCAGCTGACCAGCCGTGGG  
GACCATGAGCTGCTGGTTCTCCTGGAGGACTGGGGGGGCGTGGAGCACGTGCCCACTAT  
GATGGCTTCTCCCTGGAACCCGAGAGCGACCACTACCGCTGCGGCTTGGCCAGTACCAT  
GGTGATGCTGGAGACTCTCTTTCTGGCACAATGACAAGCCCTTCAGCACCGTGGATAGG  
GACCGAGACTCCTATTCTGGTAACTGTGCCCTGTACCAGCGGGGAGGCTGGTGGTACCAT  
GCCTGTGCCCCACTCCAACCTCAACGGTGTGTGGCACCACGGCGGCCACTACCGAAGCCGC  
TACCAGGATGGTGTCTACTGGGCTGAGTTTCGTGGTGGGGCATATTCTCTCAGGAAGGCC  
GCCATGCTCATTTCGGCCCCCTGAAGCTGTGACTCTGTGTTTCTGTCCCCCTAGGCCCTAG  
AGGACATTGGTCAGCAGGAGCCCAAGTTGTTCTGGCCACACCTTCTTTGTGGCTCAGTGC  
CAATGTGTCCACAGAACTTCCCACTGTGGATCTGTGACCCTGGGCGCTGAAAATGGGAC  
CCAGGAATCCCCCGTCAATATCTTGGCCTCAGATGGCTCCCCAAGGTCATTATATCT  
CGGTTTGAGCTCATATCTTATAATAACACAAAGTAGCCAC

4/392

**FIGURE 4**

MGKPWLRALQLLLLLLGASWARAGAPRCTYTFVLPPQKFTGAVCWSGPASTRATPEAANAS  
ELAALRMVRVGRHEELLRELQRLAADGAVAGEVRALRKESRGLSARLGQLRAQLQHEAGP  
GAGPGADLGAEPAAALALLGERVLNASAEQAARFHQLDVKFRELAQLVTQSSLIAR  
LERLCPGGAGGQQQVLPPPPLVPVVPVRLVGSTSDTSRMLDPAPEPQDQTORQQEPMAS  
PMPAGHPAVPTKPVGPWQDCAEARQAGHEQSGVYELRVGRHVSVWCEQQLEGGGWTVIQ  
RRQDGSVNFFTTWQHYKAGFGRPDGEYWLGLEPVYQLTSRGDHELLVLLEDWGGRGARAH  
YDGFSLPEPSDHYRLRLGQYHGDAGDSLWHDNDKPFSTVDRDRDSYSGNCALYQRGGWWY  
HACAHSNLNGVWHHGGHYRSRYQDGVYWAEFRGGAYSLRKAAMLIRPLKL

**Signal peptide:**

Amino acids 1-20

**N-glycosylation sites:**

Amino acids 58-62;145-149

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

Amino acids 97-101

**Tyrosine kinase phosphorylation site:**

Amino acids 441-448

**N-myristoylation sites:**

Amino acids

16-22;23-29;87-93;108-114;121-127;125-131;129-135;187-193;29  
3-299;353-359;378-384;445-451;453-459**Cell attachment sequence:**

Amino acids 340-343

**Fibrinogen beta and gamma chains C-terminal domain signature:**

Amino acids 418-431

5/392

**FIGURE 5**

CCCACGCGTCCGGCGCCGTGGCCTCGCGTCCATCTTTGCCGTTCTCTCGGACCTGTCACA  
AAGGAGTCGCGCCGCCGCCGCCGCCCTCCCTCCGGTGGGCCCCGGGAGGTAGAGAAAGT  
CAGTGCCACAGCCCGACCGCGCTGCTCTGAGCCCTGGGCACGCGGAACGGGAGGGAGTCT  
GAGGGTTGGGGACGTCTGTGAGGGAGGGGAACAGCCGCTCGAGCCTGGGGCGGGCGGACC  
GGA CTGGGGCCGGGGTAGGCTCTGGAAGGGCCCGGGAGAGAGGTGGCGTTGGTCAGAAC  
CTGAGAAACAGCCGAGAGGTTTTCCACCGAGGCCCGCGCTTGAGGGATCTGAAGAGGTTT  
CTAGAAGAGGGTGTTCCCTCTTTCCGGGGGTCTCACCAGAAGAGGTTCTTGGGGGTGCGC  
CTTCTGAGGAGGCTGCGGCTAACAGGGCCAGAACTGCCATTGGATGTCCAGAATCCCCCT  
GTAGTTGATAATGTTGGGAATAAGCTCTGCAACTTTCTTTGGCATTCA GTTGTAAAAAC  
AAATAGGATGCAAATTCCTCAACTCCAGGTTATGAAAACAGTACTTGAAAACTGAAAAC  
TACCTAAATGATCGTCTTTGGTTGGGGCCGTGTTCTTAGCGAGCAGAAGCCTTG GCCAGGG  
TCTGTTGTTGACTCTCGAAGAGCACATAGCCCACTTCCTAGGGACTGGAGGTGCCGCTAC  
TACCATGGGTAAATTCCTGTATCTGCCGAGATGACAGTGGAACAGATGACAGTGTGACAC  
CCAACAGCAACAGGCCGAGAACAGTGCAGTACCCACTGCTGACACAAGGAGCCAACCACG  
GGACCCTGTTCCGGCCACCAAGGAGGGGCCGAGGACCTCATGAGCCAAGGAGAAAGAAACA  
AAATGTGGATGGGCTAGTGTTGGACACACTGGCAGTAATACGGA CTCTGTAGATAAGTA  
AGTATCTGACTCACGGTCACCTCCAGTGGAATGAAAAGTGTTCTGCCCGGAACCATGACT  
TTAGGACTCCTTCAGTTCCTTTAGGACATACTCGCCAAGCCTTG TGCTCACAGGGCAAAG  
GAGAATATTTTAATGCTCCGCTGATGGCAGAGTAAATGATAAGATTTGATGTTTTTGCTT  
GCTGTCTACTACTTTGTCTGGAAATGTCTAAATGTTTCTGTAGCAGAAAACACGATAAAG  
CTATGATCTTTATTAGAG



6/392

## FIGURE 6

MIVFGWAVFLASRSLGQGLLLTLEEHIAHFLGTGGAATTMGNSCICRDDSGTDDSVDTQQ  
QQAENSAVPTADTRSQPRDPVRPPRRGRGPHEPRRKKQNV DGLVLDTLAVIRTLVDKO

**Signal peptide:**  
amino acids 1-16

**Casein kinase II phosphorylation site:**  
amino acids 22-26, 50-54, 113-117

**N-myristoylation site:**  
amino acids 18-24, 32-38, 34-40, 35-41, 51-57

7/392

**FIGURE 7**

CGGACGCGTGGGGGAAACCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG  
GGGAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACCTGGGGCTCCCCG  
CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCCGGCTGAAGCA  
TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCA GTTGACCTACCCC  
TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT  
TCAATTTGTCA GTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA  
TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC  
CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACCTTATGTCCCTGATGCCAAAA  
ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGGACTCC  
GCACAGAGCTTCATAACCTCTTCATGGACTTTTTATCTTCAAGCCGATGACGGAAAAATA  
GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA  
AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAATGAGAAATTCACAAGCG  
CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC  
TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATTGCTTTGGATTTGT  
TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT  
GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTG  
GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT  
CTTGCTCATTCTGAAATTTAAGCATTTTTCTTTTAAAGACAAGTGTAATAGACATCTAA  
AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA  
CTATAAATGCAAATAAAGTTACTCAAATCTGTG

8/392

**FIGURE 8**

MAAPKGS LWVRTQLGLPPLLLLTALAGGSGTASAEAFDSVLGDTASCHRAQLTYPLHT  
YPKEEELYACQRGCRLEFSICQFVDDGIDLNRKLECESACTEAYSQSDEQYACHLGCONQ  
LPFAELRQEQMLSLMPKMHLFPLTLVRSFWSMMDSAQSFITSSWTFYLQADDGKIVIF  
QSKPEIQYAPHLEQEPTNLRESSLSKMSYLOMRNSQAHRNFLEDGESDGLRCLSLNSGW  
ILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSIYGDLEFMNEQKLNRYPASSLVVVR  
SKTEDHEEAGPLPTKVNLAHSEI

**Important features:**

**Signal peptide:**

amino acids 1-31

**Transmembrane domain:**

amino acids 241-260

**N-glycosylation site:**

amino acids 90-93

9/392

**FIGURE 9**

TATTTACCATATCAGATTCACATTCAGTCCTCAGCAAAATGAAGGGCTCCATTTTCACTC  
TGTTTTTATTCTCTGTCTATTTGCCATCTCAGAAGTGCGGAGCAAGGAGTCTGTGAGAC  
TCTGTGGGCTAGAATACATACGGACAGTCATCTATATCTGTGCTAGCTCCAGGTGGAGAA  
GGCATCTGGAGGGGATCCCTCAAGCTCAGCAAGCTGAGACAGGAAACTCCTTCCAGCTCC  
CACATAAACGTGAGTTTTCTGAGGAAAATCCAGCGCAAAACCTTCCGAAGGTGGATGCCT  
CAGGGGAAGACCGTCTTTGGGGTGGACAGATGCCCACTGAAGAGCTTTGGAAGTCAAAGA  
AGCATTCAGTGATGTCAAGACAAGATTTACAACTTTGTGTTGCACTGATGGCTGTTCCA  
TGA CTGATTTGAGTGCTCTTTGCTAAGACAAGAGCAAATACCCAATGGGTGGCAGAGCTT  
TATCACATGTTTAATTACAGTGTTTTACTGCCTGGTAGAACACTAATATTGTGTTATTAA  
AATGATGGCTTTTGGGTAGGCAAACTTCTTTTCTAAAAGGTATAGCTGAGCGGTTGAAA  
CCACAGTGATCTCTATTTTCTCCCTTTGCCAAGGTAAATGAACTGTTCTTTTCAAATTCT  
ACTAATGCTTTGAAATTTCAAATGCTGCGCAAAATTGCAATAAAAATGCTATAAA

10/392

**FIGURE 10**

MKGSIFTLFLFSVLFAISEVRSKESVRLCGLEYIRTVIYICASSRWRRLHLEGIPQAQQAE  
TGNSFQLPHKREFSEENPAQNLPKVDASGEDRLWGGQMPTEELWKSCKHVSMSRQDLQTL  
CCTDGCSMTDLSALC

**Important features:**

**Signal sequence:**

amino acids 1-18

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

amino acids 107-111

**N-myristoylation sites:**

amino acids 3-9,52-58,96-102,125-131

**Insulin family signature:**

amino acids 121-136

**Insulin family proteins:**

amino acids 28-46

11/392

**FIGURE 11**

CCCACGCGTCCGGACAACTGGAGGTGAAAGGAGCTGGTACTGTCCACTGTGCTGTCGGT  
GCTGAACCTGAGACGCGAGCGGACCAGTTGCTCCAGCACCTGAAGGCAACGCCCTCTTGC  
ACCTCTGTGCCCTGTGGGACCCGCTTCACCAACAGGACCCATATCAACTTGACAAAGGA  
GTGTGGTATCGGACGTGGGAGAGAGTCCTCTGTTTGCCACCTGGGCGCTCATTTCAGGCGT  
GACTTTGGAGATTTCTATAGTTTGTAGACCAAACCTATTTTTTTTTTCCCCAGCTAAGACGAT  
CTTTTGAGAGTTTTTTTTTTTTTATTGTGATTTATATTTCCACAGCGTTTAGGAATCTTTCT  
GGGGGACTTTTGTGACTGTTAAAATAAGGTGAAAAGCAATAAGGATGTTTAAAGTGCTGGT  
CAGTTGTCTTGGTTCTCGGATTCATTTTTCTGGAGTCGGAAGGAAGGCCAACCAAGAAG  
GAGGATATGGCCTTAAATCCTATCAGCCTCTAATGAGATTGCGACATAAGCAGGAAAAAA  
ATCAAGAAAGTTCAAGAGTCAAAGGATTTATGATTTCAGGATGGCCCTTTTGGATCTTGTG  
AAAATAAGTACTGTGGTTTGGGAAGACACTGTGTTACCAGCAGAGAGACAGGGCAAGCAG  
AATGTGCCTGTATGGACCTTTGCAAACGTCACTACAAACCTGTGTGTGGATCTGACGGAG  
AATTCATATGAAAACCACTGTGAAGTGCACAGAGCTGCTTGCCTGAAAAAACAAAAGATTA  
CCATTGTTCACAATGAAGACTGCTTCTTTAAAGGAGATAAGTGCAAGACTACTGAATACA  
GCAAGATGAAAAATATGCTATTAGATTTACAAAATCAAAAATATATTATGCAAGAAAATG  
AAAATCCTAATGGCGACGACATATCTCGGAAGAAGCTATTGGTGGATCAAATGTTTAAAT  
ATTTTGATGCAGACAGTAATGGACTTGTAGATATTAATGAACTAACTCAGGTGATAAAAC  
AGGAAGAAGTTGGCAAGGATCTCTTTGATTGTACTTTGTATGTTCTATTGAAATATGATG  
ATTTTAATGCTGACAAGCACCTGGCTCTTGAAGAATTTTATAGAGCATTCCAAGTGATCC  
AGTTGAGTCTGCCAGAAGATCAGAACTAAGCATCACTGCAGCAACTGTGGGACAAAGTG  
CTGTTCTGAGCTGTGCCATTCAAGGAACCCTGAGACCTCCATTATCTGGAAAAGGAACA  
ATATTATTCTAAATAATTTAGATTTGGAAGACATCAATGACTTTGGAGATGATGGGTCCT  
TGTATATTACTAAGGTTACCACAACTCACGTTGGCAATTACACCTGCTATGCAGATGGCT  
ATGAACAAGTCTATCAGACTCACATCTTCCAAGTGAATGTTCTCCTCCAGTCATCC

12/392

**FIGURE 12**

MFKCWSVVLVLGFIFLESEGRPTKEGGYGLKSYQPLMRLRHKQEKNQESSRVKGFMIQDG  
PFGSCENKYCGLGRHCVTSRETGQAECACMDLCKRHYKPVCSDGEFYENHCEVHRAACL  
KKQKITIVHNEDCFFKGDKCKTTEYSKMKNMLLDLQNQKYIMQENENPNGDDISRKLLV  
DQMFKYFDADSNGLVDINELTQVIKQEELGKDLFDCTLYVLLKYDDFNADKHLALEEFYR  
AFQVIQLSLPEDQKLSITAATVGQSAVLSCAIQGTLRPPIIWKRNNIILNNDLEDINDF  
GDDGSLYITKVTTHVGNITCYADGYEQVYQTHIFQVNVPPVI

**Signal sequence:**

Amino acids 1-20

**N-glycosylation site:**

Amino acids 318-322

**Tyrosine kinase phosphorylation sites:**

Amino acids 21-29;211-220

**N-myristoylation sites:**

Amino acids 63-69;83-89;317-323

**Prokaryotic membrane lipoprotein lipid attachment site:**

Amino acids 260-271

13/392

**FIGURE 13**

TGCCGGGCTGCGGGGCGCCTTGACTCTCCCTCCACCCTGCCTCCTCGGGCTCCACTCGTC  
TGCCCCTGGACTCCCGTCTCCTCCTGTCTCCGGCTTCCCAGAGCTCCCTCCTTATGGCA  
GCAGCTTCCCGCGTCTCCGGCGCAGCTTCTCAGCGGACGACCTCTCGCTCCGGGGCTGA  
GCCCAGTCCCTGGATGTTGCTGAAACTCTCGAGATCATGCGCGGGTTTGGCTGCTGCTTC  
CCCGCCGGGTGCCACTGCCACCGCCGCCCTCTGCTGCCGCCGTCCGCGGGATGCTCAG  
TAGCCCGCTGCCCGGCCCCCGGATCCTGTGTTCTCGGAAGCCGTTTGGCTGCTGCAGAG  
TTGCACGAACTAGTCATGGTGCTGTGGGAGTCCCCGCGGCAGTGCAGCAGCTGGACACTT  
TGCGAGGGGCTTTTGCTGGCTGCTGCTGCTGCCCGTTCATGCTACTCATCGTAGCCCGCCCG  
GTGAAGCTCGCTGCTTTCCCTACCTCCTTAAGTGACTGCCAAACGCCACCGGCTGGAAT  
TGCTCTGGTTATGATGACAGAGAAAATGATCTCTTCCTCTGTGACACCAACACCTGTAAA  
TTTGATGGGGAATGTTTAAGAAATTGGAGACACTGTGACTTGCGTCTGTCAAGTTCAAGTGC  
AACATGACTATGTGCCTGTGTGTGGCTCCAATGGGGAGAGCTACCAGAATGAGTGTTAC  
CTGCGACAGGCTGCATGCAAACAGCAGAGTGAGATACTTGTGGTGTGAGAAGGATCATGT  
GCCACAGATGCAGGATCAGGATCTGGAGATGGAGTCCATGAAGGCTCTGGAGAACTAGT  
CAAAAGGAGACATCCACCTGTGATATTTGCCAGTTTGGTGCAGAATGTGACGAAGATGCC  
GAGGATGTCTGGTGTGTGTGTAATATTGACTGTTCTCAAACCAACTTCAATCCCCTCTGC  
GCTTCTGATGGGAAATCTTATGATAATGCATGCCAAATCAAAGAAGCATCGTGTGAGAAA  
CAGGAGAAAATTGAAGTCATGTCTTTGGGTGATGTCAAGATAACACAACACTACAACACTACT  
AAGTCTGAAGATGGGCATTATGCAAGAACAGATTATGCAGAGAATGCTAACAAATTAGAA  
GAAAGTGCCAGAGAACACCACATACCTTGTCCGGAACATTACAATGGCTTCTGCATGCAT  
GGGAAGTGTGAGCATTCTATCAATATGCAGGAGCCATCTTGAGGTGTGATGCTGGTTAT  
ACTGGACAACACTGTGAAAAAAGGACTACAGTGTTCTATACGTTGTTCCCGGTCCTGTA  
CGATTTCAAGTATGTCTTAATCGCAGCTGTGATTGGAACAATTCAGATTGCTGTCATCTGT  
GTGGTGGTCCTCTGCATCACAAGGAAATGCCCCAGAAGCAACAGAATTCACAGACAGAAG  
CAAAATACAGGGCACTACAGTTCAGACAATACAACAAGAGCGTCCACGAGGTTAATCTAA  
AGGGAGCATGTTTCACAGTGGCTGGACTACCGAGAGCTTGGACTACACAATACAGTATTA  
TAGACAAAAGAATAAGACAAGAGATCTACACATGTTGCCTTGCATTTGTGGTAATCTACA  
CCAATGAAAACATGTACTACAGCTATATTTGATTATGTATGGATATATTTGAAATAGTAT  
ACATTGTCTTGATGTTTTTTCTGTAATGTAAATAAACTATTTATATCACACAATATAGTT  
TTTTCTTTCCCATGTATTTGTTATATATAATAAATACTCAGTGATGAG



14/392

**FIGURE 14**

MVLWESPRQCSSWTLCCEGFCWLLLLPVMLLIVARPVKLAAFPTSLSDCQTPTGWNC SGY  
DDRENDLFLCDTNTCKFDGECLRIGDTVTCVCQFKCNNDYVPVCGSNGESYQNECYLRQ  
AACKQQSEILVVSEGSCATDAGSGSGDGVHEGSGETSQKETSTCDICQFGAECDEDAED  
VWCVCNIDCSQTNFNPLCASDGKSYDNACQIKEASCQKQEKIEVMSLGRCQDNTTTT TK  
SEDGHYARTDYAENANKLEESAREHHIPCPEHYNGFCMHGKCEHSINMQEPSCRC DAGY  
TGQHCEKKDYSVLYVVPGPVRFQYVLIAAVIGTIQIAVICVVVLCITRKCPRSNRIHRQ  
KQNTGHYSSDNTTRASTRLI

15/392

**FIGURE 15**

GGAGCTCAGCCCAGTGGGCAGTCTGAAGATGGCCAATTACACGCTGGCACCAGAGGATGA  
ATATGATGTCCTCATAGAAGGTGAACTGGAGAGCGATGAGGCAGAGCAATGTGACAAGTA  
TGACGCCCAGGCACTCTCAGCCCAGCTGGTGCCATCACTCTGCTCTGCTGTGTTTGTGAT  
CGGTGTCCTGGACAATCTCCTGGTTGTGCTTATCCTGGTAAAATATAAAGGACTCAAACG  
CGTGGAATAATCTATCTTCTAAACTTGGCAGTTTCTAACTTGTGTTTCTTGCTTACCCT  
GCCCTTCTGGGCTCATGCTGGGGGCGATCCCATGTGTAAAATTCTCATTGGACTGTACTT  
CGTGGGCCTGTACAGTGAGACATTTTTCAATTGCCTTCTGACTGTGCAAAGGTACCTAGT  
GTTTTTGACAAGGGCAACTTTTTCTCAGCCAGGAGGAGGGTGCCCTGTGGCATCATTAC  
AAGTGTCTCTGGCATGGGTAAACAGCCATTCTGGCCACTTTGCCTGAATACGTGGTTTATAA  
ACCTCAGATGGAAGACCAGAAATACAAGTGTGCATTTAGCAGAACTCCCTTCCTGCCAGC  
TGATGAGACATTCTGGAAGCATTTTCTGACTTTAAAAATGAACATTTCCGGTTCTTGTCCT  
CCCCCTATTTATTTTTACATTTCTCTATGTGCAAATGAGAAAAACACTAAGGTTCAAGGA  
GCAGAGGTATAGCCTTTTCAAGCTTGTTTTTGCCATAATGGTAGTCTTCCTTCTGATGTG  
GGCGCCCTACAATATTGCATTTTCTGTCCACTTTCAAAGAACACTTCTCCCTGAGTGA  
CTGCAAGAGCAGCTACAATCTGGACAAAAGTGTTCACATCACTAACTCATCGCCACCAC  
CCACTGCTGCATCAACCTCTCCTGTATGCGTTTCTTGATGGGACATTTAGCAAATACCT  
CTGCCGCTGTTTCCATCTGCGTAGTAACACCCCACTTCAACCCAGGGGGCAGTCTGCACA  
AGGCACATCGAGGGAAGAACCTGACCATTCACCGAAGTGTA~~AA~~ACTAGCATCCACCAAAT  
GCAAGAAGAATAAACATGGATTTTCATCTTCTGCATTATTTTCATGTAAATTTTCTACAC  
ATTTGTATACAAAATCGGATACAGGAAGAAAAGGGAGAGGTGAGCTAACATTTGCTAAGC  
ACTGAATTTGTCTCAGGCACCGTGCAAGGCTCTTTACAAACGTGAGCTCCTTCGCCTCCT  
ACCACTTGTCATAGTGTGGATAGGACTAGTCTCATTCTCTGAGAAGAAAATAAGGCG  
CGGAAATTTGTCTAAGATCACATAACTAGGAAGTGGCAGAACTGATTCTCCAGCCCTGGT  
AGCATTTGCTCAGAGCCTACGCTTGGTCCAGAACATCAAACCTCAAACCTGGGGACAAA  
CGACATGAAATAAATGTATTTTAAACATCTAAAA

16/392

**FIGURE 16**

MANYTLAPEDEYDVLIEGELESDEAEQCDKYDAQALSAQLVPSLCSAVFVIGVLDNLLVV  
LILVKYKGLKRVENIYLLNLAVSNLCFLLTLPFWAHAGGDPCKILIGLYFVGLYSETFF  
NCLLTVQRYLVFLHKGNNFSARRRVPCGIITSVLAWVTAILATLPEYVVYKPMEDQKYK  
CAFSRTPFLPADETFWKHFLTLKMNISVLVPLFIFTFLYVQMRKTLRFREQRYSLFKLV  
FAIMVVFLLMWAPYNIAFFLSTFKEHFSLSCKSSYNLDKSVHITKLIATTHCCINPLLY  
AFLDGTFSKYLRCRPFHLRSNTPLQPRGQSAQGTSREEPDHSTEV

**Signal sequence:**

None

**Transmembrane domain:**

41-61, 76-96, 109-129, 147-167, 199-219, 237-257, 285-305

**7 transmembrane receptor (rhodopsin family):**

55-300

**N-glycosylation site:**

3-6, 205-208

**Tyrosine kinase phosphorylation site:**

70-76, 171-179, 228-234

**N-myristoylation site:**

52-57, 136-141, 148-153

**G-protein coupled receptors:**

55-85, 96-136, 209-220, 235-254, 292-308

17/392

**FIGURE 17**

CGGACGCGTG GGGCGGACGCGTG GGGCGGCCACGGCGCCCGGGGCTGGGGCGGTTCGCTTC  
TTCCTTCTCCGTGGCCTACGAGGGTCCCCAGCCTGGGTAAAGATGGCCCCATGGCCCCCG  
AAGGGCCTAGTCCCAGCTGTGCTCTGGGGCCTCAGCCTCTTCTCAACCTCCCAGGACCT  
ATCTGGCTCCAGCCCTCTCCACCTCCCCAGTCTTCTCCCCCGCCTCAGCCCCATCCGTGT  
CATACCTGCCGGGGACTGGTTGACAGCTTTAACAAGGGCCTGGAGAGAACCATCCGGGAC  
AACTTTGGAGGTGGAAACACTGCCTGGGAGGAAGAGAATTTGTCCAAATACAAAGACAGT  
GAGACCCGCTGGTAGAGGTGCTGGAGGGTGTGTGCAGCAAGTCAGACTTCGAGTGCCAC  
CGCCTGCTGGAGCTGAGTGAGGAGCTGGTGGAGAGCTGGTGGTTTCAACAAGCAGCAGGAG  
GCCCCGGACCTCTTCCAGTGGCTGTGCTCAGATTCCCTGAAGCTCTGCTGCCCCGCAGGC  
ACCTTCGGGGCCCTCCTGCCTTCCCTGTCTGGGGGAACAGAGAGGCCCTGCGGTGGCTAC  
GGGCAGTGTGAAGGAGAAGGGACACGAGGGGGCAGCGGGCACTGTGACTGCCAAGCCGGC  
TACGGGGGTGAGGCCTGTGGCCAGTGTGGCCTTGGCTACTTTGAGGCAGAACGCAACGCC  
AGCCATCTGGTATGTTTCGGCTTGTTTTGGCCCCCTGTGCCCGATGCTCAGGACCTGAGGAA  
TCAAACCTGTTTGCAATGCAAGAAGGGCTGGGCCCTGCATCACCTCAAGTGTGTAGACATT  
GATGAGTGTGGCACAGAGGGAGCCAACTGTGGAGCTGACCAATTCTGCGTGAACACTGAG  
GGCTCCTATGAGTGCCGAGACTGTGCCAAGGCCTGCCTAGGCTGCATGGGGGCAGGGCCA  
GGTCGCTGTAAGAAGTGTAGCCCTGGCTATCAGCAGGTGGGCTCCAAGTGTCTCGATGTG  
GATGAGTGTGAGACAGAGGTGTGTCCGGGAGAGAACAAAGCAGTGTGAAAACACCGAGGGC  
GGTTATCGCTGCATCTGTGCCGAGGGCTACAAGCAGATGGAAGGCATCTGTGTGAAGGAG  
CAGATCCCAGAGTCAGCAGGCTTCTTCTCAGAGATGACAGAAGACGAGTTGGTGGTGTCTG  
CAGCAGATGTTCTTTGGCATCATCATCTGTGCACTGGCCACGCTGGCTGCTAAGGGCGAC  
TTGGTGTTCACCGCCATCTTCATTGGGGCTGTGGCGGCCATGACTGGCTACTGGTTGTCA  
GAGCGCAGTGACCGTGTGCTGGAGGGCTTCATCAAGGGCAGATAATCGCGGCCACCACCT  
GTAGGACCTCCTCCCACCCACGCTGCCCCCAGAGCTTGGGCTGCCCTCCTGCTGGACACT  
CAGGACAGCTTGGTTTATTTTTGAGAGTGGGGTAAGCACCCCTACCTGCCTTACAGAGCA  
GCCCAGGTACCCAGGCCCCGGGCAGACAAGGCCCTGGGGTAAAAAGTAGCCCTGAAGGTG  
GATACCATGAGCTCTTCACCTGGCGGGGACTGGCAGGCTTCACAATGTGTGAATTTCAA  
AGTTTTTCTTAATGGTGGCTGCTAGAGCTTTGGCCCCCTGCTTAGGATTAGGTGGTCTCT  
ACAGGGGTGGGGCCATCACAGCTCCCTCCTGCCAGCTGCATGCTGCCAGTTCCTGTTCTG  
TGTTACACCATCCCCACCCCCATTGCCACTTATTTATTCATCTCAGGAAATAAAGAAA  
GGTCTTGGAAAGTTAAAAAAAAAAAAAAAAAAAAAAAAAAAA

18/392

**FIGURE 18**

MAPWPPKGLVPAVLWGLSLFLNLP GPIWLQPSPPPQSSPPPQPHPCHTCRGLVDSFNKGL  
ERTIRDNFGGNTAWEEENLSKYKDSETRLVEVLEGVCSKSDFECHRLLELSEELVESWW  
FHKQQEAPDLFQWLCSDSLKLCCPAGTFGPSCLPCPGGTERPCGGYGQCEGEGTRGSGH  
CDCQAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEESNCLQCKKGWALHH  
LKCVDIDECGTEGANCGADQFCVNTEGSYECRDCAKACLGCMGAGPGRCKKCSPGYQQVG  
SKCLDVDECETEVC PGENKQCENTEGGYRCICAEGYQMEGICVKEQIPESAGFFSEMTE  
DELVVLQQMFFGIIICALATLAAGDLVFTAIFIGAVAAMTGYWLSERSDRVLEGFIKGR

19/392

**FIGURE 19**

GCCCCGGGACTGGCGCAAGGTGCCCAAGCAAGGAAAGAAATAATGAAGAGACACATGTGTT  
AGCTGCAGCCTTTTGAAACACGCAAGAAGGAAATCAATAGTGTGGACAGGGCTGGAACCT  
TTACCACGCTTGTGGAGTAGATGAGGAATGGGCTCGTGATTATGCTGACATTCCAGCAT  
GAATCTGGTAGACCTGTGGTTAACCCGTTCCCTCTCCATGTGTCTCCTCTACAAAGTTT  
TGTTCTTATGATACTGTGCTTTTCATTCTGCCAGTATGTGTCCCAAGGGCTGTCTTTGTTT  
TTCCTCTGGGGGTTTAAATGTACCTGTAGCAATGCAAATCTCAAGGAAATACCTAGAGA  
TCTTCTCCTGAAACAGTCTTACTGTATCTGGACTCCAATCAGATCACATCTATTCCCAA  
TGAAATTTTTTAAGGACCTCCATCAACTGAGAGTTCTCAACCTGTCCAAAAATGGCATTGA  
GTTTATCGATGAGCATGCCTTCAAAGGAGTAGCTGAAACCTTGCAGACTCTGGACTTGTC  
CGACAATCGGATTCAAAGTGTGCACAAAAATGCCTTCAATAACCTGAAGGCCAGGGCCAG  
AATTGCCAACAACCCCTGGCACTGCGACTGTACTCTACAGCAAGTTCTGAGGAGCATGGC  
GTCCAATCATGAGACAGCCCACAACGTGATCTGTAAACGTCCGTGTTGGATGAACATGC  
TGGCAGACCATTCTCAATGCTGCCAACGACGCTGACCTTTGTAACCTCCCTAAAAAAC  
TACCGATTATGCCATGCTGGTCACCATGTTTGGCTGGTTCACTATGGTGATCTCATATGT  
GGTATATTATGTGAGGCAAAATCAGGAGGATGCCCGGAGACACCTCGAATACTTGAAATC  
CCTGCCAAGCAGGCAGAAGAAAGCAGATGAACCTGATGATATTAGCACTGTGGTATAGTG  
TCCAAACTGACTGTCAATTGAGAAAGAAAGAAAGTAGTTTGCGATTGCAGTAGAAATAAGT  
GGTTTACTTCTCCCATCCATTGTAAACATTTGAACTTTGTATTTTCAGTTTTTTTTGAAT  
TATGCCACTGCTGAACTTTTAACAAACACTACAACATAAATAATTGAGTTTAGGTGATC  
CACCCCTTAATTGTACCCCGATGGTATATTTCTGAGTAAGCTACTATCTGAACATTAGT  
TAGATCCATCTCACTATTTAATAATGAAATTTATTTTTTTAATTTAAAAGCAAATAAAAG  
CTTAACCTTTGAACCATGGGAAAAAAAAAAAAAAAAAAAAAAAAAACA

20/392

**FIGURE 20**

MNLVDLWLTRSLSMCLLLQSFVLMILCFHSASMC PKGCLCSSSGGLNVTCSNANLKEIPR  
DLPPETVLLYLD SNQITSIPNEIFKDLHQLRVLNLSKNGIEFIDEHAFKGVAETLQTLDL  
SDNRIQSVHKNAFNNLKARARIANNPWHCDCTLQQVLRSMASNHETAHNVICKTSVLDEH  
AGRPFLNAANDADLCNLPKTTDYAMLVTMFGWFTMVISYVVYYVRQNQEDARRHLEYLK  
SLPSRQKKADEPDDISTVV

Signal sequence:  
amino acids 1-33

Transmembrane domain:  
amino acids 205-220

N-glycosylation site:  
amino acids 47-51, 94-98

cAMP- and cGMP-dependent protein kinase phosphorylation site:  
amino acids 199-203

Casein kinase II phosphorylation site:  
amino acids 162-166, 175-179

N-myristoylation site:  
amino acids 37-43, 45-51, 110-116

21/392

**FIGURE 21**

CGCCACCACTGCGGCCACCGCCAATGAAACGCCTCCCGCTCCTAGTGGTTTTTTTCCACTT  
TGTTGAATTGTTTCTATACTCAAATTCACCAAGACACCTTGTCTCCCAAATGCAAAAT  
GTGAAATACGCAATGGAATTGAAGCCTGCTATTGCAACATGGGATTTTCAGGAAATGGTG  
TCACAATTTGTGAAGATGATAATGAATGTGGAAATTTAACTCAGTCCTGTGGCGAAAATG  
CTAATTGCACTAACACAGAAGGAAGTTATTATTGTATGTGTGTACCTGGCTTCAGATCCA  
GCAGTAACCAAGACAGGTTTATCACTAATGATGGAACCGTCTGTATAGAAAATGTGAATG  
CAAACCTGCCATTTAGATAATGTCTGTATAGCTGCAAATATTAATAAAACTTTAACAAAA  
TCAGATCCATAAAAGAACCTGTGGCTTTGCTACAAGAAGTCTATAGAAATTCCTGTGACAG  
ATCTTTCACCAACAGATATAATTACATATATAGAAATATTAGCTGAATCATCTTCATTAC  
TAGGTTACAAGAACACACTATCTCAGCCAAGGACACCCTTCTAACTCAACTCTTACTG  
AATTTGTAAAAACCGTGAATAATTTTGTTCAAAGGGATACATTTGTAGTTTGGGACAAGT  
TATCTGTGAATCATAGGAGAACACATCTTACAAAACCTCATGCACACTGTTGAACAAGCTA  
CTTTAAGGATATCCCAGAGCTTCCAAAAGACCACAGAGTTTGATACAAATTC AACGGATA  
TAGCTCTCAAAGTTTTCTTTTTTGATT CATATAACATGAAACATATTCATCCTCATATGA  
ATATGGATGGAGACTACATAAATATATTTCCAAAAGAGAAAAGCTGCATATGATTCAAATG  
GCAATGTTGCAGTTGCATTTTATATTATAAGAGTATTGGTCCTTTGCTTTCATCATCTG  
ACAACCTTCTATTGAAACCTCAAATTTATGATAATTCTGAAGAGGAGGAAAGAGTCATAT  
CTTCAGTAATTT CAGTCTCAATGAGCTCAAACCCACCCACATTATATGAACTTGAAAAAA  
TAACATTTACATTAAGT CATCGAAAGGTCACAGATAGGTATAGGAGTCTATGTGCATTTT  
GGAATTACTCACCTGATACCATGAATGGCAGCTGGTCTTCAGAGGGCTGTGAGCTGACAT  
ACTCAAATGAGACCCACACCTCATGCCGCTGTAATCACCTGACACATTTTGAATTTTGA  
TGTCCTCTGGTCCTTCCATTGGTATTAAAGATTATAATATTCTTACAAGGATCACTCAAC  
TAGGAATAATTATTTCACTGATTTGTCTTGCCATATGCATTTTACCTTCTGGTTCTTCA  
GTGAAATTCAAAGCACCAGGACAACAATTCACAAAATCTTTGCTGTAGCCTATTTCTTG  
CTGAACTTGTTTTTCTTGTTGGGATCAATACAAATACTAATAAGCTCTTCTGTTCAATCA  
TTGCCGGA CTGTACACTACTTCTTTTTAGCTGCTTTTGCATGGATGTGCATTGAAGGCA  
TACATCTCTATCTCATTTGTGTGGGTGT CATCTACAACAAGGGATTTTTGCACAAGAATT  
TTTATATCTTTGGCTATCTAAGCCCAGCCGTGGTAGTTGGATTTTTCGGCAGCACTAGGAT  
ACAGATATTATGGCACAACCAAAGTATGTTGGCTTAGCACCGAAAACAACCTTTATTTGGA  
GTTTTATAGGACCAGCATGCCTAATCATTCTTGTTAATCTCTTGGCTTTTGGAGTCATCA  
TATACAAAGTTTTTTCGTCACACTGCAGGGTTGAAACCAGAAGTTAGTTGCTTTGAGAACA  
TAAGGTCTTGTGCAAGAGGAGCCCTCGCTCTTCTGTTCTTCTCGGCACCACCTGGATCT  
TTGGGGTTCTCCATGTTGTGCACGCATCAGTGGTTACAGCTTACCTCTTCACAGTCAGCA  
ATGCTTTCCAGGGGATGTTCAATTTTTTTATTCCTGTGTGTTTTATCTAGAAAGATTCAAG  
AAGAATATTACAGATTGTTCAAAAATGTCCCCTGTTGTTTTGGATGTTTAAGGTAAACAT  
AGAGAATGGTGGATAATTACAACCTGCACAAAAATAAAAAATTC CAAGCTGTGGATGACCAA  
TGTATAAAAATGACTCATCAAATTATCCAATTATTAAC TACTAGACAAAAGTATTTTAA  
ATCAGTTTTTCTGTTTATGCTATAGGAACTGTAGATAATAAGGTAAAATTATGTATCATA  
TAGATATACTATGTTTTTCTATGTGAAATAGTTCTGTCAAAAATAGTATTGCAGATATTT  
GGAAAGTAATTGGTTTTCTCAGGAGTGATATCACTGCACCCAAGGAAAGATTTTCTTTCTA  
ACACGAGAAGTATATGAATGTCCTGAAGGAAACCACTGGCTTGATATTTCTGTGACTCGT  
GTTGCCCTTTGAAACTAGTCCCCTACCACCTCGGTAATGAGCTCCATTACAGAAAGTGGAA  
CATAAGAGAATGAAGGGGCAGAATATCAAACAGTGAAAAGGGAATGATAAGATGTATTTT  
GAATGAACTGTTTTTTCTGTAGACTAGCTGAGAAATTGTTGACATAAAAATAAAGAATTGA  
AGAAACACATTTTACCATTTTGTGAATTGTTCTGAACTTAAATGTCCACTAAAACAACCTT  
AGACTTCTGTTTGCTAAATCTGTTTCTTTTTCTAATATTCTAAAAA AAAAAAAGGTTT  
ACCTCCACAAATTGAAA



22/392

**FIGURE 22**

MKRLPLL VVFSTLLNCSYTQNCTKTPCLPNAKCEIRNGIEACYCNMGFSGNGVTICEDDN  
ECGNLTQSCGENANCTNTEGSYYCMCVPGFRSSSNQDRFITNDGTVCIENTVNANCHLDNV  
CIAANINKTLTKIRSIKEPVALLQEVYRNSVTDLSPTDIITYIEILAESSLLGYKNNTI  
SAKDTLSNSTLTTEFVKTVNNFVQORDTFVWWDKLSVNHRRTHLTKLMHTVEQATLRISQSF  
QKTTEFDTNSTDIALKVFFFDSYNMKHIHPHMNDGDYINIFPKRKAAYDSNGNVAVAF  
YYKSIGPLLSSSDNFKLPQNYDNSEEEERVISSVISVSMSSNPPTLYELEKITFTLSHR  
KVTDRYRSLCAFWNYSPTMNGSWSSEGCETYSNETHTSCRCNHLTHFAILMSSGPSIG  
IKDYNILTRITQLGIIISLICLAICIFTFWFFSEIQSTRTTIHKNLCCSLFLAELVFLVG  
INTNTNKLFCSSIIAGLLHYFFLAFAWMCIEGIHLYLIVGVYINKGFLHKNFYIFGYLS  
PAVVVGFSAAALGYRYYGTTKVCWLSTENNFIWSFIGPACLIILVNLLAFGVIIYKVRHT  
AGLKPEVSCFENIRSCARGALALLFLLGTTWIFGVLHVHASVVTAYLFTVSNAFQGMFI  
FLFLCVLSRKIQEYYRLFKNPCCFGCLR

23/392

## FIGURE 23

CTCCTCTTAACATACTTGCAGCTAAAACTAAATATTGCTGCTTGGGGACCTCCTTCTAGC  
CTTAAATTTTCAGCTCATCACCTTCACCTGCCTTGGTCATGGCTCTGCTATTCTCCTTGAT  
CCTTGCCATTTGCACCAGACCTGGATTCCTAGCGTCTCCATCTGGAGTGCGGCTGGTGGG  
GGGCCTCCACCGCTGTGAAGGGCGGGTGGAGGTGGAACAGAAAGGCCAGTGGGGCACCCT  
GTGTGATGACGGCTGGGACATTAAGGACGTGGCTGTGTTGTGCCGGGAGCTGGGCTGTGG  
AGCTGCCAGCGGAACCCCTAGTGGTATTTTGTATGAGCCACCAGCAGAAAAAGAGCAAAA  
GGTCCTCATCCAATCAGTCAGTTGCACAGGAACAGAAGATACATTGGCTCAGTGTGAGCA  
AGAAGAAGTTTATGATTGTTTCACATGATGAAGATGCTGGGGCATCGTGTGAGAACCCAGA  
GAGCTCTTTCTCCCCAGTCCCAGAGGGTGTGAGGCTGGCTGACGGCCCTGGGCATTGCAA  
GGGACGCGTGGAAGTGAAGCACCAGAACCAGTGGTATACCGTGTGCCAGACAGGCTGGAG  
CCTCCGGGCCGCAAAGGTGGTGTGCCGGCAGCTGGGATGTGGGAGGGCTGTACTGACTCA  
AAAACGCTGCAACAAGCATGCCTATGGCCGAAAACCCATCTGGCTGAGCCAGATGTCATG  
CTCAGGACGAGAAGCAACCCTTCAGGATTGCCCTTCTGGGCCTTGGGGGAAGAACACCTG  
CAACCATGATGAAGACACGTGGGTGCAATGTGAAGATCCCTTTGACTTGAGACTAGTAGG  
AGGAGACAACCTCTGCTCTGGGCGACTGGAGGTGCTGCACAAGGGCGTATGGGGCTCTGT  
CTGTGATGACAACTGGGGAGAAAAAGGAGGACCAGGTGGTATGCAAGCAACTGGGCTGTGG  
GAAGTCCCTCTCTCCCTCCTTCAGAGACCGGAAATGCTATGGCCCTGGGGTTGGCCGCAT  
CTGGCTGGATAATGTTTCGTTGCTCAGGGGAGGAGCAGTCCCTGGAGCAGTGCCAGCACAG  
ATTTTGGGGGTTTCACGACTGCACCCACCAGGAAGATGTGGCTGTCTGCTCAGTGTA  
GGTGGGCATCATCTAATCTGTTGAGTGCCTGAATAGAAGAAAAACACAGAAGAAGGGAGC  
ATTTACTGTCTACATGACTGCATGGGATGAACACTGATCTTCTTCTGCCCTTGGACTGGG  
ACTTATACTTGGTGCCCTGATTCTCAGGCCTTCAGAGTTGGATCAGAACTTACAACATC  
AGGTCTAGTTCTCAGGCCATCAGACATAGTTTGGAACTACATCACCACCTTTCCTATGTC  
TCCACATTGCACACAGCAGATTCCAGCCTCCATAATTGTGTGTATCAACTACTTAAATA  
CATTCTCACACACACACACACACACACACACACACACACACATACACCATTTGTCC  
TGTTTCTCTGAAGAACTCTGACAAAATACAGATTTTGGTACTGAAAGAGATTCTAGAGGA  
ACGGAATTTTAAAGGATAAAATTTTCTGAATTGGTTATGGGGTTTCTGAAATTGGCTCTATA  
ATCTAATTAGATATAAAATTTCTGGTAACTTTATTTACAATAATAAAGATAGCACTATGTG  
TTCAAA

24/392

**FIGURE 24**

MALLFSLILAICTRPGFLASPSGVRLVGGLHRCEGRVEVEQKGQWGTVCDDGWDIKDVAV  
LCRELGCGAASGTPSGILYEPPAEKEQKVLIQSVSCTGTEDTLAQCEQEVEYDCSHDEDA  
GASCENPESSFSVPPEGVRLADGPGHCKGRVEVKHQNQWYTVCTGWSLRAAKVVCRLG  
CGRAVLTQKRCNKHAYGRKPIWLSQMSCSGREATLQDCPSGPWGKNTCNHDEDTWVECED  
PFDLRLVGDNLCSGRLEVLHKGWGSVCDDNWGEKEDQVVCKQLGCGKSLSPSFRDRKC  
YGPVGRIWLDNVRCSGEEQSLEQCQHRFWGFHDCTHQEDVAVICSV

**Signal sequence:**

amino acids 1-15

**Casein kinase II phosphorylation site:**amino acids 47-51, 97-101, 115-119, 209-213, 214-218, 234-238,  
267-271, 294-298, 316-320, 336-340**N-myristoylation site:**amino acids 29-35, 43-49, 66-72, 68-74, 72-78, 98-104, 137-143,  
180-186, 263-269, 286-292**Amidation site:**

amino acids 196-200

**Speract receptor repeated domain signature:**

amino acids 29-67, 249-287

25/392

**FIGURE 25**

CGGACGCGTGGGCGTCCGGCGGTTCGACAGCCAGGAGGCGGAGGCGCGGGCCAGCCTG  
GGCCCCAGCCACACCTTCACCAGGGCCCAGGAGCCACCAATGTGGCGATGTCCACTGGGG  
CTACTGCTGTTGCTGCCGCTGGCTGGCCACTTGGCTCTGGGTGCCCAGCAGGGTTCGTGGG  
CGCCGGGAGCTAGCACCGGGTCTGCACCTGCCGGGGCATCCGGGACGCGGGAGGCCGGTAC  
TGCCAGGAGCAGGACCTGTGCTGCCGCGGCCGTGCCGACGACTGTGCCCTGCCCTACCTG  
GGCGCCATCTGTTACTGTGACCTCTTCTGCAACCGCACGGTCTCCGACTGCTGCCCTGAC  
TTCTGGGACTTCTGCCTCGGCGTGCCACCCCTTTTCCCCCGATCCAAGGATGTATGCAT  
GGAGGTCGTATCTATCCAGTCTTGGGAACGTACTGGGACAACTGTAACCGTTGCACCTGC  
CAGGAGAACAGGCAGTGGCATGGTGGATCCAGACATGATCAAAGCCATCAACCAGGGCAA  
CTATGGCTGGCAGGCTGGGAACCACAGCGCCTTCTGGGGCATGACCCTGGATGAGGGCAT  
TCGCTACCGCCTGGGCACCATCCGCCCATCTTCTCGGTTCATGAACATGCATGAAATTTA  
TACAGTGCTGAACCCAGGGGAGGTGCTTCCCACAGCCTTCGAGGCCTCTGAGAAGTGGCC  
CAACCTGATTCATGAGCCTCTTGACCAAGGCAACTGTGCAGGCTCCTGGGCCTTCTCCAC  
AGCAGCTGTGGCATCCGATCGTGTCTCAATCCATTCTCTGGGACACATGACGCCTGTCTT  
GTGCCCCAGAACCTGCTGTCTTGTGACACCCACCAGCAGCAGGGCTGCCGCGGTGGGCG  
TCTCGATGGTGCCTGGTGGTTCTTGCCTGCGCGAGGGGTGGTGTCTGACCACTGCTACCC  
CTTCTCGGGCCGTGAACGAGACGAGGCTGGCCCTGCGCCCCCTGTATGATGCACAGCCG  
AGCCATGGGTGCGGGCAAGCGCCAGGCCACTGCCCACTGCCCAACAGCTATGTTAATAA  
CAATGACATCTACCAGGTCACTCCTGTCTACCGCCTCGGCTCCAACGACAAGGAGATCAT  
GAAGGAGCTGATGGAGAATGGCCCTGTCCAAGCCCTCATGGAGGTGCATGAGGACTTCTT  
CCTATACAAGGGAGGCATCTACAGCCACACGCCAGTGAGCCTTGGGAGGCCAGAGAGATA  
CCGCCGGCATGGGACCCACTCAGTCAAGATCACAGGATGGGGAGAGGAGACGCTGCCAGA  
TGGAAGGACGCTCAAATACTGGACTGCGGCCAACTCCTGGGGGCCAGCCTGGGGCGAGAG  
GGGCCACTTCCGCATCGTGCGCGGCGTCAATGAGTGCGACATCGAGAGCTTCGTGCTGGG  
CGTCTGGGGCCGCGTGGGCATGGAGGACATGGGTTCATCACTGAGGCTGCGGGCACACGC  
GGGGTCCGGCCTGGGATCCAGGCTAAGGGCCGGCGGAAGAGGCCCAATGGGGCGGTGAC  
CCCAGCCTCGCCCGACAGAGCCCGGGGCGCAGGCGGGCGCCAGGGCGCTAATCCCGGCGC  
GGGTTCCGCTGACGCAGCGCCCCGCTGGGAGCCGCGGGCAGGCGAGACTGGCGGAGCCC  
CCAGACCTCCCAGTGGGGACGGGGCAGGGCCTGGCCTGGGAAGAGCACAGCTGCAGATCC  
CAGGCCTCTGGCGCCCCCACTCAAGACTACCAAAGCCAGGACACCTCAAGTCTCCAGCCC  
CAATACCCCAACCCCAATCCCGTATTCTTTTTTTTTTTTTTTTAGACAGGGTCTTGCTCCG  
TTGCCCAGGTTGGAGTGCAGTGGCCCATCAGGGCTCACTGTAACCTCCGACTCCTGGGTT  
CAAGTGACCCTCCACCTCAGCCTCTCAAGTAGCTGGGACTACAGGTGCACCACCACACC  
TGGCTAATTTTTGTATTTTTTGTAAAGAGGGGGGTCTCACTGTGTTGCCCAGGCTGGTTT  
CGAACTCCTGGGCTCAAGCGGTCCACCTGCCTCCGCTCCCAAAGTGCTGGGATTGCAGG  
CATGAGCCACTGCACCCAGCCCTGTATTCTTATTCTTCAGATATTTATTTTTCTTTTCAC  
TGTTTTAAATAAAACCAAAGTATTGATAAAAAAAA

26/392

**FIGURE 26**

MWRCPLGLLLLLPLAGHLALGAQQGRGRRELAPGLHLRGIRDAGGRYCQEQLCCRGRAD  
DCALPYLGAICYDLFCNRTVSDCCPDFWDFCLGVPPFPPIQGCMHGGRIYPVLGTYWD  
NCNRCTCQENRQWHGGSRHDQSHQPGQLWLAGWEPQRLLGHDPG

**N-glycosylation site:**

amino acids 78-82, 161-165

**Casein kinase II phosphorylation site:**

amino acids 80-84, 117-121, 126-130, 169-173, 205-209, 296-300,  
411-415

**N-myristoylation site:**

amino acids 21-27, 39-45, 44-50, 104-110, 160-164, 224-230,  
269-275, 378-384, 442-448

**Amidation site:**

amino acids 26-30, 318-322

**Eukaryotic thiol (cysteine) proteases histidine active site:**

amino acids 398-409

27/392

**FIGURE 27**

CCCACGCGTCCGGCAGGTTTTCTTCAAGCCAAGAAGGACACGGATTGGCTGAAGGAGAA  
AGTGCAGAGCTTGCAGACACTGGCTGCCAACAACTCTGCGTTGGCCAAAGCCAACAACGA  
CACCTTGGAGGATATGAACAGCCAGCTCAACTCATTACAGGTCAGATGGAGAACATCAC  
CACTATCTCTCAAGCCAACGAGCAGAACCTGAAAGACCTGCAGGACTTACACAAAGATGC  
AGAGAATAGAACAGCCATCAAGTTCAACCAACTGGAGGAACGCTTCCAGCTCTTTGAGAC  
GGATATTGTGAACATCATTAGCAATATCAGTTACACAGCCCACCACCTGCGGACGCTGAC  
CAGCAATCTAAATGAAGTCAGGACCACCTTGCACAGATACCTTACCAAACACACAGATGAT  
CTGACCTCCTTGAATAATACCCTGGCCAACATCCGTTTGGATTCTGTTTCTCTCAGGATG  
CAACAAGATTTGATGAGGTCGAGGTTAGACACTGAAGTAGCCAACTTATCAGTGATTATG  
GAAGAAATGAAGCTAGTAGACTCCAAGCATGGTCAGCTCATCAAGAATTTTACAATACTA  
CAAGGTCCACCGGGCCCCAGGGGTCCAAGAGGTGACAGAGGATCCCAGGGACCCCCCTGGC  
CCAACCTGGCAACAAGGGACAGAAAGGAGAGAAGGGGGAGCCTGGACCACCTGGCCCTGCG  
GGTGAGAGAGGGCCCAATTGGACCAGCTGGTCCCCCGGAGAGCGTGGCGGCAAAGGATCT  
AAAGGCTCCCAGGGCCCCAAAGGCTCCCGTGGTTCCCCCTGGGAAGCCCGGCCCTCAGGGC  
CCCAGTGGGGACCCAGGCCCCCGGGCCCCACCAGGCAAAGAGGGACTCCCCGGGCCCTCAG  
GGCCCTCCTGGCTTCCAGGGACTTCAGGGCACCGTTGGGGAGCCTGGGGTGCTGGACCT  
CGGGGACTGCCAGGCTTGCTGGGGTACCAGGCATGCCAGGCCCCAAGGGCCCCCCCCGGC  
CCTCCTGGCCCATCAGGAGCGGTGGTGGCCCTGGCCCTGCAGAAATGAGCCAACCCCGGCA  
CCGGAGGACAATAGCTGCCCGCCTCACTGGAAGAACTTCACAGACAAATGCTACTATTTT  
TCAGTTGAGAAAGAAATTTTGGAGGATGCAAAGCTTTTCTGTGAAGACAAGTCTTCACAT  
CTTGTTTTTCATAAACTAGAGAGGAACAGCAATGGATAAAAAAACAGATGGTAGGGAGA  
GAGAGCCACTGGATCGGCCTCACAGACTCAGAGCGTGAAAATGAATGGAAGTGGCTGGAT  
GGGACATCTCCAGACTACAAAAATTGGAAAGCTGGACAGCCGGATAACTGGGGTCATGGC  
CATGGGCCAGGAGAAGACTGTGCTGGGTTGATTTATGCTGGGCAGTGGAAACGATTTCCAA  
TGTGAAGACGTCAATAACTTCATTTGCGAAAAAGACAGGGAGACAGTACTGTCATCTGCA  
TTATAACGGACTGTGATGGGATCACATGAGCAAATTTTCAGCTCTCAAAGGCAAAGGACA  
CTCCTTTCTAATTGCATCACCTTCTCATCAGATTGAAAAAAAAAAGCACTGAAAACCAA  
TTACTGAAAAAAAAATTGACAGCTAGTGTTTTTTTACCATCCGTCATTACCCAAAGACTTGG  
GAACTAAAATGTTCCCCAGGGTGATATGCTGATTTTCATTGTGCACATGGACTGAATCAC  
ATAGATTCTCCTCCGTCAAGTAACCGTGCGATTATACAAATTATGCTTTCCAAAGTATGGA  
ACACTCCAATCAGAAAAAGGTTATCATTGGTCGTTGAGTTATGGGAAGAACTTAAGCATA  
TACTGTGTAAACAGTGCCATACATTTCTAAATCCCAAGTGTAGGAAAAATATGCAGACA  
TACAGATATATAGGCCAACTATTAGTAATAATATGAAATATACTTAAAGAGCTTTTAAAA  
CTTTGTATTTTTTGTACAAAAAAA

28/392

**FIGURE 28**

MQQDLMSRLDTEVANLSVIMEEMKLVDSKHGQLIKNFTILQGPPGPRGPRGDRGSQGPP  
GPTGNKGQKGEKGEPPGPAGERGPIGPAGPPGERGGKSGSKGSQGPKGSRGSPGKPGPQ  
GPSGDPGPPGPPGKEGLPGPQGPFGQLQGTVGEPGVPGPRGLPGLPGVPGMPGPKGPP  
GPPGPSGAVVPLALQNEPTPAPEDNSCPHWNFTDKCYYFSVEKEIFEDAKLFCEDKSS  
HLVFINTREEQQWIKKQMVGRESHWIGLTDSERENEWKWLDGTSPDYKNWKAGQPDNWDH  
GHGPGEDCAGLIYAGQWDFQCEDVNNFICEKDRETVLSSAL

**Signal sequence:**

None

**Transmembrane domain:**

None

**N-glycosylation site:**

16-19, 37-40, 213-216

**Tyrosine kinase phosphorylation site:**

212-220

**N-myristoylation site:**

97-102, 100-105, 148-153, 267-272, 293-298, 310-315

**Cell attachment sequence:**

51-53

**C-type lectin domain signature:**

308-330

**Lectin C-type domain:**

233-330

**Collagen triple helix repeat:**

43-102, 127-186

29/392

**FIGURE 29**

GGACTAATCTGTGGGAGCAGTTTATTCCAGTATCACCCAGGGTGCAGCCACACCAGGACT  
GTGTTGAAGGGTGTTTTTTTTCTTTTAAATGTAATACCTCCTCATCTTTTCTTCTTACAC  
AGTGTCTGAGAACATTACATTATAGATAAGTAGTACATGGTGGATAAATTCTACTTTTA  
GGAGGACTACTCTCTTCTGACAGTCCTAGACTGGTCTTCTACACTAAGACACCAATGAAGG  
AGTATGTGCTCCTATTATTCTGGCTTTGTGCTCTGCCAAACCCTTCTTTAGCCCTTCAC  
ACATCGCACTGAAGAATATGATGCTGAAGGATATGGAAGACACAGATGATGATGATGATG  
ATGATGATGATGATGATGATGATGAGGACAACTCTCTTTTCCAACAAGAGAGCCAAGAA  
GCCATTTTTTTCCATTTGATCTGTTTCCAATGTGTCCATTTGGATGTCAGTGCTATTTCAC  
GAGTTGTACATTGCTCAGATTTAGGTTTGACCTCAGTCCCAACCAACATTTCCATTTGATA  
CTCGAATGCTTGATCTTCAAAACAATAAAATTAAGGAAATCAAAGAAAATGATTTTAAAG  
GACTCACTTCACTTTATGGTCTGATCCTGAACAACAACAAGCTAACGAAGATTCACCCAA  
AAGCCTTTCTAACCACAAAGAAGTTGCGAAGGCTGTATCTGTCCCACAATCAACTAAGTG  
AAATACCACTTAATCTTCCCAAATCATAGCAGAACTCAGAAATTCATGAAAATAAAGTTA  
AGAAAATACAAAAGGACACATTCAAAGGAATGAATGCTTTACACGTTTTGGAAATGAGTG  
CAAACCCCTCTTGATAATAATGGGATAGAGCCAGGGGCATTTGAAGGGGTGACGGTGTTCC  
ATATCAGAATTGCAGAAGCAAACTGACCTCAGTTCCCTAAAGGCTTACCACCAACTTTAT  
TGGAGCTTCACTTAGATTATAATAAAATTTCAACAGTGGAACCTTGAGGATTTTAAACGAT  
ACAAAGAACTACAAAGGCTGGGCCTAGGAAACAACAATAATCACAGATATCGAAAATGGGA  
GTCTTGCTAACATAACCAGTGTGAGAGAAATACATTTGGAAAACAATAAACTAAAAAAA  
TCCCTTCAGGATTACCAGAGTTGAAATACCTCCAGATAATCTTCCTTCATTCTAATTCAA  
TTGCAAGAGTGGGAGTAAATGACTTCTGTCCAACAGTGCCAAAGATGAAGAAATCTTTAT  
ACAGTGCAATAAGTTTATTCAACAACCCGGTGAAATACTGGGAAATGCAACCTGCAACAT  
TTCGTTGTGTTTTGAGCAGAATGAGTGTTTCACTTGGGAACCTTGGAATGTAATAATTAG  
TAATTGGTAATGTCCATTTAATATAAGATTCAAAAATCCCTACATTTGGAATACTTGAAC  
TCTATTAATAATGGTAGTATTATATATACAAGCAAAATATCTATTCTCAAGTGGTAAGTCC  
ACTGACTTATTTTATGACAAGAAATTTCAACGGAATTTTGCCAAACTATTGATACATAAG  
GGGTTGAGAGAAACAAGCATCTATTGCAGTTTCTTTTTTGCGTACAAATGATCTTACATA  
AATCTCATGCTTGACCATTCCTTTCTTCATAACAAAAAAGTAAGATATTTCGGTATTTAAC  
ACTTTGTTATCAAGCACATTTTAAAAAGAACTGTACTGTAAATGGAATGCTTGACTTAGC  
AAAATTTGTGCTCTTTTCAATTTGCTGTTAGAAAAACAGAATTAACAAAGACAGTAATGTGA  
AGAGTGCAATTACACTATTCTTATTCTTTAGTAACCTTGGGTAGTACTGTAATATTTTTAAT  
CATCTTAAAGTATGATTTGATATAATCTTATTGAAATTACCTTATCATGTCTTAGAGCCC  
GTCTTTATGTTTTAAACTAATTTCTTAAAAATAAAGCCTTCAGTAAATGTTTATTACCAAC  
TTGATAAATGCTACTCATAAGAGCTGGTTTGGGGCTATAGCATATGCTTTTTTTTTTTTA  
ATTATTACCTGATTTAAAAATCTCTGTAAAAACGTGTAGTGTTCATAAAATCTGTAACCT  
CGCATTTTAATGATCCGCTATTATAAGCTTTTAATAGCATGAAAATTGTTAGGCTATATA  
ACATTGCCACTTCAACTCTAAGGAATATTTTTGAGATATCCCTTTGGAAGACCTTGCTTG  
GAAGAGCCTGGACACTAACAATTCTACACCAAAATGTCTCTTCAAATACGTATGGACTGG  
ATAACTCTGAGAAACACATCTAGTATAACTGAATAAGCAGAGCATCAAATTAACAGACA  
GAAACCGAAAGCTCTATATAAATGCTCAGAGTTCTTTATGTATTTCTTATTGGCATTCAA  
CATATGTAAATCAGAAAACAGGGAAATTTTCATTAAAAATATTGGTTTGAAAT



30/392

**FIGURE 30**

MKEYVLLLFLALCSAKPFFSPSHIALKNMMLKDMEDTDDDDDDDDDDDDDEDNSLFPTRE  
PRSHFFPFDLFPMCPFGCQCYSRVVHCSDLGLTSVPTNIPFDTRMLDLQNNKIKEIKEND  
FKGLTSLYGLILNNNKLTKIHPKAFLTTKKLRRLYLSHNQLSEIPLNLPKSLAELRIHEN  
KVKKIQKDTFKGMNALHVLEMSANPLDNNGIEPGAFEGVTVFHIRIAEAKLTSVPKGLPP  
TLLELHLDYNKISTVELEDFKRYKELQRLGLGNNKITDIENGLANIPRVREIHLENNKL  
KKIPSGLPPELKYLQIIFLHSNSIARVGVNDFCPTVPKMKKSLSAISLFNNPVKYWEMQP  
ATFRCVLSRMSVQLGNFGM

**Signal sequence:**

amino acids 1-15

**N-glycosylation site:**

amino acids 281-285

**N-myristoylation sites:**amino acids 129-135, 210-216, 214-220, 237-243, 270-276,  
282-288**Leucine zipper pattern:**

amino acids 154-176

31/392

## FIGURE 31

AGCAGGGAAATCCGGATGTCTCGGTTATGAAGTGGAGCAGTGAGTGTGAGCCTCAACATA  
GTTCCAGAACTCTCCATCCGGACTAGTTATTGAGCATCTGCCTCTCATATCACCAGTGGC  
CATCTGAGGTGTTTCCCTGGCTCTGAAGGGGTAGGCACGATGGCCAGGTGCTTCAGCCTG  
GTGTTGCTTCTCACTTCCATCTGGACCACGAGGCTCCTGGTCCAAGGCTCTTTGCGTGCA  
GAAGAGCTTTCCATCCAGGTGTTCATGCAGAATTATGGGGATCACCTTGTGAGCAAAAAG  
GCGAACCAGCAGCTGAATTTACAGAAAGCTAAGGAGGCCTGTAGGCTGCTGGGACTAAGT  
TTGGCCGGCAAGGACCAAGTTGAAACAGCCTTGAAAGCTAGCTTTGAAACTTGCAGCTAT  
GGCTGGGTTGGAGATGGATTTCGTGGTTCATCTCTAGGATTAGCCCAAACCCCAAGTGTGGG  
AAAAATGGGGTGGGTGTCTGATTGGAAGGTTCCAGTGAGCCGACAGTTTGCAGCCTAT  
TGTTACAACCTCATCTGATACTTGGACTAACTCGTGCATTCCAGAAATTATCACCACCAA  
GATCCCATATTTCAACACTCAAACGCAACACAAACAAGAAATTTATTGTGAGTGACAGT  
ACCTACTCGGTGGCATCCCCTTACTCTACAATACCTGCCCCTACTACTCCTCCTGCT  
CCAGCTTCCACTTCTATTCCACGGAGAAAAAATTGATTTGTGTACAGAAAGTTTTTATG  
GAACTAGCACCATGTCTACAGAACTGAACCATTGTTGAAAATAAAGCAGCATTCAAG  
AATGAAGCTGCTGGGTTTGGAGGTGTCCCCACGGCTCTGCTAGTGCTTGCTCTCCTCTTC  
TTTGGTGCTGCAGCTGGTCTTGGATTTTGCTATGTCAAAGGTATGTGAAGGCCTTCCCT  
TTTACAAACAAGAATCAGCAGAAGGAAATGATCGAAACCAAAGTAGTAAAGGAGGAGAAG  
GCCAATGATAGCAACCCTAATGAGGAATCAAAGAAAACCTGATAAAAACCCAGAAGAGTCC  
AAGAGTCCAAGCAAACTACCGTGCGATGCCTGGAAGCTGAAGTTTAGATGAGACAGAAA  
TGAGGAGACACACCTGAGGCTGGTTTTCTTTCATGCTCCTTACCCTGCCCCAGCTGGGGAA  
ATCAAAGGGCCAAAGAACCAAAGAAGAAAGTCCACCCTTGGTTCCTAACTGGAATCAGC  
TCAGGACTGCCATTGGACTATGGAGTGCACCAAAGAGAATGCCCTTCTCCTTATTGTAAC  
CCTGTCTGGATCCTATCCTCCTACCTCCAAAGCTTCCCACGGCCTTTCTAGCCTGGCTAT  
GTCCTAATAATATCCCCTGAGGAGAAAGGAGTTTTGCAAAGTGCAAGGACCTAAAACATC  
TCATCAGTATCCAGTGGTAAAAAGGCCTCCTGGCTGTCTGAGGCTAGGTGGGTTGAAAGC  
CAAGGAGTCACTGAGACCAAGGCTTTCTCTACTGATTCCGCAGCTCAGACCCTTTCTTCA  
GCTCTGAAAGAGAAACACGTATCCCACCTGACATGTCTTCTGAGCCCGGTAAGAGCAAA  
AGAATGGCAGAAAAGTTTAGCCCCTGAAAGCCATGGAGATTCTCATAACTTGAGACCTAA  
TCTCTGTAAAGCTAAAATAAAGAAATAGAACAAGGCTGAGGATACGACAGTACACTGTCA  
GCAGGACTGTAAACACAGACAGGGTCAAAGTGTTTTCTCTGAACACATTGAGTTGGAAT  
CACTGTTTGTAAACACACACACTTACTTTTTCTGGTCTCTACCACTGCTGATATTTTCTCT  
AGGAAATATACTTTTACAAGTAACAAAAATAAAAACCTTATAAATTTCTATTTTTATCT  
GAGTTACAGAAATGATTACTAAGGAAGATTACTCAGTAATTTGTTTAAAAAGTAATAAAA  
TTCAACAAACATTTGCTGAATAGCTACTATATGTCAAGTGCTGTGCAAGGTATTACACTC  
TGTAATTGAATATTATTCTCAAAAAATTGCACATAGTAGAACGCTATCTGGGAAGCTAT  
TTTTTTCAGTTTTGATATTTCTAGCTTATCTACTTCCAAACTAATTTTTTATTTTTGCTGA  
GACTAATCTTATTCATTTTCTCTAATATGGCAACCATTATAACCTTAATTTATTATTAAC  
ATACCTAAGAAGTACATTGTTACCTCTATATACCAAAGCACATTTTAAAAGTGCCATTAA  
CAAATGTATCACTAGCCCTCCTTTTTCCAACAAGAAGGACTGAGAGATGCAGAAATATT  
TGTGACAAAAAATTAAAGCATTTAGAAAACCT

32/392

**FIGURE 32**

MARCFSLVLLLTSIWTTTRLLVQGSLRAEELSIQVSCRIMGITLVSKKANQQLNFTEAKEA  
CRLGLSLAGKDQVETALKASFETCSYGWVGDFVVISRISPNPKCGKNGVGVLWKVPV  
SRQFAAYCYNSSDTWTNSCIPEIITTKDPIFNTQTATQTTEFIVSDSTYSVASPYSTIPA  
PTTTPPAPASTSIPRRKKLICVTEVFMETSTMSTETEPFVENKAAFKNAAAGFGGVPTAL  
LVLALLFFGAAAGLGFCYVKRYVKAFPTNKNQQKEMIETKVVKEEKANDSNPNEESKKT  
DKNPEESKSPSKTTVRCLEAEV

**Signal sequence:**

amino acids 1-16

**Transmembrane domain:**

amino acids 235-254

**N-glycosylation site:**

amino acids 53-57, 130-134, 289-293

**Casein kinase II phosphorylation site:**

amino acids 145-149, 214-218

**Tyrosine kinase phosphorylation site:**

amino acids 79-88

**N-myristoylation site:**

amino acids 23-29, 65-71, 234-240, 235-239, 249-255, 253-259

33/392

**FIGURE 33**

[illegible]

34/392

TCTACTTATGTTGGACACTTGGCAGAAGGACCGTGCCCGGCGGCCTCATTTTGACCAGCT  
GGTGGCTGCATTTGACAAGATGATCCGCAAGCCAGATACCCTGCAGGCTGGCGGGGACCC  
AGGGGAAAGGCCTTCCCAGGCCCTTCTGACCCCTGTGGCCCTGGACTTTCTTGTCTGGA  
CTCACCCCAGGCCTGGCTTTCAGCCATTGGACTGGAGTGCTACCAGGACAACCTTCTCCAA  
GTTTGGCCTCTGTACCTTCAGTGATGTGGCTCAGCTCAGCCTAGAAGACCTGCCTGCCCT  
GGGCATCACCTGGCTGGCCACCAGAAGAAGCTGCTGCACCACATCCAGCTCCTTCAGCA  
ACACCTGAGGCAGCAGGGCTCAGTGGAGGTCTGAGAATGACGATACCCGTGACTCAGCCC  
TGGACACTGGTCCGAGAAGGGACATGTGGGACGTGAGCCGGGCTCCAACAGCCTCTGTGA  
GAGATGCCCCACACCAAACCCAACCTCCGATGGCTGCATTCCCTGGTCCTCCGCTTTTC  
CACCAGCCCCCTCCTCATTAAGGGAAAGAAGGGAATTTGCAAAAAAAAAAAAAAAAAAA  
AAAAAA

35/392

**FIGURE 34**

MATEGAAQLGNRVAGMVC SLWVLLLVSSVLAL EEVLLD TTGETSEIGWLTYP PGGWDEVS  
VLDDQRRLTRTFEACHVAGAPPGTGQDNWLQTHFVERRGAQRAHIRLHFSVRACSSLGVS  
GGTCRETTFTLYRQAE EPDSPDSVSSWHLKRWTKVDTIAADESFPSSSSSSSSSSSSA  
AVGPHGAGQRAGLQLNVKERSFGPLTQRGFYVAFQDTGACLALVAVRLF SYTCPAVLR SF  
ASFPETQASGAGGASLVA AVGTCVAHA EPEEDGVGGQAGGSP PRLHCN GEGKMMVAVGGC  
RCQPGYQPARGDKACQACPRGLYKASAGNAPCSPCPARSHAPNPAAPV CPCLEGFYRASS  
DPPEAPCTGPPSAPQELWFEVQGSALMLHWRLPRELGGRGDLLFN VVCKECEGRQEPASG  
GGGTCHRCRDEVHFDPRQRLTESRVLVGGLRAHVPIILEVQAVNGVSELSPDPPQAAAI  
NVSTSHVPSAVPVVHQVSRANSITVSWPQPDQTNGNILDYQLRYDQAEDESHSFTLT  
SETNTATVTQLSPGHIYGFQVRARTAAGHGPGYGGKVYFQTL PQGELSSQLPERLSLVIGS  
TLGALAFLLLLAAITVLAVVFQRKRGTGYTEQLQQYSSPGLGVKYYIDPSTYEDPCQAIR  
ELAREVDPAYIKIEEVIGTGSFGEVRQGR LQPRGRREQTVAIQALWAGGAESLQMTFLGR  
AAVLGQFQHPNILRLEGVVTKSRPLMVLTEFMELGPLDSFLRQREGQFSSQLQVAMQRGV  
AAAMQYLSSFAFVHRSLSAHSVLVNSHLVCKVARLGHSPQGPSCLLRWAAPEVIAHGKHT  
HVGSDDELWRTALLGHE

**signal sequence:**

Amino acids 1-31

**Transmembrane domains:**

Amino acids 217-234;598-618

**N-glycosylation site:**

Amino acids 481-485

**Glycosaminoglycan attachment sites:**

Amino acids 249-253;419-423

**cAMP- and cGMP-dependent protein kinase phosphorylation sites:**

Amino acids 66-70;150-154;624-628

**Tyrosine kinase phosphorylation sites:**

Amino acids 644-673;664-671

**N-myristoylation sites:**

Amino acids 10-16;15-21;79-85;99-105;118-124;188-194;  
192-198;218-224;250-256;261-267;275-281;276-282;298-304;321-  
327;328-334;420-426;421-427;440-446;449-455;599-605;626-632;  
708-714;766-772;779-785

**Amidation site:**

Amino acids 693-697

**Cell attachment sequences:**

Amino acids 310-313;399-402

36/392

**FIGURE 35**

GGGGTCTCCCTCAGGGCCGGGAGGCACAGCGGTCCCTGCTTGCTGAAGGGCTGGATGTAC  
GCATCCGCAGGTTCCCGCGGACTTGGGGGCGCCCGCTGAGCCCCGGCGCCCGCAGAAGAC  
TTGTGTTTGCCTCCTGCAGCCTCAACCCGGAGGGCAGCGAGGGCCTACCACCATGATCAC  
TGGTGTGTTTCAGCATGCGCTTGTGGACCCAGTGGGCGTCCTGACCTCGCTGGCGTACTG  
CCTGCACCAGCGGCGGGTGGCCCTGGCCGAGCTGCAGGAGGCCGATGGCCAGTGTCCGGT  
CGACCGCAGCCTGCTGAAGTTGAAAATGGTGCAGGTCGTGTTTCGACACGGGGCTCGGAG  
TCCTCTCAAGCCGCTCCCGCTGGAGGAGCAGGTAGAGTGGAACCCCCAGCTATTAGAGGT  
CCCACCCCAAACCTCAGTTTGATTACACAGTCACCAATCTAGCTGGTGGTCCGAAACCATA  
TTCTCCTTACGACTCTCAATACCATGAGACCACCCCTGAAGGGGGGCATGTTTGCTGGGCA  
GCTGACCAAGGTGGGCATGCAGCAAATGTTTGCTTGGGAGAGAGACTGAGGAAGAATA  
TGTGGAAGACATTCCCTTTCTTTCACCAACCTTCAACCCACAGGAGGTCTTTATTCTGTTT  
CACTAACATTTTTTCGGAATCTGGAGTCCACCCGTTGTTTGCTGGCTGGGCTTTTCCAGTG  
TCAGAAAGAAGGACCCATCATCATCCACACTGATGAAGCAGATTCAGAAGTCTTGTATCC  
CAACTACCAAAGCTGCTGGAGCCTGAGGCAGAGAACCAGAGGCCGGAGGCAGACTGCCTC  
TTTACAGCCAGGAATCTCAGAGGATTTGAAAAAGGTGAAGGACAGGATGGGCATTGACAG  
TAGTGATAAAGTGGACTTCTTCATCCTCCTGGACAACGTGGCTGCCGAGCAGGCACACAA  
CCTCCCAAGCTGCCCCATGCTGAAGAGATTTGCACGGATGATCGAACAGAGAGCTGTGGA  
CACATCCTTGTACATACTGCCCAAGGAAGACAGGGAAAGTCTTCAGATGGCAGTAGGCC  
ATTCCTCCACATCCTAGAGAGCAACCTGCTGAAAGCCATGGACTCTGCCACTGCCCCCGA  
CAAGATCAGAAAGCTGTATCTCTATGCGGCTCATGATGTGACCTTCATACCGCTCTTAAT  
GACCCCTGGGGATTTTTGACCACAAATGGCCACCGTTTGCTGTTGACCTGACCATGGA  
TTACCAGCACCTGGAATCTAAGGAGTGGTTTGTGCAGCTCTATTACCACGGGAAGGAGCA  
GGTGCCGAGAGGTTGCCCTGATGGGCTCTGCCCCTGGACATGTTCTTGAATGCCATGTC  
AGTTTATACCTTAAGCCCAGAAAAATACCATGCACTCTGCTCTCAAACCTCAGGTGATGGA  
AGTTGGAAATGAAGAGTAACTGATT'TATAAAAGCAGGATGTGTTGATTTTAAATAAAGT  
GCCTTTATACAATG

37/392

**FIGURE 36**

MITGVFSMRLWTPVGVLTSLAYCLHQRRVALAELQEADGQCPVDRSLLKLKMOVVFRHG  
ARSPLKPLPLEEQVEWNPQLLEVPPQTQFDYTVTNLAGGPKPYSPYDSQYHETTLKGGMF  
AGQLTKVGMQOMFALGERLRKNYVEDIPFLSPTFNPQEVFIRSTNIFRNLESTRCLLAGL  
FQCQKEGPIIIHTDEADSEVLYPNYQSCWSLRQTRGRRTASLQPGISEDLKKVKDRMG  
IDSSDKVDFFILLDNVAAEQAHNLPSCPMLKRFAARMIEQRAVDTSLYILPKEDRESLQMA  
VGPFLHILESNNLLKAMDSATAPDKIRKLYLYAAHDVTFIPLMLTLGIFDHKWPPFAVDLT  
MELYQHLESKEWFVQLYYHGKEQVPRGCPDGLCPLDMFLNAMS VYTLSP EKYHALCSQTQ  
VMEVGNEE

**Signal sequence:**

amino acids 1-23

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 218-222

**Casein kinase II phosphorylation site:**

amino acids 87-91, 104-108, 320-324

**Tyrosine kinase phosphorylation site:**

amino acids 280-288

**N-myristoylation site:**

amino acids 15-21, 117-123, 118-124, 179-185, 240-246, 387-393

**Amidation site:**

amino acids 216-220

**Leucine zipper pattern:**

amino acids 10-32

**Histidine acid phosphatases phosphohistidine signature:**

amino acids 50-65



38/392

**FIGURE 37**

ACTGCACTCGGTTCTATCGATTGAATTCCCCGGGGATCCTCTAGAGATCCCTCGACCTCG  
ACCCACGCGTCCGCGGACGCGTGGGCGGACGCGTGGGCCGGCTACCAGGAAGAGTCTGCC  
GAAGGTGAAGGCCATGGACTTCATCACCTCCACAGCCATCCTGCCCCCTGCTGTTTCGGCTG  
CCTGGGCGTCTTCGGCCTCTTCCGGCTGCTGCAGTGGGTGCGCGGGAAGGCCTACCTGCG  
GAATGCTGTGGTGGTGATCACAGGCGCCACCTCAGGGCTGGGCAAAGAATGTGCAAAAGT  
CTTCTATGCTGCGGGTGCTAAACTGGTGCTCTGTGGCCGGAATGGTGGGGCCCTAGAAGA  
GCTCATCAGAGAACTTACCGCTTCTCATGCCACCAAGGTGCAGACACACAAGCCTTACTT  
GGTGACCTTCGACCTCACAGACTCTGGGGCCATAGTTGCAGCAGCAGCTGAGATCCTGCA  
GTGCTTTGGCTATGTGACATACTTGTCAACAATGCTGGGATCAGCTACCGTGGTACCAT  
CATGGACACCACAGTGGATGTGGACAAGAGGGTTCATGGAGACAACTACTTTGGCCCAGT  
TGCTCTAACGAAAGCACTCCTGCCCTCCATGATCAAGAGGAGGCAAGGCCACATTGTGCG  
CATCAGCAGCATCCAGGGCAAGATGAGCATTCCTTTTCGATCAGCATATGCAGCCTCCAA  
GCACGCAACCCAGGCTTTCTTTGACTGTCTGCGTGCCGAGATGGAACAGTATGAAATTGA  
GGTGACCGTCATCAGCCCCGGCTACATCCACACCAACCTCTCTGTAAATGCCATCACCGC  
GGATGGATCTAGGTATGGAGTTATGGACACCACCACAGCCCAGGGCCGAAGCCCTGTGGA  
GGTGGCCCAGGATGTTCTTGCTGCTGTGGGGAAGAAGAAGAAAGATGTGATCCTGGCTGA  
CTTACTGCCTTCCTTGGCTGTTTATCTTCGAACTCTGGCTCCTGGGCTCTTCTTCAGCCT  
CATGGCCTCCAGGGCCAGAAAAGAGCGGAAATCCAAGAACTCCTAGTACTCTGACCAGCC  
AGGGCCAGGGCAGAGAAGCAGCACTCTTAGGCTTGCTTACTCTACAAGGGACAGTTGCAT  
TTGTTGAGACTTTAATGGAGATTTGTCTCACAAGTGGGAAAGACTGAAGAAACACATCTC  
GTGCAGATCTGCTGGCAGAGGACAATCAAAAACGACAACAAGCTTCTTCCCAGGGTGAGG  
GGAAACACTTAAGGAATAAATATGGAGCTGGGGTTTAACACTAAAACTAGAAATAAACA  
TCTCAAACAGTAAAAAAAAAAAAAAAAAGGGCGGCCGACTCTAGAGTCGACCTGCAGAAG  
CTTGGCCGCCATGGCCCACTTGTTTATTGCAGCTTATAATGGTTAC

39/392

**FIGURE 38**

MDFITSTAILPLLFGCLGVFGLFRLLQWVRGKAYLRNAVVVITGATSGLGKECAKVFYAA  
GAKLVLCGRNGGALEELIRELTASHATKVQTHKPYLVTFDLTDSGAIVAAAAEILQCFGY  
VDILVNNAGISYRGTIMDTTVDVDKRVMETNYFGPVALTKALLPSMIKRRQGHIVAISII  
QGKMSIPFRSAYAASKHATQAFFDCLRAEMEQYEIEVTVISPGYIHTNLSVNAITADGSR  
YGVMDTTTAQGRSPVEVAQDVLA AVGKKKKDVILADLLPSLAVYLRTLAPGLFFSLMASR  
ARKERKSKNS

**Signal sequence:**  
amino acids 1-21

**Transmembrane domain:**  
amino acids 104-120, 278-292

**N-glycosylation site:**  
amino acids 228-232

**Glycosaminoglycan attachment site:**  
amino acids 47-51

**Casein kinase II phosphorylation site:**  
amino acids 135-139, 139-143, 253-257

**Tyrosine kinase phosphorylation site:**  
amino acids 145-153, 146-153

**N-myristoylation site:**  
amino acids 44-50, 105-111, 238-244, 242-248, 291-297

**Amidation site:**  
amino acids 265-269

**Prokaryotic membrane lipoprotein lipid attachment site:**  
amino acids 6-17

40/392

## FIGURE 39

GCAAGCCAAGGCGCTGTTTGTAGAAGGTGAAGAAGTTCCGGACCCATGTGGAGGAGGGGGACATTGT  
GTACCGCCTCTACATGCGGCAGACCATCATCAAGGTGATCAAGTTCATCCTCATCATCTGTCTACAC  
CGTCTACTACGTGCACAACATCAAGTTCGACGTGGACTGCACCGTGGACATTGAGAGCCTGACGGG  
CTACCGCACCTACCGCTGTGCCACCCCTGGCCACACTCTTCAAGATCCTGGCGTCTTCTACAT  
CAGCCTAGTCATCTTCTACGGCCTCATCTGCATGTACACACTGTGGTGGATGCTACGGCGCTCCCT  
CAAGAAGTACTCGTTTGTAGTCGATCCGTGAGGAGAGCAGCTACAGCGACATCCCCGACGTCAAGAA  
CGACTTCGCCTTCATGCTGCACCTCATTGACCAATACGACCCGCTCTACTCCAAGCGCTTCGCCGT  
CTTCCTGTCTGGAGGTGAGTGAGAACAAAGCTGCGGCAGCTGAACCTCAACAACGAGTGGACGCTGGA  
CAAGCTCCGGCAGCGGCTCACCAAGAACGCGCAGGACAAGCTGGAGCTGCACCTGTTTCATGCTCAG  
TGGCATCCCTGACACTGTGTTTGACCTGGTGGAGCTGGAGGTCCTCAAGCTGGAGCTGATCCCCGA  
CGTGACCATCCCCGCCAGCATTGCCAGCTCACGGGCCTCAAGGAGCTGTGGCTCTACCACACAGC  
GGCCAAGATTGAAGCGCCTGCGCTGGCCTTCTGCGCGAGAACCTGCGGGCGCTGCACATCAAGTT  
CACCGACATCAAGGAGATCCCGCTGTGGATCTATAGCCTGAAGACACTGGAGGAGCTGCACCTGAC  
GGGCAACCTGAGCGCGGAGAACCAACCGCTACATCGTCATCGACGGGCTGCGGGAGCTCAAACGCCT  
CAAGGTGCTGCGGCTCAAGAGCAACCTAAGCAAGCTGCCACAGGTGGTCAAGATGTGGGCGTGCA  
CCTGCAGAAGCTGTCCATCAACAATGAGGGCACCAGCTCATCGTCTCAACAGCCTCAAGAAGAT  
GGCGAACCTGACTGAGCTGGAGCTGATCCGCTGCGACCTGGAGCGCATCCCCACTCCATCTTCAG  
CCTCCACAACCTGCAGGAGATTGACCTCAAGGACAACAACCTCAAGACCATCGAGGAGATCATCAG  
CTTCCAGCACCTGCACCGCCTCACCTGCCTTAAGCTGTGGTACAACCACATCGCCTACATCCCCAT  
CCAGATCGGCAACCTCACCAACCTGGAGCGCCTCTACCTGAACCGCAACAAGATCGAGAAGATCCC  
CACCCAGCTCTTCTACTGCCGCAAGCTGCGCTACCTGGACCTCAGCCACAACAACCTGACCTTCT  
CCCTGCCGACATCGGCCTCCTGCAGAACCTCCAGAACCTAGCCATCACGGCCAACCGGATCGAGAC  
GCTCCCTCCGGAGCTCTTCCAGTGCCGGAAGCTGCGGGCCCTGCACCTGGGCAACAACGTGCTGCA  
GTCACTGCCCTCCAGGGTGGGCGAGCTGACCAACCTGACGCAGATCGAGCTGCGGGGCAACCGGCT  
GGAGTGCTGCTGTGGAGCTGGGCGAGTGCCCACTGCTCAAGCGCAGCGGCTTGGTGGTGGAGGA  
GGACCTGTTCAACACACTGCCACCCGAGGTGAAGGAGCGGCTGTGGAGGGCTGACAAGGAGCAGGC  
CTGAGCGAGGCCGGCCAGCACAGCAAGCAGCAGGACCGCTGCCCAGTCTCAGGCCCGGAGGGG  
AGGCCTAGCTTCTCCAGAACTCCCGGACAGCCAGGACAGCCTCGCGGCTGGGCAAGGAGCCTGGGG  
CCGCTTGTGAGTCAGGCCAGAGCGAGAGGACAGTATCTGTGGGGCTGGCCCCCTTTCTCCCTCTGA  
GACTCAGTCCCCCAGGGCAAGTGCTTGTGGAGGAGAGCAAGTCTCAAGAGCGCAGTATTTGGATA  
ATCAGGGTCTCCTCCCTGGAGGCCAGCTTGCCCCAGGGGCTGAGCTGCCACCAGAGGTCCTGGGA  
CCCTCACTTTAGTTCTTGGTATTTATTTTCTCCATCTCCACCTCCTTCATCCAGATAACTATA  
CATTCCCAAGAAAGTTTCAGCCAGATGGAAGGTGTTTCAGGGAAAGGTGGGCTGCCTTTTCCCTTG  
TCCTTATTTAGCGATGCCGCCGGGCATTTAACACCCACCTGGACTTCAGCAGAGTGGTCCGGGGCG  
AACCAGCCATGGGACGGTCACCCAGCAGTGCCGGGCTGGGCTCTGCGGTGCGGTCCACGGGAGAGC  
AGGCCTCCAGCTGGAAAGGCCAGGCCTGGAGCTTGCTCTTCAGTTTTTGTGGCAGTTTTAGTTTT  
TTGTTTTTTTTTTTTTTAATCAAAAAACAATTTTTTTTTAAAAAAAGCTTTGAAAATGGATGGTTT  
GGGTATTAAGAAAGAAAAAAACTTAAAAAAAGACACTAACGGCCAGTGAGTTGGAGTCTC  
AGGGCAGGGTGGCAGTTTTCCCTTGAGCAAGCAGCCAGACGTTGAAGTGTGTTTCCCTTTCCCTGGG  
CGCAGGGTGCAGGGTGTCTTCCGGATCTGGTGTGACCTTGGTCCAGGAGTCTATTTGTTCTCTGGG  
GAGGGAGGTTTTTTTTGTTTTGTTTTTGGGTTTTTTTTGGTGTCTTGTTTTTCTTCTCCTCATGTGT  
CTTGGCAGGCACTCATTTCTGTGGCTGTGCGCCAGAGGGAATGTTCTGGAGCTGCCAAGGAGGGAG  
GAGACTCGGGTTGGCTAATCCCCGGATGAACGGTGCTCCATTGCGACCTCCCCCTCCTGCTGCCTGC  
CCTGCCTCTCCACGCACAGTGTTAAGGAGCCAAGAGGAGCACTTCGCCCAGACTTTGTTTTCCCA  
CCTCCTGCGGCATGGGTGTGTCCAGTGCCACCGCTGGCCTCCGCTGCTTCCATCAGCCCTGTGCGC  
ACCTGGTCTCTTCATGAAGAGCAGACACTTAGAGGCTGGTCCGGGAATGGGGAGGTCGCCCCCTGGGAG  
GGCAGGCGTTGGTTCCAAGCCGGTTCCCGTCCCTGCGCCTGGAGTGACACAGCCCCCTGCGCAC  
CTGGTGGCTGGAAGCCAACCTGCTTTAGATCACTCGGGTCCCCACCTTAGAAGGGTCCCCGCCTTA  
GATCAATCACGTGGACACTAAGGCAGTTTTAGAGTCTCTTGTCTTAATGATTATGTCCATCCGTC  
TGTCGGTCCATTTGTGTTTTCTGCGTGTGTGTCATTGGATATAATCCTCAGAAATAATGCACACTAG  
CCTCTGACAACCATGAAGCAAAAATCCGTTACATGTGGGTCTGAAGTTGTAGACTCGGTACAGTA  
TCAAATAAATCTATAACAGAAAAA

41/392

**FIGURE 40**

MRQTIKVIKFIILICYTVYYVHNKFDVDCTVDIESLTGYRTYRCAHPLATLFKILASF  
YISLVIFYGLICMYTLWWMLRRSLKKYSFESTIREESSYSDIPDVKNDFAFMLHLIDQYDP  
LYSKRFAVFLSEVSENKLRQLNLNNEWTLDKLRQRLTKNAQDKLEHLFMLSIGIPDTVFD  
LVELEVLKLELIPDVTIPPSIAQLTGLKELWLYHTAAKIEAPALAFLENLRALHIKFTD  
IKEIPLWIYSLKTEELHLTGNLSAENNRYIVIDGLRELKRLKVLRLKSNLSKLPQVVTD  
VGVHLQKLSINNEGTKLIVLNSLKKMANLTELELIRCDLERIPHSIFSLHNLQEIDLKDN  
NLKTIEEIIISFQHLHRLTCLKLWYNHIAIYIPIQIGNLTNLERLYLNRNKIEKIPTQLFYC  
RKLRYLDLSHNNLTFLPADIGLLQNLQNLAITANRIETLPPELFQCRKLRLHLGNNVLQ  
SLPSRVGELTNLTQIELRGNRLECLPVELGECPLLKRSGLVVEEDLFNTLPPEVKERLWR  
ADKEQA

**Transmembrane domain:**

amino acids 51-75 (type II)

**N-glycosylation site:**amino acids 262-266, 290-294, 328-332, 396-400, 432-436,  
491-495**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 85-89

**Casein kinase II phosphorylation site:**amino acids 91-95, 97-101, 177-181, 253-257, 330-334, 364-368,  
398-402, 493-497**N-myristoylation site:**

amino acids 173-179, 261-267, 395-401, 441-447

42/392

**FIGURE 41**

GGGGGAGAAGGCGGCCGAGCCCCAGCTCTCCGAGCACCGGGTCGGAAGCCGCGACCCGAG  
CCGCGCAGGAAGCTGGGACCGGAACCTCGGCGGACCCGGCCCCACCCAACCTCACCTGCGC  
AGGTCACCAGCACCCCTCGGAACCCAGAGGCCCGCGCTCTGAAGGTGACCCCCCTGGGGAG  
GAAGGCGATGGCCCCCTGCGAGGACGATGGCCCCGCGCCCGCTCGCCCCGGCCGGCATCCC  
TGCCGTGCGCTTGTGGCTTCTGTGCACGCTCGGCCTCCAGGGCACCCAGGCCGGGCCACC  
GCCCCGCCCCCTGGGCTGCCCCGCGGAGCCGACTGCCTGAACAGCTTTACCGCCGGGGT  
GCCTGGCTTCGTGCTGGACACCAACGCCTCGGTGAGCAACGGAGCTACCTTCTGGAGTC  
CCCCACCGTGCGCCGGGGCTGGGACTGCGTGCGCGCCTGCTGCACCACCCAGAAGTCAA  
CTTGGCGCTAGTGGAGCTGCAGCCCCGACCGCGGGGAGGACGCCATCGCCGCTGCTTCCT  
CATCAACTGCCTCTACGAGCAGAACTTCGTGTGCAAGTTCGCGCCCAGGGAGGGCTTCAT  
CAACTACCTCACGAGGGAAGTGTACCGCTCCTACCGCCAGCTGCGGACCCAGGGCTTTGG  
AGGGTCTGGGATCCCCAAGGCCTGGGACGGCATAGACTTGAAGGTACAACCCAGGAACC  
CCTGGTGCTGAAGGATGTGGAAAACACAGATTGGCGCCTACTGCGGGGTGACACGGATGT  
CAGGGTAGAGAGGAAAGACCCAAACCAGGTGGAAGTGTGGGGACTCAAGGAAGGCACCTA  
CCTGTTCCAGCTGACAGTGAAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGAC  
CACTGTGCTGTCCACCAAGCAGACAGAAAGTGTGACAGTGTGACAGTGTGACAGTGTGAC  
CTGCCGGGGCTCTTTCCACGCTGGTACTATGACCCACGGAGCAGATCTGCAAGAGTTT  
CGTTTATGGAGGCTGCTTGGGCAACAAGAACAACCTTTCGGGAAGAAGAGTGCATTCT  
AGCCTGTGCGGGGTGTGCAAGGTGGGCTTTGAGAGGCAGCTCTGGGGCTCAGGCGACTTT  
CCCCCAGGGCCCCCTCCATGGAAAGGCGCCATCCAGTGTGCTCTGGCACCTGTGACGCCAC  
CCAGTTCGCGTGACAGCAATGGCTGCTGCATCGACAGTTTCTGGAGTGTGACGACACCCC  
CAACTGCCCCGACGCCTCCGACGAGGCTGCCTGTGAAAAATACACGAGTGGCTTTGACGA  
GCTCCAGCGCATCCATTTCCCCAGTGACAAAGGGCACTGCGTGGACCTGCCAGACACAGG  
ACTCTGCAAGGAGAGCATCCCGCGCTGGTACTACAACCCCTTCAGCGAACACTGCGCCCG  
CTTTACCTATGGTGGTTGTTATGGCAACAAGAACAACCTTTGAGGAAGAGCAGCAGTGCCT  
CGAGTCTTGTGCGGCGCATCTCCAAGAAGGATGTGTTTGGCCTGAGGCGGGAAATCCCCAT  
TCCAGCACAGGCTCTGTGGAGATGGCTGTGACAGTGTTCCTGGTGCATCTGCATTGTGGT  
GGTGGTAGCCATCTTGGGTTACTGCTTCTTCAAGAACCAGAGAAAGGACTTCCACGGACA  
CCACCACCAACCCACCCACCCCTGCCAGCTCCACTGTCTCCACTACCGAGGACACGGA  
GCACCTGGTCTATAACCAACACCCCGGCCCTCTGAGCCTGGGTCTCACCGGCTCTCAC  
CTGGCCCTGCTTCTGCTTGCCAAGGCAGAGGCCTGGGCTGGGAAAACTTTGGAACCAG  
ACTCTTGCCTGTTTCCCAGGCCCCACTGTGCCTCAGAGACCAGGGCTCCAGCCCCCTTTGG  
AGAAGTCTCAGCTAAGCTCACGTCTGAGAAAGCTCAAAGGTTTGGAGGAGCAGAAAC  
CCTTGGGCCAGAAGTACCAGACTAGATGGACCTGCCTGCATAGGAGTTTGGAGGAAGTTG  
GAGTTTGTGTTCTCTGTTCAAAGCTGCCTGTCCCTACCCCATGGTGTAGGAAGAGGAG  
TGGGGTGGTGTGACACCTGGAGGCCCCAACCTGTCTCCCGAGCTCCTCTTCCATGCT  
GTGCGCCCAGGGCTGGGAGGAAGGACTTCCCTGTGTAGTTTGTGCTGTAAAGAGTTGCTT  
TTTGTGTTATTTAATGCTGTGGCATGGGTGAAGAGGAGGGGAAGAGGCCTGTTTGGCCTCT  
CTGTCTCTCTTCTTCCCCAAGATTGAGCTCTCTGCCCTTGATCAGCCCCACCCCTG  
GCCTAGACCAGCAGACAGAGCCAGGAGAGGCTCAGCTGCATTCCGCAGCCCCCACCCTG  
AGGTTCTCAACATCACAGCCAGCCACCCACTGGGTAATAAAAGTGTTTGTGAAAAA  
AAAAAAAAAAAAAAAAAAAAA

43/392

**FIGURE 42**

MAPARTMARARLAPAGIPAVALWLLCTLGLQGTQAGPPPAPPGLPAGADCLNSFTAGVPG  
FVLDTNASVSNGATFLESPTVRRGWDCVRACCTTQNCNLALVELQPDRGEDAIAACFLIN  
CLYEQNFVCKFAPREGFINYLTVREYRSYRQLRTQGFGSGIPKAWAGIDLKVPQPEPLV  
LKDVENTDWRLLRGDTDVVERKDPNQVELWGLKEGTYLFQLTVTSSDHPEDTANVTVTV  
LSTKQTEDYCLASNKVGRCRGSFPRWYYDPTEQICKSFVYGGCLGNKNNYLREEECILAC  
RGVQGGPLRGSSGAQATFPQGSPMERRHPVCSGTCQPTQFRCSNGCCIDSFLECDDTPNC  
PDASDEAAACEKYTSGFDELQRIHFPSDKGHCVDLPDTGLCKESIPRWYYNPFSEHCARFT  
YGGCYGNKNNFEEEQQCLESRCRGISKDVFGLRREIPIPTSGSVEMAVTVFLVICIVVVV  
AILGYCFFKNQRKDFHGHHPPTPASSTVSTTEDTEHLVYNHTTRPL

**signal sequence:**

Amino acids 1-35

**transmembrane domain:**

Amino acids 466-483

**N-glycosylation sites:**

Amino acids 66-70;235-239;523-527

**N-myristoylation sites:**

A        m        i        n        o                    a        c        i        d        s  
29-35;43-49;161-167;212-218;281-287;282-288;285-291;  
310-316;313-319;422-428;423-429;426-432

**Cell attachment sequence:**

Amino acids 193-199

**Pancreatic trypsin inhibitor (Kunitz) family signatures:**

Amino acids 278-298;419-438

44/392

**FIGURE 43**

CCCACGCGTCCGCACCTCGGCCCCGGGCTCCGAAGCGGCTCGGGGGCGCCCTTTCGGTCA  
ACATCGTAGTCCACCCCCTCCCCATCCCCAGCCCCCGGGATTTCAGGCTCGCCAGCGCCC  
AGCCAGGGAGCCGGCCGGGAAGCGCGATGGGGGGCCCCAGCCGCCTCGCTCCTGCTCCTGC  
TCCTGCTGTTTCGCCTGCTGCTGGGCGCCCCGGCGGGGGCCAACCTCTCCCAGGACGACAGCC  
AGCCCTGGACATCTGATGAAACAGTGGTGGCTGGTGGCACCGTGGTGGTCAAGTGCCAAG  
TGAAAGATCACGAGGACTCATCCCTGCAATGGTCTAACCCTGCTCAGCAGACTCTCTACT  
TTGGGGAGAAGAGAGCCCTTCGAGATAATCGAATTTCAGCTGGTTACCTCTACGCCCCACG  
AGCTCAGCATCAGCATCAGCAATGTGGCCCTGGCAGACGAGGGCGAGTACACCTGCTCAA  
TCTTCACTATGCCTGTGCGAACTGCCAAGTCCCTCGTCACTGTGCTAGGAATTCACAGA  
AGCCCATCATCACTGGTTATAAATCTTCATTACGGGAAAAAGACACAGCCACCCTAACT  
GTCAGTCTTCTGGGAGCAAGCCTGCAGCCCGGCTCACCTGGAGAAAGGGTGACCAAGAAC  
TCCACGGAGAACCAACCCGCATACAGGAAGATCCCAATGGTAAACCTTCACTGTGAGCA  
GCTCGGTGACATTCCAGGTTACCCGGGAGGATGATGGGGCGAGCATCGTGTGCTCTGTGA  
ACCATGAATCTCTAAAGGGAGCTGACAGATCCACCTCTCAACGCATTGAAGTTTATACA  
CACCAACTGCGATGATTAGGCCAGACCCTCCCCATCCTCGTGAGGGCCAGAAGCTGTTGC  
TACACTGTGAGGGTTCGCGGCAATCCAGTCCCCCAGCAGTACCTATGGGAGAAGGAGGGCA  
GTGTGCCACCCCTGAAGATGACCCAGGAGAGTGCCCTGATCTTCCCTTTCTCAACAAGA  
GTGACAGTGGCACCTACGGCTGCACAGCCACCAGCAACATGGGCAGCTACAAGGCCTACT  
ACACCCTCAATGTTAATGACCCAGTCCGGTGCCCTCCTCCTCCAGCACCTACCACGCCA  
TCATCGGTGGGATCGTGGCTTTCATTGTCTTCCTGCTGCTCATCATGCTCATCTTCCTTG  
GCCACTACTTGATCCGGCACAAAGGAACCTACCTGACACATGAGGCAAAAAGGCTCCGACG  
ATGCTCCAGACGCGGACACGGCCATCATCAATGCAGAAGGCGGGCAGTCAGGAGGGGACG  
ACAAGAAGGAATATTTTCATCTAGAGGCGCCTGCCCCACTTCCTGCGCCCCCAGGGGCCCT  
GTGGGGACTGCTGGGGCCGTACCAACCCGGACTTGTACAGAGCAACCGCAGGGCCGCCC  
CTCCCGCTTGCTCCCCAGCCACCCACCCCTGTACAGAATGTCTGCTTTGGGTGCGGT  
TTTGTACTCGGTTTGGAAATGGGGAGGGAGGAGGGCGGGGGAGGGGAGGGTTGCCCTCAG  
CCCTTTCGCTGGCTTCTCTGCATTTGGGTTATTATTATTTTGTAAACAATCCCAAATCAA  
ATCTGTCTCCAGGCTGGAGAGGCAGGAGCCCTGGGGTGAGAAAAGCAAAAACAAACAAA  
AAACA

45/392

**FIGURE 44**

MGAPAASLLLLLLLLFACCWAPGGANLSQDDSQPWTSDETVVAGGTVVVLKCQVKDHEDSSL  
QWSNPAQQTLYFGEKRALRDNRIQLVTSTPHELSSISNVALADEGEYTCSTFTMPVRTA  
KSLVTVLGIPQKPIITGYKSSLREKDTATLNCQSSGSKPAARLTWRKGDQELHGEPTRIQ  
EDPNGKTFTVSSSVTFQVTREDDGASIVCSVNHESLKGADRSTSQRIEVLYTPTAMIRPD  
PPHPREGQKLLHCEGRGNPVPQQYLWEKEGSVPPLKMTQESALIFPFLNKSDSGTYGCT  
ATSNMGSYKAYYTLNVNDPSPVSSSSTYHAIIGGIVAFIVFLLIMLIFLGHYLIRHKG  
TYLTHEAKGSDDAPDADTAIINAEGGQSGGDDKKEYFI

**Signal sequence:**

amino acids 1-20

**Transmembrane domain:**

amino acids 331-352

**N-glycosylation site:**

amino acids 25-29, 290-294

**Casein kinase II phosphorylation site:**

amino acids 27-31, 35-39, 89-93, 141-145, 199-203, 388-392

**N-myristoylation site:**amino acids 2-8, 23-29, 156-162, 218-224, 295-301, 298-304,  
306-310, 334-340, 360-364, 385-389, 386-390**Prokaryotic membrane lipoprotein lipid attachment site:**

amino acids 7-18



46/392

**FIGURE 45**

ACTTGCCATCACCTGTTGCCAGTGTGGAAAAATTCTCCCTGTTGAATTTTTTGCACATGG  
AGGACAGCAGCAAAGAGGGCAACACAGGCTGATAAGACCAGAGACAGCAGGGAGATTATT  
TTACCATACGCCCTCAGGACGTTCCTCTAGCTGGAGTTCTGGACTTCAACAGAACCCCA  
TCCAGTCATTTTGATTTTGCTGTTTATTTTTTTTTTCTTTTCTTTTCCCACCACATTG  
TATTTTATTTCCGTACTTCAGAAATGGGCCTACAGACCACAAAGTGGCCCAGCCATGGGG  
CTTTTTTCTGAAGTCTTGGCTTATCATTTCCCTGGGGCTCTACTCACAGGTGTCCAAAC  
TCCTGGCCTGCCCTAGTGTGTGCCGCTGCGACAGGAACCTTTGTCTACTGTAATGAGCGAA  
GCTTGACCTCAGTGCCTCTTGGGATCCCGGAGGGCGTAACCGTACTCTACCTCCACAACA  
ACCAAATTAATAATGCTGGATTTCCCTGCAGAACTGCACAATGTACAGTCGGTGCACACGG  
TCTACCTGTATGGCAACCAACTGGACGAATTCCCCATGAACCTTCCCAAGAATGTCAGAG  
TTCTCCATTTGCAGGAAAACAATATTAGACCATTTTACGGGCTGCTCTTGCCAGCTCT  
TGAAGCTTGAAGAGCTGCACCTGGATGACAACTCCATATCCACAGTGGGGGTGGAAGACG  
GGGCCTTCCGGGAGGCTATTAGCCTCAAAATTGTTGTTTTTGTCTAAGAATCACCTGAGCA  
GTGTGCCTGTTGGGCTTCTGTGGACTTGCAAGAGCTGAGAGTGGATGAAAATCGAATTG  
CTGTCATATCCGACATGGCCTTCCAGAATCTCACGAGCTTGGAGCGTCTTATTGTGGACG  
GGAACCTCCTGACCAACAAGGGTATCGCCGAGGGCACCTTACGCCATCTCACCAAGCTCA  
AGGAATTTTCAATTGTACGTAATTCGCTGTCCACCCCTCCTCCCGATCTCCAGGTACGC  
ATCTGATCAGGCTCTATTTGCAGGACAACCAGATAAACACATTCCTTTGACAGCCTTCT  
CAAATCTGCGTAAGCTGGAACGGCTGGATATATCCAACAACCAACTGCGGATGCTGACTC  
AAGGGGTTTTTGATAATCTCTCAACCTGAAGCAGCTCACTGCTCGGAATAACCTTGGT  
TTTGTGACTGCAGTATTAAATGGGTACAGAATGGCTCAAATATATCCCTTCATCTCTCA  
ACGTGCGGGGTTTTCATGTGCCAAGGTCTTGAACAAGTCCGGGGGATGGCCGTACAGGAAT  
TAAATATGAATCTTTTGTCTGTCCACCACGACCCCCGGCCTGCCTCTCTTACCCCCAG  
CCCCAAGTACAGCTTCTCCGACCACTCAGCCTCCACCCCTCTCTATTCCAAACCTTAGCA  
GAAGCTACACGCCTCCAACCTCTACCATCGAACTTCCACGATTCTTGACTGGGATG  
GCAGAGAAAGAGTGACCCACCTATTTCTGAACGGATCCAGCTCTCTATCCATTTTGTGA  
ATGATACTTCCATTCAAGTCAGCTGGCTCTCTCTCTTACCCGTGATGGCATACAAACCTCA  
CATGGGTGAAAATGGGCCACAGTTTAGTAGGGGGCATCGTTCAGGAGCGCATAGTCAGCG  
GTGAGAAGCAACACCTGAGCCTGGTTAACTTAGAGCCCCGATCCACCTATCGGATTTGTT  
TAGTGCCACTGGATGCTTTTAACTACCGCGCGGTAGAAGACACCATTTGTTTCAGAGGCCA  
CCACCCATGCCTCCTATCTGAACAACGGCAGCAACACAGCGTCCAGCCATGAGCAGACGA  
CGTCCCACAGCATGGGCTCCCCCTTTCTGCTGGCGGGCTTGATCGGGGGCGCGGTGATAT  
TTGTGCTGGTGGTCTTGCTCAGCGTCTTTTGTCTGGCATATGCACAAAAGGGGCGCTACA  
CCTCCCAGAAAGTGGAAATACAACCGGGGCGGGCGGAAAGATGATTATTGCGAGGCAGGCA  
CCAAGAAGGACAACCTCCATCCTGGAGATGACAGAAACAGTTTTTCAGATCGTCTCCTTAA  
ATAACGATCAACTCCTTAAAGGAGATTTTCACTGTCAGCCCATTTACACCCCAAATGGGG  
GCATTAATTACACAGACTGCCATATCCCCAACAACATGCGATACTGCAACAGCAGCGTGC  
CAGACCTGGAGCACTGCCATACGTGACAGCCAGAGGCCAGCGTTATCAAGGCGGACAAT  
TAGACTCTTGAGAACACACTCGTGTGTGCACATAAAGACACGCAGATTACATTTGATAAA  
TGTTACACAGATGCATTTGTGCATTTGAATACTCTGTAATTTATACGGTGTACTATATAA  
TGGGATTTAAAAAAGTGCTATCTTTTCTATTTCAAGTTAATTACAAACAGTTTTGTAAAC  
TCTTTGCTTTTTTAAATCTT

47/392

**FIGURE 46**

MGLQTTKWPSHGAFFLKSWLIISLGLYSQVSKLLACPSVCRCDRNFVYCNERSLTSVPLG  
IPEGVTVLYLHNNQINNAGFPAELHNVQSVHTVYLYGNQLDEFPMNLPKNVRVLHLQENN  
IQTISRALAQLLKLEELHLDNNSISTVGVEDGAFREAISLKLFLSKNHLSSVPVGLPV  
DLQELRVDENRIAVISDMAFQNLTSLERLIVDGNLLTNKGIAEGTFSHLTKLKEFSIVRN  
SLSHPPDLPGTHLIRLYLQDNQINHPLTAFSNLRKLERLDISNNQLRMLTQGVFDNLS  
NLKQLTARNNPWFCDCSIKWVTEWLKYIPSSLNVRGFMCGPEQVRGMVRELNMNLLSC  
PTTTPGLPLFTPAPSTASPTTQPPTLSIPNPSRSYTPPTPTTSKLPTIPDWDGRERVTPP  
ISERIQLSIHFNVDTSIQVSWLSLFTVMAYKLTWVKMGHSLVGGIVQERIVSGEKQHL  
VNLEPRSTYRICLVPLDAFNRYRAVEDTICSEATTHASYLNNGSNTASSHEQTTSHSMGSP  
FLLAGLIGGAVIFVLVLLSVFCWHMHKKGRYTSQKWYNRGRRKDDYCEAGTKKDNSIL  
EMTETSFQIVSLNNDQLLKGD FRLQPIYTPNGGINYTDCHIPNNMRYCNSSVPDLEHCHT

**Signal peptide:**

amino acids 1-42

**Transmembrane domain:**

amino acids 542-561

**N-glycosylation site:**amino acids 202-206, 298-302, 433-437, 521-525, 635-639,  
649-653**Casein kinase II phosphorylation site:**amino acids 204-208, 407-411, 527-531, 593-597, 598-602,  
651-655**Tyrosine kinase phosphorylation site:**

amino acids 319-328

**N-myristoylation site:**amino acids 2-8, 60-66, 149-155, 213-219, 220-226, 294-300,  
522-528, 545-551, 633-639**Amidation site:**

amino acids 581-585

**Leucine zipper pattern:**

amino acids 164-186

**Phospholipase A2 aspartic acid active site:**

amino acids 39-50

48/392

**FIGURE 47**

GCAGCGAGCGCCGGGTGCGGCCCTGCCGCCGCAGGGATGTGACCTTCACCGTCGCTTAGC  
CAGGATGACCGGAGCCCGTGTCTCGCGGCGTCCGCGCCTCGCTTCAGCCTCCCGGGTGCT  
CTGACCGCACGCTCCCGGCTGCTAGGCTCCCCGGCACCGGCCTCGCCATGCCGCCACCGC  
CCGGGCCCGCCGCCCGCCCTGGGCACTGCGCTTCTGCTGCTCCTGCTGGCTTCGAGTCTT  
CTCACACTGTGCTGTTGCGGGCGCGTGAGGCGGCGCAGTTTCTGCGGCCCAGGCAGCGCC  
GCGCCTACCAAGTCTTCGAGGAGGCCAAGCAGGGCCACCTGGAACGGGAGTGCGTGAGG  
AGGTGTGCAGCAAAGAGGAGGCCAGAGAGGTGTTGAGAACGACCCCGAGACGGAGTATT  
TCTATCCACGATATCAAGAGTGCATGAGAAAAATATGGCAGGCCTGAAGAAAAAACCCAG  
ATTTGCGCCAAATGTGTTTCAAGAACTTGCTGACCAAGTGCACCCCAAACCTTGTGATAAGA  
AGGGTACTCATATCTGCCAAGACCTCATGGGCAACTTCTTCTGCGTGTGCACAGATGGCT  
GGGGAGGCCGGCTCTGTGACAAAGATGTCAATGAGTGTGTCCAGAAGAATGGGGGCTGCA  
GCCAGGTCTGCCACAACAAACCAGGAAGCTTCCAATGTGCCTGCCATAGTGGCTTCTCGC  
TTGCATCAGACGGCCAGACCTGCCAAGATATCGATGAATGCACAGACTCAGACACCTGTG  
GGGACGCGCGATGCAAGAACTTGCCAGGCTCCTACTCTTGCTCTGCGATGAGGGATATA  
CATACAGCTCCAAGGAGAAGACCTGCCAAGATGTGGACGAGTGCCAGCAGGATCGCTGTG  
AGCAGACCTGTGTCAACTCCCAGGCAGCTATACCTGCCACTGTGATGGGCGAGGGGGCC  
TAAAACTATCCCAGACATGGATACTTGTGAGGACATCTTACCATGTGTGCCCTTCAGCA  
TGGCCAAGAGCGTGAAGTCCTTGTACCTGGGCCGATGTTTACGCGGACCCCCGTGATTA  
GACTACGCTTCAAGAGGCTTACGCCTACCAGGCTGCTGGCTGAATTTGACTTCCGCACTT  
TTGACCCTGAAGGAGTCTTCTTCTGCTGGAGGCCGTTTACAGACAGCACCTGGATTGTCC  
TGGGCCCTAAGAGCTGGGCGGCTTGAGCTGCAGCTTCCGTACAATGGCGTTGGGCGCATCA  
CCAGCAGCGGGCCAACCATCAACCACGGCATGTGGCAAACTATCTCCGTGGAAGAGCTGG  
AACGTAACCTTGTTCATCAAGGTCAACAAAGATGCTGTAATGAAGATCGCGGTAGCTGGGG  
AGCTGTTTTAGCTGGAGAGGGGCCCTTATCACCTGAATCTCACCGTGGGCGGCATTCCCT  
TCAAGGAGAGTGAGCTCGTCCAGCCGATTAAACCTCGCCTGGATGGGTGCATGAGGAGTT  
GGAAGTGGCTGAACGGGGGAAGACAGCGCCATCCAGGAGACAGTCAAGGCAACACAAAAA  
TGCAGTGCTTCTCTGTGACAGAAAGGGGCTCCTTCTTCCCGGGGAATGGATTGTACCT  
ACAGGCTCAACTACACCCGAACATCGCTGGATGTCCGCACGGAAACCACCTGGGAAGTTA  
AAGTTGTGGCTCGGATCCGCCCTGCCACGGACACGGGGGTGCTGCTGGCGCTGGTGGGGG  
ACGACGATGTCTCATCTCTGTGGCCCTAGTCGACTACCACTCTACAAAGAAGCTCAAGA  
AGCAGTTGGTGGTCCTGGCAGTTGAGGATGTTGCCCTGGCACTGATGGAAATCAAGGTGT  
GCGACAGCCAGGAACACACGGTCACTGTCTCCCTGCGGGAGGGTGAGGCCACCTAGAAG  
TGGATGGCACAAAGGGCCAGAGTGAAGTGAGCACTGCCAGCTGCAGGAGCGACTGGACA  
CACTTAAGACACATCTGCAAGGCTCTGTGCACACCTATGTTGGAGGCCTGCCAGAAGTAT  
CGGTGATTTCTGCACCCGTCCTGCGTTCTACCGCGGATGCATGACTCTGGAGGTAAACG  
GGAAAATCCTGGACCTGGATACGGCCTCGTACAAGCACAGTGACATCACCTCCCACTCCT  
GCCCCCTGTGGAGCATGCCACCCCTAGACCGAGCTGCAAGAGGGCTCCACACCTAAAG  
ACAAAAATGAAGCAGGGTTTGGACACACAGCACTGGCTCCTCTCGCATGGTCTTGCACAA  
CTGGAGCAGCGTGGACCGCCCTTGTGGTTTTTTTTTCTTGAGATCTTTCTTTTGCCTTG  
TAACATATCTGTACATAATGGACGGGTGTCGGGTACCGGCTGCTCAGAGAGAGCCACGT  
GACCTGGTGGGAGCTGGCTGGAAGGGGCTGGGCTAGAGGGGCTGGCAGTTTGCAGCAGAA  
CGGATGTGAAGAAAATAATTCTCTATTATTTTATTACTACATGCTTCTTTCTGACTCTA  
AAATATGGAATAAAATATTTACAGAAACCTTTTAAAAA

49/392

**FIGURE 48**

MPPPPGPAAALGTALLLLLLLASESSHTVLLRAREAAQFLRPRQRRAYQVFEEAKQGHLE  
ECVEEVCSKEEAREVFENDPETEYFYPRYQECMRKYGRPEEKNPDAKCVQNLDPDQCTPN  
PCDKKGTHICQDLMGNFFCVCTDGGWGGRLCDKDVNECVQKNGGCSQVCHNKPGSFQCACH  
SGFSLASDGQTCQDIDECTDSDTCGDARCKNLPGSYSCLCDEGYTYSSKEKTCQDVDECQ  
QDRCEQTCVNSPGSYTCHCDGRGGLKLSPDMDTCEDILPCVPFMAKSVKSLYLGRMFSG  
TPVIRLRFKRLQPTRLLAEFDFTFDPEGVLFFAGGRSDSTWIVLGLRAGRLELQLRYNG  
VGRITSSGPTINHGMWQTISVEELERNLVIKVNKDAVMKIAVAGELFQLERGLYHLNLT  
GGIPFKESELVQPINPRLDGCMSWNWLNGEDSAIQETVKANTKMOCFSVTERGSFFPGN  
GFATYRLNYTRTSLDVGTETTWEVKVVARIRPATDTGVLLALVGDDDVVISVALVDYHST  
KKLKKQLVVLAVEDVALALMEIKVCDSEHTVTVSLREGEATLEVDGTKGQSEVSTAQLQ  
ERLDTLKTHLQGSVHTYVGGLPEVSVISAPVTAFYRGCMTELVNGKILDLDTASYKHSDI  
TSHSCPPVEHATP

50/392

## FIGURE 49

CGCCGCGCTCCCGCACCCGCGGCCCGCCACCGCGCCGCTCCCGCATCTGCACCCGCAGC  
CCGGCGGCCTCCCGGCGGGAGCGAGCAGATCCAGTCCGGCCCCGAGCGCAACTCGGTCCA  
GTCGGGGCGGCGGCTGCGGGCGCAGAGCGGAGATGAGCGGGCTTGGGGCCACCCTGCTGT  
GCCTGCTGCTGGCGGGCGGCGGTCCCCACGGCCCCCGCGCCCGCTCCGACGGCGACCTCGG  
CTCCAGTCAAGCCCGGCCCGGCTCTCAGCTACCCGCAGGAGGAGGCCACCCTCAATGAGA  
TGTTCCGCGAGGTTGAGGAACTGATGGAGGACACGCAGCACAAATTGCGCAGCGCGGTGG  
AAGAGATGGAGGCAGAAGAAGCTGCTGCTAAAGCATCATCAGAAGTGAACCTGGCAAACCT  
TACCTCCCAGCTATCACAATGAGACCAACACAGACACGAAGGTTGGAAATAATACCATCC  
ATGTGCACCGAGAAATTCACAAGATAACCAACAACCAGACTGGACAAATGGTCTTTTCAG  
AGACAGTTATCACATCTGTGGGAGACGAAGAAGGCAGAAGGAGCCACGAGTGCATCATCG  
ACGAGGACTGTGGGCCCAGCATGTACTGCCAGTTTGGCCAGCTTCCAGTACACCTGCCAGC  
CATGCCGGGGCCAGAGGATGCTCTGCACCCGGGACAGTGAGTGCTGTGGAGACCAGCTGT  
GTGTCCTGGGGTCACTGCACCAAAATGGCCACCAGGGGCAGCAATGGGACCATCTGTGACA  
ACCAGAGGGACTGCCAGCCGGGGCTGTGCTGTGCCTTCCAGAGAGGCCCTGCTGTTCCCTG  
TGTGCACACCCCTGCCCGTGGAGGGCGAGCTTTGCCATGACCCCGCCAGCCGGCTTCTGG  
ACCTCATCACCTGGGAGCTAGAGCCTGATGGAGCCTTGGACCGATGCCCTTGTGCCAGTG  
GCCTCCTCTGCCAGCCCCACAGCCACAGCCTGGTGTATGTGTGCAAGCCGACCTTCGTGG  
GGAGCCGTGACCAAGATGGGGAGATCCTGCTGCCAGAGAGGTCCCCGATGAGTATGAAG  
TTGGCAGCTTCATGGAGGAGGTGCGCCAGGAGCTGGAGGACCTGGAGAGGAGCCTGACTG  
AAGAGATGGCGCTGGGGGAGCCTGCGGCTGCCGCCGCTGCACTGCTGGGAGGGGAAGAGA  
TTTAGATCTGGACCAGGCTGTGGGTAGATGTGCAATAGAAATAGCTAATTTATTTCCCA  
GGTGTGTGCTTTAGGCGTGGGCTGACCAGGCTTCTTCTACATCTTCTTCCCAGTAAGTT  
TCCCCCTCTGGCTTGACAGCATGAGGTGTTGTGCATTTGTTTCCAGCTCCCCCAGGCTGTTCT  
CCAGGCTTCACAGTCTGGTGCTTGGGAGAGTCAGGCAGGGTTAAACTGCAGGAGCAGTTT  
GCCACCCCTGTCCAGATTATTGGCTGCTTTGCCCTCTACCACTTGGCAGACAGCCGTTTGT  
TCTACATGGCTTTTGATAATTGTTTGGAGGGAGGAGATGGAAACAATGTGGAGTCTCCCTC  
TGATTGGTTTTGGGGAAATGTGGAGAAGAGTGCCCTGCTTTGCAAACATCAACCTGGCAA  
AAATGCAACAAATGAATTTTCCACGCAGTTCTTTCCATGGGCATAGGTAAGCTGTGCCTT  
CAGCTGTTGCAGATGAAATGTTCTGTTCACCCCTGCATTACATGTGTTTATTCATCCAGCA  
GTGTTGCTCAGCTCCTACCTCTGTGCCAGGGCAGCATTTTTCATATCCAAGATCAATTCCT  
TCTCTCAGCACAGCCTGGGGAGGGGGTCATTGTTCTCCTCGTCCATCAGGGATCTCAGAG  
GCTCAGAGACTGCAAGCTGCTTGCCCAAGTCACACAGCTAGTGAAGACCAGAGCAGTTTC  
ATCTGGTTGTGACTCTAAGCTCAGTGCTCTCTCCACTACCCACACCAGCCTTGGTGCCA  
CCAAAAGTGCTCCCCAAAAGGAAGGAGAATGGGATTTTTCTTGAGGCATGCACATCTGGA  
ATTAAGGTCAAACCTAATCTCACATCCCTCTAAAAGTAAACTACTGTTAGGAACAGCAGT  
GTTCTCACAGTGTGGGGCAGCCGTCCTTCTAATGAAGACAATGATATTGACACTGTCCCT  
CTTTGGCAGTTGCATTAGTAACCTTTGAAAGGTATATGACTGAGCGTAGCATAACAGTTAA  
CCTGCAGAAACAGTACTTAGGTAATTGTAGGGCGAGGATTATAAATGAAATTTGCAAAAT  
CACTTAGCAGCAACTGAAGACAATTATCAACCACGTGGAGAAAATCAAACCGAGCAGGGC  
TGTGTGAAACATGGTTGTAATATGCGACTGCGAACAACCTGAACCTCTACGCCACTCCACAAA  
TGATGTTTTAGGTGTGATGACTGTTGCCACCATGTATTATCCAGAGTTCTTAAAGTT  
TAAAGTTGCACATGATTGTATAAGCATGCTTTCTTTGAGTTTTAAATTATGTATAAACAT  
AAGTTGCATTTAGAAATCAAGCATAAATCACTTCAACTGCAAAAAAAAAAAAAAAAAAAAA  
AAAAAA

51/392

**FIGURE 50**

MQRLGATLLCLLLAAAVPTAPAPAPTATSAPVKPGPALSYPQEEATLNEMFREVEELMED  
TQHKLRSAVEEMEAEEAAAKASSEVNLANLPSPYHNETNTDTKVGNNTIHVHREIHKITN  
NQTGQMVFSETVITSVGDEEGRRSHECIIDEDCGPSMYCQFASFQYTCQPCRGQRM LCTR  
DSECCGDQLCVWGHCTKMATRGSNGTICDNQRDCQPLCCAFQRGLLFPVCTPLPVEGEL  
CHDPASRLLDLITWELEPDGALDRCPASGLLCQPHSHSLVYVCKPTFVGSRDQDGEILL  
PREVPDEYEVGSFMEEVRQELEDLERSLTEEMALGEPAAAAAALLGGEI

**Signal sequence:**

amino acids 1-19

**N-glycosylation site:**

amino acids 96-100, 106-110, 121-125, 204-208

**Casein kinase II phosphorylation site:**amino acids 46-50, 67-71, 98-102, 135-139, 206-210, 312-316,  
327-331**N-myristoylation site:**

amino acids 202-208, 217-223

**Amidation site:**

amino acids 140-144

52/392

**FIGURE 51**

GCCTGTTGCTGATGCTGCCGTGCGGTACTTGTCATGGAGCTGGCACTGCGGCGCTCTCCC  
GTCCCGCGGTGGTTGCTGCTGCTGCCGTGCTGCTGGGCCTGAACGCAGGAGCTGTCATT  
GACTGGCCACAGAGGAGGGCAAGGAAGTATGGGATTATGTGACGGTCCGCAAGGATGCC  
TACATGTTCTGGTGGCTCTATTATGCCACCAACTCCTGCAAGAACTTCTCAGAACTGCCC  
CTGGTCATGTGGCTTCAGGGCGGTCCAGGCGGTTCTAGCACTGGATTGGAACCTTTGAG  
GAAATTGGGCCCCCTTGACAGTGATCTCAAACCACGGAAAACACCTGGCTCCAGGCTGCC  
AGTCTCCTATTTGTGGATAATCCCGTGGGCACTGGGTTCA GTTATGTGAATGGTAGTGGT  
GCCTATGCCAAGGACCTGGCTATGGTGGCTTCAGACATGATGGTTCTCCTGAAGACCTTC  
TTCAGTTGCCACAAAGAATTCCAGACAGTTCATTCTACATTTTCTCAGAGTCTATGGA  
GGAAAAATGGCAGCTGGCATTGGTCTAGAGCTTTATAAGGCCATTACGCGAGGGACCATC  
AAGTGCAACTTTGCGGGGGTTGCCTTGGGTGATTCTCCTGGATCTCCCCTGTTGATTGCGGTG  
CTCTCCTGGGGACCTTACCTGTACAGCATGTCTCTTCTCGAAGACAAAGGTCTGGCAGAG  
GTGTCTAAGGTTGCAGAGCAAGTACTGAATGCCGTAAATAAGGGGCTCTACAGAGAGGCC  
ACAGAGCTGTGGGGGAAAGCAGAAATGATCATTGAACAGAACACAGATGGGGTGAACCTC  
TATAACATCTTAACTAAAAGCACTCCACGTCTACAATGGAGTCGAGTCTAGAATTCACA  
CAGAGCCACCTAGTTTGTCTTTGTGTCAGCGCCACGTGAGACACCTACAACGAGATGCCTTA  
AGCCAGCTCATGAATGGCCCCATCAGAAAGAAGCTCAAAATTATTCTGAGGATCAATCC  
TGGGGAGGCCAGGCTACCAACGTCTTTGTGAACATGGAGGAGGACTTCATGAAGCCAGTC  
ATTAGCATTGTGGACGAGTTGCTGGAGGCAGGGATCAACGTGACGGTGTATAATGGACAG  
CTGGATCTCATCGTAGATAACCATGGGTGAGGAGGCCTGGGTGCGGAAACTGAAGTGGCCA  
GAACTGCCTAAATTCAGTCAGCTGAAGTGGAAGGCCCTGTACAGTGACCCTAAATCTTTG  
GAAACATCTGCTTTTGTCAAGTCCTACAAGAACCTTGCTTTCTACTGGATTCTGAAAGCT  
GGTCATATGGTTCCTTCTGACCAAGGGGACATGGCTCTGAAGATGATGAGACTGGTGA  
CAGCAAGAATAGGATGGATGGGGCTGGAGATGAGCTGGTTTGGCCTTGGGGCACAGAGCT  
GAGCTGAGGCCGCTGAAGCTGTAGGAAGCGCCATTCTTCCCTGTATCTAACTGGGGCTGT  
GATCAAGAAGGTTCTGACCAGCTTCTGCAGAGGATAAAATCATTGTCTCTGGAGGCAATT  
TGGAATTATTTCTGCTTCTTAAAAAACCTAAGATTTTTTAAAAAATTGATTTGTTTTG  
ATCAAAATAAAGGATGATAATAGATATTAA

53/392

**FIGURE 52**

MELALRRSPVPRWLLLLLPLLLGLNAGAVIDWPTEEGKEVWDYVTVRKDAYMFWWLYYATN  
SCKNFSELPLVMWLQGGPGGSSTGFGNFEEIGPLDSDLKPRKTTWLQAASLLFVDNPVGT  
GFSYVNGSGAYAKDLAMVASDMMVLLKTFFSCHKEFQTVPFYIFSESYGGKMAAGIGLEL  
YKAIQRGTIKCNFAGVALGDSWISPVDSVLSWGPYLYSMSLLEDKGLAEVSKVAEQVLNA  
VNGGLYREATELWGKAEMIEQNTDGVNFYNILTKSTPTSTMESSLEFTQSHLVCLCQRH  
VRHLQORDALSQLMNGPIRKCLKIIPEDQSWGQATNVFVNMEEDFMKPVISIVDELLEAG  
INVTVYNGQLDLIVDTMGQEAWVRKLKWPELPKFSQLKWKALYSDPKSLETSFAFVKS YKN  
LAFYWILKAGHMVPSDQGDMAKMMRLVTQQE

**Signal sequence:**

amino acids 1-25

**N-glycosylation site:**

amino acids 64-68, 126-130, 362-366

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 101-105

**Casein kinase II phosphorylation site:**

amino acids 204-208, 220-224, 280-284, 284-288, 351-355, 449-453

**N-myristoylation site:**

amino acids 22-28, 76-82, 79-85, 80-86, 119-125, 169-175, 187-193, 195-201, 331-337, 332-338, 360-366



54/392

**FIGURE 53**

GTCTGTTCCAGGAGTCCTTCGGCGGCTGTTGTGTGTCAGTGGCCTGATCGCGATGGGGACA  
AAGGCGCAAGTCGAGAGGAACTGTTGTGCCTCTTCATATTGGCGATCCTGTTGTGCTCC  
CTGGCATTGGGCAGTGTTACAGTGCACTCTTCTGAACCTGAAGTCAGAATTCCTGAGAAT  
AATCCTGTGAAGTTGTCCTGTGCCTACTCGGGCTTTTCTTCTCCCCGTGTGGAGTGGAAG  
TTTGACCAAGGAGACACCACCAGACTCGTTTGCTATAATAACAAGATCACAGCTTCCTAT  
GAGGACCGGGTGACCTTCTTGCCAACTGGTATCACCTTCAAGTCCGTGACACGGGAAGAC  
ACTGGGACATACACTTGTATGGTCTCTGAGGAAGGCGGCAACAGCTATGGGGAGGTCAAG  
GTCAAGCTCATCGTGCTTGTGCCTCCATCCAAGCCTACAGTTAACATCCCCCTCCTCTGCC  
ACCATTTGGGAACCGGGCAGTGCTGACATGCTCAGAACAAGATGGTTCCCCACCTTCTGAA  
TACACCTGGTTCAAAGATGGGATAGTGATGCCTACGAATCCCAAAAGCACCCGTGCCTTC  
AGCAACTCTTCCTATGTCCTGAATCCCACAACAGGAGAGCTGGTCTTTGATCCCCGTGCA  
GCCTCTGATACTGGAGAATACAGCTGTGAGGCACGGAATGGGTATGGGACACCCATGACT  
TCAAATGCTGTGCGCATGGAAGCTGTGGAGCGGAATGTGGGGGTGTCATCGTGGCAGCCGTC  
CTTGTAACCTGATTCTCCTGGGAATCTTGGTTTTTGGCATCTGGTTTGCCTATAGCCGA  
GGCCACTTTGACAGAAACAAAGAAAAGGACTTCGAGTAAGAAGGTGATTTACAGCCAGCCT  
AGTGCCCGAAGTGAAGGAGAATTCAAACAGACCTCGTCATTCCTGGTGTGAGCCTGGTCCG  
GCTCACCGCCTATCATCTGCATTTGCCTTACTCAGGTGCTACCGGACTCTGGCCCCTGAT  
GTCTGTAGTTTACAGGATGCCTTATTTGTCTTCTACACCCACAGGGCCCCCTACTTCT  
TCGGATGTGTTTTTAATAATGTCAGCTATGTGCCCCATCCTCCTTCATGCCCTCCCTCCC  
TTTCCTACCACTGCTGAGTGGCCTGGAACCTGTTTAAAGTGTATTATCCCCATTCTTTG  
AGGGATCAGGAAGGAATCCTGGGTATGCCATTGACTTCCCTTCTAAGTAGACAGCAAAAA  
TGGCGGGGGTCGCAGGAATCTGCACTCAACTGCCCACCTGGCTGGCAGGGATCTTTGAAT  
AGGTATCTTGAGCTTGGTTCTGGGCTCTTTCCTTGTGTACTGACGACCAGGGCCAGCTGT  
TCTAGAGCGGGAATTAGAGGCTAGAGCGGCTGAAATGGTTGTTTGGTGATGACACTGGGG  
TCCTTCCATCTCTGGGGCCCACTCTCTTCTGTCTTCCCATGGGAAGTGCCACTGGGATCC  
CTCTGCCCTGTCCTCCTGAATACAAGCTGACTGACATTGACTGTGTCTGTGGAAAATGGG  
AGCTCTTGTTGTGGAGAGCATAGTAAATTTTCAGAGAACTTGAAGCCAAAAGGATTTAAA  
ACCGCTGCTCTAAAGAAAAGAAAAGTGGAGGCTGGGCGCAGTGGCTCACGCCTGTAATCC  
CAGAGGCTGAGGCAGGCGGATCACCTGAGGTGGGAGTTTCGGGATCAGCCTGACCAACAT  
GGAGAAACCTACTGGAAATACAAAGTTAGCCAGGCATGGTGGTGCATGCCTGTAGTCCC  
AGCTGCTCAGGAGCCTGGCAACAAGAGCAAACTCCAGCTCAAAAAAAAAAAAAAAAAA

55/392

**FIGURE 54**

MGTKAQVERKLLCLFILAILLCSLALGSVTVHSSEPEVRIPENNPVKLSCAYSGFSSPRV  
EWKFDQGDITRLVCYNNKITASYEDRVTFLLPTGITFKSVTREDTGTYTCMVSEEGGNSYG  
EVKVKLIVLVPPSKPTVNI PSSATIGNRAVLTCSEQDGSPPEYTWFKDGIVMPTNPKST  
RAFSNSSYVLNPTTGELVFDPLSASDTGEYSCEARNGYGTTPMTSNAVRMEAVERNVGVIV  
AAVLVTLILLGILVFGIWFAYSRGHFDRTKKGTSSKKVIYSQPSARSEGEFKQTSSFLV

**Signal sequence:**  
amino acids 1-27

**Transmembrane domain:**  
amino acids 238-255

**N-glycosylation site:**  
amino acids 185-189

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**  
amino acids 270-274

**Casein kinase II phosphorylation site:**  
amino acids 34-38, 82-86, 100-104, 118-122, 152-156,  
154-158, 193-197, 203-207, 287-291

**N-myristoylation site:**  
amino acids 105-111, 116-122, 158-164, 219-225, 237-243,  
256-262

56/392

**FIGURE 55**

GTTGTGTCCTTCAGCAAAACAGTGGATTTAAATCTCCTTGACAAAGCTTGAGAGCAACAC  
AATCTATCAGGAAAGAAAGAAAGAAAAAACCGAACCTGACAAAAAGAAGAAAAAGAAG  
AAGAAAAAAATCATGAAAACCATCCAGCCAAAAATGCACAATTCTATCTCTTGGGCAAT  
CTTCACGGGGCTGGCTGCTCTGTGTCTCTTCCAAGGAGTGCCCGTGCGCAGCGGAGATGC  
CACCTTCCCCAAAGCTATGGACAACGTGACGGTCCGGCAGGGGGAGAGCGCCACCCTCAG  
GTGCACTATTGACAACCGGGTCACCCGGGTGGCCTGGCTAAACCGCAGCACCATCCTCTA  
TGCTGGGAATGACAAGTGGTGCCTGGATCCTCGCGTGGTCCTTCTGAGCAACACCCAAAC  
GCAGTACAGCATCGAGATCCAGAACGTGGATGTGTATGACGAGGGCCCTTACACCTGCTC  
GGTGCAGACAGACAACCACCCAAAGACCTCTAGGGTCCACCTCATTGTGCAAGTATCTCC  
CAAAATTGTAGAGATTTCTTCAGATATCTCCATTAATGAAGGGAACAATATTAGCCTCAC  
CTGCATAGCAACTGGTAGACCAGAGCCTACGGTTACTTGGAGACACATCTCTCCCAAAGC  
GGTTGGCTTTGTGAGTGAAGACGAATACTTGGAAATTGAGGGCATCACCCGGGAGCAGTC  
AGGGGACTACGAGTGCAGTGCCTCCAATGACGTGGCCGCGCCCGTGGTACGGAGAGTAAA  
GGTCACCGTGAACCTATCCACCATACATTTTCAAGCCAAGGGTACAGGTGTCCCCGTGGG  
ACAAAAGGGGACACTGCAGTGTGAAGCCTCAGCAGTCCCCCTCAGCAGAATTCCAGTGGTA  
CAAGGATGACAAAAGACTGATTGAAGGAAAGAAAGGGGTGAAAGTGAAAACAGACCTTT  
CCTCTCAAAACTCATCTTCTTCAATGTCTCTGAACATGACTATGGGAACTACACTTGCGT  
GGCCTCCAACAAGCTGGGGCCACACCAATGCCAGCATCATGCTATTTGGTCCAGGCGCCGT  
CAGCGAGGTGAGCAACGGCAGTCGAGGAGGGCAGGCTGCGTCTGGCTGCTGCCTCTTCT  
GGTCTTGACCTGCTTCTCAAATTTTGATGTGAGTGCCACTTCCCCACCCGGGAAAGGCT  
GCCGCCACCACCACCACCAACACAACAGCAATGGCAACACCGACAGCAACCAATCAGATA  
TATACAAATGAAATTAGAAGAAACACAGCCTCATGGGACAGAAATTTGAGGGAGGGGAAC  
AAAGAATACTTTGGGGGGAAAAGAGTTTTTAAAAAAGAAATTGAAAATTGCCTTGCAATA  
TTTAGGTACAATGGAGTTTTCTTTTCCCAAACGGGAAGAACACAGCACACCCGGCTTGGA  
CCCACTGCAAGCTGCATCGTGCAACCTCTTTGGTGCCAGTGTGGGCAAGGGCTCAGCCTC  
TCTGCCCACAGAGTGCCCCACGTGGAACATTCTGGAGCTGGCCATCCCAAATTCATCA  
GTCCATAGAGACGAACAGAATGAGACCTTCCGGCCCAAGCGTGGCGCTGCGGGCACCTTG  
GTAGACTGTGCCACCACGGCGTGTGTTGTGAAACGTGAAATAAAAAGAGCAAAAAAAA

57/392

**FIGURE 56**

MKTIQPKMHNSISWAI FTGLAALCLFQGV PVRSGDATFPKAMD NVTVRQGESATLRCTID  
NRVTRVAWLN RSTILYAGNDKWCLDPRV VLLSNTQTQYSIEIQNV DVYDEGPYTCSVQTD  
NHPKTSRVHLIVQVSPKIVEISSDISINEGNNISLT CIATGRPEPTVTWRHISPKAVGFV  
SEDEYLEIQGITREQSGDYEC SASNDVAAPVRRVKVT VNYPPYISEAKGTGVPVGQKGT  
LQCEASAVPSAEFQWKDDKRLIEGKKGVKVENRPFLSKLI FFNVSEHDYGN YTCVASNK  
LGHTNASIMLFGPGAVSEVSNGTSRRAGCVWLLPLLVLHLL LKF

58/392

**FIGURE 57**

GCTGCGCCGGCTGCGGCTGCAGGGGAATCCGCTGTGGTGCGGCTGCCAGGCGCGGCCCT  
ACTCGAGTGGCTGGCGCGGGCGCGCTGCGCTCGGACGGCGCGTGCCAGGGGCGCGGGCG  
CCTGCGGGGCGAGGCTCTGGACGCCCTGCGGCCCTGGGACCTGCGCTGCCCTGGGGACGC  
GGCGCAGGAAGAGGAAGAGCTGGAAGAGCGGGCTGTGGCCGGGCCCCGCGCCCCCTCCGCG  
CGGCCCTCCGCGCGGGCCCCGGGGAGGAGCGGGCAGTCGCGCCTTGCCCTCGCGCCTGCGT  
GTGCGTCCCCGAGTCCCGGCACAGCAGCTGCGAGGGCTGCGGCCTGCAGGCGGTGCCCCG  
CGGCTTCCCCAGCGACACCCAGCTCCTGGACCTGAGGCGGAACCACTTCCCCCTCGGTGCC  
CCGAGCGGCCCTTCCCCGGNCTGGGCCACCTGGTGTGCTGACCTGCAGCACTGCGGCAT  
CGCGGAGCTGGAAGCGGGCGCCCTGGCCGGGCTGGGCCGCTGATCTACCTGTACCTCTC  
CGACAACCAGCTCGCAGGCCTCAGCGCTGCTGCCCTTGAAGGGGCTCCCCGCCTCGGCTA  
CCTGTACCTAGAACGCAACCGTTTCTGTCAGGTGCCAGGGGCTGCCNTGCGCGCCCTGCC  
CAGCCTCTTCTCCCTGCACCTGCAGGACAACGCTGTGGACCGCCTGGCACCTGGGGACCT  
GGGGAGAACACGGGCCTTGCGCTGGGTCTACCTGAGTGGAACCGCATCACCGAAGTGTC  
CCTTGGGGCGCTGGGCCAGCTCGGGAGCTGGAGAAGCTGCACCTGGACAGGAATCAGCT  
GCGAGAGGTGCCCACTGGGGCCTTGAGGGGCTGCCTGCCCTCCTGGAGCTGCAGCTCTC  
GGGCAACCCACTCAGGGCCTTGCGTGACGGAGCCTTCCAGCCTGTGGGCAGGTGCTGCA  
GCACCTCTTCTGAAACAGCAGTGGCCTGGAGCAGATTTGTCCTGGGGCCTTTTCAGGCCT  
GGGGCCCCGGGCTCCAGAGCCTGCACCTGCAGAGAACCAGCTTCCGGGCCCTGCCTGCCCT  
GCCCAGTCTCAGCCAGCTGGAGCTCATCGACCTCAGCAGCAATCCCTTCCCCCTGTGACTG  
CCAGCTGCTTCCGCTGCACAGGTGGCTTACTGGGCTGAACCTGCGGGTGGGGGCCACCTG  
CGCCACCCCTCCCAATGCCCGTGGCCAGAGGGTGAAGGCTGCAGCTGCTGTCTTTGAAGA  
CTGCCCGGGCTGGGCTGCCAGAAAGGCCAAGCGGACACCAGCCTCCAGGCCCAGTGCCAG  
GAGAACCCCATCAAAGGAAGACAGTGTGGAGCAGATAAGAACATCCTCTTCCCCACATG  
GTACCACACTGTGGAGCCCACCTCGCTGTCTAGAGCCTGCGGCTCTGAAGGATGGCTTTG  
CCCGCTCCCGCTCTGCCCCCTCAAGTGGAACCCAAGCTGGGCTCAGAATCTGTAGAGTGAG  
GCCCCACCAAGGGAAACGACACCCACGGCCTGAGAGCCAGGTGGAGTCCTGCCACTCAGC  
TGCTTGCCTTTGCTCCCACCTCTCCACCCCTCAAAGAGGTCTCGAGGGGACACTCTGAA  
GGCACCTGGCTCAGAACCCTGCCATCCAAGGAGCGAGGAGTCCCAGGGCTGAGCAAATG  
CAGCGGGGAGGTGCGCAGTTCCCCTGCTTCCCGATCCTCATTTTCTGCTTCACTTGACTC  
CTCCAGATAGGAGCTGCTCTCACTGCCACACTGCTG

59/392

**FIGURE 58**

LRRLRLQGNPLWCGCQARPLLEWLLARARVRSDGACQGPRLRGEALDALRPWDLRCPGDA  
AQEEEELEERAVAGPRAPPRGPPRGPGEEERAVAPCPACVCVPESRHSSCEGCGLQAVPR  
GFPSDTQLLDLRRNHFPSVPRAAFPGLGHLVSLHLQHCGIAELEAGALAGLGRLIYLYLS  
DNQLAGLSAAALEGAPRLGYLYLERNRFLQVPGAAXRALPSLFSHLQDNAVDR LAPGDL  
GRTRALRWVYLSGNRITEVSLGALGPARELEKLHLDRNQLREVPTGALEGLPALLELQLS  
GNPLRALRDGAFQPVGRSLQHLFLNSSGLEQICPGAFSGLGPGQLSLHLQKNQLRALPAL  
PSLSQLELIDLSSNPFPCDCQLLPLHRWLTGLNLRVGATCATPPNARGQRVKAAAVFED  
CPGWAARKAKRTPASRPSARRTPIKGRQCGADKNILFPTWYHTVEPTSLS

**Signal sequence:**

None

**Transmembrane domain:**

None

**N-glycosylation site:**

325-328

**Glycosaminoglycan attachment site:**

338-341

**Protein kinase C phosphorylation site:**

438-440

**N-myristoylation site:**

166-171, 186-191, 253-258, 286-291, 335-340, 339-344, 450-455

**Leucine rich repeat N-terminal domain:**

94-123

**Leucine Rich Repeat:**

125-148, 149-172, 173-196, 197-220, 221-244, 245-268, 269-292, 293-316, 318-341, 343-364, 365-386

**Leucine rich repeat C-terminal domain:**

374-422

60/392

**FIGURE 59**

CTCCACGGTGTCCAGCGCCAGAAATGCGGCTTCTGGTCCTGCTATGGGGTTGCCTGCTG  
CTCCACGGTTATGAAGCCCTGGAGGGCCAGAGGAAATCAGCGGGTTCGAAGGGGACACT  
GTGTCCCTGCAGTGCACCTACAGGGAAGAGCTGAGGGACCACCGGAAGTACTGGTGCAGG  
AAGGGTGGGATCCTCTTCTCTCGCTGCTCTGGCACCATCTATGCAGAAGAAGAAGGCCAG  
GAGACAATGAAGGGCAGGGTGTCCATCCGTGACAGCCGCCAGGAGCTCTCGCTCATTGTG  
ACCCTGTGGAACCTCACCTGCAAGACGCTGGGGAGTACTGGTGTGGGGTCGAAAAACGG  
GGCCCCGATGAGTCTTTACTGATCTCTCTGTTTCGTCTTTCCAGGACCCTGCTGTCTCTCC  
TCCCTTCTCCACCTTCCAGCCTCTGGCTACAACACGCCTGCAGCCCAAGGCAAAAGCT  
CAGCAAACCCAGCCCCCAGGATTGACTTCTCCTGGGCTCTACCCGGCAGCCACCACAGCC  
AAGCAGGGGAAGACAGGGGGCTGAGGCCCTCCATTGCCAGGGACTTCCAGTACGGGCAC  
GAAAGGACTTCTCAGTACACAGGAACCTCTCCTCACCCAGCGACCTCTCCTCCTGCAGGG  
AGCTCCCCGGCCCCCATGCAGCTGGACTCCACCTCAGCAGAGGACACCAGTCCAGCTCTC  
AGCAGTGGCAGCTCTAAGCCCAGGGTGTCCATCCCGATGGTCCGCATACTGGCCCCAGTC  
CTGGTGTCTGTGAGCCTTCTGTGAGCCGCAGGCCTGATCGCCTTCTGCAGCCACCTGCTC  
CTGTGGAGAAAGGAAGCTCAACAGGCCACGGAGACACAGAGGAACGAGAAGTTCTGGCTC  
TCACGCTTGACTGCGGAGGAAAAGGAAGCCCCCTTCCAGGCCCTGAGGGGGACGTGATC  
TCGATGCCTCCCCTCCACACATCTGAGGAGGAGCTGGGCTTCTCGAAGTTTGTCTCAGCG  
TAGGGCAGGAGGCCCTCCTGGCCAGGCCAGCAGTGAAGCAGTATGGCTGGCTGGATCAGC  
ACCGATTCCCGAAAGCTTTCCACCTCAGCCTCAGAGTCCAGCTGCCCGGACTCCAGGGCT  
CTCCCCACCTTCCCCAGGCTCTCCTCTTGCATGTTCCAGCCTGACCTAGAAGCGTTTGTG  
AGCCCTGGAGCCCAGAGCGGTGGCCTTGCTCTTCCGGCTGGAGACTGGGACATCCCTGAT  
AGGTTACATCCCTGGGCAGAGTACCAGGCTGCTGACCCTCAGCAGGGCCAGACAAGGCT  
CAGTGGATCTGGTCTGAGTTTCAATCTGCCAGGAACCTCCTGGGCCTCATGCCCAGTGTG  
GACCCTGCCTTCTCTCCACTCCAGACCCACCTTGTCTTCCCTCCCTGGCGTCTCAGAC  
TTAGTCCCACGGTCTCCTGCATCAGCTGGTGATGAAGAGGAGCATGCTGGGGTGAGACTG  
GGATTCTGGCTTCTCTTTGAACCACCTGCATCCAGCCCTTCCAGGAAGCCTGTGAAAAACG  
TGATTCTGGCCCCACCAAGACCCACCAAAACCATCTCTGGGCTTGGTGCAGGACTCTGA  
ATTCTAACAATGCCCAGTGACTGTGCACTTGAGTTTGAGGGCCAGTGGGCCTGATGAAC  
GCTCACACCCCTTCCAGCTTAGAGTCTGCATTTGGGCTGTGACGTCTCCACCTGCCCAAT  
AGATCTGCTCTGTCTGCGACACCAGATCCACGTGGGGACTCCCCTGAGGCCTGCTAAGTC  
CAGGCCTTGGTCAGGTGAGGTGCACATTGCAGGATAAGCCAGGACCGGCACAGAAGTGG  
TTGCCTTTNCCATTTGCCCTCCCTGGNCCATGCCTTCTTGCCTTTGGAAAAAATGATGAA  
GAAAACCTTGGCTCCTTCTTGTCTGGAAAGGGTTACTTGCCTATGGGTTCTGGTGGCTA  
GAGAGAAAAGTAGAAAACAGAGTGCACGTAGGTGTCTAACACAGAGGAGAGTAGGAACA  
GGGCGGATACCTGAAGGTGACTCCGAGTCCAGCCCCCTGGAGAAGGGGTCGGGGGTGGTG  
GTAAAGTAGCACAATACTACTATTTTTTTTCTTTTTTCCATTATTATTGTTTTTTAAGACAGA  
ATCTCGTGCTGCTGCCAGGCTGGAGTGCAGTGGCACGATCTGCAAACTCCGCTCCTGG  
GTTCAAGTGATTCTTCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCACGCACCACC  
ACACCTGGCTAATTTTTTGTACTTTTAGTAGAGATGGGGTTTACCATTGTTGGCCAGGCTG  
GTCTTGAACCTCCTGACCTCAAATGAGCCTCCTGCTTCAGTCTCCCAAATTGCCGGGATTA  
CAGGCATGAGCCACTGTGTCTGGCCCTATTTCTTTAAAAAGTGAAATTAAGAGTTGTTT  
AGTATGCAAACTTGGAAAGATGGAGGAGAAAAAGAAAAGGAAGAAAAAATGTCACCCA  
TAGTCTCACCAGAGACTATCATTATTTTCGTTTTGTGTACTTCTTCCACTCTTTTCTTC  
TTCACATAATTTGCCGGTGTCTTTTTTACAGAGCAATTATCTTGTATATACAACCTTGTA  
TCCTGCCTTTTCCACCTTATCGTTCCATCACTTTATTCCAGCACTTCTCTGTGTTTTACA  
GACCTTTTTTATAAATAAAATGTTTCATCAGCTGCATAAAAAAAAAAAAAA

61/392

**FIGURE 60**

MRLLVLLWGCLLLPGYEALLEGPEEISGFEGDTVSLQCTYREELRDHRKYWCRKGGILFSR  
CSGTIYAEEEGQETMKGRVSIIRDSRQELSLIVTLWNLTLDAGEYWCGVEKRGPDSELLI  
SLFVFPGPCCPPSPSPTFQPLATTRLQPKAKAQQTQPPGLTSPGLYPAATTAKQGKTGAE  
APPLPGTSQYGHERTSQYTGTSPPHATSPAGSSRPPMQLDSTSAEDTSPALSSGSSKPR  
VSIPMVRILAPVLVLLSLLSAAGLIAFCSHLLLRKEAQQATETQRNEKFWLSRLTAEEK  
EAPSQAPEGDVISMPLHTSEELGFSKFVSA

**Important features:**

**Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 248-269

**N-glycosylation site:**

amino acids 96-99

**Fibrinogen beta and gamma chains C-terminal domain:**

amino acids 104-113

**Ig like V-type domain:**

amino acids 13-128



62/392

**FIGURE 61**

CGGGCCAGCCTGGGGCGGGCCGGCCAGGAACCAACCCGTTAAGGTGTCTTCTCTTTAGGGAT  
GGTGAGGTTGGAAAAAGACTCCTGTAACCCTCCTCCAGGATGAACCACCTGCCAGAAGAC  
ATGGAGAACGCTCTCACCGGGAGCCAGAGCTCCCATGCTTCTCTGCGCAATATCCATTCC  
ATCAACCCACACAACCTCATGGCCAGGATTGAGTCCATGAAGGAAGGGAAAAGAAAGGC  
ATATCTGATGTCAGGAGGACTTTCTGTTTGTTCACCTTTGACCTCTTATTCTGTAACA  
TTACTGTGGATAATAGAGTTAAATGTGAATGGAGGCATTGAGAACACATTAGAGAAGGAG  
GTGATGCAGTATGACTACTATTCTTCATATTTTGATATATTTCTTCTGGCAGTTTTTCGA  
TTTAAAGTGTTAATACTTGCATATGCTGTGTGCAGACTGCGCCATTGGTGGGCAATAGCG  
TTGACAACGGCAGTGACCAGTGCCTTTTTACTAGCAAAAGTGATCCTTTCGAAGCTTTTC  
TCTCAAGGGGCTTTTGGCTATGTGCTGCCCATCATTTTCATTTCATCCTTGCCTGGATTGAG  
ACGTGGTTCTGGATTTCAAAGTGTTACCTCAAGAAGCAGAAGAAGAAAACAGACTCCTG  
ATAGTTCAGGATGCTTCAGAGAGGGCAGCACTTATACCTGGTGGTCTTCTGATGGTCAG  
TTTTATTCCCCTCCTGAATCCGAAGCAGGATCTGAAGAAGCTGAAGAAAAACAGGACAGT  
GAGAAACCACTTTTAGAACTATGAGTACTACTTTTTGTTAAATGTGAAAAACCTTCACAGA  
AAGTCATCGAGGCAAAAAGAGGCAGGCAGTGGAGTCTCCCTGTCGACAGTAAAGTTGAAA  
TGGTGACGTCCACTGCTGGCTTTATTGAACAGCTAATAAAGATTTATTTATTGTAATACC  
TCACAAACGTTGTACCATATCCATGCACATTTAGTTGCCTGCCTGTGGCTGGTAAGGTAA  
TGTCATGATTATCCTCTCTTCAGTGAGACTGAGCCTGATGTGTTAACAAATAGGTGAAG  
AAAGTCTTGTGCTGTATTCCTAATCAAAGACTTAATATATTGAAGTAACACTTTTTTTAG  
TAAGCAAGATACCTTTTTTATTTCAATTACAGAAATGGAATTTTTTTTGTTTTCATGTCTCAG  
ATTTATTTTGTATTTCTTTTTTAACACTCTACATTTCCCTTGTTTTTTTAACTCATGCACA  
TGTGCTCTTTGTACAGTTTTAAAAAGTGTAATAAAATCTGACATGTCAATGTGGCTAGTT  
TTATTTTTCTTGTTTTGCATTATGTGTATGGCCTGAAGTGTTGGACTTGCAAAAGGGGAA  
GAAAGGAATTGCGAATACATGTAAAATGTCACCAGACATTTGTATTATTTTTATCATGAA  
ATCATGTTTTTCTCTGATTGTTCTGAAATGTTCTAAATACTCTTATTTTGAATGCACAAA  
ATGACTTAAACCATTCATATCATGTTTCCTTTGCGTTTCAGCCAATTTCAATTAAAATGAA  
CTAAATTAAAAA

63/392

**FIGURE 62**

MNHLPEDMENALTGSQSSHASLRNIHSINPTQLMARIESYEGREKKGISDVRRTFCLFVT  
FDLLFVTLLWIIELNVNGGIENTLEKEVMQYDYSSYFDIFLLAVFRFKVLILAYAVCRL  
RHWWAIALTTAVTSAFLLAKVILSKLFSQGAFGYVLPIISFILAWIETWFLDFKVLQPQA  
EEENRLLIVQDASERAALIPGGLSDGQFYSPPESEAGSEEAEEKQDSEKPLLEL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-20

**Transmembrane domains:**

amino acids 54-72, 100-118, 130-144, 146-166

**N-myristoylation sites:**

amino acids 14-20, 78-84, 79-85, 202-208, 217-223

64/392

**FIGURE 63**

GCGCCGGGAGCCCATCTGCCCCCAGGGGCACGGGGCGCGGGGCCGGCTCCCGCCCCGGCAC  
ATGGCTGCAGCCACCTCGCGCGCACCCCGAGGCGCCGCGCCAGCTCGCCCCAGGTCCGT  
CGGAGGCGCCCGGCCGCCCCGGAGCCAAGCAGCAACTGAGCGGGGAAGCGCCCGCGTCCG  
GGGATCGGGATGTCCCTCCTCCTTCTCCTCTTGCTAGTTTTCTACTATGTTGGAACCTTG  
GGGACTCACACTGAGATCAAGAGAGTGGCAGAGGAAAAGGTCACCTTGCCCTGCCACCAT  
CAACTGGGGCTTCCAGAAAAAGACACTCTGGATATTGAATGGCTGCTCACCGATAATGAA  
GGGAACCAAAAAGTGGTGATCACTTACTCCAGTCGTCTATGTCTACAATAACTTGACTGAG  
GAACAGAAGGGCCGAGTGGCCTTTGCTTCCAATTTCTTGGCAGGAGATGCCTCCTTGAG  
ATTGAACCTCTGAAGCCCAGTGATGAGGGCCGGTACACCTGTAAGGTTAAGAATTCAGGG  
CGCTACGTGTGGAGCCATGTCATCTTAAAAGTCTTAGTGAGACCATCCAAGCCCAAGTGT  
GAGTTGGAAGGAGAGCTGACAGAAGGAAGTGACCTGACTTTGCAGTGTGAGTCATCCTCT  
GGCACAGAGCCCATTTGTGTATTACTGGCAGCGAATCCGAGAGAAAAGAGGGAGAGGATGAA  
CGTCTGCCTCCCAAATCTAGGATTGACTACAACCACCTGGACGAGTTCTGCTGCAGAAAT  
CTTACCATGTCCTACTCTGGACTGTACCAGTGCACAGCAGGCAACGAAGCTGGGAAGGAA  
AGCTGTGTGGTGCGAGTAACTGTACAGTATGTACAAAGCATCGGCATGGTTGCAGGAGCA  
GTGACAGGCATAGTGGCTGGAGCCCTGCTGATTTTTCTTCTTGGTGTGGCTGCTAATCCGA  
AGGAAAGACAAAGAAAGATATGAGGAAGAAGAGAGACCTAATGAAATTCGAGAAGATGCT  
GAAGCTCCAAAAGCCCGTCTTGTGAAACCCAGCTCCTCTTCTCCTCAGGCTCTCGGAGCTCA  
CGCTCTGGTTCTTCTCCACTCGCTCCACAGCAAATAGTGCCTCACGCAGCCAGCGGACA  
CTGTCAACTGACGCAGCACCCAGCCAGGGCTGGCCACCCAGGCATACAGCCTAGTGGGG  
CCAGAGGTGAGAGGTTCTGAACCAAGAAAGTCCACCATGCTAATCTGACCAAGCAGAA  
ACCACACCCAGCATGATCCCCAGCCAGAGCAGAGCCTTCCAAACGGTCTGAATTACAATG  
GACTTGACTCCCACGCTTTCTTAGGAGTCAGGGTCTTTGGACTCTTCTCGTCATTGGAGC  
TCAAGTCAACAGCCACACAACCAGATGAGAGGTCATCTAAGTAGCAGTGAGCATTGCACG  
GAACAGATTGAGATGAGCATTTCCTTATACAATACCAAACAAGCAAAAGGATGTAAGCT  
GATTCATCTGTAAAAAGGCATCTTATTGTGCCTTTAGACCAGAGTAAGGGAAAGCAGGAG  
TCCAAATCTATTTGTTGACCAGGACCTGTGGTGAGAAGGTTGGGGAAAGGTGAGGTGAAT  
ATACCTAAAACTTTTAAATGTGGGATATTTTGTATCAGTGCTTTGATTACAAATTTTCAAG  
AGGAAATGGGATGCTGTTTGTAATTTTCTATGCATTTCTGCAAACTTATTGGATTATTA  
GTTATTGAGACAGTCAAGCAGAAACCCACAGCCTTATTACACCTGTCTACACCATGTACTG  
AGCTAACCACTTCTAAGAAACTCCAAAAAAGGAAACATGTGTCTTCTATTCTGACTTAAC  
TTCATTTGTGATAGGTTTGGATATTAATTTCAAGGGGAGTTGAAATAGTGGGAGATGGA  
GAAGAGTGAATGAGTTTCTCCCACTCTATACTAATCTCACTATTTGTATTGAGCCCAAAA  
TAACTATGAAAGGAGACAAAAATTTGTGACAAAGGATTGTGAAGAGCTTTCCATCTTCAT  
GATGTTATGAGGATTGTTGACAAACATTAGAAAATATATAATGGAGCAATTGTGGATTTCC  
CCTCAAATCAGATGCCTCTAAGGACTTTCTGCTAGATATTTCTGGAAGGAGAAAATACA  
ACATGTCATTTATCAACGTCCTTAGAAAGAATTCTTCTAGAGAAAAAGGGATCTAGGAAT  
GCTGAAAGATTACCCAACATACCATTAAGTCTCTTCTTTCTGAGAAAATGTGAAACCAG  
AATTGCAAGACTGGGTGGACTAGAAAGGGAGATTAGATCAGTTTTCTCTTAATATGTCAA  
GGAAGGTAGCCGGGCATGGTGCCAGGCACCTGTAGGAAAATCCAGCAGGTGGAGGTTGCA  
GTGAGCCGAGATTATGCCATTGCACTCCAGCCTGGGTGACAGAGCGGGACTCCGTCTC

65/392

**FIGURE 64**

MSLLLLLLLVSYVGTLGTHTEIKRVAEEKVTLPCHHQLGLPEKDTLDIEWLLTDNEGNQ  
KVVITYSSRHVYNNLTTEEQKGRVAFASNFLAGDASLQIEPLKPSDEGRYTCKVKNSSGRYV  
WSHVILKVLVRPSKPKCELEGELTEGSDTLQCESSSGTEPIVYYWQRIREKEGEDERLP  
PKSRIDYNHPGRVLLQNLTMSYSGLYQCTAGNEAGKESCVVRVTQYVQSIGMVAGAVTG  
IVAGALLIFLLVWLLIRRKDKERYEEEEERPNEIREDAEAPKARLVKPSSSSSGSRSSRS  
SSSTRSTANSASRSQRTLSTDAAPQPGLATQAYSLVGPEVRGSEPKKVHHANLTKAETTP  
SMIPSQSRAFQTV

**Signal sequence:**  
amino acids 1-16

**Transmembrane domain:**  
amino acids 232-251

66/392

**FIGURE 65**

GTCTGGGGCTGCGCGACGGCGCAGGGGCTGCGGGGAGCGCCGCGCAGGCCGTGCAGTTCCT  
AGCGAGGAGGCGCCCGCCGCGCCATTGCCGCTCTCTCGGTGAGCGCAGCCCCGCTCTCCGGGC  
CGGGCCTTCGCGGGCCACCGGCGCCATGGGCCAGTGCGGCATCACCTCCTCCAAGACCGT  
GCTGGTCTTTCTCAACCTCATCTTCTGGGGGCGAGCTGGCATTATGCTATGTGGGAGC  
CTATGTCTTCATCACTTATGATGACTATGACCACTTCTTTGAAGATGTGTACACGCTCAT  
CCCTGCTGTAGTGATCATAGCTGTAGGAGCCCTGCTTTTCATCATTGGGGCTAATTGGCTG  
CTGTGCCACAATCCGGGAAAGTCGCTGTGGACTTGCCACGTTTGTTCATCATCCTGCTCTT  
GGTTTTTGTGCACAGAAGTTGTTGTAGTGGTTTTGGGATATGTTTACAGAGCAAAGGTGGA  
AAATGAGGTTGATCGCAGCATTGAGAAAGTGTATAAGACCTACAATGGAACCAACCCTGA  
TGCTGCTAGCCGGGCTATTGATTATGTACAGAGACAGCTGCATTGTTGTGGAATTCACAA  
CTACTCAGACTGGGAAAATACAGATTGGTTCAAAGAAAACCAAAACCAGAGTGTCCCTCT  
TAGCTGCTGCAGAGAGACTGCCAGCAATTGTAATGGCAGCCTGGCCCCACCCTTCCGACCT  
CTATGCTGAGGGGTGTGAGGCTCTAGTAGTGAAGAAGCTACAAGAAATCATGATGCATGT  
GATCTGGGCCGCACTGGCATTTCAGCTATTGAGCTGCTGGGCATGCTGTGTGCTTGCAT  
CGTGTTGTGCAGAAGGAGTAGAGATCCTGCTTACGAGCTCCTCATCACTGGCGGAACCTA  
TGCATAGTTGACAACTCAAGCCTGAGCTTTTTGGTCTTGTCTGATTGGAAGGTGAATT  
GAGCAGGTCTGCTGCTGTTGGCCTCTGGAGTTCATTTAGTTAAAGCACATGTACACTGGT  
GTTGGACAGAGCAGCTTGGCTTTTCATGTGCCACCTACTTACCTACTACCTGCGACTTT  
CTTTTTCCTTGTCTAGCTGACTCTTCATGCCCTAAGATTTTAAAGTACGATGGTGAACG  
TTCTAATTTGAGAACCAATTGCGAGTCATGTAGTGTGGTAGAATTAAAGGAGGACACGAG  
CCTGCTTCTGTTACCTCCAAGTGGTAACAGGACTGATGCCGAAATGTCACCAGGTCCTTT  
CAGTCTTCACAGTGGAGAACTCTTGGCCAAAGGTTTTTTCGGGGAGGAGGAGGAAACCAG  
CTTTCTGGTTAAGGTTAACACCAGATGGTGCCCTCATTGGTGTCTTTTAAAAAATATT  
TACTGTAGTCCAATAAGATAGCAGCTGTACAAAATGACTAAAATAGATTGTAGGATCATA  
TGGCGTATATCTTGGTTTCATCTTCAAATCAGAGACTGAGCTTTGAAACTAGTGGTTTTTT  
AATCAAAGTTGGCTTTATAGGAGGAGTATAATGTATGCACTACTGTTTTTAAAGAATTAG  
TGTGAGTGTGTTTTTGTATGAATGAGCCCATTCATGGTAAGTCTTAAGCTTGTGGAAT  
AATGTACCCATGTAGACTAGCAAAATAGTATGTAGATGTGATCTCAGTTGTAAATAGAAA  
AATCTAATTCAATAAACTCTGTATCAGCCCCCAAAAAAAAAAAAAA

67/392

**FIGURE 66**

MGQCGITSSKTVLVFLNLIFWGAAGILCYVGAYVFITYDDYDHFEDVYTLPVAVVIAV  
GALLFIIGLIGCCATIRESRCGLATFVIIILLVFVTEVVVVVLGYVYRAKVENEVDRSIQ  
KVYKTYNGTNPDAASRAIDYVQQLHCCGIHNYSDWENTDWFKETKNQSVPLSCCRETAS  
NCNGSLAHPDLYAEGCEALVVKKLQEIMMHVIWAALAFAAIQLLGMLCACIVLCRRSRD  
PAYELLITGGTYA

**Signal peptide:**

none

**Type II transmembrane domain:**

11-38

**Other transmembrane domains:**

48-68, 87-107, 208-235

**N-glycosylation site:**

127-131, 152-156, 167-171, 183-187

**Tyrosine kinase phosphorylation site:**

236-244

**N-myristoylation site:**

5-11, 68-74, 71-77, 226-232

**Prokaryotic membrane lipoprotein lipid attachment site:**

62-73, 221-232

**Transmembrane 4 family proteins:**

7-35, 56-106

68/392

**FIGURE 67**

GCGGCACCTGGAAGATGCGCCCATTTGGCTGGTGGCCTGCTCAAGGTGGTGTTCGTGGTCT  
TCGCCTCCTTGTGTGCCTGGTATTCGGGGTACCTGCTCGCAGAGCTCATTCCAGATGCAC  
CCCTGTCCAGTGCTGCCTATAGCATCCGCAGCATCGGGGAGAGGCCTGTCCTCAAAGCTC  
CAGTCCCCAAAAGGCAAAAATGTGACCACTGGACTCCCTGCCCATCTGACACCTATGCCT  
ACAGGTTACTCAGCGGAGGTGGCAGAAGCAAGTACGCCAAAATCTGCTTTGAGGATAACC  
TACTTATGGGAGAACAGCTGGGAAATGTTGCCAGAGGAATAAACATTGCCATTGTCAACT  
ATGTAACCTGGGAATGTGACAGCAACACGATGTTTTGATATGTATGAAGGCGATAACTCTG  
GACCGATGACAAAGTTTATTCAGAGTGCTGCTCCAAAATCCCTGCTCTTCATGGTGACCT  
ATGACGACGGAAGCACAAGACTGAATAACGATGCCAAGAATGCCATAGAAGCACTTGGA  
GTAAAGAAATCAGGAACATGAAATTCAGGTCTAGCTGGGTATTTATTGCAGCAAAAGGCT  
TGGAACCTCCCTTCCGAAATTCAGAGAGAAAAGATCAACCACTCTGATGCTAAGAACAACA  
GATATTCTGGCTGGCCTGCAGAGATCCAGATAGAAGGCTGCATACCCAAAGAACGAAGCT  
GACACTGCAGGGTCCTGAGTAAATGTGTTCTGTATAAACAAATGCAGCTGGAATCGCTCA  
AGAATCTTATTTTTCTAAATCCAACAGCCCATATTTGATGAGTATTTTGGGTTTGTGTA  
AACCAATGAACATTTGCTAGTTGTATCAAATCTTGGTACGCAGTATTTTATAACAGTAT  
TTTATGTAGTGAAGATGTCAATTAGCAGGAACTAAAATGAATGGAAATTCCTTAAAAAA  
AAA

69/392

**FIGURE 68**

MRPLAGGLLKVVVFVVFASLCAWYSGYLLAELIPDAPLSSAAYSIRSIGERPVLKAPVPKR  
QKCDHWTPCPSDTYAYRLLSGGGRSKYAKICFEDNLLMGEQLGNVARGINIAIVNYVTGN  
VTATRCFDMYEGDNSGPMTKFIQSAAPKSLLFMVTYDDGSTRLNNDKNAIEALGSKEIR  
NMKFRSSWVFIAAKGLELPSEIQREKINHSDAKNNRYSGWPAEIQIEGCI PKERS

**Signal sequence:**

amino acids 1-20

**N-glycosylation sites:**

amino acids 120-124, 208-212

**Glycosaminoglycan attachment site:**

amino acids 80-84

**N-myristoylation sites:**

amino acids 81-87, 108-114, 119-125



70/392

**FIGURE 69**

ACACAACTTTACACCTGAATGAACGCCAAACCTCTATGGATATATAAAGGGAAGCTTGAG  
GAGGAATTTACAGTTACAGTGCAGAAGCAGAAGCAAAGAATTAACCAGCTCTTCAGTC  
AAGCAAATCCTCTACTCACCATGCTTCCTCCTGCCATTCATTTCTATCTCCTTCCCCTTG  
CATGCATCCTAATGAAAAGCTGTTTGGCTTTTAAAAATGATGCCACAGAAATCCTTTATT  
CACATGTGGTTAAACCTGTTCCAGCACACCCCAGCAGCAACAGCACGTTGAATCAAGCCA  
GAAATGGAGGCAGGCATTTTCAGTAACACTGGACTGGATCGGAACACTCGGGTTCAAGTGG  
GTTGCCGGGAAGTGCCTTCCACCAAATACATCTCTGATGGCCAGTGCACCAGCATCAGCC  
CTCTGAAGGAGCTGGTGTGTGCTGGCGAGTGCTTGCCCCTGCCAGTGCTCCCTAACTGGA  
TTGGAGGAGGCTATGGAACAAAGTACTGGAGCAGGAGGAGCTCCAGGAGTGGCGGTGTG  
TCAATGACAAAACCCGTACCCAGAGAATCCAGCTGCAGTGCCAAGATGGCAGCACACGCA  
CCTACAAAATCACAGTAGTCACTGCCTGCAAGTGCAAGAGGTACACCCGGCAGCACAAAG  
AGTCCAGTCACAACTTTGAGAGCATGTACCTGCCAAGCCAGTCCAGCATCACAGAGAGC  
GGAAAAGAGCCAGCAAATCCAGCAAGCACAGCATGAGTTAGAACTCAGACTCCATAACT  
AGACTTACTAGTAACCATCTGCTTTACAGATTTGATTGCTTGGAAGACTCAAGCCTGCCA  
CTGCTGTTTTCTCACTTGAAAATATATGCTTTCTGCTTTGATCAAACCCAGCAAGCTGTC  
TTAAGTATCAGGACCTTCTTTGGGAATAGTTTTTTCCTTTTAAAGTTTTTCAAGATGTAGG  
TATATCCATGAATGCAATTTGCATTTAAATTCACGTATCCCTGTAGTTTAAATTCCTCA  
TTGGTCTTAAAGACTGTTGATACTATAAACATCAGTGGAATCAATTATATTTTAAACA  
GAAAAGGGCTT

71/392

**FIGURE 70**

MLPPAIHFYLLPLACILMKSCLA FKNDAT EILYSHVV KVPVPAHPSSNSTLNQARNGGRHF  
SNTGLDRNTRVQVGCRELRSTKYISDGQCT SISPLKELVCAGECLPLPVL PNWIGGGYGT  
KYWSRRSSQEWRCVNDKTRTQRIQLQCQDGSTR TYKITVVTACKCKRYTRQHNESSHNFE  
SMSPAKPVQHHRRERKRASKSSKHSMS

**Signal sequence:**

1-23

**Transmembrane domain:**

None

**N-glycosylation site:**

47-50, 173-176

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

125-128, 166-169, 195-198

**N-myristoylation site:**

64-69, 87-92, 115-120, 116-121, 150-155

72/392

**FIGURE 71**

CCCAGGCTCTAGTGCAGGAGGAGAAGGAGGAGGAGCAGGAGGTGGAGATTCCCAGTTAAA  
AGGCTCCAGAATCGTGTACCAGGCAGAGAACTGAAGTACTGGGGCCTCCTCCACTGGGTC  
CGAATCAGTAGGTGACCCCGCCCCTGGATTCTGGAAGACCTCACCATGGGACGCCCCCGA  
CCTCGTGCGGCCAAGACGTGGATGTTCTTGCTCTTGCTGGGGGGAGCCTGGGCAGGACAC  
TCCAGGGCACAGGAGGACAAGGTGCTGGGGGGTCTAGAGTGCCAACCCCATTCGCAGCCT  
TGGCAGGCGGCCTTGTTCCAGGGCCAGCAACTACTCTGTGGCGGTGTCCTTGTTAGGTGGC  
AACTGGGTCTTACAGCTGCCCCTGTAAAAAACGAAATACACAGTACGCCTGGGAGAC  
CACAGCCTACAGAATAAAGATGGCCCAGAGCAAGAAATACCTGTGGTTCAGTCCATCCCA  
CACCCTGCTACAACAGCAGCGATGTGGAGGACCACAACCATGATCTGATGCTTCTTCAA  
CTGCGTGACCAGGCATCCCTGGGGTCCAAAGTGAAGCCCATCAGCCTGGCAGATCATTGC  
ACCCAGCCTGGCCAGAAGTGACCCGTCTCAGGCTGGGGCACTGTCACCAGTCCCCGAGAG  
AATTTTCCTGACACTCTCAACTGTGCAGAAGTAAAAATCTTTCCCCAGAAGAAGTGTGAG  
GATGCTTACCCGGGGCAGATCACAGATGGCATGGTCTGTGCAGGCAGCAGCAAAGGGGCT  
GACACGTGCCAGGGCGATTCTGGAGGCCCCCTGGTGTGTGATGGTGCCTCCAGGGCATC  
ACATCCTGGGGCTCAGACCCCTGTGGGAGGTCCGACAAACCTGGCGTCTATACCAACATC  
TGCCGCTACCTGGACTGGATCAAGAAGATCATAGGCAGCAAGGGCTGATTCTAGGATAAG  
CACTAGATCTCCCTTAATAAACTCACAACCTCTCTGGTTC

73/392

**FIGURE 72**

MGRPRPRAAKTWMFLLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAALFQGQQLLCGG  
VLVGGNWWLTAAHCKKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHD  
LMLLQLRDQASLGSKVKPISLADHCTQPGQKCTVSGWGTVTSPRENF PDTLNCAEVKIFP  
QKKCEDAYPGQITDGMVCAGSSKGADTCQGDSSGGLVCDGALQGITSWGSDPCGRSDKPG  
VYTNICRYLDWIKKIIGSKG

**Important Features:****Signal peptide:**

amino acids 1-23

**Transmembrane domain:**

amino acids 51-71

**N-glycosylation site:**

amino acids 110-113

**Serine proteases, trypsin family, histidine active site:**

amino acids 69-74 and 207-217

**Tyrosine kinase phosphorylation site:**

amino acids 182-188

**Kringle domain proteins motif:**

amino acids 205-217

74/392

**FIGURE 73**

CTCGGGCGCGCACAGGCAGCTCGGTTTGCCTTGCATTGAGCTGCGGGTTCGCGGCCGGCG  
CCGGCCTCTCCAATGGCAAATGTGTGTGGCTGGAGGCGAGCGGAGGCTTTCGGCAAAGG  
CAGTCGAGTGTTTGCAGACCGGGGCGAGTCCTGTGAAAGCAGATAAAAGAAAACATTTAT  
TAACGTGTATTACGAGGGGAGCGCCCGGGCGGGGCTGTCGCACTCCCCGCGGAACATTT  
GGCTCCCTCCAGCTCCGAGAGAGGAGAAGAAGAAAGCGGAAAAGAGGCAGATTCACGTCTG  
TTTCCAGCCAAGTGGACCTGATCGATGGCCCTCCTGAATTTATCACGATATTTGATTTAT  
TAGCGATGCCCCCTGGTTTGTGTGTTACGCACACACACGTGCACACAAGGCTCTGGCTCG  
CTTCCCTCCCTCGTTTCCAGCTCCTGGGCGAATCCCACATCTGTTTCAACTCTCCGCCGA  
GGGCGAGCAGGAGCGAGAGTGTGTGCAATCTGCGAGTGAAGAGGGACGAGGGAAAAGAAA  
CAAAGCCACAGACGCAACTTGAGACTCCCGCATCCCCAAAAGAAGCACCAGATCAGCAAAA  
AAAGAAGATGGGGCCCCCGAGCCTCGTGCTGTGCTTGCTGTCCGCAACTGTGTTCTCCCT  
GCTGGGTGGAAGCTCGGCCTTCTGTGCGACCACCGCCTGAAAGGCAGGTTTCAGAGGGA  
CCGCAGGAACATCCGCCCCAACATCATCTGGTGTGCTGACGGACGACCAGGATGTGGAGCT  
GGGTTCCATGCAGGTGATGAACAAGACCCGGCGCATCATGGAGCAGGGCGGGGCGCACTT  
CATCAACGCCTTCGTGACCACACCCATGTGCTGCCCTCACGCTCCTCCATCCTCACTGG  
CAAGTACGTCCACAACCAACACCTACACCAACAATGAGAACTGCTCCTCGCCCTCCTG  
GCAGGCACAGCACGAGAGCCGCACCTTTGCCGTGTACCTCAATAGCACTGGCTACCGGAC  
AGCTTTCTTCGGGAAGTATCTTAATGAATACAACGGCTCCTACGTGCCACCCGGCTGGAA  
GGAGTGGGTGCGACTCCTTAAAAACTCCCGCTTTTATAACTACACGCTGTGTGCGGAACGG  
GGTGAAGAGAGACCGGCTCCGACTACTCCAAGGATTACCTCACAGACCTCATCACCAA  
TGACAGCGTGAGCTTCTTCGCGACGTCCAAGAAGATGTACCCGCACAGGCCAGTCCTCAT  
GGTCATCAGCCATGCAGCCCCCACGGCCCTGAGGATTCAGCCCCACAATATTCACGCCT  
CTTCCCAAACGCATCTCAGCACATCACGCCGAGCTACAACTACGCGCCCAACCCGGACAA  
ACACTGGATCATGCGCTACACGGGGCCCATGAAGCCCATCCACATGGAATTACCAACAT  
GCTCCAGCGGAAGCGCTTGACAGCCCTCATGTGCGGTGGACGACTCCATGGAGACGATTTA  
CAACATGCTGGTTGAGACGGGCGAGCTGGACAACACGTACATCGTATACACCGCCGACCA  
CGGTTACCACATCGGCCAGTTTGGCCTGGTGAAGGGGAAATCCATGCCATATGAGTTTGA  
CATCAGGGTCCCCTTCTACGTGAGGGGCCCCAACGTGGAAGCCGGCTGTCTGAATCCCCA  
CATCGTCTCAACATTGACCTGGCCCCCACCATCCTGGACATTGCAGGCCTGGACATACC  
TGCGGATATGGACGGGAAATCCATCCTCAAGCTGCTGGACACGGAGCGGCCGGTGAATCG  
GTTTCACTTGAAAAAGAAGATGAGGGTCTGGCGGGAATCCTTCTTGGTGGAGAGAGGCAA  
GCTGCTACACAAGAGAGACAATGACAAGGTGGACGCCCAGGAGGAGAACTTTCTGCCCAA  
GTACCAGCGTGTGAAGGACCTGTGTGACGCGTGTGAGTACCAGACGGCGTGTGAGCAGCT  
GGGACAGAAGTGGCAGTGTGTGGAGGACGCCACGGGGAAAGCTGAAGCTGCATAAGTGCAA  
GGGCCCCATGCGGTGGGCGGCAGCAGAGCCCTCTCCAACCTCGTGCCCAAGTACTACGG  
GCAGGGCAGCGAGGCCTGCACCTGTGACAGCGGGGACTACAAGCTCAGCCTGGCCGGACG  
CCGGAAAAAACTCTTCAAGAAGAAGTACAAGGCCAGCTATGTCCGCGAGTCGCTCCATCCG  
CTCAGTGGCCATCGAGGTGGACGGCAGGGTGTACACGTAGGCCTGGGTGATGCCGCCCA  
GCCCCGAAACCTCACCAAGCGGCACTGGCCAGGGGCCCCCTGAGGACCAAGATGACAAGGA  
TGGTGGGGACTTCAGTGGCACTGGAGGCCTTCCCGACTACTCAGCCGCCAACCCCATTA  
AGTGACACATCGGTGCTACATCCTAGAGAACGACACAGTCCAGTGTGACCTGGACCTGTA  
CAAGTCCCTGCAGGCCTGGAAAGACCACAAGCTGCACATCGACCACGAGATTGAAACCT  
GCAGAACAAAATTAAGAACCTGAGGGAGTCCGAGGTACCTGAAGAAAAAGCGGCCAGA  
AGAATGTGACTGTCAAAAATCAGCTACCACACCCAGCACAAAGGCCGCCCTCAAGCACAG  
AGGCTCCAGTCTGCATCCTTTAGGAAGGGCCTGCAAGAGAAGGACAAGGTGTGGCTGTT  
GCGGGAGCAGAAGCGCAAGAAGAACTCCGCAAGCTGCTCAAGCGCCTGCAGAACACGA  
CACGTGCAGCATGCCAGGCCTCACGTGCTTACCCACGACAACCGACTGGCAGACGGC

75/392

GCCTTTCTGGACACTGGGGCCTTTCTGTGCCTGCACCAGCGCCAACAATAACACGTACTG  
GTGCATGAGGACCATCAATGAGACTCACAATTTCTCTTCTGTGAATTTGCAACTGGCTT  
CCTAGAGTACTTTGATCTCAACACAGACCCCTACCAGCTGATGAATGCAGTGAACACACT  
GGACAGGGATGTCCTCAACCAGCTACACGTACAGCTCATGGAGCTGAGGAGCTGCAAGGG  
TTACAAGCAGTGTAACCCCCGGACTCGAAACATGGACCTGGATGGAGGAAGCTATGAGCA  
ATACAGGCAGTTTCAGCGTCGAAAGTGGCCAGAAATGAAGAGACCTTCTTCCAAATCACT  
GGGACAACTGTGGGAAGGCTGGGAAGGTTAAGAAAACAACAGAGGTGGACCTCCAAAAACA  
TAGAGGCATCACCTGACTGCACAGGCAATGAAAAACCATGTGGGTGATTTCCAGCAGACC  
TGTGCTATTGGCCAGGAGGCCTGAGAAAGCAAGCACGCACTCTCAGTCAACATGACAGAT  
TCTGGAGGATAACCAGCAGGAGCAGAGATAACTTCAGGAAGTCCATTTTTTGCCCCTGCTT  
TTGCTTTGGATTATACCTCACCAGCTGCACAAAATGCATTTTTTTCGTATCAAAAAGTCAC  
CACTAACCCCTCCCCCAGAAGCTCACAAAGGAAAAACGGAGAGAGCGAGCGAGAGAGATTTT  
CTTGGAATTTTCTCCCAAGGGCGAAAGTCATTGGAATTTTTTAAATCATAGGGGAAAAGCA  
GTCCTGTTCTAAATCCTCTTATTCTTTTGGTTTGTCAAAAGAAGGAACTAAGAAGCAGG  
ACAGAGGCAACGTGGAGAGGCTGAAAACAGTGCAGAGACGTTTGACAATGAGTCAGTAGC  
ACAAAAGAGATGACATTTACCTAGCACTATAAACCCCTGGTTGCCTCTGAAGAACTGCCT  
TCATTGTATATATGTGACTATTTACATGTAATCAACATGGGAAC'TTTTAGGGGAACCTAA  
TAAGAAATCCCAATTTTTCAGGAGTGGTGGTGTCAATAAACGCTCTGTGGCCAGTGTAAAA  
GAAAAA

76/392

**FIGURE 74**

MGPPSLVLCCLLSATVFSLLGGSSAFLSHHRLKGRFQDRRNIRPNIIILVLTDDQDVELGS  
MQVMNKTRRIMEQGGAHFINAFVTPMCCPSRSSILTGKYVHNHNTYTNNENCSSPSWQA  
QHESRTFAVYLNSTGYRTAFFGKYLNEYNGSYVPPGWKEWVGLLKNSRFYNYTLCRNGVK  
EKHGS DYSKDYLTDLITNDSVSFFRTSKKMPHRPVL MVISHAAPHGPEDSAPQYSRLFP  
NASQHITPSYNYAPNPDKHWIMRYTGPMKPIHMEFTNMLQRKRLQTLMSVDDSMETIYNM  
LVETGELDNTYIVYTADHGYHIGQFGLVKGKSMPEYFDIRVPFYVRGPNVEAGCLNPHIV  
LNIDLAPTILDIAGLDIPADM DGKSILKLLDTERPVNRFHLKKKMRVWRDSFLVERGKLL  
HKRDNDKVDAQEENFLPKYQRVKDLQRAEYQTACEQLGQKWQCVEDATGKLKLHKCKGP  
MRLGGSRALSNLVPKYYGQGSEACTCDSGDYKLSLAGRRKKLFKKKYKASYVRSRSIRSV  
AIEVDGRVYHVGLGDAAQPRNLTKRHWPGAPEDQDDKDGGDFSGTGGLPDYSAANPIKVT  
HRCYILENDTVQCDDLKYKSLQAWKDHKLHIDHEIETLQNKIKNLREVRGHLKKRPEEC  
DCHKISYHTQHKGRLLKHRGSSSLHPFRKGLQEKDKVWLLREQRKKKLRKLLKRLQNNDT  
SMPGLTCFTHDNQHWQTAPFWTLGPFCACTSANNNNTYWCMTINETHNFLFCFATGFLE  
YFDLNTDPYQLMNAVNLTDRDVLNQLHVQLMELRSCKGYKQCNPRTRNMDLDGGSYEQYR  
QFQRRKWPEMKRPSSKSLGQLWEGWEG

**Important features:****Signal peptide:**

amino acids 1-17

**Sulfatases signature 1:**

amino acids 86-99

**Homologous region to sulfatase:**

amino acids 87-106, 133-146, 216-229, 291-320, 365-375

**N-glycosylation sites:**amino acids 65-69, 112-116, 132-136, 149-153, 171-175,  
198-202, 241-245, 561-565, 608-612, 717-721, 754-758,  
764-768

77/392

**FIGURE 75**

CCCACGCGTCCGCCCACGCGTCCGGTGGACTATGGGCCAGTTTTTTGTGCAAGAACCAGAT  
GATATTATTTTTTCCAACTGATTCTGATGAAAAGAAGGTAGCATTGAATTGTGAAGTTCGT  
GGCAATCCAGTTCCAGTTACAGATGGCTTCGAAATGGAACAGAAATAGATCTGGAAAGT  
GATTATCGCTACAGTTTGATAGATGGCACCTTCATTATAAGCAATCCAAGTGAAGCAAAG  
GATTCTGGTCATTATCAGTGTCTTAGCAACCAACACTGTGGGGAGTATTCTTAGTAGAGAA  
GCTACACTGCAGTTTGCCTATCTGGGAAATTTTAGTGGCCGGACAAGAAGTGCAGTCTCT  
GTGAGGGAAGGCCAGGGTGTCTGTTCTGATGTGCTCTCCTCCGCCACATTCAACCAGAGATC  
ATCTATAGCTGGGTATTTAATGAGTTCCTTCCCTTGTGGCGGAAGACAGCCGGCGGTTTC  
ATCTCCCAGGAGACAGGCAACCTTTATATTTCTAAAGTCCAAACATCAGATGTTGGCAGC  
TATATTTGTCTGGTGAAAAACACAGTGACGAATGCTAGAGTCCTTAGTCCTCCAACGCCA  
CTCACTCTGCGTAATGATGGTGTGATGGGAGAATATGAGCCGAAAATTGAGGTCCATTTT  
CCTTTCACGGTTACAGCTGCTAAAGGAACAACCTGTTAAGATGGAATGCTTTGCACTTGGC  
AACCCCGTTCCAACAATCACATGGATGAAGGTTAATGGTTATATTCCTAGTAAGGCACGT  
CTGCGGAAATCTCAGGCGGTGCTGGAAATACCGAATGTACAGCTGGATGATGCAGGCATT  
TATGAGTGCAGAGCTGAAAACCTCACGTGGAAAAAATTCCTTTCTGGACAATTACAAGTA  
TACACCTACCCACACTGGGTAGAAAAACTGAATGATACTCAGTTAGACAGTGGGAGCCCT  
CTCCGATGGGAATGTAAGGCTACTGGAAAAACCAGACCCACGTATCGTTGGCTGAAGAAT  
GGAGTACCCCTCTCACCTCAGAGTAGGGTTGAGATGGTTAATGGAGTATTGATGATCCAC  
AATGTGAATCAATCAGATGCTGGAATGTATCAGTGTCTGGCTGAAAATAAGTATGGAGCC  
ATTTACGCTAGTGCTGAGCTGAAGATTCTAGCTTCAGCTCCCACTTTTGCACTGAATCAA  
CTGAAGAAAACAATAATTGTTACCAAAGACCAAGAAGTTGTCATAGAGTGCAAACCCCAA  
GGCTCTCCAAAACCAACCATCTCTTGGAAGAAAGGAGACAGAGCAGTTAGAGAAAAACAAA  
AGAATAGCTATTCTTCCAGACGGGAGTCTACGGATCCTAAATGCTTCCAAATCAGACGAG  
GGAAAGTACGTTTGCCGAGGGGAAAACGTCTTTGGTTCTGCTGAAAT



78/392

**FIGURE 76**

MCSPPPHSPEIIYSWVFNEFP SFVAEDSRRFISQETGNLYISKVQTS DVGSIYICLVKNTV  
TNARVLSPPPTPLTLRNDGVMGEYEPKIEVHFPEFTVTAAGTTVKMECFALGNPVPTITWM  
KVNGYIPSKARLRKSQAVLEIPNVQLDDAGIYECRAENSRGKNSFRGQLQVYTYPHWVEK  
LNDTQLDSGSPLRWECKATGKPRPTYRWLKNGVPLSPQSRVEMVNGVLMIHNVNQSDAGM  
YQCLAENKYGAIYASAE LKILASAPTFALNQLKKTIIIVTKDQEVVIECKPQGSPKPTISW  
KKGDRAVRENKRIAILPDGSLRILNASKSDEGKYVCRGENVFGSAE

**Signal sequence:**

None

**Transmembrane domain:**

None

**N-glycosylation site:**

182-185, 234-237, 325-328

**Tyrosine kinase phosphorylation site:**

328-334

**N-myristoylation site:**

50-55, 150-155, 239-244, 250-255

**Immunoglobulin domain:**

2-56, 100-156, 189-245, 281-338

79/392

## FIGURE 77

GCTCCCAGCCAAGAACCTCGGGGCCGCTGCGCGGTGGGGAGGAGTTCCCCGAAACCCGGC  
CGCTAAGCGAGGCCTCCTCCTCCCGCAGATCCGAACGGCCTGGGCGGGGTACCCCCGGCT  
GGGACAAGAAGCCCGCCGCTGCTGCCCCGGGCCCGGGGAGGGGGCTGGGGCTGGGGCCGG  
AGGCGGGGTGTGAGTGGGTGTGTGCGGGGGGCGGAGGCTTGATGCAATCCCGATAAGAAA  
TGCTCGGGTGTCTTGGGCACCTACCCGTGGGGCCCCGTAAGGCGCTACTATATAAGGCTGC  
CGGCCCCGAGCCGCGCGCCGTGAGAGCAGGAGCGCTGCGTCCAGGATCTAGGGCCACGA  
CCATCCCAACCCGGCACTCACAGCCCCGAGCGCATCCCGGTGCGCGCCAGCCTCCCGC  
ACCCCCATCGCCGGAGCTGCGCCGAGAGCCCCAGGGAGGTGCCATGCGGAGCGGGTGTGT  
GGTGGTCCACGTATGGATCCTGGCCGGCCTCTGGCTGGCCGTGGCCGGGCGCCCCCTCGC  
CTTCTCGGACGCGGGGCCCCACGTGCACTACGGCTGGGGCGACCCCATCCGCCTGCGGCA  
CCTGTACACCTCCGGCCCCCACGGGCTCTCCAGCTGCTTCTGCGCATCCGTGCCGACGG  
CGTCGTGGACTGCGCGCGGGGCCAGAGCGCGCACAGTTTGCTGGAGATCAAGGCAGTCGC  
TCTGCGGACCGTGGCCATCAAGGGCGTGACAGCGTGCGGTACCTCTGCATGGGCGCCGA  
CGGCAAGATGCAGGGGCTGCTTCAGTACTCGGAGGAAGACTGTGCTTTTCGAGGAGGAGAT  
CCGCCCAGATGGCTACAATGTGTACCGATCCGAGAAGCACCGCCTCCCGGTCTCCCTGAG  
CAGTGCCAAACAGCGGCAGCTGTACAAGAACAGAGGCTTTCTTCCACTCTCTCATTTCTT  
GCCCATGCTGCCATGGTCCCAGAGGAGCCTGAGGACCTCAGGGGGCCACTTGGAATCTGA  
CATGTTCTCTTCGCCCCCTGGAGACCGACAGCATGGACCCATTTGGGCTTGTACCCGACT  
GGAGGCCGTGAGGAGTCCCAGCTTTGAGAAAGTAACTGAGACCATGCCCGGGCCTCTTCAC  
TGCTGCCAGGGGCTGTGGTACCTGCAGCGTGGGGGACGTGCTTCTACAAGAACAGTCCTG  
AGTCCACGTTCTGTTTAGCTTTAGGAAGAAACATCTAGAAGTTGTACATATTCAGAGTTT  
TCCATTGGCAGTGCCAGTTTCTAGCCAATAGACTTGTCTGATCATAACATTGTAAGCCTG  
TAGCTTGCCCAGCTGCTGCCTGGGCCCCCACTTCTGCTCCCTCGAGGTTGCTGGACAAGCT  
GCTGCACTGTCTCAGTTCTGCTTGAATACCTCCATCGATGGGGAACTCACTTCCTTTGGA  
AAAATTCTTATGTCAAGCTGAAATTCTCTAATTTTTTCTCATCACTTCCCCAGGAGCAGC  
CAGAAGACAGGCAGTAGTTTTAATTTTCAAGAACAGGTGATCCACTCTGTAAAAACAGCAGG  
TAAATTTCACTCAACCCCATGTGGGAATTGATCTATATCTCTACTTCCAGGGACCATTG  
CCCTTCCCAAATCCCTCCAGGCCAGAACTGACTGGAGCAGGCATGGCCCACCAGGCTTCA  
GGAGTAGGGGAAGCCTGGAGCCCCACTCCAGCCCTGGGACAACCTTGAGAATTCCCCCTGA  
GGCCAGTTCTGTATGGATGCTGTCTGAGAATAACTTGCTGTCCCGGTGTACCTGCTT  
CCATCTCCAGCCCCACCAGCCCTCTGCCCACCTCACATGCCTCCCCATGGATTGGGGCCT  
CCCAGGCCCCCACCTTATGTCAACCTGCACTTCTTGTTCAAAAAATCAGGAAAAGAAAAG  
ATTTGAAGACCCCAAGTCTTGTCATAACTTGCTGTGTGGAAGCAGCGGGGAAGACCTA  
GAACCCTTTCCCCAGCACTTGGTTTTTCCAACATGATATTTATGAGTAATTTATTTTGATA  
TGTACATCTCTTATTTTCTTACATTATTTATGCCCCAAATTATATTTATGTATGTAAGT  
GAGGTTTGTTTTGTATATTAAATGGAGTTTGTTTGT

80/392

**FIGURE 78**

MRSGCVVVHVWILAGLWLAVAGRPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFL  
RIRADGVVDCARGQSAHSLLLEIKAVLRRTVAIKGVHVSRYLCMGADGKMQLQYSEEDC  
AFEEEIRPDGYNVYRSEKHLRPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLR  
GHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK

**Signal peptide:**

amino acids 1-22

**Casein kinase II phosphorylation site:**

amino acids 78-82, 116-120, 190-194, 204-208

**N-myristoylation site:**

amino acids 15-21, 54-60, 66-72, 201-207

**Prokaryotic membrane lipoprotein lipid attachment site:**

amino acids 48-59

81/392

## FIGURE 79

CGGACGCGTGGGCGGACGCGTGGGCGTGGGCAAGGGCCGGGGCGCCGGGGCCGAGCCACCTCTTCCC  
CTCCCCCGCTTCCCTGTGCGGCTCCGCTGGCTGGACGCGCTGGAGGAGTGGAGCAGCACCCGGCCG  
GCCCTGGGGGCTGACAGTCGGCAAAGTTTGGCCCGAAGAGGAAGTGGTCTCAAACCCCGGCAGGTG  
GCGACCAGGCCAGACCAGGGGCGCTCGCTGCGCTGCGGGCGGGCTGTAGGCGAGGGCGCGCCCCAGT  
GCCGAGACCCGGGGCTTCAAGAGCCGGCCCCGGGAGAGAAGAGTGCGGCGGGCGGACGGAGAAAAACA  
ACTCCAAAGTTGGCGAAAGGCACCGCCCCCTACTCCCGGGCTGCCGCGCCTCCCCGCCCCCAGCCC  
TGGCATCCAGAGTACGGGTGAGCCCCGGGCCATGGAGCCCCCTGGGGAGGCGGCACCAGGGAGCC  
TGGGCGCCCCGGGGCTCCGCCGCGACCCCCATCGGGTAGACCACAGAAGCTCCGGGACCCCTTCCGGCA  
CCTCTGGACAGCCCAGGATGCTGTGGCCACCCTCCTCCTCCTCCTCCTTGGAGGCGCTCTGGCCC  
ATCCAGACCGGATTATTTTTTCAAATCATGCTTGTGAGGACCCCCCAGCAGTGCTCTTAGAAGTGC  
AGGGCACCTTACAGAGGCCCCCTGGTCCGGGACAGCCGCACCTCCCCTGCCAACTGCACCTGGCTCA  
TCCTGGGCAGCAAGGAACAGACTGTACCATCAGGTTCCAGAAGCTACACCTGGCCTGTGGCTCAG  
AGCGCTTAACCCCTACGCTCCCCTCTCCAGCCACTGATCTCCCTGTGTGAGGCACCTCCCAGCCCTC  
TGCAGCTGCCCCGGGGGCAACGTACCATCACTTACAGCTATGCTGGGGCCAGAGCACCCATGGGGC  
AGGGCTTCTCTGCTCTCCTACAGCCAAGATTGGCTGATGTGCCTGCAGGAAGAGTTTCACTGCTGA  
ACCACCGCTGTGTATCTGCTGTCCAGCGCTGTGATGGGGTTGATGCCTGTGGCGATGGCTCTGATG  
AAGCAGCTTGCAGCTCAGACCCCTTCCCTGGCCTGACCCCAAGACCCGTCCCCTCCCTGCCTTGCA  
ATGTACCTTGGAGGACTTCTATGGGGTCTTCTCCTCCTCCTGGATATACACACCTAGCCTCAGTCT  
CCCACCCCCAGTCTGCCATTGGCTGCTGGACCCCCATGATGGCCGGCGGCTGGCCGTGCGCTTCA  
CAGCCCTGGACTTGGGCTTTGGAGATGCAGTGCATGTGTATGACGGCCCTGGGCCCCCTGAGAGCT  
CCCGACTACTGCGTAGTCTCACCCACTTCAGCAATGGCAAGGCTGTCACTGTGGAGACACTGTCTG  
GCCAGGCTGTTGTGTCTTACCACACAGTTGCTTGGAGCAATGGTTCGTGGCTTCAATGCCACCTACC  
ATGTGCGGGGCTATTGCTTGCCTTGGGACAGACCCCTGTGGCTTAGGCTCTGGCCTGGGAGCTGGCG  
AAGGCCTAGGTGAGCGCTGCTACAGTGAGGCACAGCGCTGTGACGGCTCATGGGACTGTGCTGACG  
GCACAGATGAGGAGGACTGCCCAGGCTGCCACCTGGACACTTCCCCTGTGGGGCTGCTGGCACCT  
CTGGTGCCACAGCCTGCTACCTGCCTGCTGACCGCTGCAACTACCAGACTTTCTGTGCTGATGGAG  
CAGATGAGAGACGCTGTGCGCATTGCCAGCCTGGCAATTTCCGATGCCGGGACGAGAAGTGCGTGT  
ATGAGACGTGGGTGTGCGATGGGCAGCCAGACTGTGCGGACGGCAGTGATGAGTGGGACTGCTCCT  
ATGTTCTGCCCCGCAAGGTCATTACAGCTGCAGTCATTGGCAGCCTAGTGTGCGGCCTGCTCCTGG  
TCATCGCCCTGGGCTGCACCTGCAAGCTCTATGCCATTGCGACCCAGGAGTACAGCATCTTTGCC  
CCCTCTCCCGGATGGAGGCTGAGATTGTGACAGCAGGACCCCTTCTACGGGCAGCTCATTG  
CCCAGGGTGCCATCCCACCTGTAGAAGACTTTCTCAGACAGAAATCCTAATGATAACTCAGTCTGG  
GCAACCTGCGTTCTCTGCTACAGATCTTACGCCAGGATATGACTCCAGGAGGTGGCCAGGTGCC  
GCCGTGCTCAGCGGGGCGCTTGTGACGACGCTGGTACGCCGTCTCCGCCGTGGGGCTTGTCTCC  
CTCGAACCAACACCCCGGCTCGGGCCTCTGAGGCCAGATCCCAGGTACACCTTCTGCTGCTCCCC  
TTGAGGCCCTAGATGGTGGCACAGGTCCAGCCGTGAGGGCGGGGAGTGGGTGGGCAAGATGGGG  
AGCAGGCACCCCCACTGCCCATCAAGGCTCCCCTCCCATCTGCTAGCACGTCTCCAGCCCCACTA  
CTGTCCCTGAAGCCCCAGGGCCACTGCCCTCACTGCCCTAGAGCCATCACTATTGTCTGGAGTGG  
TGCAGGCCCTGCGAGGCCGCTGTGCCCAGCCTGGGGCCCCCAGGACCAACCCGGAGCCCCCTG  
GACCCACACAGCAGTCCCTGGCCCTGGAAGATGAGGACGATGTGCTACTGGTGCCACTGGCTGAGC  
CGGGGGTGTGGGTAGCTGAGGCAGAGGATGAGCCACTGCTTACCTGAGGGGACCTGGGGGCTCTAC  
TGAGGCCTCTCCCCTGGGGGCTCTACTCATAGTGGCACAACCTTTTAGAGGTGGGTGAGCCTCCCC  
TCCACCACTTCTTCCCTGTCCCTGGATTTCAGGGACTTGGTGGGCCTCCCGTTGACCCTATGTAG  
CTGCTATAAAGTTAAGTGTCCCTCAGGCAGGGAGAGGGCTCACAGAGTCTCCTCTGTACGTGGCCA  
TGGCCAGACACCCAGTCCCTTACCACCACCTGCTCCCCACGCCACCACCATTTGGGTGGCTGTT  
TTTAAAAGTAAAGTTCTTAGAGGATCATTAGTCTGGACACTCCATCCTTGCCAAACCTTACCCA  
AAAGTGGCCTTAAGCACCGGAATGCCAATTAAGTACAGACCTCCAGCCCCCAAGGGGAGGATTG  
GGCAGAACCTGAGGTTTTGCCATCCACAATCCCTCCTACAGGGCCTGGCTCACAAAAGAGTGCAA  
CAAATGCTTCTATTCCATAGCTACGGCATTGCTCAGTAAGTTGAGGTCAAAAATAAGGAATCATA  
CATCTC

82/392

**FIGURE 80**

MLLATLLLLLLGGALAHDPRIIFPNHACEDPPAVLLEVGTLQRPLVRDSRTSPANCTWL  
ILGSKEQTVTIRFQKLHLACGSERLTLSPLQPLISLCEAPPSPLQLPGGNVTITYSYAG  
ARAPMGQGFLLSYSQDWLMCLQEEFQCLNHRCVSAVQRCDGVDACGDGSDEAGCSSDPFP  
GLTPRPVPSLPCNVTLEDFYGVFSSPGYTHLASVSHPOSCHWLLDPHDGRRLAVRFTALD  
LGFGDAVHVYDGPGPPESSRLLRSLTHFSNGKAVTVETLSGQAVVSYHTVAWSNGRGFNA  
TYHVRGYCLPWDRPCGLGSGLGAGEGLGERCYSEAQRCDGSWDCADGTDEEDCPGCPPGH  
FPCGAAGTSGATACYLPADRCNYQTFCADGADERRCRHCQPGNFRRCRDEKCVYETWVCDG  
QPCADGSDEWDCSYVLPRKVITA AVIGSLVCGLLLVIALGCTCKLYAIRTQEYSIFAPL  
SRMEAEIVQQQAPPSYGQLIAQGAIPPVEDFPTENPNDNSVLGNLRSLLQILRQDMTPGG  
GPGARRRQGRMLMRRLVRRLRRWGLLPRTNTPARASEARSQVTPSAAPLEALDGGTGPAR  
EGGAVGGQDGEQAPPLPIKAPLPSASTSPAPTTVPEAPGPLPSLPLEPSLLSGVVQALRG  
RLLPSLGPFGPTRSPPGPHTAVLALEDEDDVLLVPLAEPGVWVAEAEDEPLLT

**Important features:**

**Signal peptide:**

amino acids 1-16

**Transmembrane domain:**

amino acids 442-462

**LDL-receptor class A (LDLRA) domain proteins:**

amino acids 411-431, 152-171, 331-350 and 374-393

83/392

**FIGURE 81**

CTTCTGTGCTGTTCCCTTCTTGCCTCTAACTTGTAACAAGACGTACTAGGACGATGCTAA  
TGGAAGTCAAAACCGCTGGGTTTTTGAAAGGATCCTTGGGACCTCATGCACATTTGTG  
GAACTGGATGGAGAGATTTGGGGAAGCATGGACTCTTTAGCCAGCTTAGTTCTCTGTGG  
AGTCAGCTTGCTCCTTTCTGGAAGTGTGGAAGGTGCCATGGACTTGATCTTGATCAATTC  
CCTACCTCTTGTATCTGATGCTGAAACATCTCTCACCTGCATTGCCTCTGGGTGGCGCCC  
CCATGAGCCCATCACCATAGGAAGGGACTTTGAAGCCTTAATGAACCAGCACCAGGATCC  
GCTGGAAGTTACTCAAGATGTGACCAGAGAATGGGCTAAAAAAGTTGTTTGGAAAGAGAGA  
AAAGGCTAGTAAGATCAATGGTGCTTATTTCTGTGAAGGGCGAGTTCGAGGAGAGGCAAT  
CAGGATACGAACCATGAAGATGCGTCAACAAGCTTCCTTCCTACCAGCTACTTTAACTAT  
GACTGTGGACAAGGGAGATAACGTGAACATATCTTTCAAAAAGGTATTGATTAAAGAAGA  
AGATGCAGTGATTTACAAAAATGGTTCCTTCATCCATTCAGTGCCCCGGCATGAAGTACC  
TGATATTCTAGAAGTACACCTGCCTCATGCTCAGCCCCAGGATGCTGGAGTGTACTCGGC  
CAGGTATATAGGAGGAAACCTCTTCACCTCGGCCTTCACCAGGCTGATAGTCCGGAGATG  
TGAAGCCCAGAAGTGGGGACCTGAATGCAACCATCTCTGTACTGCTTGTATGAACAATGG  
TGTCTGCCATGAAGATACTGGAGAATGCATTTGCCCTCCTGGGTTTATGGGAAGGACGTG  
TGAGAAGGCTTGTGAAGTGCACACGTTTGGCAGAACTTGTAAGAAAGGTGCAGTGGACA  
AGAGGGATGCAAGTCTTATGTGTTCTGTCTCCCTGACCCCTATGGGTGTTCTCTGTGCCAC  
AGGCTGGAAGGGTCTGCAGTGCAATGAAGCATGCCACCCTGGTTTTTACGGGCCAGATTG  
TAAGCTTAGGTGCAGCTGCAACAATGGGGAGATGTGTGATCGCTTCCAAGGATGTCTCTG  
CTCTCCAGGATGGCAGGGGCTCCAGTGTGAGAGAGAAGGCATACCGAGGATGACCCCAA  
GATAGTGGATTTGCCAGATCATATAGAAGTAAACAGTGGTAAATTTAATCCCATTGTCAA  
AGCTTCTGGCTGGCCGCTACCTACTAATGAAGAAATGACCCTGGTGAAGCCGGATGGGAC  
AGTGCTCCATCCAAAAGACTTTAAACCATACGGATCATTTCCTCAGTAGCCATATTCACCAT  
CCACCGGATCCTCCCCCTGACTCAGGAGTTTGGGTCTGCAGTGTGAACACAGTGGCTGG  
GATGGTGGAAAAGCCCTTCAACATTTCTGTAAAGTTCTTCCAAAGCCCCTGAATGCCCC  
AAACGTGATTGACACTGGACATAACTTTGCTGTCAACATCAGCTCTGAGCCTTACTT  
TGGGGATGGACCAATCAAATCCAAGAAGCTTCTATACAAACCCGTTAATCACTATGAGGC  
TTGGCAACATATTCAAGTGACAAATGAGATTGTTACACTCAACTATTTGGAACCTCGGAC  
AGAATATGAACTCTGTGTGCAACTGGTCCGTGCGTGGAGAGGGTGGGGAAGGGCATCCTGG  
ACCTGTGAGACGCTTCACAACAGCTTCTATCGGACTCCCTCCTCCAAGAGGTCTAAATCT  
CCTGCCTAAAAGTCAGACCACTCTAAATTTGACCTGGCAACCAATATTTCCAAGCTCGGA  
AGATGACTTTTATGTTGAAGTGGAGAGAAGGTCTGTGCAAAAAAGTGATCAGCAGAATAT  
TAAAGTTCAGGCAACTTGACTTCGGTGCTACTTAACAACCTTACATCCCAGGGAGCAGTA  
CGTGGTCCGAGCTAGAGTCAACACCAAGGCCAGGGGAATGGAGTGAAGATCTCACTGC  
TTGGACCCTTAGTGACATTCTTCCTCCTCAACCAGAAAACATCAAGATTTCCAACATTAC  
ACACTCCTCGGCTGTGATTTCTTGGACAATATTGGATGGCTATTCTATTTCTTCTATTAC  
TATCCGTTACAAGGTTCAAGGCAAGAATGAAGACCAGCACGTTGATGTGAAGATAAAGAA  
TGCCACCATCATTCAGTATCAGCTCAAGGGCCTAGAGCCTGAAACAGCATACCAGGTGGA  
CATTTTGTGAGAGAACAACATAGGGTCAAGCAACCCAGCCTTTTCTCATGAACTGGTGAC  
CCTCCAGAAATCTCAAGCACCAGCGGACCTCGGAGGGGGGAAGATGCTGCTTATAGCCAT  
CCTTGGCTCTGCTGGAATGACCTGCCTGACTGTGCTGTTGGCCTTTCTGATCATATTGCA  
ATTGAAGAGGGCAAATGTGCAAAGGAGAATGGCCCAAGCCTTCCAAAACGTGAGGGAAGA  
ACCAGCTGTGCAGTTCAACTCAGGGACTCTGGCCCTAAACAGGAAGGTCAAAAACAACCC  
AGATCCTACAATTTATCCAGTGCTTGACTGGAATGACATCAAATTTCAAGATGTGATTGG  
GGAGGGCAATTTTGGCCAAGTTCTTAAGGCGCGCATCAAGAAGGATGGGTACGGATGGA  
TGCTGCCATCAAAAGAATGAAAGAATATGCCTCCAAGATGATCACAGGGACTTTGCAGG  
AGAACTGGAAGTTCTTTGTAAACTTGGACACCATCCAACATCATCAATCTCTTAGGAGC

84/392

ATGTGAACATCGAGGCTACTTGTACCTGGCCATTGAGTACGCGCCCCATGGAAACCTTCT  
GGACTTCCTTCGCAAGAGCCGTGTGCTGGAGACGGACCCAGCATTTGCCATTGCCAATAG  
CACCGCGTCCCACTGTCCTCCAGCAGCTCCTTCACTTCGCTGCCGACGTGGCCCGGGG  
CATGGACTACTTGAGCCAAAAACAGTTTATCCACAGGGATCTGGCTGCCAGAAACATTTT  
AGTTGGTGAAAACATATGTGGCAAAAATAGCAGATTTTGGATTGTCCCGAGGTCAAGAGGT  
GTACGTGAAAAAGACAATGGGAAGGCTCCCACTGCGCTGGATGGCCATCGAGTCACTGAA  
TTACAGTGTGTACACAACCAACAGTGATGTATGGTCCTATGGTGTGTTACTATGGGAGAT  
TGTTAGCTTAGGAGGCACACCCTACTGCGGGATGACTTGTGCAGAACTCTACGAGAAGCT  
GCCCCAGGGCTACAGACTGGAGAAGCCCCCTGAACGTGTGATGATGAGGTGTATGATCTAAT  
GAGACAATGCTGGCGGGAGAAGCCTTATGAGAGGCCATCATTTGCCCAGATATTGGTGTCT  
CTTAAACAGAATGTTAGAGGAGCGAAAGACCTACGTGAATACCACGCTTTATGAGAAGTT  
TACTTATGCAGGAATTGACTGTTCTGCTGAAGAAGCGGCCTAGGACAGAACATCTGTATA  
CCCTCTGTTTCCCTTTCCTGTCATGGGAGACCCTTGACAACCTGCTGAGAAAACATGCCT  
CTGCCAAAGGATGTGATATATAAGTGTACATATGTGCTGGAATTCTAACAAGTCATAGGT  
TAATATTTAAGACACTGAAAAATCTAAGTGATATAAATCAGATTCTTCTCTCTCATTTTA  
TCCCTCACCTGTAGCATGCCAGTCCCGTTTCATTTAGTCATGTGACCACTCTGTCTTG  
TTTCCACAGCCTGCAAGTTCAGTCCAGGATGCTAACATCTAAAAATAGACTTAAATCTCA  
TTGCTTACAAGCCTAAGAATCTTTAGAGAAGTATACATAAGTTTAGGATAAAATAATGGG  
ATTTTCTTTTCTTTTCTCTGGTAATATTGACTTGTATATTTTAAGAAATAACAGAAAGCC  
TGGGTGACATTTGGGAGACATGTGACATTTATATATTGAATTAATATCCCTACATGTATT  
GCACATTGTAAAAAGTTTGTAGTTTGTGAGTTGTGAGTTTACCTTGTATACTGTAGGCA  
CACTTTGCACTGATATATCATGAGTGAATAAATGTCTTGCCTACTCAAAAAAAAAAAAA

85/392

**FIGURE 82**

MDSLASLVLCGVSLLLSGTVEGAMDILILINSLPLVSDAETSLTCIASGWRPHEPITIGRD  
FEALMNQHQDPLEVTQDVTREWAKKVWVKREKASKINGAYFCEGRVVRGEAIRITMKMRQ  
QASFLPATLTMTVDKGDVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPH  
AQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNGVCHEDTGEC  
ICPPGFMGRTCEKACELHTFGRTCKERC SGQEGCKSYVFCLPDYPYGCSCATGWKGLQCNE  
ACHPGFYGPDCKLRCSNNGEMCDRFQGCCLSPGWQGLQCEREGIPRMTPKIVDLPDHIE  
VNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSG  
VWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFVINISSEPYFGDGPIKSKK  
LLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTAS  
IGLPPPRGLNLLPKSQTTNLNTWQPIFPSSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSV  
LLNNLHPPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWT  
ILDGYSISSITIRYKVQGNEDQHV DVKIKNATIIQYQLKGLEPETAYQVDIFAENNIGS  
SNPAFSHELVTLPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQLKRANVQRR  
MAQAFQNVREEPVQFNSGTLALNRKVKNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLK  
ARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHPNIINLLGACEHRGYLYL  
AIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQF  
IHRDLAARNILVGENVAKIADFGLSRGQEVYVKKTMGRPLPVRWMAIESLNYSVYTTNSD  
VWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPGQYRLEKPLNCDDEVYDLMRQCWREKPY  
ERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEAAA

**Signal sequence:**

1-38

**Transmembrane domain:**

750-770

**N-glycosylation site:**140-143, 158-161, 399-402, 438-441, 464-467, 560-563, 596-  
599, 649-652, 691-694, 930-933, 1011-1014, 1104-1107**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

534-537

**Tyrosine kinase phosphorylation site:**

149-156, 808-816, 1094-1102

**N-myristoylation site:**18-23, 98-103, 187-192, 196-201, 270-275, 286-291, 295-300,  
420-425, 595-600, 984-989, 1036-1041, 1041-1046, 1115-1120**Prokaryotic membrane lipoprotein lipid attachment site:**

882-892



86/392

EGF-like domain cysteine pattern signature:

240-251, 287-298, 329-340

Tyrosine protein kinases specific active-site signature:

960-972

Protein kinase domain:

824-1092

Fibronectin type III domain:

444-529, 543-626, 639-724

EGF-like domain:

220-251, 268-298

laminin\_EGF Laminin EGF-like (Domains III and V):

219-268

Immunoglobulin domain:

156-193

Zinc finger:

295-313

Receptor tyrosine kinase:

844-868, 869-898, 936-982, 986-1024, 1025-1052, 1052-1088

87/392

## FIGURE 83

CGCGCCGGGCGCAGGGAGCTGAGTGGACGGCTCGAGACGGCGGCGCGTGCAGCAGCTCCA  
GAAAGCAGCGAGTTGGCAGAGCAGGGCTGCATTTCCAGCAGGAGCTGCGAGCACAGTGCT  
GGCTCACAACAAGATGCTCAAGGTGTCAGCCGTACTGTGTGTGTGTGCAGCCGCTTGGTG  
CAGTCAGTCTCTCGCAGCTGCCGCGGCGGTGGCTGCAGCCGGGGGGCGGTCCGACGGCGG  
TAATTTTCTGGATGATAAACAATGGCTCACCACAATCTCTCAGTATGACAAGGAAGTCGG  
ACAGTGGAAACAAATTCCGAGACGAAGTAGAGGATGATTATTTCCGCACTTGGAGTCCAGG  
AAAACCCTTCGATCAGGCTTTAGATCCAGCTAAGGATCCATGCTTAAAGATGAAATGTAG  
TCGCCATAAAGTATGCATTGCTCAAGATTCTCAGACTGCAGTCTGCATTAGTCACCGGAG  
GCTTACACACAGGATGAAAGAAGCAGGAGTAGACCATAGGCAGTGGAGGGGTCCCATATT  
ATCCACCTGCAAGCAGTGCCAGTGGTCTATCCAGCCCTGTTTGTGGTTTCAGATGGTCA  
TACCTACTCTTTTCAGTGCAAACTAGAATATCAGGCATGTGTCTTAGGAAAACAGATCTC  
AGTCAAATGTGAAGGACATTGCCCCATGTCCTTCAGATAAGCCCACCAGTACAAGCAGAAA  
TGTTAAGAGAGCATGCAGTGACCTGGAGTTCAGGGAAGTGGCAAACAGATTGCGGGACTG  
GTTCAAGGCCCTTCATGAAAGTGGAAGTCAAAAACAAGAAGACAAAAACATTGCTGAGGCC  
TGAGAGAAGCAGATTTCGATACACAGCATCTTGCCAAATTTGCAAGGACTCACTTGGCTGGAT  
GTTTAACAGACTTGATACAACTATGACCTGCTATTGGACCAGTCAGAGCTCAGAAGCAT  
TTACCTTGATAAGAATGAACAGTGTACCAAGGCATTCTTCAATTCTTGTGACACATACAA  
GGACAGTTTAAATATCTAATAATGAGTGGTGCTACTGCTTCAGAGACAGCAAGACCCACC  
TTGCCAGACTGAGCTCAGCAATATTCAGAAGCGGCAAGGGGTAAAGAAGCTCCTAGGACA  
GTATATCCCCCTGTGTGATGAAGATGGTTACTACAAGCCAACACAATGTCATGGCAGTGT  
TGGACAGTGCTGGTGTGTTGACAGATATGGAAATGAAGTCATGGGATCCAGAATAAATGG  
TGTTGCAGATTGTGCTATAGATTTTGAGATCTCCGGAGATTTTGCTAGTGGCGATTTTCA  
TGAATGGACTGATGATGAGGATGATGAAGACGATATTATGAATGATGAAGATGAAATTGA  
AGATGATGATGAAGATGAAGGGGATGATGATGATGGTGGTATGACCATGATGTATACAT  
TTGATTGATGACAGTTGAAATCAATAAATTCTACATTTCTAATATTTACAAAAATGATAG  
CCTATTTAAAATTATCTTCTTCCCCAATAACAAAATGATTCTAAACCTCACATATATTTT  
GTATAATTATTTGAAAAATTGCAGCTAAAGTTATAGAAGCTTTATGTTTAAATAAGAATCA  
TTTGCTTTGAGTTTTTTATATTCCTTACACAAAAAGAAAATACATATGCAGTCTAGTCAGA  
CAAAATAAAGTTTTGAAAGTGCTACTATAATAAATTTTTTCACGAGAACAACTTTGTAAAT  
CTTCATAAGCAAAATGACAGCTAGTGCTTGGGATCGTACATGTTAATTTTTTTGAAAGAT  
AATTCTAAGTGAATTTTAAATAAATAAATTTTTTAATGACCTGGGTCTTAAGGATTTAGG  
AAAAATATGCATGCTTTAATTGCATTTCCAAAGTAGCATCTTGCTAGACCTAGATGAGTC  
AGGATAACAGAGAGATACCACATGACTCCAAAAAAAAAAAAAAAAA

88/392

**FIGURE 84**

MLKVSAVLCVCAAAWCSQSLAAAAVAAAGGRSDGGNFLDDKQWLTTISQYDKEVGQWNK  
FRDEVEDDYFRTWSPGKPFQALDPAKDPCLKMKCSRHKVCIAQDSQTAVCISHRRLTHR  
MKEAGVDHRQWRGPILSTCKQCPVVYPSPVCGSDGHTYSFQCKLEYQACVLGKQISVKCE  
GHCPSPDKPTSTSRNVKRACSDLEFREVANRLRDWFKALHESGSQNKKTKTLLRPERSR  
FDTSILPICKDSLGMFNRDLDTNYDLLLDQSELRSIYLDKNEQCTKAFFNSCDTYKDSL  
SNNEWCYCFQRQQDPPCQTELSNIQKRQGVKKLLGQYIPLCDEDGYKPTQCHGSVGQCW  
CVDRYGNEVMGSRINGVADCAIDFEISGDFASGDFHEWTDDEDEDDIMNDEDEIEDDDE  
DEGDDDDGGDDHDVYI

**Important features:****Signal peptide:**

amino acids 1-16

**Leucine zipper pattern:**

amino acids 246-267

**N-myristoylation sites:**

amino acids 357-362, 371-376 and 376-381

**Thyroglobulin type-1 repeat proteins:**

amino acids 353-365 and 339-352

89/392

**FIGURE 85**

CCCACGCGTCCGGCACTGCAGTCTCCAGCCTGAGCCATGGGCGCGCGAGCCCTCCTGCTC  
CTGCTTCTGTCTTTTCTGGCGCCCTGGGCCACCATAGCCCTCCGGCCGGCCTTAAGGGCC  
CTCGGCAGCCTACACTTGCCAACCAACCCACATCCCTCCCGGCTGTAGCCAAGAACTAT  
TCGGTTCTCTACTTCCAACAGAAGGTTGATCATTTTGGATTTAATACTGTGAAAACTTT  
AATCAGCGGTACCTAGTAGCTGATAAATACTGGAAGAAAAATGGTGGATCAATACTTTTC  
TACACTGGTAATGAAGGGGACATTATCTGGTTTTGTAAATAACACGGGGTTCATGTGGGAT  
GTGGCTGAGGAACTGAAAGCTATGTTGGTGTGTGCTGAACATCGATACTATGGAGAGTCT  
CTCCCCCTTTGGTGACAACCTCATTCAAGGATTCCAGACACTTGAATTTCTGACATCAGAA  
CAAGCTCTGGCTGATTTTGCAGAGTTAATCAAACACTTGAAAAGAACAAATCCAGGAGCT  
GAAAATCAACCTGTCAATTGCCATAGGAGGCTCCTATGGTGGCATGCTTGCCGCTGGTTT  
AGGATGAAATATCCTCATATGGTAGTTGGAGCTCTTGACAGCTTCTGCCCCCTATCTGGCAG  
TTTGAGGATTTAGTACCTTGTGGTGTATTTATGAAGATCGTAACTACAGATTTTAGGAAA  
AGCGGTCCACATTGTTTCAGAGAGCATCCACAGGTCCTGGGATGCCATTAATCGACTCTCA  
AATACTGGCAGTGGTTTGCAGTGGCTTACTGGAGCCCTTCACTTATGCAGCCCATTAAC  
TCTCAGGACATCCAACATTTGAAAAGACTGGATCTCTGAAACCTGGGTGAATCTGGCAATG  
GTGGACTATCCTTATGCCTCTAACTTTTTACAGCCTTTGCCTGCTTGGCCTATCAAGGTA  
GTGTGCCAGTATTTGAAAAATCCCAATGTATCTGATTCATGCTGCTGCAGAATATTTTC  
CAAGCTCTGAATGTATATTACAATTATTCGGGCCAGGTGAAATGCCTGAATATTTTCAGAG  
ACAGCAACTAGCAGTCTGGGAACACTGGGTTGGAGCTATCAGGCCTGCACAGAACTAGTC  
ATGCCCTTTTGTACTAATGGTGTGATGACATGTTTGAACCTCACTCATGGAACTTAAAG  
GAACTTTCTGATGACTGTTTTCAACAGTGGGGTGTGAGACCAAGGCCCTCCTGGATCACT  
ACTATGTATGGAGGCAAAAACATTAGTTTACACACAAAACATTGTTTTTTCAGCAATGGTGAA  
CTAGACCCCTGGTCAGGAGGTGGAGTAACTAAGGATATCACAGACACTCTGGTTGCAGTC  
ACCATCTCAGAGGGGGGCCACCACTTAGATCTCCGCACCAAGAATGCCTTGGATCCTATG  
TCTGTGCTGTTAGCCCGCTCCTTGGAAAGTTAGACATATGAAGAATTGGATCAGAGATTT  
TATGACAGTGCGGGAAAGCAGCACTGAGAAACTTTTGATTGTTTTCAATTTCTTCTTTTA  
TGTTTCACACCACCACATTCCCATTCACTTTGATTTTCTACATGTAATTACCTTCTTTTGT  
TTATCATTAGATTTGATGGGGCCAAAGTTGAGATAGAATAGAGGGTGATGACGGTAAGAG  
CAAGTGTCCCATGAATGTGATTTCTGGGTTCTCACTGTCCTTTGCACCACGTCTAGGAA  
GAATCTTCTTGATAGCTCTCCACACCATCAGTGGCCCTCATAACTGGAGTAGAGTTCCT  
GGTTGCTTTTCATAAGAGGGAGAGTTACTTTC

90/392

**FIGURE 86**

MGRRALLLLLLSFLAPWATIALRPALRALGSLHLPTNPTSLPAVAKNYSVLYFQOKVDHF  
GFNTVKTFFNQRYLVADKYWKKNSSILFYTGNEGDIWFCNNTGFMWDVAEELKAMLVFA  
EHRYYGESLPFGDNSFKDSRHLNFLTSEQALADFAELIKHLKRTIPGAENQPVIAIGGSY  
GGMLAAWFRMKYPHVMVGALAASAPIWQFEDLVPCGVFMKIVTTDFRKSGPHCSESIHRS  
WDAINRLSNTGSGLOWLTGALHLCSPLTSQDIQHLKDWISETWVNLAMVDYPYASNFLQP  
LPAWPIKVVCQYLKNPNVSDSLLLQNIQALNVYYNYSQGVKCLNISETATSSLGTLGWS  
YQACTEVVMPFCTNGVDDMFEPHSWNLKELSDDCFQQWGVPRPSWITTMYGKNISSHT  
NIVFSNGELDPWSGGGVTKDITDTLVAVTISEGAHHLDLRTKNALDPMSVLLARSLEVRH  
MKNWIRDFYDSAGKQH

**Signal sequence:**

1-18

**Transmembrane domain:**

None

**N-glycosylation site:**

47-50, 101-104, 317-320, 336-339, 345-348, 415-418

**Glycosaminoglycan attachment site:**

433-436

**N-myristoylation site:**

178-183, 181-186, 182-187, 198-203, 339-344, 434-439

**Amidation site:**

1-4

**alpha/beta hydrolase fold:**

115-372

91/392

**FIGURE 87**

GGCGGCGTCCGTGAGGGGCTCCTTTGGGCAGGGGTAGTGTGTTGGTGTCCCTGTCTTGCGT  
GATATTGACAACTGAAGCTTTCCTGCACCACTGGACTTAAGGAAGAGTGACTCGTAGG  
CGGACAGCTTTAGTGGCCGGCCGGCCGCTCTCATCCCCCGTAAGGAGCAGAGTCCTTTGT  
ACTGACCAAGATGAGCAACATCTACATCCAGGAGCCTCCACGAATGGGAAGGTTTTATT  
GAAACTACAGCTGGAGATATTGACATAGAGTTGTGGTCCAAAGAAGCTCCTAAAGCTTG  
CAGAAATTTTATCCAACCTTTGTTTGGAAGCTTATTATGACAATACCATTTTTCATAGAGT  
TGTGCCTGGTTTCATAGTCCAAGGCGGAGATCCTACTGGCACAGGGAGTGGTGGAGAGTC  
TATCTATGGAGCGCCATTCAAAGATGAATTTTCATTACGGTTGCGTTTTAATCGGAGAGG  
ACTGGTTGCCATGGCAAATGCTGGTTCTCATGATAATGGCAGCCAGTTTTTCTTCACACT  
GGGTCGAGCAGATGAACTTAACAATAAGCATACCATCTTTGGAAAAGTTACAGGGGATAC  
AGTATATAACATGTTGCGACTGTCAGAAGTAGACATTGATGATGACGAAAGACCACATAA  
TCCACACAAAATAAAAAAGCTGTGAGGTTTTGTTTAAATCCTTTTGATGACATCATTTCCAAG  
GGAAATTAAAAGGCTGAAAAAAGAGAAACCAGAGGAGGAAGTAAAGAAATTGAAACCCAA  
AGGCACAAAAAATTTTAGTTTTACTTTTCATTTGGAGAGGAAGCTGAGGAAGAAGAGGAGGA  
AGTAAATCGAGTTAGTCAGAGCATGAAGGGCAAAGCAAAAGTAGTCATGACTTGCTTAA  
GGATGATCCACATCTCAGTTCTGTTCCAGTTGTAGAAAAGTAAAAAAGGTGATGCACCAGA  
TTTAGTTGATGATGGAGAAGATGAAAGTGCAGAGCATGATGAATATATTGATGGTGATGA  
AAAGAACCTGATGAGAGAAAGAATTGCCAAAAAATTAAAAAAGGACACAAAGTGCGAATGT  
TAAATCAGCTGGAGAAGGAGAAGTGGAGAAGAAATCAGTCAGCCGAGTGAAGAGCTCAG  
AAAAGAAGCAAGACAATTAAAACGGGAACCTTAGCAGCAAAACAAAAAAGTAGAAAA  
TGCAGCAAAACAAGCAGAAAAAAGAAAGTGAAGAGGAAGAAGCCCCCTCAGATGGTGCTGT  
TGCCGAATACAGAAGAGAAAAGCAAAAGTATGAAGCTTTGAGGAAGCAACAGTCAAAGAA  
GGGAACCTTCCCGGGAAGATCAGACCCTTGCACTGCTGAACCAGTTTAAATCTAAACTCAC  
TCAAGCAATTGCTGAAACACCTGAAAATGACATTCCTGAAACAGAAAGTAGAAGATGATGA  
AGGATGGATGTCACATGTACTTTCAGTTTTGAGGATAAAAGCAGAAAAGTGAAAGATGCAAG  
CATGCAAGACTCAGATACATTTGAAATCTATGATCCTCGGAATCCAGTGAATAAAAGAAG  
GAGGGAAGAAAGCAAAAAGCTGATGAGAGAGAAAAAAGAAAGAAGATAAAATGAGAATAA  
TGATAACCAGAACTTGCTGGAAATGTGCCTACAATGGCCTTGTAACAGCCATTGTTCCCA  
ACAGCATCACTTAGGGGTGTGAAAAGAAGTATTTTTGAACCTGTTGTCTGGTTTTGAAAA  
ACAATTATCTTGTGTTTTCGAAATTGTGGAATGATGTAAGCAAATGCTTTTGGTTACTGGTA  
CATGTGTTTTTTCCTAGCTGACCTTTTATATTGCTAAATCTGAAATAAAATAACTTTCTT  
TCCACAAAAA

92/392

**FIGURE 88**

MSNIYIQEPPTNGKVLLKTTAGDIDIELWSKEAPKACRNFIQLCLEAYYDNTIFHRVVP  
FIVQGGDPTGTGSGGESIYGAPFKDEFHSRLRFNRRGLVAMANAGSHDNGSQFFFTLGRA  
DELNNKHTIFGKVTGDTVYNMLRLSEVDIDDERPHNPHKIKSCEVLFPFDDIIPREIK  
RLKKEKPEEEVKKLKPKGTKNFSLLSFGEAEAEAEAEAEVNRVSQSMKGKSKSSHDLKDDP  
HLSSVPVVESEKGDAPDLVDDGEDESAEHDEYIDGDEKNLMRERIAKKLKKDTSANVKS  
GEGEVEKKSVSRSEELRKEARQLKRELLAAKQKKVENAAKQAEKRSEEEEAPPDGAVAEY  
RREKQKYEALRKQQSKGTSREDQTLALLNQFKSKLTQAI AETPENDIPETEVEDDEGWM  
SHVLQFEDKSRKVKDASMQSDTFEIIDPRNPVNKRREESKKLMREKKERR

**Important features:****Signal peptide:**

amino acids 1-21

**N-glycosylation sites:**

amino acids 109-112 and 201-204

**Cyclophilin-type peptidyl-prolyl cis-trans isomerase****signature:**

amino acids 49-66

**Homologous region to Cyclophilin-type peptidyl-prolyl cis-trans isomerase:**

amino acids 96-140, 49-89 and 22-51

93/392

**FIGURE 89**

CCCGGCTCCGCTCCCTCTGCCCCCTCGGGGTCGCGCGCCACGATGCTGCAGGGCCCTGG  
CTCGCTGCTGCTGCTCTTCCTCGCCTCGCACTGCTGCCTGGGCTCGGCGCGCGGGCTCTT  
CCTCTTTGGCCAGCCCGACTTCTCCTACAAGCGCAGCAATTGCAAGCCCATCCCGGTCAA  
CCTGCAGCTGTGCCACGGCATCGAATACCAGAACATGCGGCTGCCCAACCTGCTGGGCCA  
CGAGACCATGAAGGAGGTGCTGGAGCAGGCCGCGCTTGATCCCGCTGGTCATGAAGCA  
GTGCCACCCGGACACCAAGAAGTTCCTGTGCTCGCTCTTCGCCCCCGTCTGCCTCGATGA  
CCTAGACGAGACCATCCAGCCATGCCACTCGCTCTGCGTGCAGGTGAAGGACCGCTGCGC  
CCCGGTCTGTCCGCCTTCGGCTTCCCCTGGCCCGACATGCTTGAGTGCGACCGTTTCCC  
CCAGGACAACGACCTTTGCATCCCCCTCGCTAGCAGCGACCACCTCCTGCCAGCCACCGA  
GGAAGCTCCAAAGGTATGTGAAGCCTGCAAAAATAAAAATGATGATGACAACGACATAAT  
GGAAACGCTTTGTAAAAATGATTTTGCACTGAAAATAAAAAGTGAAGGAGATAACCTACAT  
CAACCGAGATACCAAAATCATCCTGGAGACCAAGAGCAAGACCATTTACAAGCTGAACGG  
TGTGTCCGAAAGGGACCTGAAGAAATCGGTGCTGTGGCTCAAAGACAGCTTGCAGTGCAC  
CTGTGAGGAGATGAACGACATCAACGCGCCCTATCTGGTCTGCGGACAGAAACAGGGTGG  
GGAGCTGGTGATCACCTCGGTGAAGCGGTGGCAGAAGGGGCAGAGAGAGTTCAAGCGCAT  
CTCCCGCAGCATCCGCAAGCTGCAGTGCTAGTCCCGGCATCCTGATGGCTCCGACAGGCC  
TGCTCCAGAGCACGGCTGACCATTTCTGCTCCGGGATCTCAGCTCCCGTTCCCCAAGCAC  
ACTCCTAGCTGCTCCAGTCTCAGCCTGGGCAGCTTCCCCCTGCCTTTTGCACGTTTGCAT  
CCCCAGCATTTCTGAGTTATAAGGCCACAGGAGTGGATAGCTGTTTTACCTAAAGGAA  
AAGCCCACCCGAATCTTGTAGAAATATTCAAACATAATAAATCATGAATATTTTAA



94/392

**FIGURE 90**

MLQGPGLLLLLFLASHCCIGSARGLFLFGQPDFSYKRSNCKPIPVNLQLCHGIEYQNMRL  
PNLLGHETMKEVLEQAGAWIPLVMKQCHPDTKKFLCSLFAPVCLDDLDDETIQPCHS LCVQ  
VKDRCAPVMSAFGFPWPDMLECDRFPQDNDLCIPLASSDHLLPATEEAPKVCEACKNKND  
DDNDIMETLCKNDFALKIKVKEITYINRDTKIILETKSKTIYKLNGVSEDLKKSVLWLK  
DSLQCTCEEMNDINAPYLVMGQKQGGELVITSVKRWQKGQREFKRISRSIRKLQC

**Important features:**

**Signal peptide:**

amino acids 1-20

**Cysteine rich domain, homologous to frizzled N terminus:**

amino acids 6-153

95/392

**FIGURE 91**

GGAAGGGGAGGAGCAGGCCACACAGGCACAGGCCGGTGAGGGACCTGCCCAGACCTGGAG  
GGTCTCGCTCTGTACACAGGCTGGAGTGCAGTGGTGTGATCTTGGCTCATCGTAACCTC  
CACCTCCCGGGTTCAAGTGATTCTCATGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGT  
GGTGACTTCCAAGAGTGAATCCGTCGGAGGAAATGACTCCCCAGTCGCTGCTGCAGACG  
ACACTGTTCTGCTGAGTCTGCTCTTCTGCTGCAAGGTGCCACGGCAGGGGCCACAGG  
GAAGACTTTCGCTTCTGCAGCCAGCGGAACCAGACACACAGGAGCAGCCTCCACTACAAA  
CCCACACCAGACCTGCGCATCTCCATCGAGAACTCCGAAGAGGCCCTCACAGTCCATGCC  
CCTTTCCCTGCAGCCACCCCTGCTTCCCGATCCTTCCCTGACCCCAGGGGCTCTACCAC  
TTCTGCCTCTACTGGAACCGACATGCTGGGAGATTACATCTTCTCTATGGCAAGCGTGAC  
TTCTTGCTGAGTGACAAAGCCTCTAGCCTCCTCTGCTTCCAGCACCAGGAGGAGAGCCTG  
GCTCAGGGCCCCCGCTGTAGCCACTTCTGTACCTCCTGGTGAGCCCTCAGAACATC  
AGCCTGCCCAGTGCCGCCAGCTTCACCTTCTCCTTCCACAGTCCTCCCCACACGGCCGCT  
CACAATGCCTCGGTGGACATGTGCGAGCTCAAAGGGGACCTCCAGCTGCTCAGCCAGTTC  
CTGAAGCATCCCCAGAAGGCCTCAAGGAGGCCCTCGGCTGCCCCCGCCAGCCAGCAGTTG  
CAGAGCCTGGAGTCGAAACTGACCTCTGTGAGATTATGAGGGGACATGGTGCTCTTCGAG  
GAGGACCGGATCAACGCCACGGTGTGGAAGCTCCAGCCACAGCCGGCCTCCAGGACCTG  
CACATCCACTCCCGGCAGGAGGAGGAGCAGAGCGAGATCATGGAGTACTCGGTGCTGCTG  
CCTCGAACACTCTTCCAGAGGACGAAAGGCCGGAGCGGGGAGGCTGAGAAGAGACTCCTC  
CTGGTGACTTCAGCAGCCAAGCCCTGTTCCAGGACAAGAATTCAGCCAAGTCTTGGGT  
GAGAAGGTCTTGGGGATTGTGGTACAGAACACCAAAGTAGCCAACCTCACGGAGCCCGTG  
GTGCTCACTTTCAGCACCAGCTACAGCCGAAGAATGTGACTCTGCAATGTGTGTTCTGG  
GTTGAAGACCCACATTGAGCAGCCCGGGGCATTGGAGCAGTGCTGGGTGTGAGACCGTC  
AGGAGAGAAACCCAAACATCCTGCTTCTGCAACCACTTGACCTACTTTGCAGTGCTGATG  
GTCTCCTCGGTGGAGGTGGACGCCGTGCACAAGCACTACCTGAGCCTCCTCTCTACGTG  
GGCTGTGTCTCTGCCCCTGGCCTGCCTTGTCCACATTGCCGCTACCTCTGCTCCAGG  
GTGCCCCTGCCGTGCAGGAGGAAACCTCGGGACTACACCATCAAGGTGCACATGAACCTG  
CTGCTGGCCGTCTTCTGCTGGACACGAGCTTCTGCTCAGCGAGCCGGTGGCCCTGACA  
GGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATCTTCTGCACTTCTCCCTGCTCACCTGC  
CTTTCCTGGATGGGCCTCGAGGGGTACAACCTCTACCGACTCGTGGTGGAGGTCTTTGGC  
ACCTATGTCCCTGGCTACCTACTCAAGCTGAGCGCCATGGGCTGGGGCTTCCCCATCTTT  
CTGGTGACGCTGGTGGCCCTGGTGGATGTGGACAACTATGGCCCCATCATCTTGGCTGTG  
CATAGGACTCCAGAGGGCGTCATCTACCCTTCCATGTGCTGGATCCGGGACTCCCTGGTC  
AGCTACATCACCAACCTGGGCCTCTTACGCTGGTGTCTTCTGTTCAACATGGCCATGCTA  
GCCACCATGGTGGTGCAGATCCTGCGGCTGCGCCCCACACCCAAAAGTGGTCACATGTG  
CTGACACTGCTGGGCCTCAGCCTGGTCTTGGCCTGCCCTGGGCCTTGATCTTCTTCTCC  
TTTGCTTCTGGCACCTTCCAGCTTGTGCTCTACCTTTTCAGCATCATCACCTCCTTC  
CAAGGCTTCTCATCTTTCATCTGGTACTGGTCCATGCGGCTGCAGGCCCGGGGTGGCCCC  
TCCCCCTCTGAAGAGCAACTCAGACAGCGCCAGGCTCCCCATCAGCTCGGGCAGCACCTCG  
TCCAGCCGCATCTAGGCCTCCAGCCCACCTGCCATGTGATGAAGCAGAGATGCGGCCTC  
GTCCGCACTGCCTGTGGCCCCGAGCCAGGCCAGCCCCAGGCCAGTCAGCCGCAGACT  
TTGGAAAGCCCAACGACCATGGAGAGATGGGCCGTTGCCATGGTGGACGGACTCCCGGGC  
TGGGCTTTTGAATTGGCCTTGGGGACTACTCGGCTCTCACTCAGCTCCACGGGACTCAG  
AAGTGCGCCGCATGCTGCCTAGGGTACTGTCCCCACATCTGTCCCAACCCAGCTGGAGG  
CCTGGTCTCTCCTTACAACCCCTGGGCCAGCCCTCATTGCTGGGGGCCAGGCCTTGGAT  
CTTGAGGGTCTGGCACATCCTTAATCCTGTGCCCTGCCTGGGACAGAAATGTGGCTCCA  
GTTGCTCTGTCTCTCGTGGTCACCCCTGAGGGCACTCTGCATCCTCTGTCATTTTAACCTC  
AGGTGGCACCCAGGGCGAATGGGGCCAGGGCAGACCTTCAGGGCCAGAGCCCTGGCGGA

96/392

GGAGAGGCCCTTTGCCAGGAGCACAGCAGCAGCTCGCCTACCTCTGAGCCCAGGCCCCCT  
CCCTCCCTCAGCCCCCAGTCCCTCCCTCCATCTTCCCTGGGGTTCTCCTCCTCTCCCAGG  
GCCTCCTTGCTCCTTCGTTTACAGCTGGGGGTCCCCGATTCCAATGCTGTTTTTTGGGGA  
GTGGTTTTCCAGGAGCTGCCTGGTGTCTGCTGTAAATGTTTGTCTACTGCACAAGCCTCGG  
CCTGCCCCCTGAGCCAGGCTCGGTACCGATGCGTGGGCTGGGCTAGGTCCCTCTGTCCATC  
TGGGCCTTTGTATGAGCTGCATTGCCCTTGCTCACCCCTGACCAAGCACACGCCTCAGAGG  
GGCCCTCAGCCTCTCCTGAAGCCCTCTTGTGGCAAGAACTGTGGACCATGCCAGTCCCGT  
CTGGTTTTCCATCCCACCACTCCAAGGACTGAGACTGACCTCCTCTGGTGACACTGGCCTA  
GAGCCTGACACTCTCCTAAGAGGTTCTCTCCAAGCCCCCAAATAGCTCCAGGCGCCCTCG  
GCCGCCCATCATGGTTAATTCTGTCCAACAAACACACACGGGTAGATTGCTGGCCTGTTG  
TAGGTGGTAGGGACACAGATGACCGACCTGGTCACTCCTCCTGCCAACATTCACTCTGGT  
ATGTGAGGCGTGCGTGAAGCAAGAACTCCTGGAGCTACAGGGACAGGGAGCCATCATTCC  
TGCCTGGGAATCCTGGAAGACTTCCTGCAGGAGTCAGCGTTCAATCTTGACCTTGAAGAT  
GGGAAGGATGTTCTTTTTACGTACCAATTCTTTTGTCTTTTGATATTAAAAAGAAGTACA  
TGTTCAATTGTAGAGAATTTGGAAACTGTAGAAGAGAATCAAGAAGAAAAATAAAAATCAG  
CTGTTGTAATCGCCTAGCAA  
AAA

97/392

**FIGURE 92**

MTPQSLLQTTFLFLSLLFLVQGAHGRGHREDFRFCSQRNQTHRSSLHYKPTPDLRISIEN  
SEEALTVHAPFPAAHPASRSFPDPRGLYHFCLYWNRHAGRLHLLYGKRDFLLSDKASSLL  
CFQHQEESLAQGPPLLATSVTSWWSPQNISLPSAASFSTFSFHSPHTAAHNASVDMCELK  
RDLQLLSQFLKHPQKASRRPSAAPASQQLQSLESKLTSVRFMGDMVSFEEDRINATVWKL  
QPTAGLQDLHIHSRQEEEQSEIMEYSVLLPRTLFTQRTKGRSGEAEKRLLLVDFSSQALFQ  
DKNSSQVLGEKVLGIVVQNTKVANLTEPVVLTTFQHQQLQPKNVTLQCVFWVEDPTLSSPGH  
WSSAGCETVRRETQTSCFCNHLTYFAVLMVSSVEVDVAVHKHYLSLLSYVGCVVVSALACLV  
TIAAYLCSRVPLPCRKRPRDYTIKVHMNLLLAVFLLDTSFLLSEPVALTGSEAGCRASAI  
FLHFSLLTCLSWMGLEGYNLYRLVVEVFQTYVPGYLLKLSAMGWGFPIFLVTLVALVDVD  
NYGPILAVHRTPEGVIYPSMCWIRDSLVSYITNLGLFSLVFLFNMAMLATMVVQILRLR  
PHTQKWSHVLTLGLSLVLGLPWALIFFSFASGTFQLVVLVLFSLIITSFQGFIFIWYWS  
MRLQARGGPSPLKSNSDSARLPISSGSTSSRI

**Important features:****Signal peptide:**

amino acids 1-25

**Putative transmembrane domains:**amino acids 382-398, 402-420, 445-468, 473-491, 519-537,  
568-590 and 634-657**Microbodies C-terminal targeting signal:**

amino acids 691-693

**cAMP- and cGMP-dependent protein kinase phosphorylation sites:**

amino acids 198-201 and 370-373

**N-glycosylation sites:**amino acids 39-42, 148-151, 171-174, 234-237, 303-306, 324-  
327 and 341-344**G-protein coupled receptors family 2 proteins:**

amino acids 475-504

98/392

**FIGURE 93**

CCCACGCGTCCGAAGGCAGACAAAGGTTCAATTTGTAAAGAAGCTCCTTCCAGCACCTCCT  
CTCTTCTCCTTTTGCCCAAACACCCAGTGAGTGTGAGCATTTAAGAAGCATCCTCTGC  
CAAGACCAAAGGAAAGAAGAAAAAGGGCCAAAGCCAAATGAAACTGATGGTACTTGT  
TTTCACCATTTGGGCTAACTTTGCTGCTAGGAGTTCAAGCCATGCCTGCAAATCGCCTCTC  
TTGCTACAGAAAGATACTAAAAGATCACAACCTTCCGGAAGGAGTAGCTGA  
CCTGACACAGATTGATGTCAATGTCCAGGATCATTTCTGGGATGGGAAGGGATGTGAGAT  
GATCTGTTACTGCAACTTCAGCGAATTGCTCTGCTGCCCAAAGACGTTTTCTTTGGACC  
AAAGATCTCTTTCGTGATTCCTTGCAACAATCAATGAGAATCTTCATGTATTCTGGAGAA  
CACCATTCTGATTTCCCAAACTGCACTACATCAGTATAACTGCATTTCTAGTTTCTA  
TATAGTGCAATAGAGCATAGATTCTATAAATTCTTACTTGTCTAAGACAAGTAAATCTGT  
GTTAAACAAGTAGTAATAAAAGTTAATTCAATCTAAAAAAAAAAAAA

99/392

## FIGURE 94

MKLMVLVFTIGLTLLLGVQAMPANRLSCYRKILKDHNCHNLPEGVADLTQIDVNVQDHF  
W  
DGKGCEMICYCNFSELLCCPKDVFFGPKISFVIPCNNQ

**Important features:**

**Signal peptide:**

amino acids 1-20

**N-glycosylation site:**

amino acids 72-76

**Tyrosine kinase phosphorylation site:**

amino acids 63-71

100/392

**FIGURE 95**

GAATTCCGGGCCCCAGGATGCCAACTTTGAATAGGATGAAGACTACAACCTGTTCCCTTC  
TCATCTGCATCTCCCTGCTCCAGCTGATGGTCCCAGTGAATACTGATGAGACCATAGAGA  
TTATCGTGGAGAATAAGGTCAAGGAACTTCTTGCCAATCCAGCTAACTATCCCTCCACTG  
TAACGAAGACTCTCTCTTGCACTAGTGTCAAGACTATGAACAGATGGGCCTCCTGCCCTG  
CTGGGATGACTGCTACTGGGTGTGCTTGTGGCTTTGCCTGTGGATCTTGGGAGATCCAGA  
GTGGAGATACTTGCAACTGCCTGTGCTTACTCGTTGACTGGACCACTGCCCCGCTGCTGCC  
AACTGTCCTAGAATGAAGAGGTGGAGAACCAGCTTTGATATGATGAATCTAACAAAAA  
CTGCAGTCTCAATTTGGAAATCTGACTCATGTGCCTTTAAATGTGTTTCATATTGCCCAT  
TACCCTGCTTCTTGAAATGCTTCTTGAAAAATAAAGACAAATTTGCATGTG

101/392

## FIGURE 96

MKTTTCSLLICISLLQLMVPVNTDETIEIIVENKVKELLANPANYPSTVTKTLSCTSVK  
TMNRWASCPAGMTATGCACGFACGSWEIQSGDTCNCLCLLDWTTARCCQLS



102/392

**FIGURE 97**

GAGGCAGAAAGGCAGAAAGGAGAAAATTCAGGATAACTCTCCTGAGGGGTGAGCCAAGCC  
CTGCCATGTAGTGACGCAGGACATCAACAAACACAGATAACAGGAAATGATCCATTCCC  
TGTGGTCACTTATTCTAAAGGCCCAACCTTCAAAGTTCAAGTAGTGATATGGATGACTC  
CACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACT  
GAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGA  
CGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGT  
GTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCA  
GGGCCACACGCGGAGAAGCTGCCAGCAGGAGCAGGAGCCCCCAAGGCCGGCCTGGAGGA  
AGCTCCAGCTGTCAACGCGGGACTGAAAATCTTTGAACCACCAGCTCCAGGAGAAGGCAA  
CTCCAGTCAGAACAGCAGAAATAAGCGTGCCGTTTCAGGGTCCAGAAGAAACAGTCACTCA  
AGACTGCTTGCAACTGATTGCAGACAGTGAAACACCAACTATACAAAAAGGATCTTACAC  
ATTTGTTCCATGGCTTCTCAGCTTTAAAAGGGGAAGTGCCCTAGAAGAAAAAGAGAATAA  
AATATTGGTCAAAGAACTGGTTACTTTTTTATATATGGTCAGGTTTTATATACTGATAA  
GACCTACGCCATGGGACATCTAATTCAGAGGAAGAAGGTCCATGTCTTTGGGGATGAATT  
GAGTCTGGTGACTTTGTTTCGATGTATTCAAAATATGCCTGAAACACTACCCAATAATTC  
CTGCTATTCAGCTGGCATTGCAAACTGGAAGAAGGAGATGAACTCCAACCTTGCAATACC  
AAGAGAAAATGCACAAATATCACTGGATGGAGATGTCACATTTTTTGGTGCATTGAAACT  
GCTGTGACCTACTTACACCATGTCTGTAGCTATTTTCCTCCCTTTCTCTGTACCTCTAAG  
AAGAAAGAATCTAACTGAAAATACCAAAAAAAAAAAAAAAAAA

103/392

**FIGURE 98**

MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCC  
LTVVSFYQVAALQGD LASLRAELQGHHA EKLPA GAGAPKAGLEEAPAVTAGLKIF EPPAP  
GEGNSSQNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSAL EE  
KENKILVKETGYFFIYGQVLYTDKTYAMGH LIQRKKVHVFGDELSLVTLFR CIQNMPETL  
PNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL

**Transmembrane domain:**

amino acids 47-72

**N-glycosylation site:**

amino acids 124-127, 242-245

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

amino acids 33-36, 173-176

**N-myristoylation site:**

amino acids 96-101

**TNF family proteins:**

amino acids 172-206

104/392

**FIGURE 99**

GCGAGGTGGCGATCGCTGAGAGGCAGGAGGGCCGAGGCGGGCCTGGGAGGCGGCCCCGGAG  
GTGGGGCGCCGCTGGGGCCGGCCCGCACGGGCTTCATCTGAGGGCGCACGGCCCCGCGACC  
GAGCGTGCGGACTGGCCTCCCAAGCGTGGGGCGACAAGCTGCCGGAGCTGCAATGGGCGG  
CGGCTGGGGATTCTTGTTTGGCCTCCTGGGCGCCGTGTGGCTGCTCAGCTCGGGCCACGG  
AGAGGAGCAGCCCCCGGAGACAGCGGCACAGAGGTGCTTCTGCCAGGTTAGTGGTTACTT  
GGATGATTGTACCTGTGATGTTGAAACCATTGATAGATTTAATAACTACAGGCTTTTCCC  
AAGACTACAAAACTTCTTGAAAGTGACTACTTTAGGTATTACAAGGTAAACCTGAAGAG  
GCCGTGTCTTTCTGGAATGACATCAGCCAGTGTGGAAGAAGGGACTGTGCTGTCAAACC  
ATGTCAATCTGATGAAGTTCCTGATGGAATTAAATCTGCGAGCTACAAGTATTCTGAAGA  
AGCCAATAATCTCATTGAAGAATGTGAACAAGCTGAACGACTTGGAGCAGTGGATGAATC  
TCTGAGTGAGGAAACACAGAAGGCTGTTCTTCAGTGGACCAAGCATGATGATTCTTCAGA  
TAACTTCTGTGAAGCTGATGACATTCACTCCCCTGAAGCTGAATATGTAGATTTGCTTCT  
TAATCCTGAGCGCTACACTGGTTACAAGGGACCAGATGCTTGGAAAATATGGAATGTCAT  
CTACGAAGAAAACCTGTTTAAAGCCACAGACAATTAAAGACCTTTAAATCCTTTGGCTTC  
TGGTCAAGGGACAAGTGAAGAGAACACTTTTTACAGTTGGCTAGAAGGTCTCTGTGTAGA  
AAAAAGAGCATTCTACAGACTTATATCTGGCCTACATGCAAGCATTAAATGTGCATTTGAG  
TGCAAGATATCTTTTACAAGAGACCTGGTTAGAAAAGAAATGGGGACACAACATTACAGA  
ATTTCAACAGCGATTTGATGGAATTTTGAAGTGAAGGAGAAGGTCCAAGAAGGCTTAAGAA  
CTTGATTTTTCTCTACTTAATAGAACTAAGGGCTTTATCCAAAGTGTTACCATTCTTCGA  
GCGCCAGATTTTCAACTCTTTACTGGAATAAAATTCAGGATGAGGAAAACAAAATGTT  
ACTTCTGGAATACTTCATGAAATCAAGTCATTTCCCTTTGCATTTTGATGAGAATTCATT  
TTTTGCTGGGGATAAAAAAGAAGCACAACTAAAGGAGGACTTTTCGACTGCATTTTAG  
AAATATTTCAAGAATTATGGATTGTGTTGGTTGTTTTAAATGTCGTCTGTGGGGAAAGCT  
TCAGACTCAGGGTTTGGGCACTGCTCTGAAGATCTTATTTTCTGAGAAATTGATAGCAA  
TATGCCAGAAAGTGGACCTAGTTATGAATTCCATCTAACCAGACAAGAAATAGTATCATT  
ATTCAACGCATTTGGAAGAATTTCTACAAGTGTGAAAGAATTAGAAAACCTCAGGAACCT  
GTTACAGAATATTCATTAAAGAAAACAAGCTGATATGTGCCTGTTTCTGGACAATGGAGG  
CGAAAGAGTGGAATTTCAATCAAAGGCATAATAGCAATGACAGTCTTAAGCCAAACATTT  
TATATAAAGTTGCTTTTGTAAAGGAGAATTATATTGTTTTAAGTAAACACATTTTAAAA  
ATTGTGTTAAGTCTATGTATAATACTACTGTGAGTAAAAGTAATACTTTAATAATGTGGT  
ACAAATTTTAAAGTTTAAATATTGAATAAAAGGAGGATTATCAAATTAATAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAA

105/392

**FIGURE 100**

MGRGWGFLFGLLGAVWLLSSSGHGEEQPPETAQRCFCQVSGYLDDCTCDVETIDRFNNYR  
LFPRLQKLLESDFRYKYNLKRPCPFWNDISQCGRDCAVKPCQSDEVPDGIKSASYKY  
SEEANNLIEECEQAERLGAVDESLSEETQKAVLQWTKHDDSSDNFCEADDIQSPEAEYVD  
LLLNPERYTGYKGPDAWKIWNVIYEENCFKPQTIKRPLNPLASGQGTSEENTFYSWLEGL  
CVEKRAFYRLISGLHASINVHLSARYLLQETWLEKKWGHNITEFQQRFDGILTEGEGPRR  
LKNLYFLYLIELRALSKVLPFFERPDLFTGNKIQDEENKMLLLEILHEIKSFPLHFDE  
NSFFAGDKKEAHKLKEDFRLHFRNISRIMDCVGCFCRLWGKLQTQGLGTALKILFSEKL  
IANMPESGPSYEFHLTRQEIVSLFNAFGRISTSVKELENFRNLLQNIH

**Important features:****Signal peptide:**

amino acids 1-23

**N-glycosylation site:**

amino acids 280-283 and 384-387

**Amidation site:**

amino acids 94-97

**Glycosaminoglycan attachment site:**

amino acids 20-23 and 223-226

**Aminotransferases class-V pyridoxal-phosphate:**

amino acids 216-222

**Interleukin-7 proteins:**

amino acids 338-343

106/392

**FIGURE 101**

GCCTAGCCAGGCCAAGAATGCAATTGCCCCGGTGGTGGGAGCTGGGAGACCCCTGTGCTT  
GGACGGGACAGGGTCGGGGGACACGCAGGATGAGCCCCGCGACCACTGGCACATTCTTGC  
TGACAGTGTACAGTATTTTCTCCAAGGTACACTCCGATCGGAATGTATACCCATCAGCAG  
GTGTCCTCTTTGTTTCATGTTTTGGAAAGAGAATATTTTAAGGGGGAATTTCCACCTTACC  
CAAAACCTGGCGAGATTAGTAATGATCCCATAACATTTAATACAAATTTAATGGGTACC  
CAGACCGACCTGGATGGCTTCGATATATCCAAAGGACACCATATAGTGATGGAGTCCCTAT  
ATGGGTCCCCAACAGCTGAAAATGTGGGGAAGCCAACAATCATTGAGATAACTGCCTACA  
ACAGGCGCACCTTTGAGACTGCAAGGCATAATTTGATAATTAATATAATGTCTGCAGAAG  
ACTTCCCGTTGCCATATCAAGCAGAATTCTTCATTAGAATATGAATGTAGAAGAAATGT  
TGGCCAGTGAGGTTCTTGGGAGACTTTCTTGGCGCAGTGAAAAATGTGTGGCAGCCAGAGC  
GCCTGAACGCCATAAACATCACATCGGCCCTAGACAGGGGTGGCAGGGTGCCACTTCCCA  
TTAATGACCTGAAGGAGGGCGTTTATGTTCATGGTTGGTGCAGATGTCCCGTTTTCTTCTT  
GTTTACGAGAAGTTGAAAATCCACAGAATCAATTGAGATGTAGTCAAGAAATGGAGCCTG  
TAATAACATGTGATAAAAAATTTTCGTAATCAATTTTACATTGACTGGTGCAAATTTTCAT  
TGGTTGATAAAACAAAGCAAGTGTCCACCTATCAGGAAGTGATTCGTGGAGAGGGGATTT  
TACCTGATGGTGGAGAATACAAACCCCTTCTGATTCTTTGAAAAGCAGAGACTATTACA  
CGGATTTCTTAATTACACTGGCTGTGCCCTCGGCAGTGGCACTGGTCCTTTTTCTAATAC  
TTGCTTATATCATGTGCTGCCGACGGGAAGGCGTGGAAAAGAGAAACATGCAAACACCAG  
ACATCCAACCTGGTCCATCACAGTGCTATTCAGAAATCTACCAAGGAGCTTCGAGACATGT  
CCAAGAATAGAGAGATAGCATGGCCCCTGTCAACGCTTCCTGTGTTCCACCCTGTGACTG  
GGGAAATCATACCTCCTTTACACACAGACAACATATGATAGCACAAACATGCCATTGATGC  
AAACGCAGCAGAACTTGCCACATCAGACTCAGATTCCCCAACAGCAGACTACAGGTAAAT  
GGTATCCCTGAAGAAAGAAAAGTGAAGCAATGAATTTATAATCAGACAATATAGCA  
GTTACATCACATTTCTTTCTTCCAATAATGCATGAGCTTTTCTGGCATATGTTATGC  
ATGTTGGCAGTATTAAGTGTATACCAAATAATACAACATAACTTTTCAATTTTACTAATGTA  
TTTTTTTGTACTTAAAGCATTTTGTGACAATTTGTAAACATTGATGACTTTATATTTGTT  
ACAATAAAAGTTGATCTTTAAAATAAATATTATTAATGAAGCCTAAAAAAAAAAAA

107/392

**FIGURE 102**

MQLPRWWELGDPCAWTGQGRGTRRMSPATTGTFLTVYSIFSKVHSDRNVYPSAGVLFVH  
VLEREYFKGEFPPYPKPGEISNDPITFNTNLMGYPDRPGWLRYSIQRTPYSDGVLYGSPTA  
ENVGKPTIIETAYNRRTFETARHNLIINIMSAEDFPLPYQAEFFIKNMNVEEMLASEVL  
GDFLGAVKNVWQPERLNAINITSALDRGGRVPLPINDLKEGVYVMVGADVFPSSCLREVE  
NPQNQLRCSQEMEPVITCDKKFRTQFYIDWCKISLVDKTKQVSTYQEVIRGEGILPDGGE  
YKPPSDSLKSRDYYTDFLITLAVPSAVALVFLILAYIMCCRREGVEKRNMQTPDIQLVH  
HSAIQKSTKELRDMSKNREIAWPLSTLPVFHPVTGEIIPPLHTDNYDSTNMPLMQTQQNL  
PHQTQIPQQOTTGKWYP

**signal sequence:**

Amino acids 1-46

**transmembrane domain:**

Amino acids 319-338

**N-glycosylation site:**

Amino acids 200-204

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

Amino acids 23-27

**Tyrosine kinase phosphorylation site:**

Amino acids 43-52

**N-myristoylation sites:**

Amino acids 17-23;112-118;116-122;185-191

108/392

**FIGURE 103**

CAGAAGAGGGGGCTAGCTAGCTGTCTCTGCGGACCAGGGAGACCCCCGCGCCCCCCCCGGT  
GTGAGGCGGCCTCACAGGGCCGGGTGGGCTGGCGAGCCGACGCGGCGGGCGGAGGAGGCTG  
TGAGGAGTGTGTGGAACAGGACCCGGGACAGAGGAACCATGGCTCCGCAGAACCTGAGCA  
CCTTTTGCTGTGTGCTGCTATACCTCATCGGGGCGGTGATTGCCGGACGAGATTTCTATA  
AGATCTTGGGGGTGCCTCGAAGTGCCTCTATAAAGGATATTAAAAAGGCCTATAGGAAAC  
TAGCCCTGCAGCTTCATCCCGACCGGAACCTGATGATCCACAAGCCCAGGAGAAATTCC  
AGGATCTGGGTGCTGCTTATGAGGTTCTGTGAGATAGTGAGAAACGGAAACAGTACGATA  
CTTATGGTGAAGAAGGATTAAAAGATGGTCATCAGAGCTCCCATGGAGACATTTTTTCAC  
ACTTCTTTGGGGATTTTGGTTTCATGTTTGGAGGAACCCCTCGTCAGCAAGACAGAAATA  
TTCCAAGAGGAAGTGATATTATTGTAGATCTAGAAGTCACTTTGGAAGAAGTATATGCAG  
GAAATTTTGTGGAAGTAGTTAGAAACAAACCTGTGGCAAGGCAGGCTCCTGGCAAACCGA  
AGTGCAATTGTGCGCAAGAGATGCGGACCACCCAGCTGGGCGCTTCCAAATGA  
CCCAGGAGGTGCTGCTGCGACGAATGCCCTAATGTCAAAGTAGTGAATGAAGAACGAACGC  
TGGAAAGTAGAAATAGAGCCTGGGGTGAGAGACGGCATGGAGTACCCCTTTATTGGAGAAG  
GTGAGCCTCACGTGGATGGGGAGCCTGGAGATTTACGGTTCCGAATCAAAGTTGTCAAGC  
ACCCAATATTTGAAAGGAGAGGAGATGATTTGTACACAAATGTGACAATCTCATTAGTTG  
AGTCACTGGTTGGCTTTGAGATGGATATTACTCACTTGGATGGTCACAAGGTACATATTT  
CCCGGGATAAGATCACCAGGCCAGGAGCGAAGCTATGGAAGAAAGGGGAAGGGCTCCCCA  
ACTTTGACAACAACAATATCAAGGGCTCTTTGATAATCACTTTTGATGTGGATTTTCCAA  
AAGAACAGTTAACAGAGGAAGCGAGAGAAGGTATCAAACAGCTACTGAAACAAGGGTCAG  
TGCAGAAGGTATACAATGGACTGCAAGGATATTGAGAGTGAATAAAATTGGACTTTGTTT  
AAAATAAGTGAATAAGCGATATTTATTATCTGCAAGGTTTTTTTTGTGTGTGTTTTGTTT  
TTATTTTCAATATGCAAGTTAGGCTTAATTTTTTTTATCTAATGATCATCATGAAATGAAT  
AAGAGGGCTTAAGAATTTGTCCATTTGCATTGCGAAAAGAATGACCAGCAAAAGGTTTAC  
TAATACCTCTCCCTTTGGGGATTTAATGTCTGGTGCTGCCGCTGAGTTTCAAGAATTAA  
AGCTGCAAGAGGACTCCAGGAGCAAAAGAAACACAATATAGAGGGTTGGAGTTGTTAGCA  
ATTTCAATCAAATGCCAACTGGAGAAGTCTGTTTTTAAATACATTTTGTGTTATTTTTTA

109/392

**FIGURE 104**

MAPQNLSTFCLLLLYLIGAVIAGRDFYKILGVPRASIKDIKKAYRKLALQLHPDRNPDD  
PQAQEKFDLGAAYEVLSDSEKQYDQTYGEEGLKDGHQSSHGDI FSHFFGDFGFMFGGT  
PRQQDRNIPRGSDIIVDLEVTLEEYAGNFVEVVRNKPVARQAPGKRKCNCROEMRTTQL  
GPGRFQMTQEVVCDECPNVKLVNEERTLEVEIEPGVRDGM EYPFIGEGEPHVDGEPGDLR  
FRIKVVKHPIFERRGDDLYTNVTISLVESLVGFEMDITHLDGHKVHISRDKITRPGAKLW  
KKGEGLPNFDNNNIKGLIITFDVDFPKEQLTEEAREGIKQLLKQGSVQKVYNGLQGY

**Important features:****Signal peptide:**

amino acids 1-22

**Cell attachment sequence:**

amino acids 254-257

**Nt-dnaJ domain signature:**

amino acids 67-87

**Homologous region to Nt-dnaJ domain proteins:**

amino acids 26-58

**N-glycosylation site:**

amino acids 5-9, 261-265

**Tyrosine kinase phosphorylation site:**

amino acids 253-260

**N-myristoylation site:**

amino acids 18-24, 31-37, 93-99, 215-221

**Amidation site:**

amino acids 164-168



110/392

**FIGURE 105**

GGCACGAGGCGGCGGGGCGAGTCGCGGGGATGCGCCCGGAGCCACAGCCTGAGGCCCTCAG  
GTCTCTGCAGGTGTCGTGGAGGAACCTAGCACCTGCCATCCTCTTCCCCAATTTGCCACT  
TCCAGCAGCTTTAGCCCATGAGGAGGATGTGACCGGGACTGAGTCAGGAGCCCTCTGGAA  
GCATGGGAGACTGTGGTGATTGTTGCCATAGGTGTGCTGGCCACCATCTTTCTGGCTTCGT  
TTGCAGCCTTGGTGCTGGTTTGACGGCAGCGCTACTGCCGGCCGCGAGACCTGCTGCAGC  
GCTATGATTCTAAGCCCATTGTGGACCTCATTGGTGCCATGGAGACCCAGTCTGAGCCCT  
CTGAGTTAGAACTGGACGATGTCTGTTATCACCAACCCCCACATTGAGGCCATTCTGGAGA  
ATGAAGACTGGATCGAAGATGCCTCGGGTCTCATGTCCCACTGCATTGCCATCTTGAAGA  
TTTGTACACTCTGACAGAGAAGCTTGTTGCCATGACAATGGGCTCTGGGGCCAAGATGA  
AGACTTCAGCCAGTGTCAGCGACATCATTGTGGTGCCCAAGCGGATCAGCCCCAGGGTGG  
ATGATGTTGTGAAGTCGATGTACCCTCCGTTGGACCCCCAACTCCTGGACGCACGGACGA  
CTGCCCTGCTCCTGTCTGTGAGTCACCTGGTGCTGGTGACAAGGAATGCCTGCCATCTGA  
CGGGAGGCCTGGACTGGATTGACCAGTCTCTGTGGGCTGCTGAGGAGCATTGGAAGTCC  
TTCGAGAAGCAGCCCTAGCTTCTGAGCCAGATAAAGGCCTCCCAGGCCCTGAAGGCTTCC  
TGCAGGAGCAGTCTGCAATTTAGTGCCTACAGGCCAGCAGCTAGCCATGAAGGCCCTGC  
CGCCATCCCTGGATGGCTCAGCTTAGCCTTCTACTTTTTCCTATAGAGTTAGTTGTTCTC  
CACGGCTGGAGAGTTCAGCTGTGTGTGCATAGTAAAGCAGGAGATCCCCGTCAGTTTATG  
CCTCTTTTGCAGTTGCAAACCTGTGGCTGGTGAGTGGCAGTCTAATACTACAGTTAGGGGA  
GATGCCATTCACTCTCTGCAAGAGGAGTATTGAAAACCTGGTGGACTGTCAGCTTTATTTA  
GCTCACCTAGTGTTTTCAAGAAAATTGAGCCACCGTCTAAGAAATCAAGAGGTTTACAT  
TAAAATTAGAATTTCTGGCCTCTCTCGATCGGTGAGAAATGTGTGGCAATTCTGATCTGCA  
TTTTTCAGAAGAGGACAATCAATTGAAACTAAGTAGGGGTTTCTTCTTTTGGCAAGACTTG  
TACTCTCTCACCTGGCCTGTTTCATTTATTTGTATTATCTGCCTGGTCCCTGAGGCGTCT  
GGGTCTCTCCTCTCCCTTGACAGTTTTGGGTTTGAAGCTGAGGAACTACAAAGTTGATGAT  
TTCTTTTTTATCTTTATGCCTGCAATTTTACCTAGCTACCACTAGGTGGATAGTAAATTT  
ATACTTATGTTTCCCTCAAAAAAAAAAAAAA

111/392

## FIGURE 106

METVVIVAIGVLATIFLASFAALVLVCRQRYCRPRDLLQRYDSKPIVDLIGAMETQSEPS  
ELELDDVVITNPHIEAILENEDWIEDASGLMSHCIAILKICHTLTEKLVAMTMGSGAKMK  
TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLSVSHLVLVTRNACHLT  
GGLDWIDQSLSAAEEHLEVLREAALASEPDKGLPGPEGFLQEQSAI

112/392

**FIGURE 107**

GCTTCATTTCTCCCGACTCAGCTTCCCACCCCTGGGCTTTCCGAGGTGCTTTCGCCGCTGT  
CCCCACCACTGCAGCCATGATCTCCTTAACGGACACGCAGAAAATTGGAATGGGATTAAC  
AGGATTTGGAGTGTTTTTCTGTTCTTTGGAATGATTCTCTTTTTTGACAAAGCACTACT  
GGCTATTGGAAATGTTTTATTTGTAGCCGGCTTGGCTTTTGTAATTGGTTTAGAAAGAAC  
ATTCAGATTCTTCTTCCAAAAACATAAAATGAAAGCTACAGGTTTTTTTTCTGGGTGGTGT  
ATTTGTAGTCCTTATTGGTTGGCCTTTGATAGGCATGATCTTCGAAATTTATGGATTTTT  
TCTCTTGTTTCAGGGGCTTCTTTCTGTCGTTGTTGGCTTTATTAGAAGAGTGCCAGTCCT  
TGGATCCCTCCTAAATTTACCTGGAATTAGATCATTTGTAGATAAAGTTGGAGAAAGCAA  
CAATATGGTATAACAACAAGTGAATTTGAAGACTCATTTAAAATATTGTGTTATTTATAA  
AGTCATTTGAAGAATATTCAGCACAAAATTAAATTACATGAAATAGCTTGTAATGTTCTT  
TACAGGAGTTTAAACGTATAGCCTACAAAGTACCAGCAGCAAATTAGCAAAGAAGCAGT  
GAAAACAGGCTTCTACTCAAGTGAACCTAAGAAGAAGTCAGCAAGCAAAGCTGAGAGAGGTG  
AAATCCATGTTAATGATGCTTAAGAACTCTTGAAGGCTATTTGTGTTGTTTTTCCACAA  
TGTGCGAAACTCAGCCATCCTTAGAGAACTGTGGTGCCTGTTTCTTTTCTTTTATTTTG  
AAGGCTCAGGAGCATCCATAGGCATTTGCTTTTTAGAAAGTGTCCACTGCAATGGCAAAAA  
TATTTCCAGTTGCACTGTATCTCTGGAAGTGATGCATGAATTCGATTGGATTGTGTCATT  
TTAAAGTATTAAAACCAAGGAAACCCCAATTTTGATGTATGGATTACTTTTTTTTNGNCGN  
CAGGGCC

113/392

## FIGURE 108

MISLTDTQKIGMGLTGFGVFLLFFGMILFFDKALLAIGNVLFVAGLAFVIGLERTFRFFF  
QKHKMKATGFFLGGVFVVLIGWPLIGMIFEIYGFFLLFRGFFPVVVGFIIRVPVLGSLN  
LPGIRSFVDKVGESNNMV

**Important features:**

**Transmembrane domains:**

amino acids 12-30 (typeII), 33-52, 69-89 and 93-109

**N-myristoylation sites:**

amino acids 11-16, 51-56 and 116-121

**Aminoacyl-transfer RNA synthetases class-II protein:**

amino acids 49-59

114/392

**FIGURE 109**

CCAGTCTGTCGCCACCTCACTTGGTGTCTGCTGTCCCCGCCAGGCAAGCCTGGGGTGAGA  
GCACAGAGGAGTGGGCGGGACCATGCGGGGGACGCGGCTGGCGCTCCTGGCGCTGGTGC  
TGGCTGCCTGCGGAGAGCTGGCGCCGGCCCTGCGCTGCTACGTCTGTCCGGAGCCCACAG  
GAGTGTGGGACTGTGTCACCATCGCCACCTGCACCACCAACGAAACCATGTGCAAGACCA  
CACTCTACTCCCGGGAGATAGTGTACCCCTTCCAGGGGGACTCCACGGTGACCAAGTCCT  
GTGCCAGCAAGTGTAAGCCCTCGGATGTGGATGGCATCGGCCAGACCCTGCCCCGTGTCCT  
GCTGCAATACTGAGCTGTGCAATGTAGACGGGGCGCCCGCTCTGAACAGCCTCCACTGCG  
GGGCCCTCACGCTCCTCCCACTCTTGAGCCTCCGACTGTAGAGTCCCCGCCCACCCCAT  
GGCCCTATGCGGCCAGCCCCGAATGCCTTGAAGAAGTGCCCCCTGCACCAGGAAAAAA  
AAAAA

115/392

## FIGURE 110

MRGTRLALLALVLAACGELAPALRCYVCPEPTGVSDCVTIATCTTNETMCKTTLYSREIV  
YPFQGDSTVTKSCASKCKPSDVDGIGQTLFVSCCNTELCNVDGAPALNSLHCGALTLLPL  
LSLRL

**Important features:**

**Signal peptide:**

amino acids 1-17

**N-glycosylation site:**

amino acids 46-49

116/392

**FIGURE 111**

GC GCCCGCCAGGCGTAGGCGGGGTGGCCCTTGCGTCTCCCGCTTCCTTGAAAAACCCGGCG  
GGCGAGCGAGGCTGCGGGCCGGCCGCTGCCCTTCCCCACACTCCCCGCCGAGAAGCCTCG  
CTCGGCGCCCAACATGGCGGGTGGGCGCTGCGGCCCGCAGCTAACGGCGCTCCTGGCCGC  
CTGGATCGCGGCTGTGGCGGCGACGGCAGGCCCGAGGAGGCCGCGCTGCCGCCGGAGCA  
GAGCCGGGTCCAGCCCATGACCGCCTCCAACCTGGACGCTGGTGATGGAGGGCGAGTGGAT  
GCTGAAATTTTACGCCCCATGGTGTCCATCCTGCCAGCAGACTGATTGAGAATGGGAGGC  
TTTTGCAAAGAATGGTGAAATACTTCAGATCAGTGTGGGGAAGGTAGATGTCATTCAAGA  
ACCAGGTTTGAGTGGCCGCTTCTTTGTCACTCTCTCCAGCATTTTTTTCATGCAAAGGA  
TGGGATATTCCGCCGTTATCGTGGCCAGGAATCTTCGAAGACCTGCAGAATTATATCTT  
AGAGAAGAAATGGCAATCAGTCGAGCCTCTGACTGGCTGGAAATCCCCAGCTTCTCTAAC  
GATGTCTGGAATGGCTGGTCTTTTTAGCATCTCTGGCAAGATATGGCATCTTCACAACCTA  
TTTCACAGTGAATCTTGGAATCCTGCTTGGTGTCTTATGTGTTTTTCGTATAGCCAC  
CTTGGTTTTTGGCCCTTTTTATGGGTCTGGTCTTGGTGGTAATATCAGAAATGTTTTCTATGT  
GCCACTTCCAAGGCATTTATCTGAGCGTCTCTGAGCAGAATCGGAGATCAGAGGAGGCTCA  
TAGAGCTGAACAGTTGCAGGATGCGGAGGAGGAAAAAGATGATTCAAATGAAGAAGAAAA  
CAAAGACAGCCTTGATAGATGATGAAGAAGAGAAAGAAAGATCTTGGCGATGAGGATGAAGC  
AGAGGAAGAAGAGGAGGAGGACAACTTGGCTGCTGGTGTGGATGAGGAGAGAAGTGAGGC  
CAATGATCAGGGGCCCCCAGGAGAGGACGGTGTGACCCGGGAGGAAGTAGAGCCTGAGGA  
GGCTGAAGAAGGCATCTCTGAGCAACCTGCCCCAGCTGACACAGAGGTGGTGGAAAGACTC  
CTTGAGGCAGCGTAAAGTCAGCATGCTGACAAGGGACTGTAGATTTAATGATGCGTTTT  
CAAGAATACACACCAAACAATATGTCAGCTTCCCTTTGGCCTGCAGTTTGTACCAAATC  
CTTAATTTTTCTGAATGAGCAAGCTTCTCTTAAAGATGCTCTCTAGTCATTTGGTCTC  
ATGGCAGTAAGCCTCATGTATACTAAGGAGAGTCTTCCAGGTGTGACAAATCAGGATATAG  
AAAAACAAACGTAGTGTGGGATCTGTTTGGAGACTGGGATGGGAACAAGTTCAATTTACT  
TAGGGGTGAGAGAGTCTCGACCAGAGGAGGCCATTCAGTCCTAATCAGCACCTTCCAG  
AGACAAGGCTGCAGGCCCTGTGAAATGAAAGCCAAGCAGGAGCCTTGGCTCCTGAGCATC  
CCCAAAGTGTAACGTAGAAGCCTTGATCCTTTTTCTTGTGTAAAGTATTTATTTTTGTCA  
AATTGCAGGAAACATCAGGCACCAAGTGCATGAAAAATCTTTCACAGCTAGAAATTGAA  
AGGGCCTTGGGTATAGAGAGCAGCTCAGAAGTCATCCCAGCCCTCTGAATCTCCTGTGCT  
ATGTTTTATTTCTTACCTTTAATTTTTCCAGCATTTCCACCATGGGCATTCAGGCTCTCC  
ACACTCTTCACTATTATCTCTTGGTCAGAGGACTCCAATAACAGCCAGGTTTACATGAAC  
TGTGTTTGTTCATTCTGACCTAAGGGGTTTAGATAATCAGTAACCATAACCCCTGAAGCT  
GTGACTGCCAAACATCTCAAATGAAATGTTGTGGCCATCAGAGACTCAAAGGAAGTAAG  
GATTTTACAAGACAGATTAAAAAAAATTTGTTTTGTCCAAAATATAGTTGTTGTTGATTT  
TTTTTTAAGTTTTCTAAGCAATATTTTTCAAGCCAGAAGTCCTCTAAGTCTTGCCAGTAC  
AAGGTAGTCTTGTGAAGAAAAGTTGAATACTGTTTTGTTTTCATCTCAAGGGGTTCCCTG  
GGTCTTGAACACTTTAATAATACTAAAAAACCTTCTGATTTTCTTTCAGTGATGTG  
CTTTTGGTGAAAGAATTAATGAACCTCAGTACCTGAAAGTGAAAGATTTGATTTTGTTC  
CATCTTCTGTAATCTTCCAAAGAATTATATCTTTGTAAATCTCTCAATACTCAATCTACT  
GTAAGTACCCAGGGAGGCTAATTTCTTT

117/392

**FIGURE 112**

MAGGRCGPQLTALLAAWIAAVAATAGPEEAALPPEQSRVQPMTASNWTLVMEGEWMLKFY  
APWCPSCQQT DSEWEAFKNGEILQISVGKVDVIOEPGLSGRFFVTTLPAFFHAKDGIFR  
RYRGP GIGFEDLQNYILEKKWQSVEPLTGWKSPASLTMSGMAGLFSISGKIWHLHNYFTVT  
LGIPAWCSYVFFVIATLVFGLFMGLVLVVISSECFYVPLPRHLSESEQNRRSEEAHRAEQ  
LQDAEEEKDDSN EEEENKDSLVDDEEEKEDLGDEDEAE EEEEEEDNLAAGVDEERSEANDQG  
PPGEDGVTREEVEPEEAEEGISEQPCPADTEVVEDSLRQRKSQHADKGL

**Important features:****Signal peptide:**

amino acids 1-22

**Transmembrane domain:**

amino acids 191-211

**N-glycosylation site:**

amino acids 46-49

**Thioredoxin family proteins:** (homologous region to disulfide isomerase)

amino acids 56-72

**Flavodoxin proteins:**

amino acids 173-187



118/392

**FIGURE 113**

GAGGAACCTACCGGTACCGGCCGCGCGCTGGTAGTCGCCGGTGTGGCTGCACCTCACCAA  
TCCCGTGCGCCGCGGGCTGGGCCGTCCGAGAGTGCCTGTGCTTCTCTCCTGCACGCGGTGC  
TTGGGCTCGGCCAGGCGGGTCCGCCGCCAGGGTTTGAGGATGGGGGAGTAGCTACAGGA  
AGCGACCCCGCGATGGCAAGGTATATTTTTGTGGAATGAAAAGGAAGTATTAGAAATGAG  
CTGAAGACCATTACAGATTAATATTTTTGGGGACAGATTTGTGATGCTTGATTCACCCCT  
TGAAGTAATGTAGACAGAACTTCTCAAATTTGCATATTACATCAACTGGAACCAGCAGTG  
AATCTTAATGTTCACTTAAATCAGAACTTGCATAAGAAAGAGAATGGGAGTCTGGTTAAA  
TAAAGATGACTATATCAGAGACTTGAAAAGGATCATTCTCTGTTTTCTGATAGTGTATAT  
GGCCATTTTAGTGGGCACAGATCAGGATTTTTACAGTTTACTTGGAGTGTCCAAAACCTGC  
AAGCAGTAGAGAAATAAGACAAGCTTTCAAGAAATTGGCATTGAAGTTACATCCTGATAA  
AAACCCGAATAACCCAAATGCACATGGCGATTTTTTAAAAATAAATAGAGCATATGAAGT  
ACTCAAAGATGAAGATCTACGGAAAAAGTATGACAAATATGGAGAAAAGGGACTTGAGGA  
TAATCAAGGTGGCCAGTATGAAAGCTGGAACATTATCGTTATGATTTTGGTATTTATGA  
TGATGATCCTGAAATCATAACATTGGAAGAAGAGAATTTGATGCTGCTGTTAATTCTGG  
AGAACTGTGGTTTGTAATTTTTACTCCCCAGGCTGTTCACTGCCATGATTTAGCTCC  
CACATGGAGAGACTTTGCTAAAGAAGTGGATGGGTACTTCGAATTGGAGCTGTTAACTG  
TGGTGATGATAGAATGCTTTGCCGAATGAAAGGAGTCAACAGCTATCCCAGTCTCTTCAT  
TTTTCGGTCTGGAATGGCCCCAGTGAAATATCATGGAGACAGATCAAAGGAGAGTTTAGT  
GAGTTTTGCAATGCAGCATGTTAGAAGTACAGTGACAGAACTTTGGACAGGAAATTTTGT  
CAACTCCATACAACTGCTTTTGCTGCTGGTATTGGCTGGCTGATCACTTTTTGTTCAA  
AGGAGGAGATTGTTGACTTCACAGACACGACTCAGGCTTAGTGGCATGTTGTTTCTCAA  
CTCATTGGATGCTAAAGAAATATATTTGGAAGTAATACATAATCTTCAGATTTTGAAC  
ACTTTCCGGCAAACACACTAGAGGATCGTTTGGCTCATCATCGGTGGCTGTTATTTTTTCA  
TTTTGGAAAAAATGAAAATTCAAATGATCCTGAGCTGAAAAAACTAAAACTCTACTTAA  
AAATGATCATATTCAAGTTGGCAGGTTTGACTGTTCTCTGCACCAGACATCTGTAGTAA  
TCTGTATGTTTTTCAGCCGTCTCTAGCAGTATTTAAAGGACAAGGAACCAAAGAATATGA  
AATTCATCATGGAAAGAAGATTCTATATGATATACTTGCCTTTGCCAAAGAAAGTGTGAA  
TTCTCATGTTACCACGCTTGACCTCAAATTTTCTGCCAATGACAAAGAACCATGGCT  
TGTTGATTTCTTTGCCCCCTGGTGTCCACCATGTCGAGCTTTACTACCAGAGTTACGAAG  
AGCATCAAATCTTCTTTATGGTCAGCTTAAGTTTGGTACACTAGATTGTACAGTTTCATGA  
GGGACTCTGTAACATGTATAACATTCAAGGCTTATCCAACAACAGTGGTATTCAACCAGTC  
CAACATTCATGAGTATGAAGGACATCACTCTGCTGAACAAATCTTGGAGTTTCATAGAGGA  
TCTTATGAATCCTTCAGTGGTCTCCCTTACACCCACCACCTTCAACGAACTAGTTACACA  
AAGAAAACACAACGAAGTCTGGATGGTTGATTTCTATTCTCCGTGGTGTATCCTTGCCA  
AGTCTTAATGCCAGAATGGAAGAATGGCCCGGACATTAACCTGGACTGATCAACGTGGG  
CAGTATAGATTGCCAACAGTATCATTCTTTTTGTGCCCAGGAAAACGTTCAAAGATACCC  
TGAGATAAGATTTTTTCCCCCAAATCAAATAAAGCTTATCAGTATCACAGTTACAATGG  
TTGGAATAGGGATGCTTATCCCTGAGAATCTGGGGTCTAGGATTTTTTACCTCAAGTATC  
CACAGATCTAACACCTCAGACTTTTCAGTGAAAAAGTTCTACAAGGGAAAAATCATTGGGT  
GATTGATTTCTATGCTCCTTGGTGTGGACCTTGCCAGAATTTTGCTCCAGAATTTGAGCT  
CTTGGCTAGGATGATTAAAGGAAAAGTGAAAGCTGGAAAAGTAGACTGTCAGGCTTATGC  
TCAGACATGCCAGAAAGCTGGGATCAGGGCCTATCCAACGTGTTAAGTTTTATTTCTACGA  
AAGAGCAAAGAGAAATTTTCAAGAAGAGCAGATAAATACCAGAGATGCAAAAGCAATCGC  
TGCCTTAATAAGTGAAAATTTGAAAATCTCCGAAATCAAGGCAAGAGGAATAAGGATGA  
ACTTTGATAATGTTGAAGATGAAGAAAAAGTTTTAAAGAAATTTCTGACAGATGACATCAG  
AAGACACCTATTTAGAATGTTACATTTATGATGGGAATGAATGAACATTATCTTAGACTT

119/392

GCAGTTGTACTGCCAGAATTATCTACAGCACTGGTGTAAAAGAAGGGTCTGCAAACTTTT  
TCTGTAAAGGGCCGGTTTATAAATATTTTAGACTTTGCAGGCTATAATATATGGTTCACA  
CATGAGAAACAAGAATAGAGTCATCATGTATTCTTTGTTATTTGCTTTTAACAACCTTTAA  
AAAATATTAAACGATTCTTAGCTCAGAGCCATACAAAAGTAGGCTGGATTCCAGTCCATG  
GACCATAGATTGCTGTCCCCCTCGACGGACTTATAATGTTTCAGGTGGCTGGCTTGAACA  
TGAGTCTGCTGTGCTATCTACATAAATGTCTAAGTTGTATAAAGTCCACTTTCCCTTCAC  
GTTTTTTGGCTGACCTGAAAAGAGGTAACCTTAGTTTTTGGTCACTTGTTCTCCTAAAAAT  
GCTATCCCTAACCATATATTTATATTTTCGTTTTTAAAAACACCCATGATGTGGCACAGTAA  
ACAAACCCTGTTATGCTGTATTATTATGAGGAGATTCTTCATTGTTTTCTTTCCTTCTCA  
AAGGTTGAAAAAATGCTTTTAATTTTTCACAGCCGAGAAACAGTGCAGCAGTATATGTGC  
ACACAGTAAGTACACAAATTTGAGCAACAGTAAGTGCACAAATTCGTAGTTTGCTGTAT  
CATCCAGGAAAACCTGAGGGAAAAAATTATAGCAATTAAGTGGGCATTGTAGAGTATCC  
TAAATATGTTATCAAGTATTTAGAGTTCTATATTTTAAAGATATATGTGTTTCATGTATTT  
TCTGAAATTGCTTTCATAGAAATTTTCCCACTGATAGTTGATTTTTTGAGGCATCTAATAT  
TTACATATTTGCCTTCTGAACTTTGTTTTGACCTGTATCCTTTATTTACATTGGGTTTTT  
CTTTCATAGTTTTTGGTTTTTCACTCCTGTCCAGTCTATTTATTATTCAAATAGGAAAAAT  
TACTTTACAGGTTGTTTTACTGTAGCTTATAATGATACTGTAGTTATTCCAGTTACTAGT  
TTACTGTCAGAGGGCTGCCTTTTTCAGATAAATATTGACATAATAACTGAAGTTATTTTT  
ATAAGAAAATCAAGTATATAAATCTAGGAAAGGGATCTTCTAGTTTCTGTGTTGTTTAGA  
CTCAAAGAATCACAAATTTGTCAGTAACATGTAGTTGTTTAGTTATAAATTCAGAGTGTAC  
AGAATGGTAAAAATTCCAATCAGTCAAAGAGGTCAATGAATTAAAAGGCTTGCAACTTT  
TTCAAAAAAAAAAAAAAAAAA

120/392

**FIGURE 114**

MGVWLNKDDYIRD LKRIILCFLIVYMAILVGTDQDFYSLLGVSKTASSREIRQAFKKLAL  
KLHPDKNPNNPNAHGDFLKINRAYEVLKDEDLRKKYDKYGEKGLEDNQGQYESWNYRY  
DFGIYDDDPEIITLERREFDAAVNSGELWFVNFYSPGCSHCHDLAPTWRDFAKEVDGLLR  
IGAVNCGDDRMLCRMKGVNSYPSLFIFRSGMAPVKYHGDRSKESLVSFAMQHVRSTVTEL  
WTGNFVNSIQTAFAAGIGWLITFCSKGGDCLTSQTRLRLSGMLFLNSLDAKEIYLEVIHN  
LPDFELLSANTLEDRLAHHRWLLFFHFGKNENSNDPELKKLKTLLKNDHIQVGRFDCSSA  
PDICSNLYVFQPSLAVFKGQGTKEYEIIHHGKKILYDILAFAKESVNSHVTTLGPQNFPAN  
DKEPWLVDFFAPWCPPCRALLPELRRASNLLYGQLKFGTLDCTVHEGLCNMYNIQAYPTT  
VVFNQSNIEYEGHHS AEQILEFIEDLMNPSVVS LTPTTFNELVTQRKHNEVWVDFYSP  
WCHPCQVLMPEWKRMARTLTGLINVGSIDCQQYHSFCAQENVQRYPEIRFFPPKSNKAYQ  
YHSYNGWNRDAYSLRIWGLGFLPQVSTDLTPTQTFSEKVLQGNHWVIDFYAPWCGPCQNF  
APEFELLARMIKGVKAGKVDCQAYAQTQKAGIRAYPTVKFYFYERAKRNFQEEQINTR  
DAKAIAALISEKLETLRNQGRNKDEL

**Important features:**

**Endoplasmic reticulum targeting sequence:**

amino acids 744-747

**Cytochrome c family heme-binding site signature:**

amino acids 158-163

**Nt-dnaJ domain signature:**

amino acids 77-96

**N-glycosylation site:**

amino acids 484-487

121/392

## FIGURE 115

GCGGGCTGTTGACGGCGCTGCGATGGCTGCCTGCGAGGGCAGGAGAAGCGGAGCTCTCGG  
TTCCTCTCAGTCGGACTTCCTGACGCCGCCAGTGGGCGGGGCCCTTGGGCGGTCGCCAC  
CACTGTAGTCATGTACCCACCGCCGCCGCCGCCCTCATCGGGACTTCATCTCGGTGAC  
GCTGAGCTTTGGCGAGAGCTATGACAACAGCAAGAGTTGGCGGGCGGCGCTCGTGCTGGAG  
GAAATGGAAGCAACTGTCGAGATTGCAGCGGAATATGATTCTCTTCCTCCTTGCCCTTTCT  
GCTTTTCTGTGGACTCCTCTTCTACATCAACTTGGCTGACCATTGGAAAGCTCTGGCTTT  
CAGGCTAGAGGAAGAGCAGAAGATGAGGCCAGAAATTGCTGGGTAAACAGCAAATCC  
ACCCGTCTTACCAGCTCCTCAGAAGGCGGACACCGACCCCTGAGAACTTACCTGAGATTTC  
GTCACAGAAGACACAAAGACACATCCAGCGGGGACCACCTCACCTGCAGATTAGACCCCC  
AAGCCAAGACCTGAAGGATGGGACCCAGGAGGAGGCCACAAAAGGCAAGAAGCCCCCTGT  
GGATCCCCGCCCCGGAAGGAGATCCGCAGAGGACAGTCATCAGCTGGAGGGGAGCGGTGAT  
CGAGCCTGAGCAGGGCACCGAGCTCCCTTCAAGAAGAGCAGAAGTGCCACCAAGCCTCC  
CCTGCCACCGGCCAGGACACAGGGCACACCAGTGCATCTGAACTATCGCCAGAAGGGCGT  
GATTGACGTCTTCCTGCATGCATGGAAAGGATACCGCAAGTTTGCATGGGGCCATGACGA  
GCTGAAGCCTGTGTCCAGGTCTTCAGTGAGTGGTTTGGCCTCGGTCTCACACTGATCGA  
CGCGCTGGACACCATGTGGATCTTGGGTCTGAGGAAAGAATTTGAGGAAGCCAGGAAGTG  
GGTGTCAAGAAGTTACACTTTGAAAAGGACGTGGACGTCAACCTGTTTGAGAGCACGAT  
CCGCATCCTGGGGGGGCTCCTGAGTGCCTACCACCTGTCTGGGGACAGCCTCTTCCTGAG  
GAAAGCTGAGGATTTTGAAATCGGCTAATGCCTGCCTTCAGAACACCATCCAAGATTCC  
TTACTCGGATGTGAACATCGGTACTGGAGTTGCCACCCGCCACGGTGGACCTCCGACAG  
CACTGTGGCCGAGGTGACCAGCATTGAGCTGGAGTTCCGGGAGCTCTCCCGTCTCACAGG  
GGATAAGAAGTTTCAGGAGGCAGTGGAGAAGGTGACACAGCACATCCACGGCCTGTCTGG  
GAAGAAGGATGGGCTGGTGCCCATGTTTCATCAATACCCACAGTGGCCTCTTACCCACCT  
GGGCGTATTACGCTGGGCGCCAGGGCCGACAGCTACTATGAGTACCTGCTGAAGCAGTG  
GATCCAGGGCGGGAAGCAGGAGACACAGCTGCTGGAAGACTACGTGGAAGCCATCGAGGG  
TGTCAGAACGCACCTGCTGCGGCACTCCGAGCCAGTAAGCTCACCTTTGTGGGGGAGCT  
TGCCACCGGCCGCTTCAGTGCCAAGATGGACCACCTGGTGTGCTTCTGCCAGGGACGCT  
GGCTCTGGGCGTCTACCACGGCCTGCCCCGCCAGCCACATGGAGCTGGCCCAGGAGCTCAT  
GGAGACTTGTTACCAGATGAACCGGCAGATGGAGACGGGGCTGAGTCCCGAGATCGTGCA  
CTTCAACCTTTACCCCCAGCCGGGCCGTCGGGACGTGGAGGTCAAGCCAGCAGACAGGCA  
CAACCTGCTGCGGCCAGAGACCGTGGAGAGCCTGTTCTACCTGTACCGCGTCACAGGGGA  
CCGCAAATACCAGGACTGGGGCTGGGAGATTCTGCAGAGCTTCAGCCGATTACACGGGT  
CCCCTCGGGTGGCTATTCTTCCATCAACAATGTCCAGGATCCTCAGAAGCCCCGAGCCTAG  
GGACAAGATGGAGAGCTTCTTCCTGGGGGAGACGCTCAAGTATCTGTTCTTGCTCTTCTC  
CGATGACCCAAACCTGCTCAGCCTGGACGCCTACGTGTTCAACACCGAAGCCACCCCTCT  
GCCTATCTGGACCCCTGCCTAGGGTGGATGGCTGCTGGTGTGGGGACTTCGGGTGGGCAG  
AGGCACCTTGCTGGGTCTGTGGCATTTCCTCAAGGGCCACGTAGCACCGGCAACCGCCAA  
GTGGCCCAGGCTCTGAACTGGCTCTGGGCTCCTCCTCGTCTCTGCTTTAATCAGGACACC  
GTGAGGACAAGTGAGGCCGTGAGTCTTGGTGTGATGCGGGGTGGGCTGGGCCGCTGGAGC  
CTCCGCTGCTTCTCCTCCAGAAGACACGAATCATGACTCACGATTGCTGAAGCCTGAGCAG  
GTCTCTGTGGCCGACCAGAGGGGGGCTTCGAGGTGGTCCCTGGTACTGGGGTGACCGAG  
TGGACAGCCCAGGGTGCAGCTCTGCCCGGGCTCGTGAAGCCTCAGATGTCCCAATCCAA  
GGGTCTGGAGGGGCTGCCGTGACTCCAGAGGCCTGAGGCTCCAGGGCTGGCTCTGGTGT  
TACAAGCTGGACTCAGGGATCCTCCTGGCCGCCCCGAGGGGGCTTGAGGGGCTGGACGG  
CAAGTCCGTCTAGCTCACGGGCCCTCCAGTGGAATGGGTCTTTTCGGTGGAGATAAAG  
TTGATTGCTCTAACCGCAA

122/392

**FIGURE 116**

MAACEGRRSGALGSSQSDFLTPPVGGAPWAVATTVMYPPPPPPPHRDFISVTLSFGESY  
DNSKSWRRRSCWRKWKQLSRLQRMILFLLAFLFCGLLFYINLADHWKALAFRLEEEQK  
MRPEIAGLKPANPPVLPAPOKADTDPENLPEISSQKTQRHIQRGPPHLQIRPPSQDLKDG  
TQEEATKRQEAPVDPRPEGDPQRTVISWRGAVIEPEQGTELPSRRAEVPTKPPLPPARTQ  
GTPVHLNRYRQKGVIDVFLHAWKGYRKFAWGHDELKPVSRSFSEWFGLGLTLIDALDTMWI  
LGLRKEFEEARKWVSKKLHFEKDVDVNLFEESTIRILGGLLSAYHLSGDSLFLRKAEDFGN  
RLMPAFRTPSKIPYSDVNIGTGVAHPPRWTSDSTVAEVTSIQLEFRELSRLTGDKKFQEA  
VEKVTQHIGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSYEYLLKQWIQGGKQE  
TQLLEDYVEAIEGVRTHLLRHSEPSKLTFFVGE LAHGRFSAKMDHLVCFLPGTLALGVYHG  
LPASHMELAQELMETCYQMNRMETGLSPEIVHFNLYPQPGRRDVEVKPADRHNLRLPET  
VESLFYLYRVGTGDRKYQDWGWEILQSFSRFRTRVPSGGYSSINNVQDPQKPEPRDKMESFF  
LGETLKYLFLLFSDDPNLLSLDAYVFNTAHPLPIWTPA

Important features of the protein:

Transmembrane domain:

amino acids 21-40 and 84-105 (type II)

123/392

**FIGURE 117**

GTGGGATTTATTTGAGTGCAAGATCGTTTTCTCAGTGGTGGTGGGAAGTTGCCTCATCGCA  
GGCAGATGTTGGGGCTTTGTCCGAACAGCTCCCCTCTGCCAGCTTCTGTAGATAAGGGTT  
AAAACTAATATTTATATGACAGAAGAAAAAGATGTCATTCCGTAAAGTAAACATCATCA  
TCTTGGTCCTGGCTGTTGCTCTCTTCTTACTGGTTTTGCACCATAACTTCCTCAGCTTGA  
GCAGTTTGTTAAGGAATGAGGTTACAGATTCAGGAATTGTAGGGCCTCAACCTATAGACT  
TTGTCCCAAATGCTCTCCGACATGCAGTAGATGGGAGACAAGAGGAGATTCTGTGGTCA  
TCGCTGCATCTGAAGACAGGCTTGGGGGGGCCATTGCAGCTATAAACAGCATTTCAGCACA  
ACACTCGCTCCAATGTGATTTTCTACATTGTTACTCTCAACAATACAGCAGACCATCTCC  
GGTCTGGCTCAACAGTGATTCCCTGAAAAGCATCAGATACAAAATTGTCAATTTTGACC  
CTAAACTTTTGGAAGGAAAAGTAAAGGAGGATCCTGACCAGGGGGAATCCATGAAACCTT  
TAACCTTTGCAAGGTTCTACTTGCCAATTCTGGTTCCCAGCGCAAAGAAGGCCATATACA  
TGGATGATGATGTAATTGTGCAAGGTGATATTCTTGCCCTTTACAATACAGCACTGAAGC  
CAGGACATGCAGCTGCATTTTCAGAAGATTGTGATTTCAGCCTCTACTAAAGTTGTTCATCC  
GTGGAGCAGGAAACCAGTACAATTACATTGGCTATCTTGA CTATAAAAAGGAAAGAATTC  
GTAAGCTTTCCATGAAAGCCAGCACTTGCTCATTTAATCCTGGAGTTTTTGTGCAAACC  
TGACGGAATGGAAACGACAGAATATAACTAACCAACTGGAAAAATGGATGAAACTCAATG  
TAGAAGAGGGACTGTATAGCAGAACCCCTGGCTGGTAGCATCACAACACCTCCTCTGCTTA  
TCGTATTTTATCAACAGCACTCTACCATCGATCCTATGTGGAATGTCCGCCACCTTGGTT  
CCAGTGCTGGAAAACGATATTCACCTCAGTTTGTAAGGCTGCCAAGTTACTCCATTGGA  
ATGGACATTTGAAGCCATGGGGAAGGACTGCTTCATATACTGATGTTTGGGAAAAATGGT  
ATATTCCAGACCCAACAGGCAAATTCACCTAATCCGAAGATATACCGAGATCTCAAACA  
TAAAGTGAAACAGAATTTGAACTGTAAGCAAGCATTTCTCAGGAAGTCCTGGAAGATAGC  
ATGCATGGGAAGTAACAGTTGCTAGGCTTCAATGCCTATCGGTAGCAAGCCATGGAAAAA  
GATGTGTCAGCTAGGTAAAGATGACAACTGCCCTGTCTGGCAGTCAGCTTCCAGACAG  
ACTATAGACTATAAATATGTCTCCATCTGCCCTTACCAAGTGTTTTCTTACTACAATGCTG  
AATGACTGGAAAGAAGAACTGATATGGCTAGTTCAGCTAGCTGGTACAGATAATTCAAAA  
CTGCTGTTGGTTTTAATTTTGTAACCTGTGGCCTGATCTGTAAATAAACTTACATTTTC

124/392

**FIGURE 118**

MSFRKVNIIILVLAVALFLLVLHHNFLSLSSLRNEVTD SGIVGPQPIDFVPNALRHA VD  
GRQEEIPV VIAASEDR LGGAIAAINS IQHNTRSNVIFYIVTLNNTADHLRSWLNSDSLKS  
IRYKIVNFDPKLLEGKV KEDPDQGESMKPLTFARFYLPILVPSAKKAIYMDDD VIVQGDI  
LALYNTALKPGHAAAFSEDCDSASTKV VIRGAGNQYNYIGYLDYKKERIRKLSMKASTCS  
FNPGVFVANLTEWKRQ NITNQLEKWMKLNVEEGLYSRTL AGSITTPPLLIVFYQQHSTID  
PMWNVRLGSSAGKRYSPQFVKA AKLLHWNGHLKPWGRTASYTDVWEKWI IPDPTGKFNL  
IRRYTEISNIK

125/392

**FIGURE 119**

CCATCCCTGAGATCTTTTTATAAAAAACCCAGTCTTTGCTGACCAGACAAAGCATAACCAG  
ATCTCACCAGAGAGTCGCAGACACTATGCTGCCTCCCATGGCCCTGCCCAGTGTGTCCTG  
GATGCTGCTTTCCTGCCTCATTCTCCTGTGTCAGGTTCAAGGTGAAGAAACCCAGAAGGA  
ACTGCCCTCTCCACGGATCAGCTGTCCCAAAGGCTCCAAGGCCTATGGCTCCCCCTGCTA  
TGCCTTGTTTTTGTACCAAAATCCTGGATGGATGCAGATCTGGCTTGCCAGAAGCGGCC  
CTCTGGAAAACTGGTGTCTGTGCTCAGTGGGGCTGAGGGATCCTTCGTGTCTCCTCCCTGGT  
GAGGAGCATTAGTAACAGCTACTCATACATCTGGATTGGGCTCCATGACCCACACAGGG  
CTCTGAGCCTGATGGAGATGGATGGGAGTGGAGTAGCACTGATGTGATGAATTACTTTGC  
ATGGGAGAAAAATCCCTCCACCATCTTAAACCCTGGCCACTGTGGGAGCCTGTCAAGAAG  
CACAGGATTTCTGAAGTGGAAGATTATAACTGTGATGCAAAGTTACCCTATGTCTGCAA  
GTTCAAGGACTAGGGCAGGTGGGAAGTCAGCAGCCTCAGCTTGGCGTGCAGCTCATCATG  
GACATGAGACCAGTGTGAAGACTCACCTGGAAGAGAATATTCTCCCCAACTGCCCTAC  
CTGACTACCTTGTCATGATCCTCCTTCTTTTCTTTTCTTTTCTTACCTTCATTTCAGGCTT  
TTCTCTGTCTTCCATGTCTTGAGATCTCAGAGAATAATAATAAAAATGTTACTTTATAAA  
AAAAAAAAAAAAAAAAAAAA



126/392

## FIGURE 120

MLPPMALPSVSWMLLSCLILLCQVQGEETQKELPSPRISCPKGSKAYGSPCYALFLSPKS  
WMDADLACQKRPSGKLVSVLSGAEGSFVSSLVRSISNSYSYIWIGLHDPTQGSEPDGDGW  
EWSSTDVMNYFAWEKNPSTILNPGHCGSLSRSTGFLKWKDYNCDAKLPYCKFKD

**Important features:**

**Signal peptide:**

amino acids 1-26

**C-type lectin domain signature:**

amino acids 146-171

127/392

## FIGURE 121

AAAGTTACATTTTCTCTGGAACCTCTCCTAGGCCACTCCCTGCTGATGCAACATCTGGGTT  
TGGGCAGAAAGGAGGGTGCTTCGGAGCCCCGCCCTTTCTGAGCTTCCTGGGCCGGCTCTAG  
AACAAATTCAGGCTTCGCTGCGACTCAGACCTCAGCTCCAACATATGCATTCTGAAGAAAG  
ATGGCTGAGATGGACAGAATGCTTTATTTTGGAAAGAAACAATGTTCTAGGTCAAACCTGA  
GTCTACCAAATGCAGACTTTTACAATGGTTCTAGAAGAAATCTGGACAAGTCTTTTTCATG  
TGGTTTTTCTACGCATTGATTCCATGTTTGCTCACAGATGAAGTGGCCATTCTGCCTGCC  
CCTCAGAACCTCTCTGTACTCTCAACCAACATGAAGCATCTCTTGATGTGGAGCCCAGTG  
ATCGCGCCTGGAGAAACAGTGTACTATTCTGTGCAATACCAGGGGGAGTACGAGAGCCTG  
TACACGAGCCACATCTGGATCCCCAGCAGCTGGTGCTCACTCACTGAAGGTCCTGAGTGT  
GATGTCACTGATGACATCACGGCCACTGTGCCATACAACCTTCGTGTCAGGGCCACATTG  
GGCTCACAGACCTCAGCCTGGAGCATCCTGAAGCATCCCTTTAATAGAAACTCAACCATC  
CTTACCCGACCTGGGATGGAGATCACCAAAGATGGCTTCCACCTGGTTATTGAGCTGGAG  
GACCTGGGGCCCCAGTTTGAGTTCCTTGTGGCCTACTGGAGGAGGGAGCCTGGTGCCGAG  
GAACATGTCAAAATGGTGAGGAGTGGGGGTATTCCAGTGCACCTAGAAACCATGGAGCCA  
GGGGCTGCATACTGTGTGAAGGCCCAGACATTCGTGAAGGCCATTGGGAGGTACAGCGCC  
TTCAGCCAGACAGAATGTGTGGAGGTGCAAGGAGAGGCCATTCCCCCTGGTACTGGCCCTG  
TTTGCCTTTGTTGGCTTCATGCTGATCCTTGTGGTTCGTGCCACTGTTTCGTCTGGAAAATG  
GGCCGGCTGCTCCAGTACTCCTGTTGCCCCGTGGTGGTCCTCCCAGACACCTTGAAAATA  
ACCAATTCACCCCAGAAGTTAATCAGCTGCAGAAGGGAGGAGGTGGATGCCTGTGCCACG  
GCTGTGATGTCTCCTGAGGAACTCCTCAGGGCCTGGATCTCATAGGTTTTGCGGAAGGGCC  
CAGGTGAAGCCGAGAACCTGGTCTGCATGACATGGAAACCATGAGGGGACAAGTTGTGTT  
TCTGTTTTCCGCCACGGACAAGGGATGAGAGAAGTAGGAAGAGCCTGTTGTCTACAAGTC  
TAGAAGCAACCATCAGAGGCAGGGTGGTTTTGTCTAACAGAACACTGACTGAGGCTTAGGG  
GATGTGACCTCTAGACTGGGGGCTGCCACTTGCTGGCTGAGCAACCCTGGGAAAAGTGAC  
TTCATCCCTTCGGTCCTAAGTTTTCTCATCTGTAATGGGGGAATTACCTACACACCTGCT  
AAACACACACACACAGAGTCTCTCTATATATACACACGTACACATAAATACACCCAGC  
ACTTGCAAGGCTAGAGGGAAACTGGTGACACTCTACAGTCTGACTGATTCACTGTTTCTG  
GAGAGCAGGACATAAATGTATGATGAGAATGATCAAGGACTCTACACACTGGGTGGCTTG  
GAGAGCCCACTTTCCCAAGAATAATCCTTGAGAGAAAAGGAATCATGGGAGCAATGGTGTT  
GAGTTCACCTTCAAGCCCAATGCCGGTGCAGAGGGGAATGGCTTAGCGAGCTCTACAGTAG  
GTGACCTGGAGGAAGGTCACAGCCCACTGAAAATGGGATGTGCATGAACACGGAGGATC  
CATGAACTACTGTAAAGTGTGACAGTGTGTGCACACTGCAGACAGCAGGTGAAATGTAT  
GTGTGCAATGCGACGAGAATGCAGAAGTCAGTAACATGTGCATGTTTGTGTGCTCCTTT  
TTTCTGTTGGTAAAGTACAGAATTCAGCAAATAAAAAGGGCCACCCTGGCCAAAAGCGGT  
AAAAAAAAAAAAAAAA

128/392

**FIGURE 122**

MQFTMVLEEIWTSLFMWFFYALIPCLLTDEVAILPAPQNLSVLSTNMKLLMWSPVIAP  
GETVYYSVEYQGEYESLYTSHIWIPSSWCSLTEGPECDVTDDITATVPYNLRVRATLGSQ  
TSAWSILKHFPNRRNSTILTRPGMEITKDGPHLVIELEDLGPQFEFLVAYWRREPGAEHV  
KMVRSGGIPVHLETMEPGAAYCVKAQTFVKAIGRYSAFSQTECEVEVQGEAIPVLALFAF  
VGFMLILVVVPLFVWKMGRLLQYSCCPVVVLPDTLKITNSPQKLISCRREEVDACATVM  
SPEELLRAWIS

**Important features:****Signal peptide:**

amino acids 1-29

**Transmembrane domain:**

amino acids 230-255

**N-glycosylation sites:**

amino acids 40-43 and 134-137

**Tissue factor proteins homology:**

amino acids 92-119

**Integrins alpha chain protein homology:**

amino acids 232-262

129/392

**FIGURE 123**

CGGACGCGTGGGCCCGCCACCTCCGGAACAAGCCATGGTGGCGGCGACGGTGGCAGCGGCG  
TGGCTGCTCCTGTGGGCTGCGGCCTGCGCGCAGCAGGAGCAGGACTTCTACGACTTCAAG  
GCGGTCAACATCCGGGGCAAACCTGGTGTGCTGGAGAAGTACCGCGGATCGGTGTCCCTG  
GTGGTGAATGTGGCCAGCGAGTGCGGCTTACAGACCAGCACTACCGAGCCCTGCAGCAG  
CTGCAGCGAGACCTGGGCCCCCACCCTTTAACGTGCTCGCCTTCCCCCTGCAACCAGTTT  
GGCCAACAGGAGCCTGACAGCAACAAGGAGATTGAGAGCTTTGCCCCGCCGACCTACAGT  
GTCTCATTCCCCATGTTTAGCAAGATTGCAGTCACCGGTACTGGTGCCCATCCTGCCTTC  
AAGTACCTGGCCCAGACTTCTGGGAAGGAGCCCACCTGGAACCTTCTGGAAGTACCTAGTA  
GCCCCAGATGGAAAGGTGGTAGGGGCTTGGGACCCAACTGTGTGAGTGGAGGAGGTCAGA  
CCCCAGATCACAGCGCTCGTGAGGAAGCTCATCCTACTGAAGCGAGAAGACTTATAACCA  
CCGCGTCTCCTCCTCCACCACCTCATCCCGCCCACCTGTGTGGGGCTGACCAATGCAAAC  
TCAAATGGTGCTTCAAAGGGAGAGACCCACTGACTCTCCTTCTTTACTCTTATGCCATT  
GGTCCCATCATTTCTTGTGGGGGAAAAATTCTAGTATTTTGATTATTTGAATCTTACAGCA  
ACAAATAGGAATCCTGGCCAATGAGAGCTCTTGACCAGTGAATCACCAGCCGATACGAA  
CGTCTTGCCAACAAAAATGTGTGGCAAATAGAAGTATATCAAGCAATAATCTCCACCCA  
AGGCTTCTGTAAACTGGGACCAATGATTACCTCATAGGGCTGTTGTGAGGATTAGGATGA  
AATACCTGTGAAAGTGCCTAGGCAGTGCCAGCCAAATAGGAGGCATTCAATGAACATTTT  
TTGCATATAAACCAAAAAATAACTTGTTATCAATAAAAACTTGCATCCAACATGAATTTCT  
CAGCCGATGATAATCCAGGCCAAAGGTTTAGTTGTTGTTATTTCTCTGTATTATTTTCT  
TCATTACAAAAGAAATGCAAGTTCATTGTAACAATCCAAACAATACCTCACGATATAAAA  
TAAAAATGAAAGTATCCTCCTCAAAAA

130/392

## FIGURE 124

MVAATVAAAWLLLWAAACAQQEQDFYDFKAVNIRGKLVSLVKYRGSVSLVNVASECGFT  
DQHYRALQQLQORDLGPHHFNVLAFFPCNQFGQQEPDSNKEIESFARRTYSVSFPMFSKIAV  
TGTGAHPAFKYLAQTSKGKEPTWNFWKYL VAPDGKVVGAWDPTVSVEEVRPQITALVRKLI  
LLKREDL

131/392

**FIGURE 125**

CGGACGCGTGGGCGGACGCGTGGGCGGACGCGTGGGTTGGGAGGGGGCAGGATGGGAGGG  
AAAGTGAAGAAAACAGAAAAGGAGAGGGACAGAGGCCAGAGGACTTCTCATACTGGACAG  
AAACCGATCAGGCATGGAACTCCCCCTTCGTCACTCACCTGTTCTTGCCCCCTGGTGTTCCT  
GACAGGTCTCTGCTCCCCCTTTAACCTGGATGAACATCACCCACGCCTATTCCCAGGGCC  
ACCAGAAGCTGAATTTGGATACAGTGTCTTACAACATGTTGGGGGTGGACAGCGATGGAT  
GCTGGTGGGCGCCCCCTGGGATGGGCCTTCAGGCGACCGGAGGGGGGACGTTTATCGCTG  
CCCTGTAGGGGGGGCCCCACAATGCCCCATGTGCCAAGGGCCACTTAGGTGACTACCAACT  
GGGAAATTCATCTCATCCTGCTGTGAATATGCACCTGGGGATGTCTCTGTTAGAGACAGA  
TGGTGATGGGGGATTTCATGGTGAGCTAAGGAGAGGGGTGGTGGCAGTGTCTCTGAAGGTCC  
ATAAAAGAAAAAAGAGAAGTGTGGTAAGGGAAAATGGTCTGTGTGGAGGGGTCAAGGAGT  
TAAAAACCCTAGAAAGCAAAAGGTAGGTAATGTCAGGGAGTAGTCTTCATGCCTCCTTCA  
ACTGGGAGCATGTTCTGAGGGTGCCCTCCCAAGCCTGGGAGTAACTATTTCCCCCATCCC  
CAGGCCTGTGCCCCCTCTCTGGTCTCGTGCTTGTGGCAGCTCTGTCTTCAGTTCTGGGATA  
TGTGCCCCGTGTGGATGCTTCATTCCAGCCTCAGGGAAGCCTGGCACCCACTGCCCAACGT  
GAGCCAGAGGAAGGCTGAGTACTTGTTTCCAGAAGGAGATACTGGGTGGGAAAAAGATG  
GGGCAAAGCGGTATGATGCCTGGCAAAGGGCCTGCATGGCTATCCTCATTGCTACCTAAT  
GTGCTTGCAAAAGCTCCATGTTTCCTAACAGATTGAGACTCCTGGCCAGGTGTGGTGGCC  
CACACCTGTAATTCTAGCACTTTGGGAGGCCAAGGTGGGCAGATCACTTGAGGTGAGGAG  
TTCAAGACCAGCCTGGCCAACATGGTGAACTCCATCTCTACTAAAAAAAAAAAAAATACA  
AAAATTAGCTGGGTGCGCTAGTGATGCCTGTAATCTCATCTACTCGGGAGGCTAAGACA  
GGAGACTCTCACTTCAACCCAGGAGGTGGAGGTGCGGTGAGCCAAGATTGTGCCTCTGC  
ACTCTAGCGTGGGTGACAGAGTAAGCGAGACTCCATCTCAAAAATAATAATAATAATAAT  
TCAGACTCCTTATCAGGAGTCCATGATCTGGCCTGGCACAGTAACTCATGCCTGTAATCC  
CAACATTTTGGGAGGCCAACGCAGGAGGATTGCTTGAGGTCTGGAGGTTTGAGACCAGCC  
TGGGCAACATAGAAAGACCCCATCTCTAAATAAATGTTTTAAAAAT

132/392

## FIGURE 126

MELPFVTHLFLPLVFLTGLCSPFNLDEHHPRLFPGPPEAEFGYSVLQHVGGGQRWMLVGA  
PWDGPSGDRRGDVYRCPVGGAHNAPCAKGHLGDYQLGNSSHPAVNMHLGMSLLETGDGG  
FMVS

**Important features:**

**Signal peptide:**

amino acids 1-22

**Cell attachment sequence:**

amino acids 70-73

**N-glycosylation site:**

amino acids 98-101

**Integrins alpha chain proteins:**

amino acids 67-81

133/392

**FIGURE 127**

GAGAGGACGAGGTGCCGCTGCCTGGAGAATCCTCCGCTGCCGTCCGGCTCCCGGAGCCAC  
CCCTTTCTTAACCCAACCCAACCTAGCCCAGTCCCAGCCGCCAGCGCCTGTCCCTGTCAC  
GGACCCAGCGTTACCAATGCATCCTGCCGTCTTCTTATCCTTACCCGACCTCAGATGCTC  
CCTTCTGCTCCTGGTAACCTTGGGTTTTTACTCCTGTAACAACCTGAAATAACAAGTCTTG  
TACAGAGAATATAGATGAAATTTTAAACAATGCTGATGTTGCTTTAGTAAATTTTTATG  
TGACTGGTGTCTGTTTCAGTCAGATGTTGCATCCAATTTTTGAGGAAGCTTCCGATGTCAT  
TAAGGAAGAAATTTCCAAATGAAATCAAGTAGTGTGTTGCCAGAGTTGATTGTGATCAGCA  
CTCTGACATAGCCAGAGATACAGGATAAGCAAATACCCAACCCTCAAATTGTTTCGTAA  
TGGGATGATGATGAAGAGAGAATACAGGGGTCAGCGATCAGTGAAAGCATTGGCAGATTA  
CATCAGGCAACAAAAAAGTGACCCCATTCAGAAATTCGGGACTTAGCAGAAATCACCAC  
TCTTGATCGCAGCAAAAAGAAATATCATTGGATATTTTTGAGCAAAAGGACTCGGACAAC  
TAGAGTTTTTTGAACGAGTAGCGAATATTTTTGCATGATGACTGTGCCTTTCTTTCTGCATT  
TGGGGATGTTTCAAACCGGAAAGATATAGTGGCGACAACATAATCTACAAACCACCAG  
GCATTCTGCTCCGGATATGGTGTACTTGGGAGCTATGACAAATTTTGATGTGACTTACAA  
TTGGATTCAAGATAAATGTGTTCTCTTGTCCGAGAAATAACATTTGAAAATGGAGAGGA  
ATTGACAGAAGAAGGACTGCCTTTTCTCATACTCTTTCACATGAAAGAAGATACAGAAAG  
TTTAGAAATATTCCAGAATGAAGTAGCTCGGCAATTAATAAGTGAAAAAGGTACAATAAA  
CTTTTTTACATGCCGATTGTGACAAATTTAGACATCCTCTTCTGCACATACAGAAAAC  
AGCAGATTGTCTGTAATCGCTATTGACAGCTTTAGGCATATGTATGTGTTTGGAGACTT  
CAAAGATGTATTAATTCTTGAAAACTCAAGCAATTCGTATTTGACTTACATTCTGGAAA  
ACTGCACAGAGAATTCCATCATGGACCTGACCCAACTGATACAGCCCCAGGAGAGCAAGC  
CCAAGATGTAGCAAGCAGTCCACCTGAGAGCTCTTCCAGAAACTAGCACCAGTGAATA  
TAGGTATACTCTATTGAGGGATCGAGATGAGCTTTTAAAAACTTGAAAAACAGTTTGTAAG  
CCTTTCAACAGCAGCATCAACCTACGTGGTGGAATAAGTAAACCTATATTTTTCATAATTC  
TATGTGTATTTTTTATTTTGAATAAAACAGAAAGAAATTTAAAAA  
AAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAA



134/392

**FIGURE 128**

MHPAVFLSLPDLRCSLLLLVTWVFTPVTTEITSLATENIDEILNNADVALVNFYADWCRF  
SQMLHPIFEEASDVIKEEFPNENQVVVFARVDCDQHS DIAQRYRISKYPTLKLFRNGMMMK  
REYRGQRSVKALADYIRQOKSDPIQEIRDLAEITTLDRSKRNIIGYFEQKSDSNYRVFER  
VANILHDDCAFLSAFGDVSKPERYSGDNI IYKPPGHSAPDMVYLGAMTNFDVTYNWIQDK  
CVPLVREITFENGEEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHAD  
CDKFRHPLLHIQKTPADCPVIAIDSFHMYVFGDFKDVLI PGKCLKQFVFDLHSGKLHREF  
HHGPDPTDTAPGEQAQDVASSPPESSFQKLAPSEYRYTLLRDRDEL

**Important features:**

**Signal peptide:**

amino acids 1-29

**Endoplasmic reticulum targeting sequence:**

amino acids 403-406

**Tyrosine kinase phosphorylation site:**

amino acids 203-211

**Thioredoxin family proteins:**

amino acids 50-66

135/392

**FIGURE 129**

GAGCAGGACGGAGCCATGGACCCCGCCAGGAAAGCAGGTGCCCAGGCCATGATCTGGACT  
GCAGGCTGGCTGCTGCTGCTGCTGCTTTCGCGGAGGAGCGCAGGCCCTGGAGTGCTACAGC  
TGCGTGACAGAAAGCAGATGACGGATGCTCCCCGAACAAGATGAAGACAGTGAAGTGCGCG  
CCGGGCGTGACGTCTGCACCGAGGCCGTGGGGGCGGTGGAGACCATCCACGGACAATTC  
TCGCTGGCAGTGCGGGGTTGCGGTTTCGGGACTCCCCGGCAAGAATGACCGCGGCCTGGAT  
CTTCACGGGCTTCTGGCGTTTCATCCAGCTGCAGCAATGCGCTCAGGATCGCTGCAACGCC  
AAGCTCAACCTCACCTCGCGGGCGCTCGACCCGGCAGGTAATGAGAGTGCATACCCGCC  
AACGGCGTGAGTGCTACAGCTGTGTGGGCTGAGCCGGGAGGCGTGCCAGGGTACATCG  
CCGCCGGTCGTGAGCTGCTACAACGCCAGCGATCATGTCTACAAGGGCTGCTTCGACGGC  
AACGTCACCTTGACGGCAGCTAATGTGACTGTGTCTTGCCTGTCCGGGGCTGTGTCCAG  
GATGAATTCTGCACTCGGGATGGAGTAACAGGCCAGGGTTACGCTCAGTGGCTCCTGT  
TGCCAGGGGTCCCCTGTAACTCTGACCTCCGCAACAAGACCTACTTCTCCCCTCGAATC  
CCACCCCTTGTCCGGCTGCCCCCTCCAGAGCCCACGACTGTGGCCTCAACCACATCTGTC  
ACCACCTTCTACCTCGGCCCCAGTGAGACCCACATCCACCACCAAACCCATGCCAGCGCCA  
ACCAGTCAGACTCCGAGACAGGGAGTAGAACACGAGGCCTCCCGGGATGAGGAGCCCAGG  
TTGACTGGAGGCGCCGCTGGCCACCAGGACCGCAGCAATTCAGGGCAGTATCCTGCAAAA  
GGGGGGCCCCCAGCAGCCCCATAATAAAGGCTGTGTGGCTCCACAGCTGGATTGGCAGCC  
CTTCTGTTGGCCGTGGCTGCTGGTGTCTTACTGTGAGCTTCTCCACCTGGAAATTTCCCT  
CTCACCTACTTCTCTGGCCCTGGGTACCCCTCTTCTCATCACTTCCTGTTCCCACTG  
GACTGGGCTGGCCAGCCCCTGTTTTTCCAACATTCCCCAGTATCCCCAGCTTCTGCTGC  
GCTGGTTTTGCGGCTTTGGGAAATAAAATACCGTTGTATATATTCTGCCAGGGGTGTTCTA  
GCTTTTTGAGGACAGCTCCTGTATCCTTCTCATCCTTGTCTCTCCGCTTGTCTCTTGTG  
ATGTTAGGACAGAGTGAGAGAAGTCAGCTGTACGGGGAAGGTGAGAGAGAGGATGCTAA  
GCTTCCTACTCACTTTCTCCTAGCCAGCCTGGACTTTGGAGCGTGGGGTGGGTGGGACAA  
TGGCTCCCCACTCTAAGCACTGCCTCCCCTACTCCCCGCATCTTTGGGGAATCGGTTCCC  
CATATGTCTTCTTACTAGACTGTGAGCTCCTCGAGGGGGGGCCCGGTACCCAATTGCCC  
CTATAGTGAGTCGTA

136/392

**FIGURE 130**

MDPARKAGAQAMIWTAGWLLLLLLRGGQAQALECYSCVQKADDGCSPNKMKTVCAPGVDV  
CTEAVGAVETIHGQFSLAVRGCGSGLPGKNDRGLDLHGLLAFIQLQQCAQDRCAKLNLT  
SRALDPAGNESAYPPNGVECYSCVGLSREACQGTSPPVVSCYNASDHVYKGCFDGNVTLT  
AANVTVSLPVRGCVQDEFCTRDGVTGPGFTLSGSCCQGSRCNSDLRNKTYFSPRIPLVR  
LPPPEPTTVASTTSVTTSTAPVRPTSTTKPMPAPTSQTPRQGVHEASRDEEPRLTGGA  
AGHQDRSNSGQYPAKGGPQQPHNKGCVAPTAGLAALLLAVAAGVLL

137/392

**FIGURE 131**

AAACTTGACGCCATGAAGATCCCGGTCCTTCCTGCCGTGGTGCTCCTCTCCCTCCTGGTG  
CTCCACTCTGCCCAGGGAGCCACCCTGGGTGGTCCTGAGGAAGAAAGCACCATTGAGAAT  
TATGCGTCACGACCCGAGGCCTTTAACACCCCGTTCTTGAACATCGACAAATTGCGATCT  
GCGTTTAAGGCTGATGAGTTCCTGAACTGGCACGCCCTCTTTGAGTCTATCAAAAGGAAA  
CTTCCTTTCCTCAACTGGGATGCCTTTCCTAAGCTGAAAGGACTGAGGAGCGCAACTCCT  
GATGCCCAGTGACCATGACCTCCACTGGAAGAGGGGGCTAGCGTGAGCGCTGATTCTCAA  
CCTACCATAACTCTTTCCTGCCTCAGGAACTCCAATAAAACATTTTCATCCAAA

138/392

## FIGURE 132

MKIPVLPVAVLLSLLVLHSAQGATLGGPEEESTIENYASRPEAFNTPFLNIDKLRSAFKA  
DEFLNWHALFESIKRKLPFLNWDAPPKLKGLRSATPDAQ

139/392

**FIGURE 133**

CAGTTCTGAAATCAATGGAGTTAATTTAGGGAATACAAACCAGCCATGGGGGTGGAGATT  
GCCTTTGCCTCAGTGATTCTCACCTGCCTCTCCCTTCTGGCAGCAGGAGTCTCCAGGTT  
GTTCTTCTCCAGCCAGTTCCAACCTCAGGAGACAGGTCCCAAGGCCATGGGAGATCTCTCC  
TGTGGCTTTGCCGGCCACTCATGAGAGTGTTTTTGTGTAAAGTATTTTTTAGAATACTGT  
TGACTTCTTCATGATTTAATAACCATCCTTTGCGAAGTTTTATGAGGCTTTAGGGGAATG  
TCAACCCTCAAATTTTTGTTATACTAGATGGCTTCCATTTACCCACCACTATTTTAAGGT  
CCCTTTATTTTTAGGTTCAAGGTTCAATTTGACTTGAGAAAGTGCCCTTCTGCAGCTTCAT  
TGATTTTGTTTATCTTCACTATTAATTGTAACGATTAAAAAGAATAAGAGCACGCAGAC  
CTCTAGGAGAATATTTTATCCCTGGGTGCCCCTGACACATTTATGTAGTGATCCCACAAA  
TGTGATTGTTAATTTAAATGTTATTCTAATATTAGTACATTCAGTTGTGATGTAATATGA  
ATAACCAGAATCTATTTCTTAAAAGTTTTGAGTATATTTTTCAACTAGATATTGTATAG  
AAAGACTGAATAGTGATG

140/392

## FIGURE 134

MGVEIAFASVILTCLSLLAAGVSQVLLQPVPQTQETGPKAMGDLSCGFAGHS

141/392

**FIGURE 135**

GGGGAATCTGCAGTAGGTCTGCCGGCGATGGAGTGGTGGGCTAGCTCGCCGCTTCGGCTC  
TGGCTGCTGTTGTTCTCCTGCCCTCAGCGCAGGGCCGCCAGAAGGAGTCAGGTTCAAAA  
TGGAAAGTATTTATTGACCAAATTAACAGGTCTTTGGAGAATTACGAACCATGTTCAAGT  
CAAACTGCAGCTGCTACCATGGTGT CATAGAAGAGGATCTAACTCCTTTCCGAGGAGGC  
ATCTCCAGGAAGATGATGGCAGAGGTAGTCAGACGGAAGCTAGGGACCCACTATCAGATC  
ACTAAGAACAGACTGTACCGGGAATGACTGCATGTTCCCTCAAGGTGTAGTGGTGT  
GAGCACTTTATTTTGGAAAGTGATCGGGCGTCTCCCTGACATGGAGATGGTGATCAATGTA  
CGAGATTATCCTCAGGTTCTTAAATGGATGGAGCCTGCCATCCCAGTCTTCTCCTTCAGT  
AAGACATCAGAGTACCATGATATCATGTATCCTGCTTGGACATTTTGGGAAGGGGACCT  
GCTGTTTGGCCAATTTATCCTACAGGTCTTGGACGGTGGGACCTCTTCAGAGAAGATCTG  
GTAAGGTGAGCAGCACAGTGGCCATGGAAAAAGAAAACTCTACAGCATATTTCCGAGGA  
TCAAGGACAAGTCCAGAACGAGATCCTCTCATTCTTCTGTCTCGGAAAAACCCAAAACTT  
GTTGATGCAGAATACACCAAAAACCAGGCCTGGAAATCTATGAAAGATACCTTAGGAAAG  
CCAGCTGCTAAGGATGTCCATCTTGTGGATCACTGCAAATACAAGTATCTGTTTAAATTTT  
CGAGGCGTAGCTGCAAGTTTCCGGTTTAAACACCTCTTCTGTGTGGCTCACTTGTTTTT  
CATGTTGGTGATGAGTGGCTAGAATTCTTCTATCCACAGCTGAAGCCATGGGTTCACTAT  
ATCCCAGTCAAAACAGATCTCTCCAATGTCCAAGAGCTGTTACAATTTGTAAAAGCAAA  
GATGATGTAGCTCAAGAGATTGCTGAAAGGGGAAGCCAGTTTATTAGGAACCATTTGCAG  
ATGGATGACATCACCTGTTACTGGGAGAACCTCTTGAGTGAATACTCTAAATTCCTGTCT  
TATAATGTAACGAGAAGGAAAGGTTATGATCAAATTATTCCCAAATGTTGAAAACCTGAA  
CTATAGTAGTCATCATAGGACCATAGTCCTCTTTGTGGCAACAGATCTCAGATATCCTAC  
GGTGAGAAGCTTACCATAAGCTTGGCTCCTATACCTTGAATATCTGCTATCAAGCCAAAT  
ACCTGGTTTTTCCTTATCATGCTGCACCCAGAGCAACTCTTGAGAAAAGATTTAAAATGTGT  
CTAATACACTGATATGAAGCAGTTCACCTTTTGGATGAATAAGGACCAGAAATCGTGAG  
ATGTGGATTTTGAACCCAACTCTACCTTTTCATTTTCTTAAGACCAATCACAGCTTGTGCC  
TCAGATCATCCACCTGTGTGAGTCCATCACTGTGAAATTGACTGTGTCCATGTGATGATG  
CCCTTTGTCCCATTTATTTGGAGCAGAAAATTCGTCAATTTGGAAGTAGTACAACCTCATTGC  
TGGAATTGTGAAATTATTCAAGGCGTGATCTCTGTCACTTTATTTTAAATGTAGGAAACCC  
TATGGGGTTTATGAAAAATACTTGGGGATCATTTCTCTGAATGGTCTAAGGAAGCGGTAGC  
CATGCCATGCAATGATGTAGGAGTTCTCTTTTGTAAAACCATAAACTCTGTACTCAGGA  
GGTTTCTATAATGCCACATAGAAAGAGGCCAATTGCATGAGTAATTATTGCAATTGGATT  
TCAGGTTCCCTTTTTGTGCCTTCATGCCCTACTTCTTAATGCCTCTCTAAAGCCAAA



142/392

**FIGURE 136**

MEWWASSPLRLWLLLLFLLPSAQGRQKESGSKWKVFIDQINRSLENYEPCSSQNCSCYHGV  
IEEDLTPFRGGISRKMAEVVRRKLGTHYQITKNRLYREND CMFPSRCSGVEHFILEVIG  
RLPDMEMVINVRDYPQVPKWMEPAIPVFSFSKTSEYHDIMYPAWTFWEGGPAVWPIYPTG  
LGRWDLFREDLVRSAQWPWKKNSTAYFRGSRTSPERDPLILLSRKNPKLVD AEYTKNQ  
AWKSMKDTLGKPAAKDVHLVDHCKYKYLNFNFRGVAASFRFKHLFLCGSLVFHVGDEWLEF  
FYPQLKPWWHYIPVKTDLSNVQELLQFVKANDDVAQEIAERGSQFIRNHLQMD DITCYWE  
NLLSEYSKFLSYNVTRRKGYDQIIPKMLKTEL

143/392

**FIGURE 137**

ATTCTCCTAGAGCATCTTTGGAAGCATGAGGCCACGATGCTGCATCTTGGCTCTTGTCTG  
CTGGATAACAGTCTTCCTCCTCCAGTGTTCAAAGGAACTACAGACGCTCCTGTTGGCTC  
AGGACTGTGGCTGTGCCAGCCGACACCCAGGTGTGGGAACAAGATCTACAACCCTTCAGA  
GCAGTGCTGTTATGATGATGCCATCTTATCCTTAAAGGAGACCCGCCGCTGTGGCTCCAC  
CTGCACCTTCTGGCCCTGCTTTGAGCTCTGCTGTCCCGAGTCTTTTGGCCCCCAGCAGAA  
GTTTCTTGTGAAGTTGAGGGTTCTGGGTATGAAGTCTCAGTGTCACTTATCTCCCATCTC  
CCGGAGCTGTACCAGGAACAGGAGGCACGTCTGTACCCATAAAAAACCCAGGCTCCACT  
GGCAGACGGCAGACAAGGGGAGAAGAGACGAAGCAGCTGGACATCGGAGACTACAGTTGA  
ACTTCGGAGAGAAGCAACTTGACTTCAGAGGGATGGCTCAATGACATAGCTTTGGAGAGG  
AGCCCAGCTGGGGATGGCCAGACTTCAGGGGAAGAATGCCTTCCTGCTTCATCCCCTTTC  
CAGCTCCCCTTCCCGCTGAGAGCCACTTTCATCGGCAATAAAATCCCCACATTACCATCT

144/392

## FIGURE 138

MRPRCCILALVCWITVFLQCSKGTDDAPVGSGLWLCQPTPRCGNKIYNPSEQCCYDDAI  
LSLKETRRCGSTCTFWPCFELCCPESFGPQQKFLVKLRVLGMKSQCHLSPISRSCTRNRR  
HVLYP

**Important features:**

**Signal sequence:**

amino acids 1-21

**N-myristoylation sites:**

amino acids 33-39, 70-76

145/392

**FIGURE 139**

CCTCTGTCCACTGCTTTTCGTGAAGACAAGATGAAGTTCACAATTGTCTTTGCTGGACTTC  
TTGGAGTCTTTCTAGCTCCTGCCCTAGCTAACTATAATATCAACGTCAATGATGACAACA  
ACAATGCTGGAAGTGGGCAGCAGTCAGTGAGTGTCAACAATGAACACAATGTGGCCAATG  
TTGACAATAACAACGGATGGGACTCCTGGAATTCCATCTGGGATTATGGAAATGGCTTTG  
CTGCAACCAGACTCTTTCAAAAGAAGACATGCATTGTGCACAAAATGAACAAGGAAGTCA  
TGCCCTCCATTCAATCCCTTGATGCACTGGTCAAGGAAAAGAAGCTTCAGGGTAAGGGAC  
CAGGAGGACCACCTCCCAAGGGCCTGATGTACTCAGTCAACCCAAACAAAGTCGATGACC  
TGAGCAAGTTCGGAAAAAACATTGCAAACATGTGTTCGTGGGATTCCAACATACATGGCTG  
AGGAGATGCAAGAGGCAAGCCTGT'TTTTTTACTCAGGAACGTGCTACACGACCAGTGTAC  
TATGGATTGTGGACATTTCTTTCTGTGGAGACACGGTGGAGAACTAAACAATTTTTTAAA  
GCCACTATGGATTTAGTCATCTGAATATGCTGTGCAGAAAAAATATGGGCTCCAGTGGTT  
TTTACCATGTCATTCTGAAATTTTCTCTACTAGTTATGTTTGATTCTTTAAGTTTCAA  
TAAATCATTTAGCATTGAAAAAA

146/392

**FIGURE 140**

MKFTIVFAGLLGVFLAPALANYNINVNDDNNNAGSGQQSVSVNNEHNVANVDNNNGWDSW  
NSIWDYGNNGFAATRLFQKKTCTIVHKMNKEVMPSIQSLDALVKEKKLQGKGPGGPPPKGLM  
YSVNPKNKVDDLSKFGKNIANMCRGIPTYMAEEMQEASLFFYSGTCYTTSVLWIVDISFCG  
DTVEN

**Signal Peptide:**

amino acids 1-20

**N-myristoylation Sites:**

amino acids 67-72, 118-123, 163-168

**Flavodoxin protein homology:**

amino acids 156-174

147/392

**FIGURE 141**

GGTCCTTAATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCC  
TGCTGTCCGGCTGGTCCCGGGCTGGGCGAGCCGACCTCACTCTCTTTGCTATGACATCA  
CCGTCATCCCTAAGTTCAGACCTGGACCACGGTGGTGTGCGGTTCAAGGCCAGGTGGATG  
AAAAGACTTTTCTTCACTATGACTGTGGCAACAAGACAGTCACACCTGTCAGTCCCTTGG  
GGAAGAACTAAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTACTGAGAGAGGTGG  
TGGACATACTTACAGAGCAACTGCGTGACATTAGCTGGAGAATTACACACCCAAGGAAC  
CCCTCACCTTGCAGGCAAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGAT  
CTTGGCAGTTCAGTTTCGATGGGCAGATCTTCCTCCTCTTTGACTCAGAGAAGAGAATGT  
GGACAACGGTTCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTG  
TGGCCATGTCCTTCCATTACTTCTCAATGGGAGACTGTATAGGATGGCTTGAGGACTTCT  
TGATGGGCATGGACAGCACCTTGGAGCCAAGTGCAGGAGCACCACTCGCCATGTCCTCAG  
GCACAACCCAACCTCAGGGCCACAGCCACCACCCTCATCCTTTGCTGCCTCCTCATCATCC  
TCCCCTGCTTCATCCTCCCTGGCATCTGAGGAGAGTCCTTTAGAGTGACAGGTTAAAGCT  
GATACCAAAAGGCTCCTGTGAGCACGGTCTTGATCAAACCTCGCCCTTCTGTCTGGCCAGC  
TGCCACGACCTACGGTGTATGTCCAGTGGCCTCCAGCAGATCATGATGACATCATGGAC  
CCAATAGCTCATTCACTGCCTTGATTCTTTTGCCAACAATTTTACCAGCAGTTATACCT  
AACATATTATGCAATTTTCTCTTGGTGCTACCTGATGGAATTCCTGCACTTAAAGTTCTG  
GCTGACTAAACAAGATATATCATTTTCTTTCTTCTTTTTGTTTGGAAAATCAAGTACT  
TCTTTGAATGATGATCTCTTTCTTGCAAATGATATTGTCAGTAAAATAATCACGTTAGAC  
TTCAGACCTCTGGGGATTCTTTCCGTGTCCTGAAAGAGAATTTTAAATTATTTAATAAG  
AAAAAATTTATATTAATGATTGTTTCCTTTAGTAATTTATTGTTCTGTACTGATATTTAA  
ATAAAGAGTTCTATTTCCCAAAAAAAAAAAAAAAAAAAAA

148/392

**FIGURE 142**

MAAAAATKILLCLPLLLLLLSGWSRAGRADPHSLCYDITVIPKFRPGPRWCAVQGQVDEKT  
FLHYDCGNKTVTPVSP LGKKLNVT TAWKAQNPVLREVVDILTEQLRDIQLENYTPKEPLT  
LQARMSCEQKAEGHSSGSWQFSFDGQIFLLFDSEKRMWTTVHPGARKMKEKWENDKVVAM  
SFHYFSMGDCIGWLEDFLMGMDSTLEPSAGAPLAMSSGTTQLRATATTLILCCLLIILPC  
FILPGI

**Important features:****Signal peptide:**

amino acids 1-25

**Transmembrane domain:**

amino acids 224-246

**N-glycosylation site:**

amino acids 68-72, 82-86

**N-myristoylation site:**

amino acids 200-206, 210-216

**Amidation site:**

amino acids 77-81

149/392

## FIGURE 143

AATGTGAGAGGGGCTGATGGAAGCTGATAGGCAGGACTGGAGTGTTAGCACCAGTACTGG  
ATGTGACAGCAGGCAGAGGAGCACTTAGCAGCTTATTAGTGTCCTGATTCTGATTCCGGC  
AAGGATCCAAGCATGGAATGCTGCCGTGCGGCAACTCCTGGCACACTGCTCCTCTTTCTG  
GCTTTCCTGCTCCTGAGTTCCAGGACCGCACGCTCCGAGGAGGACCGGGACGGCCTATGG  
GATGCCTGGGGCCCATGGAGTGAATGCTCACGCACCTGCGGGGGAGGGGCCTCCTACTCT  
CTGAGGCGCTGCCTGAGCAGCAAGAGCTGTGAAGGAAGAAATATCCGATACAGAACATGC  
AGTAATGTGGACTGCCCACCAGAAGCAGGTGATTTCCGAGCTCAGCAATGCTCAGCTCAT  
AATGATGTCAAGCACCATGGCCAGTTTTATGAATGGCTTCCTGTGTCTAATGACCCTGAC  
AACCCATGTTCACTCAAGTGCCAAGCCAAAGGAACAACCCTGGTTGTTGAAC TAGCACCT  
AAGGTCTTAGATGGTACGCGTTGCTATACAGAATCTTTGGATATGTGCATCAGTGGTTTA  
TGCCAAATTGTTGGCTGCGATCACCAGCTGGGAAGCACCGTCAAGGAAGATAACTGTGGG  
GTCTGCAACGGAGATGGGTCCACCTGCCGGCTGGTCCGAGGGCAGTATAAATCCCAGCTC  
TCCGCAACCAAAATCGGATGATACTGTGGTTGCACTTCCCTATGGAAGTAGACATATTCGC  
CTTGTCTTAAAGGTCTGATCACTTATATCTGGAACCAAAACCCTCCAGGGGACTAAA  
GGTGAACACAGTCTCAGCTCCACAGGAACCTTCTTGTGGACAATTCTAGTGTGGACTTC  
CAGAAATTTCCAGACAAAGAGATACTGAGAATGGCTGGACCACTCACAGCAGATTTTCAAT  
GTCAAGATTTCGTAACCTCGGGCTCCGCTGACAGTACAGTCCAGTTCATCTTCTATCAACCC  
ATCATCCACCGATGGAGGGAGACGGATTTCTTTCCTTGCTCAGCAACCTGTGGAGGAGGT  
TATCAGCTGACATCGGCTGAGTGCTACGATCTGAGGAGCAACCGTGTGGTTGCTGACCAA  
TACTGTCACTATTACCCAGAGAACATCAAACCCAAACCCAAGCTTCAGGAGTGCAACTTG  
GATCCTTGTTCCAGCCAGTGACGGATACAAGCAGATCATGCCTTATGACCTCTACCATCCC  
CTTCTCGGTGGGAGGCCACCCCATGGACCGCTGCTCCTCCTCGTGTGGGGGGGGCATC  
CAGAGCCGGGCAGTTTTCTGTGTGGAGGAGGACATCCAGGGGCATGTCACTTCAGTGGAA  
GAGTGGAATGCATGTACACCCCTAAGATGCCCATCGCGCAGCCCTGCAACATTTTTTGAC  
TGCCCTAAATGGCTGGCACAGGAGTGGTCTCCGTGCACAGTGACATGTGGCCAGGGCCTC  
AGATACCGTGTGGTCTCTGCATCGACCATCGAGGAATGCACACAGGAGGCTGTAGCCCA  
AAAACAAAGCCCCACATAAAAGAGGAATGCATCGTACCCACTCCCTGCTATAAACCCAAA  
GAGAACTTCCAGTCGAGGCCAAGTTGCCATGGTTCAAACAAGCTCAAGAGCTAGAAGAA  
GGAGCTGCTGTGTCAGAGGAGCCCTCGTAAAGTTGTAAGACACAGACTGTTCTATATTTG  
AAACTGTTTTGTTTAAAGAAAGCAGTGTCTCACTGGTTGTAGCTTTCATGGGTTCTGAAC  
TAAGTGTAATCATCTCACCAAAGCTTTTTGGCTCTCAAATTAAAGATTGATTAGTTTTCAA  
AAAAAAAAA



150/392

**FIGURE 144**

MECCRRATPGTLLLLFLAFLLLSSRTARSEEDRDGLWDAWGPWSECSRTC GGGASYS LRRC  
LSSKSCEGRNIRYRTCSNVDCPPEAGDFRAQQCSAHNDVKHHGQFYEWLPVSNDPDNPCS  
LKCQAKGTTLVVELAPKVLDGTRCYTESLDMCISGLCQIVGCDHQLGSTVKEDNCGVCNG  
DGSTCRLVRGQYKSQLSATKSDDTVVALPYGSRHIRLV LKGPDLHYLET KT LQG TKGENS  
LSSTGTFLVDNSSVDFQKFPDKEILRMAGPLTADFIVKIRNSGSADSTVQFIFYQPIIHR  
WRETDFFP CSATCGGGYQLTSAECYDLRSNRVVADQYCHYYPENIKPKPKLQECNLDPCP  
ASDGYKQIMPYDLYHPLPRWEATPWTACSSSCGGGIQSRAVSCVEEDIQGHVTSVEEWKC  
MYTPKMPIAQPCNIFDCPKWLAQEWSPCTVT CGQGLRYRVVLCIDHRGMHTGGCSPKTKP  
HIKEECIVPTPCYKPKEKLPVEAKLPWFKQAQELEEGA AVSEEPS

**Important features:**

**Signal peptide:**

amino acids 1-25

**N-glycosylation site:**

amino acids 251-254

**Thrombospondin 1:**

amino acids 385-399

**von Willebrand factor type C domain proteins:**

amino acids 385-399, 445-459 and 42-56

151/392

## FIGURE 145

GGAGGAGGGAGGGCGGGCAGGCGCCAGCCCAGAGCAGCCCCGGGCACCAGCACGGACTCT  
CTCTTCCAGCCCAGGTGCCCCCACTCTCGCTCCATTTCGGCGGGAGCACCCAGTCCTGTA  
CGCCAAGGAAGTGGTCTTGGGGGCACCATGGTTTCGGCGGCAGCCCCCAGCCTCCTCATC  
CTTCTGTTGCTGCTGCTGGGGTCTGTGCTGCTACCGACGCCCCGCTCTGTGCCCCCTGAAG  
GCCACGTTCTTGGAGGATGTGGCGGGTAGTGGGGAGGCCGAGGGCTCGTCGGCCTCCTCC  
CCGAGCCTCCCGCCACCCTGGACCCCGGCCCTCAGCCCCACATCGATGGGGGCCCCAGCCC  
ACAACCCTGGGGGGCCCATCACCCCCACCAACTTCTTGGATGGGATAGTGGACTTCTTC  
CGCCAGTACGTGATGCTGATTGCTGTGGTGGGCTCCCTGGCCTTTCTGCTGATGTTTCATC  
GTCTGTGCCGCGGTTCATCACCCGGCAGAAGCAGAAGGCCTCGGCCTATTACCCATCGTCC  
TTCCCAAGAAGAAGTACGTGGACCAGAGTGACCGGGCCGGGGGCCCCGGGCCTTCAGT  
GAGGTCCCCGACAGAGCCCCCGACAGCAGGCCCGAGGAAGCCCTGGATTCTCCTCCCGGCAG  
CTCCAGGCCGACATCTTGGCCGCCACCCAGAACCTCAAGTCCCCCACCAGGGCTGCACTG  
GGCGGTGGGGACGGAGCCAGGATGGTGGAGGGCAGGGGCGCAGAGGAAGAGGAGAAGGGC  
AGCCAGGAGGGGGACAGGAAGTCCAGGGACATGGGGTCCCAGTGGAGACACCAGAGGCG  
CAGGAGGAGCCGTGCTCAGGGGTCTTGGAGGGGCTGTGGTGGCCGGTGAGGGGCCAAGGG  
GAGCTGGAAGGGTCTCTCTTGTAGCCAGGAAGCCAGGGACCAGTGGGTCCCCCGAA  
AGCCCCTGTGCTTGCAGCAGTGTCCACCCAGTGTCTAACAGTCTCCTCCCGGGCTGCCAGC  
CCTGACTGTGCGGGCCCCCAAGTGGTCACCTCCCCGTGTATGAAAAGGCCTTCAGCCCTGA  
CTGCTTCTTGACACTCCCTCCTTGGCCTCCCTGTGGTGCCAATCCCAGCATGTGCTGATT  
CTACAGCAGGCAGAAATGCTGGTCCCCGGTGCCCCGGAGGAATCTTACCAAGTGCCATCA  
TCCTTCACCTCAGCAGCCCCAAAGGGCTACATCCTACAGCACAGTCCCCCTGACAAAGTG  
AGGGAGGGCACGTGTCCCTGTGACAGCCAGGATAAAACATCCCCCAAAGTGCTGGGATTA  
CAGGCGTGAGCCACCGTGCCCGGCCCAAACCTACTTTTAAACAGCTACAGGGTAAATC  
CTGCAGCACCCACTCTGGAATACTGCTCTTAATTTTCTGAAGGTGGCCCCCTGTTC  
TAGTTGGTCCAGGATTAGGGATGTGGGGTATAGGGCATTTAAATCCTCTCAAGCGCTCTC  
CAAGCACCCCCGGCCTGGGGGTGAGTTTCTCATCCCGCTACTGCTGCTGGGATCAGGTTG  
AATGAATGGAAGTCTTCTGTCTGGCCTCCAAAGCAGCCTAGAAGCTGAGGGGCTGTGTT  
TGAGGGGACCTCCACCTGGGGAAGTCCGAGGGGCTGGGGAAGGGTTTCTGACGCCCAGC  
CTGGAGCAGGGGGGCCCTGGCCACCCCTGTTGCTCACACATTGTCTGGCAGCCTGTGTC  
CACAATATTCTGTCAGTCTTCGACAGGGAGCCTGGGCTCCGTCCTGCTTTAGGGAGGCTCT  
GGCAGGAGGTCTCTCCCCATCCCTCCATCTGGGGCTCCCCCAACCTCTGCACAGCTCT  
CCAGGTGCTGAGATATAATGCACCAGCACATAAACCTTTATTCCGGCCTGAAAAAAA  
AAGA

152/392

**FIGURE 146**

MVSAAAPSLILLILLLLGSPATDARSVPLKATFLEDVAGSGEAEAGSSASSPSLPPPWTP  
ALSPTSMGPQPTTLGGPSPPTNFLDGIVDFFRQYVMLIAVVGSLAFLLMFIVCAAVITRQ  
KQKASAYYPSSFPPKKKYVDQSDRAGGPRAFSEVPDRAPDSRPEEALDSSRQLQADILAAT  
QNLKSPTRAALGGGDGARMVEGRGAEEEEKGSQEGDQEVQGHGVPVETPEAQEEPCSGVL  
EGAVVAGEGQGELEGSLLLAQEAQGPVGPPEPCACSSVHPSV

**Signal peptide:**  
amino acids 1-25

**Transmembrane domain:**  
amino acids 94-118

**N-myristoylation site:**  
amino acids 18-24, 40-46, 46-52, 145-151, 192-198, 193-199,  
211-217, 238-244, 242-248

153/392

**FIGURE 147**

GAAAGACGTGGTCCTGACAGACAGACAATCCTATTCCCTACCAAAATGAAGATGCTGCTG  
CTGCTGTGTTTGGGACTGACCCTAGTCTGTGTCCATGCAGAAGAAGCTAGTTCTACGGGA  
AGGAACTTTAATGTAGAAAAGATTAATGGGGAATGGCATACTATTATCCTGGCCTCTGAC  
AAAAGAGAAAAGATAGAAGAACATGGCAACTTTTAGACTTTTTCTGGAGCAAATCCATGTC  
TTGGAGAATTCCTTAGTTCTTAAAGTCCATACTGTAAGAGATGAAGAGTGCTCCGAATTA  
TCTATGGTTGCTGACAAAACAGAAAAGGCTGGTGAATATTCTGTGACGTATGATGGATTCT  
AATACATTTACTATACCTAAGACAGACTATGATAACTTTCTTATGGCTCACCTCATTAACT  
GAAAAGGATGGGGAAACCTTCCAGCTGATGGGGCTCTATGGCCGAGAACCAGATTTGAGT  
TCAGACATCAAGGAAAGGTTTGCACAACATATGTGAGGAGCATGGAATCCTTAGAGAAAAT  
ATCATTGACCTATCCAATGCCAATCGCTGCCTCCAGGCCCGAGAATGAAGAATGGCCTGA  
GCCTCCAGTGTTGAGTGGACACTTCTCACCAGGACTCCACCATCATCCCTTCCTATCCAT  
ACAGCATCCCCAGTATAAAATTCTGTGATCTGCATTCCATCCTGTCTCACTGAGAAGTCCA  
ATTCCAGTCTATCAACATGTTACCTAGGATACCTCATCAAGAATCAAAGACTTCTTTAAA  
TTTCTCTTTGATACACCCTTGACAATTTTTTCATGAAATTATTCCTCTTCCTGTTCAATAA  
ATGATTACCCTTGCACTTAA

154/392

## FIGURE 148

MKMLLLLCGLTLVCVHAEASSTGRNFNVEKINGEWHTIILASDKREKIEEHGNFRLFL  
EQIHVLENSLVLKVHTVRDEECSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYDNFLM  
AHLINERKDGETFQLMGLYGREPDLSSDIKERFAQLCEEHGILRENIIDLSNANRCLQARE

155/392

**FIGURE 149**

GTGGACTCTGAGAAGCCCAGGCAGTTGAGGACAGGAGAGAGAAGGCTGCAGACCCAGAGG  
GAGGGAGGACAGGGAGTCGGAAGGAGGAGGACAGAGGAGGGCACAGAGACGCAGAGCAAG  
GGCGGCAAGGAGGAGACCCCTGGTGGGAGGAAGACACTCTGGAGAGAGAGGGGGCTGGGCA  
GAGATGAAGTTCCAGGGGCCCCCTGGCCTGCCTCCTGCTGGCCCTCTGCCTGGGCAGTGGG  
GAGGCTGGCCCCCTGCAGAGCGGAGAGGAAAGCACTGGGACAAATATTGGGGAGGCCCTT  
GGACATGGCCTGGGAGACGCCCTGAGCGAAGGGGTGGGAAAGGCCATTGGCAAAGAGGCC  
GGAGGGGGCAGCTGGCTCTAAAGTCAGTGAGGCCCTTGGCCAAGGGACCAGAGAAGCAGTT  
GGCACTGGAGTCAGGCAGGTTCCAGGCTTTGGCGCAGCAGATGCTTTGGGCAACAGGGTC  
GGGGAAGCAGCCCATGCTCTGGGAAACACTGGGCACGAGATTGGCAGACAGGCAGAAGAT  
GTCATTGACACGGAGCAGATGCTGTCCGCGGCTCCTGGCAGGGGGTGCCTGGCCACAGT  
GGTGCTTGGGAACTTCTGGAGGCCATGGCATCTTTGGCTCTCAAGGTGGCCTTGGAGGC  
CAGGGCCAGGGCAATCCTGGAGGTCTGGGGACTCCGTGGGTCCACGGATACCCCGGAAAC  
TCAGCAGGCAGCTTTGGAATGAATCCTCAGGGAGCTCCCTGGGGTCAAGGAGGCAATGGA  
GGGCCACCAAACCTTTGGGACCAACACTCAGGGAGCTGTGGCCCAGCCTGGCTATGGTTCA  
GTGAGAGCCAGCAACCAGAATGAAGGGTGACGAATCCCCCACCATCTGGCTCAGGTGGA  
GGCTCCAGCAACTCTGGGGGAGGCAGCGGCTCACAGTCGGGCAGCAGTGGCAGTGGCAGC  
AATGGTGACAACAACAATGGCAGCAGCAGTGGTGGCAGCAGCAGTGGCAGCAGCAGTGGC  
AGCAGCAGTGGCGGCAGCAGTGGCGGCAGCAGTGGTGGCAGCAGTGGCAACAGTGGTGGC  
AGCAGAGGTGACAGCGGCAGTGAGTCCTCCTGGGGATCCAGCACCGGCTCCTCCTCCGGC  
AACCACGGTGGGAGCGGCGGAGGAAATGGACATAAACCCGGGTGTGAAAAGCCAGGGAAT  
GAAGCCCGCGGGAGCGGGGAATCTGGGATTGAGGGCTTCAGAGGACAGGGAGTTTCCAGC  
AACATGAGGGAAATAAGCAAGAGGGCAATGGCCTCCTTGGAGGCTCTGGAGACAAATTAT

156/392

**FIGURE 150**

MKFQGPLACLLLLALCLGSGEAGPLQSGEESTGTNIGEALGHGLGDALSEGVGKAIGKEAG  
 GAAGSKVSEALGQGTREAVGTGVRQVPGFGAADALGNRVGEAAHALGNTGHEIGRQAEDV  
 IRHGADAVRGSWQGVPGHSGAWETSGGHGIFGSQGGGLGGQGGQGNPGGLGTPWVHGYPGNS  
 AGSFGMNPQGAPWGQGGNGGPPNFGTNTQGAVAQPGYGSVRASNQNEGCTNPPSGSGGG  
 SSNSGGGSGSGSGSSGSGSNGDNNNGSSSGGSSSGSSSGSSSGGSSGGSSGSGNSGGS  
 RGDSGSESSWGSSTGSSSGNHGGSGGGNGHKPGCEKPGNEARGSGESGIQGFRGQGVSSN  
 MREISKEGNRLLGSGDNYRGQGSSWGSGGGDAVGGVNTVNSETPGMFNFDTFWKNFKS  
 KLGFINWDAINKDORSSRIP

Signal peptide:  
amino acids 1-21

N-glycosylation site:  
amino acids 265-269

**Glycosaminoglycan attachment site:**  
amino acids 235-239, 237-241, 244-248, 255-259, 324-328,  
388-392

**Casein kinase II phosphorylation site:**  
amino acids 26-30, 109-113, 259-263, 300-304, 304-308

**N-myristoylation site:**  
amino acids 17-23, 32-38, 42-48, 50-56, 60-66, 61-67, 64-70,  
74-80, 90-96, 96-102, 130-136, 140-146, 149-155, 152-158,  
155-161, 159-165, 163-169, 178-184, 190-196, 194-200,  
199-205, 218-224, 236-242, 238-244, 239-245, 240-246,  
245-251, 246-252, 249-252, 253-259, 256-262, 266-272,  
270-276, 271-277, 275-281, 279-285, 283-289, 284-290,  
287-293, 288-294, 291-297, 292-298, 295-301, 298-304,  
305-311, 311-317, 315-321, 319-325, 322-328, 323-329,  
325-331, 343-349, 354-360, 356-362, 374-380, 381-387,  
383-389, 387-393, 389-395, 395-401

Cell attachment sequence:  
amino acids 301-304

157/392

**FIGURE 151**

CGGCCACAGCTGGCATGCTCTGCCTGATCGCCATCCTGCTGTATGTCCTCGTCCAGTACC  
TCGTGAACCCCGGGGTGCTCCGCACGGACCCAGATGTCAAGAAATATGAACACGTGGCTG  
CTGTTCTCTCCCTGTTCCCGGTGCAGGTGCAGACCCTGATAGTCGTGATCATCGGGATG  
CTCGTGCTCCTGCTGGACTTTCTTGGCTTGGTGCACCTGGGCCAGCTGCTCATCTTCCAC  
ATCTACCTGAGTATGTCCCCACCCTAAGCCCCCGATCCCCCAAGGCTGGGTGGTCAGA  
GCTGCTCATCTTACACCTCTACTTGAGTATGTCCCTAACCCCTGAGCCCCCACGCCTGGG  
GCCAGAGTCTTTGTCCCCCGTGTGCGCATGTGTTTCAGGGTCAGCCTCTCCAGAAAGTGAG  
ATCATGGACAAAAAGGGCAAATCACAGGAAGAAATTAAATCCATGAGGACCCAGCAGGCC  
CAGCAAGAAGCTGAACTCACGCCGAGACCTGCAGGAGTGGTGCCAGGTGCTTGAAGTAAC  
AAGTTTAAATGTTTCAGAGACAATGGAATGGAATCTATTAGGCAAGAACAGGACATTATG  
AAATAAGGACAGGTGGACTTCCAAAAACACAAGTAGAAATTCTAACAATGAAATATATTA  
CAGGCAGGTCACCCACTAACCAACAACCTGAAGCGAGAGCTGTGGTCTTGCTTGGTCTCA  
CAGTGGGCACAGCGGTAGGCGGTGAGTCATGTTGCTGAACGACGGAGGGTAAACTCCCCA  
GCCCCAAGAAAACCTGTGTTGGAAGTAACAACAACCTCCCTGCTCCTGGCACCAGCCGTT  
TTGGTCATGGTGGGCCAGCTGCAAAGCGTCTTCCATTCTCTGGGCAGTGGTGGCCCCGAG  
GCTGTGGCCTCTCAGGGGGTTTCTGTGGACACGGGCAGCAGAGTGTGTCCAGGCCAGCCC  
CCAAGAATGCCCTGCTCCTGACAGCTTGGCCAACCCCTGGTCAGGGCAGAGGGAGTTGGG  
TGGGTCAGGCTCTGGGCTCACCTCCATCTCCAGAGCATCCCCTGCCTGCAGTTGTGGCAA  
GAACGCCCAGCTCAGAATGAACACACCCACCAAGAGCCTCCTTGTTTCATAACCACAGGT  
TACCCTACAAACCACTGTCCCCACACAACCTGGGGATGTTTTTAAACACACACCTCTAA  
CGCATATCTTACAGTCACTGTTGTCTTGCTGAGGGTTGAATTTTTTTTAAATGAAAGTGC  
AATGAAAATCACTGGATTAAATCCTACGGACACAGAGCTGAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAA



158/392

## FIGURE 152

MNTWLLFLPLFPVQVQTLIVVIIGMLVLLLDLGLVHLGQLLIFHIYLSMSPTLSPRSPQ  
GWVVRAAHLTPLLEYVPNPEPPTPGARVFVPRVRMCSGSASPRSEIMDKKGKSQEEIKSM  
RTQQAQQEAEELTPRPAGVPGA

159/392

**FIGURE 153**

AACTGGAAGGAAAGAAAGAAAGGTCAGCTTTGGCCCAGATGTGGTTACCCCTTGGTCTCC  
TGTCTTTATGTCTTTCTCCTCTTCCTATTCTGTTCATCTCCCTCACTTAAGTCTCAGGCCT  
GTCAGCAGCTCCTGTGGACATTGCCATCCCCCTCTGGTAGCCTTCAGAGCAAACAGGACAA  
CCTATGTTATGGATGTTTCCACCAACCAGGGTAGTGGCATGGAGCACCGTAACCATCTGT  
GCTTCTGTGATCTCTATGACAGAGCCACTTCTCCACCTCTGAAATGTTCCCTGCTCTGAA  
ATCTGGCATGAGATGGCACAGGTGACCACGCAGAAGCCACCAGAATCTTGCCTGCCCTAT  
TCCTCCTCCCAAGTCTGTTCTCTTATTGTCAACCTCAGCACAAACAGGCTGGCGCCAATGG  
CATTACAGAGAAAGCAATCTGTGTGGCTAGTGGGCAGATTACCATGCAAGCCCCAGGAGA  
AATGGAGGAGCTTTGTAGCCACCTCCCTGTCAGCCAGTATTAACATGTCCCCTTCCCCCT  
GCCCCGCCGTAGATTCAGGACATTCGCCCCCTGTGTGCCACCAAACCAGGACTTTCCCCCT  
GGCTTGGCATCCCTGGCTCTCTCCTGGTACCCAGCAAGACGTCTGTTCCAGGGCAGTGTA  
GCATCTTTCAAGCTCCGTTACTATGGCGATGGCCATGATGTTACAATCCCACCTTGCCTGA  
ATAATCAAGTGGGAAGGGGAAGCAGAGGGAAATGGGGCCATGTGAATGCAGCTGCTCTGT  
TCTCCCTACCCTGAGGAAAAACCAAAGGGAAGCAACAGGAACTTCTGCAACTGGTTTTTA  
TCGGAAAGATCATCCTGCCTGCAGATGCTGTTGAAGGGGCACAAGAAATGTAGCTGGAGA  
AGATTGATGAAAGTGCAGGTGTGTAAGGAAATAGAACAGTCTGCTGGGAGTCAGACCTGG  
AATTCTGATTCCAACTCTTTATTACTTTGGGAAGTCACTCAGCCTCCCCGTAGCCATCT  
CCAGGGTGACGGAACCCAGTGTATTACCTGCTGGAACCAAGGAACTAACAATGTAGGTT  
ACTAGTGAATACCCCAATGGTTTCTCCAATTATGCCCATGCCACCAAAACAATAAAACAA  
AATTCTCTAACACTGAAA

160/392

## FIGURE 154

MWLPLGLLSLCLSPILSSPSLKSQLQQLLWTLPSPLVAFRANRTTYVMDVSTNQSG  
MEHRNHLCFCDLYDRATSPPLKCSLL

161/392

**FIGURE 155**

GTAGCGCGTCTTGGGTCTCCCGGCTGCCGCTGCTGCCGCCGCCGCTCGGGTCTGTTGGAGC  
CAGGAGCGACGTCACCGCCATGGCAGGCATCAAAGCTTTGATTAGTTTGTCTTTGGAGG  
AGCAATCGGACTGATGTTTTTTGATGCTTGGATGTGCCCTTCCAATATACAACAAATACTG  
GCCCCCTCTTTGTTCTATTTTTTTACATCCTTTCACCTATTCCATACTGCATAGCAAGAAG  
ATTAGTGGATGATACAGATGCTATGAGTAACGCTTGTAAGGAAC TTGCCATCTTTCTTAC  
AACGGGCATTGTTCGTGTCAGCTTTTGGACTCCCTATTGTATTTGCCAGAGCACATCTGAT  
TGAGTGGGGAGCTTGTGCACTTGTTCACAGGAAACACAGTCATCTTTGCAACTATACT  
AGGCTTTTTCTTGGTCTTTGGAAGCAATGACGACTTCAGCTGGCAGCAGTGGTGA AAAAGA  
AATTACTGAACTATTGTCAAATGGACTTCCTGTCAATTTGTTGGCCATTACAGCACACAGG  
AGATGGGGCAGTTAATGCTGAATGGTATAGCAAGCCTCTTGGGGGTATTTTAGGTGCTCC  
CTTCTCACTTTTATTGTAAGCATACTATTTTTCACAGAGACTTGCTGAAGGATTA AAAGGA  
TTTTCTCTTTTGGAAAAGCTTGACTGATTTTCACACTTATCTATAGTATGCTTTTTGTGGT  
GTCCTGCTGAATTTAAATATTTATGTGTTTTTCTGTAGGTGATTTTTTTTGGAAATCA  
ATATGCAATGTTAAACACTTTTTTAATGTAATCATTTGCATTGGTTAGGAATTCAGAATT  
CCGCCGCTCTATTACTGGTCAAGTACATCTTTTCTCTTAAATATTATTTAGCCTCCATTA  
TTACAAAAAATATAAAAAATAAGTTTTTCAGTCAGTCAGGATGACATCACTCCCAATGTTA  
TGCAGACATACAGACGGTTGGCATACTTATAGACTGTATACTCAGTGCAAAATATAGCTG  
CATTTATACCTCAGAGGGGCCAAGTGTTAATGCCCATGCCCTCCGTTAAGGGTTGTTGGT  
TTTACTGGTAGACAGATGTTTTGTGATTGAAAATTATTTTATGGAATTGCTACAGAGGA  
GTGCTTTTCTCTCAATTGTTAGAAGAATTTATGTTAACTTTAAGGTAAGGGTGTAAAA  
ACATTTTGTAGATAAGGTTTTTATTATGTTTATTATTGTTAGAGTGAGTTGCAATGTGG  
GAAGAAATGACATTGAAATCCAGTTTTTGAATCCTGTTTCTATTTATAAGTGAAATTTG  
TGATCTCCTATCAACCTTTCATGTTTTACCCTGTTAAATGGACATACATGGAACCACTA  
CTGATGAGGGACAGTTGTATGTTTGCATCATATATGCCAGAAAACCTTCCTCTGCTTCCT  
CCTTTTGACTTATTTGGTATGTTGTATATATTACATAAAATAACTTTTCAAATATAGTTT  
AATAACACTTAGAAGTGTTTACTTACCTGGAAAATAATTGCTATGCCGTACATTACAGAGT  
GCCCCCTCCCCTGCAAGGCCTTGCCATGATTAACAAGTAACTTGTTAGTCTTACAGATAA  
TTCATGCATTAAACAGTTTAAGATTTAGACCATGGTAATAGTAGTTCTTATTCTCTAAGGT  
TATATCATATGTAATTTAAAAGTATTTTAAAGACAAGTTTCCTGTATACCTCTGAACTGT  
TTTGATTTTGTAGTTTATCATGATAGATCTGCTGTTTCTTATAAAAGGCATTTGTTGTGT  
GAGTTAATGCAAAGTAGCCAAGTCCAGCTATATAGCAGCTTCAGAAACATACCTGACCAA  
AAAATTTCCAGTAACCAGGCATGATCAATTTATAGTGGTCGTTTACATCTAATAATTATC  
AGGACTTTTTTTCAGGAGTGGGTTATAAAAAACATTCAGTTGGTCTGACAGTATTTTGTTA  
AGGATATTTGTTTGTATGTTTATTTCAGTATACTTACATAAAATATTTCGCCATCAGCC  
AAAACCTCAGTAATCATGACAGCTGTCTGTTGTTTTATGAAGTTTATTTCTCAAGAAAATG  
GGAATAAATTTGGGATTTGTTTCAGCTTTTTTACTAAAGATGCCTAAAGCCACAGGTTTTTA  
TTGCCTAACTTAAGCCATGACTTTTATAGATATGAGATGACGGGAAGCAGGACGAAATATCG  
GCGTGTGGCTGGAGCCTTCCCACTGGAGGCTGAAAGTGGCTTGTGGTATTATAATGTTCA  
GATTTCAAGAGGAAGGTGCAGGTACACATGAGTTAGAGAGCTGGTGAGACAGTTGGGAAC  
TCTTTGTGCTTGTGATCTACTGGACTTTTTTTTTTGCAGGAAGTGCATTCTCTGGTCCTTC  
CCTATTTTCTGTTCTGGATGTCAGTGCAGTGCAGTGCAGTGTCTGATTTTATCCACTTGGCCAC  
AGACTTTTTCTAACAGCTGCGTATTATTTCTATATACTAATTGCATTGGCAGCATTGTGT  
CTTTGACCTTGTATACTAGCTTGACATAGTGCTGTCTCTGATTTCTAGGCTAGTTACTTG  
AGATATGAATTTTCCATAGAATATGCACTGATACAACATTACCATTCTTCTATGGAAGA  
AACTTTTGATGATGAAACAATAAAGATTTTAAATATCTATTTTAAAAA

162/392

## FIGURE 156

MAGIKALISLSFGGAIGLMFLMLGCALPIYNKYWPLFVLFFYILSPIPYCIARRLVDDTD  
AMSNACKELAIFLTGTGIVVSAFGLPIVFARAHLEWGACALVLTGNTVIFATILGFFLVF  
GSNDDFSWQQW

163/392

## FIGURE 157

GTTTCTCATAGTTGGCGTCTTCTAAAGGAAAAACACTAAAATGAGGAACTCAGCGGACCG  
GGAGCGACGCAGCTTGAGGGAAGCATCCCTAGCTGTTGGCGCAGAGGGGCGAGGCTGAAG  
CCGAGTGGCCCGAGGTGTCTGAGGGGCTGGGGCAAAGGTGAAAGAGTTTTCAGAACAAAGCT  
TCCTGGAACCCATGACCCATGAAGTCTTGTGACATTTATACCGTCTGAGGGTAGCAGCT  
CGAAACTAGAAGAAGTGGAGTGTGTCAGGGACGGCAGTATCTCTTGTGTGACCCCTGGC  
GGCCTATGGGACGTTGGCTTCAGACCTTTGTGATACACCATGCTGCGTGGGACGATGACG  
GCGTGGAGAGGAATGAGGCCTGAGGTACACTGGCTTGCCCTCCTCCTAGCCACAGCAGGC  
TGCTTTGTGTGACTTGAACGAGGTCCCTCAGGTACCGTCCAGCCTGCGTCCACCGTCCAG  
AAGCCCGGAGGCACTGTGATCTTGGGCTGCGTGGTGGAAACCTCCAAGGATGAATGTAAAC  
TGGCGCCTGAATGGAAAGGAGCTGAATGGCTCGGATGATGCTCTGGGTGTCTCATCACC  
CACGGGACCCCTCGTCATCACTGCCCTTAACAACCACACTGTGGGACGGTACCAGTGTGTG  
GCCCCGATGCTGCGGGGGCTGTGGCCAGCGTGCCAGCCACTGTGACACTAGCCAATCTC  
CAGGACTTCAAGTTAGATGTGCAGCACGTGATTGAAGTGGATGAGGGAAACACAGCAGTC  
ATTGCCTGCCACCTGCCCTGAGAGCCACCCCAAAGCCAGGTCCGGTACAGCGTCAAACAA  
GAGTGGCTGGAGGCCTCCAGAGGTAACCTGATCATGCCCTCAGGGAACCTCCAGATT  
GTGAATGCCAGCCAGGAGACGAGGGCATGTACAAGTGTGCAGCCTACAACCCAGTGACC  
CAGGAAGTGAAAACCTCCGGCTCCAGCGACAGGCTACGTTGTCGCGCGCTCCACCGCTGAG  
GCTGCCCCGCATCATCTACCCCCCAGAGGGCCCAAACCATCATCGTCACCAAAGGCCAGAGT  
CTCATTTCTGGAGTGTGTGGCCAGTGGAAATCCACCCCCACGGGTACCTGGGCCAAGGAT  
GGGTCCAGTGTACCCGGCTACAACAAGACGCGCTTCTGCTGAGCAACCTCCTCATCGAC  
ACCACCAGCGAGGAGGACTCAGGCACCTACCGCTGCATGGCCGACAATGGGGTTGGGCAG  
CCCGGGGCGAGCGGTTCATCCTCTACAATGTCCAGGTGTTTGAACCCCTGAGGTACCATG  
GAGCTATCCCAGCTGGTTCATCCCTGGGGCCAGAGTGCCAAGCTTACCTGTGAGGTGCGT  
GGGAACCCCCCGCCCTCCGTGCTGTGGCTGAGGAATGCTGTGCCCTCATCTCCAGCCAG  
CGCCTCCGGCTCTCCCGCAGGGCCCTGCGCGTGCTCAGCATGGGGCCTGAGGACGAAGGC  
GTCTACCAAGTGACATGGCCGAGAACGAGGTTGGGAGCGCCCATGCCGTAGTCCAGTGCAG  
ACCTCCAGGCCAAGCATAACCCCAAGGCTATGGCAGGATGCTGAGCTGGCTACTGGCACA  
CCTCCTGTATCACCTCCAAACTCGGCAACCCTGAGCAGATGCTGAGGGGGCAACCGGCG  
CTCCCCAGACCCCAACGTCACTGGGGCCTGCTTCCCCGAAGTGTCCAGGAGAGAAGGGG  
CAGGGGGCTCCCGCCGAGGCTCCCATCATCTCAGCTCGCCCCGCACCTCCAAGACAGAC  
TCATATGAACTGGTGTGGCGGCCTCGGCATGAGGGCAGTGGCCGGGCGCCAATCTCTAC  
TATGTGGTGAAACACCGCAAGCAGGTCAAAATTCCTCTGACGATTGGACCATCTCTGGC  
ATTCCAGCCAACCAGCACCGCCTGACCTCACCAGACTTGACCCGGGAGCTTGTATGAA  
GTGGAGATGGCAGCTTACAACCTGTGCGGGAGAGGGCCAGACAGCCATGGTCACTTCCGA  
ACTGGACGGCGGCCAAACCCGAGATCATGGCCAGCAAGAGCAGCAGATCCAGAGAGAC  
GACCTTGGAGCCAGTCCCCAGAGCAGCAGCCAGACACGGCCGCTCTCCCCCCCA  
GAAGCTCCCGACAGGCCCCACCATCTCCACGGCCTCCGAGACCTCAGTGTACGTGACCTGG  
ATTCCCCGTGGGAATGGTGGGTTCCTCAATCCAGTCTTCCGTGTGGAGTACAAGAAGCTA  
AAGAAAGTGGGAGACTGGATTCTGGCCACCAGCGCCATCCCCCATCGCGGCTGTCCGTG  
GAGATCACGGGCCTAGAGAAAGGCACCTCCTACAAGTTTTCGAGTCCGGGCTCTGAACATG  
CTGGGGGAGAGCGAGCCAGCGCCCCCTCTCGGCCCTACGTGGTGTGCGGGCTACAGCGGT  
CGCGTGTACGAGAGGCCCCGTGGCAGGTCTTATATACCTTCACGGATGCGGTCAATGAG  
ACCACCATCATGCTCAAGTGGATGTACATCCAGCAAGTAACAACAACACCCCAATCCAT  
GGCTTTTATATCTATTATCGACCCACAGACAGTGACAATGATAGTACTACAAGAAGGAT  
ATGGTGGAAGGGGACAAGTACTGGCACTCCATCAGCCACCTGCAGCCAGAGACCTCTTAC  
GACATTAAGATGCAGTGCTTCAATGAAGGAGGGGAGAGCGAGTTTCAGCAACGTGATGATC  
TGTGAGACCAAAGCTCGGAAGTCTTCTGGCCAGCCTGGTTCGACTGCCACCCCAACTCTG  
GCCCCACCACAGCCGCCCCCTTCTGAAACCATAGAGCGGCGGCTGGGCACCTGGGGCCATG  
GTGGCTCGCTCCAGCGACCTGCCCTATCTGATTGTGCGGGGTCGTCTGGGCTCCATCGTT  
CTCATCATCGTCACCTTCATCCCTTCTGCTTGTGGAGGGCCTGGTCTAAGCAAAAACAT  
ACAACAGACCTGGGTTTTCTCGAAGTGCCCTTCCACCCTCCTGCCCCGTATACTATGGTG  
CCATTGGGAGGACTCCAGGCCACCAGGCCAGTGGACAGCCCTACCTCAGTGGCATCAGT

164/392

GGACGGGCCTGTGCTAATGGGATCCACATGAATAGGGGCTGCCCCTCGGCTGCAGTGGGC  
TACCCGGGCATGAAGCCCCAGCAGCACTGCCCAGGCGAGCTTCAGCAGCAGAGTGACACC  
AGCAGCCTGCTGAGGCAGACCCATCTTGGCAATGGATATGACCCCCAAAGTCACCAGATC  
ACGAGGGGTCCCAAGTCTAGCCCGGACGAGGGCTCTTTCTTATACACACTGCCCCGACGAC  
TCCACTCACCAGCTGCTGCAGCCCCATCACGACTGCTGCCAACGCCAGGAGCAGCCTGCT  
GCTGTGGGCCAGTCAGGGGTGAGGAGAGCCCCGACAGTCCTGTCTGGAAGCAGTGTGG  
GACCCTCCATTTCACTCAGGGCCCCCATGCTGCTTGGGCCTTGTGCCAGTTGAAGAGGTG  
GACAGTCCTGACTCCTGCCAAGTGAGTGAGGAGACTGGTGTCCCCAGCACCCCGTAGGG  
GCCTACGTAGGACAGGAACCTGGAATGCAGCTCTCCCCGGGGCCACTGGTGCGTGTGTCT  
TTTGAAACACCACCTCTCACAATTTAGGCAGAAGCTGATATCCAGAAAGACTATATATT  
GTTTTTTTTTTTAAAAAAAAGAGAAAAAGAGACAGAGAAAATTGGTATTTATTTTTC  
TATTATAGCCATATTTATATATTTATGCACTTGTAATAAATGTATATGTTTTATAATTC  
TGGAGAGACATAAGGAGTCCTACCCGTTGAGGTTGGAGAGGGAAAATAAAGAAGCTGCCA  
CCTAACAGGAGTCACCCAGGAAAGCACCGCACAGGCTGGCGCGGGACAGACTCCTAACCT  
GGGGCCTCTGCAGTGGCAGGCGAGGCTGCAGGAGGCCACAGATAAGCTGGCAAGAGGAA  
GGATCCCAGGCACATGGTTCATCACGAGCATGAGGGAACAGCAAGGGGCACGGTATCACA  
GCCTGGAGACACCCACACAGATGGCTGGATCCGGTGCTACGGGAAACATTTTCCTAAGAT  
GCCCATGAGAACAGACCAAGATGTGTACAGCACTATGAGCATTAAAAAACCTTCCAGAAT  
CAATAATCCGTGGCAACATATCTCTGTAAAAACAAACACTGTAACCTTCTAAATAAATGTT  
TAGTCTTCCCTGTAAAA

165/392

**FIGURE 158**

MLRGTMTAWRGMRPEVTLACLLLATAGCFADLNEVPQVTVQPASTVQKPGGTVILGCVVE  
PPRMNVTWRLNGKELNGSDDALGVLITHGTLVITALNNHTVGRYQCVARMPAGAVASVPA  
TVTLANLQDFKLDVQHVIIEVDEGNTAVIACHLPESHKPAQVRYSVKQEWLEASRGNYLIM  
PSGNLQIVNASQEDEGMYKCAAYNPVTQEVKTSGSSDRLRVRRSTAEAAARIITYPPEAQT  
IVTKGQSLILECVASGIPPPRVTWAKDGSSVTGYNKTRFLLSNLLIDTTSEEDSGTYRCM  
ADNGVGQPGAIVILYNVQVFEPPEVTMELSOLVIPWGQSAKLTCEVRGNPPPSVLWLRNA  
VPLISSQRLRLSRRALRVLSMGPEDEGVYQCAENEVGSAAHAVVQLRTSRPSITPRLWQD  
AELATGTPPVSPSKLGNPEQMLRGQPALPRPPTS VGPASPKCPGEKGQGAPAEAPIILSS  
PRTSKTDSYELVWRPRHEGSGRAPILYYVVKHRKQVTNSSDDWTISGIPANQHRLLTLRL  
DPGSLYEVEVMAAYNCAGEGQTAMVTFRTGRRPKPEIMASKEQQIQRDDPGAS PQSSSQPD  
HGRLSPPEAPDRPTISTASETSVYVTWIPRGNGGFPIQSFVEYKKLKKVGDWILATSAI  
PPSRLSVEITGLEKGT SYKFRVRALNMLGESEPSAPSRPYVVS GYSGRVYERPVAGPYIT  
FTDAVNETTIMLKWMIYPASNNNTPIHGFYIYYRPTDSNDSDYKKDMVEGDKYWH SISH  
LQPETSYDIKMQCFNEGGESEFSNVMICETKARKSSGQPGRLPPPTLAPPQPLPETIER  
PVG TGAMVARSSDLPYLIVGVVLGSI VLIIVTFIPFCLWRWSKQKHTTDLGFPR SALPP  
SCPYTMVPLGGLPGHQASGQPYLSGISGRACANGIHMNRGCP SAAVGYPGMKPQ QHCPGE  
LQQQSDTSSLLRQTHLGNGYDPQSHQITRGPKSSPDEGSFLYTL PDDSTHQLLQPHHDC  
QRQEQPAAVGQSGVRRAPDSPVLEAVWDPPFHS GPPCCLGLVPVEEVDSPDSCQVSGGDW  
CPQHPVGAYVGQEPGMQLSPGPLVRV SFETPPLTI

**Signal peptide:**

amino acids 1-30

**Transmembrane domain:**

amino acids 16-30 (type II), 854-879



166/392

## FIGURE 159

CCCACGCGTCCGCCCCACGCGTCCGCCCCACGCGTCCGCCCCACGCGTCCGCCCCACGCGTCCG  
CCCACGCGTCCGCCCCACGCGTCCGGTGCAAGCTCGCGCCGCACACTGCCTGGTGGAGGGA  
AGGAGCCCCGGGCGCCTCTCGCCGCTCCCCGCGCCGCGTCCGCACCTCCCCACCGCCCGC  
CGCCCGCCGCCCCGCGCCCGCAAAGCATGAGTGAGCCCGCTCTCTGCAGCTGCCCGGGGC  
GCGAATGGCAGGCTGTTTCCGCGGAGTAAAAGGTGGCGCCGGTCAGTGGTCTGTTTCCAAT  
GACGGACATTAACCAGACTGTCAGATCCTGGGGAGTCGCGAGCCCCGAGTTTGGAGTTTTT  
TCCCCCCCCACAACGTACAGTCCGAACTGCAGAGGGAAAGGAAGGCGGCAGGAAGGCGAA  
GCTCGGGCTCCGGCACGTAGTTGGGAACTTGCGGGTCTTAGAAGTCGCTCCCCGCCTT  
GCCGGCCGCCCTTGACAGCCCCGAGCCGAGCAGCAAAGTGAGACATTGTGCGCCTGCCAGA  
TCCGCGCGCCCGCGGACCGGGGCTGCCTCGGAAACACAGAGGGGTCTTCTCTCGCCCTGCA  
TATAATTAGCCTGCACACAAAGGGAGCAGCTGAATGGAGGTTGTCACTCTCTGGAAAAGG  
ATTTCTGACCGAGCGCTTCCAATGGACATTCTCCAGTCTCTCTGGAAAGATTCTCGCTAA  
TGGATTTCTGCTGCTCGGTCTCTGTCTATACTGGCTGCTGAGGAGGCCCTCGGGGGTGG  
TCTTGTGTCTGCTGGGGGCTGCTTTCAGATGCTGCCCGCCGCCCCCAGCGGGTGCCCGC  
AGCTGTGCCGGTGCAGAGGGGCGGCTGCTGTACTGCGAGGCGCTCAACCTCACCGAGGCGC  
CCCACAACCTGTCCGGCCTGCTGGGCTTGTCCCTGCGCTACAACAGCCTCTCGGAGCTGC  
GCGCCGGCCAGTTACGGGGTTAATGCAGCTCACGTGGCTCTATCTGGATCACAATCACA  
TCTGCTCCGTGCAGGGGGACGCCTTTCAGAACTGCGCCGAGTTAAGGAACTCACGCTGA  
GTTCCAACCAGATCACCCAACCTGCCCAACACCACCTTCCGGCCCATGCCCAACCTGCGCA  
GCGTGGACCTCTCGTACAACAAGCTGCAGGCGCTCGCGCCCGACCTCTTCCACGGGCTGC  
GGAAGCTCACACGCTGCATATGCGGGCCAACGCCATCCAGTTTGTGCCCGTGCGCATCT  
TCCAGGACTGCCGCAGCCTCAAGTTTCTCGACATCGGATAACAATCAGCTCAAGAGTCTGG  
CGCGCAACTCTTTGCGCCGCTTGTTTAAGCTCACCGAGCTGCACCTCGAGCACAACGACT  
TGGTCAAGGTGAACTTCCGCCACTTCCCGCGCCTCATCTCCCTGCACTCGCTCTGCCTGC  
GGAGGAACAAGGTGGCCATTGTGGTCAGCTCGCTGGACTGGGTTTGGAACTTGAGAAAA  
TGGACTTGTGCGGCAACGAGATCGAGTACATGGAGCCCCATGTGTTGAGACCGTGCCGC  
ACCTGCAGTCCCTGCAGCTGGACTCCAACCGCCTCACCTACATCGAGCCCCGGATCCTCA  
ACTCTTGGAAGTCCCTGACAAGCATCACCTGGCCGGGAACCTGTGGGATTGCGGGCGCA  
ACGTGTGTGCCCTAGCCTCGTGGCTCAGCAACTTCCAGGGGCGCTACGATGGCAACTTGC  
AGTGCGCCAGCCCGGAGTACGCACAGGGCGAGGACGTCTTGACGCGCGTGTACGCCTTCC  
ACCTGTGCGAGGATGGGGCCGAGCCCAACAGCGGCCACCTGCTCTCGGCCGTACCAACC  
GCAGTGATCTGGGGCCCCCTGCCAGCTCGGCCACCACGCTCGCGGACGGCGGGGAGGGGC  
AGCACGACGGCACATTTCGAGCCTGCCACCGTGGCTCTTCCAGGCGGCGAGCACGCCGAGA  
ACGCCGTGCAGATCCACAAGGTGGTCACGGGCACCATGGCCCTCATCTTCTCCTTCTCA  
TCGTGGTCCCTGGTGCTCTACGTGTCTGGAAGTGTTCCTCAGCCAGCCTCAGGCAGCTCA  
GACAGTGCTTTGTACGCAGCGCAGGAAGCAAAAGCAGAAACAGACCATGCATCAGATGG  
CTGCCATGTCTGCCAGGAATACTACGTTGATTACAAACCGAACCACATTGAGGGAGCCC  
TGGTGATCATCAACGAGTATGGCTCGTGTACCTGCCACCAGCAGCCCCGCGAGGGAATGCG  
AGGTGTGATTGTCCCAGTGGCTCTCAACCCATGCGCTACCAAATACGCCTGGGCAGCCGG  
GACGGGCCGGCGGGCACCAGGCTGGGGTCTCCTTGTCTGTGCTCTGATATGCTCCTTGAC  
TGAAACTTTAAGGGGATCTCTCCAGAGACTTGACATTTTAGCTTTATTGTGTCTTAAAA  
ACAAAAGCGAATTAAAAACACAACAAAAAACCCACCCCAACCTTCAGGACAGTCTATC  
TTAAATTTTATATGAGAACTCCTTCCTCCCTTTGAAGATCTGTCCATATTGAGGAATCTG  
AGAGTGTAAGGAGGTGGCCATAAGACAGAGAGAGAATAATCGTGCTTTGTTTTATGCTA  
CTCCTCCACCCCTGCCCATGATTAAACATCATGTATGTAGAAGATCTTAAGTCCATACGC  
ATTTTCATGAAGAACCATTGGAAAGAGGAATCTGCAATCTGGGAGCTTAAGAGCAAATGAT

167/392

GACCATAGAAAGCTATGTTCTTACTTTGTGTGTGTGTCTGTATGTTTCTGCGTTGTGTGT  
CTTTGTAGGCAAGCAAACGTTGTCTACACAAACGGGAATTTAGCTCACATCATTTCATGC  
CCCTGTGCCTCTAGCTCTGGAGATTGGTGGGGGGAGGTGGGGGGAAACGGCAGGAATAAG  
GGAAAGTGGTAGTTTTAACTAAGGTTTTGTAACTTGAATCTTTTCTTCTCAAATTA  
ATTATCTTTAAGCTTCAAGAACTTGCTCTGACCCCTCTAAGCAAATACTAAGCATTTA  
AAAGAGAATCTAATTTTTAAAGGTGTAGCACCTTTTTTTTTTATTCTTCCCACAGAGGGTG  
CTAATCTCATTATGCTGTGCTATCTGAAAAGAACTTAAGGCCACAATTCACGTCTCGTCC  
TGGGCATTGTGATGGATTGACCCCTCCATTTGCAGTACCTTCCCAGCTGATTAAAGTTCAG  
CAGTGGTATTGAGGTTTTTCGAATATTTATATAGAAAAAAAGTCTTTTCACATGACAAAT  
GACACTCTCACACCAGTCTTAGCCCTAGTAGTTTTTTAGGTTGGACCAGAGGAAGCAGGT  
TAAATGAGACCTGTCCTCTGCTGCACTCAGAAAAAATAGGCAGTCCCTGATGCTCAGATC  
TTAGCCTTGATATTAATAGTTGAGACCACCTACCCACAATGCAGCCTATACTCCCAAGAC  
TACAAAGTTACCATCGCAAAGGAAAGGTTATTCAGTAAAAGGAAATAGTTTTCTCAACC  
ATTTAAAAATATTCTTCTGAACTCATCAAAGTAGAAGAGCCCCAACCTTTTCTCTCTGC  
CTTCAAGAAGGCAGACATTTGGTATGATTAGCATCAACAACACATTTATGAGTATATGT  
AAGTAATCAGAGGGGCAAATGCCACTTGTTATTCCTCCCAAGTTTTCCAAGCAAGTACAC  
ACAGATCTCTGGTAGGATTAGGGGCCACTTGTTTCCGGCTTATTTTAGTCGACTTGTC  
AGCAAGTTTGATGCCTAGTCTATCTGACATGGCCCAGTAGAACAGGGCATTGATGGATCA  
CATGAGATGGTAGAAGGAACATCATCACATACCCCTCTCACAGAGAAAATTATCAAAGAA  
CCAGAAATTATATCTGTTTTGGAGCAAGAGTGTGATAATGTTTCAGGGTAGTCAAATAA  
ACATAAATTATCTCCTCTAGATGAGTGGCGATGTTGGCTGATTTGGGTCTGCCATTGACA  
GAATGTCAAATAAAAAGGAATTAGCTAGAATATGACCATTAAATGTGCTTCTGAAATATA  
TTTTGAGATAGGTTTAGAATGTCA

168/392

**FIGURE 160**

MDFLLLGLCLYWLLRRPSGVVLCLLGACFQMLPAAPSGCPQLCRCEGRLLYCEALNLTEA  
PHNLSGLLGLSLRYNSLSELRAGQFTGLMQLTWLYLDHNIHICSVQGDAFQKLRRVKELTL  
SSNQITQLPNTTFRPMPNLRSDLSYNKLQALAPDLFHGLRKLTTLHMRANAIQFVPVRI  
FQDCRSLKFLDIGYNQLKSLARNSFAGLFKLTELHLEHNDLVKVNFAHFPRILISLHSLCL  
RRNKVAIVVSSLDWVWNLEKMDLSGNEIEYMEPHVFETVPHLQSLQLDSNRLTYIEPRIL  
NSWKSLSITLAGNLWDCGRNVCALASWLSNFQGRYDGNLQCASPEYAQGEDVLDVYAF  
HLCEDGAEP TSGHLLSAVTNRSDLGPPASSATTADGGEGQHDGTFEPATVALPGGEHAE  
NAVQIHKVVTGTMALIFSFLIVVLVLYVSWKCFPASLRQLRQCFVTQRRKQKQKQTMHQM  
AAMSAQEYYVDYKPNHIEGALVIINEYGSCTCHQQPARECEV



170/392

**FIGURE 162**

MAPQSLPSSRMAPLGMLLGLLMAACFTFCLSHQNLKEFALTNPEKSSTKETERKETKAEE  
ELDAEVLEVFHPTHEWQALQPGQAVPAGSHVRLNLQTGEREAKLOYEDKFRNNLKGKRLD  
INTNTYTSQDLKSALAKFKEGAEMESSKEDKARQAEVKRLFRPIEELKKDFDELNVVIET  
DMQIMVRLINKFNSSSSSLEEKIAALFDLEYVYVHQMDNAQDLLSFGGGLQVVINGLNSTEP  
LVKEYAAFVLGAASFSSNPKVQVEAIEGGALQKLLVILATEQPLTAKKKVLFALCSLLRHF  
PYAQRQFLKLGGGLQVLRRTLQVEKGTAVLAVRVVTLVLDLVTEKMFEEEEAEELTQEMSPEK  
LQQYRQVHLLPGLWEQGWCEITAHLLALPEHDAREKVLQTLGVLLTTCRDRYRQDPQLGR  
TLASLQAEYQVLASLELQDGEDEGYFQELLGVSNSLLKELR

**Important features:**

**Signal peptide:**

amino acids 1-29

**Hypothetical YJL126w/YLR351c/yhcX family protein:**

amino acids 364-373

**N-glycosylation site:**

amino acids 193-197, 236-240

**N-myristoylation site:**

amino acids 15-21, 19-25, 234-240, 251-257, 402-408, 451-457

**Homologous region SLS1 protein:**

amino acids 68-340

171/392

**FIGURE 163**

CAGAGAGGAGGCTTTGGGAATTGTCCAGCAGAAACAGAGAAGTCTGAGGTGGTGTCAAGA  
CAAAAGATGCTTCAGCTTTGGAAACTTGTTCTCCTGTGCGGCGTGCTCACTGGGACCTCA  
GAGTCTCTTCTTGACAATCTTGGCAATGACCTAAGCAATGTCGTGGATAAGCTGGAACCT  
GTTCTTCACGAGGGACTTGAGACAGTTGACAATACTCTTAAAGGCATCCTTGAGAACTG  
AAGGTCGACCTAGGAGTGCTTCAGAAATCCAGTGCTTGGCAACTGGCCAAGCAGAAGGCC  
CAGGAAGCTGAGAAATTGCTGAACAATGTCATTTCTAAGCTGCTTCCAACCTAACACGGAC  
ATTTTGGGGTTGAAAATCAGCAACTCCCTCATCCTGGATGTCAAAGCTGAACCGATCGAT  
GATGGCAAAGGCCTTAACCTGAGCTTCCCTGTCACCGCGAATGTCAGTGTGGCCGGGCCC  
ATCATTGGCCAGATTATCAACCTGAAAGCCTCCTTGGACCTCCTGACCGCAGTCACAATT  
GAAACTGATCCCCAGACACACCAGCCTGTTGCCGTCTGGGAGAATGCGCCAGTGACCCA  
ACCAGCATCTCACTTTCCTTGCTGGACAAACACAGCCAAATCATCAACAAGTTCGTGAAT  
AGCGTGATCAACACGCTGAAAAGCACTGTATCCTCCCTGCTGCAGAAGGAGATATGTCCA  
CTGATCCGCATCTTCATCCACTCCCTGGATGTGAATGTCATTGAGCAGGTCGTGATAAT  
CCTCAGCACAAAACCCAGCTGCAAACCCTCATCTGAAGAGGACGAATGAGGAGGACCACT  
GTGGTGCATGCTGATTGGTTCCAGTGGCTTGCCCCACCCCTTATAGCATCTCCCTCCA  
GGAAGCTGCTGCCACCACCTAACCAGCGTGAAAGCCTGAGTCCCACCAGAAGGACCTTCC  
CAGATACCCCTTCTCCTCACAGTCAGAACAGCAGCCTCTACACATGTTGTCTGCCCCCTG  
GCAATAAAGGCCCATTTCTGCACCCTTAA

172/392

**FIGURE 164**

MLQLWKLVLLCGVLTGTSESLLDNLGNDLSNVVDKLEPVLHEGLETVDNTLKGILEKLKV  
DLGVLQKSSAWQLAKQKAQEAELNNVISKLLPTNTDIFGLKISNSLILDVKAEPIDDG  
KGLNLSFPVTANVTVAGPIIGQIINLKASLDLLTAVTIETDPQTHQPVAVLGECASDPTS  
ISLSLLDKHSQIINKFVNSVINTLKSTVSSLLQKEICPLIRIFIHSLDVNVIQQVVDNPQ  
HKTQLQTLI

**Important features:****Signal peptide:**

1-15

**Transmembrane domain:**

none

**N-glycosylation site:**

124-128, 132-136

**N-myristoylation site:**

12-18, 16-22, 26-32, 101-107, 122-128, 141-147

**Leucine zipper pattern:**

44-66

173/392

**FIGURE 165**

GCAGTACAGAGACTTCCCCTGCCCTCGCTGGGAAAGAACATTAGGAATGCCCTTTTAGTGC  
CTTGCTTCCTGAACTAGCTCACAGTAGCCCGCGGCCAGGGCAATCCGACCACATTTCA  
CTCTCACCGCTGTAGGAATCCAGATGCAGGCCAAGTACAGCAGCACGAGGGACATGCTGG  
ATGATGATGGGGACACCACCATGAGCCTGCATTCTCAAGCCTCTGCCACAACCTCGGCATC  
CAGAGCCCCGGCGCACAGAGCACAGGGCTCCCTCTTCAACGTGGCGACCAGTGGCCCTGA  
• CCCTGCTGACTTTGTGCTTGGTGCTGCTGATAGGGCTGGCAGCCCTGGGGCTTTTGT  
TTTCACTACTACCAGCTCTCCAATACTGGTCAAGACACCATTTCTCAAATGGAAGAAAGAT  
TAGGAAATACGTCCCAAGAGTTGCAATCTCTTCAAGTCCAGAATATAAAGCTTGCAGGAA  
GTCTGCAGCATGTGGCTGAAAAACTCTGTGCTGAGCTGTATAACAAAGCTGGAGCACACA  
GGTGCAGCCCTTGTAACAGAACAATGGAAATGGCATGGAGACAATTGCTACCAGTTCTATA  
AAGACAGCAAAAGTTGGGAGGACTGTAAATATTTCTGCCTTAGTGAAAACCTTACCATGC  
TGAAGATAAAACAAACAAGAAGACCTGGAATTTGCCGCGTCTCAGAGCTACTCTGAGTTTT  
TCTACTCTTATTGGACAGGGCTTTTGGCGCCCTGACAGTGGCAAGGCCTGGCTGTGGATGG  
ATGGAACCCCTTTCACTTCTGAACTGTTCCATATTATAATAGATGTCACCAGCCCAAGAA  
GCAGAGACTGTGTGGCCATCCTCAATGGGATGATCTTCTCAAAGGACTGCAAAGAATTGA  
AGCGTTGTGTCTGTGAGAGAAGGGCAGGAATGGTGAAGCCAGAGAGCCTCCATGTCCCCC  
CTGAAAACATTAGGCGAAGGTGACTGATTTCGCCCTCTGCAACTACAAATAGCAGAGTGAGC  
CAGGCGGTGCCAAAGCAAGGGCTAGTTGAGACATTGGGAAATGGAACATAATCAGGAAAG  
ACTATCTCTCTGACTAGTACAAAATGGGTTCTCGTGTTCCTGTTTCCAGGATCACCAGCAT  
TTCTGAGCTTGGGTTTATGCACGTATTTAACAGTCAACAAGAAGTCTTATTTACATGCCAC  
CAACCAACCTCAGAAACCCATAATGTCATCTGCCTTCTTGGCTTAGAGATAACTTTTAGC  
TCTCTTTCTTCTCAATGTCTAATATCACCTCCCTGTTTTCATGTCTTCTTACACTTGGT  
GGAATAAGAACTTTTTGAAGTAGAGGAAATACATTGAGGTAACATCCTTTTTCTCTGACA  
GTCAAGTAGTCCATCAGAAATTGGCAGTCACTTCCCAGATTGTACCAGCAAATACACAAG  
GAATTCTTTTTGTTTGTTCAGTTCATACTAGTCCCTTCCCAATCCATCAGTAAAGACCC  
CATCTGCCCTTGTCCATGCCGTTTCCCAACAGGGATGTCACCTTGATATGAGAATCTCAAAT  
CTCAATGCCCTTATAAGCATTCCTTCCCTGTGTCCATTAAAGACTCTGATAATTGTCTCCCT  
CCATAGGAATTTCTCCCAGGAAAGAAATATATCCCCATCTCCGTTTCATATCAGAACTAC  
CGTCCCCGATATTCCCTTCAGAGAGATTAAAGACCAGAAAAAAGTGAGCCTCTTCATCTG  
CACCTGTAATAGTTTCAGTTCCTATTTTCTTCCATTGACCCATATTTATACCTTTTCAGGT  
ACTGAAGATTTTAATAATAATAAATGTAAATACTGTGAAAAA



174/392

**FIGURE 166**

MQAKYSSTRDMLDDDGD TTMSLHSQASATTRHPEPRRTEHRAPSSTWRPVALTLLTLCV  
LLIGLAALGLLFFQYYQLSNTGQDTISQMEERLGNTSQELQSLQVQNIKLAGSLQHVAEK  
LCRELYNKAGAHRCSPCTEQWKWHGDNCYQFYKDSKSWEDCKYFCLSENSTMLKINKQED  
LEFAASQSYSEFFYSYWTGLLRPDSGKAWLWMDGTPFTSELFHIIIDVTSPRSRDCVAIL  
NGMIFSKDCKELKRCVCERRAGMVKPESLHVPPETLGED

175/392

**FIGURE 167**

GCGACGGGCAGGACGCCCCGTTTCGCCTAGCGCGTGCTCAGGAGTTGGTGTCTGCCTGCG  
CTCAGGATGAGGGGGAATCTGGCCCTGGTGGGCGTTCTAATCAGCCTGGCCTTCCTGTCA  
CTGCTGCCATCTGGACATCCTCAGCCGGCTGGCGATGACGCCTGCTCTGTGCAGATCCTC  
GTCCCTGGCCTCAAAGGGGATGCGGGAGAGAAGGGAGACAAAGGCGCCCCCGGACGGCCT  
GGAAGAGTCGGCCCCACGGGAGAAAAAGGAGACATGGGGGACAAAGGACAGAAAGGCAGT  
GTGGGTCTGTCATGGAAAAATTGGTCCCATTTGGCTCTAAAGGTGAGAAAGGAGATTCCGGT  
GACATAGGACCCCCCTGGTCCTAATGGAGAACCAGGCCTCCCATGTGAGTGCAGCCAGCTG  
CGCAAGGCCATCGGGGAGATGGACAACCAGGTCTCTCAGCTGACCAGCGAGCTCAAGTTC  
ATCAAGAATGCTGTGCGCCGGTGTGCGCGAGACGGAGAGCAAGATCTACCTGCTGGTGAAG  
GAGGAGAAGCGCTACGCGGACGCCCAGCTGTCCTGCCAGGGCCGCGGGGGCACGCTGAGC  
ATGCCCAAGGACGAGGCTGCCAATGGCCTGATGGCCGCATACCTGGCGCAAGCCGGCCTG  
GCCCCGTGTCTTCATCGGCATCAACGACCTGGAGAAGGAGGGCGCCTTCGTGTACTCTGAC  
CACTCCCCCATGCGGACCTTCAACAAGTGGCGCAGCGGTGAGCCCAACAATGCCTACGAC  
GAGGAGGACTGCGTGGAGATGGTGGCCTCGGGCGGCTGGAACGACGTGGCCTGCCACACC  
ACCATGTACTTCATGTGTGAGTTTGACAAGGAGAACATGTGAGCCTCAGGCTGGGGCTGC  
CCATTGGGGGCCCCACATGTCCCTGCAGGGTTGGCAGGGACAGAGCCCAGACCATGGTGC  
CAGCCAGGGAGCTGTCCCTCTGTGAAGGGTGGAGGCTCACTGAGTAGAGGGCTGTTGTCT  
AAACTGAGAAAATGGCCTATGCTTAAGAGGAAAATGAAAGTGTTCTGGGGTGTGTCTC  
TGAAGAAGCAGAGTTTCATTACCTGTATTGTAGCCCCAATGTCATTATGTAATTATTACC  
CAGAATTGCTCTTCCATAAAGCTTGTGCCTTTGTCCAAGCTATACAATAAAATCTTTAAG  
TAGTGCAGTAGTTAAGTCCAAAAAAAAAAAAAAAAAAAAA

176/392

**FIGURE 168**

MRGNLALVGVLI SLAFLSLLPSGHPQ PAGDDACSVQILVPGLKGDAGEKGDKGAPGRPGR  
VGPTGEKGDMDKGQKGSVGRHGKIGPIGSKGEKGDSDIGPPGPNGEPGLPCECSQLRK  
AIGEMDNQVSQLTSELKFIKNAVAGVRETESKIYLLVKEEKRYADAQLSCQGRGGTLSMP  
KDEAANGLMAAYLAQAGLARVFIGINDLEKEGAFVYSDHSPMRTFNKWRSGEPNNAYDEE  
DCVEMVASGGWNDVACHTTMYFMCEFDKENM

177/392

**FIGURE 169**

AGTGACTGCAGCCTTCCTAGATCCCCTCCACTCGGTTTCTCTCTTTGCAGGAGCACCGGC  
AGCACCAGTGTGTGAGGGGAGCAGGCAGCGGTCCTAGCCAGTTCCTTGATCCTGCCAGAC  
CACCCAGCCCCCGGCACAGAGCTGCTCCACAGGCACCATGAGGATCATGCTGCTATTAC  
AGCCATCCTGGCCTTCAGCCTAGCTCAGAGCTTTGGGGCTGTCTGTAAGGAGCCACAGGA  
GGAGGTGGTTCCTGGCGGGGGCCGCAGCAAGAGGGATCCAGATCTCTACCAGCTGCTCCA  
GAGACTCTTCAAAGCCACTCATCTCTGGAGGGATTGCTCAAAGCCCCTGAGCCAGGCTAG  
CACAGATCCTAAGGAATCAACATCTCCCGAGAAACGTGACATGCATGACTTCTTTGTGGG  
ACTTATGGGCAAGAGGAGCGTCCAGCCAGAGGGAAAGACAGGACCTTTCTTACCTTCAGT  
GAGGGTTCCTCGGCCCCCTTCATCCCAATCAGCTTGGATCCACAGGAAAGTCTTCCCTGGG  
AACAGAGGAGCAGAGACCTTTATAAGACTCTCCTACGGATGTGAATCAAGAGAACGTCCC  
CAGCTTTGGCATCCTCAAGTATCCCCCGAGAGCAGAATAGGTACTCCACTTCCGGACTCC  
TGGACTGCATTAGGAAGACCTCTTCCCTGTCCCAATCCCCAGGTGCGCACGCTCCTGTT  
ACCCTTTCTCTTCCCTGTTCTTGTAACATTCTTGTGCTTTGACTCCTTCTCCATCTTTTC  
TACCTGACCCTGGTGTGGAACTGCATAGTGAATATCCCCAACCCCAATGGGCATTGACT  
GTAGAATACCCTAGAGTTCCTGTAGTGTCTACATTAAAAATATAATGTCTCTCTCTATT  
CCTCAACAATAAAGGATTTTTGCATATGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAA

178/392

## FIGURE 170

MRIMLLFTAILAFSLAQSFQAVCKEPQEEVVPGGGRSKRDPDLYQLLQRLFKSHSSLEGL  
LKALSQASTDPKESTSPEKRDMDHDFVGLMGKRSVQPEGKTGPFLPSVRVPRPLHPNQLG  
STGKSSSLGTEEQRPL

**Important features:**

**Signal peptide:**

amino acids 1-18

**Tyrosine kinase phosphorylation site:**

amino acids 36-45

**N-myristoylation site:**

amino acids 33-39, 59-65

**Amidation site:**

amino acids 90-94

**Leucine zipper pattern:**

amino acids 43-65

**Tachykinin family signature:**

amino acids 86-92

179/392

**FIGURE 171**

TGGCCTCCCCAGCTTGCCAGGCACAAGGCTGAGCGGGAGGAAGCGAGAGGCATCTAAGCA  
GGCAGTGTTTTGCCTTCACCCCAAGTGACCATGAGAGGTGCCACGCGAGTCTCAATCATG  
CTCCTCCTAGTAACTGTGTCTGACTGTGCTGTGATCACAGGGGCTGTGAGCGGGATGTC  
CAGTGTGGGGCAGGCACCTGCTGTGCCATCAGCCTGTGGCTTCGAGGGCTGCGGATGTGC  
ACCCCGCTGGGGCGGGAAGGCGAGGAGTGCCACCCCGGCAGCCACAAGGTCCCCTTCTTC  
AGGAAACGCAAGCACACACCTGTCTTGCTTGCCCAACCTGCTGTGCTCCAGGTTCCCG  
GACGGCAGGTACCGCTGCTCCATGGACTTGAAGAACATCAATTTTTAGGCGCTTGCCCTGG  
TCTCAGGATACCCACCATCCTTTTCTTGAGCACAGCCTGGATTTTATTCTGCCATGAA  
ACCCAGCTCCCATGACTCTCCAGTCCCTACACTGACTACCCTGATCTCTCTTGTCTAGT  
ACGCACATATGCACACAGGCAGACATACTCCCATCATGACATGGTCCCCAGGCTGGCCT  
GAGGATGTCACAGCTTGAGGCTGTGGTGTGAAAGGTGGCCAGCCTGGTTCTCTTCCCTGC  
TCAGGCTGCCAGAGAGGTGGTAAATGGCAGAAAGGACATTCCCCCTCCCCTCCCAGGTG  
ACCTGCTCTCTTTCCTGGGCCCCTGCCCTCTCCCCACATGTATCCCTCGGTCTGAATTAG  
ACATTCCTGGGCACAGGCTCTTGGGTGCATTGCTCAGAGTCCCAGGTCTTGGCCTGACCC  
TCAGGCCCTTCACGTGAGGTCTGTGAGGACCAATTTGTGGGTAGTTCATCTTCCCTCGAT  
TGGTTAACTCCTTAGTTTCAGACCACAGACTCAAGATTGGCTCTTCCCAGAGGGCAGCAG  
ACAGTCACCCCAAGGCAGGTGTAGGGAGCCCAGGGAGGCCAATCAGCCCCCTGAAGACTC  
TGGTCCCAGTCAGCCTGTGGCTTGTGGCCTGTGACCTGTGACCTTCTGCCAGAATTGTCA  
TGCTCTGAGGCCCCCTCTTACCACACTTTACCAGTTAACCCTGAAGCCCCCAATTCCC  
ACAGCTTTTCCATTAAAAATGCAAAATGGTGGTGGTTCAATCTAATCTGATATTGACATATT  
AGAAGGCAATTAGGGTGTTCCTTAAACAACCTCTTCCAAGGATCAGCCCTGAGAGCAG  
GTTGGTGACTTTGAGGAGGGCAGTCTCTGTCCAGATTGGGGTGGGAGCAAGGGACAGGG  
AGCAGGGCAGGGGCTGAAAGGGGCACTGATTGAGACCAGGGAGGCAACTACACACCAACA  
TGCTGGCTTTAGAATAAAAGCACCAACTGAAAAA

180/392

## FIGURE 172

MRGATRVSIMLLLVTVSDCAVITGACERDVQCGAGTCCAISLWLRGLRMCTPLGREGEEC  
HPGSHKVPFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF

**Signal peptide:**  
amino acids 1-19

**Tyrosine kinase phosphorylation site:**  
amino acids 88-95

**N-myristoylation sites:**  
amino acids 33-39, 35-41, 46-52

181/392

**FIGURE 173**

AGCGCCCGGGCGTCCGGGCGGTAAAAGGCCGGCAGAAGGGAGGCACTTGAGAAATGTCCTT  
TCCTCCAGGACCCAAGTTTCTTCACCATGGGGATGTGGTCCATTGGTGCAGGAGCCCTGG  
GGGCTGCTGCCTTGGCATTGCTGCTTGCCAACACAGACGTGTTTCTGTCCAAGCCCCAGA  
AAGCGGCCCTGGAGTACCTGGAGGATATAGACCTGAAAACACTGGAGAAGGAACCAAGGA  
CTTTCAAAGCAAAGGAGCTATGGGAAAAAATGGAGCTGTGATTATGGCCGTGCGGAGGC  
CAGGCTGTTTCTCTGTGCGAGAGGAAGCTGCGGATCTGTCCTCCCTGAAAAGCATGTTGG  
ACCAGCTGGGCGTCCCCCTCTATGCAGTGGTAAAGGAGCACATCAGGACTGAAGTGAAGG  
ATTTCCAGCCTTATTTCAAAGGAGAAATCTTCCTGGATGAAAAGAAAAAGTTCTATGGTC  
CACAAAGGCGGAAGATGATGTTTATGGGATTTATCCGTCTGGGAGTGTGGTACAACCTTCT  
TCCGAGCCTGGAACGGAGGCTTCTCTGGAAACCTGGAAGGAGAAGGCTTCATCCTTGGGG  
GAGTTTTTCGTGGTGGGATCAGGAAAGCAGGGCATTCTTCTTGAGCACCGAGAAAAAGAAT  
TTGGAGACAAAGTAAACCTACTTTCTGTTCTGGAAGCTGCTAAGATGATCAAACCACAGA  
CTTTGGCCTCAGAGAAAAAATGATTGTGTGAAACTGCCCAGCTCAGGGATAACCAGGGAC  
ATTCACCTGTGTTTCATGGGATGTATTGTTTCCACTCGTGTCCCTAAGGAGTGAGAAACCC  
ATTTATACTCTACTCTCAGTATGGATTATTAATGTATTTTAATATTCTGTTTAGGCCAC  
TAAGGCAAAATAGCCCCAAAACAAGACTGACAAAAATCTGAAAACTAATGAGGATTATT  
AAGCTAAAACCTGGGAAATAGGAGGCTTAAAATTGACTGCCAGGCTGGGTGCAGTGGCTC  
ACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGAGCAAGTCACTTGAGGTGCGGAGT  
TCGAGACCAGCCTGAGCAACATGGCGAAACCCGTCTCTACTAAAAATACAAAATCACC  
CGGGTGTGGTGGCAGGCACCTGTAGTCCCAGCTACCCGGGAGGCTGAGGCAGGAGAATCA  
CTTGAACCTGGGAGGTGGAGGTTGCGGTGAGCTGAGATCACACCACTGTATTCCAGCCTG  
GGTGA CTGAGACTCTAACTAA



182/392

## FIGURE 174

MSFLQDPSFFTGMWSIGAGALGAAALALLANTDVFLSKPQKALEYLEDIDLKTLEKE  
PRTFKAKELWEKNGAVIMAVRRPGCFLCREEAADLSSLKSMLDQLGVPLYAVVKEHIRTE  
VKDFQPYFKGEIFLDEKKKFYGPQRRKMMFMGFIRLGWYNFFRAWNGGFSGNLEGEFGFI  
LGGVFVVGSGKQGILLEHREKEFGDKVNLLSVLEAAKMIKPQTLASEKK

183/392

## FIGURE 175

GACAGTGGAGGGCAGTGGAGAGGACCGCGCTGTCCTGCTGTACCAAGAGCTGGAGACAC  
CATCTCCCACCGAGAGTCATGGCCCCATTGGCCCTGCACCTCCTCGTCCTCGTCCCCATC  
CTCCTCAGCCTGGTGGCCTCCCAGGACTGGAAGGCTGAACGCAGCCAAGACCCCTTCGAG  
AAATGCATGCAGGATCCTGACTATGAGCAGCTGCTCAAGGTGGTGACCTGGGGGCTCAAT  
CGGACCCTGAAGCCCCAGAGGGTGATTGTGGTTGGCGCTGGTGTGGCCGGGCTGGTGGCC  
GCCAAGGTGCTCAGCGATGCTGGACACAAGGTCACCATCCTGGAGGCAGATAACAGGATC  
GGGGGCCGCATCTTACCTACCGGGACCAGAACACGGGCTGGATTGGGGAGCTGGGAGCC  
ATGCGCATGCCCAGCTCTCACAGGATCCTCCACAAGCTCTGCCAGGGCCTGGGGCTCAAC  
CTGACCAAGTTCACCCAGTACGACAAGAACACGTGGACGGAGGTGCACGAAGTGAAGCTG  
CGCAACTATGTGGTGGAGAAGGTGCCCGAGAAGCTGGGCTACGCCTTGCGTCCCCAGGAA  
AAGGGCCACTCGCCCCGAAGACATCTACCAGATGGCTCTCAACCAGGCCCTCAAAGACCTC  
AAGGCACTGGGCTGCAGAAAGGCGATGAAGAAATTTGAAAGGCACACGCTCTTGGAATAT  
CTTCTCGGGGAGGGGAACCTGAGCCGGCCGGCCGTGCAGCTTCTGGGAGACGTGATGTCC  
GAGGATGGCTTCTTCTATCTCAGCTTTCGCCGAGGCCCTCCGGGCCCACAGCTGCCTCAGC  
GACAGACTCCAGTACAGCCGCATCGTGGGTGGCTGGGACCTGCTGCCGCGCGCGCTGCTG  
AGCTCGCTGTCCGGGCTTGTGCTGTTGAACGCGCCCGTGGTGGCGATGACCCAGGGACCG  
CACGATGTGCACGTGCAGATCGAGACCTCTCCCCCGGCGCGGAATCTGAAGGTGCTGAAG  
GCCGACGTGGTGTGCTGCTGACGGCGAGCGGACCGGCGGTGAAGCGCATCACCTTCTCGCCG  
CCGCTGCCCCGCCACATGCAGGAGGCGCTGCGGAGGCTGCACTACGTGCCGGCCACCAAG  
GTGTTCTTAAGCTTCCGCAGGCCCTTCTGGCGCGAGGAGCACATTGAAGGCGGCCACTCA  
AACACCGATCGCCCGTCGCGCATGATTTTCTACCCGCCCGCGCGAGGGCGCGCTGCTG  
CTGGCCTCGTACACGTGGTTCGACGCGCGGCGGCAGCGTTCGCCGGCTTGAGCCGGGAAGAG  
GCGTTGCGCTTGGCGCTCGACGACGTGGCGGCATTGCACGGGCCTGTGCTGCGCCAGCTC  
TGGGACGGCACCGGCGTCGTCAAGCGTTGGGCGGAGGACCAGCACAGCCAGGGTGGCTTT  
GTGGTACAGCCCGCGCGCTCTGGCAAACCGAAAAGGATGACTGGACGGTCCCTTATGGC  
CGCATCTACTTTGCCGGCGAGCACACCGCCTACCCGCACGGCTGGGTGGAGACGGCGGT  
AAGTCGGCGCTGCGCGCCGCCATCAAGATCAACAGCCGGAAGGGGCTGCATCGGACACG  
GCCAGCCCCGAGGGGCACGCATCTGACATGGAGGGGCAGGGGCATGTGCATGGGTGGCC  
AGCAGCCCCCTCGCATGACCTGGCAAAGGAAGAAGGCAGCCACCCTCCAGTCCAAGGCCAG  
TTATCTCTCAAAACACGACCCACACGAGGACCTCGCATTAAAGTATTTTCGGAAAAAA  
AA

184/392

**FIGURE 176**

MAPLALHLLVLPILLSLVLASQDWKAERSQDPFEKCMQDPDYEQLLKVVWGLNRTLKPQ  
RVIVVGAGVAGLVAAKVLSDAGHKVTILEADNRIGGRIFTYRDQNTGWIGELGAMRMPSS  
HRILHKLCQGLGLNLTKFTQYDKNTWTEVHEVKLRNYVVEKVPEKLGALRPQEKGHSPE  
DIYQMALNQALKDLKALGCRKAMKKFERHTLLEYLLGEGNLSRPAVQLLGDVMSSEDGFFY  
LSFAEALRAHSCLSDRLQYSRIVGGWDLPLRALLSSLSGLVLLNAPVVAMTQGPHDVHVQ  
IETSPPARNLKVLKADVLLTASGPAVKRITFSPPLPRHMQEALRRLHYVPATKVFLSFR  
RPFWREEHIEGGHSNTDRPSRMIFYPPPREGALLLASYTWSDAAAAFAGLSREEALRLAL  
DDVAALHGPVVRQLWDGTGVVKRWAEDQHSQGGFVVQPPALWQTEKDDWTVPYGRIYFAG  
EHTAYPHGWVETAVKSALRAAIKINSRKGPASDTASPEGHASDMEGQGHVHGVAASSPSHD  
LAKEEGSHPPVQGQLSLQNTTHTRTSH.

Signal peptide:  
amino acids 1-21

185/392

**FIGURE 177**

CCGGGGAGGGGAGGGCCCGTCCCGCCCCCTCCCGTCTCTCCCCGCCCTCCCGTCCCTC  
CCGCCGAAGCTCCGTCCCGCCCCGCGGGCCGGCTCCGCCCTCACCTCCCGGCCGCGGCTGC  
CCTCTGCCCGGGTTGTCCAAGATGGAGGGCGCTCCACCGGGGTGCTCGCCCTCCGGCTC  
CTGCTGTTCTGTGGCGCTACCCGCCTCCGGCTGGCTGACGACGGGCGCCCCGAGCCGCCG  
CCGCTGTCCGGAGCCCCACAGGACGGCATCAGAATTAATGTAAC TACACTGAAAGATGAT  
GGGACATATCTAAACAGCAGGTTGTTCTTAACATAACCTATGAGAGTGGACAGGTGTAT  
GTAAATGACTTACCTGTAAATAGTGGTGTAAACCCGAATAAGCTGTCAGACTTTGATAGTG  
AAGAATGAAAATCTTGAAAATTTGGAGGAAAAAGAATATTTTGGAATTGTCAGTGTAAGG  
ATTTTAGTTTCATGAGTGGCCTATGACATCTGGTTCCAGTTTGCAACTAATTGTCATTCAA  
GAAGAGGTAGTAGAGATTGATGGAAAACAAGTTT CAGCAAAGGATGTCACTGAAATTGAT  
ATTTTAGTTAAGAACCGGGGAGTACTCAGACATTCAA CTATAACCCTCCCTTTGGAAGAA  
AGCATGCTCTACTCTATTTCTCGAGACAGTGACATTTTATTTACCCTTCCTAACCTCTCC  
AAAAAAGAAAGTGTTAGTTCACTGCAAACCACTAGCCAGTATCTTATCAGGAATGTGGAA  
ACCACTGTAGATGAAGATGTTTTACCTGGCAAGTTACCTGAAACTCCTCTCAGAGCAGAG  
CCGCCATCTTCATATAAGGTAATGTGTCAGTGGATGGAAAAGTTTAGAAAAGATCTGTGT  
AGGTTCTGGAGCAACGTTTTCCAGTATTCTTTCAGTTTTTGAACATCATGGTGGTTGGA  
ATTACAGGAGCAGCTGTGGTAATAACCATCTTAAAGGTGTTTTTCCAGTTTCTGAATAC  
AAAGGAATTCTTCAGTTGGATAAAGTGGACGT CATACTGTGACAGCTATCAACTTATAT  
CCAGATGGTCCAGAGAAAAGAGCTGAAAACCTTGAAGATAAAACATGTATTTAAAACGCC  
ATCTCATATCATGGACTCCGAAGTAGCCTGTTGCCTCCAAATTTGCCACTTGAATATAAT  
TTTCTTTAAATCGTT

186/392

**FIGURE 178**

MEGAPPGSLALRLLLFVALPASGWLTGAPPEPPPLSGAPQDGIRINVTTLKDDGDISKQQ  
VVLNITYESGQVYVNDLPVNSGVTRISCQTLIVKNENLENLEEKEYFGIVSVRILVHEWP  
MTSGSSLQLIVIQEEVVEIDGKQVQKQDVTEIDILVKNRGVLRRHSNYTLPLEESMLYSIS  
RDS DILFTLPNLSKKESVSSLQTT SQYLIRNVETT VDEDVLP GKLPETPLRAEPPSSYKV  
MCQWMEKFRKDL CRFWSNVFPVFFQFLNIMVVGITGA AVVITILKVFFPVSEYKGILQLD  
KVDVIPVTAINLYPDGPEKRAENLEDKTCI

**Signal peptide:**

1-23

**Transmembrane domain:**

266-284

**Leucine zipper pattern:**

155-177

**N-glycosylation site:**

46-50, 64-68, 166-170, 191-195

**Motif name: N-myristoylation site:**

3-9, 42-48, 273-279

187/392

## FIGURE 179

CTCCTTAGGTGGAAACCCTGGGAGTAGAGTACTGACAGCAAAGACCGGGAAAGACCATAC  
GTCCCCGGGCAGGGGTGACAAACAGGTGTATCTTTTTGATCTCGTGTGTGGCTGCCTTCC  
TATTTCAAGGAAAGACGCCAAGGTAATTTTGACCCAGAGGAGCAATGATGTAGCCACCTC  
CTAACCTTCCCTTCTTGAACCCCCAGTTATGCCAGGATTTACTAGAGAGTGTCAACTCAA  
CCAGCAAGCGGCTCCTTCGGCTTAACTTGTGGTTGGAGGAGAGAACCTTTGTGGGGCTGC  
GTTCTCTTAGCAGTGCTCAGAAGTGACTTGCCTGAGGGTGGACCAGAAGAAAGGAAAGGT  
CCCCTCTTGCTGTTGGCTGCACATCAGGAAGGCTGTGATGGGAATGAAGGTGAAAACTTG  
GAGATTTCACTTCAGTCATTGCTTCTGCCTGCAAGATCATCCTTTAAAAGTAGAGAAGCT  
GCTCTGTGTGGTGGTTAACTCCAAGAGGCAGAACTCGTTCTAGAAGGAAATGGATGCAAG  
CAGCTCCGGGGGGCCCCAAACGCATGCTTCTGTGGTCTAGCCCAGGGAAGCCCTTCCGTG  
GGGGCCCCGGCTTTGAGGGATGCCACCGGTTCTGGACGCATGGCTGATTCTGAATGATG  
ATGGTTCGCCGGGGGGCTGCTTGCCTGGATTTCGCCGGTGGTGGTTTTGTCTGGTGCTCCTC  
TGCTGTGCTATCTCTGTCTGTACATGTTGGCCTGCACCCCCAAAAGGTGACGAGGAGCAG  
CTGGCACTGCCCAGGGCCAACAGCCCCACGGGGAAGGAGGGGTACCAGGCCGTCTCTTCAG  
GAGTGGGAGGAGCAGCACCGCAACTACGTGAGCAGCCTGAAGCGGCAGATCGCACAGCTC  
AAGGAGGAGCTGCAGGAGAGGAGTGAGCAGCTCAGGAATGGGCAGTACCAAGCCAGCGAT  
GCTGCTGGCCTGGGTCTGGACAGGAGCCCCCAGAGAAAACCCAGGCCGACCTCCTGGCC  
TTCCTGCACTCGCAGGTGGACAAGGCAGAGGTGAATGCTGGCGTCAAGCTGGCCACAGAG  
TATGCAGCAGTGCCCTTTCGATAGCTTTACTCTACAGAAGGTGTACCAGCTGGAGACTGGC  
CTTACCCGCCACCCCGAGGAGAAGCCTGTGAGGAAGGACAAGCGGGATGAGTTGGTGGAA  
GCCATTGAATCAGCCTTGGAGACCCTGAACAATCCTGCAGAGAACAGCCCCAATCACCGT  
CCTTACACGGCCTCTGATTTTCATAGAAGGGATCTACCGAACAGAAAGGGACAAAGGGACA  
TTGTATGAGCTCACCTTCAAAGGGGACCACAAACACGAATTCAAACGGCTCATCTTATTT  
CGACCATTACAGCCCCATCATGAAAGTGAAAAATGAAAAGCTCAACATGGCCAAACACGCTT  
ATCAATGTTATCGTGCCTCTAGCAAAAAGGGTGGACAAGTTCGGGCAGTTCATGCAGAAT  
TTCAGGGAGATGTGCATTGAGCAGGATGGGAGAGTCCATCTCACTGTTGTTTACTTTGGG  
AAAGAAGAAATAAATGAAGTCAAAGGAATACTTGAAAAACTTCCAAAGCTGCCAACTTC  
AGGAACCTTTACCTTCATCCAGCTGAATGGAGAATTTTCTCGGGGAAAGGGACTTGATGTT  
GGAGCCCGCTTCTGGAAGGGAAGCAACGTCTTCTCTTTTCTGTGATGTGGACATCTAC  
TTCACATCTGAATTCCTCAATACGTGTAGGCTGAATACACAGCCAGGGAAGAAGGTATTT  
TATCCAGTTCTTTTCAGTCAGTACAATCCTGGCATAATATACGGCCACCATGATGCAGTC  
CCTCCCTTGGAAACAGCAGCTGGTCATAAAGAAGGAAACTGGATTTTGGAGAGACTTTGGA  
TTTGGGATGACGTGTCTAGTATCGGTCTAGACTTCATCAATATAGGTGGGTTTGATCTGGAC  
ATCAAAGGCTGGGGCGGAGAGGATGTGCACCTTTATCGCAAGTATCTCCACAGCAACCTC  
ATAGTGGTACGGACGCCTGTGCGAGGACTCTTCCACCTCTGGCATGAGAAGCGCTGCATG  
GACGAGCTGACCCCGAGCAGTACAAGATGTGCATGCAGTCCAAGGCCATGAACGAGGCA  
TCCCACGGCCAGCTGGGCATGCTGGTGTTCAGGCACGAGATAGAGGCTCACCTTCGCAAA  
CAGAAACAGAAGACAAGTAGCAAAAAAACATGAACCTCCAGAGAAGGATTGTGGGAGACA  
CTTTTTCTTTCTTTTGAATTAAGTGGCTGCAACAGAGAAAAGACTTCCATAAA  
GGACGACAAAAGAATTGGACTGATGGGTGAGAGATGAGAAAGCCTCCGATTTCTCTCTGT  
TGGGCTTTTTACAACAGAAATCAAAATCTCCGCTTTGCCTGCAAAAGTAACCCAGTTGCA  
CCCTGTGAAGTGTCTGACAAAGGCAGAATGCTTGTGAGATTATAAGCCTAATGGTGTGGA  
GGTTTTGATGGTGTTTACAATACACTGAGACCTGTTGTTTTGTGTGCTCATTGAAATATT  
CATGATTTAAGAGCAGTTTTGTAAAAAATTCATTAGCATGAAAGGCAAGCATATTTCTCC  
TCATATGAATGAGCCTATCAGCAGGGCTCTAGTTTCTAGGAATGCTAAAATATCAGAAGG  
CAGGAGAGGAGATAGGCTTATTATGATACTAGTGAGTACATTAAGTAAAATAAAATGGAC  
CAGAAAAGAAAAGAAACCATAAATATCGTGTCTATTTTTCCCAAGATTAACCAAAAATA

188/392

ATCTGCTTATCTTTTTGGTTGTCCTTTTAACTGTCTCCGTTTTTTTCTTTTATTTAAAAA  
TGCACTTTTTTCCCTTGTGAGTTATAGTCTGCTTATTTAATTACCACCTTTGCAAGCCTT  
ACAAGAGAGCACAAGTTGGCCTACATTTTTATATTTTTTAAGAAGATACTTTGAGATGCA  
TTATGAGAACTTTTCAGTTCAAAGCATCAAATTGATGCCATATCCAAGGACATGCCAAATG  
CTGATTCTGTCAGGCACTGAATGTCAGGCATTGAGACATAGGGAAGGAATGGTTTGTACT  
AATACAGACGTACAGATACTTTCTCTGAAGAGTATTTTCGAAGAGGAGCAACTGAACACT  
GGAGGAAAAGAAAATGACACTTTCTGCTTTACAGAAAAGGAAACTCATTGAGACTGGTGA  
TATCGTGATGTACCTAAAAGTCAGAAACCACATTTTCTCCTCAGAAGTAGGGACCGCTTT  
CTTACCTGTTTAAATAAACCAAAGTATACCGTGTGAACCAAACAATCTCTTTTCAAAACA  
GGGTGCTCCTCCTGGCTTCTGGCTTCCATAAGAAGAAATGGAGAAAAATATATATATATA  
TATATATATTGTGAAAGATCAATCCATCTGCCAGAATCTAGTGGGATGGAAGTTTTTGCT  
ACATGTTATCCACCCAGGCCAGGTGGAAGTAACTGAATTATTTTTTAAATTAAGCAGTT  
CTACTCAATCACCAAGATGCTTCTGAAAATTGCATTTTATTACCATTTCAAACATTTTTT  
TAAAAATAAATACAGTTAACATAGAGTGGTTTCTTCATTCATGTGAAAATTATTAGCCAG  
CACCAGATGCATGAGCTAATTATCTCTTTGAGTCCTTGCTTCTGTTTGCTCACAGTAAAC  
TCATTGTTTAAAAGCTTCAAGAACATTCAGCTGTTGGTGTGTTAAAAAATGCATTGTAT  
TGATTTGTACTGGTAGTTTATGAAATTTAATTAAAACACAGGCCATGAATGGAAGGTGGT  
ATTGCACAGCTAATAAAATATGATTTGTGGATATGAA

189/392

**FIGURE 180**

MMVRRGLLAWISRVVLLVLLCCAISVLYMLACTPKGDEEQLALPRANSPTGKEGYQAV  
LQEWEEQHRNYVSSLKRQIAQLKEELQERSEQLRNGQYQASDAAGLGLDRSPPEKTQADL  
LAFLHSQVDKAEVNAGVKLATEYAAPFDSFTLQKVYQLETGLTRHPPEKPVRKDKRDEL  
VEAIESALETLNPAENSPNHRPYTASDFIEGIYRTERDKGTLYELTFKGDHKHEFKRLI  
LFRPFSPIMKVKNEKLNMAN TLIN VIVPLAKRVDKFRQFMQNFREMCIEQDGRVHLTVVY  
FGKEEINEVKGILENTSKAANFRNFTFIQLNGEFSRGKGLDVGARFWKGSNVLLFFCDVD  
IYFTSEFLNTCRLNTQPGKKVFYPVLF SQYNPGIIYGHHD AVPPLEQQLVIKKETGFWRD  
FGFGMTCQYRSDFINIGGFDLDIKGWGGEDVHLYRKYLHSNLI VVRTPVRGLFHLWHEKR  
CMDELTPEQYKMCMQSKAMNEASHGQLGMLVFRHEIEAHLRKQKQKTSSKKT



190/392

**FIGURE 181**

CGTCTCTGCGTTTCGCCATGCGTCCCGGGGCGCCAGGGCCACTCTGGCCTCTGCCCTGGGG  
GGCCCTGGCTTGGGCCGTGGGCTTCGTGAGCTCCATGGGCTCGGGGAACCCCGCGCCCGG  
TGGTGTTCGCTGGCTCCAGCAGGGCCAGGAGGCCACCTGCAGCCTGGTGCTCCAGACTGA  
TGTACCCCGGGCCGAGTGCTGTGCCTCCGGCAACATTGACACCGCCTGGTCCAACCTCAC  
CCACCCGGGGAACAAGATCAACCTCCTCGGCTTCTTGGGCCTTGTCCACTGCCTTCCCTG  
CAAAGATTCTGTGCGACGGCGTGGAGTGC GGCCCGGGCAAGGCGTGCCGCATGCTGGGGGG  
CCGCCCCGCGCTGCGAGTGCGCGCCCGACTGCTCGGGGCTCCCGGCGCGGCTGCAGGTCTG  
CGGCTCAGACGGCGCCACCTACCGCGACGAGTGCAGAGTGC GCGCGCCGCGCTGCCGCGG  
CCACCCGGACCTGAGCGTCATGTACCGGGGCCGCTGCCGCAAGTCCGTGTGAGCACGTGGT  
GTGCCCCGCGGCCACAGTTCGTGCGTTCGTGGACCAGACGGGCAGCGCCCACTGCGTGGTGTG  
TCGAGCGGCGCCCTGCCCTGTGCCCTCCAGCCCCGGCCAGGAGCTTTGCGGCAACAACAA  
CGTCACCTACATCTCCTCGTGCCACATGCGCCAGGCCACCTGCTTCCTGGGCCGCTCCAT  
CGGCGTGCGCCACGCGGGCAGCTGCGCAGGCACCCCTGAGGAGCCGCCAGGTGGTGAGTC  
TGCAGAAGAGGAAGAGAACTTCGTGTGAGCCTGCAGGACAGGCCTGGGCCTGGTGCCCGA  
GGCCCCCATCATCCCCTGTTATTTATTGCCACAGCAGAGTCTAATTTATATGCCACGGA  
CACTCCTTAGAGCCCCGATTTCGGACCACTTGGGGATCCAGAACCTCCCTGACGATATCC  
TGGAAGGACTGAGGAAGGGAGGCCTGGGGGCCGGCTGGTGGGTGGGATAGACCTGCGTTC  
CGGACACTGAGCGCCTGATTTAGGGGCCCTTCTCTAGGATGCCCCAGCCCCCTACCCTAAGA  
CCTATTGCCGGGGAGGATTCCACACTTCCGCTCCTTTGGGGATAAACCTATTAATTATTG  
CTACTATCAAGAGGGCTGGGCATTCTCTGCTGGTAATTCCTGAAGAGGCATGACTGCTTT  
TCTCAGCCCCAAGCCTCTAGTCTGGGTGTGTACGGAGGGTCTAGCCTGGGTGTGTACGGA  
GGGTCTAGCCTGGGTGAGTACGGAGGGTCTAGCCTGGGTGAGTACGGAGGGTCTAGCCTG  
GGTGAGTACGGAGGGTCTAGCCTGGGTGTGTATGGAGGATCTAGCCTGGGTGAGTATGGA  
GGGTCTAGCCTGGGTGAGTATGGAGGGTCTAGCCTGGGTGTGTATGGAGGGTCTAGCCTG  
GGTGAGTATGGAGGGTCTAGCCTGGGTGTGTATGGAGGGTCTAGCCTGGGTGAGTATGGA  
GGGTCTAGCCTGGGTGTGTACGGAGGGTCTAGTCTGAGTGCGTGTGGGGACCTCAGAACAA  
CTGTGACCTTAGCCCAGCAAGCCAGGCCCTTCATGAAGGCCAAGAAGGCTGCCACCATTTC  
CCTGCCAGCCCCAAGAACTCCAGCTTCCCCACTGCCTCTGTGTGCCCTTTGCGTCCCTGTG  
AAGGCCATTGAGAAATGCCAGTGTGCCCCCTGGGAAAGGGCACGGCCTGTGCTCCTGAC  
ACGGGCTGTGCTTGGCCACAGAACCCACCCAGCGTCTCCCCCTGCTGCTGTCCACGTCA GTT  
CATGAGGCAACGTCGCGTGGTCTCAGACGTGGAGCAGCCAGCGGCAGCTCAGAGCAGGGC  
ACTGTGTCCGGCGGAGCCAAGTCCACTCTGGGGGAGCTCTGGCGGGGACCACGGGCCACT  
GCTCACCCACTGGCCCCGAGGGGGGTGTAGACGCCAAGACTCACGCATGTGTGACATCCG  
GAGTCTTGAGCCGGGTGTCCCAGTGGCACCCTAGGTGCCCTGCTGCCCTCCACAGTGGGG  
TTCACACCCAGGGCTCCTTGGTCCCCCACAACCTGCCCCGGCCAGGCCTGCAGACCCAGA  
CTCCAGCCAGACCTGCCCTACCCACCAATGCAGCCGGGGCTGGCGACACCAGCCAGGTGC  
TGGTCTTGGGCCAGTTCTCCCACGACGGCTCACCCCTCCCCTCCATCTGCGTTGATGCTCA  
GAATCGCCTACCTGTGCCTGCGTGTAACCCACAGCCTCAGACCAGCTATGGGGAGAGGAC  
AACACGGAGGATATCCAGCTTCCCCGGTCTGGGGTGAGGAATGTGGGGAGCTTGGGCATC  
CTCCTCCAGCCTCCTCCAGCCCCCAGGCAGTGCCCTTACCTGTGGTGCCAGAAAAGTGCC  
CCTAGGTTGGTGGGTCTACAGGAGCCTCAGCCAGGCAGCCACCCACCCCTGGGGCCCTG  
CCTCACCAAGGAAATAAAGACTCAAGCCATAAAAAAA

191/392

**FIGURE 182**

MRPGAPGPLWPLPWGALAWAVGFVSSMSGGNPAPGGVCWLQQGQEATCSLVLQTDVTRAE  
CCASGNIDTAWSNLTHPGNKINLLGFLGLVHCLPCKDSCDGVCEGPGKACRMLGGRPRCE  
CAPDCSGLPARLQVCGSDGATYRDECELRAARCRGHPDLSVMYRGRCRKSCEHVVCPRPQ  
SCVVDQTGSAHCVVCRAAPCFVPSSPGQELCGNNNVTYISSCHMRQATCFLGRSIGVRHA  
GSCAGTPEEPPGGESAEEEENFV

**Important features:****Signal peptide:**

amino acids 1-20

**N-glycosylation sites:**

amino acids 73-77, 215-219

**Osteonectin domain proteins:**

amino acids 97-130, 169-202

192/392

**FIGURE 183**

CACTCATTTCATTCCAAAGGGTCTCTCAAGGCAATGGTAATGTGCAAGGAGGTGATACCTA  
AATGAATGACCAAAAGAACATGCTTCTGCTTTTGTGTGTCTCCTACATTTTAGACATTTG  
TTTGTCTCTCTTGGTAGCCTTTAAATTCCTTGAAGCCCAGGACCATGTCTCACTTACCTT  
TGTGTTTCCACTAACTAGTCTACCTCCTGGAATTGGCAGATACTCAGTGAAAAGCCTGTGA  
AATAAGTGATGTCTATTTCTAGCATATTATTCTGAGATTTAATGATAGATTTAGTGATTG  
AATGAGATTTCCATTTTCAAATACAGCAAAAGCATAACTATTTTCATTCATTTCATATTCA  
TTCAACTTCATTCTCAAAATTAGGTCTGAGTTAACTAATAATTACCTTTGAAATGTGTG  
GGTTATTTGAGGCAATCAGGTGGTGACATTGAGCTCTCAGCCAGAGTTTGTCTGGAAT  
TGATTTCAGTTCCATTGCATTGATTTTTGTTCTCAGAAGCCAAGGTTTCCCATGAAAAATC  
ATTCCCACCTTGAATTGGGCTGTGATTCTTGCTGCGTTTAAGTAAAGGAAGCCTCTTGTTT  
CTAGTTCTGCAAACCTTACACACTGAACTGGGACAAGTTTTTGTCTTAGAGTAATGGCTGGG  
AAAAGAGGAACCTTTTCATTTTATTTCAGAAGTCAAAAACAAAGGCCTCCCAGCCACCTGGA  
GATGTTTTGTTGCAGACACCAGCCTGGCTCTGTCTTTATGCCTAACAAATTGAGCATCCAG  
TCTTCTTTGTGCTGGGACCATTGCTCAGCTCTGCAAGGGGAAAAGAGGGAGAAAAGCCAGA  
GCTGCCAGGCTTCTTGCACTGGGGCCGGGGGAGGGTTTCTGGGAAGCAGGTGCTCTCTGG  
CTTCTTGGTACGTGAGGCTCTCGGAGCTGCCTCTCCTCTGACCCTCAGGTCTCTCACCGAG  
TTTGCTCCAGGAGTATATTGAAAACATACCCAGTGCTCTCTCAAGCACCCACTGCTTAGA  
GGGCCCAGATTTCTTTTCTTTTCCCTTGCAAGAGCTGGAGACTGCATCGGGCATCTGG  
TGTTTAACTAAACAGGAAAACGACTAAAGGTCCACAGTGCTCATTGTGTAGACTAGCT  
GCCCTCCGATGGGTGCTCTGATTATCAGTGGTTCCAGTGCAGGGCCTGTCACTAAACAGG  
CCTCACTTCCTCCTTGGGGGCTTTCCCATGGGAGGTGTGGCTTTTTTACTCTACATGGAAA  
TGACTCTCTGCAGCCACAGAACACAGTCATTTTCTGAATTATCCCAGTCTCTCATGCGCC  
CTGGATTCTCCTCAGATGCCTTATATCTCTTGTGCAAAGTTGTCTAAAATTTGGTTCCAG  
CTTCCAAGCCTTGCCCTTTTGGCCTTCTTGGAAGTATTTTGTGATGAGTCGTCTGTCTAT  
TATTCTCTAAAATGATTTGCTTTTTGTTTCTTTTCATTTCCTATTTCCACCCACATATACA  
CACATGCTTCTTAACTTAGGGGATTACATGCCAATAAATCTATTGTTGAAAATGCACTAA  
TACTATCGCAAAGACGAAAATTCACAGGCTGAACCGTTGTAAGTCCATATGCTCCTCAAC  
TTACATGTGTGATGGAGTTATGCCCAAATAAGTCCATCGTCAAGTTGAAAATCAAATC  
AAGCCATCTTAGGTTGAGGACCATTGTGTTGTACCTCCAAAGATGTCATATCTTTAAACA  
TACTCCCTAGCTTTTCTTTTACTTTTATTTTGAAGTAATTATAGAATCACAGAAAGTT  
GCAAAAAA

193/392

## FIGURE 184

MGALIISGSSAGPVTQASLPPWGLSHGRCGFLLYMENTLCSHRTQSFSELSQSLMRPGF  
LQMPYISCAKLSKIWFPAKPCLLAFLEVFLLMSRLSLFSKMICFLFLSFLFPPIHYTHAS

Important features of the protein:

Signal peptide:

amino acids 1-41

Transmembrane domain:

amino acids 88-107

Casein kinase II phosphorylation site:

amino acids 47-50

N-myristoylation site:

amino acids 24-29

194/392

**FIGURE 185**

AACTCAAACCTCCTCTCTCTGGGAAAACGCGGTGCTTGCTCCTCCCGGAGTGGCCTTGGCA  
GGGTGTTGGAGCCCTCGGTCTGCCCCGTCCGGTCTCTGGGGCCAAGGCTGGGTTTCCCTC  
ATGTATGGCAAGAGCTCTACTCGTGCGGTGCTTCTTCTCCTTGGCATAACAGCTCACAGCT  
CTTTGGCCTATAGCAGCTGTGGAAATTTATACCTCCCGGGTGTGGAGGCTGTTAATGGG  
ACAGATGCTCGGTTAAAATGCACTTTCTCCAGCTTTGCCCCTGTGGGTGATGCTCTAACA  
GTGACCTGGAATTTTCGTCTCTAGACGGGGGACCTGAGCAGTTTGTATTCTACTACCAC  
ATAGATCCCTTCCAACCCATGAGTGGGCGGTTTAAGGACCGGGTGTCTTGGGATGGGAAT  
CCTGAGCGGTACGATGCCTCCATCCTTCTCTGAAACTGCAGTTCGACGACAATGGGACA  
TACACCTGCCAGGTGAAGAACCCACCTGATGTTGATGGGGTGATAGGGGAGATCCGGCTC  
AGCGTCGTGCACACTGTACGCTTCTCTGAGATCCACTTCCTGGCTCTGGCCATTGGCTCT  
GCCTGTGCACTGATGATCATAATAGTAATTGTAGTGGTCCTCTTCCAGCATTACCGGAAA  
AAGCGATGGGCCGAAAGAGCTCATAAAGTGGTGGAGATAAAATCAAAAGAAGAGGAAAGG  
CTCAACCAAGAGAAAAAGGTCTCTGTTTATTTAGAAGACACAGACTTACAATTTTAGATG  
GAAGCTGAGATGATTTCCAAGAACAAGAACCCTAGTATTTCTTGAAGTTAATGGAAACTT  
TTCTTTGGCTTTTCCAGTTGTGACCCGTTTCCAACCAGTTCTGCAGCATATTAGATTCT  
AGACAAGCAACACCCCTCTGGAGCCAGCACAGTGCTCCTCCATATCACCAGTCATACACA  
GCCTCATTATTAAGGTCTTATTTAATTTTCAAGTGTCTCATTAGG  
TTTTATAAACAAGAAGCTACATTTTGGCCCTTAAGACACTACTTACAGTGTTATGACTTG  
TATACACATATATTGGTATCAAAGGGGATAAAAGCCAATTTGTCTGTTACATTTCTTTTC  
ACGTATTTCTTTTAGCAGCACTTCTGCTACTAAAGTTAATGTGTTTACTCTCTTTCCTTC  
CCACATTCTCAATTAAGGTGAGCTAAGCCTCCTCGGTGTTTCTGATTAACAGTAAATC  
CTAAATTCAAACGTGTTAAATGACATTTTATTTTATGTCTCTCCTTAACATGAGACAC  
ATCTTGTTTTACTGAATTTCTTTCAATATTCCAGGTGATAGATTTTGTGCG

195/392

## FIGURE 186

MYGKSSTRAVLLLLLGIQLTALWPAAVEIYTSRVLEAVNGTDARLKCTFSSFAPVGDALT  
VTWNFRPLDGGPEQVFYHYHIDPFQPMGRFKDRVSWDGNPERYDASILLWKLQFDDNGT  
YTCQVKNPPDVGVIIEIRLSVVHTVRFSEIHFLALAIGSACALMIIIVIVVVLFFQHYRK  
KRWAEARAHKVVEIKSKEEERLNQEKVSVYLETD

196/392

**FIGURE 187**

GCATTTTGTCTGTGCTCCCTGATCTTCAGGTCACCACCATGAAGTTCTTAGCAGTCCTG  
GTA CTCTTGGGAGTTTCCATCTTTCTGGTCTCTGCCCAGAATCCGACAACAGCTGCTCCA  
GCTGACACGTATCCAGCTACTGGTCCTGCTGATGATGAAGCCCCTGATGCTGAAACCACT  
GCTGCTGCAACCACTGCGACCACTGCTGCTCCTACCACTGCAACCACCGCTGCTTCTACC  
ACTGCTCGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTCCCGAATGGTAGA  
GTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTGCAATTGGTCACAAC TATTCATGCT  
TCCTGTGATTT CATCCA ACTACTTACCTTGCC TACGATATCCCCTTTATCTCTAATCAGT  
TTATTTTCTTTCAAATAAAAAATAACTATGAGCAACATAAAAAAAAAAAAAA

197/392

## FIGURE 188

MKFLAVLVLLGVSI FLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAATTATTAAPT  
ATTAASTTARKDIPVLPKWVGDLPNGRVCP



198/392

**FIGURE 189**

GAGCGAACATGGCCAGCGCGTTGGCGGTTTTGGTGTGTCTCTGTGACCATGGTGGTGGCGC  
TGCTCATCGTTTTGCGACGTTCCCTCAGCCTCTGCCCAAAGAAAGAAGGAGATGGTGTTAT  
CTGAAAAGGTTAGTCAGCTGATGGAATGGACTAACAAAAGACCTGTAATAAGAATGAATG  
GAGACAAGTTCCGTCGCCTTGTGAAAGCCCCACCGAGAAATTACTCCGTTATCGTCATGT  
TCACTGCTCTCCAACTGCATAGACAGTGTGTGCTTTGCAAGCAAGCTGATGAAGAATTCC  
AGATCCTGGCAAACCTCCTGGCGATACTCCAGTGCATTACCAACAGGATATTTTTTTGCCA  
TGGTGGATTTTTGATGAAGGCTCTGATGTATTTTCTGATGCTAAACATGAATTCAGCTCCAA  
CTTTCATCAACTTTTCTGCAAAGGGAAACCCAAACGGGGTGATACATATGAGTTACAGG  
TGCGGGGTTTTTTCAGCTGAGCAGATTGCCCGGTGGATCGCCGACAGAACTGATGTCAATA  
TTAGAGTGATTAGACCCCAAATATGCTGGTCCCTTATGTTGGGATTGCTTTTGGCTG  
TTATTGGTGGACTTGTGTATCTTCGAAGAAGTAATATGGAATTTCTCTTTAATAAAACTG  
GATGGGCTTTTTGCAGCTTTGTGTTTTGTGCTTGCTATGACATCTGGTCAAATGTGGAACC  
ATATAAGAGGACCACCATATGCCCATAGAATCCCCACACGGGACATGTGAATTATATCC  
ATGGAAGCAGTCAAGCCAGTTTGTAGCTGAAACACACATTGTTCTTCTGTTAATGGTG  
GAGTTACCTTAGGAATGGTGCTTTTATGTGAAGCTGCTACCTCTGACATGGATATTGGAA  
AGCGAAAGATAATGTGTGTGGCTGGTATTGGACTTGTGTATTATTCTTCAGTTGGATGC  
TCTCTATTTTTAGATCTAAATATCATGGCTACCCATACAGCTTTCTGATGAGTTAAAAAG  
GTCCCAGAGATATATAGACACTGGAGTACTGGAAATTGAAAAACGAAAATCGTGTGTGTT  
TGAAAAGAAGAATGCAACTTGTATATTTTGTATTACCTCTTTTTTTCAAGTGATTTAAAT  
AGTTAATCATTTAACCAGAAAGATGTGTAGTGCCTTAACAAGCAATCCTCTGTCAAAAT  
CTGAGGTATTTGAAAATAATTATCCTCTTAACCTTCTCTTCCCAGTGAACCTTTATGGAAC  
ATTTAATTTAGTACAATTAAGTATATTATAAAAATTTGTAAACTACTACTTTGTTTTAGT  
TAGAACAAAGCTCAAACTACTTTAGTTAACTTGGTCATCTGATTTTATATTGCCTTATC  
CAAAGATGGGGAAAGTAAGTCTTGACCAGGTGTTCCACATATGCCTGTTACAGATAACT  
ACATTAGGAATTCATTCTTAGCTTCTTCATCTTTGTGTGGATGTGTATACTTTACGCATC  
TTTCCTTTTGGAGTAGAGAAATTATGTGTGTATGTGGTCTTCTGAAAATGGAACACCATT  
CTTCAGAGCACACGTCTAGCCCTCAGCAAGACAGTTGTTTCTCCTCCTCCTTGCATATTT  
CCTACTGCGCTCCAGCCTGAGTGATAGAGTGAGACTCTGTCTCAAAAAAAGTATCTCTA  
AATACAGGATTATAATTTCTGCTTGAGTATGGTGTTAACTACCTTGTATTTAGAAAGATT  
TCAGATTCATTCCATCTCCTTAGTTTTCTTTTAAGGTGACCCATCTGTGATAAAAATATA  
GCTTAGTGCTAAAAATCAGTGTAACCTTATACATGGCCTAAAATGTTTCTACAAATTAGAGT  
TTGTCACTTATTCCATTTGTACCTAAGAGAAAAATAGGCTCAGTTAGAAAAGGACTCCCT  
GGCCAGGCGCAGTGACTTACGCCTGTAATCTCAGCACTTTGGGAGGCCAAGGCAGGCAGA  
TCACGAGGTGAGGAGTTTCGAGACCATCCTGGCCAACATGGTGAAACCCCGTCTCTACTAA  
AAATATAAAAATTAGCTGGGTGTGGTGGCAGGAGCCTGTAATCCCAGCTACACAGGAGGC  
TGAGGCACGAGAATCACTTGAACCTCAGGAGATGGAGGTTTCAGTGAGCCGAGATCACGCC  
ACTGCACTCCAGCCTGGCAACAGAGCGAGACTCCATCTCAAAAAAAAAAAAAA

199/392

**FIGURE 190**

MAARWRFWCVSVTMVALLIVCDVPSASAQRKKEMVLSEKVSQLMWETNKRFPVIRMNGDK  
FRRLVKAPPRNYSVIVMFTALQLHRQCVVCKQADEEFQILANSWRYSSAFTNRIFFAMVD  
FDEGSDVFQMLNMNSAPTFFINFPKGGKPKRGDTYELQVRGFSAEQIARWIADRTDVNIRV  
IRPPNYAGPLMLGLLLA VIGGLVYLRRSNMEFLFNKTGWAFALCFVLAMTSGQMWNHIR  
GPPYAHKNPHTGHVNYIHGSSQAQFVAETHIVLLFNGGVTLG MVLLCEAATSDMDIGKRK  
IMCVAGIGLVVLF FSWMLSIFRSKYHGYPSFLMS

**Signal peptide:**

amino acids 1-29

**Transmembrane domains:**

amino acids 183-205, 217-237, 217-287, 301-321

200/392

**FIGURE 191**

GAGAGAAGTCAGCCTGGCAGAGAGACTCTGAAATGAGGGATTAGAGGTGTTCAAGGAGCA  
AGAGCTTCAGCCTGAAGACAAGGGAGCAGTCCCTGAAGACGCTTCTACTGAGAGGTCTGC  
CATGGCCTCTCTTGGCCTCCAACCTTGTTGGGCTACATCCTAGGCCTTCTGGGGCTTTTGGG  
CACACTGGTTGCCATGCTGCTCCCCAGCTGGAAAACAAGTTCTTATGTCGGTGCCAGCAT  
TGTGACAGCAGTTGGCTTCTCCAAGGGCCTCTGGATGGAATGTGCCACACACAGCACAGG  
CATCACCCAGTGTGACATCTATAGCACCCCTTCTGGGCCTGCCCGCTGACATCCAGGCTGC  
CCAGGCCATGATGGTGACATCCAGTGCAATCTCCTCCCTGGCCTGCATTATCTCTGTGGT  
GGGCATGAGATGCACAGTCTTCTGCCAGGAATCCCGAGCCAAAGACAGAGTGGCGGTAGC  
AGGTGGAGTCTTTTTTCATCCTTGGAGGCCTCCTGGGATTTCATTCTGTTGCCTGGAATCT  
TCATGGGATCCTACGGGACTTCTACTCACCACTGGTGCCTGACAGCATGAAATTTGAGAT  
TGGAGAGGCTCTTTACTTGGGCATTATTTCTTCCCTGTTCTCCCTGATAGCTGGAATCAT  
CCTCTGCTTTTCTTGCTCATCCCAGAGAAATCGCTCCAACCTACTACGATGCCTACCAAGC  
CCAACCTCTTGCCACAAGGAGCTCTCCAAGGCCTGGTCAACCTCCCAAAGTCAAGAGTGA  
GTTCAATTCCTACAGCCTGACAGGGTATGTGTGGAAGAACCAGGGGCCAGAGCTGGGGGGT  
GGCTGGGTCTGTGAAAAACAGTGGACAGCACCCCGAGGGCCACAGGTGAGGGACACTACC  
ACTGGATCGTGTGAGAAAGTGCTGCTGAGGATAGACTGACTTTGGCCATTGGATTGAGCA  
AAGGCAGAAATGGGGGCTAGTGTAACAGCATGCAGGTTGAATTGCCAAGGATGCTCGCCA  
TGCCAGCCTTTCTGTTTTCTCACCTTGCTGCTCCCCTGCCCTAAGTCCCCAACCCCTCAA  
CTTGAAACCCCATTTCCCTTAAGCCAGGACTCAGAGGATCCCTTTGCCCTCTGGTTTACCT  
GGGACTCCATCCCCAAACCCACTAATCACATCCCACTGACTGACCCTCTGTGATCAAAGA  
CCCTCTCTCTGGCTGAGGTTGGCTCTTAGCTCATTGCTGGGGATGGGAAGGAGAAGCAGT  
GGCTTTTGTGGGCATTGCTCTAACCTACTTCTCAAGCTTCCCTCCAAAGAACTGATTGG  
CCCTGGAACCTCCATCCCACTCTTGTTATGACTCCACAGTGTCCAGACTAATTTGTGCAT  
GAACTGAAATAAAACCATCCTACGGTATCCAGGGAACAGAAAGCAGGATGCAGGATGGGA  
GGACAGGAAGGCAGCCTGGGACATTTAAAAAATA

201/392

**FIGURE 192**

MASLGLQLVGYILGLLGLLGTLVAMLLPSWKTSSYVGASIVTAVGFSKGLWMECATHSTG  
ITQCDIYSTLLGLPADIQAAQAMMTSSAIISSVLGMRCTVFCQESRAKDRVAVA  
GGVFFILGLLGFIPVAWNLHGILRDFYSPLVPDSMKFEIGEALYLGIISSLFSLIAGII  
LCFSCSSQRNRSNYYDAYQAQPLATRSSPRPGQPPKVKSEFNSSYSLTGYV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-24

**Transmembrane domains:**

amino acids 82-102, 117-140, 163-182

**N-glycosylation site:**

amino acids 190-193

**PMP-22 / EMP / MP20 family proteins:**

amino acids 46-59

202/392

**FIGURE 193**

CTCCACTGCAACCACCCAGAGCCATGGCTCCCCGAGGCTGCATCGTAGCTGTCTTTGCCA  
TTTTCTGCATCTCCAGGCTCCTCTGCTCACACGGAGCCCCAGTGGCCCCCATGACTCCTT  
ACCTGATGCTGTGCCAGCCACACAAGAGATGTGGGGACAAGTTCTACGACCCCTGCAGC  
ACTGTTGCTATGATGATGCCGTCGTGCCCTTGGCCAGGACCCAGACGTGTGGAAACTGCA  
CCTTCAGAGTCTGCTTTGAGCAGTGCTGCCCCCTGGACCTTCATGGTGAAGCTGATAAACC  
AGAACTGCGACTCAGCCCGGACCTCGGATGACAGGCTTTGTGCGCAGTGTGAGCTAATGGA  
ACATCAGGGGAACGATGACTCCTGGATTCTCCTTCCTGGGTGGGCCTGGAGAAAGAGGCT  
GGTGTACCTGAGATCTGGGATGCTGAGTGGCTGTTTGGGGGCCAGAGAAACACACACTC  
AACTGCCCCACTTCATTCTGTGACCTGTCTGAGGCCACCCTGCAGCTGCCCTGAGGAGGC  
CCACAGGTCCCCCTTCTAGAATTCTGGACAGCATGAGATGCGTGTGCTGATGGGGGGCCAG  
GGACTCTGAACCCTCCTGATGACCCCTATGGCCAACATCAACCCGGCACCACCCCAAGGC  
TGGCTGGGGAAACCCTTCACCCTTCTGTGAGATTTTCCATCATCTCAAGTTCTCTTCTATC  
CAGGAGCAAAGCACAGGATCATAATAAATTTATGTACTTTATAAATGAAAA

203/392

## FIGURE 194

MAPRGCIVAVFAIFCISRLLC SHGAPVAPMTPYLMLCQPHKRCGDKFYDPLQHCCYDDAV  
VPLARTQTCGNCTFRVCFEQCCPWTFMVKLINQNCD SARTSDDRLCRSVS

Signal peptide:  
amino acids 1-24

204/392

**FIGURE 195**

CATTTCCAACAAGAGCACTGGCCAAGTCAGCTTCTTCTGAGAGAGTCTCTAGAAGACATG  
ATGCTACACTCAGCTTTGGGTCTCTGCCTCTTACTCGTCACAGTTTCTTCCAACCTTGCC  
ATTGCAATAAAAAAGGAAAAGAGGCCTCCTCAGACACTCTCAAGAGGATGGGGAGATGAC  
ATCACTTGGGTACAACTTATGAAGAAGGTCTCTTTTATGCTCAAAAAAGTAAGAAGCCA  
TTAATGGTTATTTCATCACCTGGAGGATTGTCAATACTCTCAAGCACTAAAGAAAGTATTT  
GCCCCAAATGAAGAAATACAAGAAATGGCTCAGAATAAGTTCATCATGCTAAACCTTATG  
CATGAAACCACTGATAAGAATTTATCACCTGATGGGCAATATGTGCCTAGAATCATGTTT  
GTAGACCCTTCTTTAACAGTTAGAGCTGACATAGCTGGAAGATACTCTAACAGATTGTAC  
ACATATGAGCCTCGGGATTTACCCCTATTGATAGAAAACATGAAGAAAGCATTAAAGACTT  
ATTCAGTCAGAGCTATAAGAGATGATGGAAAAAGCCTTCACCTCAAAGAAGTCAAATTT  
CATGAAGAAAACCTCTGGCACATTGACAAATACTAAATGTGCAAGTATATAGATTTTGTA  
ATATTACTATTTAGTTTTTTTAATGTGTTTGCAATAGTCTTATTAAAATAAATGTTTTTT  
AAATCTGA

205/392

## FIGURE 196

MMLHSALGLCLLLVTVSSNLAIKKEKRPPQTL SRGWGDDITWVQTYEEGLFYAQSKK  
PLMVIHHLED CQYSQALKKVFAQNEEQEMAQNKFIMLNL MHETTDKNLSPDGQYVPRIM  
FVDPSLTVRADIAGRYSNRLYTYEPRDLPLLIENMKKALRLIQSEL

**Important features:**

**Signal peptide:**  
amino acids 1-23

**N-myristoylation site:**  
amino acids 51-57



206/392

**FIGURE 197**

GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC  
AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCTCCCGCCCGCTCCCCGGCACCAGAAAGTTC  
CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC  
TGGGGATCCCTGCTCTTTCGCTCTCTTCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC  
AAGGTGCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCCTCACC  
TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC  
CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGGCCCATCCGCAACCTCACG  
TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG  
GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG  
CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC  
CACCCTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT  
GCACCATCCAACCTGTGTGGTGTACCCATCCTCCTCCAGGATAGTGAACACATCACGGCT  
GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCTGCTC  
CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCAGGAGCTGGTGGCGATG  
GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCAGGGG  
ATACCCGAGGCCAAAGTCAGGCACCCCTGTCTATGTGGCCAGCGGCAGCCTTCTGAG  
TCTGGGCGGCATCTGCTTTCGGAGCCACGACCCCTGTCTCCTCCAGGCCCGGAGAC  
GTCTTCTTCCCATCCCTGGACCCCTGTCCCTGACTCTCCAAACTTTGAGGTCTCTAGCCC  
AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT  
GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA  
GATACTGTGACATCCCAGAAGCCCAGCCCTCAACCCCTCTGGATGCTACATGGGGATGC  
TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCTAGAGACCT  
GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG  
CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA  
AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC  
CCCCGTGGCCGCTTGGCTCCCCCGTTTTGGCCGAGGCTGCTCTTCTGTGAGACTTCTC  
TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC  
CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG  
CTTCCACTGCCTGCATTCCAGTCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT  
TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT  
GTTGCCCCACCCACTGGAGATGGTGTCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA  
GTGGAGAGGGGCACCTGCCCCCGCCCTCCCCATCCCCTACTCCCCTGCTCAGCGCGGG  
CCATTGCAAGGGTGCCACACAATGTCTGTCCACCCTGGGACACTTCTGAGTATGAAGCG  
GGATGCTATTAAAACTACATGGGGAAAAAAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAGA

207/392

**FIGURE 198**

MGVPTALEAGSWRWGSLFLAASLGPVAAFQVATPYSLYVCPEGQNVTLTCRLLGPV  
DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE  
SASDHHGNFSITMRNLTLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV  
YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRAQELVRMDSNIQGI  
ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD  
PVPDSPNFEVI

**Signal peptide:**  
amino acids 1-28

**Transmembrane domain:**  
amino acids 190-216

208/392

**FIGURE 199**

CTAGCCTGCGCCAAGGGGTAGTGAGACCGCGCGGCAACAGCTTGCGGGCTGCGGGGAGCTC  
CCGTGGGCGCTCCGCTGGCTGTGCAGGCGGCCATGGATTCTTGCGGAAAATGCTGATCT  
CAGTCGCAATGCTGGGCGCAGGGGCTGGCGTGGGCTACGCGCTCCTCGTTATCGTGACCC  
CGGGAGAGCGGCGGAAGCAGGAAATGCTAAAGGAGATGCCACTGCAGGACCCAAGGAGCA  
GGGAGGAGGCGGCCAGGACCCAGCAGCTATTGCTGGCCACTCTGCAGGAGGCAGCGACCA  
CGCAGGAGAACGTGGCCTGGAGGAAGAACTGGATGGTTGGCGGCGAAGGCGGCGCCAGCG  
GGAGGTCACCGTGAGACCGGACTTGCCCTCCGTGGGCGCCGGACCTTGGCTTGGGCGCAGG  
AATCCGAGGCAGCCTTTCTCCTTCGTGGGCCAGCGGAGAGTCCGGACCGAGATACCATG  
CCAGGACTCTCCGGGGTCTGTGAGCTGCCGTGCGGTGAGCACGTTTCCCCCAAACCCTG  
GACTGACTGCTTTAAGGTCCGCAAGGCGGGCCAGGGCCGAGACGCGAGTCGGATGTGGTG  
AACTGAAAGAACCAATAAAATCATGTTCTCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

209/392

## FIGURE 200

MDSLRLKMLISVAMLGAGAGVGYALLVIVTPGERRKQEMLKEMPLQDPRSREEAARTQQLL  
LATLQEAATTQENVAWRKNWMVGEGGASGRSP

Signal peptide:  
amino acids 1-18

210/392

**FIGURE 201**

GACAGCTGTGTCTCGATGGAGTAGACTCTCAGAACAGCGCAGTTTGGCCCTCCGCTCACGC  
AGAGCCTCTCCGTGGCTTCCGCACCTTGAGCATTAGGCCAGTTCTCCTCTTCTCTCTAAT  
CCATCCGTCACCTCTCCTGTTCATCCGTTTCCATGCCGTGAGGTCCATTCACAGAACACAT  
CCATGGCTCTCATGCTCAGTTTGGTTCTGAGTCTCCTCAAGCTGGGATCAGGGCAGTGGC  
AGGTGTTTGGGCCAGACAAGCCTGTCCAGGCCTTGGTGGGGAGGACGCAGCATTCTCCT  
GTTTCCTGTCTCCTAAGACCAATGCAGAGGCCATGGAAGTGCAGTTCTTTCAGGGGCCAGT  
TCTCTAGCGTGGTCCACCTCTACAGGGACGGGAAGGACCAGCCATTTATGCAGATGCCAC  
AGTATCAAGGCAGGACAAAACCTGGTGAAGGATTCTATTGCGGAGGGGGCGCATCTCTCTGA  
GGCTGGAAAACATTACTGTGTTGGATGCTGGCCTCTATGGGTGCAGGATTAGTTCCCAGT  
CTTACTACCAGAAGGCCATCTGGGAGCTACAGGTGTCAGCACTGGGCTCAGTTCCCTCTCA  
TTTCCATCACGGGATATGTTGATAGAGACATCCAGCTACTCTGTCACTCCTCGGGCTGGT  
TCCCCCGGCCACAGCGAAGTGGAAAGGTCCACAAGGACAGGATTTGTCCACAGACTCCA  
GGACAAACAGAGACATGCATGGCCTGTTTGATGTGGAGATCTCTCTGACCGTCCAAGAGA  
ACGCCGGGAGCATATCCTGTTCCATGCGGCATGCTCATCTGAGCCGAGAGGTGGAATCCA  
GGGTACAGATAGGAGATACCTTTTTCGAGCCTATATCGTGGCACCTGGCTACCAAAGTAC  
TGGGAATACTCTGCTGTGGCCTATTTTTTGGCATTGTTGGACTGAAGATTTTCTTCTCCA  
AATTCAGTGGAATCCAGGCGGAACCTGGACTGGAGAAGAAAGCACGGACAGGCAGAAT  
TGAGAGACGCCCCGAAACACGCAGTGGAGGTGACTCTGGATCCAGAGACGGCTCACCCGA  
AGCTCTGCGTTTCTGATCTGAAAACCTGTAACCCATAGAAAAGCTCCCCAGGAGGTGCCTC  
ACTCTGAGAAGAGATTTACAAGGAAGAGTGTGGTGGCTTCTCAGAGTTTCCAAGCAGGGA  
AACATTACTGGGAGGTGGACGGAGGACACAATAAAAGGTGGCGCGTGGGAGTGTGCCGGG  
ATGATGTGGACAGGAGGAAGGAGTACGTGACTTTGTCTCCCGATCATGGGTACTGGGTCC  
TCAGACTGAATGGAGAACATTTGTATTTACATTAAATCCCCGTTTATCAGCGTCTTCC  
CCAGGACCCACCTACAAAATAGGGGTCTTCCTGGACTATGAGTGTGGGACCATCTCCT  
TCTTCAACATAAATGACCAGTCCCTTATTTATACCCTGACATGTCGGTTTGAAGGCTTAT  
TGAGGCCCTACATTGAGTATCCGTCTATAATGAGCAAAATGGAACCTCCCATAGTCATCT  
GCCCAGTCACCCAGGAATCAGAGAAAGAGGCCTCTTGGCAAAGGGCCTCTGCAATCCAG  
AGACAAGCAACAGTGAGTCCTCCTCACAGGCAACCACGCCCTTCTCCCCAGGGGTGAAA  
TGTAGGATGAATCACATCCACATTCTTCTTTAGGGATATTAAGGTCTCTCTCCAGATC  
CAAAGTCCCGCAGCAGCCGGCCAAGGTGGCTTCCAGATGAAGGGGGACTGGCCTGTCCAC  
ATGGGAGTCAGGTGTCATGGCTGCCCTGAGCTGGGAGGGAAGAAGGCTGACATTACATTT  
AGTTTGCTCTCACTCCATCTGGCTAAGTGATCTTGAAATACCACCTCTCAGGTGAAGAAC  
CGTCAGGAATTCCTATCTCACAGGCTGTGGTGTAGATTAAGTAGACAAGGAATGTGAATA  
ATGCTTAGATCTTATTGATGACAGAGTGTATCCTAATGGTTTGTTCATTATATTACACTT  
TCAGTAAAAAAA

211/392

**FIGURE 202**

MALMLSLVLSLLKLGSGQWQVFGPDKPVQALVGEDAAFSCFLSPKTNAEAMEVRFFRGQF  
SSVVHLYRDGKDQPFMQMPQYQGRTKLVKDSIAEGRISLRLENITVLDAGLYGCRISQS  
YYQKAIWELQVSALGSVPLISITGYVDRDIQLLCQSSGWFPPTAKWKGPQGDLSTDSR  
TNRDMHGLFDVEISLTVQENAGSISCSMRHAHLSREVESRVQIGDTFFEPISWHLATKVL  
GILCCGLFFGIVGLKIFFSKFQWKIQAELEDWRRKHGQAEIRDARKHAVEVTLDPETAHPK  
LCVSDLKTVTHRKAPOEVPHSEKRFTRKSVVASQSFQAGKHYWEVDGGHNKRWRVGVCRD  
DVDRRKEYVTLSPDHGYWVLRNLNGEHLFTLNPRFISVFPPTKIGVFLDYECGTISF  
FNINDQSLIYTLTCRFEGLLRPYIEYPSYNEQNGTPIVICPVTQESEKEASWQRASAIPE  
TSNSESSSQATTPFLPRGEM

**Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 239-255

212/392

**FIGURE 203**

TGCGGCGCAGTGTAGACCTGGGAGGATGGGCGGCCTGCTGCTGGCTGCTTTTCTGGCTTT  
GGTCTCGGTGCCCAGGGCCCAGGCCGTGTGGTTGGGAAGACTGGACCCTGAGCAGCTTCT  
TGGGCCCTGGTACGTGCTTGCGGTGGCCTCCCGGGAAAAGGGCTTTGCCATGGAGAAGGA  
CATGAAGAACGTTCGTGGGGGTGGTGGTGACCCTCACTCCAGAAAACAACCTGCGGACGCT  
GTCCTCTCAGCACGGGCTGGGAGGGTGTGACCAGAGTGTGATGGACCTGATAAAGCGAAA  
CTCCGGATGGGTGTTTGAGAAATCCCTCAATAGGCGTGCTGGAGCTCTGGGTGCTGGCCAC  
CAACTTCAGAGACTATGCCATCATCTTCACTCAGCTGGAGTTCGGGGACGAGCCCTTCAA  
CACCGTGGAGCTGTACAGTCTGACGGAGACAGCCAGCCAGGAGGCCATGGGGCTCTTCAC  
CAAGTGGAGCAGGAGCCTGGGCTTCCTGTACAGTAGCAGGCCCAGCTGCAGAAGGACCT  
CACCTGTGCTCACAAGATCCTTCTGTGAGTGCTGCGTCCCCAGTAGGGATGGCGCCCACA  
GGGTCCTGTGACCTCGGCCAGTGTCCACCCACCTCGCTCAGCGGCTCCCGGGGGCCAGCA  
CCAGCTCAGAATAAAGCGATTCCACAGCA

213/392

## FIGURE 204

MGGLLLAAFLALVSVPRQAVWLGRDLDEQLLGPWYVLAVASREKGFAMEKDMKNVVGVV  
VTLPENNLRTLSSQHGLGGCDQSVMDLIKRN SGWVFENPSIGVLELWVLATNFRDYAII  
FTQLEFGDEPFNTVELYSLTETASQEAMGLFTKWSRSLGFLSQ

Signal peptide:  
amino acids 1-20



214/392

**FIGURE 205**

GACGCCCAGTGACCTGCCGAGGTCGGCAGCACAGAGCTCTGGAGATGAAGACCCTGTTCC  
TGGGTGTCACGCTCGGCCTGGCCGCTGCCCTGTCCTTCACCCCTGGAGGAGGAGGATATCA  
CAGGGACCTGGTACGTGAAGGCCATGGTGGTCGATAAGGACTTCCCGGAGGACAGGAGGC  
CCAGGAAGGTGTCCCCAGTGAAGGTGACAGCCCTGGGCGGTGGGAAGTTGGAAGCCACGT  
TCACCTTCATGAGGGAGGATCGGTGCATCCAGAAGAAAATCCTGATGCGGAAGACGGAGG  
AGCCTGGCAAATACAGCGCCTATGGGGGCAGGAAGCTCATGTACCTGCAGGAGCTGCCCCA  
GGAGGGACCACTACATCTTTTACTGCAAAGACCAGCACCATGGGGGCCTGCTCCACATGG  
GAAAGCTTGTGGGTAGGAATTCTGATACCAACCGGGAGGCCCTGGAAGAATTTAAGAAAT  
TGGTGCAGCGCAAGGGACTCTCGGAGGAGGACATTTTCACGCCCCTGCAGACGGGAAGCT  
GCGTTCCCGAACACTAGGCAGCCCCCGGGTCTGCACCTCCAGAGCCCACCCTACCACCAG  
ACACAGAGCCCGGACCACCTGGACCTACCCTCCAGCCATGACCCTTCCCTGCTCCCACCC  
ACCTGACTCCAAATAAAGTCCTTTTCCCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAA

215/392

## FIGURE 206

MKTLFLGVTLGLAAALSFTLEEDITGTWYVKAMVVDKDFPEDRRPRKVSPVKVTALGGG  
KLEATFTFMREDRCIQKKILMRKTEEPGKYSAYGGRKLMYLQELPRRDHYIFYCKDQHHG  
GLLHMGKLVGRNSDTNREALLEEFKKLVQRKGLSEEDIFTPLQTGSCVPEH

**Important features:**

**Signal peptide:**

amino acids 1-17

216/392

**FIGURE 207**

GTTCCGCAGATGCAGAGGTTGAGGTGGCTGCGGGACTGGAAGTCATCGGGCAGAGGTCTC  
ACAGCAGCCAAGGAACCTGGGGCCCGCTCCTCCCCCTCCAGGCCATGAGGATTCTGCAG  
TTAATCCTGCTTGCTCTGGCAACAGGGCTTGTAAGGGGAGAGACCAGGATCATCAAGGGG  
TTCGAGTGCAAGCCTCACTCCCAGCCCTGGCAGGCAGCCCTGTTTCGAGAAGACGCGGCTA  
CTCTGTGGGGCGACGCTCATCGCCCCAGATGGCTCCTGACAGCAGCCCACTGCCTCAAG  
CCCCGCTACATAGTTACCTGGGGCAGCACAACTCCAGAAGGAGGAGGGCTGTGAGCAG  
ACCCGGACAGCCCACTGAGTCCTTCCCCACCCCGGCTTCAACAACAGCCTCCCCAACAA  
GACCACCGCAATGACATCATGCTGGTGAAGATGGCATCGCCAGTCTCCATCACCTGGGCT  
GTGCGACCCCTCACCCCTCTCCTCACGCTGTGTCACTGCTGGCACCAGCTGCCTCATTTCC  
GGCTGGGGCAGCACGTCCAGCCCCAGTTACGCCTGCCTCACACCTTGCGATGCGCCAAC  
ATCACCATCATTGAGCACCAGAAGTGTGAGAACGCCTACCCCGGCAACATCACAGACACC  
ATGGTGTGTGCCAGCGTGCAGGAAGGGGGCAAGGACTCCTGCCAGGGTGACTCCGGGGGC  
CCTCTGGTCTGTAACCAGTCTCTTCAAGGCATTATCTCCTGGGGCCAGGATCCGTGTGCG  
ATCACCCGAAAGCCTGGTGTCTACACGAAAGTCTGCAAATATGTGGACTGGATCCAGGAG  
ACGATGAAGAACAATTAGACTGGACCCACCCACCACAGCCCATCACCTCCATTTCCACT  
TGGTGTTTGGTTCCTGTTCACTCTGTTAATAAGAAACCCTAAGCCAAGACCCCTTACGAA  
CATTCTTTGGGCCTCCTGGACTACAGGAGATGCTGTCACTTAATAATCAACCTGGGGTTC  
GAAATCAGTGAGACCTGGATTCAAATTCTGCCTTGAAATATTGTGACTCTGGGAATGACA  
ACACCTGGTTTGTCTCTGTTGTATCCCAGCCCCAAAGACAGCTCCTGGCCATATATCA  
AGGTTTCAATAAATATTTGCTAAATGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAA

217/392

**FIGURE 208**

MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA  
AHCLKPRYIVHLGQHNLOKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPV  
SITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIEHQKCENAYPG  
NITDTMVCASVQEGGKSDSCQGDSSGGLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYV  
DWIQETMKNN

**Important features:****Signal peptide:**

amino acids 1-18

**Serine proteases, trypsin family, histidine active site:**

amino acids 58-63

**N-glycosylation sites:**

amino acids 99-102, 165-168, 181-184, 210-213

**Glycosaminoglycan attachment site:**

amino acids 145-148

**Kringle domain proteins:**

amino acids 197-209, 47-64

**Serine proteases, trypsin family, histidine protein:**

amino acids 199-209, 47-63, 220-243

**Apple domain proteins:**

amino acids 222-249, 189-222

218/392

**FIGURE 209**

GCGGCCACACGCAGCTAGCCGGAGCCCGGACCAGGCGCCTGTGCCTCCTCCTCGTCCCTC  
GCCGCGTCCGCGAAGCCTGGAGCCGGCGGGAGCCCCGCGCTCGCCATGTCGGGCGAGCTC  
AGCAACAGGTTCCAAGGAGGGAAGGCGTTTCGGCTTGCTCAAAGCCCGGCAGGAGAGGAGG  
CTGGCCGAGATCAACCGGGAGTTTCTGTGTGACCAGAAGTACAGTGATGAAGAGAACCTT  
CCAGAAAAGCTCACAGCCTTCAAAGAGAAGTACATGGAGTTTGACCTGAACAATGAAGGC  
GAGATTGACCTGATGTCTTTAAAGAGGATGATGGAGAAGCTTGGTGTCCCCAAGACCCAC  
CTGGAGATGAAGAAGATGATCTCAGAGGTGACAGGAGGGGTGAGTGACACTATATCCTAC  
CGAGACTTTGTGAACATGATGCTGGGGAAACGGTCGGCTGTCTCAAGTTAGTCATGATG  
TTTGAAGGAAAAGCCAACGAGAGCAGCCCCAAGCCAGTTGGCCCCCTCCAGAGAGAGAG  
ATTGCTAGCCTGCCCTGAGGAGCCCCGCGCTGGACTCCCCAGCCTTCCACCCCCATACCTCC  
CTCCCGATCTTGCTGCCCTTCTTGACACACTGTGATCTCTCTCTCTCTCATTGTTTGGT  
CATTGAGGGTTTGTGTTTTCATCAATGTCTTTGTAAAGCACAAATTATCTGCCTTA  
AAGGGGCTCTGGGTCGGGGAATCCTGAGCCTTGGGTCCCCCTCCCTCTCTTCTCCCTCCT  
TCCCCGCTCCCTGTGCAGAAGGGCTGATATCAAACCAAAAAGTAGAGGGGGCAGGGCCAG  
GGCAGGGAGGCTTCCAGCCTGTGTTCCCCCTCACTTGGAGGAACCAGCACTCTCCATCCTT  
TCAGAAAGTCTCCAAGCCAAGTTCAGGCTCACTGACCTGGCTCTGACGAGGACCCAGGC  
CACTCTGAGAAGACCTTGGAGTAGGGACAAGGCTGCAGGGCCTCTTTCGGGTTTCCTTGG  
ACAGTGCCATGGTTCCAGTGCTCTGGTGTCAACCAGGACACAGCCACTCGGGGCCCCGCT  
GCCCCAGCTGATCCCCACTCATTCCACACCTCTTCTCATCCTCAGTGATGTGAAGGTGGG  
AAGGAAAGGAGCTTGGCATTGGGAGCCCTTCAAGAAGGTACCAGAAGGAACCTCCAGTC  
CTGCTCTCTGGCCACACCTGTGCAGGCAGCTGAGAGGCAGCGTGCAGCCCTACTGTCCCT  
TACTGGGGCAGCAGAGGGCTTCGGAGGCAGAAGTGAGGCCTGGGGTTGGGGGAAAGGT  
CAGCTCAGTGCTGTTCCACCTTTTAGGGAGGATACTGAGGGGACCAGGATGGGAGAATGA  
GGAGTAAAATGCTCACGGCAAAGTCAGCAGCACTGGTAAGCCAAGACTGAGAAATACAAG  
GTTGCTTGTCTGACCCCAATCTGCTTGAAAAAAAAAAAAAAAAAAAA

219/392

## FIGURE 210

MSGELSNRFQGGKAFGLLKARQERRLAEGINREFLCDQKYSDEENLPEKLTAFFEKEYMEFD  
LNNEGEIDLMSLKRMMEKLGVPKTHLEMKKMISEVTGGVSDTISYRDFVNMMLGKRSAVL  
KLVMFEGKANESSPKPVGPPPERDIASLP

220/392

**FIGURE 211**

CTGGGATCAGCCACTGCAGCTCCCTGAGCACTCTCTACAGAGACGCGGACCCCAGACATG  
AGGAGGCTCCTCCTGGTCACCAGCCTGGTGGTTGTGCTGCTGTGGGAGGCAGGTGCAGTC  
CCAGCACCCAAGGTCCCTATCAAGATGCAAGTCAAACACTGGCCCTCAGAGCAGGACCCA  
GAGAAGGCCTGGGGCGCCCGTGTGGTGGAGCCTCCGGAGAAGGACGACCAGCTGGTGGTG  
CTGTTCCCTGTCCAGAAGCCGAAACTCTTGACCACCGAGGAGAAGCCACGAGGTGAGGGC  
AGGGGCCCCATCCTTCCAGGCACCAAGGCCTGGATGGAGACCGAGGACACCCTGGGCCGT  
GTCCTGAGTCCCGAGCCCGACCATGACAGCCTGTACCACCCTCCGCCTGAGGAGGACCAG  
GGCGAGGAGAGGCCCCGGTTGTGGGTGATGCCAAATCACCAGGTGCTCCTGGGACCGGAG  
GAAGACCAAGACCACATCTACCACCCCCAGTAGGGCTCCAGGGGCCATCACTGCCCCCGC  
CCTGTCCCAAGGCCAGGCTGTTGGGACTGGGACCCCTCCCTACCCTGCCCCAGCTAGACA  
AATAAACCCCAGCAGGCAAAAAAAAAAAAAAAAAAAAA

221/392

## FIGURE 212

MRLLLLVTSLVVLLWEAGAVPAPKVPIKMQVKHWPSEQDPEKAWGARVVEPPEKDDQLV  
VLFPVQKPKLLTTEEKPRGQGRGPILPGTKAWMETEDTLGRVLSPEPDHDSLYHPPPEED  
QGEERPRLWVMPNHQVLLGPPEEDQDHIYHPQ



222/392

**FIGURE 213**

CAGGCAGAAGCGAACAAAGACCCAGCAAGAGAAGGCAGAGGCTAAGACCCATCCCGTATC  
TGCTCTCCTGAAATAATTCTGGAGTCATGCCTGAAATGCCAGAGGACATGGAGCAGGAGG  
AAGTTAACATCCCTAATAGGAGGGTTCTGGTTACTGGTGCCACTGGGCTTCTTGGCAGAG  
CTGTACACAAAGAATTTTCAGCAGAATAATTGGCATGCAGTTGGCTGTGGTTTCAGAAGAG  
CAAGACCAAAATTTGAACAGGTTAATCTGTTGGATTCTAATGCAGTTTCATCACATCATT  
ATGATTTTTTCAGCCCCATGTTATAGTACATTGTGCAGCAGAGAGAAGACCAGATGTTGTAG  
AAAATCAGCCAGATGCTGCCTCTCACTTAATGTGGATGCTTCTGGGAATTTAGCAAAGG  
AAGCAGCTGCTGTTGGAGCATTCTCATCTACATTAGCTCAGATTATGTATTTGATGGAA  
CAAATCCACCTTACAGAGAGGAAGACATAACCAGCTCCCCTAAATTTGTATGGCAAACAA  
AATTAGATGGAGAAAAGGCTGTCTTGGAGAACAATCTAGGAGCTGCTGTTTTGAGGATT  
CTATTCTGTATGGGGAAGTTGAAAAGCTCGAAGAAAGTGCTGTGACTGTTATGTTTGATA  
AAGTGCAGTTTCAGCAACAAGTCAGCAAACATGGATCACTGGCAGCAGAGGTTCCCCACAC  
ATGTCAAAGATGTGGCCACTGTGTGCCGGCAGCTAGCAGAGAAGAGAATGCTGGATCCAT  
CAATTAAGGGAACCTTTCACTGGTCTGGCAATGAACAGATGACTAAGTATGAAATGGCAT  
GTGCAATTGCAGATGCCTTCAACCTCCCCAGCAGTCACTTAAGACCTATTACTGACAGCC  
CTGTCTTAGGAGCACACGTCGGAGAAATGCTCAGCTTGACTGCTCCAAATTGGAGACCT  
TGGGCATTGGCCAACGAACACCATTTCGAATTGGAATCAAAGAATCACTTTGGCCTTTCC  
TCATTGACAAGAGATGGAGACAAACGGTCTTTCATTAGTTTTATTGTGTTGGGTTCTTTT  
TTTTTTTAAATGAAAAGTATAGTATGTGGCACTTTTTTAAAGAACAAAGGAAATAGTTTTG  
TATGAGTACTTTAATTGTGACTCTTAGGATCTTTCAGGTAAATGATGCTCTTGCACTAGT  
GAAATTGTCTAAAGAACTAAAGGGCAGTCATGCCCTGTTTGCAGTAATTTTTCTTTTTA  
TCATTTTGTTTGTCCTGGCTAAACTTGGAGTTTGAGTATAGTAAATTATGATCCTTAAAT  
ATTTGAGAGTCAGGATGAAGCAGATCTGCTGTAGACTTTTCAGATGAAATTGTTCACTCT  
CGTAACCTCCATATTTTCAGGATTTTTGAAGCTGTTGACCTTTTCATGTTGATTATTTTA  
AATTGTGTGAAATAGTATAAAAATCATTGGTGTTCATTATTTGCTTTGCCTGAGCTCAGA  
TCAAAATGTTTGAAGAAAGGAACCTTTATTTTTTGCAAGTTACGTACAGTTTTTATGCTTGA  
GATATTTCAACATGTTATGTATATTGGAACCTTCTACAGCTTGATGCCTCCTGCTTTTATA  
GCAGTTTATGGGGAGCACTTGAAAGAGCGTGTGTACATGTATTTTTTTTCTAGGCAAACA  
TTGAATGCAAACGTGTATTTTTTTTAAATATAAATATATAACTGTCCTTTTCATCCCATGTT  
GCCGCTAAGTGATATTTTCATATGTGTGGTTATACTCATAATAATGGGCCTTGTAAGTCTT  
TTCACCATTCATGAATAATAATAAATATGTACTGCTGGCATGTAATGCTTAGTTTTCTTG  
TATTTACTTCTTTTTTTTTTAAATGTAAGGACCAACTTCTAAACTAATTGTTCTTTTGTTGC  
TTTAATTTTTTAAAAATTACATTCTTCTGATGTAACATGTGATACATACAAAAGAATATAG  
TTTAATATGTATTGAAATAAAACACAATAAAATT

223/392

**FIGURE 214**

MPEMPEDMEQEEVNIPNRRVLVTGATGLLGRAVHKEFQQNNWHAVGCGFRRARPKFEQVN  
LLDSNAVHHIIHDFQPHVIVHCAAERRPDVVENQPDAAASQLNVDASGNLAKEAAAVGAFL  
IYISSDYVFDGTNPPYREEDIPAPLNLYGKTKLDGEKAVLENNLGA AVLRIPILYGEVEK  
LEESAVTVMFDKVVQFSNKSANMDHWQQRFP THVKDVATVCRQLAEKRMLDPSIKGTFHWS  
GNEQMTKYEMACAIADAFNLPSSHLRPITDSPVLGAQRPRNAQLDCSKLET LGIGQRTPF  
RIGIKESLWPFLIDKRWRQTVFH

**Signal peptide:**  
amino acids 1-30

**Transmembrane domain:**  
amino acids 105-127

**N-glycosylation site:**  
amino acids 197-201

**N-myristoylation site:**  
amino acids 303-309

**Short-chain dehydrogenases/reductases family proteins:**  
amino acids 18-30

224/392

## FIGURE 215

GTGAATGTGAGGGTTTGATGACTTTCAGATGTCTAGGAACCAGAGTGGGTGCAGGGGGCCC  
CAGGCAGGGCTGATTCTTGGGCGGAGGAGAGTAGGGTAAAGGGTTCTGCATGAGCTCCTT  
AAAGGACAAAGGTAACAGAGCCAGCGAGAGAGCTCGAGGGGAGACTTTGACTTCAAGCCA  
CAGAATTGGTGGAAGTGTGCGCGCCGCCGCCGCTCGCTCCTGCAGCGCTGTGACCTA  
GCCGCTAGCATCTTCCCGAGCACCGGGATCCCGGGGTAGGAGGCGACGCGGGCGAGCACC  
AGCGCCAGCCGGCTGCGGCTGCCCACACGGCTCACCATGGGCTCCGGGCGCCGGGCGCTG  
TCCGCGGTGCCGGCCGTGCTGCTGGTCTCAGCTGCCGGGGCTGCCCGTCTGGGCACAG  
AACGACACGGAGCCCATCGTGCTGGAGGGCAAGTGTCTGGTGGTGTGCGACTCGAACCCG  
GCCACGGACTCCAAGGGCTCCTCTTCTCCCGCTGGGGATATCGGTCCGGGCGGCCAAC  
TCCAAGGTCGCCTTCTCGGCGGTGCGGAGCACCAACCACGAGCCATCCGAGATGAGCAAC  
AAGACGCGCATCATTTACTTCGATCAGATCCTGGTGAATGTGGTAATTTTTTTCATTG  
GAGTCTGTCTTTGTAGCACCAAGAAAAGGAATTTACAGTTTCAGTTTTTCAGTGATTAAA  
GTCTACCAGAGCCAAACTATCCAGGTTAACTTGATGTTAAATGGAAAACCAGTAATATCT  
GCCTTTGCGGGGGACAAAGATGTTACTCGTGAAGCTGCCACGAATGGTGTCTGCTCTAC  
CTAGATAAAGAGGATAAGGTTTACCTAAAACTGGAGAAAGGTAATTTGGTTGGAGGCTGG  
CAGTATTCACGTTTTCTGGCTTTCTGGTGTTCCTCCCTATAGGATTCAATTTCTCCATGA  
TGTTTCATCCAGGTGAGGGATGACCCACTCCTGAGTTATTGGAAGATCATTTTTTTCATCAT  
TGGATTGATGTCCTTTTATTGGTTTCTCATGGGTGGATATGGATTCTAAGGATTCTAGCCT  
GTCTGAACCAATACAAAATTTACAGATTATTTGTGTGTGTCTGTTTTCAGTATATTTGGA  
TTGGGACTCTAAGCAGATAATACCTATGCTTAAATGTAACAGTCAAAGCTGTCTGCAAG  
ACTTATTCGAATTTCAATTTCTGGGATTACTGAATTAGTTACAGATGTGGAATTTTATT  
TGTTTTAGTTTTTAAAGACTGGCAACCAGGTCTAAGGATTAGAAAACCTCTAAAGTTCTGAC  
TTCAATCAACGGTTAGTGTGATACTGCCAAAGAACTGTATACTGTGTTAATATATTGATT  
ATATTTGTTTTTATTCTTTTGAATTAGTTTGTGTTGGTTCTTGTAATAAACTTGGATTTT  
TTTTTTCAGTAACTGGTATTATGTTTTCTCTTAAATAAGGTAATGAATGGCTTGCCAC  
AAATTTACCTTGACTACGATATCATCGACATGACTTCTCTCAAAAAAAGAATGCTTCA  
TAGTTGTATTTTAATTGTATATGTGAAAGAGTCATATTTTCCAAGTTATATTTTCTAAGA  
AGAAGAATAGATCATAAATCTGACAAGGAAAAAGTTGCTTACCCAAAATCTAAGTGCTCA  
ATCCCTGAGCCTCAGCAAAACAGCTCCCTCCGAGGGAAATCTTATACTTTATTGCTCAA  
CTTTAATTAAATGATTGATAATAACCACTTTATTAAAAACCTAAGGTTTTTTTTTTTC  
CGTAGACATGACCACTTTATTAAGTGGTGGTGGATGCTGTTGTTTCTAATTATACCTAT  
TTTTCAAGGCTTCTGTTGTATTTGAAGTATCATCTGGTTTTGCCTTAACTCTTTAAATTG  
TATATATTTATCTGTTTAGCTAATATTAAATTCAAATATCCCATATCTAAATTTAGTGCA  
ATATCTTGCTTTTGTATAGGTCATATGAATTCATAAAATTATTTATGTCTGTTATAGAA  
TAAAGATTAATATATGTTAAAAAA

225/392

## FIGURE 216

MSGRRALSAVPAVLLVLTLPGLPVWAQNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPL  
GISVRAANSKVAFS AVRSTNHEPSEMSNKTRI IYFDQILVNVGNFFTTLESV FVAPRKG IY  
SFSFHVIKVYQSQTIQVNLMLNGKPVISAFAGDKDVTREAAATNGVLLYLDKEDKVYLKLE  
KGNLVGGWQYSTFSGFLVFPL

Signal peptide:  
amino acids 1-27

226/392

**FIGURE 217**

CGGCAACCAGCCGCCGCCACCACCGCTGCCACTGCCGCCCTGCCGGGGCCATGTTCGCTC  
TGGGCTTGCCCTTCTTGGTGCTCTTGGTGGCCTCGGTTCGAGAGCCATCTGGGGGTTCTGG  
GGCCCAAGAACGTCTCGCAGAAAGACGCCGAGTTTGAGCGCACCTACGTGGACGAGGTCA  
ACAGCGAGCTGGTCAACATCTACACCTTCAACCATACTGTGACCCGCAACAGGACAGAGG  
GCGTGCGTGTGTCTGTGAACGTCTGAACAAGCAGAAGGGGGCGCCGTTGCTGTTTGTGG  
TCCGCCAGAAGGAGGCTGTGGTGTCTTCCAGGTGCCCTAATCCTGCGAGGGATGTTTC  
AGCGCAAGTACCTCTACCAAAAAGTGGAACGAACCCTGTGTGAGCCCCCACCAGAATG  
AGTCGGAGATTCACTTCTTCTACGTGGATGTGTCCACCCTGTCACCAGTCAACACCACAT  
ACCAGCTCCGGGTGAGCCGCATGGACGATTTTGTGCTCAGGACTGGGGAGCAGTTCAGCT  
TCAATACCACAGCAGCACAGCCCCAGTACTTCAAGTATGAGTTCCTGAAGGCGTGGACT  
CGGTAATTGTCAAGGTGACCTCCAACAAGGCCTTCCCTGCTCAGTCATCTCCATTCAAG  
ATGTGCTGTGTCCTGTCTATGACCTGGACAACAACGTAGCCTTCATCGGCATGTACCAGA  
CGATGACCAAGAAGGCGGCCATCACCGTACAGCGCAAAGACTTCCCCAGCAACAGCTTTT  
ATGTGGTGGTGGTGGTGAAGACCGAAGACCAAGCCTGCGGGGGCTCCCTGCCTTTCTACC  
CCTTCGCAGAAGATGAACCGGTGATCAAGGGCACCGCCAGAAAACCCTGTCAGTGCTGG  
TGTCTCAAGCAGTCACGTCTGAGGCATACGTGAGTGGGATGCTCTTTTGCCTGGGTATAT  
TTCTCTCCTTTTACCTGCTGACCGTCTCCTGGCCTGCTGGGAGAACTGGAGGCAGAAGA  
AGAAGACCCTGCTGGTGGCCATTGACCGAGCCTGCCCAGAAAGCGGTCAACCCTCGAGTCC  
TGGCTGATTCTTTTCTGGCAGTTCCCTTATGAGGGTTACAACCTATGGCTCCTTTGAGA  
ATGTTTCTGGATCTACCGATGGTCTGGTTGACAGCGCTGGCACTGGGGACCTCTCTTACG  
GTTACCAGGGCCGCTCCTTTGAACCTGTAGGTACTCGGCCCCGAGTGGACTCCATGAGCT  
CTGTGGAGGAGGATGACTACGACACATTGACCGACATCGATTCCGACAAGAATGTCATTTC  
GCACCAAGCAATACCTCTATGTGGCTGACCTGGCACGGAAGGACAAGCGTGTCTCTGCGGA  
AAAAGTACCAGATCTACTTCTGGAACATTGCCACCATTGCTGTCTTCTATGCCCTTCTTG  
TGGTGCAGCTGGTGATCACCTACCAGACGGTGGTGAATGTCACAGGGAATCAGGACATCT  
GCTACTACAACTTCTCTGCGCCCACTGGGCAATCTCAGCGCTTCAACAACATCC  
TCAGCAACCTGGGGTACATCCTGCTGGGGCTGCTTTTCTGCTCATCATCTGCAACGGG  
AGATCAACCACAACCGGGGCCCTGCTGCGCAATGACCTCTGTGCCCTGGAATGTGGGATCC  
CCAAACACTTTGGGCTTTTCTACGCCATGGGCACAGCCCTGATGATGGAGGGGCTGCTCA  
GTGCTTGCTATCATGTGTGCCCAACTATAACCAATTTCCAGTTTGACACATCGTTCATGT  
ACATGATCGCCGACTCTGCATGCTGAAGCTCTACCAGAAAGCGGCACCCGGACATCAACG  
CCAGCGCTACAGTGCCTACGCCTGCCTGGCCATTGTGATCTTCTTCTCTGTGCTGGGCG  
TGGTCTTTGGCAAAGGGAACACGGCGTTCTGGATCGTCTTCTCCATCATTACATCATCG  
CCACCCTGCTCCTCAGCACGCAGCTCTATTACATGGGCCGGTGGAAACTGGACTCGGGGA  
TCTTCCGCCGCATCCTCCACGTGCTCTACACAGACTGCATCCGGCAGTGCAGCGGGCCGC  
TCTACGTGGACCGCATGGTGTGCTGGTTCATGGGCAACGTGATCAACTGGTGGCTGGCTG  
CCTATGGGCTTATCATGCGCCCCAATGATTTTCGCTTCTTCTTGTGGCCATTGGCATCT  
GCAACCTGCTCCTTTACTTTCGCTTCTACATCATCATGAAGCTCCGGAGTGGGGAGAGGA  
TCAAGCTCATCCCCCTGCTCTGCATCGTTTGACCTCCGTGGTCTGGGGCTTCGCGCTCT  
TCTTCTTCTTCCAGGGACTCAGCACCTGGCAGAAAACCCCTGCAGAGTCGAGGGAGCACA  
ACCGGGACTGCATCCTCCTCGACTTCTTTGACGACCACGACATCTGGCACTTCTCTCCT  
CCATCGCCATGTTTCGGGTCTTCTCTGGTGTGCTGACACTGGATGACGACCTGGATACTG  
TGCAGCGGGACAAGATCTATGTCTTCTAGCAGGAGCTGGGCCCTTCGCTTCACTCAAGG  
GGCCCTGAGCTCCTTTGTGTGATAGACCGGTCACTCTGTGCTGTGTGGGGATGAGTCCC  
AGCACCGCTGCCAGCACTGGATGGCAGCAGGACAGCCAGGTCTAGCTTAGGCTTGGCCT  
GGGACAGCCATGGGGTGGCATGGAACCTTGACGCTGCCCTCTGCCGAGGAGCAGGCCTGC  
TCCCTGGAACCCCCAGATGTTGGCCAAATTGCTGCTTTCTTCTCAGTGTGGGGCCTTC

227/392

CATGGGGCCCCTGTCCTTTGGCTCTCCATTTGTCCCTTTGCAAGAGGAAGGATGGAAGGGA  
CACCTCCCCATTTATGCCTTGCATTTTGCCCGTCCTCCTCCCCACAATGCCCCAGCCT  
GGGACCTAAGGCCTCTTTTTCTCCCATACTCCCACTCCAGGGCCTAGTCTGGGGCCTGA  
ATCTCTGTCCTGTATCAGGGCCCCAGTTCTCTTTGGGCTGTCCCTGGCTGCCATCACTGC  
CCATTCCAGTCAGCCAGGATGGATGGGGGTATGAGATTTTGGGGGTGGCCAGCTGGTGC  
CAGACTTTTGGTGCTAAGGCCTGCAAGGGGCCTGGGGCAGTGCGTATTCTCTTCCCTCTG  
ACCTGTGCTCAGGGCTGGCTCTTTAGCAATGCGCTCAGCCCAATTTGAGAACCGCCTTCT  
GATTCAAGAGGCTGAATTCAGAGGTCACCTCTTCATCCCATCAGCTCCCAGACTGATGCC  
AGCACCAGGACTGGAGGGAGAAGCGCCTCACCCCTTCCCTTCTTCCAGGCCCTTA  
GTCTTGCCAAACCCCAGCTGGTGGCCTTTCAGTGCCATTGACACTGCCCAAGAATGTCCA  
GGGGCAAAGGAGGGATGATACAGAGTTCAGCCCGTTCTGCCTCCACAGCTGTGGGCACCC  
CAGTGCCTACCTTAGAAAGGGGCTTCAGGAAGGGATGTGCTGTTTCCCTCTACGTGCCCA  
GTCCTAGCCTCGCTCTAGGACCCAGGGCTGGCTTCTAAGTTTCCGTCCAGTCTTCAGGCA  
AGTTCTGTGTAGTCATGCACACACATACCTATGAAACCTTGGAGTTTACAAAGAATTGC  
CCCAGCTCTGGGCACCCCTGGCCACCCTGGTCCTTGGATCCCCTTCGTCCCACCTGGTCCA  
CCCCAGATGCTGAGGATGGGGGAGCTCAGGCGGGGCCTCTGCTTTGGGGATGGGAATGTG  
TTTTTCTCCCAAACCTTGTTTTTATAGCTCTGCTTGAAGGGCTGGGAGATGAGGTGGGTCT  
GGATCTTTTCTCAGAGCGTCTCCATGCTATGGTTGCATTTCCGTTTTCTATGAATGAATT  
TGCATTCAATAACAACCAGACTCAAAAAAAAAAAAAA

228/392

**FIGURE 218**

MFALGLPFLVLLVASVESH LGVLGPKNVSQKDAEFERTYVDEVNSELVNIYTFNHTVTRN  
RTEGVRVSVNVLNKQKGAPLLFVVRQKEAVVSFQVPLILRGMFQRKYLYQKVERTLCQPP  
TKNESEIQFFYVDVSTLSPVNTTYQLRVSRMDDFVLRTGEQFSFNTTAAQPQYFKYEFPE  
GVDSVIVKVTSNKAFFPCSVISIQDVLCPVYDLNNAFIGMYQTMKKAAITVQRKDFPS  
NSFYVVVVVKTEDQACGGS LPFYFPAEDEPVDQGHRQKTL SVLVVSQAVTSEAYVSGMLFC  
LGIFLSFYLLTVLLACWENWRQKKKTLLVAIDRACPE SGHPRVLADSFP GSSPYEGYNYG  
SFENVSGSTDGLVDSAGTGDL SYGYQGRSFEPVGTRPRVDSMSSVEEDDYDTLTDIDSDK  
NVIRTKQYLYVADLARKDKRVLRRKQIYFWNIATIAVFYALPVVQLVITYQTVNVNVTGN  
QDICYNFLCAHPLGNLSAFNNILSNLGYILLGLLFLLIILQREINHNRALLRNDLCALE  
CGIPKHFGFLFYAMGTALMMEGLLSACYHVC PNYTNFQFDT SFMYMIAGLCMLKLYQKRHP  
DINASAYSAYACLAIVIFFSVLGVVFGKGN TAFWIVFSIIHIIATLLLSTQLYYMGRWKL  
DSGIFRRILHVLYTDCIRQCSGPLYVDRMVLLVMGNVINWSLAAYGLIMRPNDFASYLLA  
IGICNLLLYFAFYIIMKLRSGERIKLIPLLCIVCTSVVWGFALFFFQGLSTWQKTPAES  
REHNRDCILLDFDHDHDIWHFLSSIAMFGSFLVLLTLDDDLDTVQRDKIYVF

**Important features of the protein:**

**Signal peptide:**

amino acids 1-18

**Transmembrane domains:**

amino acids 292-317, 451-470, 501-520, 607-627, 751-770

**Leucine zipper pattern:**

amino acids 497-518

**N-glycosylation sites:**

amino acids 27-30, 54-57, 60-63, 123-126, 141-144, 165-168,  
364-367, 476-479, 496-499, 572-575, 603-606, 699-702





230/392

## FIGURE 220

MRSTILLFCLLGSTRSLPQLKPALGLPPTKLAPDQGTLPNQQQSNQVFPSLSLIPLTQML  
TLGPDHLHLLNPAAGMTPGTQTHPLTLGGLNVQQQLHPHVLPIFVTQLGAQGTLSSSEELP  
QIFTSLIIHSLFPGGILPTSQAGANPDVQDGSLPAGGAGVNPATQGTPAGRLPTPSGTDD  
DFAVTTPAGIQRSTHAIEEATTESANGIQ

Signal peptide:  
amino acids 1-16

**FIGURE 221**

[illegible]

232/392

**FIGURE 222**

MARMSFVIAACQLVLGLLMTSLTESSIONSECPQLCVCEIRPWFTPOSTYREATTVDCND  
LRLTRIPSNLSSDTQVLLQLSQNNIAKTVDELQQLFNLTDELDFSQNNFTNIKEVGLANLTQ  
LTTLHLEENQITEMTDYCLQDLSNLQELYINHNQISTISAHAFAGLKNLLRLHLNSNKLK  
VIDSRWFDSTPNLEILMIGENPVIGILDMNFKPLANLRSLVLAGMYLTDIPGNALVGLDS  
LESLSFYDNKLVKVPQALALQKVPNLKFLDLNKNPIHKIQEGDFKNMLRLKELGINNMGEL  
VSVDRYALDNLPELTKLEATNNPKLSYIHRLAFRSVPALSLMLNNNALNAIYQKTVESL  
PNLREISIHNSNPLRCDCVIHWINSNKTNIRFMEPLSMFCAMPPEYKQGHQVKEVLIQDSSE  
QCLPMISHDSFPNRLNVDIGTTVFLDCRAMAEPEPEIYWVTPIGNKITVETLSDKYKLSS  
EGTLEISNIQIEDSGRYTCVAQNVQGADTRVATIKVNGTLLDGTQVLKIYVKQTESHSIL  
VSWKVNSNVMTSNLKWSSATMKIDNPHITYTARVPVDVHEYNLTHLQPOSTDYEVCLTVSN  
IHQQTQKSCVNVTTKNAFAVDISDQETSTALAAVMGSMFAVISLASIAVYFAKRFKRKN  
YHSLKQKYMOKTSSIPLNELYPPPLINLWEGDSEKDKDGSADTKPTQVDTSRSYYMW

**Important features:**

**Signal peptide:**

Amino acids 1-25

**Transmembrane domain:**

Amino acids 508-530

**N-glycosylation sites:**

Amino acids 69-73;96-100;106-110;117-121;385-389;517-521;  
582-586;611-615

**Tyrosine kinase phosphorylation site:**

Amino acids 573-582

**N-myristoylation sites:**

Amino acids 16-22;224-230;464-470;637-643;698-704

**FIGURE 223**

[illegible]

234/392

**FIGURE 224**

MASYLYGVLFVAVGLCAPIYCVSPANAPSAYPRPSSTKSTPASQVYSLNTDFAFRLYRRLV  
LETPSQNIFFSPVSVSTSLAMLSLGAHSVTKTQILQGLGFNLTHTPESAIHQGFQHLVHS  
LTVPSKDLTLKMGSALFVKKELQLQANFLGNVKRLYEAEVFSTDFSNPSIAQARINSHVK  
KKTQKGKVDIIQGLDLLTAMVLVNHIFFKAKWEKPFHLEYTRKNFPFLVGEQVTVQVPM  
HQKEQFAFGVDTLNCFLVQMDYKGDVAFFVLPSKGKMRQLEQALSARTLIKWSHSLQK  
RWIEVFIPRFSISASYNLETILPKMGIQNAFDKNADFSGIAKRDSLQVSKATHKAVLDVS  
EEGTEATAATTTKFIVRSKDGPSYFTVSNRTFLMMITNKATDGILFLGKVENPTKS

**Signal peptide:**  
amino acids 1-20

235/392

**FIGURE 225**

GGGAGAGAGGATAAAATAGCAGCGTGGCTTCCCTGGCTCCTCTCTGCATCCTTCCCGACCT  
TCCCAGCAATATGCATCTTGCACGTCTGGTCGGCTCCTGCTCCCTCCTTCTGCTACTGGG  
GGCCCTGTCTGGATGGGCGGCCAGCGATGACCCCATTGAGAAGGTCATTGAAGGGATCAA  
CCGAGGGCTGAGCAATGCAGAGAGAGAGGTGGGCAAGGCCCTGGATGGCATCAACAGTGG  
AATCACGCATGCCGGAAGGGAAGTGGAGAAGGTTTTCAACGGACTTAGCAACATGGGGAG  
CCACACCGGCAAGGAGTTGGACAAAGGCGTCCAGGGGCTCAACCACGGCATGGACAAGGT  
TGCCCATGAGATCAACCATGGTATTGGACAAGCAGGAAAGGAAGCAGAGAAGCTTGGCCA  
TGGGGTCAACAACGCTGCTGGACAGGCCGGAAGGAAGCAGACAAAGCGGTCCAAGGGTT  
CCCACTGGGGTCCACCAGGCTGGGAAGGAAGCAGAGAACTTGGCCAAGGGGTCAACCA  
TGCTGCTGACCAGGCTGGAAAGGAAGTGGAGAAGCTTGGCCAAGGTGCCCACCATGCTGC  
TGGCCAGGCCGGAAGGAGCTGCAGAATGCTCATAATGGGGTCAACCAAGCCAGCAAGGA  
GGCCAACCAGCTGCTGAATGGCAACCATCAAAGCGGATCTTCCAGCCATCAAGGAGGGGC  
CACAACCACGCCGTTAGCCTCTGGGGCCTCAGTCAACACGCCTTTCATCAACCTTCCCGC  
CCTGTGGAGGAGCGTCGCCAACATCATGCCCTAAACTGGCATCCGGCCTTGCTGGGAGAA  
TAATGTCGCCGTTGTACATCAGCTGACATGACCTGGAGGGGTTGGGGGTGGGGGACAGG  
TTTCTGAAATCCCTGAAGGGGGTTGTACTGGGATTTGTGAATAAACTTGATACACCA

236/392

**FIGURE 226**

MHLARLVGSCSLLLLLLGALSGWAASDDPIEKVIEGINRGLSNAEREVGKALDGINSGITH  
AGREVEKVFNGLSNMGSHGTGKELDKGVQGLNHGMDKVAHEINHGIGQAGKEAEKLGHGYN  
NAAGQAGKEADKAVQGFHTGVHQAGKEAEKLGQGVNHAADQAGKEVEKLGQGAHHAAGQA  
GKELQNAHNGVNVQASKEANQLLNGNHQSGSSSHQGGATTTPLASGASVNTPFINLPALWR  
SVANIMP

**Important features of the protein:**

**Signal peptide:**

amino acids 1-25

**Homologous region to circumsporozoite (CS) repeats:**

amino acids 35-225

237/392

## FIGURE 227

GAAGTAGAGGTGTTGTGCTGAGCGGCGCTCGGCGAACTGTGTGGACCGTCTGCTGGGACT  
CCGGCCCTGCGTCCGCTCAGCCCCGTGGCCCCGCGCACCTACTGCCATGGAGACGCGGCC  
TCGTCTCGGGGCCACCTGTTTGCTGGGCTTCAGTTTCCTGCTCCTCGTCATCTCTTCTGA  
TGGACATAATGGGCTTGGAAGGGTTTTGGAGATCATATTCATTGGAGGACACTGGAAGA  
TGGGAAGAAAGAAGCAGCTGCCAGTGGACTGCCCCCTGATGGTGATTATTCATAAATCCTG  
GTGTGGAGCTTGCAAAGCTCTAAAGCCCAATTTGCAGAATCTACGGAAATTTTCAGAACT  
CTCCCATAAATTTTGTTATGGTAAATCTTGAGGATGAAGAGGAACCCAAAGATGAAGATTT  
CAGCCCTGACGGGGGTATATTCCACGAATCCTTTTTCTGGATCCCAGTGGCAAGGTGCA  
TCCTGAAATCATCAATGAGAATGGAAACCCAGCTACAAGTATTTTTATGTCAGTGCCGA  
GCAAGTTGTTTCAGGGGATGAAGGAAGCTCAGGAAAGGCTGACGGGTGATGCCTTCAGAAA  
GAAACATCTTGAAGATGAATTGTAAATGAATGTGCCCCCTTCTTTCATCAGAGTTAGTGT  
TCTGGAAGGAAAGCAGCAGGGAAGGGAATATTGAGGAATCATCTAGAACAATTAAGCCGA  
CCAGGAAACCTCATTCTACCTACACTGGAAGGAGCGCTCTCACTGTGGAAGAGTTCTGC  
TAACAGAAGCTGGTCTGCATGTTTGTGGATCCAGCGGAGAGTGGCAGACTTTCTTCTCCT  
TTTCCCTCTCACCTAAATGTCAACTTGTGATTGAATGTAAAGAATGAAACCTTCTGACAC  
AAAA



238/392

## FIGURE 228

METRPRLGATCLLGFSFLLLVISSDGHNGLGKGFGDHIHWRTLEDGKKEAAASGLPLMVI  
IHKSWCGACKALKPKFAESTEISELSHNFVMVNLEDEEPEKDEDFSPDGGYIPRILFLDP  
SGKVHPEIINENGNPYSYKYFYVSAEQVVQGMKEAQRILTGDFAFRKKHLEDEL

Signal peptide:

Amino acids 1-23

Thioredoxin family proteins Homology Block:

Amino acids 58-75

239/392

## FIGURE 229

CCCACGCGTCCGCCCCACGCGTCCGGGTGCCACTCGCGCGCCGGCCGCGCTCCGGGCTTCT  
CTTTTCCCTCCGACGCGCCACGGCTGCCCAGACATTCCGGCTGCCGGGTCTGGAGAGCTC  
CCCGAACCCCTCCGCGGAGAGGAGCGAGGCGGCGCCAGGGTGGCCCCCGGGGCGCGCTTG  
GTCTCGGAGAAGCGGGGACGAGGCCGGAGGATGAGCGACTGAGGGCGACGCGGGCACTGA  
CGCGAGTTGGGGCCGCGACTACCGGCAGCTGACAGCGCGATGAGCGACTCCCCAGAGACG  
CCCTAGCCCCGGTGTGCGCGCCAGGCGGAGCGCGCAGGTGGGGCTGGGCTGTTAGTGGTCC  
GCCCCACGCGGGTCCGCCGGCCGGCCAGGATGGGCGCTGGCAACCCGGGCCCCGCGCCCCG  
CGCTGCTACCCCTGCGCCCCGTGCGAGCCCCGGCGTCCGGCCCCGCGCCCTGCGCTCATGGA  
CGGCGGCTCCCGGCTGGCGGCGGCGCGCCCCCGGGCTGTGAATGCGACTCGCCCCCTCGGC  
CGCGCTCCCCGCCCCGCCCGCCCGGGACGTGGTAGGGGATGCCAGCTCCACTGCGAT  
GGCAGTTGGCGCGCTCTCCAGTTCCCTCCTGGTCACCTGCTGCCTGATGGTGGCTCTGTG  
CAGTCCGAGCATCCCGCTGGAGAAGCTGGCCCAGGCACCAGAGCAGCCGGGGCCAGGAGAA  
GCGTGAGCACGCCACTCGGGACGGCCCCGGGGCGGGTGAACGAGCTCGGGCGCCCCGGCGAG  
GGACGAGGGCGGCAGCGGCCGGGACTGGAAGAGCAAGAGCGGCCGTGGGCTCGCCGGCCCC  
TGAGCCGTGGAGCAAGCTGAAGCAGGCCTGGGTCTCCCAGGGCGGGGGCGCCAAGGCCGG  
GGATCTGCAGGTCCGGCCCCGCGGGGACACCCCCGAGGCGGAAGCCCTGGCCGCAGCCGC  
CCAGGACGCGATTGGCCCCGGAACCTCGCGCCACGCCCCGAGCCACCCGAGGAGTACGTGTA  
CCCGGACTACCGTGGCAAGGGCTGCGTGGACGAGAGCGGCTTCGTGTACGCGATCGGGGA  
GAAGTTCGCGCCGGGCCCCCTCGGCCTGCCCCGTGCCTGTGCACCGAGGAGGGGCCGTGTG  
CGCGCAGCCCCGAGTGGCCGAGGCTGCACCCGCGCTGCATCCACGTGACACGAGCCAGTG  
CTGCCCCGAGTGCAAGGAGAGGAAGAACTACTGCGAGTTCGGGGGCAAGACCTATCAGAC  
TTTGGAGGAGTTCGTGGTGTCTCCATGCGAGAGGTGTGCTGTGAAGCCAACGGTGAGGT  
GCTATGCACAGTGTGACGCTGTCCCCAGACGGAGTGTGTGGACCCTGTGTACGAGCCTGA  
TCAGTGCTGTCCCATCTGCAAAAATGGTCCAAACTGCTTTGCAGAAACCGCGGTGATCCC  
TGCTGGCAGAGAAGTGAAGACTGACGAGTGCACCATATGCCACTGTACTTATGAGGAAGG  
CACATGGAGAATCGAGCGGCAGGCCATGTGCACGAGACATGAATGCAGGCAAATGTAGAC  
GCTTCCCAGAACACAAACTCTGACTTTTTCTAGAACATTTTACTGATGTGAACATTCTAG  
ATGACTCTGGGAACATATCAGTCAAAGAAGACTTTTGATGAGGAATAATGGAAAATTGTTG  
GTACTTTTCCTTTTCTTGATAACAGTTACTACAACAGAAGGAAATGGATATATTTCAAAA  
CATCAACAAGAACTTTGGGCATAAAATCCTTCTCTAAATAAATGTGCTATTTTCACAGTA  
AGTACACAAAAGTACACTATTATATATCAAATGTATTTCTATAATCCCTCCATTAGAGAG  
CTTATATAAGTGTTCCTATAGATGCAGATTAAAAATGCTGTGTTGTCAACCGTCAAAAA  
AAAAAAAAAAAAAAAAAAAAA

240/392

**FIGURE 230**

MPSSTAMAVGALSSSLLVTCCLMVALCSPSIPLEKLAQAPEQPGQEKREHATRDGPGRVN  
ELGRPARDEGGSGRDWKS KSGRGLAGREPWSKLQAWVSQGGGAKAGDLQVRPRGDTPQA  
EALAAAAQDAIGPELAPTPEPPPEEYVYPDYRGKGCVDSESGFVYAIGKFAFGPSACPCLC  
TEEGPLCAQPECPR LHPRCIHVDTSQCCPQCKERKNYCEFRGKTYQTLEEFVVS PCERCR  
CEANGEVLCTVSACPQTECVDPVYEPDQCCPICKNGPNCFAETAVIPAGREVKTDECTIC  
HCTYEETWRIERQAMCTRHECRQM

**Important features of the protein:**

**Signal peptide:**

amino acids 1-27

**Transmembrane domain:**

amino acids 11-30

**Glycosaminoglycan attachment site:**

amino acids 80-83

**N-myristoylation sites:**

amino acids 10-15, 102-107, 103-108

**Cell attachment sequence:**

amino acids 114-117

**EGF-like domain cysteine pattern signature:**

amino acids 176-187

241/392

## FIGURE 231

GGCCGGACGCCTCCGCGTTACGGGATGAATTAACGGCGGGTTCCGCACGGAGGTTGTGAC  
CCCTACGGAGCCCCAGCTTGCCACGCACCCCACTCGGCGTCGCGCGGCGTGCCCTGCTT  
GTCACAGGTGGGAGGCTGGAACATCAGGCTGAAAAACAGAGTGGGTACTCTCTTCTGGG  
AAGCTGGCAACAAATGGATGATGTGATATATGCATTCCAGGGGAAGGGAAATTGTGGTGC  
TTCTGAACCCATGGTCAATTAACGAGGCAGTTTCTAGCTACTGCACGTACTTCATAAAGC  
AGGACTCTAAAAGCTTTGGAATCATGGTGTGATGGAAGGGATTTACTTTTATACTGACTC  
TGTTTTGGGGAAGCTTTTGGGAAGCATTTCATGCTGAGTCCCTTTTTACCTTTGATGT  
TTGTAAACCCATCTTGGTATCGCTGGATCAACAACCGCCTTGTGGCAACATGGCTCACCC  
TACCTGTGGCATTATTGGAGACCATGTTTGGTGTAAAAGTGATTATAACTGGGGATGCAT  
TTGTTCTTGAGAAAGAAGTGTCAATTATCATGAACCATCGGACAAGAATGGACTGGATGT  
TCCTGTGGAATTGCCTGATGCGATATAGCTACCTCAGATTGGAGAAAATTTGCCTCAAAAG  
CGAGTCTCAAAGGTGTTCTGGATTGTGGTTGGGCCATGCAGGCTGCTGCCTATATCTTCA  
TTCATAGGAAATGGAAGGATGACAAGAGCCATTTTCGAAGACATGATTGATTACTTTTGTG  
ATATTCACGAACCACTTCAACTCCTCATATTTCCAGAAAGGGACTGATCTCACAGAAAACA  
GCAAGTCTCGAAGTAATGCATTTGCTGAAAAAATGGACTTCAGAAATATGAATATGTTT  
TACATCCAAGAACTACAGGCTTTACTTTTGTGGTAGACCGTCTAAGAGAAGGTAAGAACC  
TTGATGCTGTCCATGATATCACTGTGGCGTATCCTCACAAACATTCCTCAATCAGAGAAGC  
ACCTCCTCCAAGGAGACTTTCCAGGGGAAATCCACTTTCACGTCCACCGGTATCCAATAG  
ACACCCTCCCCACATCCAAGGAGGACCTTCAACTCTGGTGCCACAAACGGTGGGAAGAGA  
AAGAAGAGAGGCTGCGTTCCTTCTATCAAGGGGAGAAGAATTTTTATTTTACCGGACAGA  
GTGTCATTCCACCTTGCAAGTCTGAACTCAGGGTCCTTGTGGTCAAATTGCTCTCTATAC  
TGTATTGGACCTGTTTCAAGCCCTGCAATGTGCCTACTCATATATTTGTACAGTCTTGTTA  
AGTGGTATTTTATAATCACCATTGTAATCTTTGTGCTGCAAGAGAGAATATTTGGTGGAC  
TGGAGATCATAGAACTTGCATGTTACCGACTTTTACACAAACAGCCACATTTAAATTCAA  
AGAAAAATGAGTAAGATTATAAGGTTTGCCATGTGAAAACCTAGAGCATATTTTGGAAT  
GTTCTAAACCTTTCTAAGCTCAGATGCATTTTGCATGACTATGTCGAATATTTCTTACT  
GCCATCATTATTTGTTAAAGATATTTTGCACCTTAATTTTGTGGGAAAAATATTGCTACAA  
TTTTTTTTTAATCTCTGAATGTAATTTTCGATACTGTGTACATAGCAGGGAGTGATCGGGGT  
GAAATAACTTGGGCCAGAATATTATTAAACAATCATCAGGCTTTTAAA

242/392

**FIGURE 232**

MHSRGREIVLLNPWSINEAVSSYCTYFIKQDSKSF GIMVSWKGIYFILTLFWGSFFGSI  
FMLSPFLPLMFVNPSWYRWINNRLVATWLTLPVALLETMFGVKVIITGDAFVPGERSVII  
MNRHTRMDWMFLWNCLMRYSYLRLEKICLKASLKGVPFGFWAMQAAAYIFIHRKWKDDKS  
HFEDMIDYFCDIHEPLQLLIFPEGTDLTENSKSRSNFAEKNGLQKYEYVLHPRTTGFTF  
VVDRLREGKNLDAVHDITVAYPHNIPQSEKHLQGDFFPREIHFHVHRYPIDTLPTS KEDL  
QLWCHKRWEEKEERLRSFYQGEKNFYFTGQSVIPPCKSELRLVVKLLSILYWTLFSPAM  
CLLIYLYSLVKWYFIITIVIFVLQERIFGGLEIIEI LACYRLLHKQPHLNSKKNE

**Important features of the protein:**

**Signal peptide:**

amino acids 1-22

**Transmembrane domains:**

amino acids 44-63, 90-108, 354-377

243/392

**FIGURE 233**

CGGCTCGAGTGCAGCTGTGGGGAGATTTCAAGTGCATTGCCTCCCCTGGGTGCTCTTCATC  
TTGGATTTGAAAGTTGAGAGCAGCATGTTTTGCCCACTGAAACTCATCCTGCTGCCAGTG  
TTACTGGATTATTCCTTGGGCCTGAATGACTTGAATGTTTCCCCGCCTGAGCTAACAGTC  
CATGTGGGTGATTGAGCTCTGATGGGATGTGTTTTCCAGAGCACAGAAGACAAATGTATA  
TTCAAGATAGACTGGACTCTGTCAACCAGGAGAGCACGCCAAGGACGAATATGTGCTATAC  
TATTACTCCAATCTCAGTGTGCCTATTGGGCGCTTCCAGAACC CGCTACACTTGATGGGG  
GACATCTTATGCAATGATGGCTCTCTCCTGCTCCAAGATGTGCAAGAGGCTGACCAGGGA  
ACCTATATCTGTGAAATCCGCCTCAAAGGGGAGAGCCAGGTGTTCAAGAAGGCGGTGGTA  
CTGCATGTGCTTCCAGAGGAGCCCCAAAGAGCTCATGGTCCATGTGGGTGGATTGATTGAG  
ATGGGATGTGTTTTCCAGAGCACAGAAGTGAAACACGTGACCAAGGTAGAATGGATATTT  
TCAGGACGGCGCGCAAAGGAGGAGATTGTATTTGTTACTACCACAAACTCAGGATGTCT  
GTGGAGTACTCCAGAGCTGGGGCCACTTCCAGAATCGTGTGAACCTGGTGGGGGACATT  
TTCCGCAATGACGGTTCATCATGCTTCAAGGAGTGAGGGAGTCAGATGGAGGAAACTAC  
ACCTGCAGTATCCACCTAGGGAACCTGGTGTTCAGAAAACCATTTGTGCTGCATGTCAGC  
CCGGAAGAGCCTCGAACACTGGTGACCCCGGCAGCCCTGAGGCCTCTGGTCTTGGGTGGT  
AATCAGTTGGTGATCATTGTGGGAATTGTCTGTGCCACAATCCTGCTGCTCCCTGTTCTG  
ATATTGATCGTGAAGAAGACCTGTGGAAATAAGAGTTCAAGTGAATTTCTACAGTCTTGGTG  
AAGAACACGAAGAAGACTAATCCAGAGATAAAAGAAAAACCCTGCCATTTTGAAAGATGT  
GAAGGGGAGAAACACATTTACTCCCCAATAATTGTACGGGAGGTGATCGAGGAAGAAGAA  
CCAAGTGAAAAATCAGAGGCCACCTACATGACCATGCACCCAGTTTGGCCTTCTCTGAGG  
TCAGATCGGAACAACTCACTTGAAAAAAGTCAGGTGGGGGAATGCCAAAAACACAGCAA  
GCCTTTTGAGAAGAATGGAGAGTCCCTTCATCTCAGCAGCGGTGGAGACTCTCTCCTGTG  
TGTGTCCTGGGCCACTCTACCAGTGATTTTCAGACTCCCGCTCTCCAGCTGTCTCCTGTG  
CTCATTTGTTTGGTCAATACACTGAAGATGGAGAATTTGGAGCCTGGCAGAGAGACTGGAC  
AGCTCTGGAGGAACAGGCCTGCTGAGGGGAGGGGAGCATGGACTTGGCCTCTGGAGTGGG  
ACACTGGCCCTGGGAACCAGGCTGAGCTGAGTGGCCTCAAACCCCCCGTTGGATCAGACC  
CTCCTGTGGGCAGGGTTCTTAGTGGATGAGTTACTGGGAAGAATCAGAGATAAAAACCAA  
CCCAAATCAA

244/392

**FIGURE 234**

MFCPLKLILLPVLLDYSLGLNDLNVSPPELTVHVGDSALMGCVFQSTEDKCIFKIDWTLS  
PGEHAKDEYVLYYYSNLSVPIGRFQNRVHLMGDILCNDGSLLLQDVQEADQGTyceIRL  
KGESQVFKKAVVLHVLPEEPKELMVHVGGLIQMGCVFQSTEVKHVTKVEWIFSGRRAKEE  
IVFRYYHKLMSVEYSQSWGHFQNRVNLVGDI FRNDGSIMLQGVRES DGGNYTCSIHLGN  
LVFKKTIVLHVSPEEPRTLVT PAALRPLVLGGNQLVIIVGIVCATILLLPVLILIVKKT  
GNKSSVNSTVLVKNTKKTNPEIKEKPCHFERCEGEKHIYSPIIVREVIEEEEPSEKSEAT  
YMTMHPVWPSLRSDRNNNSLEKKSGGMPKTQQAF

245/392

**FIGURE 235**

TAAAACAGCTACAATATTCCAGGGCCAGTCACTTGCCATTTCTCATAACAGCGTCAGAGA  
GAAAGAACTGACTGAAACGTTTGAGATGAAGAAAGTTCTCCTCCTGATCACAGCCATCTT  
GGCAGTGGCTGTTGGTTTCCAGTCTCTCAAGACCAGGAACGAGAAAAAAGAAGTATCAG  
TGACAGCGATGAATTAGCTTCAGGGTTTTTGTGTTCCCTTACCCATATCCATTTGCCC  
ACTTCCACCAATTCCATTTCCAAGATTTCCATGGTTTAGACGTAATTTTCTATTCCAAT  
ACCTGAATCTGCCCCCTACAACCTCCCCTTCCTAGCGAAAAGTAAACAAGAAGGATAAGTCA  
CGATAAACCTGGTCACCTGAAATTGAAATTGAGCCACTTCCTTGAAGAATCAAATTCCT  
GTTAATAAAAGAAAAACAAATGTAATTGAAATAGCACACAGCATTCTCTAGTCAATATCT  
TTAGTGATCTTCTTTAATAAACATGAAAGCAAAGATTTTGTTTTCTTAATTTCCACA



246/392

## FIGURE 236

MKKVLLLLITAILAVAVGFPVSQDQEREKRSISDSDELASGFFVFPYPYFPRPLPPIPFPR  
FPWFRRNFPIPIPIESAPTTPLPSEK

Important features of the protein:

Signal peptide:

amino acids 1-17

Homologous region to B3-hordein:

amino acids 47-85

247/392

**FIGURE 237**

TCGCCATGGCCTCTGCCGGAATGCAGATCCTGGGAGTCGTCCTGACACTGCTGGGCTGGG  
TGAATGGCCTGGTCTCCTGTGCCCTGCCCATGTGGAAGGTGACCGCTTTCATCGGCAACA  
GCATCGTGGTGGCCCAGGTGGTGTGGGAGGGCCTGTGGATGTCCTGCGTGGTGCAGAGCA  
CCGGCCAGATGCAGTGCAAGGTGTACGACTCACTGCTGGCGCTGCCACAGGACCTGCAGG  
CTGCACGTGCCCTCTGTGTCATCGCCCTCCTTGTGGCCCTGTTTCGGCTTGCTGGTCTACC  
TTGCTGGGGCCAAGTGTACCACCTGTGTGGAGGAGAAGGATTCCAAGGCCCGCCTGGTGC  
TCACCTCTGGGATTGTCTTTGTCTATCTCAGGGGTCCTGACGCTAATCCCCGTGTGCTGGA  
CGGCGCATGCCATCATCCGGGACTTCTATAACCCCCCTGGTGGCTGAGGCCCAAAAGCGGG  
AGCTGGGGGCCTCCCTCTACTTGGGCTGGGCGGCCTCAGGCCTTTTGTTGCTGGGTGGGG  
GGTTGCTGTGCTGCACTTGCCCCCTCGGGGGGGTCCCAGGGCCCCAGCCATTACATGGCCC  
GCTACTCAACATCTGCCCCCTGCCATCTCTCGGGGGCCCTCTGAGTACCCTACCAAGAATT  
ACGTCTGACGTGGAGGGGAATGGGGGCTCCGCTGGCGCTAGAGCCATCCAGAAGTGGCAG  
TGCCCAACAGCTTTGGGATGGGTTTCGTACCTTTTGTTTCTGCCTCCTGCTATTTTCTTT  
TGACTGAGGATATTTAAATTCATTTGAAACTGAGCCAAGGTGTTGACTCAGACTCTCA  
CTTAGGCTCTGCTGTTTCTCACCTTGGATGATGGAGCCAAAGAGGGGATGCTTTGAGAT  
TCTGGATCTTGACATGCCCATCTTAGAAGCCAGTCAAGCTATGGAACATAATGCGGAGGCT  
GCTTGCTGTGCTGGCTTTGCAACAAGACAGACTGTCCCCAAGAGTTCTTGCTGCTGCTGG  
GGGCTGGGCTTCCCTAGATGTCACTGGACAGCTGCCCCCATCCTACTCAGGTCTCTGGA  
GCTCCTCTCTTCACCCCTGGAAAAACAAATCATCTGTTAACAAGGACTGCCCACCTCCG  
GAACTTCTGACCTCTGTTTCCTCCGTCCTGATAAGACGTCCACCCCCCAGGGCCAGGTCC  
CAGCTATGTAGACCCCCGCCCCACCTCCAACACTGCACCCTTCTGCCCTGCCCCCTCG  
TCTCACCCCTTTTACACTCACATTTTTATCAAATAAAGCATGTTTTGTTAGTGCA

248/392

**FIGURE 238**

MASAGMQILGVVLTLLGWVNGLVSCALPMWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTG  
QMCKVYDSLALPQDLQAARALCVIALLVALLVYLAGAKCTTCVEEKDSKARLVLT  
SGIVFVISGVLTLPVCWTAHAIRDFYNPLVAEAQKRELGASLYLGWAASGLLLGGGL  
LCCTCPSGGSQGPHYMARYSTSAPAISRGPSYPTKNYV

**Transmembrane domains:**

amino acids 8-30 (type II), 82-102, 121-140, 166-186

249/392

**FIGURE 239**

AGTGACAATCTCAGAGCAGCTTCTACACCACAGCCATTTCCAGCATGAAGATCACTGGGG  
GTCTCCTTCTGCTCTGTACAGTGGTCTATTTCTGTAGCAGCTCAGAAGCTGCTAGTCTGT  
CTCCAAAAAAGTGGACTGCAGCATTTACAAGAAGTATCCAGTGGTGGCCATCCCCTGCC  
CCATCACATACCTACCAGTTTGTGGTTCTGACTACATCACCTATGGGAATGAATGTCACT  
TGTGTACCGAGAGCTTGAAAAGTAATGGAAGAGTTCAGTTTCTTCACGATGGAAGTTGCT  
AAATTCTCCATGGACATAGAGAGAAAGGAATGATATTCTCATCATCATCTTCATCATCCC  
AGGCTCTGACTGAGTTTCTTTCAGTTTTACTGATGTTCTGGGTGGGGGACAGAGCCAGAT  
TCAGAGTAATCTTGACTGAATGGAGAAAGTTTCTGTGCTACCCCTACAAACCCATGCCTC  
ACTGACAGACCAGCATTTTTTTTTTAAACACGTCAATAAAAAAATAATCTCCCAGA

250/392

## FIGURE 240

MKITGGLLLLCTVVYFCSSSEAAASLSPKKVDCSIYKKYPVVAIPCPITYLPVCGSDYITY  
GNECHLCTESLKSNGRVQFLHDGSC

Signal peptide:  
amino acids 1-19

251/392

**FIGURE 241**

CCCGCGCCCGGTTCTCCCTCGCAGCACCTCGAAGTGCGCCCTCGCCCTCCTGCTCGCGC  
CCCGCGCCCATGGCTGCCTCCCCCGCGCGGCCTGCTGTCCTGGCCCTGACCGGGCTGGCG  
CTGCTCCTGCTCCTGTGCTGGGGCCCAGGTGGCATAAGTGGAATAAACTCAAGCTGATG  
CTTCAAAAACGAGAAGCACCTGTTCCAATAAGACTAAAGTGGCCGTTGATGAGAATAAA  
GCCAAAGAATTCTTGGCAGCCTGAAGCGCCAGAAGCGGCAGCTGTGGGACCGGACTCGG  
CCCGAGGTGCAGCAGTGGTACCAGCAGTTTCTCTACATGGGCTTTGATGAAGCGAAATTT  
GAAGATGACATCACCTATTGGCTTAACAGAGATCGAAATGGACATGAATACTATGGCGAT  
TACTACCAACGTCACTATGATGAAGACTCTGCAATTGGTCCCCGGAGCCCCCTACGGCTTT  
AGGCATGGAGCCAGCGTCAACTACGATGACTACTAAACCATGACTTGCCACACGCTGTACA  
AGAAGCAAATAGCGATTCTCTTCATGTATCTCCTAATGCCTTACACTACTTGGTTTCTGA  
TTTGCTCTATTTTCAAGCAGATCTTTTCTACCTACTTTGTGTGATCAAAAAGAAGAGTTAA  
AACCAACACATGTAAATGCCTTTTGATATTTTCATGGGAATGCCTCTCATTTAAAAATAGAA  
ATAAAGCATTTTGTAAAAAGA

252/392

## FIGURE 242

MAASPARPAVLALTGLALLLLLCWGPGGISGNKLLMLQKREAPVPTTKKVAVDENKAKE  
FLGSLKRQKRQLWDRTRPEVQQWYQQFLYMGFDEAKFEDDITYWLNDRDRNGHEYDYYQ  
RHYDEDSAIGPRSPYGFRHGASVNYDDY

Signal peptide:  
amino acids 1-30

253/392

## FIGURE 243

CTCCATTAAACCACCACCAGCTCCCCAAGCCACCCCTTCAGCCATGAAGTTCCTGCTCCT  
GGTCTTGGCAGCCCTCGGATTCTTGACCCAGGTGATCCCAGCCAGTGCCAGGTGGGTCAAA  
ATGTGTGAGTAACACCCACAGGATACTGCAGGACATGTTGCCACTGGGGGGAGACAGCATT  
GTTTCATGTGCAACGCTTCCAGAAAATGCTGCATCAGCTACTCCTTCCTGCCGAAGCCTGA  
CCTACCACAGCTCATCGGTAACCACTGGCAATCAAGGAGAAGAAACACACAAAGGAAAGA  
CAAGAAGCAACAAACGACCGTAACATCATAATAACCACTGCTATCGCCTCCACCAACTCA  
GAGAAATATCATTTCCACAGTTCCAATTCTCTACATTGCTGAGTACTAGCCAAGGCTC  
CTCTTTATGGGGCAGATATCTATAGCCAACCCCAAACTTCTGTCTTCTATCATTCTGTC  
ATTCATCTAGTAACATAATTGGAGTTTGTATCTATCTTACGAGAAACAATCATCATGCAGA  
TTCGTCCACAGGGGATCTGTGAGTTTGGGTCCTCCAAATGAAAAATGTCAAGACAGAATT  
GGACATGCAAAAGATTGACTGGGAGAACACACCTCTGATGGACAAAGGTGAGACAGAGCA  
GCCACAGGCAGGGAGAGCCTTCAGACTGCAACGCTGGCCTGATACGTGTCAAAGGAGAGA  
GGGATAGAGGAGGATTGAATAGAAGGAGACTAAGACTGCAGCTCTAAGAAAGTCTCAGCC  
AAACAGATGGGGAGGCCCAAAGCAAGGCTTGCCCCCTCAGAGGAGCTCACGCAGGGCAGGA  
ATAGCCAGGTTCTCATATCCCAGGGGTTTCAGACTTGGCTGAGAACAGCCCCCTGGAGAACA  
TGGGGTGACTGCTACCATAGGTCTGGAAGTATGAGGCTGTCCACCAACTATCCCCTTGAA  
GCAAGTTCTCTTGAAAGGAAATCTAAACAGTGCACCCCATGGCTGCCACGGAGTATAAG  
GAGGGAGAGAAAGGAGCTGAAAGTCTAGGTTTGGCCAGCTAGGTAGACTGACTTGTGAGG  
TATTTATTTATTCATTTGAGTAACAAAGCAGACAGAATACATAGCCACCATTGGTAGTAC  
ACCCCAAAAGCAAGGATGGCATGATGCTGGTGACTCAAACGTGCCTACTCATGGTGTCAA  
ATTGGCATAATCCTCTTGGAAGCTGTGTGGAATAAGCACAGAGAAGCAGAACTCTAAT  
TGCTTAATCCACTAAACATTACTTCTGGGAATTGGCTCATCATAAATTATCCAAGAGAAA  
GCACAAAGTTATGGGCACAAAGGTTTTCCATATAATATTATTTAAAAATGCTGAGAAAATG  
AAAAATCTAAATGGTGAAATATATACTAATGCCATCTATAAATACAAACAAATAGAATG  
TTTATAGAATAATGGAACATAATAACATTATTCAAATTTGCATTTATGCTATAGTTGTCA  
AAATTGTCTCCTTATATGATACAAAACCTCATGAAAATTATGACTTTTTTGTGGTTGGA  
AAGCAGAATTATGCATAAATTTCTCTTACAGTTCGATGCCCATTAGTTTTATATAACAT  
TTATTTGACACGTAAGTACTGACTTCTATCTGAGAAGAACAAACCAAAACACTCAGGCCTAAT  
AATTAACAAACGGTCCTAAAAACTAGCAAACCAGATAAGAAAAGATGTTAATGCCCATTTCC  
CTAACTTATGTCTTAGACCAAATTAATTTCTAGATGGTTTTAAATGACAGTGTAAGT  
AAAGTATTAAAGATTGTGTGGTCAAATATTCAATTTAAGAGCAAGGAAATTTCTATAAA  
TATAACAATAGAGGCAGAACTCATGTAAGAATAAATTGATTAGGTGGTATTAAATATTAA  
GTTCTTATGTATGTCAAAAGATATCATTTTGAATTCATCCATCTTATTGGGTATTGCAG  
GAGTTCATTCTTTTTTGTATATAAATACTCTTCCGTCATATGAATAGTATTCATTTGTAT  
ACTGGTTTGTGATGGACATTTGGGTTGTTCCAGTTTATGGCTATTACAAATAAGCTT  
CTATGAACATTTATGTACA



254/392

## FIGURE 244

MKFLLLVLAALGFLTQVIPASAGGSKCVSNTPGYCRTCCHWGETALFMCNASRKCCISYS  
FLPKPDLPLQIGNHWQSRRTQQRKDKKQQTTS

Important features of the protein:

Signal peptide:

amino acids 1-16

Transmembrane domain:

amino acids 1-22

N-glycosylation site:

amino acids 50-53

cAMP- and cGMP-dependent protein kinase phosphorylation site:

amino acids 79-82

N-myristoylation site:

amino acids 23-28

255/392

**FIGURE 245**

GGAGAGAGGCGCGCGGGTGAAAGGCGCATTGATGCAGCCTGCGGCGGCCTCGGAGCGCGG  
CGGAGCCAGACGCTGACCACGTTCTCTCCTCGGTCTCCTCCGCTCCAGCTCCGCGCTG  
CCCGGCAGCCGGGAGCCATGCGACCCCAGGGCCCCGCGCCTCCCCGCAGCGGCTCCGCG  
GCCTCCTGCTGCTCCTGCTGCTGCAGCTGCCCGCGCCGTCGAGCGCCTCTGAGATCCCCA  
AGGGGAAGCAAAAGGCGCAGCTCCGGCAGAGGGAGGTGGTGGACCTGTATAATGGAATGT  
GCTTACAAGGGCCAGCAGGAGTGCCTGGTCGAGACGGGAGCCCTGGGGCCAATGTTATTCT  
CGGGTACACCTGGGATCCCAGGTCCGGATGGATTCAAAGGAGAAAAGGGGGAATGTCTGA  
GGGAAAGCTTTGAGGAGTCCTGGACACCCAACTACAAGCAGTGTTTATGGAGTTCATTGA  
ATTATGGCATAGATCTTGGGAAAATTGCCGAGTGTACATTTACAAAGATGCGTTCAAATA  
GTGCTCTAAGAGTTTTGTTTCAAGTGGCTCACTTCGGCTAAAATGCAGAAATGCATGCTGTC  
AGCGTTGGTATTTTACATTCAATGGAGCTGAATGTTTCAAGACCTCTTCCCATTGAAGCTA  
TAATTTATTTGGACCAAGGAAGCCCTGAAATGAATTCAACAATTAATATTCATCGCACTT  
CTTCTGTGGAAGGACTTTGTGAAGGAATTGGTGTGCTGGATTAGTGGATGTTGCTATCTGGG  
TTGGCACTTGTTTCAAGATTACCCAAAAGGAGATGCTTCTACTGGATGGAATTCAGTTTCTC  
GCATCATTATTGAAGAACTACCAAAATAAATGCTTTAATTTTCAATTTGCTACCTCTTTTT  
TTATTATGCCTTGGAATGGTTCACTTAAATGACATTTTAAATAAGTTTATGTATACATCT  
GAATGAAAAGCAAAGCTAAATATGTTTACAGACCAAAGTGTGATTTACACTGTTTTTAA  
ATCTAGCATTATTCATTTTGCTTCAATCAAAAGTGGTTTCAATATTTTTTTTAGTTGGTT  
AGAATACTTTCTTCATAGTCACATTCTCTCAACCTATAATTTGGAATATTGTTGTGGTCT  
TTTGTTTTTTCTCTTAGTATAGCATTTTTTAAAAAATATAAAAGCTACCAATCTTTGTAC  
AATTTGTAAATGTTAAGAATTTTTTTTATATCTGTAAATAAAAATTATTTCCAACA

256/392

**FIGURE 246**

MRPQGPAASPQRLRGLLLLLLLQLPAPSSASEIPKGKQKAQLRQREVVDLYNGMCLOGPA  
GVPGRDGSPGANVIPGTPGIPGRDGFKEKGECLRESFEESWTPNYKQCSWSSLNYGIDL  
GKIAECTFTKMRSNSALRVLFSGSLRLKCRNACCQRWYFTFNGAECGPLPIEAIYLDQ  
GSPENSTINIHRITSSVEGLCEGIGAGLVDVAIWVGTCSDYPKGDASTGWNSVSRIIIEE  
LPK

**Signal peptide:**  
amino acids 1-30

**Transmembrane domain:**  
amino acids 195-217

257/392

**FIGURE 247**

GGCCGTTGGTTGGTGCGCGGCTGAAGGGTGTGGCGCGAGCAGCGTCGTTGGTTGGCCGGC  
GGCGGGCCGGGACGGGCATGGCCCTGCTGCTGTGCCTGGTGTGCCTGACGGCGGCGCTGG  
CCCACGGCTGTCTGCACTGCCACAGCAACTTCTCCAAGAAGTTCTCCTTCTACCGCCACC  
ATGTGAACTTCAAGTCTTGGTGGGTGGGCGACATCCCCGTGTGAGGGGCGCTGCTCACC  
ACTGGAGCGACGACACGATGAAGGAGCTGCACCTGGCCATCCCCGCCAAGATCACCCGGG  
AGAAGCTGGACCAAGTGGCGACAGCAGTGTACCAGATGATGGATCAGCTGTACCAGGGGA  
AGATGTACTTCCCCGGGTATTTCCCCAACGAGCTGCGAAACATCTTCCGGGAGCAGGTGC  
ACCTCATCCAGAACGCCATCATCGAAAGGCACCTGGCACCAGGCAGCTGGGGAGGAGGGC  
AGCTCTCCAGGGAGGGACCCAGCCTAGCACCTGAAGGATCAATGCCATCACCCCGCGGGG  
ACCTCCCCCTAAGTAGCCCCCAGAGGCGCTGGGAGTGTGCCACCGCCCTCCCCTGAAGTT  
TGCTCCATCTCACGCTGGGGGTCAACCTGGGGACCCCTTCCCTCCGGGGCCATGGACACAC  
ATACATGAAAACCAGGCCGCATCGACTGTGACACCGCTGTGGCATCTTCCAGTACGAGA  
CCATCTCCTGCAACAACCTGCACAGACTCGCACGTCGCCTGCTTTGGCTATAACTGCGAGT  
AGGGCTCAGGCATCACACCCACCCGTGCCAGGGCCCTACTGTCCCTGGGGTCCCAGGCTC  
TCCTTGGAGGGGGCTCCCCGCTTCCACCTGGCTGTGATCGGGTAGGGCGGGGCCGTGGG  
TTCAGGGGCGCACCACTTCCAAGCCTGTGTCCACAGGTCCTCGGCGCAGTGGAAGTCAG  
CTGTCCAGGGCCTCCTGAACCTACATAAATAACTGGCACAAGTAAGTCCCCTCCTCAAACC  
AACACAGGCAGTGTGTGTATGTGAGCACCTCGTGGGTGAGTATGTGTGGGGCACAGGCTG  
GCTCCCTCAGCTCCACGTCCTAGAGGGGCTCCCGAGGAGGTGGAACCTCAACCCAGCTC  
TGCGCAGGAGGCGGCTGCAGTCCTTTTCTCCCTCAAAGGTCTCCGACCCTCAGCTGGAGG  
CGGGCATCTTTCCTAAAGGGTCCCCATAGGGTCTGGTTCCACCCCATCCCAGGTCTGTGG  
TCAGAGCCTGGGAGGGTTCCCTACGATGGTTAGGGGTGCCCCATGGAGGGGCTGACTGCC  
CCACATTGCCTTTCAGACAGGACACGAGCATGAGGTAAGGCCGCCCTGACCTGGACTTCA  
GGGGGAGGGGGTAAAGGGAGAGAGGAGGGGGGCTAGGGGGTCTCTAGATCAGTGGGGGC  
ACTGCAGGTGGGGCTCTCCCTATACCTGGGACACCTGCTGGATGTACCTCTGCAACCAC  
ACCCATGTGGTGGTTTTCATGAACAGACCACGCTCCTCTGCCTTCTCCTGGCCTGGGACAC  
ACAGAGCCACCCCGGCCTTGTGAGTGACCCAGAGAAGGGAGGCCTCGGGAGAAGGGGTGC  
TCGTAAGCCAACACCAGCGTGCCGCGGCCTGCACACCCTTCGGACATCCCAGGCACGAGG  
GTGTGCTGGATGTGGCCACACATAGGACCACACGTCCCAGCTGGGAGGAGAGGCCTGGGG  
CCCCCAGGGAGGGAGGCAGGGGGTGGGGGACATGGAGAGCTGAGGCAGCCTCGTCTCCCC  
GCAGCCTGGTATCGCCAGCCTTAAGGTGTCTGGAGCCCCCACACTTGGCCAACCTGACCT  
TGGAAGATGCTGCTGAGTGTCTCAAGCAGCACTGACAGCAGCTGGGCCTGCCCCAGGGCA  
ACGTGGGGGCGGAGACTCAGCTGGACAGCCCCCTGCCTGTCACTCTGGAGCTGGGCTGCTG  
CTGCCTCAGGACCCCTCTCCGACCCCGGACAGAGCTGAGCTGGCCAGGGCCAGGAGGGC  
GGGAGGGAGGGAATGGGGGTGGGCTGTGCGCAGCATCAGCGCCTGGGCAGGTCCGCAGAG  
CTGCGGGATGTGATTAAAGTCCCTGATGTTTCTC

258/392

## FIGURE 248

MALLLCLVCLTAALAHGCLHCHSNFSKKFSFYRHHVNFKSWWVGDI PVSGALLTDWSDDT  
MKELHLAIPAKITREKLDQVATAVYQMDQLYQGKMYFPGYFPNELRNIFREQVHLIQNA  
I IERHLAPGSWGGGQLSREGPSLAPEGSMPSPRGDLP

Signal peptide:  
amino acids 1-15

259/392

## FIGURE 249

CGACGATGCTACGCGCGCCCGGCTGCCTCCTCCGGACCTCCGTAGCGCCTGCCGCGGCCC  
TGGCTGCGGCGCTGCTCTCGTCGCTTGCGCGCTGCTCTCTTCTAGAGCCGAGGGACCCGG  
TGGCCTCGTCGCTCAGCCCCCTATTTTCGGCACCAAGACTCGCTACGAGGATGTCAACCCCG  
TGCTATTGTGCGGGCCCCGAGGCTCCGTGGCGGGACCCCTGAGCTGCTGGAGGGGACCTGCA  
CCCCGGTGACGCTGGTCGCCCTCATTGCCACGGCACCCGCTACCCACGGTCAAACAGA  
TCCGCAAGCTGAGGCAGCTGCACGGGTTGCTGCAGGCCCCGCGGGTCCAGGGATGGCGGGG  
CTAGTAGTACCGGCAGCCGCGACCTGGGTGCAGCGCTGGCCGACTGGCCTTTGTGGTACG  
CGGACTGGATGGACGGGCAGCTAGTAGAGAAGGGACGGCAGGATATGCGACAGCTGGCGC  
TGCGTCTGGCCTCGCTCTTCCCGGCCCTTTTCAGCCGTGAGAACTACGGCCGCTGCGGC  
TCATCACCAGTTCCAAGCACCGCTGCATGGATAGCAGCGCCGCTTCCTGCAGGGGCTGT  
GGCAGCACTACCACCCTGGCTTGCCGCGCGCCGGACGTGCGCAGATATGGAGTTTGGACCTC  
CAACAGTTAATGATAAACTAATGAGATTTTTTGTACTGTGAGAAGTTTTTAAGTGAAG  
TAGAAAAAATGCTACAGCTCTTTATCACGTGGAAGCCTTCAAACTGGACCAGAAATGC  
AGAACATTTTAAAAAAGTTGCAGCTACTTTGCAAGTGCCAGTAAATGATTTAAATGCAG  
ATTTAATTCAAGTAGCCTTTTTTCACTGTTCATTTGACCTGGCAATTAAAGGTGTTAAAT  
CTCCTTGGTGTGATGTTTTTGACATAGATGATGCAAAGGTATTAGAATATTTAAATGATC  
TGAAACAATATTGAAAAGAGGATATGGGTATACTATTAAACAGTCGATCCAGCTGCACCT  
TGTTTTCAGGATATCTTTTCACTTGGACAAAGCAGTTGAACAGAAACAAAGGTCTCAGC  
CAATTTCTTCTCCAGTCATCCTCCAGTTTGGTTCATGCAGAGACTCTTCTTCCACTGCTTT  
CTCTCATGGGCTACTTCAAAGACAAGGAACCCCTAACAGCGTACAATTACAAAAACAAA  
TGCATCGGAAGTTCGGAAGTGGTCTCATTGTACCTTATGCCTCGAACCTGATATTTGTGC  
TTTACCAGTGTGAAAATGCTAAGACTCCTAAAGAACAATTCCGAGTGCAGATGTTATTAA  
ATGAAAAGGTGTTACCTTTGGCTTACTCACAAGAACTGTTTCATTTTATGAAGATCTGA  
AGAACCCTACAAGGACATCCTTCAAGTGTCAAACCAGTGAAGAATGTGAATTAGCAA  
GGGCTAACAGTACATCTGATGAACATGAGTAAGTGAAGAACATTTTTTAATTCTTTAGGA  
ATCTGCAATGAGTGATTACATGCTTGTAAATAGGTAGGCAATTCCTTGATTACAGGAAGCT  
TTTATATTACTTGAGTATTTCTGTCTTTTACAGAAAAACATTGGGTTTCTCTCTGGGTT  
TGGACATGAAATGTAAGAAAAGATTTTTTCACTGGAGCAGCTCTCTTAAGGAGAAACAAAT  
CTATTTAGAGAAACAGCTGGCCCTGCAAATGTTTACAGAAATGAAATTCCTTCTACTTAT  
ATAAGAAATCTCACACTGAGATAGAATTGTGATTTTATAATAACACTTGAAAAGTGCTGG  
AGTAACAAAATATCTCAGTTGGACCATCCTTAACTTGATTGAACTGTCTAGGAACCTTTAC  
AGATTGTTCTGCAGTTCTCTCTTTTCTCCTCAGGTAGGACAGCTCTAGCATTCTTAA  
TCAGGAATATTGTGGTAAGCTGGGAGTATCACTCTGGAAGAAAGTAACATCTCCAGATGA  
GAATTTGAAACAAGAAACAGAGTGTGTAAAAGGACACCTTCACTGAAGCAAGTCGGAAA  
GTACAATGAAAATAAATATTTTTGGTATTTATTTATGAAATATTTGAACATTTTTTCAAT  
AATTCCTTTTTTACTTCTAGGAAGTCTCAAAGACCATCTTAAATTATTATATGTTTGGAC  
AATTAGCAACAAGTCAGATAGTTAGAATCGAAGTTTTTCAAATCCATTGCTTAGCTAACT  
TTTTCATTTCTGTCACTTGGCTTCGATTTTTTATATTTTCTATTATATGAAATGTATCTTT  
TGGTTGTTTGATTTTTTCTTCTTTCTTTGTAAATAGTTCTGAGTTCTGTCAAATGCCGTG  
AAAGTATTTGCTATAATAAAGAAATTCCTGTGACTTTAAAAA

260/392

**FIGURE 250**

MLRAPGCLLRTSVAPAAALAAALLSSLARCSLLEPRDPVASSLSPYFGTKTRYEDVNPVL  
LSGPEAPWRDPELLEGTCTPVQLVALIRHGTRYPTVKQIRKLRQLHGLLQARGSRDGGAS  
STGSRDLGAALADWPLWYADWMDGQLVEKGRQDMRQLALRLASLFPALFSRENYGRLRLI  
TSSKHRCMDSSAAFLQGLWQHYHPGLPPPVDADMEFGPPTVNDKLMRFFDHCEKFLTEVE  
KNATALYHVEAFKTGPEMQNILKKVAATLQVPVNDLNADLIQVAFFTCSFDLAIKGVKSP  
WCDVFDIDDAKVLEYLNDLKQYWKRGYGYTINSRSSCTLFQDIFQHLDKAVEQKQRSQPI  
SSPVILQFGHAETLLPLLSLMGYFKDKEPLTAYNYKKQMRKFRSGLIVPYASNLI FVLY  
HCENAKTPKEQFRVQMLLNEKVLPLAYSQETVSFYEDLKNHYKDILQSCQTSEECELARA  
NSTSDEL

**Important features:****Signal sequence**

amino acids 1-30

**N-glycosylation sites:**

amino acids 242-246, 481-485

**N-myristoylation sites.**

amino acids 107-113, 113-119, 117-123, 118-124, 128-134

**Endoplasmic reticulum targeting sequence:**

amino acids 484-489

261/392

**FIGURE 251**

GGAGAGCCGCGGCTGGGACCGGAGTGGGGAGCGCGGCGTGGAGGTGCCACCCGGCGCGGG  
TGGCGGAGAGATCAGAAGCCTCTTCCCCAAGCCGAGCCAACCTCAGCGGGGACCCGGGCT  
CAGGGACGCGGCGGCGGCGGCGGCGACTGCAGTGGCTGGACGATGGCAGCGTCCGCCGGA  
GCCGGGGCGGTGATTGCAGCCCCAGACAGCCGCGCGCTGGCTGTGGTCTGGTGTGGCGGCG  
GCGCTTGGGCTCTTGACAGCTGGAGTATCAGCCTTGGAAGTATATACGCCAAAAGAAATC  
TTCGTGGCAAATGGTACACAAGGGAAGCTGACCTGCAAGTTCAAGTCTACTAGTACGACT  
GGCGGGTTGACCTCAGTCTCCTGGAGCTTCCAGCCAGAGGGGGCCGACACTACTGTGTCTG  
TTTTTCCACTACTCCCAAGGGCAAGTGTACCTTGGGAATTATCCACCATTTTAAAGACAGA  
ATCAGCTGGGCTGGAGACCTTGACAAGAAAGATGCATCAATCAACATAGAAAATATGCAG  
TTTATACACAATGGCACCTATATCTGTGATGTCAAAAACCCTCCTGACATCGTTGTCCAG  
CCTGGACACATTAGGCTCTATGTCTGTAGAAAAAGAGAATTTGCCTGTGTTTTCCAGTTTG  
GTAGTGGTGGGCATAGTTACTGCTGTGGTCCTAGGTCTCACTCTGCTCATCAGCATGATT  
CTGGCTGTCTCTATAGAAGGAAAACTCTAAACGGGATTACACTGGCTGCAGTACATCA  
GAGAGTTTGTCAACAGTTAAGCAGGCTCCTCGGAAGTCCCCCTCCGACACTGAGGGTCTT  
GTAAAGAGTCTGCCTTCTGGATCTCACCAGGGCCCAGTCATATATGCACAGTTAGACCAC  
TCCGGCGGACATCACAGTGACAAGATTAACAAGTCAGAGTCTGTGGTGTATGCGGATATC  
CGAAAGAATTAAGAGAATACCTAGAACATATCCTCAGCAAGAAACAAAACCAAACCTGGAC  
TCTCGTGCAGAAAATGTAGCCATTACCACATGTAGCCTTGGAGACCAGGCAAGGACAA  
GTACACGTGTACTCACAGAGGGAGAGAAAGATGTGTACAAAGGATATGTATAAATATTCT  
ATTTAGTCATCCTGATATGAGGAGCCAGTGTGTCATGATGAAAAGATGGTATGATTCTAC  
ATATGTACCCATTGTCTTGCTGTTTTTGTACTTTCTTTTCAGGTCAATTTACAATTGGGAG  
ATTTCAGAAACATTTCTTTTACCATTCAATTTAGAAATGGTTTGCCTTAATGGAGACAATAG  
CAGATCCTGTAGTATTTCCAGTAGACATGGCCTTTTAAATCTAAGGGCTTAAGACTGATTA  
GTCTTAGCATTTTACTGTAGTTGGAGGATGGAGATGCTATGATGGAAGCATACCCGGGTG  
GCCTTTAGCACAGTATCAGTACCATTATTTGTCTGCCGCTTTTAAAAAATACCCATTGG  
CTATGCCACTTGAAAACAATTTGAGAAAGTTTTTTTGAAGTTTTTCTCACTAAAAATATGGG  
GCAATTGTTAGCCTTACATGTTGTGTAGACTTACTTTAAGTTTGCACCCTTGAAATGTGT  
CATATCAATTTCTGGATTCAATAAGCAAGATTAGCAAAGGATAAATGCCGAAGGTCACT  
TCATTCTGGACACAGTTGGATCAATACTGATTAAGTAGAAAATCCAAGCTTTGCTTGAGA  
ACTTTTGTAACTGGAGAGTAAAAAGTATCGGTTTTTA



262/392

**FIGURE 252**

MAASAGAGAVIAAPDSRRWLWSVLAAALGLLTAGVSALEVYTPKEIFVANGTQGKLTCKF  
KSTSTTGGLTSVSWSFQPEGADTTVSFFHYSQGQVYLGNYPPFKDRISWAGDLDKKDASI  
NIENMQFIHNGTYICDVKNPPDIVVQPGHIRLYVVEKENLPVFPVWVVVGIVTAVVLGLT  
LLISMILAVLYRRKNSKRDTGCTSESLSPVKQAPRKSPSDTEGLVKSLPSGSHQGPVI  
YAQLDHSGGHHSDKINKSESVVYADIRKN

**Signal peptide:**  
amino acids 1-37

**Transmembrane domain:**  
amino acids 161-183

263/392

**FIGURE 253**

GTGACACTATAGAAGAGCTATGACGTCGCATGCACGCGTACGTAAGCTCGGAATTCGGCT  
CGAGGCTGGTGGGAAGAAGCCGAGATGGCGGCAGCCAGCGCTGGGGCAACCCGGCTGCTC  
CTGCTCTTGCTGATGGCGGTAGCAGCGCCAGTCGAGCCCGGGGCAGCGGCTGCCGGGCC  
GGGACTGGTGC GCGAGGGGCTGGGGCGGAAGGTCGAGAGGGCGAGGCCTGTGGCACGGTG  
GGGCTGCTGCTGGAGCACTCATTTGAGATCGATGACAGTGCCAACTTCCGGAAGCGGGGC  
TCACTGCTCTGGAACCAGCAGGATGGTACCTTGTCCTGTTCACAGCGGCAGCTCAGCGAG  
GAGGAGCGGGGCCGACTCCGGGATGTGGCAGCCCTGAATGGCCTGTACCGGGTCCGGATC  
CCAAGGCGACCCGGGGCCCTGGATGGCCTGGAAGCTGGTGGCTATGTCTCCTCCTTTGTC  
CCTGCGTGCTCCCTGGTGGAGTCGCACCTGTTCGACCACTGACCCCTGCACGTGGATGTG  
GCCGGAACGTGGTGGGCGTGTCGGTGGTGACGCACCCCGGGGGCTGCCGGGGCCATGAG  
GTGGAGGACGTGGACCTGGAGCTGTTCAACACCTCGGTGCAGCTGCAGCCGCCACCACA  
GCCCCAGGCCCTGAGACGGCGGCCTTCATTGAGCGCCTGGAGATGGAACAGGCCCCAGAAG  
GCCAAGAACCCCCAGGAGCAGAAGTCCTTCTTCGCCAAATACTGGATGTACATCATTTCC  
GTCGTCCTGTTCTCATGATGTCAGGAGCGCCAGACACCGGGGGCCAGGGTGGGGGTGGG  
GGTGGGGGTGGTGGTGGGGGTAGTGGCCTTTGCTGTGTGCCACCCTCCCTGTAAAGTCTAT  
TTAAAAACATCGACGATACATTGAAATGTGTGAACGTTTTGAAAAGCTACAGCTTCCAGC  
AGCCAAAAGCAACTGTTGTTTTGGCAAGACGGTCCTGATGTACAAGCTTGATTGAAATTC  
ACTGCTCACTTGATACGTTATTCAGAAACCCAAGGAATGGCTGTCCCCATCCTCATGTGG  
CTGTGTGGAGCTCAGCTGTGTTGTGTGGCAGTTTATTAACTGTCCCCCAGATCGACACG  
CAAAAAAAA

264/392

**FIGURE 254**

MAAASAGATRLLLLLLLMAVAAPSRARGSGCRAGTGARGAGAEGREGEACGTVGLLLEHSF  
EIDDSANFRKRGSLLWNQQDGTLSLSQRQLSEEERGLRDVAALNGLYRVRI PRRP GALT  
GLEAGGYVSSFVPACSLVESHLS DQLTLHVDVAGNVVGVS VVTHPGGCRGHEVEDVDLEL  
FNTSVQLQPPTTAPGPETA AAFIERLEMEQAQKAKNPQEKSFFAKYWMYIIPVVLFLMMS  
GAPDTGGQGGGGGGGGGGGSGGLCCVPPSL

Signal peptide:  
amino acids 1-24

Transmembrane domain:  
amino acids 226-243

265/392

**FIGURE 255**

GCGACGCGCGGCGGGGCGGCGAGAGGAAACGCGGCGCCGGGCGGGCCCGGCCCTGGAGA  
TGGTCCCCGGCGCCGCGGGCTGGTGTGTTGTCTCGTGCTCTGGCTCCCCGCGTGCGTCCGCGG  
CCCACGGCTTCCGTATCCATGATTATTTGTACTTTCAAGTGCTGAGTCCTGGGGACATTC  
GATACATCTTCACAGCCACACCTGCCAAGGACTTTGGTGGTATCTTTCACACAAGGTATG  
AGCAGATTCACCTTGTCCTCCGCTGAACCTCCAGAGGCCTGCGGGGAACCTCAGCAACGGTT  
TCTTCATCCAGGACCAGATTGCTCTGGTGGAGAGGGGGGGCTGCTCCTTCCTCTCCAAGA  
CTCGGGTGGTCCAGGAGCACGGCGGGCGGGCGGTGATCATCTCTGACAACGCAGTTGACA  
ATGACAGCTTCTACGTGGAGATGATCCAGGACAGTACCCAGCGCACAGCTGACATCCCCG  
CCCTCTTCCTGCTCGGCCGAGACGGCTACATGATCCGCCGCTCTCTGGAACAGCATGGGC  
TGCCATGGGCCATCATTTCCATCCCAGTCAATGTCACCAGCATCCCCACCTTTGAGCTGC  
TGCAACCGCCCTGGACCTTCTGGTAGAAGAGTTTGTCCCACATTCCAGCCATAAGTGACT  
CTGAGCTGGGAAGGGGAAACCCAGGAATTTTGCTACTTGGAATTTGGAGATAGCATCTGG  
GGACAAGTGGAGCCAGGTAGAGGAAAAGGGTTTGGGCGTTGCTAGGCTGAAAGGGAAGCC  
ACACCACTGGCCTTCCCTTCCCCAGGGCCCCCAAGGGTGTCTCATGCTACAAGAAGAGGC  
AAGAGACAGGCCCCAGGGCTTCTGGCTAGAACCCGAAACAAAAGGAGCTGAAGGCAGGTG  
GCCTGAGAGCCATCTGTGACCTGTCACACTCACCTGGCTCCAGCCTCCCCTACCCAGGGT  
CTCTGCACAGTGACCTTCACAGCAGTTGTTGGAGTGGTTTAAAGAGCTGGTGTGTTGGGGA  
CTCAATAAACCTCACTGACTTTTTAGCAATAAAGCTTCTCATCAGGGTTGCAAAAAAAA  
AAAAAAAAAAAAAAAAAAAA

266/392

## FIGURE 256

MVPGAAGWCCLVLWLPAACVAAHGFRIDYLYFQVLSPGDIRYIFTATPAKDFGGIFHTRY  
EQIHLVPAEPPEACGELSNGFFIQDQIALVERGGCSFLSKTRVVQEHGGRAVIISDNAV  
NDSFYVEMIQDSTQRTADIPALFLLGRDGYMIRRSLEQHGLPWAIISIPVNVTSIPTFEL  
LQPPWTFW

signal peptide:  
amino acids 1-20

267/392

**FIGURE 257**

CTCGCTTCTTCCTTCTGGATGGGGGCCCAGGGGGCCCAGGAGAGTATAAAGGCGATGTGG  
AGGGTGCCCGGCACAACCAGACGCCCAGTCACAGGCGAGAGCCCTGGGATGCACCGGCCA  
GAGGCCATGCTGCTGCTGCTCACGCTTGCCCTCCTGGGGGGCCCCACCTGGGCAGGGAAG  
ATGTATGGCCCTGGAGGAGGCAAGTATTTTCAGCACCACTGAAGACTACGACCATGAAATC  
ACAGGGCTGCGGGTGTCTGTAGGTCTTCTCCTGGTGAAAAGTGTCAGGTGAAACTTGGA  
GACTCCTGGGACGTGAAACTGGGAGCCTTAGGTGGGAATACCCAGGAAGTCACCCTGCAG  
CCAGGCGAATACATCACAAAAGTCTTTGTGCGCTTCCAAGCTTTCCTCCGGGGTATGGTC  
ATGTACACCAGCAAGGACCGCTATTTCTATTTTGGGAAGCTTGATGGCCAGATCTCCTCT  
GCCTACCCAGCCAAGAGGGGCAGGTGCTGGTGGGCATCTATGGCCAGTATCAACTCCTT  
GGCATCAAGAGCATTGGCTTTGAATGGAATTATCCACTAGAGGAGCCGACCACTGAGCCA  
CCAGTTAATCTCACATACTCAGCAAACTCACCCGTGGGTGCTAGGGTGGGGTATGGGGC  
CATCCGAGCTGAGGCCATCTGTGTGGTGGTGGCTGATGGTACTGGAGTAACTGAGTCGGG  
ACGCTGAATCTGAATCCACCAATAAATAAGCTTCTGCAGAAAA

268/392

## FIGURE 258

MHRPEAML L L L L T L A L L G G P T W A G K M Y G P G G G K Y F S T T E D Y D H E I T G L R V S V G L L L V K S V Q  
V K L G D S W D V K L G A L G G N T Q E V T L Q P G E Y I T K V F V A F Q A F L R G M V M Y T S K D R Y F Y F G K L D G  
Q I S S A Y P S Q E G Q V L V G I Y G Q Y Q L L G I K S I G F E W N Y P L E E P T T E P P V N L T Y S A N S P V G R

Signal peptide:  
amino acids 1-22

269/392

**FIGURE 259**

CAGACATGGCTCAGTCACTGGCTCTGAGCCTCCTTATCCTGGTTCTGGCCTTTGGCATCC  
CCAGGACCCAAGGCAGTGATGGAGGGGCTCAGGACTGTTGCCTCAAGTACAGCCAAAGGA  
AGATTCCCGCCAAGGTTGTCCGCAGCTACCGGAAGCAGGAACCAAGCTTAGGCTGCTCCA  
TCCCAGCTATCCTGTTCTTGCCCCGCAAGCGCTCTCAGGCAGAGCTATGTGCAGACCCAA  
AGGAGCTCTGGGTGCAGCAGCTGATGCAGCATCTGGACAAGACACCATCCCCACAGAAAC  
CAGCCCAGGGCTGCAGGAAGGACAGGGGGGCCTCCAAGACTGGCAAGAAAGGAAAGGGCT  
CCAAAGGCTGCAAGAGGACTGAGCGGTCACAGACCCCTAAAGGGCCATAGCCCCAGTGAGC  
AGCCTGGAGCCCTGGAGACCCACCCAGCCTCACCAGCGCTTGAAGCCTGAACCCAAGATG  
CAAGAAGGAGGCTATGCTCAGGGGCCCTGGAGCAGCCACCCCATGCTGGCCTTGCCACAC  
TCTTTCTCCTGCTTTAACCACCCCATCTGCATTCCCAGCTCTACCCTGCATGGCTGAGCT  
GCCACAGCAGGCCAGGTCCAGAGAGACCGAGGAGGGAGAGTCTCCCAGGGAGCATGAGA  
GGAGGCAGCAGGACTGTCCCCTTGAAGGAGAATCATCAGGACCCTGGACCTGATACGGCT  
CCCCAGTACACCCACCTCTTCCTTGTAATATGATTTATACCTAACTGAATAAAAAGCT  
GTTCTGTCTTCCCNCCCA



270/392

## FIGURE 260

MAQSLALSLLILVLAFGIPRTQGS DGG A QDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIP  
AILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSK  
GCKRTERSQTPKGP

**Important features of the protein:**

**Signal peptide:**

amino acids 1-17

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 67-71

**N-myristoylation sites:**

amino acids 17-23, 23-29, 27-33, 108-114, 118-124, 121-127

**Amidation site:**

amino acids 112-116

**Small cytokines:**

amino acids 51-91

271/392

## FIGURE 261

GGGACTACAAGCCGCGCCGCGCTGCCGCTGGCCCCCTCAGCAACCCCTCGACATGGCGCTGA  
GGCGGCCACCGCGACTCCGGCTCTGCGCTCGGCTGCCTGACTTCTTCCTGCTGCTGCTTT  
TCAGGGGCTGCCTGATAGGGGCTGTAAATCTCAAATCCAGCAATCGAACCCCAAGTGGTAC  
AGGAATTTGAAAGTGTGGAAGTGTCTTGCATCATTACGGATTTCGAGACAAAGTGACCCCA  
GGATCGAGTGGAAGAAAATTCAAGATGAACAAACCACATATGTGTTTTTTTGACAACAAAA  
TTCAGGGGAGACTTGGCGGGTGTGTCAGAAATACTGGGGAAGACATCCCTGAAGATCTGGA  
ATGTGACACGGAGAGACTCAGCCCTTTATCGCTGTGAGGTCGTTGCTCGAAATGACCCGA  
AGGAAATTGATGAGATTGTGATCGAGTTAACTGTGCAAGTGAAGCCAGTGACCCCTGTCT  
GTAGAGTGCCGAAGGCTGTACCAGTAGGCAAGATGGCAACACTGCCTGCCAGGAGAGTG  
AGGGCCACCCCGGCCTCACTACAGCTGGTATCGCAATGATGTACCCTGCCACGGATT  
CCAGAGCCAATCCCAGATTTTCGAATTTCTTTTCCACTTAAACTCTGAAACAGGCACCTT  
TGGTGTTCACTGCTGTTTACAAGGACGACTCTGGGCAGTACTACTGCATTGCTTCCAATG  
ACGCAGGCTCAGCCAGGTGTGAGGAGCAGGAGATGGAAGTCTATGACCTGAACATTGGCG  
GAATTATTGGGGGGGTTCTGGTTGTCCTTGCTGTACTGGCCCTGATCACGTTGGGCATCT  
GCTGTGCATACAGACGTGGCTACTTCATCAACAATAAACAGGATGGAGAAAGTTACAAGA  
ACCCAGGGAACAGATGGAGTTAACTACATCCGCACTGACGAGGAGGGCGACTTCAGAC  
ACAAGTCATCGTTTGTGATCTGAGACCCGCGGTGTGGCTGAGAGCGCACAGAGCGCACGT  
GCACATACCTCTGCTAGAACTCCTGTCAAGGCAGCGAGAGCTGATGCACTCGGACAGAG  
CTAGACACTCATTGAGAAGCTTTTCGTTTTGGCCAAAGTTGACCACTACTCTTCTTACTC  
TAACAAGCCACATGAATAGAAGAATTTTCTCAAGATGGACCCGGTAAATATAACCACAA  
GGAAGCGAACTGGGTGCGTTCACTGAGTTGGGTTCTAATCTGTTTCTGGCCTGATTCC  
CGCATGAGTATTAGGGTGATCTTAAAGAGTTTGCTCACGTAAACGCCCGTGCTGGGCCCT  
GTGAAGCCAGCATGTTTACCCTGGTTCGTTTCAAGCAGCCACGACAGCACCATTGTGAGATGG  
CGAGGTGGCTGGACAGCACCAGCAGCGCATCCCGGCGGGAACCCAGAAAAGGCTTCTTAC  
ACAGCAGCCTTACTTCATCGGCCACAGACACCACCGCAGTTTCTTCTTAAAGGCTCTGC  
TGATCGGTGTTGCAAGTGTCCATTGTGGAGAAGCTTTTTTGGATCAGCATTTTGTAAAAACA  
ACCAAAATCAGGAAGGTAAATTGGTTGCTGGAAGAGGGATCTTGCTGAGGAACCTGCT  
TGTTCAACAGGGTGTGAGGATTTAAGGAAAACCTTCGTCTTAGGCTAAGTCTGAAATGGT  
ACTGAAATATGCTTTTCTATGGGTCTTGTATTTTATAAAATTTTACATCTAAATTTTT  
GCTAAGGATGTATTTGATTATTGAAAAGAAAATTTCTATTTAAACTGTAAATATATTGT  
CATACAATGTTAAATAACCTATTTTTTTTAAAAAAGTTCAACTTAAGGTAGAAGTTCCAAG  
CTACTAGTGTTAAATTTGAAAATATCAATAATTAAGAGTATTTTACCCAAGGAATCCTCT  
CATGGAAGTTTACTGTGATGTTCTTTTCTCACACAAGTTTATAGCCTTTTTTACAAGGGA  
ACTCATACTGTCTACACATCAGACCATAGTTGCTTAGGAAACCTTTAAAAATTCAGTTA  
AGCAATGTTGAAATCAGTTTGCATCTCTTCAAAGAAACCTCTCAGGTTAGCTTTGAACT  
GCCTCTTCTGAGATGACTAGGACAGTCTGTACCCAGAGGCCACCCAGAAGCCCTCAGAT  
GTACATACACAGATGCCAGTCAGCTCCTGGGGTTGCGCCAGGCGCCCCCGCTCTAGCTCA  
CTGTTGCCTCGCTGTCTGCCAGGAGGCCCTGCCATCCTTGGGCCCTGGCAGTGGCTGTGT  
CCCAGTGAGCTTTACTCACGTGGCCCTTGCTTCATCCAGCACAGCTCTCAGGTGGGCACT  
GCAGGGACACTGGTGTCTTCCATGTAGCGTCCCAGCTTTGGGCTCCTGTAACAGACCTCT  
TTTTGGTTATGGATGGCTCACAAAATAGGGCCCCCAATGCTATTTTTTTTTTTTAAAGTTT  
GTTTAATTATTTGTTAAGATTGTCTAAGGCCAAAGGCAATTGCGAAATCAAGTCTGTCAA  
GTACAATAACATTTTTTAAAAGAAAATGGATCCCAGTGTTCCTCTTTGCCACAGAGAAAGC  
ACCCAGACGCCACAGGCTCTGTGCGATTTCAAACAAACCATGATGGAGTGGCGGCCAGT  
CCAGCCTTTTAAAGAACGTGAGGTGGAGCAGCCAGGTGAAAGGCCTGGCGGGGAGGAAAG  
TGAAACGCCTGAATCAAAGCAGTTTTTCTAATTTTGACTTTAAATTTTTTCATCCGCCGGA

272/392

GACACTGCTCCCATTTGTGGGGGGACATTAGCAACATCACTCAGAAGCCTGTGTTCTTCA  
AGAGCAGGTGTTCTCAGCCTCACATGCCCTGCCGTGCTGGACTCAGGACTGAAGTGCTGT  
AAAGCAAGGAGCTGCTGAGAAGGAGCACTCCACTGTGTGCCTGGAGAATGGCTCTCACTA  
CTCACCTTGCTTTTCAGCTTCCAGTGTCTTGGGTTTTTTTATACTTTGACAGCTTTTTTTT  
AATTGCATACATGAGACTGTGTTGACTTTTTTTTAGTTATGTGAAACACTTTGCCGCAGGC  
CGCCTGGCAGAGGCAGGAAATGCTCCAGCAGTGGCTCAGTGCTCCCTGGTGTCTGCTGCA  
TGGCATCCTGGATGCTTAGCATGCAAGTTCCTCCATCATTGCCACCTTGGTAGAGAGGG  
ATGGCTCCCCACCCTCAGCGTTGGGGATTACGCTCCAGCCTCCTTCTTGGTTGTCATAG  
TGATAGGGTAGCCTTATTGCCCCCTCTTCTTATACCCTAAAACCTTCTACACTAGTGCCA  
TGGAACCAGGTCTGAAAAAGTAGAGAGAAGTGAAAGTAGAGTCTGGGAAGTAGCTGCCT  
ATAACTGAGACTAGACGGAAAAGGAATACTCGTGTATTTTAAGATATGAATGTGACTCAA  
GACTCGAGGCCGATACGAGGCTGTGATTCTGCCTTTGGATGGATGTTGCTGTACACAGAT  
GCTACAGACTTGTAATAACACACCGTAATTTGGCATTGTGTTAACCTCATTTATAAAAGC  
TTCAAAAAAACCA

273/392

**FIGURE 262**

MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT  
SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLSKIWNVTRRDSALYRCEVVAR  
NDRKEIDEIVIELTVQVKPVPVPCRVPKAVPVGKMATLHCQSEGHPRPHYSWYRNDVPL  
PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVDL  
NIGGIIGGVLVVLAVLALITLGICCAYYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG  
DFRHKSSFVI

**Important features of the protein:****Signal peptide:**

amino acids 1-30

**Transmembrane domain:**

amino acids 243-263

**N-glycosylation sites:**

amino acids 104-107, 192-195

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 107-110

**Casein kinase II phosphorylation site:**

amino acids 106-109, 296-299

**Tyrosine kinase phosphorylation site:**

amino acids 69-77

**N-myristoylation sites:**

amino acids 26-31, 215-220, 226-231, 243-248, 244-249, 262-267

274/392

## FIGURE 263

CCAGGACCAGGGCGCACCGGCTCAGCCTCTCACTTGTGAGAGGCCGGGGAAGAGAAGCAA  
AGCGCAACGGTGTGGTCCAAGCCGGGGCTTCTGCTTCGCCTCTAGGACATACACGGGACC  
CCCTAACTTCAGTCCCCCAAACGCGCACCCCTCGAAGTCTTGAACTCCAGCCCCGCACATC  
CACGCGCGGCACAGGCGCGGCAGGCGGCAGGTCCCGGCCGAAGGCGATGCGCGCAGGGGG  
TCGGGCAGCTGGGCTCGGGCGGCGGGAGTAGGGCCCCGGCAGGGAGGCAGGGAGGCTGCAT  
ATTCAGAGTCGCGGGCTGCGCCCTGGGCAGAGGCCGCCCTCGCTCCACGCAACACCTGCT  
GCTGCCACCGCGCCGCGATGAGCCGCGTGGTCTCGCTGCTGCTGGGCGCCGCGCTGCTCT  
GCGGCCACGGAGCCTTCTGCCGCCGCGTGGTCAGCGGCCAAAAGGTGTGTTTTGCTGACT  
TCAAGCATCCCTGCTACAAAATGGCCTACTTCCATGAACTGTCCAGCCGAGTGAGCTTTC  
AGGAGGCACGCCTGGCTTGTGAGAGTGAGGGAGGAGTCCTCCTCAGCCTTGAGAATGAAG  
CAGAACAGAAGTTAATAGAGAGCATGTTGCAAAACCTGACAAAACCCGGGACAGGGATTT  
CTGATGGTGATTTCTGGATAGGGCTTTGGAGGAATGGAGATGGGCAAACATCTGGTGCCCT  
GCCCAGATCTCTACCAGTGGTCTGATGGAAGCAATTCCAGTACCGAAACTGGTACACAG  
ATGAACCTTCCCTGCGGAAGTGAAAAGTGTGTTGTGATGTATCACCAACCAACTGCCAATC  
CTGGCCTTGGGGGTCCCTACCTTTACCAGTGGAAATGATGACAGGTGTAACATGAAGCACA  
ATTATATTTGCAAGTATGAACCAGAGATTAATCCAACAGCCCCTGTAGAAAAGCCTTATC  
TTACAAATCAACCAGGAGACACCCATCAGAATGTGGTTGTTACTGAAGCAGGTATAATTC  
CCAATCTAATTTATGTTGTTATAACCAACAATACCCCTGCTCTTACTGATACTGGTTGCTT  
TTGGAACCTGTTGTTTCCAGATGCTGCATAAAAAGTAAAGGAAGAACAAAAACTAGTCCAA  
ACCAGTCTACACTGTGGATTTCAAAGAGTACCAGAAAAGAAAGTGGCATGGAAGTATAAT  
AACTCATTTGACTTGGTTCCAGAATTTTGTAATTTCTGGATCTGTATAAGGAATGGCATCAG  
AACAATAGCTTGGAAATGGCTTGAAATCACAAGGATCTGCAAGATGAACTGTAAGCTCCC  
CCTTGAGGCAAATATTAAAGTAATTTTATATGTCTATTATTTTATTAAAGAATATGCT  
GTGCTAATAATGGAGTGAGACATGCTTATTTTGCTAAAGGATGCACCCAAACTTCAAAC  
TCAAGCAAATGAAATGGACAATGCAGATAAAGTTGTTATCAACACGTCGGGAGTATGTGT  
GTTAGAAGCAATTCCTTTTATTTCTTTCACCTTTCATAAGTTGTTATCTAGTCAATGTAA  
TGTATATTGTATTGAAATTTACAGTGTGCAAAAGTATTTTACCTTTGCATAAGTGTGTTGA  
TAAAAATGAACTGTTCTAATATTTATTTTTATGGCATCTCATTTTTCAATACATGCTCTT  
TTGATTAAAGAACTTATTACTGTTGTCAACTGAATTCACACACACACAAATATAGTACC  
ATAGAAAAAGTTTGTTTTCTCGAAATAATTCATCTTTCAGCTTCTCTGCTTTTGGTCAAT  
GTCTAGGAAATCTCTTCAGAAATAAGAAGCTATTTTATTAAAGTGTGATATAAACCTCCTC  
AAACATTTTACTTAGAGGCAAGGATTGTCTAATTTCAATTGTGCAAGACATGTGCCTTAT  
AATTATTTTACTTAAATTTAAACAGATTTTGTAAATAATGTAACCTTGTAAATAGGTGC  
ATAAACACTAATGCAGTCAATTTGAACAAAAGAGTGACATACACAATATAAATCATATG  
TCTTCACACGTTGCCTATATAATGAGAAAGCAGCTCTCTGAGGGTTCTGAAATCAATGTGG  
TCCCTCTCTTGCCCACTAAACAAAGATGGTTGTTTCGGGGTTTGGGATTGACACTGGAGGC  
AGATAGTTGCAAAGTTAGTCTAAGGTTTCCCTAGCTGTATTTAGCCTCTGACTATATTAG  
TATACAAAGAGGTCATGTGGTTGAGACCAGGTGAATAGTCACTATCAGTGTGGAGACAAG  
CACAGCACACAGACATTTTAGGAAGGAAAGGAACCTACGAAATCGTGTGAAAATGGGTG  
AACCACATCAGTGATCGCATATTCATTGATGAGGGTTTGCTTGAGATAGAAAATGGTGGCT  
CCTTTCTGTCTTATCTCCTAGTTTCTTCAATGCTTACGCCTTGTTCCTCTCAAGAGAAAG  
TTGTAACCTCTGCTGCTTCATATGTCCCTGTGCTCCTTTTAACCAATAAAGAGTCTTG  
TTTCTGGGGGAAA

275/392

**FIGURE 264**

MSRVVSLLLGAALLCGHGAFRRVVSQKVCFAFDKHPCKMAYFHELSSRVSFQEARLA  
CESEGGVLLSLENEAEQKLIESMLQNLTKPGTGISDGDGFWIGLWRNGDGQTSACPDLYQ  
WSDGSNSQYRNWYTDEPSCGSEKCVVMYHQPTANPGLGGPYLYQWDDRCNMKHNYICKY  
EPEINPTAPVEKPYLTNQPQDTHQNVVVTEAGIIPNLIYVVIPTIPLLLLILVAFGTCCF  
QMLHKSKGRTKTSPNQSTLWISKSTRKESGMEV

**Important features of the protein:****Signal peptide:**

amino acids 1-21

**Transmembrane domain:**

amino acids 214-235

**N-glycosylation sites:**

amino acids 86-89 and 255-258

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 266-269

**N-myristoylation sites:**

amino acids 27-32, 66-71, 91-96, 93-98, 102-107, 109-114, 140-145 and 212-217

276/392

**FIGURE 265**

GGAGAATGGAGAGAGCAGTGAGAGTGGAGTCCGGGGTCTGGTTCGGGGTGGTCTGTCTGC  
TCCTGGCATGCCCTGCCACAGCCACTGGGCCCCGAAGTTGCTCAGCCTGAAGTAGACACCA  
CCCTGGGTCTGTGCGAGGCCGGCAGGTGGGCGTGAAGGGCACAGACCGCCTTGTGAATG  
TCTTTCTGGGCATTCCATTTGCCAGCCGCCACTGGGCCCCTGACCGTTCTCAGCCCCAC  
ACCCAGCACAGCCCTGGGAGGGTGTGCGGGATGCCAGCACTGCGCCCCCAATGTGCCTAC  
AAGACGTGGAGAGCATGAACAGCAGCAGATTTGTCTCAACGGAAAACAGCAGATCTTCT  
CCGTTTCAGAGGACTGCCTGGTCTCAACGTCTATAGCCCAGCTGAGGTCCCCGCGAGGGT  
CCGGTAGGCCGGTTCATGGTATGGGTCCATGGAGGCGCTCTGATAACTGGCGCTGCCACCT  
CCTACGATGGATCAGCTCTGGCTGCCTATGGGGATGTGGTTCGTGGTTACAGTCCAGTACC  
GCCTTGGGGTCTTGGCTTCTTCAGCACTGGAGATGAGCATGCACCTGGCAACCAGGGCT  
TCCTAGATGTGGTAGCTGCTTTGCGCTGGGTGCAAGAAAACATCGCCCCCTTCGGGGGTG  
ACCTCAACTGTGTCACTGTCTTTGGTGGATCTGCCGGTGGGAGCATCATCTCTGGCCTGG  
TCCTGTCCCCAGTGGCTGCAGGGCTGTTCCACAGAGCCATCACACAGAGTGGGTTCATCA  
CCACCCAGGGATCATCGACTCTCACCTTGGCCCCCTAGCTCAGAAAATCGCAAACACCT  
TGGCCTGCAGCTCCAGCTCCCCGGCTGAGATGGTGCAGTGCCTTCAGCAGAAAGAAGGAG  
AAGAGCTGGTCTTAGCAAGAAGCTGAAAAATACTATCTATCCTCTCACCGTTGATGGCA  
CTGTCTTCCCCAAAAGCCCCAAGGAACCTCCTGAAGGAGAAGCCCTTCCACTCTGTGCCCT  
TCCTCATGGGTGTCAACAACCATGAGTTCAGCTGGCTCATCCCCAGGGGTGGGTCTCC  
TGGATACAATGGAGCAGATGAGCCGGGAGGACATGCTGGCCATCTCAACACCCGTCTTGA  
CCAGTCTGGATGTGCCCCCTGAGATGATGCCACCGTCATAGATGAATACCTAGGAAGCA  
ACTCGGACGCACAAGCCAAATGCCAGGCGTTCCAGGAATTCATGGGTGACGTATTCATCA  
ATGTTCCACCGTCAGTTTTTTCAAGATACCTTCGAGATTCTGGAAGCCCTGTCTTTTTCT  
ATGAGTTCCAGCATCGACCCAGTTCCTTTGCGAAGATCAAACCTGCCTGGGTGAAGGCTG  
ATCATGGGGCCGAGGGTGTCTTTGTGTTTCGGAGGTCCCTTCCTCATGGACGAGAGCTCCC  
GCCTGGCCTTTCCAGAGGCCACAGAGGAGGAGAAGCAGCTAAGCCTCACCATGATGGCCC  
AGTGGACCCACTTTGCCCGGACAGGGGACCCCAATAGCAAGGCTCTGCCTCCTTGGCCCC  
AATTCAACCAGGCGGAACAATATCTGGAGATCAACCCAGTGCCACGGGCCGGACAGAAGT  
TCAGGGAGGCCTGGATGCAGTTCTGGTCAGAGACGCTCCCCAGCAAGATACAACAGTGGC  
ACCAGAAGCAGAAGAACAGGAAGGCCAGGAGGACCTCTGAGGCCAGGCCTGAACCTTCT  
TGGCTGGGGCAAACCACTCTTCAAGTGGTGGCAGAGTCCCAGCACGGCAGCCCGCCTCTC  
CCCCTGCTGAGACTTTAATCTCCACCAGCCCTTAAAGTGTGCGCCGCTCTGTGACTGGAG  
TTATGCTCTTTTGAAATGTACAAGGCCGCTCCACCTCTGGGGCATTTGTACAAGTTCT  
TCCCTCTCCCTGAAGTGCCTTTCTGCTTTCTCGTGGTAGGTTCTAGCACATTCTCTA  
GCTTCCTGGAGGACTCACTCCCCAGGAAGCCTTCCCTGCCTTCTCTGGGCTGTGCGGCC  
CGAGTCTGCGTCCATTAGAGCACAGTCCACCCGAGGCTAGCACCGTGTCTGTGTCTGTCT  
CCCCCTCAGAGGAGCTCTCTCAAATGGGGATTAGCCTAACCCCACTCTGTCACCACAC  
CAGGATCGGGTGGGACCTGGAGCTAGGGGGTGTGTTGCTGAGTGAGTGAGTGAAACACAGA  
ATATGGGAATGGCAGCTGCTGAACCTGAACCCAGAGCCTTCAGGTGCCAAAGCCATACTC  
AGGCCCCCACCACATTGTCCACCCTGGCCAGAAGGGTGCATGCCAATGGCAGAGACCTG  
GGATGGGAGAAGTCTGGGGCGCCAGGGGATCCAGCCTAGAGCAGACCTTAGCCCCCTGAC  
TAAGGCCCTCAGACTAGGGCGGGAGGGTCTCCTCTCTGCTGCCAGTCTCTGGCCCCCT  
GCACAAGACAACAGAATCCATCAGGGCCATGAGTGTCAACCCAGACCTGACCCCTACCAAT  
TCCAGCCCCCTGACCCTCAGGACGCTGGATGCCAGCTCCAGCCCCAGTGCCGGGTCTCTCC  
CTCCCTTCCTGGCTTGGGGAGACCAGTTTCTGGGGAGCTTCCAAGAGCACCCACCAAGAC  
ACAGCAGGACAGGCCAGGGGAGGGCATCTGGACCAGGGCATCCGTGCGGCTATTGTACA  
GAGAAAAGAAGAGACCCACCCACTCGGGCTGCAAAAGGTGAAAAGCACCAAGAGGTTTTCT

277/392

AGATGGAAGTGAGAGGTGACAGTGTGCTGGCAGCCCTCACAGCCCTCGCTTGCTCTCCCT  
GCCGCCTCTGCCTGGGCTCCCACTTTGGCAGCACTTGAGGAGCCCTTCAACCCGCCGCTG  
CACTGTAGGAGCCCTTTCTGGGCTGGCCAAGGCCGGAGCCAGCTCCCTCAGCTTGCGGG  
GAGGTGCGGAGGGAGAGGGGCGGGCAGGAACCGGGGCTGCGCGCAGCGCTTGCGGGCCAG  
AGTGAGTTCGGGTGGGCGTGGGCTCGGCGGGGCCCCACTCAGAGCAGCTGGCCGGCCCC  
AGGCAGTGAGGGCCTTAGCACCTGGGCCAGCAGCTGCTGTGCTCGATTTCTCGCTGGGCC  
TTAGCTGCCTCCCCGCGGGCAGGGCTCGGGACCTGCAGCCCTCCATGCCTGACCCTCCC  
CCCACCCCCCGTGGGCTCCTGTGCGGCCGGAGCCTCCCCAAGGAGCGCCGCCCTTGCTC  
CACAGCGCCCAGTCCCATCGACCACCAAGGGCTGAGGAGTGCGGGTGCACAGCGCGGGA  
CTGGCAGGCAGCTCCACCTGCTGCCCCAGTGCTGGATCCACTGGGTGAAGCCAGCTGGGC  
TCCTGAGTCTGGTGGGGACTTGGAGAACCTTTATGTCTAGCTAAGGGATTGTAAATACAC  
CGATGGGCACTCTGTATCTAGCTCAAGGTTTGTAAACACACCAATCAGCACCCTGTGTCT  
AGCTCAGTGTTTGTGAATGCACCAATCCACACTCTGTATCTGGCTACTCTGGTGGGGACT  
TGGAGAACCTTTGTGTCCACACTCTGTATCTAGCTAATCTAGTGGGGATGTGGAGAACCT  
TTGTGTCTAGCTCAGGGATCGTAAACGCACCAATCAGCACCCTGTCAAAACAGACCACTT  
GACTCTCTGTAAAATGGACCAATCAGCAGGATGTGGGTGGGGCGAGACAAGAGAATAAAA  
GCAGGCTGCCTGAGCCAGCAGTGACAACCCCCCTCGGGTCCCCTCCCACGCCGTGGAAGC  
TTTGTTCCTTCGCTCTTTGCAATAAATCTTGCTACTGCCCAAAA



278/392

**FIGURE 266**

MERAVRVESGVLVGVVCLLLACPATATGPEVAQPEVDTTLGRVRGRQVGVKGTDRLVNVF  
LGIPFAQPPLGPD RFSAPHPAQPWEGVRDASTAPPMCLQDVESMNSSRFVLNGKQQIFSV  
SEDCVLNVYSPA EVPAGSGRPVMVWVHGGALITGAATSYDGSALAAYGDVVVTVQYRL  
GVLGFFSTGDEHAPGNQGF LDVVAALRWVQENIAPFGGDLNCVTVFGGSAGGSIISGLVL  
SPVAAGLFHRAITQSGVITTPGIIDSHPWPLAQKIAN TLACSSSSPAEMVQCLQQKEGEE  
LVLSKKLKNTIYPLTVDGTVPKSPKELLKEKPFHSPFLMGVNNHEFSWLI PRGWGLLD  
TMEQMSREDMLAISTPVLTS LDVPPPEMMPTVIDEYLGSN SDAQAKCQAFQEFMGDVFINV  
PTVSFSRYLRDSGSPVFFYEFQHRPSSF AKIKPAWVKADHGAEGAFVFGGPFLMDESSRL  
AFPEATEEEKQLSLTMAQWTHFARTGDPNSKALPPWPQFNQAEQYLEINPVPRAGQKFR  
EAWMQFWSETLPSKIQQWHQKQKNRKAQEDL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-27

**Transmembrane domain:**

amino acids 226-245

**N-glycosylation site:**

amino acids 105-109

**N-myristoylation sites:**

amino acids 10-16, 49-55, 62-68, 86-92, 150-156, 155-161,  
162-168, 217-223, 227-233, 228-234, 232-238, 262-268, 357-363,  
461-467

**Prokaryotic membrane lipoprotein lipid attachment site:**

amino acids 12-23

**Carboxylesterases type-B serine active site:**

amino acids 216-232

279/392

**FIGURE 267**

TGTCGCCTGGCCCTCGCCATG CAGACCCCGGAGCGTCCCCCTCCCCGCCCGGCCCTCCTG  
CTTCTGCTGCTGCTACTGGGGGGCGCCACGGCCTCTTTCCTGAGGAGCCGCCGCCGCTT  
AGCGTGGCCCCCAGGGACTACCTGAACCACTATCCCGTGTTTGTGGGCAGCGGGCCCGGA  
CGCCTGACCCCCCGAGAAGGTGCTGACGACCTCAACATCCAGCGAGTCCTGCGGGTCAAC  
AGGACGCTGTTTATTGGGGACAGGGACAACCTCTACCGCGTAGAGCTGGAGCCCCCAGC  
TCCACGGAGCTGCGGTACCAGAGGAAGCTGACCTGGAGATCTAACCCAGCGACATAAAC  
GTGTGTCGGATGAAGGGCAAACAGGAGGGCGAGTGTCGAAACTTCGTAAAGGTGCTGCTC  
CTTCGGGACGAGTCCACGCTCTTTGTGTGCGGTTCCAACGCCTTCAACCCGGTGTGCGCC  
AACTACAGCATAGACACCCTGCAGCCCGTCGGAGACAACATCAGCGGTATGGCCCGCTGC  
CCGTACGACCCCAAGCACGCCAATGTTGCCCTCTTCTCTGACGGGATGCTCTTACAGCT  
ACTGTTACCGACTTCCTAGCCATTGATGCTGTCTATCTACCGCAGCCTCGGGGACAGGCC  
ACCCTGCGCACCGTGAAACATGACTCCAAGTGGTTCAAAGAGCCTTACTTTGTCCATGCG  
GTGGAGTGGGGCAGCCATGTCTACTTCTTCTTCCGGGAGATTGCGATGGAGTTTAACTAC  
CTGGAGAAGGTGGTGGTGTCCCGCGTGGCCCGAGTGTCGAAGAAGCAGCTGGGAGGCTCC  
CCCCGCGTGCTGGAGAAGCAGTGGACGTCCTTCTGAAGGCGCGGCTCAACTGCTCTGTA  
CCCGGAGACTCCCATTTCTACTTCAACGTGCTGCAGGCTGTACGGGCGTGGTCAGCCTC  
GGGGGCCCGGCCGCTGGTCCCTGGCCGTTTTTTCCACGCCCAGCAACAGCATCCCTGGCTCG  
GCTGTCTGCGCCTTTGACCTGACACAGGTGGCAGCTGTGTTTGAAGGCCGCTTCCGAGAG  
CAGAAGTCCCCGAGTCCATCTGGACGCCGGTGCCGGAGGATCAGGTGCCTCGACCCCGG  
CCCGGGTGCTGCGCAGCCCCCGGGATGCAGTACAATGCCTCCAGCGCCTTGCCGGATGAC  
ATCCTCAACTTTGTCAAGACCCACCCTCTGATGGACGAGGCGGTGCCCTCGCTGGGCCAT  
GCGCCCTGGATCCTGCGGACCCTGATGAGGCACAGCTGACTCGAGTGGCTGTGGACGTG  
GGAGCCGGCCCCCTGGGGCAACCAGACCGTTGTCTTCTGGGTTCTGAGGCGGGGACGGTC  
CTCAAGTTCTCTCGTCCGGCCCAATGCCAGCACCTCAGGGACGCTGGGCTCAGTGTCTTC  
CTGGAGGAGTTTGTAGACCTACCGGCCGGACAGGTGTGGACGGCCCGCGGCTGGCGAGACA  
GGGAGCGGCTGCTGAGCTTGGAGCTGGACGCAGCTTCCGGGGGCCCTGCTGGCTGCCTTC  
CCCCGTGCGTGGTCCGAGTGCCTGTGGCTCGCTGCCAGCAGTACTCGGGGTGTATGAAG  
AACTGTATCGGCAGTCAGGACCCCTACTGCGGGTGGGCCCCGACGGCTCCTGCATCTTC  
CTCAGCCCGGGCACCAGAGCCGCCTTTGAGCAGGACGTGTCCGGGGCCAGCACCTCAGGC  
TTAGGGGACTGCACAGGACTCCTGCGGGCCAGCCTCTCCGAGGACCGCGCGGGGCTGGTG  
TCGGTGAACCTGCTGGTAACGTGCTGCGTGGCGGCCTTCGTGGTGGGAGCCGTGGTGTCC  
GGCTTCAGCGTGGGCTGGTTGCTGGGCCTCCGTGAGCGGCGGGAGCTGGCCCGGCGCAAG  
GACAAGGAGGCCATCCTGGCGCACGGGGCGGGCGAGGCGGTGCTGAGCGTCAGCCGCTG  
GGCGAGCGCAGGGCGCAGGGTCCCGGGGGCCGGGGCGGAGGCGGTGGCGGTGGCGCCGGG  
GTTCCCCCGGAGGCCCTGCTGGCGGCCCTGATGCAGAACGGCTGGGCCAAGGCCACGCTG  
CTGCAGGGCGGGCCCCACGACCTGGACTCGGGGCTGCTGCCACGCCCGAGCAGACGCCG  
CTGCCGCAGAAGCGCCTGCCACTCCGCACCCGCACCCCCACGCCCTGGGCCCCCGCGCC  
TGGGACCACGGCCACCCCCTGCTCCCGGCCCTCCGCTTCATCCTCCCTCCTGCTGCTGGCG  
CCCGCCCCGGCCCCCGAGCAGCCCCCGCGCCTGGGGAGCCGACCCCCGACGGCCGCTC  
TATGCTGCCCCGGCCCCGGCCGCGCCTCCACGGCGACTTCCCGCTCACCCCCACGCCAGC  
CCGGACCGCCGGCGGGTGGTGTCCGCGCCACGGGCCCTTGGACCCAGCCTCAGCCGCC  
GATGGCCTCCCGCGGCCCTGGAGCCCGCCCCGACGGGACGCTGAGGAGGCCACTGGGC  
CCCCACGCCCCCTCCGGCCGCCACCCTGCGCCGCACCCACACGTTCAACAGCGGCGAGGCC  
CGGCCTGGGGACCGCCACCGCGGCTGCCACGCCCCGGCCGGGCACAGACTTGGCCACCTC  
CTCCCCCTATGGGGGGGCGGACAGGACTGCGCCCCCGTGCCCTAGGCGGGGGCCCCCGG  
ATGCCTTGGCAGTGCCAGCCACGGGAACCAGGAGCGAGAGACGGTGCCAGAACGCCGGGG  
CCCGGGGCAACTCCGAGTGGGTGCTCAAGTCCCCCCCCGCGACCCACCCGCGGAGTGGGGG

280/392

GCCCCCTCCGCCACAAGGAAGCACAACCAGCTCGCCCTCCCCCTACCCGGGGCCGCAGGA  
CGCTGAGACGGTTTGGGGGTGGGTGGGCGGGAGGACTTTGCTATGGATTTGAGGTTGACC  
TTATGCGCGTAGGTTTTGGTTTTTTTTTGCAGTTTTTGGTTTCTTTTGCGGTTTTCTAACC  
AATTGCACAACCTCCGTTCTCGGGGTGGCGGCAGGCAGGGGAGGCTTGACGCCGGTGGGG  
AATGGGGGGCCACAGCTGCAGACCTAAGCCCTCCCCACCCCTGGAAAGGTCCCTCCCCA  
ACCCAGGCCCCCTGGCGTGTGTGGGTGTGCGTGCGTGTGCGTGCCGTGTTCTGTGTGCAAGG  
GGCCGGGGAGGTGGGCGTGTGTGTGCGTGCCAGCGAAGGCTGCTGTGGGCGTGTGTGTCA  
AGTGGGCCACGCGTGCAGGGTGTGTGTCCACGAGCGACGATCGTGGTGGCCCCAGCGGCC  
TGGGCGTTGGCTGAGCCGACGCTGGGGCTTCCAGAAGGCCCGGGGTCTCCGAGGTGCCG  
GTTAGGAGTTTGAACCCCCCCCCACTCTGCAGAGGGAAGCGGGGACAATGCCGGGGTTTCA  
GGCAGGAGACACGAGGAGGGCCTGCCCCGGAAGTCACATCGGCAGCAGCTGTCTAAAGGC  
TTGGGGGCTGGGGGGCGGCGAAGGTGGGTGGGGCCCCCTCTGTAAATACGGCCCCAGGGT  
GGTGAGAGAGTCCCATGCCACCCGTCCCCCTTGTGACCTCCCCCTATGACCTCCAGCTGA  
CCATGCATGCCACGTGGCTGGCTGGGTCTCTGCCCTCTTTGGAGTTTGCCTCCCCCAGC  
CCCCTCCCCATCAATAAACTCTGTTTACAACCAAAAAAAAAAAAAAAAAAAAAAAAAA

281/392

**FIGURE 268**

MQTPRASPPRPALLLLLLLLGGAGHLFPPEPPPLSVAPRDYLNHYPVFVVGSGPGRLLTPAE  
GADDLNIQRVLRVNRTLFIGDRDNLRYVELEPPTSTELRYQRKLTWRSNPSDINVCRMKG  
KQEGECRNFKVLLLRDESTLFVCGSNAFNPVCANYSIDTLQPVGDNISGMARCPYDPKH  
ANVALFSDGMLFTATVTDFLAIDAVIYRSLGDRPTLRTVKHDSKWFKEPYFVHAVEWGS  
VYFFFREIAMEFNYLEKVVVSRVARVCKNDVGGSPRVLEKQWTSFLKARLNCSVPGDSHF  
YFNVLQAVTGVSLSGGRPVVLAVFSTPSNSIPGSAVCAFDLTQVAAVFEGRFREQKSPES  
IWTPVPEDQVPRPRPGCCAAPGMQYNASSALPDDILNFVKTHPLMDEAVPSLGHAPWILR  
TLMRHQLTRVAVDVGAGPWGNQTVVFLGSEAGTVLKFLVRPNASTSGTSGLSVFLEEFET  
YRPDRCGRPGGGGETGQRLLSLELDAASGGLLAAPRCVVRVPVARCQQYSGCMKNCIGSQ  
DPYCGWAPDGSCIFLSPGTRAAFEQDVSGASTSGLGDCTGLLRASLSEDRAGLVSVNLLV  
TSSVAAFVVGAVVSGFSVGWVGLRERRELARRKDKEAILAHGAGEAVLSVSRLGERRAQ  
GPGGRGGGGGGGAGVPPEALLAPLMQNGWAKATLLQGGPHDLDSGLLPTPEQTPLPQKRL  
PTPHPHPHALGPRAWDHGHPLLPASASSSLLLLAPARAPEQPPAPGEPTPDGRLYAARPG  
RASHGDFPLTPHASPDRRRVVSAPTGPLDPASAADGLPRPWSPPPTGSLRRPLGPHAPPA  
ATLRRTHTFNSGEARPGDRHRGCHARPGTDLAHLPLPYGGADRTAPPVP

**Important features of the protein:****Signal peptide:**

amino acids 1-25

**Transmembrane domains:**

amino acids 318-339, 598-617

**N-glycosylation sites.**amino acids 74-78, 155-159, 167-171, 291-295, 386-390,  
441-445, 462-466**Glycosaminoglycan attachment sites:**

amino acids 51-55, 573-577

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 102-106

**N-myristoylation sites:**amino acids 21-27, 50-56, 189-195, 333-339, 382-388, 448-454,  
490-496, 491-497, 508-514, 509-515, 531-537, 558-564, 569-575,  
574-580, 580-586, 610-616, 643-649, 663-669, 666-672, 667-673,  
668-674, 669-675, 670-676, 868-874, 879-885

282/392

**FIGURE 269**

ATCTGAGTGAGCTAACTGACACAATGAACTGTCAGGCATGTTTCTGCTCCTCTCTCTGG  
CTCTTTTCTGCTTTTAAACAGGTGTCTTCAGTCAGGGAGGACAGGTTGACTGTGGTGAGT  
TCCAGGACCCCAAGGTCTACTGCACTCGGGAATCTAACCACACTGTGGCTCTGATGGCC  
AGACATATGGCAATAAATGTGCCTTCTGTAAGGCCATAGTGAAAAGTGGTGGAAAGATTA  
GCCTAAAGCATCCTGGAAAATGCTGAGTTAAAGCCAATGTTTCTTGGTGACTTGCCAGCT  
TTTGCAGCCTTCTTTTCTCACTTCTGCTTATACTTTTGCTGGTGGATTCTTTAATTCAT  
AAAGACATACCTACTCTGCCTGGGTCTTGAGGAGTTCAATGTATGTCTATTTCTCTTGAT  
TCACTTGTCAATAAAGTACATTCTGCAAAAGCAAAAA

283/392

## FIGURE 270

MKLSGMFLLLSLALFCFLTGVFSQGGQVDCGEFQDPKVYCTRESNPFCGSDGQTYGNKCA  
FCKAIVKSGGKISLKHPGKC

**Important features of the protein:**

**Signal peptide:**

amino acids 1-23

**N-myristoylation sites:**

amino acids 26-32, 52-58, 56-62, 69-75

**Kazal serine protease inhibitors family signature:**

amino acids 40-63

284/392

**FIGURE 271**

AACTTCTACATGGGCCTCCTGCTGCTGGTGCTCTTCCTCAGCCTCCTGCCGGTGGCCTAC  
ACCATCATGTCCCTCCCACCCTCCTTTGACTGCGGGCCGTTCAAGTGCAGAGTCTCAGTT  
GCCCCGGGAGCACCTCCCCTCCCAGGCAGTCTGCTCAGAGGGCCTCGGCCCAGAATTCCA  
GTTCTGGTTTTCATGCCAGCCTGTAAAAGGCCATGGAACTTTGGGTGAATCACCGATGCCA  
TTTAAGAGGGTTTTCTGCCAGGATGGAAATGTTAGGTCGTTCTGTGTCTGCGCTGTTTTCAT  
TTCAGTAGCCACCAGCCACCTGTGGCCGTTGAGTGCTTGAAATGAGGAACTGAGAAAAATT  
AATTTCTCATGTATTTTTTCTCATTTATTTATTAATTTTTTAAGTATAGTTGTACATATTT  
GGGGGTACATGTGATATTTGGATACATGTATACAATATATAATGATCAAATCAGGGTAAC  
TGGGATATCCATCACATCAAACATTTATTTTTTATTCTTTTTAGACAGAGTCTCACTCTG  
TCACCCAGGCTGGAGTGCAGTGGTGCCATCTCAGCTTACTGCAACCTCTGCCTGCCAGGT  
TCAAGCGATTCTCATGCCTCCACCTCCCAAGTAGCTGGGACTACAGGCATGCACCACAAT  
GCCCCAACTAATTTTTTGATTTTTTAGTAGAGACGGGGTTTTGCCATGTTGCCCAGGCTGGC  
CTTGAACCTCCTGGCCTCAAACAATCCACTTGCCCTCGGCCTCCCAAAGTGTTATGATTACA  
GGCGTGAGCCACCGTGCCTGGCCTAAACATTTATCTTTTCTTTGTGTTGGGAACTTTGAA  
ATTATACAATGAATTATTGTTAACTGTCTATCTCCCTGCTGTGCTATGGAACACTGGGACT  
TCTTCCCTCTATCTAACTGTATATTGTACCAGTTAACCAACCGTACTTCATCCCCACTC  
CTCTCTATCCTTCCCAACCTCTGATCACCTCATTCTACTCTCTACCTCCATGAGATCCAC  
TTTTTTAGCTCCCACATGTGAGTAAGAAAATGCAATATTTGTCTTTCTGTGCCTGGCTTA  
TTTCACTTAACATAATGACTTCCTGTTCCATCCATGTTGCTGCAAATGACAGGATTTTCGT  
TCTTAATTTCAATTAAAATAACCACACATGGCAAAAA

285/392

## FIGURE 272

MGLLLLVLFLSLLPVAYTIMSLPPSFDCGPFRCRVSVAREHLPSRGSLLRGPRPRIPLV  
SCQPVKGHGTLGESPMPPFKRVFCQDGNVRSFCVCAVHFSSHQPPVAVECLK

Important features of the protein:

Signal peptide:

amino acids 1-18

N-myristoylation site:

amino acids 86-92

Zinc carboxypeptidases, zinc-binding region 2 signature:

amino acids 68-79



286/392

## FIGURE 273

TTCTGAAGTAACGGAAGCTACCTTGTATAAAGACCTCAACACTGCTGACCATGATCAGCG  
CAGCCTGGAGCATCTTCCTCATCGGGACTAAAATTGGGCTGTTCCCTTCAAGTAGCACCTC  
TATCAGTTATGGCTAAATCCTGTCCATCTGTGTGTCGCTGCGATGCGGGTTTCATTTACT  
GTAATGATCGCTTTCTGACATCCATTCCAACAGGAATACCAGAGGATGCTACAACCTCTCT  
ACCTTCAGAACAACCAAATAAATAATGCTGGGATTCCCTTCAGATTTGAAAACTTGCTGA  
AAGTAGAAAAGATATAACCTATACCACAACAGTTTAGATGAATTTCCCTACCAACCTCCCAA  
AGTATGTAAAAGAGTTACATTTGCAAGAAAATAACATAAGGACTATCACTTATGATTACAC  
TTTCAAAAATTCCCTATCTGGAAGAATTACATTTAGATGACAACCTCTGTCTCTGCAGTTA  
GCATAGAAGAGGGAGCATTCGAGACAGCAACTATCTCCGACTGCTTTTCCCTGTCCCGTA  
ATCACCTTAGCACAAATTCCTGGGGTTTGCCAGGACTATAGAAGAACTACGCTTGGATG  
ATAATCGCATATCCACTATTTTCATCACCATCTCTTCAAGGTCTCACTAGTCTAAAACGCC  
TGGTTCATAGATGGAAACCTGTTGAACAATCATGGTTTAGGTGACAAAGTTTCTTCAACC  
TAGTTAATTTGACAGAGCTGTCCCTGGTGCGGAATTCCTGACTGCTGCACCAGTAAACC  
TTCCAGGCACAAACCTGAGGAAGCTTTATCTTCAAGATAACCACATCAATCGGGTGCCCC  
CAAATGCTTTTTCTTATCTAAGGCAGCTCTATCGACTGGATATGTCCAATAATAACCTAA  
GTAATTTACCTCAGGGTATCTTTGATGATTTGGACAATATAACACAACCTGATTCTTCGCA  
ACAATCCCTGGTATTGCGGGTGCAAGATGAAATGGGTACGTGACTGGTTACAATCACTAC  
CTGTGAAGGTCAACGTGCGTGGGCTCATGTGCCAAGCCCCAGAAAAGGTTCTGTGGGATGG  
CTATTAAGGATCTCAATGCAGAACTGTTTGATTGTAAGGACAGTGGGATTGTAAGCACCA  
TTCAGATAACCACTGCAATACCCAACACAGTGTATCCTGCCCAAGGACAGTGGCCAGCTC  
CAGTGACCAAACAGCCAGATATTAAGAACCCCAAGCTCACTAAGGATCAACAAACCACAG  
GGAGTCCCTCAAGAAAAACAATTACAATTACTGTGAAGTCTGTACCTCTGATACCATTCT  
ATATCTCTTGAAACTTGCTCTACCTATGACTGCTTTGAGACTCAGCTGGCTTAACTGG  
GCCATAGCCCCGGCATTGTTGATCTATAACAGAAACAATTGTAACAGGGGAACGCAGTGAGT  
ACTTGGTCACAGCCCTGGAGCCTGATTCACCCTATAAAGTATGCATGGTTCCCATGGAAA  
CCAGCAACCTCTACCTATTTGATGAACTCCTGTTTGTATTGAGACTGAACTGCACCCC  
TTCGAATGTACAACCCTACAACCACCCTCAATCGAGAGCAAGAGAAAGAACCTTACAAAA  
ACCCCAATTTACCTTTGGCTGCCATCATTGGTGGGGCTGTGGCCCTGGTTACCATTTGCC  
TTCTTGCTTTAGTGTGTTGGTATGTTTCATAGGAATGGATCGCTCTTCTCAAGGAACGTGT  
CATATAGCAAAGGGAGGAGAAGAAAGGATGACTATGCAGAAGCTGGCACTAAGAAGGACA  
ACTCTATCCTGGAAATCAGGGAACTTCTTTTCAGATGTTACCAATAAGCAATGAACCCA  
TCTCGAAGGAGGAGTTTGTAATACACACCATATTTCCCTCCTAATGGAATGAATCTGTACA  
AAAACAATCACAGTGAAAGCAGTAGTAACCGAAGCTACAGAGACAGTGGTATTCCAGACT  
CAGATCACTCACACTCATGATGCTGAAGGACTCACAGCAGACTTGTGTTTTGGGTTTTT  
AAACCTAAGGGAGGTGATGGT

287/392

**FIGURE 274**

MISAAWSIFLIGTKIGLFLQVAPLSVMAKSCPSVCRC DAGFIYCND RFLTSIPTGIPEDA  
TTLYLQNNQINNAGIPSDLKNLLKVERIYLYHNSLDEFPTNLPKYVKELHLQENNIRITIT  
YDSLSKIPYLEELHLD DNSVSAVSIEEGA FRDSNYLRLLFLSRNHLSTIPWGLPRTIEEL  
RLDDNRISTISSPSLQGLTSLKRLVLDGNLLNNHGLGDKVFFNLVNLTELSLVRNSLTAA  
PVNLPGTNLRKLYLQDNHINRVPPNAFSYLRQLYRLDMSNNNLSNLPQGIFDDL DNITQL  
ILRNNPWYCGCKMKWVRDWLQSLPVKVNVRGLMCOAPEKVRGMAIKDLNAELFDCKDSGI  
VSTIQITTAIPNTVYPAQGQWPAPVTKQPDIKNPKLTKDQOTTGSPSRKTITITVKS VTS  
DTIHISWKLALPMTALRLSWLKLGHSPAFGSITETIVTGERSEYLVTALEPDSPYKVC MV  
PMETSNLYLFDETPVC IETETAPLRMYNP TTTLNREQEKEPYKNPNLPLAAIIGGAVALV  
TIAL LALVCWYVHRNGSLFSRNCAYSKGRRRKDDYAEAGTKKDNSILEIRETSFQMLPIS  
NEPISKEEFVIHTIFPPNGMNL YKNNHSESSSNRSYRDSGIPDS DSHS

**Important features of the protein:****Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 531-552

**N-glycosylation sites:**

amino acids 226-229, 282-285, 296-299, 555-558, 626-629, 633-636

**Tyrosine kinase phosphorylation site:**

amino acids 515-522

**N-myristoylation sites:**

amino acids 12-17, 172-177, 208-213, 359-364, 534-539, 556-561, 640-645

**Amidation site:**

amino acids 567-570

**Leucine zipper pattern:**

amino acids 159-180

**Phospholipase A2 aspartic acid active site:**

amino acids 34-44

288/392

## FIGURE 275

AGGGCCCGCGGGTGGAGAGAGCGACGCCCCGAGGGGATGGCGGCAGCGTCCCGGAGCGCCT  
CTGGCTGGGCGCTACTGCTGCTGGTGGCACTTTGGCAGCAGCGCGCGGCCGCTCCGGCG  
TCTTCCAGCTGCAGCTGCAGGAGTTTCATCAACGAGCGCGCGTACTGGCCAGTGGGCGGC  
CTTGCGAGCCCCGGCTGCCGGACTTTCTTCGCGTCTGCCTTAAGCACTTCCAGGCGGTG  
TCTCGCCCCGACCCCTGCACCTTCGGGACCGTCTCCACGCCGGTATTGGGCACCAACTCCT  
TCGCTGTCCGGGACGACAGTAGCGGGCGGGGGCGCAACCCTCTCCAAGTGCCTTCAATT  
TCACCTGGCCGGGTACCTTCTCGCTCATCATGAAGCTTGGCACGCGCCAGGAGACGACC  
TGCGGCCAGAGGCCTTGCCACCAGATGCACTCATCAGCAAGATCGCCATCCAGGGCTCCC  
TAGCTGTGGGTGAGAACTGGTTATTGGATGAGCAAACCAGCACCCCTCACAAGGCTGCGCT  
ACTCTTACCGGGTTCATCTGCAGTGACAACTACTATGGAGACAACTGCTCCCGCCTGTGCA  
AGAAGCGCAATGACCACCTTCGGCCACTATGTGTGCCAGCCAGATGGCAACTTGTCTGCC  
TGCCCGGTTGGACTGGGGAATATTGCCAACAGCCTATCTGTCTTTCGGGCTGTGATGAAC  
AGAATGGCTACTGCAGCAAGCCAGCAGAGTGCCCTCTGCCGCCAGGCTGGCAGGGCCGGC  
TGTGTAACGAATGCATCCCCACAATGGCTGTGCCACGGCACCTGCAGCACTCCCTGGC  
AATGTACTTGTGATGAGGGCTGGGGAGGCCTGTTTTGTGACCAAGATCTCAACTACTGCA  
CCCACCACTCCCCATGCAAGAATGGGGCAACGTGCTCCAACAGTGGGCAGCGAAGCTACA  
CCTGCACCTGTGCGCCAGGCTACACTGGTGTGGACTGTGAGCTGGAGCTCAGCGAGTGTG  
ACAGCAACCCCTGTGCAATGGAGGCAGCTGTAAGGACCAGGAGGATGGCTACCACTGCC  
TGTGTCTTCCGGGCTACTATGGCCTGCACTGTGAACACAGCACCTTGAGCTGCGCCGACT  
CCCCCTGCTTCAATGGGGGCTCCTGCCGGGAGCGCAACCAGGGGGCCAACTATGCTTGTG  
AATGTCCCCCAACTTCACCGGCTCCAAGTGCAGAGAAAGTGGACAGGTGCACCAGCA  
ACCCCTGTGCCAACGGGGGACAGTGCCTGAACCGAGGTCCAAGCCGATGTGCCGCTGCC  
GTCCTGGATTACGGGCACCTACTGTGAAGTCCACGTGAGCGACTGTGCCCGTAACCCCTT  
GCGCCACGGTGGCACTTGCCATGACCTGGAGAATGGGCTCATGTGCACCTGCCCTGCCG  
GCTTCTCTGGCCGACGCTGTGAGGTGCGGACATCCATCGATGCCTGTGCCTCGAGTCCCT  
GCTTCAACAGGGCCACCTGCTACACCGACCTCTCCACAGACACCTTGTGTGCAACTGCC  
CTTATGGCTTTGTGGGCAGCCGCTGCGAGTTCCCCGTGGGCTTGCCGCCAGCTTCCCCCT  
GGGTGGCCGTCTCGCTGGGTGTGGGGCTGGCAGTGCTGCTGGTACTGCTGGGCATGGTGG  
CAGTGGCTGTGCGGCAGCTGCGGCTTCGACGGCCGGACGACGGCAGCAGGGAAGCCATGA  
ACAACTTGTGCGACTTCCAGAAGGACAACCTGATTCCCTGCCGCCAGCTTAAAAACACAA  
ACCAGAAGAAGGAGCTGGAAGTGGACTGTGGCCTGGACAAGTCCAAGTGTGGCAAACAGC  
AAAACCACACATTGGACTATAATCTGGCCCCAGGGCCCCCTGGGGCGGGGGACCATGCCAG  
GAAAGTTTCCCCACAGTGACAAGAGCTTAGGAGAGAAGGCGCCACTGCGGTTACACAGTG  
AAAAGCCAGAGTGTGCGATATCAGCGATATGCTCCCCAGGGACTCCATGTACCAGTCTG  
TGTGTTTGATATCAGAGGAGAGGAATGAATGTGTGATTGCCACGGAGGTATAAGGCAGGA  
GCCTACCTGGACATCCCTGCTCAGCCCCGCGGCTGGACCTTCCTTCTGCATTGTTTACA

289/392

**FIGURE 276**

MAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEFINERGVLASGRPCEPGCRTFFRV  
CLKHFQAVVSPGPCTFTGTVPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIE  
AWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYY  
GDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECL  
CRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATC  
SNSGQRSYTTCTCRPGYTGVDCELELSECDSNPCRNGGSKDQEDGYHCLCPPGYGGLHCE  
HSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSGNCEKKVDRCTSNPCANGGQCLNR  
GPSRMCRCRPGFTGTYCELVSDCARNPCAHHGTCHDLENGLMCTCPAGFSGRRCVVRTS  
IDACASSPCFNRCATCYTDLSTDTFVCNCPYGFVGSRCFVPVGLPPSFPWVAVSLGVGLAV  
LLVLLGMVAVAVRQLRLRRPDDGSREAMNNLSDFQKDNLI PAAQLKNTNQKKELEVDCGL  
DKSNCGKQQNHTLDYNLAPGPLGRGTMPGKFPHSDKSLGEKAPLRLHSEKPECRISAICS  
PRDSMYQSVCLISEERNECVIATEV

**Important features of the protein:****Signal peptide:**

amino acids 1-26

**Transmembrane domain:**

amino acids 530-552

**N-glycosylation sites:**amino acids 108-112, 183-187, 205-209, 393-397, 570-574,  
610-614**Glycosaminoglycan attachment site:**

amino acids 96-100

**Tyrosine kinase phosphorylation site:**

amino acids 340-347

**N-myristoylation sites:**amino acids 42-48, 204-210, 258-264, 277-283, 297-303,  
383-389, 415-421, 461-467, 522-528, 535-541, 563-569,  
599-605, 625-631**Amidation site:**

amino acids 471-475

**Aspartic acid and asparagine hydroxylation site:**

amino acids 339-351

**EGF-like domain cysteine pattern signature:**amino acids 173-185, 206-218, 239-251, 270-282, 310-322,  
348-360, 388-400, 426-438, 464-476, 506-518**Calcium-binding EGF-like:**amino acids 224-245, 255-276, 295-316, 333-354, 373-394,  
411-432, 440-452

290/392

**FIGURE 277**

GGCAGTGCAGCCGCCTCACAGGTCGGCGGACGGGGCCAGGCGGGCGGCCTCCTGAACCGAA  
CCGAATCGGCTCCTCGGGCCGTCGTCCTCCCGCCCCCTCCTCGCCCCGCCGCGGAGTTTTC  
TTTCGGTTTCTTCCAAGATTCCTGGCCTTCCCTCGACGGAGCCGGGGCCAGTGCGGGGGC  
GCAGGGCGCGGGAGCTCCACCTCCTCGGCTTTCCTGCGTCCAGAGGCTGGCATGGCGCG  
GGCCGAGTACTGAGCGCACGGTCGGGGCACAGCAGGGCCGGGGGGTGCAGCTGGCTCGCG  
CCTCCTCTCCGGCCGCGTCTCCTCCGGTCCCTGGCGAAAGCCATTGAGACACCAGCTGG  
ACGTCACGCGCCGGAGCATGTCTGGGAGTCAGAGCGAGGTGGCTCCATCCCCGCAGAGTC  
CGCGGAGCCCCGAGATGGGACGGGACTTGCGGCCCGGGTCCCGCGTGCTCCTGCTCCTGC  
TTCTGCTCCTGCTGGTGTACCTGACTCAGCCAGGCAATGGCAACGAGGGCAGCGTCACTG  
GAAGTTGTTATTGTGGTAAAAGAATTTCTTCCGACTCCCCGCCATCGGTTCAGTTTCATGA  
ATCGTCTCCGGAAACACCTGAGAGCTTACCATCGGTGTCTATACTACACGAGGTTCCAGC  
TCCTTTCCTGGAGCGTGTGTGGGGCAACAAGGACCCATGGGTTTCAGGAATTGATGAGCT  
GTCTTGATCTCAAAGAAATGTGGACATGCTTACTCGGGGATTGTGGCCCACCAGAAGCATT  
TACTTCCTACCAGCCCCCAATTTCTCAGGCCTCAGAGGGGGCATCTTCAGATATCCACA  
CCCCTGCCCAGATGCTCCTGTCCACCTTGCACTCAGCGCCCCACCCTCCCAGTAG  
GATCACTGTCTCGGACAAAGAGCTCACTCGTCCCAATGAAACCACCATTACACTGCGG  
GCCACAGTCTGGCAGCTGGGCCTGAGGCTGGGGAGAACCAGAAGCAGCCGGAAAAAATG  
CTGGTCCCACAGCCAGGACATCAGCCACAGTGCCAGTCCTGTGCCTCCTGGCCATCATCT  
TCATCCTCACCGCAGCCCTTTCTATGTGCTGTGCAAGAGGAGGAGGGGGCAGTCACCGC  
AGTCCTCTCCAGATCTGCCGGTTCATTATATACCTGTGGCACCTGACTCTAATACCTGAG  
CCAAGAATGGAAGCTTGTGAGGGTAAACTGTGGCTTATTCTTACAAAAAGTGTAAATAAG  
GAGACTGACCCCTGACAACATGGTAGGCACCTGTAAAAA

291/392

**FIGURE 278**

MGRDLRPGSRVLLLLLLLLLVYLTQPGNGNEGSVTGSCYCGKRISSDSPPSVQFMNRLRK  
HLRAYHRCCLYYTRFQLLSWSVCGGNKDPWVQELMSCLDLKECGHAYSGIVAHQKHLPTS  
PPISQASEGASSDIHTPAQMLLSTLQSTQRPTLPVGSLSSEKELTRPNETTIHTAGHSLA  
AGPEAGENQKQPEKNAGPTARTSATVPVLCLLAIIFILTAALSYVLCKRRRGQSPQSSPD  
LPVHYIPVAPDSNT

**Important features of the protein:****Signal peptide:**

1-26

**Transmembrane domain:**

204-223

**N-glycosylation site:**

168-172

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

42-46

**N-myristoylation site:**

29-35, 32-38, 36-42, 156-162

**Amidation site:**

40-44

292/392

**FIGURE 279**

CGCGAGGCGCGGGGAGCCTGGGACCAGGAGCGAGAGCCGCCTACCTGCAGCCGCCGCCCA  
CGGCACGGCAGCCACCATGGCGCTCCTGCTGTGCTTCGTGCTCCTGTGCGGAGTAGTGGA  
TTTCGCCAGAAGTTTGAGTATCACTACTCCTGAAGAGATGATTGAAAAAGCCAAAGGGGA  
AACTGCCTATCTGCCATGCAAATTTACGCTTAGTCCCGAAGACCAGGGACCGCTGGACAT  
CGAGTGGCTGATATCACCAGCTGATAATCAGAAGGTGGATCAAGTGATTATTTTATATTC  
TGGAGACAAAATTTATGATGACTACTATCCAGATCTGAAAGGCCGAGTACATTTTACGAG  
TAATGATCTCAAATCTGGTGATGCATCAATAAATGTAACGAATTTACAAGTGCAGATAT  
TGGCACATATCAGTGCAAAGTGAAGAAAGCTCCTGGTGTTGCAAATAAGAAGATTCATCT  
GGTAGTTCTTGTTAAGCCTTCAGGTGCGAGATGTTACGTTGATGGATCTGAAGAAATTGG  
AAGTGACTTTAAGATAAAATGTGAACCAAAAGAAGGTTCACTTCCATTACAGTATGAGTG  
GCAAAAATTGTCTGACTCACAGAAAATGCCACTTCATGGTTAGCAGAAATGACTTCATC  
TGTTATATCTGTAAAAAATGCCTCTTCTGAGTACTCTGGGACATACAGCTGTACAGTCAG  
AAACAGAGTGGGCTCTGATCAGTGCCCTGTTGCGTCTAAACGTTGTCCCTCCTTCAAATAA  
AGCTGGACTAATTGCAGGAGCCATTATAGGAACCTTGTCTGCTCTAGCGCTCATTGGTCT  
TATCATCTTTTGCTGTGCTAAAAAGCGCAGAGAAGAAAAATATGAAAAGGAAGTTCATCA  
CGATATCAGGGAAGATGTGCCACCTCCAAAGAGCCGTACGTCCACTGCCAGAAGCTACAT  
CGGCAGTAATCATTATCCCTGGGGTCCATGTCTCCTTCCAACATGGAAGGATATTCCAA  
GACTCAGTATAACCAAGTACCAAGTGAAGACTTTGAACGCACCTCCTCAGAGTCCGACTCT  
CCCACCTGCTAAGTTCAAGTACCCTTACAAGACTGATGGAATTACAGTTGTATAAAATATG  
GACTACTGAAGAATCTGAAGTATTGTATTATTTGACTTTATTTTAGGCCTCTAGTAAAGA  
CTTAAATGTTTTTTAAAAAAGCACAAAGGCACAGAGATTAGAGCAGCTGTAAGAACACAT  
CTACTTTATGCAATGGCATTAGACATGTAAGTCAGATGTCATGTCAAAATTAGTACGAGC  
CAAATTCTTTGTTAAAAAACCTATGTATAGTGACACTGATAGTTAAAGATGTTTTATT  
ATATTTTCAATAACTACCACTAACAAATTTTTAACTTTTTCATATGCATATTCTGATATGT  
GGTCTTTTAGGAAAAGTATGGTTAATAGTTGATTTTTCAAAGGAAATTTTAAATTCCTTA  
CGTTCTGTTTAAATGTTTTTGCTATTTAGTTAAATACATTGAAGGGAAATACCCGTTCTTT  
TCCCTTTTATGCACACAACAGAAACACGCGTTGTCTATGCCTCAAACATTTTTTTATTTG  
CAACTACATGATTTACACAAATCTCTTAAACAACGACATAAAATAGATTTCTTGTATA  
TAAATAACTTACATACGCTCCATAAAGTAAATCTCAAAGGTGCTAGAACAATCGTCCA  
CTTCTACAGTGTTCTCGTATCCAACAGAGTTGATGCACAATATATAAATACTCAAGTCCA  
ATATTAAAACTTAGGCACCTTGACTAACCTTAAATAAAATTTCTCAAACCTATATCAATATC  
TAAAGTGCATATATTTTTTAAGAAAGATTATTCTCAATAAATTTCTATAAAAAATAAGTTTG  
ATGGTTTGGCCCATCTAACTTCACTACTATTAGTAAGAACTTTTAACTTTTAAATGTGTAG  
TAAGGTTTATTCTACCTTTTCTCAACATGACACCAACACAATCAAAAACGAAGTTAGTG  
AGGTGCTAACATGTGAGGATTAATCCAGTGATTCCGGTCACAATGCATTCCAGGAGGAGG  
TACCCATGTCACTGGAATTGGGCGATATGGTTTATTTTTCTTCCCTGATTTGGATAACC  
AAATGGAACAGGAGGAGGATAGTGATTCTGATGGCCATTCCCTCGATACATTCCCTGGCTT  
TTTTCTGGGCAAAGGGTGCCACATTGGAAGAGGTGGAATATAAGTTCTGAAATCTGTAG  
GGAAGAGAACACATTAAGTTAATTCAAAGGAAAAAATCATCATCTATGTTCCAGATTTCT  
CATTAAAGACAAAGTTACCCACAACACTGAGATCACATCTAAGTGACACTCCTATTGTCA  
GGTCTAAATACATTAAAAACCTCATGTGTAATAGGCGTATAATGTATAACAGGTGACCAA  
TGTTTTCTGAATGCATAAAGAAATGAATAAACTCAAACACAGTACTTCTTAAACAACCTTC  
AACCAAAAAAGACCAAAACATGGAACGAATGGAAGCTTGTAAGGACATGCTTGTTTTAGT  
CCAGTGGTTTCCACAGCTGGCTAAGCCAGGAGTCACTTGGAGGCTTTTAAATACAAAACA  
TTGGAGCTGGAGGCCATTATCCTTAGCAAACCTAATGCAGAAACAGAAAAATCAACTACCGC  
ATGTTCTCACTTATAAGTGGGAGGTAATGATAAGAACTTATGAACACAAAGAAGGAAACA  
ATAGACATTGGAGTCTATTTGAGAGGGGAGGGTGGGAGAAGGAAAAGGAGCAGAAAAGAT  
AACTATTGAGTACTGCCTTCACACCTGGGTGATGAAATAATATGTACAACAAATCCCTGT  
GACACATGTTTACCTATGGAACAAACCTTCATGTGTATCCCTAAACCTAAATAAAAGTT

293/392

**FIGURE 280**

MALLLCFVLLCGVVDFARSLSTTTPEEMIEKAKGETAYLPCKFTLSPEDQGPLDIEWLIS  
PADNQKVDQVIILYSGDKIYDDYYPDLKGRVHFTSNDLKSGDASINVTNLQLSDIGTYQC  
KVKKAPGVANKKIHLVVLVKPSGARCIVDGSSEIGSDFKIKCEPKEGSLPLQYEWQKLS  
SQKMPTSWLAEMTSSVISVKNASSEYSGTYSCTVRNRVGSQCLLRNLNVPPSNKAGLIA  
GAIIGTLLALALIGLIIFCCRKKRREEKYEKEVHHDIREDVPPPKSRTSTARSYIGSNHS  
SLGSMSPSNMEGYSKTQYNQVPSEDFERTPQSPTLPPAKFKYPYKTDGITVV

**Signal sequence.**

amino acids 1-19

**Transmembrane domain:**

amino acids 236-257

**N-glycosylation sites:**

amino acids 106-110, 201-205, 298-302

**Tyrosine kinase phosphorylation sites:**

amino acids 31-39, 78-85, 262-270

**N-myristoylation sites:**amino acids 116-122, 208-214, 219-225, 237-243, 241-247,  
245-251, 296-302**Myelin P0 protein:**

amino acids 96-125



294/392

**FIGURE 281**

TGCATCAGTGCCCAGGCAAGCCCAGGAGTTGACATTTCTCTGCCCAGCCATGGGCCTCAC  
CCTGCTCTTGCTGCTGCTCCTGGGACTAGAAGGTCAGGGCATAGTTGGCAGCCTCCCTGA  
GGTGCTGCAGGCACCCGTGGGAAGCTCCATTCTGGTGCCAGTGCCACTACAGGCTCCAGGA  
TGTCAAAGCTCAGAAGGTGTGGTGCCGGTTCTTGCCGGAGGGGTGCCAGCCCCTGGTGTC  
CTCAGCTGTGGATCGCAGAGCTCCAGCGGGCAGGCGTACGTTTCTCACAGACCTGGGTGG  
GGCCTGCTGCAGGTGGAAATGGTTACCCTGCAGGAAGAGGATGCTGGCGAGTATGGCTG  
CATGGTGGATGGGGCCAGGGGGCCCCAGATTTTGACAGAGTCTCTCTGAACATACTGCC  
CCCAGAGGAAGAAGAAGAGACCCATAAGATTGGCAGTCTGGCTGAGAACGCATTCTCAGA  
CCCTGCAGGCAGTGCCAACCCTTTGGAACCCAGCCAGGATGAGAAGAGCATCCCCTTGAT  
CTGGGGTGCTGTGCTCCTGGTAGGTCTGCTGGTGGCAGCGGTGGTGCTGTTTGCTGTGAT  
GGCCAAGAGGAAACAAGAATCCCTCCTCAGTGGTCCACCACGTCAGTGA<sup>1</sup>CTCTGGACCGG  
CTGCTGAATTGCCTTTGGATGTACCACACATTAGGCTTGACTCACCACCTTCATTTGACA  
ATACCACCTACACCAGCCTACCTCTTGATTCCCCATCAGGAAAACCTTCACTCCCAGCTC  
CATCCTCATTGCCCCCTCTACCTCCTAAGGTCCTGGTCTGCTCCAAGCCTGTGACATATG  
CCACAGTAATCTTCCCGGGAGGGAAACAAGGGTGGAGGGACCTCGTGTGGGCCAGCCCAGA  
ATCCACCTAACAATCAGACTCCATCCAGCTAAGCTGCTCATCACACTTTAAACTCATGAG  
GACCATCCCTAGGGGTTCTGTGCATCCATCCAGCCAGCTCATGCCCTAGGATCCTTAGGA  
TATCTGAGCAACCAGGGACTTTAAGATCTAATCCAATGTCCTAACTTTACTAGGGAAAGT  
GACGCTCAGACATGACTGAGATGTCTTGGGGAAGACCTCCCTGCACCCAACTCCCCCACT  
GGTTCTTCTACCATTACACACTGGGCTAAATAAACCTAATAATGATGTGCAAAAAAAAAA  
AA

295/392

**FIGURE 282**

MGLTLLLLLLLLGLEGQGIVGSLPEVLQAPVGSSILVQCHYRLQDVKAQKVWCRFLPEGCQ  
PLVSSAVDRRAPAGRRTFLTDLGGGLLQVEMVTLQEEDAGEYGCMVDGARGPQILHRVSL  
NILPPEEEETHKIGSLAENAFSDPAGSANPLEPSQDEKSIPLIWGAVLLVGLLVAAVVL  
FAVMAKRKQESLLSGPPRQ

**Important features of the protein:**

**Signal peptide:**

amino acids 1-15

**Transmembrane domain:**

amino acids 161-181

**N-myristoylation sites:**

amino acids 17-23, 172-178

**Amidation site:**

amino acids 73-79

296/392

**FIGURE 283**

GTAGCATAGTGTGCAGTTCCTGACCAAAAGCTTTGGCTGCACCTCTTCTGGAAAGCTG  
GCCATGGGGCTCTTCATGATCATTGCAATTCTGCTGTTCCAGAAACCCACAGTAACCGAA  
CAACTTAAGAAGTGCTGGAATAACTATGTACAAGGACATTGCAGGAAAATCTGCAGAGTA  
AATGAAGTGCCTGAGGCACTATGTGAAAATGGGAGATACTGTTGCCTCAATATCAAGGAA  
CTGGAAGCATGTAAAAAATTACAAAGCCACCTCGTCCAAAGCCAGCAACACTTGCACTG  
ACTCTTCAAGACTATGTTACAATAATAGAAAATTTCCCAAGCCTGAAGACACAGTCTACA  
TAAATCAAATACAATTCGTTTTCACTTGCTTCTCAACCTAGTCTAATAAACTAAGGTGA  
TGAGATATACATCTTCTTCCTTCTGGTTTCTTGATCCTTAAAATGACCTTCGAGCATATT  
CTAATAAAGTGCATTGCCAGTTAAAAA

297/392

## FIGURE 284

MGLFMIIAILLFQKPTVTEQLKKCWNNYVQGHCRKICRVNEVPEALCENGRYCCLNIKEL  
EACKKITKPPRPKPATLALTLDYVTIIENFPSLKTQST

Important features of the protein:

Signal peptide:

None

Transmembrane domain:

None

cAMP- and cGMP-dependent protein kinase phosphorylation site:

64-68

298/392

**FIGURE 285**

GATGGCGCAGCCACAGCTTCTGTGAGATTTCGATTTCTCCCCAGTTCCCCTGTGGGTCTGA  
GGGGACCAGAAGGGTGAGCTACGTTGGCTTTCTGGAAGGGGAGGCTATATGCGTCAATTC  
CCCAAACAAGTTTTTGACATTTCCCTGAAATGTCATTCTCTATCTATTCACTGCAAGTG  
CCTGCTGTTCCAGGCCTTACCTGCTGGGCACTAACGGCGGAGCCAGGATGGGGACAGAAT  
AAAGGAGCCACGACCTGTGCCACCAACTCGCACTCAGACTCTGAACTCAGACCTGAAATC  
TTCTCTTCACGGGAGGCTTGGCAGTTTTTCTTACTCCTGTGGTCTCCAGATTTCAAGCCCT  
AAGATGAAAGCCTCTAGTCTTGCCTTCAGCCTTCTCTCTGCTGCGTTTTATCTCCTATGG  
ACTCCTTCCACTGGACTGAAGACACTCAATTTGGGAAGCTGTGTGATCGCCACAAACCTT  
CAGGAAATACGAAATGGATTTTTCTGAGATACGGGGCAGTGTGCAAGCCAAAGATGGAAAC  
ATTGACATCAGAATCTTAAGGAGGACTGAGTCTTTGCAAGACACAAAGCCTGCGAATCGA  
TGCTGCCTCCTGCGCCATTTGCTAAGACTCTATCTGGACAGGGTATTTAAAAACTACCAG  
ACCCCTGACCATTATACTCTCCGGAAGATCAGCAGCCTCGCCAATTCCTTTCTTACCATC  
AAGAAGGACCTCCGGCTCTCTCATGCCACATGACATGCCATTGTGGGGAGGAAGCAATG  
AAGAAATACAGCCAGATTCTGAGTCACTTTGAAAAGCTGGAACCTCAGGCAGCAGTTGTG  
AAGGCTTTGGGGGAACTAGACATTCTTCTGCAATGGATGGAGGAGACAGAATAGGAGGAA  
AGTGATGCTGCTGCTAAGAATATTCGAGGTCAAGAGCTCCAGTCTTCAATACCTGCAGAG  
GAGGCATGACCCCAAACCACCATCTCTTTACTGTACTAGTCTTGTGCTGGTCACAGTGTA  
TCTTATTTATGCATTACTTGCTTCCTTGCATGATTGTCTTTATGCATCCCCAATCTTAAT  
TGAGACCATACTTGTATAAGATTTTTTGTAATATCTTTCTGCTATTGGATATATTTATTAG  
TTAATATATTTATTTATTTTTTGCTATTTAATGTATTTATTTTTTTACTTGGACATGAAA  
CTTTAAAAAAATTCACAGATTATATTTATAACCTGACTAGAGCAGGTGATGTATTTTTAT  
ACAGTAAAAAATAACCTTGTAATTCAGAAAGAGTGGCTAGGGGGGTTATTCAATTTG  
TATTCAACTAAGGACATATTTACTCATGCTGATGCTCTGTGAGATATTTGAAATTGAACC  
AATGACTACTTAGGATGGGTGTGGAATAAGTTTTGATGTGGAATTGCACATCTACCTTA  
CAATTACTGACCATCCCCAGTAGACTCCCCAGTCCCATAATTGTGTATCTTCCAGCCAGG  
AATCCTACACGGCCAGCATGTATTTCTACAAATAAAGTTTTCTTTGCATACCAAAAAA  
AAAAA

299/392

## FIGURE 286

MKASSLAFSLLSAAFYLLWTPSTGLKTLNLGSCVIATNLQEIRNGFSEIRGSVQAKDGN  
DIRILRRTESLQDTKPANRCCLLRHLLRLYLDRVFKNYQTPDHYTLRKISSIANSFLT  
IKDLRLSHAHMTCHCGEEAMKKYSQILSHFEKLEPQAADVVKALGELDILLQWMEETE

300/392

**FIGURE 287**

AATGCCCCATGCGCACCCACAGCTCGCGCTCCTGCAAGTGTTCTTTCTGGTGTTCCCCG  
ATGGCGTCCGGCCTCAGCCCTCTTCCTCCCCATCAGGGGCAGTGCCCACGTCTTTGGAGC  
TGCAGCGAGGGACGGATGGCGGAACCCTCCAGTCCCCTTCAGAGGCGACTGCAACTCGCC  
CGGCCGTGCTGGACTCCCTACAGTGGTCCCTACTCTCGTGACTCCCTCGGCCCTGGGA  
ATAGGACTGTGGACCTCTTCCCAGTCTTACCGATCTGTGTCTGTGACTTGACTCCTGGAG  
CCTGCGATATAAATTGCTGCTGCGACAGGGACTGCTATCTTCTCCATCCGAGGACAGTTT  
TCTCCTTCTGCCTTCCAGGCAGCGTAAGGTCTTCAAGCTGGGTTTTGTGTAGACAACCTCTG  
TTATCTTCAGGAGTAATTCGCCGTTTCTTCAAGAGTTTTTCATGGATTCTAATGGAATCA  
GGCAGTTTTGTGTCCATGTGAACAACTCAAACCTAAACTATTTCCAGAAGCTTCAAAAGG  
TCAATGCAACCAACTTCCAGGCCCTGGCTGCAGAGTTTGAGGGCGAATCATTCACTTCAA  
CATTCCAACTCAATCACCACCATCTTTTTACAGGGCTGGGGACCCCATCTTACTTACT  
TCCCCAAGTGGTCTGTAATAAGCTTGCTGAGACAACCTGCAGGAGTTGGAGCTGGGGGAC  
TCTGTGCTGAAAGCAATCCTGCAGGTTTTCTAGAGAGTAAAAGTACAACCTGCACTCGTT  
TTTTCAAGAACCTGGCTAGTAGCTGTACCTTGATTGAGCCCTCAATGCTGCCTCTTACT  
ATAACTTCACAGTCTTAAAGGTTCCAAGAAGCATGACTGATCCACAGAATATGGAGTTCC  
AGGTTCTGTAATACTTACCTCACAGGCTAATGCTCCTCTGTTGGCTGGAAACACTTGTC  
AGAATGTAGTTTCTCAGGTCACCTATGAGATAGAGACCAATGGGACTTTTGGAAATCCAGA  
AAGTTTCTGTGAGTTTGGGACAAACCAACCTGACTGTTGAGCCAGGCGCTTCTTACAGC  
AACACTTCATCCTTCGCTTCAGGGCTTTTCAACAGAGCACAGCTGCTTCTCTCACCAGTC  
CTAGAAGTGGGAATCCTGGCTATATAGTTGGGAAGCCACTCTTGGCTCTGACTGATGATA  
TAAGTTACTCAATGACCCTCTTACAGAGCCAGGGTAATGGAAGTTGCTCTGTTAAAAGAC  
ATGAAGTGCAGTTTGGAGTGAATGCAATATCTGGATGCAAGCTCAGGTTGAAGAAGGCAG  
ACTGCAGCCACTTGCAGCAGGAGATTTATCAGACTCTTCATGGAAGGCCAGACCAGAGT  
ATGTTGCCATCTTTGGTAATGCTGACCCAGCCAGAAAGGAGGGTGGACCAGGATCCTCA  
ACAGGCACTGCAGCATTTCAGCTATAAACTGTACTTCCTGCTGTCTCATACAGTTTCCC  
TGGAGATCCAGGTATTGTGGGCATATGTAGGTCTCCTGTCCAACCCGCAAGCTCATGTAT  
CAGGAGTTCGATTCTTATACAGTGCCAGTCTATACAGGATTCTCAGCAAGTTACAGAAG  
TATCTTTGACAACTCTTGTGAACCTTGTGGACATTACCCAGAAGCCACAGCCTCCAAGGG  
GCCAACCCAAAATGGACTGGAAATGGCCATTTCGACTTCTTCCCTTCAAAGTGGCATTCA  
GCAGAGGAGTATTCTCTCAAAAATGCTCAGTCTCTCCCATCCTTATCCTGTGCCTCTTAC  
TACTTGGAGTTCTCAACCTAGAGACTATGTGAAGAAAAGAAAATAATCAGATTTCAGTTT  
TCCCTATGAGAACTCTGAGGCAGCCACTTATCTTGGCTAAATAGAACCTCACCTGCTCA  
TGACCAGAGAGCATTTAGGATAATAGATGACCTAACTGAAGGAATCCTTGTATATGAAAG  
GAGTTATTTTAGAAAAGCAATAAAAATATTTTATTTCATCNTAAAAA

301/392

**FIGURE 288**

M RTPQLALLQVFFLVFPDGV RPQPSSSPSGAVPTSLELQ RGT DGGTLQSPSEATATRP AV  
PGLPTVVPTLVTPSAPGNRTVDLFPVLPICVCDLTPGACDINCCCDRDCYLLHPRTVFSF  
CLPGSVRSSSWVCVDNSVIFRSNSPFPSRVFMD SNGIRQFCVHVNN SNLNYFQKLQKVNA  
TNFQALAAEFGGESFTSTFQTQSPPSFYRAGDPILTYFPKWSVISLLRQPAGVGAGGLCA  
ESNPAGFLESKSTTCTRFFKNLASSCTLDSALNAASYNFTVLKVPRSM TDPQNMEFQVP  
VILTSQANAPLLAGNTCQNVVSQVTYEIETNGTFGIQKVS VSLGQTNLTVEPGASLQQHF  
ILRFRAFQQSTAASLTSPRSGNPGYIVGKPLLALTDDISYSMTLLQSQNGSCSVKRHEV  
QFGVNAISGCKLRLKKADCSHLQQEIYQTLHGRPRPEYVAIFGNADPAQKGGWTRILNRH  
CSISAINCTSCCLIPVSLEIQVLWAYVGLLSNPQAHVSGVRFLYQCQSIQDSQQVTEVSL  
TTLVNFVDITQKPQPPRGQPKMDWKWPFDFPFKVAFSRGVFSQKCSVSPILILCLLLLG  
VLNLETM

**Important features of the protein:****Signal peptide:**

amino acids 1-22

**Transmembrane domains:**

amino acids 484-505, 581-600

**N-glycosylation sites:**amino acids 78-82, 165-169, 179-185, 279-285, 331-337,  
347-351, 410-414, 487-491**N-myristoylation sites:**

amino acids 30-36, 41-47, 124-130, 232-238, 236-242, 409-415

**Prokaryotic membrane lipoprotein lipid attachment site:**

amino acids 420-431



302/392

**FIGURE 289**

CGCGGAGCCCTGCGCTGGGAGGTGCACGGTGTGCACGCTGGACTGGACCCCCATGCAACC  
CCGCGCCCTGCGCCTTAACCAGGACTGCTCCGCGCGCCCTGAGCCTCGGGCTCCGGCCC  
GGACCTGCAGCCTCCCAGGTGGCTGGGAAGAACTCTCCAACAATAAATACATTTGATAAG  
AAAGATGGCTTTAAAAGTGCTACTAGAACAAGAGAAAACGTTTTTCACTCTTTTAGTATT  
ACTAGGCTATTTGTTCATGTAAAGTGACTTGTGAATCAGGAGACTGTAGACAGCAAGAATT  
CAGGGATCGGTCTGGAACTGTGTTCCCTGCAACCAGTGTGGGCCAGGCATGGAGTTGTC  
TAAGGAATGTGGCTTCGGCTATGGGGAGGATGCACAGTGTGTGACGTGCCGGCTGCACAG  
GTTCAAGGAGGACTGGGGCTTCAGAAATGCAAGCCCTGTCTGGACTGCCAGTGGTGAA  
CCGCTTTTCAGAAGGCAAATTGTTTCAGCCACCAGTGATGCCATCTGCGGGGACTGCTTGCC  
AGGATTTTATAGGAAGACGAAACTTGTTCGGCTTTCAAGACATGGAGTGTGTGCCCTTGTGG  
AGACCCTCCTCCTCCTTACGAACCGCACTGTGCCAGCAAGGTCAACCTCGTGAAGATCGC  
GTCCACGGCCTCCAGCCCACGGGACACGGCGCTGGCTGCCGTTATCTGCAGCGCTCTGGC  
CACCGTCCTGCTGGCCCTGCTCATCCTCTGTGTCTATCTATTGTAAGAGACAGTTTATGGA  
GAAGAAACCCAGCTGGTCTCTGCGGTGCGAGGACATTCACTACAACGGCTCTGAGCTGTC  
GTGTTTTGACAGACCTCAGCTCCACGAATATGCCACAGAGCCTGCTGCCAGTGCCGCCG  
TGACTCAGTGCAGACCTGCGGGCCGGTGCCTTGCTCCCATCCATGTGCTGTGAGGAGGC  
CTGCAGCCCCAACCCGGCGACTCTTGTTGTGGGGTGCATTCTGCAGCCAGTCTTCAGGC  
AAGAAACGCAGGCCAGCCGGGGAGATGGTGCCGACTTTCTTCGGATCCCTCACGCAGTC  
CATCTGTGGCGAGTTTTTCAGATGCCTGGCCTCTGATGCAGAATCCCATGGGTGGTGACAA  
CATCTCTTTTTGTGACTCTTATCCTGAACCTCACTGGAGAAGACATTCATTCTCTCAATCC  
AGAACTTGAAAGCTCAACGTCTTTTGATTCAAATAGCAGTCAAGATTTGGTTGGTGGGGC  
TGTTCCAGTCCAGTCTCATTCTGAAAACCTTACAGCAGCTACTGATTTATCTAGATATAA  
CAACACACTGGTAGAATCAGCATCAACTCAGGATGCACTAACTATGAGAAGCCAGCTAGA  
TCAGGAGAGTGGCGCTGTCTATCCACCCAGCCACTCAGACGTCCCTCCAGGAAGCTTAAAG  
AACCTGCTTCTTTCTGCAGTAGAAGCGTGTGCTGGAACCCAAAGAGTACTCCTTTGTTAG  
GCTTATGGACTGAGCAGTCTGGACCTTGCATGGCTTCTGGGGCAAAAATAAATCTGAACC  
AAACTGACGGCATTTGAAGCCTTTTCAGCCAGTTGCTTCTGAGCCAGACCAGCTGTAAGCT  
GAAACCTCAATGAATAACAAGAAAAGACTCCAGGCCGACTCATGATACTCTGCATCTTTC  
CTACATGAGAAGCTTCTCTGCCACAAAAGTGACTTCAAAGACTGATGGGTTGAGCTGGCA  
GCCTATGAGATTGTGGACATATAACAAGAAACAGAAATGCCCTCATGCTTATTTTCATGG  
TGATTGTGGTTTTACAAGACTGAAGACCAGAGTATACTTTTTCTTTCCAGAAATAATTT  
CATAACCGCCTATGAAATATCAGATAAATTACCTTAGCTTTTATGTAGAATGGGTTCAAAA  
GTGAGTGTTTTCTATTTGAGAAGGACACTTTTTTCATCATCTAAACTGATTCGCATAGGTGG  
TTAGAATGGCCCTCATATTGCCTGCCTAAATCTTGGGTTTATTAGATGAAGTTTACTGAA  
TCAGAGGAATCAGACAGAGGAGGATAGCTCTTTCAGAAATCCACACTTCTGACCTCAGCC  
TCGGTCTCATGAACACCCGCTGATCTCAGGAGAACACCTGGGCTAGGGAATGTGGTCCGAG  
AAAGGGCAGCCCATTGCCCAGAAATTAACACATATTGTAGAGACTTGTATGCAAAGGTTGG  
CATATTTATATGAAAATTAGTTGCTATAGAAACATTTGTTGCATCTGTCCCTCTGCCTGA  
GCTTAGAAGGTTATAGAAAAAGGGTATTTATAAACATAAATGACCTTTTACTTGCAATTGT  
ATCTTATACTAAAGGCTTTAGAAATTACAACATATCAGGTTCCCCTACTACTGAAGTAGC  
CTTCCGTGAGAACACACCACATGTTAGGACTAGAAGAAAATGCACAATTTGTAGGGGTTT  
GGATGAAGCAGCTGTAACCTGCCCTAGTGTAGTTTGACCAGGACATTGTCGTGCTCCTTCC  
AATTGTGTAAGATTAGTTAGCACATCATCTCCTACTTTAGCCATCCGGTGTTGGATTTAA  
GAGGACGGTGCTTCTTTCTATTAAAGTGCTCCATCCCCTACCATCTACACATTAGCATTG  
TCTCTAGAGCTAAGACAGAAATTAACCCGTTTCAGTCACAAAGCAGGGAATGGTTCAATTT  
ACTCTTAATCTTTATGCCCTGGAGAAGACCTACTTGAACAGGGCATATTTTTTTAGACTTC  
TGAACATCAGTATGTTTCGAGGGTACTATGATATTTTGGTTTGGAATTGCCCTGCCCAAGT  
CACTGTCTTTTAACTTTTAACTGAATATTAAATGTATCTGTCTTTCCT

303/392

**FIGURE 290**

MALKVLLLEQEKTFFTLLVLLGYLSCKVTCESGDCRQQEFRDRSGNCVPCNQC GPGMELSK  
ECGFGYGEDAQCVTCLHRFKEDWGFQKCKPCLDCAVVNR FQKANCSATSDAICGDCLPG  
FYRKTCLVGFQDMECVPCGDPPPPYEPHCASKVNLVKIASTASSPRDTALAAVIC SALAT  
VLLALLILCVIYCKRQFMEEKPSWSLRSQDIQYNGSELSCFDRPQLHEYAHRACCQCR RD  
SVQTCGPVRLLP SMCCEEACSPNPATLGCGVHSAASLQARNAGPAGEMVPTFFGSLTQSI  
CGEFSDAWPLMQNPMGGDNISFCDSYPELTGEDIHSLNPELESSTSLDSNSSQDLVGGAV  
PVQSHSENFTAATDLSRYNNTLVESASTQDALTMRSQLDQESGAVIHPATQTSLQEA

**Important features of the protein:****Signal peptide:**

Amino acids 1-25

**Transmembrane domain:**

Amino acids 169-192

**N-glycosylation sites:**

Amino acids 105-109; 214-218; 319-323; 350-354; 368-372; 379-383

**cAMP- and cGMP-dependent protein kinase phosphorylation sites:**

Amino acids 200-204; 238-242

**Tyrosine kinase phosphorylation site:**

Amino acids 207-214

**N-myristoylation sites:**

Amino acids 55-61; 215-221; 270-276

**Prokaryotic membrane lipoprotein lipid attachment site:**

Amino acids 259-270

**TNFR/NGFR family cysteine-rich region proteins:**

Amino acids 89-96

304/392

**FIGURE 291**

CCTGGAGCCGGAAGCGCGGCTGCAGCAGGGCGAGGCTCCAGGTGGGGTTCGGTTCCGCATC  
CAGCCTAGCGTGTCCACGATGCGGCTGGGCTCCGGGACTTTCGCTACCTGTTGCGTAGCG  
ATCGAGGTGCTAGGGATCGCGGTCTTCCTTCGGGGATTCTTCCCGGCTCCCGTTCGTTCC  
TCTGCCAGAGCGGAACACGGAGCGGAGCCCCAGCGCCCGAACCCTCGGCTGGAGCCAGT  
TCTAACTGGACCACGCTGCCACCACCTCTCTTCAGTAAAGTTGTTATTGTTCTGATAGAT  
GCCTTGAGAGATGATTTTGTGTTTGGGTCAAAGGGTGTGAAATTTATGCCCTACACAACT  
TACCTTGTGGAAAAAGGAGCATCTCACAGTTTGTGGCTGAAGCAAAGCCACCTACAGTT  
ACTATGCCTCGAATCAAGGCATTGATGACGGGGAGCCTTCCTGGCTTTGTGACGTCATC  
AGGAACCTCAATTTCTCCTGCACTGCTGGAAGACAGTGTGATAAGACAAGCAAAAGCAGCT  
GGAAAAAGAAATAGTCTTTTATGGAGATGAAACCTGGGTTAAATTATTCCCAAAGCATT  
GTGGAATATGATGGAACAACCTCATTTTTTCGTGTGATGATACACAGAGGTGGATAATAAT  
GTCACGAGGCATTTGGATAAAGTATTAAAAAGAGGAGATTGGGACATATTAATCCTCCAC  
TACCTGGGGCTGGACCACATTGGCCACATTTACGGGCCCCAACAGCCCCCTGATTGGGCAG  
AAGCTGAGCGAGATGGACAGCGTGTGATGAAGATCCACACCTCACTGCAGTCGAAGGAG  
AGAGAGACGCCCTTTACCCAATTTGCTGGTTCTTTGTGGTGACCATGGCATGTCTGAAACA  
GGAAGTCACGGGGCCCTCCTCCACCGAGGAGGTGAATACACCTCTGATTTTAATCAGTTCT  
GCGTTTGAAAGGAAACCCGGTGATATCCGACATCCAAAGCACGTCCAATAGACGGATGTG  
GCTGCGACACTGGCGATAGCACTTGCGTTACCGATTCCAAAAGACAGTGTAGGGAGCCTC  
CTATTCCCAGTTGTGGAAGGAAGACCAATGAGAGAGCAGTTGAGATTTTTACATTTGAAT  
ACAGTGCAGCTTAGTAACTGTTGCAAGAGAATGTGCCGTATATGAAAAAGATCCTGGG  
TTTGAGCAGTTTAAAATGTCAGAAAGATTGCATGGGAACTGGATCAGACTGTACTTGGAG  
GAAAAGCATTTCAGAAGTCCTATTCAACCTGGGCTCCAAGGTTCTCAGGCAGTACCTGGAT  
GCTCTGAAGACGCTGAGCTTGTCCCTGAGTGCACAAGTGGCCCAGTTCTCACCTGCTCC  
TGCTCAGCGTCCACAGGCACTGCACAGAAAGGCTGAGCTGGAAGTCCCACTGTCTCTC  
CTGGGTTTTCTCTGCTCTTTTATTTGGTGATCCTGGTTCTTTCGGCCGTTACGTCATTG  
TGTGCACCTCAGCTGAAAGTTCGTGCTACTTCTGTGGCCTCTCGTGGCTGGCGGCAGGCT  
GCCTTTCGTTTACCAGACTCTGGTTGAACACCTGGTGTGTGCCAAGTGCTGGCAGTGCCC  
TGGACAGGGGGCCTCAGGGAAGGACGTGGAGCAGCCTTATCCCAGGCCTCTGGGTGTCCC  
GACACAGGTGTTACATCTGTGCTGTCAGGTCAGATGCCTCAGTTCTTGGAAGCTAGGT  
TCCTGCGACTGTTACCAAGGTGATTGTAAAGAGCTGGCGGTCACAGAGGAACAAGCCCCC  
CAGCTGAGGGGGTGTGTGAATCGGACAGCCTCCCAGCAGAGGTGTGGGAGCTGCAGCTGA  
GGGAAGAAGAGACAATCGGCCTGGACACTCAGGAGGGTCAAAGGAGACTTGGTGCACAC  
ACTCATCCTGCCACCCCCAGAATGCATCCTGCCTCATCAGGTCCAGATTTCTTTCCAAGG  
CGGACGTTTTCTGTTGGAATTCTTAGTCCTTGGCCTCGGACACCTTCATTCGTTAGCTGG  
GGAGTGGTGGTGAGGCAGTGAAGAAGAGGCGGATGGTCACTCAGATCCACAGAGCCCA  
GGATCAAGGGACCCACTGCAGTGGCAGCAGGACTGTTGGGCCCCCACCCTGCAC  
AGCCCTCATCCCCCTCTTGGCTTGAGCCGTGAGAGGCCCTGTGCTGAGTGTCTGACCGAGA  
CACTCACAGCTTTGTCTATCAGGGCACAGGCTTCCTCGGAGCCAGGATGATCTGTGCCACG  
CTTGACCTCGGGCCCATCTGGGCTCATGCTCTCTCTCCTGCTATTGAATTAGTACCTAG  
CTGCACACAGTATGTAGTTACCAAAGAATAAACGGCAATAATTGAGAAAAAAA

305/392

**FIGURE 292**

MRLGSGTFATCCVAIEVLGIAVFLRGFFPAPVRSSARAEGHGAEPPEPSAGASSNWTTL  
PPPLFSKVIVILIDALRDDFVFGSKGVKFMPYTTYLVEKGASHSFVAEAKPPTVTMPRIK  
ALMTGSLPGFVDVIRNLNSPALLEDVIRQAKAAGKRIVFYGDETWVKLFPKHFVEYDGT  
TSFFVSDYTEVDNNVTRHLDKVLKRGDWDILILHYLGLDGHIGHISGPN SPLIGQKLSEMD  
SVLMKIHTSLQSKERETPLPNLLVLCGDHGMSETGSHGASSTEEVNTPLILISSAFERKP  
GDIRHPKHVQ

**Important features of the protein:****Signal peptide:**

amino acids 1-34

**Transmembrane domain:**

amino acids 58-76

**N-glycosylation sites:**

amino acids 56-60, 194-198

**N-myristoylation sites:**amino acids 6-12, 52-58, 100-106, 125-131, 233-239, 270-276,  
275-281, 278-284**Amidation site:**

amino acids 154-158

**Cell attachment sequence:**

amino acids 205-208

306/392

**FIGURE 293**

AGCCAGGCAGCACATCACAGCGGGAGGAGCTGTCCCAGGTGGCCCAGCTCAGCAATGGCA  
ATGGGGGTCCCCAGAGTCATTCTGCTCTGCCTCTTTGGGGCTGCGCTCTGCCTGACAGGG  
TCCCAAGCCCTGCAGTGCTACAGCTTTGAGCACACCTACTTTGGCCCCCTTTGACCTCAGG  
GCCATGAAGCTGCCCAGCATCTCCTGTCTCATGAGTGCTTTGAGGCTATCCTGTCTCTG  
GACACCGGGTATCGCGCGCCGGTGACCCCTGGTGCGGAAGGGCTGCTGGACCGGGCCTCCT  
GCGGGCCAGACGCAATCGAACCCGGACGCGCTGCCGCCAGACTACTCGGTGGTGCGCGGC  
TGCACAACTGACAAATGCAACGCCACCTCATGACTCATGACGCCCTCCCCAACCTGAGC  
CAAGCACCCGACCCGCGACGCTCAGCGGCGCCGAGTGCTACGCCTGTATCGGGGTCCAC  
CAGGATGACTGCGCTATCGGCAGGTCCCGACGAGTCCAGTGTCACCAGGACCAGACCGCC  
TGCTTCCAGGGCAGTGGCAGAATGACAGTTGGCAATTTCTCAGTCCCTGTGTACATCAGA  
ACCTGCCACCGGCCCTCCTGCACCACCGAGGGCACCACCAGCCCCCTGGACAGCCATCGAC  
CTCCAGGGCTCCTGCTGTGAGGGGTACCTCTGCAACAGGAAATCCATGACCCAGCCCTTC  
ACCA GTGCTTCAGCCACCACCCCTCCCCGAGCACTACAGGTCCTGGCCCTGCTCCTCCA  
GTCCTCCTGCTGGTGGGGCTCTCAGCATAGACCGCCCCCTCCAGGATGCTGGGGACAGGGC  
TCACACACCTCATTCTTGCTGCTTCAGCCCCTATCACATAGCTCACTGGAAAATGATGTT  
AAAGTAAGAATTGCAAAA

307/392

**FIGURE 294**

MAMGVPRVILLCLFGAALCLTGSQALQCYSFEHTYFGPFDLRAMKLPSISCPHECFEAIL  
SLDTGYRAPVTLVVRKGCWTGPPAGQTQSNPDALPPDYSVVRGCTTDKCNALMTHDALPN  
LSQAPDPPTLSGAECYACIGVHQDDCAIGRSRRVQCHQDQTACFQSGRMTVGNFSPVY  
IRTCHRPSCCTTEGTTSPWTAIDLQGSCCEGYLCNRKSMTQPFTSASATTPPRALQVLALL  
LPVLLLVLGSLA

**Important features of the protein:****Signal peptide:**

amino acids 1-19

**Transmembrane domain:**

amino acids 233-251

**N-glycosylation sites:**

amino acids 120-124, 174-178

**N-myristoylation sites:**

amino acids 15-21, 84-90

308/392

**FIGURE 295**

AATCGGCTGATTCTGCATCTGGAACTGCCTTCATCTTGAAAGAAAAGCTCCAGGTCCCT  
TCTCCAGCCACCCAGCCCCAAGATGGTGATGCTGCTGCTGCTGCTTTCCGCACTGGCTGG  
CCTCTTCGGTGCGGCAGAGGGACAAGCATTTTCATCTTGGGAAGTGCCCCAATCCTCCGGT  
GCAGGAGAATTTTGACGTGAATAAGTATCTCGGAAGATGGTACGAAATTGAGAAGATCCC  
AACAACTTTGAGAATGGACGCTGCATCCAGGCCAACTACTCACTAATGGAAAACGGAAA  
GATCAAAGTGTTAAACCAGGAGTTGAGAGCTGATGGAAGTGTGAATCAAATCGAAGGTGA  
AGCCACCCAGTTAACCTCACAGAGCCTGCCAAGCTGGAAGTTAAGTTTTCCTGGTTTAT  
GCCATCGGCACCGTACTGGATCCTGGCCACCGACTATGAGAAGTATGCCCTCGTGTATTC  
CTGTACCTGCATCATCAACTTTTTTCACGTGGATTTTGCTTGGATCTTGGCAAGAAACCC  
TAATCTCCCTCCAGAAACAGTGGACTCTCTAAAAAATATCCTGACTTCTAATAACATTGA  
TGTCAGAAAATGACGGTCACAGACCAGGTGAACTGCCCCAAGCTCTCGTAAACCAGGTTT  
TACAGGGAGGCTGCACCCACTCCATGTTACTTCTGCTTCGCTTTCCCCTACCCACCCCC  
CCCCCATAAAGACAAACCAATCAACCACGACAAAGGAAGTTGACCTGAACATGTAACCAT  
GCCCTACCCTGTTACCTTGCTAGCTGCAAATAAACTTGTTGCTGACCTGCTGTGCTCGC  
AAAAAA

309/392

**FIGURE 296**

MVMLLLLLLSALAGLFGAAEGQAFHLGKCPNPPVQENFDVNKYLGRWYEIEKIPPTTFENG  
RCIQANYSLMENGKIKVLNQELRADGTVNQIEGEATPVNLTEPAKLEVKFSWFMPSPAY  
WILATDYENYALVYSCTCIIQLFHVDFAWILARNPNLPPETVDSLKNILTSNNIDVKKM  
TVTDQVNCPKLS

**Signal sequence:**

1-16

**N-glycosylation site:**

65-68

98-101

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

175-178

**N-myristoylation site:**

13-18

16-21

**Lipocalin proteins:**

36-47

120-130

**Lipocalin / cytosolic fatty-acid binding proteins:**

41-185



310/392

**FIGURE 297**

GGGTGATTGAACTAAACCTTCGCCGCACCGAGTTTGCAGTACGGCCGTCACCCGCACCGC  
TGCCTGCTTGCGGTTGGAGAAATCAAGGCCCTACCGGGCCTCCGTAGTCACCTCTCTATA  
GTGGGCGTGCCGAGGCCGGGGTGACCTGCCGGAGCCTCCGCTGCCAGCGACATGTTCA  
AGGTAATTCAGAGGTCCGTGGGGCCAGCCAGCCTGAGCTTGCTCACCTTCAAAGTCTATG  
CAGCACCAAAAAAGGACTCACCTCCCAAAAATTCCGTGAAGGTTGATGAGCTTTCCTCT  
ACTCAGTTCCTGAGGGTCAATCGAAGTATGTGGAGGAGGCAAGGAGCCAGCTTGAAGAAA  
GCATCTCACAGCTCCGACACTATTGCGAGCCATACACAACCTGGTGTGAGGAAACGTACT  
CCCAAATAAGCCCAAGATGCAAAGTTTGGTTCAATGGGGGTTAGACAGCTATGACTATC  
TCCAAAATGCACCTCCTGGATTTTTTCCGAGACTTGGTGTATTGGTTTTGCTGGCCTTA  
TTGGACTCCTTTTGGCTAGAGGTTCAAAAATAAAGAAGCTAGTGTATCCGCCTGGTTTCA  
TGGGATTAGCTGCCTCCCTCTATTATCCACAACAAGCCATCGTGTGTTGCCAGGTCAGTG  
GGGAGAGATTATATGACTGGGGTTTACGAGGATATATAGTCATAGAAGATTTGTGGAAGG  
AGAACTTTCAAAGCCAGGAAATGTGAAGAATTCACCTGGAAGTAAGTAGAAAACCTCCAT  
GCTCTGCCATCTTAATCAGTTATAGGTAAACATTGGAAACTCCATAGAATAAATCAGTAT  
TTCTACAGAAAAATGGCATAGAAGTCAGTATTGAATGTATTAAATTGGCTTTCTTCTTCA  
GGAAAAACTAGACCAGACCTCTGTTATCTTCTGTGAAATCATCCTACAAGCAAACCTAAC  
TGGAATCCCTTCACCTAGAGATAATGTACAAGCCTTAGAACTCCTCATTCTCATGTTGCT  
ATTTATGTACCTAATTAAAACCCAAGTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAA

311/392

**FIGURE 298**

MFKVIQRSVGPASLSLLTFKVYAAPKKDSPPKNSVKVDELSLYSVPEGQSKYVEEARSQLEESISQLRHYCEPYTTWCQETYSQTKPKMQSLVQWGLDSYDYLQNAPPGFFPRLGVIGFAGLIGLLLARGSKIKKLVYPPGFMGLAASLYYPQQAIVFAQVSGERLYDWGLRGYIVIEDLWKENFQKPGNVKNSPGTK

**Important features:****Signal peptide:**

Amino acids 1-23

**Transmembrane domain:**

Amino acids 111-130

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

Amino acids 26-30

**Tyrosine kinase phosphorylation site:**

Amino acids 36-44

**N-myristoylation sites:**

Amino acids 124-130;144-150;189-195

312/392

## FIGURE 299

CCGCTGAGATGTACGAACTTCCGGTTCTCCGGGCAGCTGCCACTGCTGTAGCTTCTGCCA  
CCTGCCACGACCGGGCCTCTCCCTGGCGTTTGGTCACCTCTGCTTCATTCTCCACCGCGC  
CTATGGTCCCTCTTGGAGCCAGCGTGGCGGGCCTGGCGGCTCCCGGGTGGTGAGAGAGCG  
GTCCGGGAACGATGAAGGCCTCGCAGTGCTGCTGCTGTCTCAGCCACCTCTTGGCTTCCG  
TCCTCCTCCTGCTGTTGCTGCCTGAACTAAGCGGGCCCCCTGGCAGTCTGCTGCAGGCAG  
CCGAGGCCGCGCCAGGTCTTGGGCCTCCTGACCCTAGACCACGGACATTACCGCCGCTGC  
CACCGGGCCCTACCCCTGCCCAGCAGCCGGGCGCGTGGTCTGGCTGAAGCTGCGGGGCCG  
GGGGCTCCGAGGGAGGCAATGGCAGCAACCCTGTGGCCGGGCTTGAGACGGACGATCACG  
GAGGAAGGCCGGGAAGGCTCGGTGGGTGGCGGCCCTTGCTGTGAGCCCCAACCTGGCG  
ACAAGCCCATGACCCAGCGGGCCCTGACCGTGTGATGGTGGTGAGCGGCGCGGTGCTGG  
TGTACTTCGTGGTCAGGACGGTCAGGATGAGAAGAAGAAACCGAAAGACTAGGAGATATG  
GAGTTTTGGACACTAACATAGAAAATATGGAATTGACACCTTTAGAACAGGATGATGAGG  
ATGATGACAACACGTTGTTTGTATGCCAATCATCCTCGAAGATAAGAATGTGCCTTTTGAT  
GAAAGAACTTTATCTTTCTACAATGAAGAGTGGAATTTCTATGTTTAAGGAATAAGAAGC  
CACTATATCAATGTTGGGGGGGTATTTAAGTTACATATATTTTAACAACCTTTAATTTGC  
TGTTGCAATAAATAACCGTATCCTTTTATTATATCTTTATATGTATAGAAGTACTCTATTA  
ATGGGCTCAGAGATGTTGGGGATAAAGTATACTGTAATAATTTATCTGTTTGAAAATTAC  
TATAAAACGGTGTTTTCTGGTCGGTTTTTGTTCCTGCTTACCATATGATTGTAAATTGT  
TTTATGTATTAATCAGTTAATGCTAATTATTTTTGCTGATGTCATATGTTAAAGAGCTAT  
AAATCCAACAACCACTGGTGTGTAAAAATAATTTAAAATTCCTTTACTGAAAGGTAT  
TTCCCATTTTTGTGGGGAAAAGAAGCCAAATTTATTACTTTGTGTTGGGGTTTTTAAAT  
ATTAAGAAATGTCTAAGTTATTGTTTGCAAAACAATAAATATGATTTTAAATTCTCTTAA  
AAAAAAA

313/392

**FIGURE 300**

MKASQCCCLSHLLASVLLLLLLPELSGFLAVLLQAAEAPGLGPPDPRPRTLPPPLPPGP  
TPAQQPGRGLAEAAGPRGSEGGNGSNPVAGLETDDHGGKAGEGSVGGGLAVSPNPGDKPM  
TQRALTVLMVVGAVLVYFVVRTVRMRRRNKTRRYGVLDTNIENMELTPLEQDDEDDDN  
TLFDANHPRR

**Signal peptide:**  
amino acids 1-28

**Transmembrane domain:**  
amino acids 124-140

**N-glycosylation site:**  
amino acids 83-87

**N-myristoylation sites:**  
amino acids 69-75, 78-84, 81-87, 97-103, 103-109, 106-112,  
157-160

314/392

**FIGURE 301**

CTCGGCTGGATTTAAGGTTGCCGCTAGCCGCTGGGAATTTAAGGGACCCACACTACCTT  
CCCGAAGTTGAAGGCAAGCGGTGATTGTTTGTAGACGGCGCTTTGTCATGGGACCTGTGC  
GGTTGGGAATATTGCTTTTCCTTTTGGCCGTGCACGAGGCTTGGGCTGGGATGTTGA  
AGGAGGAGGACGATGACACAGAACGCTTGCCCAGCAAATGCGAAGTGTGTAAGCTGCTGA  
GCACAGAGCTACAGGCGGAACCTGAGTCGCACCGGTCGATCTCGAGAGGTGCTGGAGCTGG  
GGCAGGTGCTGGATACAGGCAAGAGGAAGAGACACGTGCCTTACAGCGTTTCAGAGACAA  
GGCTGGAAGAGGCCTTAGAGAATTTATGTGAGCGGATCCTGGACTATAGTGTTACAGCTG  
AGCGCAAGGGCTCACTGAGATATGCCAAGGTCAGAGTCAGACCATGGCAACACTGAAAG  
GCCTAGTGCAGAAGGGGGTGAAGGTGGATCTGGGGATCCCTCTGGAGCTTTGGGATGAGC  
CCAGCGTGGAGGTACATACCTCAAGAAGCAGTGTGAGACCATGTTGGAGGAGTTTGAAG  
ACATTGTGGGAGACTGGTACTTCCACCATCAGGAGCAGCCCCTACAAAATTTCTCTGTG  
AAGGTCATGTGCTCCAGCTGCTGAACTGCATGTCTACAGGAACTTGGACTGGAAAGG  
AGATCACAGATGGGGAAGAGAAAACAGAAGGGGAGGAAGAGCAGGAGGAGGAGGAGGAAG  
AGGAGGAAGAGGAAGGGGGAGACAAGATGACCAAGACAGGAAGCCACCCCAAACCTTGACC  
GAGAAGATCTTTGACCCCTTGCCCTTTGAGCCCCCAGGAGGGGAAGGGATCATGGAGAGCCC  
TCTAAAGCCTGCACTCTCCCTGCTCCACAGCTTTTCAGGGTGTGTTTATGAGTGACTCCAC  
CCAAGCTTGTTAGCTGTTCTCTCCCATCTAACCTCAGGCAAGATCCTGGTGAAACAGCATG  
ACATGGCTTCTGGGGTGGAGGGTGGGGGTGGAGGTCTGCTCCTAGAGATGAACTCTATC  
CAGCCCCTTAATTGGCAGGTGTATGTGCTGACAGTACTGAAAGCTTTCTCTTTAACTGA  
TCCCACCCCCACCCAAAAGTCAGCAGTGGCACTGGAGCTGTGGGCTTTGGGGAAGTCACT  
TAGCTCCTTAAGGTCTGTTTTTAGACCCTTCCAAGGAAGAGGCCAGAACGGACATTCTCT  
GCGATCTATATACATTGCCTGTATCCAGGAGGCTACACACCAGCAAACCGTGAAGGAGAA  
TGGGACACTGGGTGATGGCCTGGAGTTGCTGATAATTTAGGTGGGATAGATACTTGGTCT  
ACTTAAGCTCAATGTAACCCAGAGCCCACCATATAGTTTTATAGGTGCTCACTTTCTAT  
ATCGCTATTAAACTTTTTTCTTTTTTTCTA

315/392

**FIGURE 302**

MGPVRLGILLFLFLAVHEAWAGMLKEEDDDTERLPSKCEVCKLLSTELQAELSRTGRSRE  
VLELGQVLDTGKRKRHVPYSVSETRLEEALENLCERILDYSVHAERKGSRLRYAKGQSQTM  
ATLKGLVQKGKVDLGIPLELWDEPSVEVTYLLKKQCETMLEEFEDIVGDWYFHHQEQPLO  
NFLCEGHVLPAAETACLQETWTGKEITDGEKTEGEEQEEEEEEEEEEGGDKMTKTGSH  
PKLDREDL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-21

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 106-110

**N-myristoylation site:**

amino acids 115-121

**Amidation site:**

amino acids 70-74

316/392

**FIGURE 303**

CTCCTGCACTAGGCTCTCAGCCAGGGATGATGCGCTGCTGCCGCCGCCGCTGCTGCTGCC  
GGCAACCACCCCATGCCCTGAGGCCGTTGCTGTTGCTGCCCCCTCGTCCTTTTACCTCCCC  
TGGCAGCAGCTGCAGCGGGCCCAAACCGATGTGACACCATATAACCAGGGCTTCGCCGAGT  
GTCTCATCCGCTTGGGGGACAGCATGGGCCGCGGAGGCGAGCTGGAGACCATCTGCAGGT  
CTTGGAATGACTTCCATGCCTGTGCCTCTCAGGTCCCTGTCAGGCTGTCCGGAGGAGGCAG  
CTGCAGTGTGGGAATCACTACAGCAAGAAGCTCGCCAGGCCCCCGTCCGAATAACTTGC  
ACACTCTGTGCGGTGCCCCGGTGCATGTTCTGGGAGCGCGGCACAGGCTCCGAAACCAACC  
AGGAGACGCTGCGGGCTACAGCGCCTGCACTCCCCATGGCCCCCTGCGCCCCCACTGCTGG  
CGGCTGCTCTGGCTCTGGCCTACCTCCTGAGGCCTCTGGCCTAGCTTGTTGGGTTGGGTA  
GCAGCGCCCGTACCTCCAGCCCTGCTCTGGCGGTGGTTGTCCAGGCTCTGCAGAGCGCAG  
CAGGGCTTTTCATTAAAGTATTTATATTTGTA

317/392

**FIGURE 304**

MMRCCRRRCCCRQPPHALRPLLLLPLVLLPPLAAAAAGPNRCDTIYQGFAECLIRLGDSM  
GRGGELETICRSWNDFHACASQVLSGCPEEAAAVWESLQQEARQAPRPNNLHTLCGAPVH  
VRERGTGSETNQETLRATAPALPMAPAPPLLAALALAYLLRPLA

**Signal peptide:**

Amino acids 1-35

**Transmembrane domain:**

Amino acids 141-157

**N-myristoylation site:**

Amino acids 127-133

**Prokaryotic membrane lipoprotein lipid attachment site:**

Amino acids 77-88



318/392

**FIGURE 305**

AAGTACTTGTGTCCGGGTGGTGGACTGGATTAGCTGCGGAGCCCTGGAAGCTGCCTGTCC  
TTCTCCCTGTGCTTAACCAGAGGTGCCCATGGGTTGGACAATGAGGCTGGTCACAGCAGC  
ACTGTTACTGGGTCTCATGATGGTGGTCACTGGAGACGAGGATGAGAACAGCCCGTGTGC  
CCATGAGGCCCTCTTGGACGAGGACACCCTCTTTTGCCAGGGCCTTGAAGTTTCTACCC  
AGAGTTGGGGAACATTGGCTGCAAGGTTGTTCTGATTGTAACAACCTACAGACAGAAGAT  
CACCTCCTGGATGGAGCCGATAGTCAAGTTCCCGGGGGCCGTGGACGGCGCAACCTATAT  
CCTGGTGATGGTGGATCCAGATGCCCCTAGCAGAGCAGAACCCAGACAGAGATTCTGGAG  
ACATTGGCTGGTAAACAGATATCAAGGGCGCCGACCTGAAGAAAGGGAAGATTCTAGGGCCA  
GGAGTTATCAGCCTACCAGGCTCCCTCCCCACCGGCACACAGTGGCTTCCATCGCTACCA  
GTTCTTTGTCTATCTTCAGGAAGGAAAAGTCATCTCTCTCCTTCCCAAGGAAAACAAAAC  
TCGAGGCTCTTGAAAAATGGACAGATTTCTGAACCGCTTCCACCTGGGCGAACCTGAAGC  
AAGCACCAGTTCATGACCCAGAACTACCAGGACTCACCAACCCTCCAGGCTCCCAGAGG  
AAGGGCCAGCGAGCCCAAGCACAAAACCAGGCAGAGATAGCTGCCTGCTAGATAGCCGGC  
TTTGCCATCCGGGCATGTGGCCCACTGCTCACCACCGACGATGTGGGTATGGAACCCCC  
TCTGGATACAGAACCCCTTCTTTTCCAAATTAAAAAAAAAAATCATCAA

319/392

**FIGURE 306**

MGWTMRLVTAALLLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV  
VPDCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSRAEPRQRFWRHWLVTDIKG  
ADLKKGKIQGQELSAYQAPSPPAHSGFHRYQFFVYLQEGKVISLLPKENKTRGSWKMDRF  
LNRFHLGEPEASTQFMTQNYQDSPTLQAPRGRASEPKHKTRQR

**Important features of the protein:**

**Signal peptide:**

amino acids 1-22

**N-glycosylation site:**

amino acids 169-173

**Tyrosine kinase phosphorylation site:**

amino acids 59-68

**N-myristoylation sites:**

amino acids 54-60, 83-89, 130-136

**Phosphatidylethanolamine signature:**

amino acids 113-157

320/392

**FIGURE 307**

AAGGAGCAGCCCGCAAGCACCAAGTGAGAGGCATGAAGTTACAGTGTGTTTCCCTTTGGC  
TCCTGGGTACAATACTGATATTGTGCTCAGTAGACAACCACGGTCTCAGGAGATGTCTGA  
TTTCCACAGACATGCACCATATAGAAGAGAGTTTCCAAGAAATCAAAAGAGCCATCCAAG  
CTAAGGACACCTTCCCAAATGTCACTATCCTGTCCACATTGGAGACTCTGCAGATCATT  
AGCCCTTAGATGTGTGCTGCGTGACCAAGAACCTCCTGGCGTTCTACGTGGACAGGGTGT  
TCAAGGATCATCAGGAGCCAAACCCCAAAATCTTGAGAAAAATCAGCAGCATTGCCAACT  
CTTTCCTCTACATGCAGAAAACCTGCGGCAATGTCAGGAACAGAGGCAGTGTCACTGCA  
GGCAGGAAGCCACCAATGCCACCAGAGTCATCCATGACAACCTATGATCAGCTGGAGGTCC  
ACGCTGCTGCCATTAAATCCCTGGGAGAGCTCGACGTCTTTCTAGCCTGGATTAATAAGA  
ATCATGAAGTAATGTTCTCAGCTTGATGACAAGGAACCTGTATAGTGATCCAGGGATGAA  
CACCCCCTGTGCGGTTTACTGTGGGAGACAGCCCACCTTGAAGGGGAAGGAGATGGGGAA  
GGCCCCCTTGAGCTGAAAGTCCCACTGGCTGGCCTCAGGCTGTCTTATTCCGCTTGAAAA  
TAGGCAAAAAGTCTACTGTGGTATTTGTAATAAACTCTATCTGCTGAAAGGGCCTGCAGG  
CCATCCTGGGAGTAAAGGGCTGCCTTCCCATCTAATTTATTGTAAAGTCATATAGTCCAT  
GTCTGTGATGTGAGCCAAGTGATATCCTGTAGTACACATTGTACTGAGTGGTTTTTCTGA  
ATAAATTCATATTTTACCTATGA

321/392

**FIGURE 308**

MKLQCVSLWLLGTILILCSVDNHGLRRCLISTDMHHIEESFQEIKRAIQAKDTFPNVTIL  
STLETLQIIKPLDVCCVTKNLLAFYVDRVFKDHQEPNPKILRKISSIANSFLYMQKTLRQ  
CQEQRQCHCRQEATNATRVIHNDNYDQLEVHAAAIKSLGELDVFLAWINKNHEVMFSA

**Signal sequence:**

amino acids 1-18

**N-glycosylation sites:**

amino acids 56-60, 135-139

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 102-106

**N-myristoylation site:**

amino acids 24-30

**Actinin-type actin-binding domain signature 1:**

amino acids 159-169

322/392

## FIGURE 309

GTCGACCCACGCGTCCGAAGCTGCTGGAGCCACGATTCAGTCCCCTGGACTGTAGATAAA  
GACCCTTTCTTGCCAGGTGCTGAGACAACCACACTATGAGAGGCACTCCAGGAGACGCTG  
ATGGTGGAGGAAGGGCCGTCTATCAATCAATCACTGTTGCTGTTATCACATGCAAGTATC  
CAGAGGCTCTTGAGCAAGGCAGAGGGGATCCATTTATTTGGGAATCCAGAATCCAGAAA  
TGTGTTTGTATTGTGAGAAGGTTGGAGAACAGCCACATTGCAGCTAAAAGAGCAGAAGA  
TCATGGATCTGTATGGCCAACCCGAGCCCGTGAAACCCTTCCTTTTCTACCGTGCCAAGA  
CTGGTAGGACCTCCACCCTTGAGTCTGTGGCCTTCCCGGACTGGTTTCATTGCCTCCTCCA  
AGAGAGACCAGCCCATCATTTCTGACTTCAGAACTTGGGAAGTCATACAACACTGCCTTTG  
AATTAAATATAAATGACTGA<sup>1</sup>ACTCAGCCTAGAGGTGGCAGCTTGGTCTTTGTCTTAAAGT  
TTCTGGTTCCCAATGTGTTTTTCGTCTACATTTTCTTAGTGTCATTTTCACGCTGGTGCTG  
AGACAGGAGCAAGGCTGCTGTTATCATCTCATTTTATAATGAAGAAGAAGCAATTACTTC  
ATAGCAACTGAAGAACAGGATGTGGCCTCAGAAGCAGGAGAGCTGGGTGGTATAAGGCTG  
TCCTCTCAAGCTGGTGCTGTGTAGGCCACAAGGCATCTGCATGAGTGACTTTAAGACTCA  
AAGACCAAACACTGAGCTTTCTTCTAGGGGTGGGTATGAAGATGCTTCAGAGCTCATGCG  
CGTTACCCACGATGGCATGACTAGCACAGAGCTGATCTCTGTTTCTGTTTGTCTTTATTC  
CCTCTTGGGATGATATCATCCAGTCTTTATATGTTGCCAATATACCTCATTGTGTGTAAT  
AGAACCTTCTTAGCATTAAAGACCTTGTAACAAAAATAATTCTTGGGGTGGGTATGAAGA  
TGCTTCAGAGCTCATGCGCGTTACCCACGATGGCATGACTAGCACAGAGCTGATCTCTGT  
TTCTGTTTTGCTTTATTCCCTCTTGGGATGATATCATCCAGTCTTTATATGTTGCCAATA  
TACCTCATTGTGTGTAATAGAACCCTTCTTAGCATTAAAGACCTTGTAACAAAAATAATTC  
TTGTGTAAAGTTAAATCATTTTTGTCCTAATTGTAATGTGTAATCTTAAAGTTAAATAAA  
CTTTGTGTATTTATATAATAATAAAGCTAA<sup>2</sup>ACTGATATAAAATAAAGAAAGAGTAAACTG

323/392

## FIGURE 310

MRGTPGDADGGGRAVYQSITVAVITCKYPEALEQGRGDPIYLGIONPEMCLYCEKVGEQP  
TLQLKEQKIMDLYGQPEPVKPFIFYRAKTGRTSTLESVAFPDWFIASSKRDQPIILTSEL  
GKSYNTAFELNIND

Signal sequence:  
amino acids 1-17

N-myristoylation site:  
amino acids 10-16

Cell attachment sequence:  
amino acids 36-39

324/392

**FIGURE 311**

GGGAGGCTGCACCAGCGCCTGGCACCATGAGGACGCCTGGGCCTCTGCCCCGTGCTGCTGC  
TGCTCCTGGCGGGAGCCCCCGCCGCGCGGCCCACTCCCCGACCTGCTACTCCCGCATGC  
GGGCCCTGAGCCAGGAGATCACCCGCGACTTCAACCTCCTGCAGGTCTCGGAGCCCTCGG  
AGCCATGTGTGAGATACCTGCCCAGGCTGTACCTGGACATACACAATTACTGTGTGCTGG  
ACAAGCTGCGGGACTTTGTGGCCTCGCCCCCGTGTGGAAAGTGGCCCAGGTAGATTCTT  
TGAAGGACAAAGCACGGAAGCTGTACACCATCATGAACTCGTTCTGCAGGAGAGATTTGG  
TATTCCTGTTGGATGACTGCAATGCCTTGGAATACCCAATCCCAGTGACTACGGTCCTGC  
CAGATCGTCAGCGCTAAGGGAAGTGAAGACCAGAGAAAGAACCCAAGAGAACTAAAGTTAT  
GTCAGCTACCCAGACTTAATGGGCCAGAGCCATGACCCCTCACAGGTCTTGTGTTAGTTGT  
ATCTGAAACTGTTATGTATCTCTCTACCTTCTGGAAAACAGGGCTGGTATTCCCTACCCAG  
GAACCTCCTTTGAGCATAGAGTTAGCAACCATGCTTCTCATTCCCTTGACTCATGTCTTG  
CCAGGATGGTTAGATACACAGCATGTTGATTTGGTCACTAAAAGAAGAAAAGGACTAAC  
AAGCTTCACTTTTATGAACAACATATTTTGAGAACATGCACAATAGTATGTTTTTATTACT  
GGTTTAATGGAGTAATGGTACTTTTATTCTTTCTTGATAGAAACCTGCTTACATTTAAC  
AAGCTTCTATTATGCCTTTTCTAACACAGACTTTCTTCACTGTCTTTTATTTAAAAGA  
AATTAATGCTCTTAAGATATATATTTTACGTAGTGCTGACAGGACCCACTCTTTCATTGA  
AAGGTGATGAAAATCAAATAAAGAATCTCTTCACATGGA

325/392

## FIGURE 312

MRTPGPLPVLLLLLAGAPAAPPTPTCYSRMRALSQEITRDFNLLQVSEPSEPCVRYLPR  
LYLDIHNYCVLDKLRDFVASPPCWKVAQVDSLKDKARKLYTIMNSFCRRDLVFLDDCNA  
LEYPIPVTTVLPDRQR

**Important features of the protein:**

**Signal peptide:**

amino acids 1-19

**Tyrosine kinase phosphorylation site:**

amino acids 60-69

**N-myristoylation site:**

amino acids 16-22



326/392

**FIGURE 313**

GAGCGACGCTGTCTCTAGTCGCTGATCCCAAATGCACCGGCTCATCTTTGTCTACACTCT  
AATCTGCGCAAACCTTTTGCAGCTGTCTGGGACACTTCTGCAACCCCGCAGAGCGCATCCAT  
CAAAGCTTTGCGCAACGCCAACCTCAGGCGAGATGACTTGTACCGAAGAGATGAGACCAT  
CCAGGTGAAAGGAAACGGCTACGTGCAGAGTCCTAGATTCCCGAACAGCTACCCCAGGAA  
CCTGCTCCTGACATGGCGGCTTCACTCTCAGGAGAATACACGGATACAGCTAGTGTTTGA  
CAATCAGTTTGGATTAGAGGAAGCAGAAAATGATATCTGTAGGTATGATTTTGTGGAAGT  
TGAAGATATATCCGAAACCAGTACCATTATTAGAGGACGATGGTGTGGACACAAGGAAGT  
TCCTCCAAGGATAAAATCAAGAACGAACCAAATTAATAATCACATTCAAGTCCGATGACTA  
CTTTGTGGCTAAACCTGGATTCAAGATTTATTATTCTTTGCTGGAAGATTTCCAACCCGC  
AGCAGCTTCAGAGACCAACTGGGAATCTGTCACAAGCTCTATTTTCAGGGGTATCCTATAA  
CTCTCCATCAGTAACGGATCCCCTCTGATTGCGGATGCTCTGGACAAAAAATTGCAGA  
ATTTGATACAGTGGAAGATCTGCTCAAGTACTTCAATCCAGAGTCATGGCAAGAAGATCT  
TGAGAATATGTATCTGGACACCCCTCGGTATCGAGGCAGGTCATACCATGACCGGAAGTC  
AAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTACAGTTGCACTCCCAGGAA  
TTACTCGGTCAATATAAGAGAAGAGCTGAAGTTGGCCAATGTGGTCTTCTTTCCACGTTG  
CCTCCTCGTGCAGCGCTGTGGAGGAAATTGTGGCTGTGGAAGTGTCAACTGGAGGTCCTG  
CACATGCAATTCAGGGAAAACCGTGAAAAAGTATCATGAGGTATTACAGTTTGAGCCTGG  
CCACATCAAGAGGAGGGGTAGAGCTAAGACCATGGCTCTAGTTGACATCCAGTTGGATCA  
CCATGAACGATGCGATTGTATCTGCAGCTCAAGACCACCTCGATAAGAGAATGTGCACAT  
CCTTACATTAAGCCTGAGAGAA

327/392

**FIGURE 314**

MHRLIFVYTLCANFCSCRDTSATPQSASIKALRNANLRRDDL YRRDETIQVKNGYVQS  
PRFPNSYPRNLLLTWRLHSQENTRIQLVFDNQFGL EEAENDICRYDFVEVEDISETSTII  
RGRWCGHKEVPPRIKSRTNQIKITFKSDDYFVAKPGFKIYYSLLED FQPAAASETNWESV  
TSSISGVSYNSPSVTDPTLIADALDKKIAEFDTVEDLLKYFNPESWQEDLENMYLDTPRY  
RGRSYHDRKSKVDLDRLNDDAKRYSCTPRNYSVNIREELKLANVVF FPRCLLVQRCGGNC  
GCGTVNWR SCTCNSGKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDCICSS  
RPPR

**Signal peptide:**  
amino acids 1-18

**N-glycosylation site:**  
amino acids 270-274

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**  
amino acids 262-266

**Tyrosine kinase phosphorylation site:**  
amino acids 256-265

**N-myristoylation sites:**  
amino acids 94-100, 186-192, 297-303, 298-304

**TonB-dependent receptor proteins signature 1:**  
amino acids 1-56

328/392

## FIGURE 315

CGGCTCGAGGCTCCCGCCAGGAGAAAGGAACATTCTGAGGGGAGTCTACACCCTGTGGAG  
CTCAAGATGTCCTGAGTGGGGCGCTGTGCTTCCGAATGAAGGACTCGGCATTGAAGGTG  
CTTTATCTGCATAATAACCAGCTTCTAGCTGGAGGGCTGCATGCAGGGAAGGTCATTAAA  
GGTGAAGAGATCAGCGTGGTCCCCAATCGGTGGCTGGATGCCAGCCTGTCCCCCGTCATC  
CTGGGTGTCCAGGGTGGAAAGCCAGTGCCTGTATGTGGGGTGGGGCAGGAGCCGACTCTA  
ACACTAGAGCCAGTGAACATCATGGAGCTCTATCTTGGTGCCAAGGAATCCAAGAGCTTC  
ACCTTCTACCGGCGGGACATGGGGCTCACCTCCAGCTTCGAGTCGGCTGCCTACCCGGGC  
TGGTTCCTGTGCACGGTGCCTGAAGCCGATCAGCCTGTGAGCTCACCCAGCTTCCCGAG  
AATGGTGGCTGGAATGCCCCCATCACAGACTTCTACTTCCAGCAGTGTGACTAGGGCAAC  
GTGCCCCCAGAACTCCCTGGGCAGAGCCAGCTCGGGTGAGGGGTGAGTGGAGGAGACCC  
ATGGCGGACAATCACTCTCTCTGCTCTCAGGACCCCCACGTCTGACTTAGTGGGCACCTG  
ACCACTTTGTCTTCTGGTTCCAGTTTGGATAAATTCTGAGATTTGGAGCTCAGTCCACG  
GTCTTCCCCCACTGGATGGTGCTACTGCTGTGGAACCTTGTAAAAACCATGTGGGGTAAA  
CTGGGAATAACATGAAAAGATTTCTGTGGGGGTGGGGTGGGGGAGTGGTGGGAATCATTC  
CTGCTTAATGGTAACTGACAAGTGTTACCCTGAGCCCCGAGGCCAACCCATCCCCAGTT  
GAGCCTTATAGGGTCAGTAGCTCTCCACATGAAGTCTGTCACTCACCCTGTGCAGGAG  
AGGGAGGTGGTCATAGAGTCAGGGATCTATGGCCCTTGGCCAGCCCCACCCCTTCCCT  
TTAATCCTGCCACTGTATATGCTACCTTTCCCTATCTCTTCCCTCATCATCTTGTGTGG  
GCATGAGGAGGTGGTGATGTGAGAAGAAATGGCTCGAGCTCAGAAGATAAAAGATAAGTA  
GGGTATGCTGATCCTCTTTTAAAAACCCAAGATACAATCAAAATCCCAGATGCTGGTCTC  
TATTTCCCATGAAAAGTGCTCATGACATATTGAGAAGACCTACTTACAAAGTGGCATATA  
TTGCAATTTATTTTAAATTAAGATACCTATTTATATATTTCTTTATAGAAAAAGTCTG  
GAAGAGTTTACTTCAATTGTAGCAATGTGAGGGTGGTGGCAGTATAGGTGATTTTTCTTT  
TAATTCTGTTAATTTATCTGTATTTCCCTAATTTTTCTACAATGAAGATGAATTCCTTGTA  
TAAAAATAAGAAAAGAAATTAATCTTGAGGTAAGCAGAGCAGACATCATCTCTGATTGTC  
CTCAGCCTCCACTTCCCCAGAGTAAATTCAAATTGAATCGAGCTCTGCTGCTCTGGTTGG  
TTGTAGTAGTGATCAGGAAACAGATCTCAGCAAAGCCACTGAGGAGGAGGCTGTGCTGAG  
TTTGTGTGGCTGGAATCTCTGGGTAAGGAACCTTAAAGAACAAAAATCATCTGGTAATTCT  
TTCCTAGAAGGATCACAGCCCCCTGGGATTCCAAGGCATTGGATCCAGTCTCTAAGAAGGC  
TGCTGTACTGGTTGAATTGTGTCCCCCTCAAATTCACATCCTTCTTGGAATCTCAGTCTG  
TGAGTTTATTTGGAGATAAGGTCTCTGCAGATGTAGTTAGTTAAGACAAGGTCTGCTGG  
ATGAAGGTAGACCTAAATTCAATATGACTGGTTTCCTTGTATGAAAAGGAGAGGACACAG  
AGACAGAGGAGACGCGGGGAAGACTATGTAAAGATGAAGGCAGAGATCGGAGTTTTGCAG  
CCACAAGCTAAGAAACACCAAGGATTGTGGCAACCATCAGAAGCTTGAAGAGGCAAAGA  
AGAATTCTTCCCTAGAGGCTTTAGAGGGATAACGGCTCTGCTGAAACCTTAATCTCAGAC  
TTCCAGCCTCCTGAACGAAGAAAGATAAATTTCCGGCTGTTTTAAGCCACCAAGGATAAT  
TGGTTACAGCAGCTCTAGGAAACTAATACAGCTGCTAAAATGATCCCTGTCTCCTCGTGT  
TTACATTCTGTGTGTGTCCCCCTCCACAATGTACCAAAGTTGTCTTTGTGACCAATAGAA  
TATGGCAGAAGTGATGGCATGCCACTTCCAAGATTAGGTTATAAAAGACACTGCAGCTTC  
TACTTGAGCCCTCTCTCTCTGCCACCCACCGCCCCCAATCTATCTTGGCTCACTCGCTCT  
GGGGGAAGCTAGCTGCCATGCTATGAGCAGGCCTATAAAGAGACTTACGTGGTAAAAAAT  
GAAGTCTCCTGCCACAGCCACATTAGTGAACCTAGAAGCAGAGACTCTGTGAGATAATC  
GATGTTTGTGTTGTTTAAAGTTGCTCAGTTTTGGTCTAACTTGTTATGCAGCAATAGATAAA  
TAATATGCAGAGAAAGAG

329/392

## FIGURE 316

MVLSGALCFRMKDSALKVLYLHNNQLLAGGLHAGKVIKGEEISVVPNRWLDASLSPVILG  
VQGSQCLSCGVGQEPTLTLEPVNIMELYLGAKESKSFTFYRRDMGLTSSFESAAYPGWF  
LCTVPEADQPVRLTQLPENGGWNAPITDFYFQQCD

**N-myristoylation sites:**

amino acids 29-34, 30-35, 60-65, 63-68, 73-78, 91-96, 106-111

**Interleukin-1 signature:**

amino acids 111-131

**Interleukin-1 proteins:**

amino acids 8-29, 83-120, 95-134, 64-103

330/392

**FIGURE 317**

ATGGAACTTGGACTTGGAGGCCTCTCCACGCTGTCCCCTGCCCCTGGCCTAGGCGGCAG  
CCTGCCCTGTGGCCACCCCTGGCCGCTCTGGCTCTGCTGAGCAGCGTCGCAGAGGCCTCC  
CTGGGCTCCGCGCCCCGCAGCCCTGCCCCCGCGAAGGCCCCCGCCTGTCCTGGCGTCC  
CCCGCCGGCCACCTGCCGGGGGACGCACGGCCCGCTGGTGCAGTGGAAGAGCCCGGCGG  
CCGCCGCCGCAGCCTTCTCGGCCCCGCGCCCCCGCCGCTGCACCCCCATCTGCTCTTCCC  
CGCGGGGGCCGCGCGGCGGGCTGGGGGCCCGGGCAGCCGCGCTCGGGCAGCGGGGGCG  
CGGGGCTGCCGCTGCGCTCGCAGCTGGTGCCGGTGCGCGCGCTCGGCCTGGGCCACCGC  
TCCGACGAGCTGGTGCGTTTCCGCTTCTGCAGCGGCTCCTGCCGCCGCGCGCGCTCTCCA  
CACGACCTCAGCCTGGCCAGCCTACTGGGCGCCGGGGGCCCTGCGACCGCCCCGGGCTCC  
CGGCCCGTCAGCCAGCCCTGCTGCCGACCCACGCGCTACGAAGCGGTCTCCTTCATGGAC  
GTCAACAGCACCTGGAGAACCGTGGACCGCCTCTCCGCCACCGCCTGCGGCTGCCTGGGC  
TGA

331/392

**FIGURE 318**

MELGLGGLSTLSHCPWPRRQPALWPTLAALALLSSVAEASLGSAPRSPAPREGPPPVLAS  
PAGHLPGGRTARWCSEGRARRPPPQPSRPAPPPAPPSALPRGGRAARAGGPGSRARAAGA  
RGCLRSQQLVPVRALGLGHRDELVRFRFCGSCRRARSPHDLSLASLLGAGALRPPPGS  
RPVSQPCCRPTRYEAVSFMDVNSTWRTVDRLSATAACGCLG

**signal sequence:**

Amino acids 1-39

**N-glycosylation site:**

Amino acids 202-206

**N-myristoylation sites:**

Amino acids 6-12;67-73;102-108;109-115;119-125

332/392

**FIGURE 319**

GTTGCTATGTTGCCCAGGCTGGTCTTGAAGTGCCTTGACCTCCTAAAGTGTGGAACCAC  
AGACGTGAGCCACTCCACCCAGCCTAAACTTCATCTTCTTTGGATGAGATGAACACTTT  
TAACAAGAGAACAGGACTCTATATAAATCGCTGTGGGCTCACCACCTCTAAGGAGGAGCA  
CTGACTGAAGACAGAAAAATTGATGAACTGAAGAAGACATGGTCCATTATGCCTTACAAA  
CTTACACAGTGCTTTGGGAATTCCAAAGTACTCAGTGGAGAGAGGTGTTTCAGGAGCCGT  
AGAGCCAGATCGTCATCATGTCTGCATTGTGGCTGCTGCTGGGCCTCCTTGCCCTGATGG  
ACTTGTCTGAAAGCAGCAACTGGGGATGCTATGGAAACATCCAAAGCCTGGACACCCCTG  
GAGCATCTTGTGGGATTGGAAGACGTCACGGCCTGAACTACTGTGGAGTTCGTGCTTCTG  
AAAGGCTGGCTGAAATAGACATGCCATACCTCCTGAAATATCAACCCATGATGCAAACCA  
TTGGCCAAAAGTACTGCATGGATCCTGCCGTGATCGCTGGTGTCTTGTCCAGGAAGTCTC  
CCGGTGACAAAATTCTGGTCAACATGGGCGATAGGACTAGCATGGTGCAGGACCCCTGGCT  
CTCAAGCTCCACATCCTGGATTAGTGAGTCTCAGGTTTCCCAGACAACCTGAAGTTCTGA  
CTACTAGAATCAAAGAAATCCAGAGGAGGTTTCCAACCTGGACCCCTGACCAGTACCTGA  
GAGGTGGACTCTGTGCCTACAGTGGGGGTGCTGGCTATGTCCGAAGCAGCCAGGACCTGA  
GCTGTGACTTCTGCAATGATGTCCTTGACGAGCCAAGTACCTCAAGAGACATGGCTTCT  
AACATCTCAGATGAAACCCAAGACCATGATCACATATGCAGCCTCAAATGTTACACAGAT  
AAAAGTAGCCAAGGGCACCTGTAAGTGGGAATCTGAGTTTGACCTAAAAGTCATTAAAAT  
AACATGAATCCCATTAATAAAAAAAAAAAAAA

333/392

## FIGURE 320

MSALWLLLGLLALMDLSESSNWGCYGNIQSLDTPGASCGIGRRHGLNYCGVRASERLAEI  
DMPYLLKYQPMQTIGQKYCMDPAVIAGVLSRKSPGDKILVNMGDRTSMVQDPGSQAPTS  
WISESQVSQTTEVLTTTRIKEIQRRFPTWTPDQYLRGGLCAYSGGAGYVRSSQDLSCDFCN  
DVLARAKYLKRHGF

**Important features of the protein:**

**Signal peptide:**

amino acids 1-19

**N-myristoylation sites:**

amino acids 23-29, 26-32, 35-41, 45-51, 50-56, 76-82, 156-162

**Amidation site:**

amino acids 40-44



334/392

**FIGURE 321**

GCCTTATAAAGTAGCCTCTGCATCTGCCTGCCTCGGGCAGAGGAGGGCTACCCTGGGGCT  
GAGAGTTCACCTGTCTCAGGAACCACCTGAGCCCACAGATCCTGTGGGCAGCGGCCAGGG  
CAGCCATGGCCTTGGGCAAGTAGGCTGGGCCTGCTGCTGGCACTGCTGCTGCCCGTGGTCTG  
GTGCCTCCACGCCAGGCACCGTGGTCCGACTCAACAAGGCAGCATTGAGCTACGTGTCTG  
AAATTGGGAAAGCCCCCTCTCCAGCGGGCCCTGCAGGTCACTGTCCCTCATTTCTGGACT  
GGAGTGGAGAGGGCGCTTCAGCCCACCAGGATCCGGATTCTGAATGTCCATGTGCCCCGCC  
TCCACCTGAAATTCATTGCTGGTTTTCGGAGTGCGCCTGCTGGCAGCAGCTAATTTTACTT  
TCAAGGTCTTTCGCGCCCCAGAGCCCCTGGAGCTGACGCTGCCTGTGGAAGTCTGGCTG  
ACACCCGCGTGACCCAGAGCTCCATCAGGACCCCTGTGGTCAGCATCTCTGCCTGCTCTT  
TATTCTCGGGCCACGCCAACGAGTTTGATGGCAGTAACAGCACCTCCCACGCGCTGCTGG  
TCCTGGTGCAAGAAGCACATTAAAGCTGTCTTGAGTAACAAGCTGTGCCTGAGCATCTCCA  
ACCTGGTGCAAGGTGTCAATGTCCACCTGGGCACCTTAATTGGCCTCAACCCCGTGGGTCT  
CTGAGTCCCAGATCCGCTATTCCATGGTCAGTGTGCCCACTGTCAACAGTGAAGTACATTT  
CCCTGGAAGTCAATGCTGTTCTCTTCTGCTGGGCAACCCCATCATCTGCCCACGGATG  
CCACCCCTTTTGTGTTGCCAAGGCATGTGGGTACCGAGGGCTCCATGGCCACCGTGGGCC  
TCTCCCAGCAGCTGTTTGACTCTGCGCTCCTGCTGCTGCAGAAGGCCGGTGGCCCTCAACC  
TGGACATCACAGGGCAGCTGAGGTCCGATGACAACCTGCTGAACACCTCTGCTCTGGGCC  
GGCTCATCCCGGAGGTGGCCCGCCAGTTTCCCGAGCCCATGCCTGTGGTGCTCAAGGTGC  
GGCTGGGTGCCACACCTGTGGCCATGCTCCACACAAACAACGCCACCCCTGCGGCTGCAGC  
CCTTCGTGGAGGTCTGGCCACAGCCTCCAACCTCGGCTTTCCAGTCCCTCTTCTCCCTGG  
ATGTGGTAGTGAACCTTGAGACTCCAGCTCTCTGTGTCCAAGGTGAAGCTTCAGGGGACCA  
CGTCTGTGCTGGGGGATGTCCAGCTCACGGTGGCCTCCTCCAACGTGGGCTTCATTGATA  
CAGATCAGGTGCGCACACTGATGGGCACCGTTTTTTGAGAAGCCCCTGCTGGACCATCTCA  
ATGCTCTCTTGGCCATGGGAATTGCCCTCCCTGGTGTGGTCAACCTCCACTATGTTGCC  
CTGAGATCTTTGTCTATGAGGGCTACGTGGTGATATCCAGTGGACTCTTCTACCAGAGCT  
GAGGCAAGACCACTGGGAGGCCTGAGAGTGGGCCAGCTCGCTGCTCAGGCGAATTTCTCA  
TTTCAAGCCACTGGGGAAACTGAGGCAAAACCATACTTAGTCATCACCAACAAGCTGGAC  
TGCTTAGCTGGGCTGTTTTATCTTCCCTGAGTGCCTGGGTCTCCCTCCCTCACTTCTGCC  
CTTTCCTTCCCTCCTCCTCTTCTCCTCCCTCTTCCCTCATCTCCCCCTCCTTCTCTGC  
CCCACCCCAAGGGGGGAGCAGACTGCTCCTCCAGGCTGTATAGACCTGCCCTCTTGCAATTA  
AACAACTTCTCTTGAGCTGC

335/392

**FIGURE 322**

MAWASRLGLLLALLLPVVGASTPGTVVRLNKAALSYVSEIGKAPLQRALQVTVPHFLDWS  
GEALQPTRIRILNVHVPRLHLKFIAGFGVRLLAANFTFKVFRAPPELELTPVELLADT  
RVTQSSIRTPVVSISACSLFSGHANEFDGSNSTSHALLVLVQKHIKAVLSNKLCLISISNL  
VQGVNVHLGTLIGLNPVGPESQIRYSMVSVPVTSDYISLEVNAVLFLLGNPIILPTDAT  
PFVLP RHVGT EGSMATVGLSQQLFDSALLLQKAGALNLDITGQLRSDDNLLNTSALGRL  
IPEVARQFPEPMPVVLKVRLGATPVAMLHTN NATLRLQPFVEVLATASNSAFQSLFSLDV  
VVNLRQLQSVSKVKLQGTTSVLGDVQLTVASSNVGFIDTDQVRTLMGTVFEKPLLDHLNA  
LLAMGIALPGVVNLHYVAPEIFVYEGYVVISSGLFYQS

**Important features of the protein:****Signal peptide:**

Amino acids 1-20

**Transmembrane domain:**

Amino acids 217-236

**N-glycosylation sites:**

Amino acids 96-100;151-155;293-297;332-336

**N-myristoylation sites:**

Amino acids 8-14;149-155;189-195;249-255;252-258;283-289

**LBP / BPI / CETP family proteins:**

Amino acids 22-50; 251-287

336/392

**FIGURE 323**

TTGAAAATCTACTCTATCAGCTGCTGTGGTTGCCACCATTCTCAGGACCCCTCGCCATGAA  
AGCCCTTATGCTGCTCACCCTGTCTGTTCTGCTCTGCTGGGTCTCAGCTGACATTGCTG  
TCACTCCTGCTACAAGGTCCCTGTGCTGGGCTGTGTGGACCGGCAGTCCTGCCGCCTGGA  
GCCAGGACAGCAATGCCTGACAACACATGCATACCTTGGTAAGATGTGGGTTTTCTCCAA  
TCTGCGCTGTGGCACACCAGAAGAGCCCTGTCAGGAGGCCTTCAACCAAACCAACCGCAA  
GCTGGGTCTGACATATAACACCACCTGCTGCAACAAGGACAACCTGCAACAGCGCAGGACC  
CCGGCCCACTCCAGCCCTGGGCCTTGTCTTCCCTTACCTCCTTGGCTGGCCTTGGCCTCTG  
GCTGCTGCACTGAGACTCATTCCATTGGCTGCCCCCTCCTCCCACCTGCCTTGGCCTGAGC  
CTCTCTCCCTGTGTCTCTGTATCCCCTGGCTTTACAGAATCGTCTCTCCCTAGCTCCCAT  
TTCTTTAATTAAACACTGTTCCGAGTGGTCTCCTCATCCATCCTTCCCACCTCACACCCT  
TCACTCTCCTTTTTCTGGGTCCCTTCCCCTTCCCTTCCAGGACCTCCATTGGCTCCTAGA  
AGGGCTCCCCACTTTGCTTCCCTATACTCTGCTGTCCCCTACTTGAGGAGGGATTGGGATC  
TGGGCCTGAAATGGGGCTTCTGTGTTGTCCCCAGTGAAGGCTCCCACAAGGACCTGATGA  
CCTCACTGTACAGAGCTGACTCCCCAAACCCAGGCTCCCATATGTACCCCATCCCCATA  
CTCACCTCTTTCATTTTGTAGTAATAAATGTCTGAGTCTGGAAAAAAAAAAAAAAAAAAAA

337/392

**FIGURE 324**

MKALMLLTLSVLLCWVSADIRCHSCYKVPVLGCVDRQSCRLEPGQQCLTTHAYLGKMWVF  
SNLRCGTPEEPCQEA FNQTNRKLG LTYNTTCCNKDNCNSAGPRPTPALGLVFLTSLAGLG  
LWLLH

**Important features of the protein:**

**Signal peptide:**

amino acids 1-18

**N-glycosylation sites:**

amino acids 77-81, 88-92

**N-myristoylation site:**

amino acids 84-90

**Ly-6 / u-PAR domain protein signature:**

amino acids 85-98

338/392

## FIGURE 325

ACGGGCCCGCAGCGGCAGTGACGTAGGGTTGGCGCACGGATCCGTTGCGGCTGCAGCTCTG  
CAGTCGGGCCCGTTCTTCGCCGCCGCCAGGGGTAGCGGTGTAGCTGCGCAGCGTCGCGCG  
CGCTACCGCACCCAGGTTTCGGCCCCGTAGGCGTCTGGCAGCCCCGGCGCCATCTTCATCGAG  
CGCCATGGCCCGCAGCCTGCGGGCCGGGAGCGGCCGGGTACTGCTTGCTCCTCGGCTTGCA  
TTTGTTCCTGCTGACCGCGGGGCCCTGCCCTGGGCTGGAACGACCCTGACAGAATGTTGCT  
GCGGGATGTAAAAGCTCTTACCCTCCACTATGACCGCTATACCACCTCCCGCAGGCTGGA  
TCCCATCCACAGTTGAAATGTGTTGGAGGCACAGCTGGTTGTGATTCTTATACCCCAA  
AGTCATACAGTGTGAGAACAAAGGCTGGGATGGGTATGATGTACAGTGGGAATGTAAGAC  
GGACTTAGATATTGCATACAAATTTGGAAAACTGTGGTGAGCTGTGAAGGCTATGAGTC  
CTCTGAAGACCAGTATGTACTAAGAGGTTCTTGTGGCTTGGAGTATAATTTAGATTATAC  
AGAACTTGGCCTGCAGAACTGAAGGAGTCTGGAAAGCAGCACGGCTTTGCCTCTTTCTC  
TGATTATTATTATAAGTGGTCCTCGGCGGATTCTCTGTAACATGAGTGGATTGATTACCAT  
CGTGGTACTCCTTGGGATCGCCTTTGTAGTCTATAAGCTGTTCTCTGAGTGACGGGCAGTA  
TTCTCCTCCACCGTACTCTGAGTATCCTCCATTTTCCACCGTTACCAGAGATTACCAA  
CTCAGCAGGACCTCCTCCCCAGGCTTTAAGTCTGAGTTCACAGGACCACAGAATACTGG  
CCATGGTGCAACTTCTGGTTTTTGGCAGTGCTTTTACAGGACAACAAGGATATGAAAATTC  
AGGACCAGGGTTCTGGACAGGCTTGGGAACTGGTGGAATACTAGGATATTTGTTTTGGCAG  
CAATAGAGCGGCAACACCCTTCTCAGACTCGTGGTACTACCCGTCCTATCCTCCCTCCTA  
CCCTGGCACGTGGAATAGGGCTTACTCACCCCTTCATGGAGGCTCGGGCAGCTATTTCGGT  
ATGTTCAAACCTCAGACACGAAAACCAGAACTGCATCAGGATATGGTGGTACCAGGAGACG  
ATAAAGTAGAAAGTTGGAGTCAAACTGGATGCAGAAATTTTGGATTTTTCATCACTTT  
CTCTTTAGAAAAAAGTACTACCTGTTAACAATTGGGAAAAGGGGATATTCAAAGTTCT  
GTGGTGTATGTCCAGTGTAGCTTTTTGTATTCTATTATTTGAGGCTAAAAGTTGATGTG  
TGACAAAATACTTATGTGTTGTATGTCAGTGTAAACATGCAGATGTATATTGCAGTTTTTG  
AAAGTGATCATTACTGTGGAATGCTAAAATAACATTAATTTCTAAACCTGTGATGCCCT  
AAGAAGCATTAGAATGAAGGTGTTGTACTAATAGAACTAAGTACAGAAAATTTTCAGTT  
TTAGGTGGTTGTAGCTGATGAGTTATTACCTCATAGAGACTATAATATTCTATTTGGTAT  
TATATTATTTGATGTTTGCTGTTCTTCAAACATTTAAATCAAGCTTTGGACTAATTATGC  
TAATTTGTGAGTTCTGATCACTTTTGAGCTCTGAAGCTTTGAATCATTCAAGTGGTGGAGA  
TGGCCTTCTGGTAACTGAATATTACCTTCTGTAGGAAAAGGTGGAAAATAAGCATCTAGA  
AGGTTGTTGTGAATGACTCTGTGCTGGCAAAAATGCTTGAAACCTCTATATTTCTTTTCGT  
TCATAAGAGGTAAAGGTCAAATTTTCAACAAAAGTCTTTTAATAACAAAAGCATGCAGT  
TCTCTGTGAAATCTCAAATATTGTTGTAATAGTCTGTTTCAATCTTAAAAAGAATCA

339/392

**FIGURE 326**

MAAACGPGAAGYCLLLGLHLFLLTAGPALGWNDPDRMLLRDVKALTLHYDRYTTSRRLLDP  
IPQLKCVGGTAGCDSYTPKVIQCQNGWDGYDVQWECKTDLDIAYKFGKTVVSCEGYESS  
EDQYVLRGSCGLEYNLDYTELGLOKLKESGKQHGFASFSDYYYKWSSADSCNMSGELITIV  
VLLGIAFVVYKFLFLSDGQYSPPPYSEYPPFSHRYQRFTNSAGPPPPGFKSEFTGPQNTGH  
GATSGFGSAFTGQQGYENSGPGFWTGLGTGGILGYLFGSNRAATPFSDSWYYPSYPPSY  
GTWNRAYSPLHGGSGSYSVCSNSDTKTRTASGYGGTRRR

**Signal peptide:**  
amino acids 1-30

**Transmembrane domain:**  
amino acids 171-190

**N-glycosylation site:**  
amino acids 172-176

**Glycosaminoglycan attachment sites:**  
amino acids 244-248, 259-263, 331-335

**Tyrosine kinase phosphorylation site:**  
amino acids 98-106

**N-myristoylation sites:**  
amino acids 68-74, 69-75, 131-137, 241-247, 247-253, 266-272,  
270-276, 278-284, 312-318

340/392

**FIGURE 327**

GGCACGAGGTGGAAGGGCTTTTACAAACAGATTGCTGGCCCCACCCCCCAGAATTTCTCA  
TCAGGAGTGGGCAAGACCAATCATTTGCATTTCTGACAAGTTCCCAGGAGCTGCAGCTGC  
TGGCCCTGGAACCACACTTTGAGAACCACTGCTTTAGACCAAACACCAAAGGAAGATGCA  
GCCACCCTCCTTTACATGTCACAACGCTCAGGGTCCATGAGTACCTCAGGCTGTCCAGCT  
GAGCTCCACCTGCAGCAGCCGAGATTCCCGACTCGCTCCACCATTGGGGGCTAGGAGTGA  
AGCGTGTCACCATGGTCAGCTCATGGCCAGCCAGGAAAGCCTCTCTGCTGTGCGTCTGTG  
CAGTTCTTGTTCTTCCCTGGAGGACTCTTGATCGCCTGTGATCTTGGCCAGGAGACCAG  
GTGCCTGGGTCCCTTCCCTGGAAGGGGACAAGTTACACACCCAGCCCCATTTTCCCACCA  
ACTTCTACATGCCTTGGGAGAACCTTCTACATGTTGGCTGCCCCCTTCCCCTATTTTCAGC  
AGTGCCCAAGTCCTGCTTATAAACCTGAGGCCTGCTCCCCATACCTTCCCTGTGCAAGTGC  
CAGCCGTTATTCCAGGCAGCCCAATGTTGTTGAGGCCAGATGGATTCCCTGGAAGCAGCTG  
GCCCATGGATGTGAGTCATCACAGTATTCTAGAAACAGAGAAGAGGTCTTAACCTAATGC  
GCATAGAGAAATTGTTCTCATTGTAAACATACCCCTGTCCTTAGCTGATCTAGGTGGAAG  
CCCAGCTTCATGTGCTAGGGGGCATGATAATGATAATAAAGGAATTGTATCTAGGACTAA

341/392

## FIGURE 328

MVSSWPARKASLLCVC AVL VLPWRTLGS PVILARRPGAWVPSWKGT SYTPQPHFPTNFYM  
PWENLLHVGCP LPLFQQCPVLLINLRPAPHTFPVQVPAVIPGSPMLLRPDGFLEAAGPWM

Signal peptide:  
amino acids 1-27

cAMP- and cGMP-dependent protein kinase phosphorylation site:  
amino acids 8-12



342/392

**FIGURE 329**

CAAAGAGTAGTCAGTCCCTTCTTGGCTCTGCTGACACTCGAGCCACATTCCATCACCTG  
CTCCCAATCATGCAGGTCTCCACTGCTGCCCTTGCCGTCCTCCTCTGCACCATGGCTCTC  
TGCAACCAGGTCTCTCTGCACCACTTGCTGCTGACACGCCGACCGCCTGCTGCTTCAGC  
TACACCTCCCGACAGATTCCACAGAATTTATAGCTGACTACTTTGAGACGAGCAGCCAG  
TGCTCCAAGCCCAGTGTCATCTTCCTAACCAAGAGAGGCCGGCAGGTCTGTGCTGACCCC  
AGTGAGGAGTGGGTCCAGAAATACGTCAGTGACCTGGAGCTGAGTGCCTGAGGGGTCCAG  
AAGCTTCGAGGCCCAGCGACCTCAGTGGGCCCAGTGGGGAGGAGCAGGAGCCTGAGCCTT  
GGGAACATGCGTGTGACCTCTACAGCTACCTCTTCTATGGACTGGTTATTGCCAAACAGC  
CACACTGTGGGACTCTTCTTAACTTAAATTTAATTTATTTATACTATTTAGTTTTTATA  
ATTTATTTTGTATTTACAGTGTGTTTGTGATTGTTTGCTCTGAGAGTTCCCCCTGTCCC  
CTCCCCCTTCCCTCACAGTGTGTCTGGTGACAACCGAGTGGCTGTCATCGGCCTGTGTAG  
GCAGTCATGGCACCAAAGCCACCAGACTGACAAATGTGTATCAAATGCTTTTGTTCAGGG  
CTGTGATCGGCCTGGGGAAATAATAAAGATGTTCTTTTAAACGGTAAAAAA

343/392

## FIGURE 330

MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSTSRQIPQNFIADYFETSSQCSK  
PSVIFLTKRGRQVCADPSEEWVQKYVSDLELSA

Signal sequence:

1-23

Small cytokines (intercrine/chemokine) C-C subfamily

signature:

1-35, 2-36, 10-44, 34-74, 50-90

Small cytokines (intercrine/chemokine):

24-89

344/392

**FIGURE 331**

GGCACGAGGTGAGACTTTAAATGAAATGTCTCACAAGCTAGGTGATCCAGGTTTTGTGGT  
CTTTGCAACCCTTGTGGTCATTGTGGCCTTGATATTAATCTTCGTGGTGGGTCCTCGCCA  
TGGACAGACAAACATTCTTGTGTACATAACAATCTGCTCTGTAATCGGCGCGTTTTTCAGT  
CTCCTGTGTGAAGGGCCTGGGCATTGCTATCAAGGAGCTGTTTGCAGGGAAGCCTGTGCT  
GCGGCATCCCCTGGCTTGGATTCTGCTGCTGAGCCTCATCGTCTGTGTGAGCACACAGAT  
TAATTACCTAAATAGGGCCCTGGATATATTCAACACTTCCATTGTGACTCCAATATATTA  
TGTATTCTTTACAACATCAGTTTTAACTTGTTCAGCTATTCTTTTTAAGGAGTGGCAAGA  
TATGCCTGTTGACGATGTCATTGGTACTTTGAGTGGCTTCTTTACAATCATTGTGGGGAT  
ATTCTTGTGTCATGCCTTTAAAGACGTCAGCTTTAGTCTAGCAAGTCTGCCTGTGTCTTT  
TCGAAAAGACGAGAAAGCAATGAATGGCAATCTCTCTAATATGTATGAAGTTCTTAATAA  
TAATGAAGAAAGCTTAACCTGTGGAATCGAACACACACTGGTGAAAATGTCTCCCGAAG  
AAATGGAAATCTGACAGCTTTTTTAAAGAAAGGTGTAATTAAAGGTTAATCTGTGATTGTTA  
TGAAGTGAATTTGAATATCATCAGAAATGTGTCTGAAAAACATTGTCCTCAAATAATGTT  
CTTTAAAGGCAATCTTTTTAAAGATTTCACTAATTTGGACCAAGAAATTACTTTTCTTGT  
ATTTAAACAAACAATGGTAGCTCACTAAAATGACCTCAGCACATGACGATTTCTATTAAC  
ATTTTATTGTTGTAGAAGTATTTTACATTTTCATCCCTTCTCCAAAAGCCGAATGCACTA  
ATGACAGTTTTTAAGTCTATGAAAAATGCTTTATTTTTTTCATTGGTGATGAAAGTCTGAAAT  
GTGCATTTTGTTCATCCCCACTCCATCAATCCCTGACCATGTAAGGCTTTTTTATTTTAAAA  
AAACAGAGTTATCCCAATACATTATCCTGTGATTTACCTTACCTACAAAAGTGGCTCCTG  
TTTGTTTGATGATGATTGGTTTTATTTTTGAAATATTTATTAAGGGAAAATAAGTTACT  
GAATGAAGGAACCTCTTTCTTACAAAACAAAAAAAAGGGCAGAAATCACCCCAAGGAACG  
ATTTCTCAGGTTGAGATGATCACCGTGAATCCGGCTTCTCTGAGCATTCGATGGCCTTA  
GCACCTCATCAAGCCAGCACATCCTGCCTGCTGTTGCAGCCTGGCTGGGTTTATTCTTCA  
GTTACCCTAATCCCATGATGCCTGGAACCTTGATTACCGTTTTTACATCAGCTCTTGTACT  
TTTCAGTATATTTTCATAATGAGTTATATTGTCATTTAGACTTTGAACAGCTCTGGGAAA  
TAGAAGACTAGGGTTGTTTCTTAAATTTAGCTCATGTTATAATAAAAAGTTGAAATG

345/392

**FIGURE 332**

MSHKLGDPGFVVFATLVVIVALILIFVVGPRHGQTNILVYITICSVIGAFSVSCVKGLGI  
AIKELFAGKPVLRHPLAWILLLSLIVCVSTQINYLNRLDIFNTSIVTPIYYVFFTTSVL  
TCSAILFKEWQDMPVDDVIGTSLSGFFTIIVGIFLLHAFKDVSFSLASLPVSFRKDEKAMN  
GNLSNMYEVLNNNEESLTCGIEQHTGENVSRNGNLTAF

**Signal sequence:**

1-33

**Transmembrane domain:**

40-60, 70-90, 103-123, 139-159

**N-glycosylation site:**

103-106, 182-185, 208-211, 215-218

**N-myristoylation site:**

57-62, 140-145, 181-186, 214-219

346/392

## FIGURE 333

GTGATGGCGGCTGGTGATGGGGACGTGAAGCTAGGCACCCTGGGGAGTGGCAGCGAGAGC  
AGCAACGACGGCGGCAGCGAGAGTCCAGGCGACGCGGGAGCGGCAGCGGAAGGGGGAGGC  
TGGGCGGCGGCGGCGTTGGCGCTTCTGA<sup>˙</sup>CGGGGGCGGGGAAATGCTGCTGAACGTGGCG  
CTGGTGGCTCTGGTGCTGCTGGGGGCCTACCGGCTGTGGGTGCGCTGGGGGCGGCGGGGT  
CTGGGGGCCGGGGCCGGGGCGGGCGAGGAGAGCCCCGCCACCTCTCTGCCTCGCATGAAG  
AAGCGGGACTTCAGCTTGGAGCAGCTGCGCCAGTACGACGGCTCCCGCAACCCGCGCATC  
CTGCTCGCGGTCAATGGGAAAGTCTTCGACGTGACCAAAGGCAGCAAGTTCTACGGCCCCG  
GCGGGTCCATATGGAATATTTGCTGGTAGGGATGCCTCCAGAGGACTGGCCACATTTTGC  
CTAGATAAAGATGCACTTAGAGATGAATATGATGATCTCTCAGATTGTAATGCAGTACAA  
ATGGAGAGTGTTGAGAAATGGGAAATGCAGTTTAAAGAAAAATATGATTATGTAGGCAGA  
CTCCTAAAACCAGGAGAAGAACCATCAGAATATACAGATGAAGAAGATACCAAGGATCAC  
AATAAACAGGATTGAACTTTGTAAACAACCAAAGTCAGGGGCCTTCAGAACTGCAATTCT  
TACTCCCTTTCACAGACTGTCCGGAGTCTTTGGGTTTGATTACCTGCTGCGAAAAACAT  
TCAACAAATTGTGTACAAGATAAATTAATCTCACTATGAAGATTTGAATAACTAGACATT  
ATTTATGCTGCCAAACTCATTGTGTCAGTTGTTTGTAATGTCTAGTGGGGCTTCATCAT  
CCTGAAAAGAAGGAGACAGGGATTTTTTTAAAGAGCAAGAAAGTCACAATATTACTTCTT  
TCCTTCCTTTTTTCCTTCTTTCTTCTTCTTCTTCTTCTTTCTTTTAAATATATTG  
AAGACAACCAGATATGTATTTGCTACTCAAGTGTACAGATCTCCTCAAGAAACATCAAGG  
G

347/392

**FIGURE 334**

MAAGDGDVKLGTLGSGSESSNDGGSESPGDAGAAAEGGGWAAAALALLTGGGEMLLNVAL  
VALVLLGAYRLWVRWGRRLGAGAGAGEESPATSLPRMKKRDFSLEQLRQYDGSRNPRIL  
LAVNGKVFDVTKGSKFYGPAGPYGIFAGRDA SRGLATFCLDKDALRDEYDDLSDLNAVQM  
ESVREWEMQFKEKYDYVGRLLKPGEEPSEYTD EEDTKDHNKQD

**Signal sequence:**

None

**Transmembrane domain:**

45-65

**Tyrosine kinase phosphorylation site:**

202-210

**N-myristoylation site:**

11-16, 16-21, 37-42, 38-43, 79-84, 81-86, 83-88, 144-149

**Amidation site:**

75-78

348/392

**FIGURE 335**

[illegible]

349/392

**FIGURE 336**

TGRGYCGDHSSFGAMEEPGATPQPYLGLLLEELRRVVAALPEGMRPDSNLYGFPWELVI  
CAAVVGFFAVLFFLWRSFRSVRSRLYVGREKKLALMLSGLIEEKSLLLEKFSLVQKEYEG  
YEVESLKDASFEKEATEAQSLATCEKLNRSNSELEDEILCLEKELKEEKSKHSEQDEL  
MADISKRIQSLEDESKSLKSQVAEAKMTFQIFQMNEERLKIAIKDALNENSQLOESQKQL  
LQAEVWKEQVSELNKQKVTTFEDSKVHAEQVLNDKESHKTLTERLLKMKDWAAMLGEDI  
TDDDNLELEMNSESENGAYLDNPPKGALKKLIHAAKLNASLKTLEGERNQIYIQLSEVDK  
TKEELTEHIKNLQTOQASLQSENTHFENENQKLQOKLKVMTELYQENEMKLHRKLTVEEN  
YRLEKEEKLSKVDEKISHATEELETYRKRKADLEEEELERTIHSYQGQIISHEKKAHDNWL  
AARNAERNLNDLRKENAHRNQKLTETELKFELLEKDPYALDVPNTAFGRGSRGPGNPLDH  
QITNERGESSCDRLTDPHRAPSDTGSLSPWDQDRRMMFPPPGQSYPPDSALPPQRQDRFC  
SNSGRLSGPAELRSFNMPSLDKMDGSMPSSEMRNDTKDDLGNLNVDPDSSLPAENEATG  
PGFVPPPLAPIRGPLFPVDARGPFLRRGPFPFPPPPPGAMFGASRDYFPPRDFPGPPPAPF  
AMRNVYPPRGFPYLPPLPPPGFFPPPPHSEGRSEFPSPGLIPPSNEPATEHPEPQQET

Signal sequence:

None

Transmembrane domain:

54-74

N-glycosylation site:

150-153, 338-341, 636-639

cAMP- and cGMP-dependent protein kinase phosphorylation  
site:

413-416

Tyrosine kinase phosphorylation site:

414-421

N-myristoylation site:

466-417, 625-630, 697-702

Leucine zipper pattern:

142-163



350/392

## FIGURE 337

GGACTGCGGTCTCGGGCAGCAATGGCCGAGAAGCGCGACACACGGGACTCCGAAGCCCAG  
CGGCTCCCCGACTCCTTCAAGGACAGCCCCAGTAAGGGCCTTGGACCTTGCGGATGGATT  
TTGGTGGCGTTCTCATTCTTATTCACCGTTATAACTTTCCCAATCTCAATATGGATGTGC  
ATAAAGATTATAAAAGAGTATGAAAGAGCCATCATCTTTAGATTGGGTGCGATTTTACAA  
GGAGGAGCCAAAGGACCTGGTTTGTTTTTTATTCTGCCATGCACTGACAGCTTCATCAAA  
GTGGACATGAGAACTATTTCAATTTGATATTCCCTCCTCAGGAGATCCTGACAAAGGATTCA  
GTGACAATTAGCGTGGATGGTGTGGTCTATTACCGCGTTTCCAGAAATGCAACCTGGCTGTG  
GCAAATATCACCAACGCTGACTCAGCAACCCGCTCTTTTGGCACAACTACTCTGAGGAAT  
GTTCTGGGCACCAAGAATCTTTCTCAGATCCTCTCTGACAGAGAAGAAATTGCACACAAC  
ATGCAGTCTACTCTGGATGATGCCACTGATGCCCTGGGGAATAAAGGTGGAGCGTGTGGAA  
ATTAAGGATGTGAAACTACCTGTGCAGCTCCAGAGAGCTATGGCTGCAGAAGCAGAAGCG  
TCCCGCGAGGCCCCGCGCCAAAGGTTATTGCAGCCGAAGGAGAAATGAATGCATCCAGGGCT  
CTGAAAGAAGCCTCCATGGTCATCACTGAATCTCCTGCAGCCCTTCAGCTCCGATACCTG  
CAGACACTGACCACCATTGCTGCTGAGAAAACTCAACAATTGTCTTCCCTCTGCCATA  
GATATGCTGCAAGGAATCATAGGGGCAAAACACAGCCATCTAGGCTAGTGTAGAGATGAG  
CGTAGCCTTCCAAGCATGAAGTCGGGGACCAAATTAGCCTTTAACTCATAAAGAGAGGG  
TAGGGCTTTTCTTTTTCCATATGTCAATTGTGGTGTTCAGAAATGTATAGCAGTTATAA  
AAATAGGTGAAAGAATTGTTAGCTTGTAATACTGAGAGATTGGTGATTTATATAAGGTA  
ATCTGTTAGTCTTAAATAGTTAAAGTTTGTATTTTAGATTATTATGTAGTAGGTTAG  
ATCCCTCTTGTTTTGACTTCCACTGACTCATTCTGAACCCCTAAGCACCCAGGCCACAG  
GCAAGAACCTGGGCTGTAACCTGCCACCTGACACCGCTGACTGGCTAAATGCTTTGCAGAA  
AGTGATGACCTTACACCACAACCAGCTTCTCCAGGTCATATGTGCCTTACCTCCAGAAGT  
CTTTTTTTTTTTTTTTTTCTGAGATGGAGTTTCACTCTTGTGGCCAGGCTGGAGTGCAA  
TAGCATGATCTCGGCTCACTGCAACCTCCGCCTCCTGGGTTCAAGAGATTCTCCTGCCTC  
AGCCTCCCCAGTAGCTGGGATTACAGGCTCATGCCACCATGCCAGCTAATTTTTGTATT  
ATTATTATTGTTTTTTAGTAGAGACGGGGTTTACCATTGTTGGCCAGGCTAGTCACGAAC  
TCCTAACCTCAGGTGATCCACCCACCTCTGCCTCCAAAGTGCTGGATTACAGGCTGAGCT  
ACCACCCTGGTTTGGAGAGTCTTAATTAATTGAAATTTCCCTAATGTTCAATTTATTTTCT  
AAATCCAGCCGTGTTTCAAGATAATCCTTACTTGAGAGTAGCCATTTTCTTGTGTACTTG  
TCAGAACTAGAGGAAATAGCCAAGACTAATGAAAAACATTACTTAACCTTAAAGACT  
TTTAAATTCATACTAGAGTGGTCATTTTAAAAATACATCCATGTTTAACTTATTTTGA  
GCCTTTCTTTTATGAGTAAATGATTCCTCCTTGTCTGTCTTTCAAACCAGCTAAATATT  
TGTCACAAAAGTGACTTTTTTCTCACTGTTGCCTATTTTCATATATCAGGTTTTAAATAG  
TTTTAATTTTTTAATAAAATTTTTCTCTACGTTCTATATGCAATTGTTATATATCTATTT  
GAATAGCTGAAGGACTAAAATACTTTTTTAAGAGATAACTTCAGGAAACCATTATATTTT  
ACTATCTGCATGCTGTTAACTGTGGTACACTGTGAAATATGTTGATTACAAACCCATTCA  
TTACATAGTATAAGGAATTCACAGTATATTGACTATATAGTGTCTAATGACTGGGCAGAT  
ACTGTCAACTTACAATATCTATATAGAGAGGCTTTAAACTTACCTTACTCATTCTCTATG  
ATGTATGACTTGATGCTGAAAGAGGAAGCTGGTCAGCTCCTCATGGACAACAAATCTTA  
GTCTATAATATTAGGAGACATCTCTAGTTTTTGCAAATGTCTGTGAATCTGAGCAACCTGG  
ACTTCTGCTTACTGGCCAGAAAGCTGGCGGGTGACATTTGTAACATTTCTCTTTGAGAC  
TCTGAGTTACCTAGAGAAGTCTAAGCATAACAGCTTTCTTTCCAGCACGAGCCTTTAT  
AGCTCTCTTTAGCTCAACCACTCTGTCCATCCAGCCAATGGATGTCCTTCCCTGTACCCA  
ATTCAGCTTATTTTAGGGAAGCCTTGAACTACCATGTATCTGGCTCTAGCTGAGTTAT  
TGAGGATTGAGCCAGTGCAACGTTAACTCAGTGCACCTTACATTTGATTTAAATGATGGT  
TTTATCTGTTGTGTGAAGTGGTTACCCCTTGAGGACCAGGAGCCTCCATATCCTGACTGA  
AAACCTTTTTCTGAGACTTAGAGTAACAGTACTTTTGGTTCTTGAGTTCTCCTGTCTCCA  
GATACCTAAATGACCTTGACTTTTTCTGCCTTGTGAATTCGTAGTCCAATCAGCTGAAATT  
AAATCACTTGGGAGGGACGCATAGAAGGAGCTCTAGGAACACAGTGCCAGTGCAAGATT  
TCTCCAGGTGGCCTCCCTTTCCAACAATGTACATAATAAAGTGTATGCACCTTTCCT

351/392

**FIGURE 338**

MAEKRDTRDSEAQRLPDSFKDSPSKGLGPCGWILVAFSFLFTVITFPISIWMCIKIKEY  
ERAIIFRLGRILQGGAKGPGLFFILPCTDSFIKVD MRTISFDIPPQEILTKDSVTISVDG  
VVYYRVQNATLAVANITNADSATRLLAQTTLRNVLGTKNLSQILSDREEIAHNMQSTLDD  
ATDAWGIKVERVEIKDVKLPVQLQRAMAAEAEASREARAKVIAAEGEMNASRALKEASMV  
ITESPAALQLRYLQTLTTIAAEKNSTIVFPLPIDMLQGIIGAKHSHLG

**Signal sequence:**

1-45

**Transmembrane domain:**

None

**N-glycosylation site:**

128-131, 135-138, 159-162, 229-232, 264-267

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

4-7

**N-myristoylation site:**

26-31, 278-283, 281-286

**SPFH domain/Band 7 family:**

39-230

352/392

## FIGURE 339

TCTAGAGCCCTCTCCCAACATGGCGGCCTCAGCAAAAAAGAAGAATAAGAAGGGGAAGAC  
TATCTCCCTAACAGACTTTCTGGCTGAGGATGGGGGTACTGGTGGAGGAAGCACCTATGT  
TTCCAAACCAGTCAGCTGGGCTGATGAAACGGATGACCTGGAAGGAGATGTTTCGACCAC  
TTGGCACAGTAACGATGACGATGTGTATAGGGCGCCTCCAATTGACCGTTCCATCCTTCC  
CACTGCTCCACGGGCTGCTCGGGAACCCAATATCGACCGGAGCCGTCTTCCCAAATCGCC  
ACCCTACACTGCTTTTCTAGGAAACCTACCCTATGATGTTACAGAAGAGTCAATTAAGGA  
ATTCTTTTCGAGGATTAAATATCAGTGCAGTGCCTTTACCACGTGAACCCAGCAATCCAGA  
GAGGTTGAAAGGTTTTGTTATGCTGAATTTGAGGACCTGGATTCCCTGCTCAGTGCCCT  
GAGTCTCAATGAAGAGTCTCTAGGTAACAGGAGAATTTCGAGTGGACGTTGCTGATCAAGC  
ACAGGATAAAGACAGGGATGATCGTTCTTTTGGCCGTGATAGAAATCGGGATTCTGACAA  
AACAGATACAGACTGGAGGGCTCGTCCTGCTACAGACAGCTTTGATGACTACCCACCTAG  
AAGAGGTGATGATAGCTTTGGAGACAAGTATCGAGATCGTTATGATTCAGACCGGTATCG  
GGATGGGTATCGGGATGGGTATCGGGATGGCCCACGCCGGGATATGGATCGATATGGTGG  
CCGGGATCGCTATGATGACCGAGGCAGCAGAGACTATGATAGAGGCTATGATTCCCGGAT  
AGGCAGTGGCAGAAGAGCATTGTCAGTGGGTATCGCAGGGATGATGACTACAGAGGAGG  
CGGGGACCGCTATGAAGACCGATATGACAGACGGGATGATCGGTTCGTGGAGCTCCAGAGA  
TGATTACTCTCGGGATGATTATAGGCGTGATGATAGAGGTCCCCCCCCAAAGACCCAACT  
GAATCTAAAGCCTCGGAGTACTCCTGAAGAAGATGATTCTCTGCTAGTACCTCCCAGTC  
CACTCGAGCTGCTTCTATCTTTGGAGGGGCAAAGCCTGTTGACACAGCTGCTAGAGAAAG  
AGAAGTAGAAGAACGGCTACAGAAGGAACAAGAGAAGTTGCAGCGTCAGTGGAATGAGCC  
AAAAC TAGAACGACGGCCTCGGGAGAGACACCCAAGCTGGCGAAGTGAAGAACTCAGGA  
ACGGGAACGGTCGAGGACAGGAAGTGAGTCATCACAACCTGGGACCTCCACCACATCTAG  
CAGAAATGCACGAAGGAGAGAGAGTGAGAAGTCTCTAGAAAATGAAACACTCAATAAGGA  
GGAAGATTGCCACTCTCCAACCTCTAAACCTCCCAAACCTGATCAGCCCCCTAAAGGTAAT  
GCCAGCCCCCTCCACCAAAGGAGAATGCTTGGGTGAAGCGAAGTTCTAACCTCCTGCTCG  
ATCTCAGAGCTCAGACACAGAGCAGCAGTCCCCCTACAAGTGGTGGGGGAAAAGTAGCTCC  
AGCTCAACCATCTGAGGAAGGACCAGGAAGGAAAGATGAAAATAAAGTAGATGGGATGAA  
TGCCCCAAAAGGCCAAACTGGGAACCTCTAGCCGTGGTCCAGGAGACGGAGGGAACAGAGA  
CCACTGGAAGGAGTCAGATAGGAAAAGATGGCAAAAAGGATCAAGACTCCAGATCTGCACC  
TGAGCCAAAGAAACCTGAGGAAAATCCAGCTTCTAAGTTTCAGTTCTGCAAGCAAGTATGC  
TGCTCTCTCTGTTGATGGTGAAGATGAAAATGAGGGAGAAGATTATGCCGAATAGACCTC  
TACATCCTGTGCTTTTCTCCTAGTTTCTCTCCACCCTGGAACATTTCGAGAGCAAATCAA  
ACCTCTATCCAGACAAGACAAAATAAACTCAACATCTCCTGAAGACCTTTCTTACCTTT  
TTTTAAAAACAAAAXTGAAATTATTTTGCATGCTGCTGCAGCCTTTAAAGTATTGAAGT  
AACTGGAGAATTGCCAATACAGCCAGAGAGAAAGGGACTACAGCTTTT TAGAGGAAAAGT  
TGTGGTGCGTTATGTCACCATGCAGTTGCCAGTGTGATTAGTGCCTAGGGGTCTCATTTA  
GCAGAAATGGTAATGACAGTGATATAATGCCTGGAACCTGGTTGGGCAGTAGGGGAGGGA  
GGTAGAAGGAAAAGTGTGAGATTTCTACCTTTTAGTTTTTCATCCTATTGTGGCATATATG  
AATTCTCAAACATTATCTGAATAAATTTTCCACTCTTGGAAGGTAGATTTAGCCTCAAG  
TTGTTCTAGTCTCCAGGAGGCTGCCAGCCCCTCCTCTTATTTAATTCTGAGTTTTGGGGG  
CCAGCCTAGAGGGAATTCTTTTTTTTTTTTTTTTTTAACCCCCCAGGGGGGTAGTTGGGAGT  
GAGACTATAGGCCATAAAGAATGGGACTGCATTGGACCAAAATAAATGGGAAAATCGTGG  
TTTGAAAAGAAGCTTTTGGGAAGTGATGAGTCATTTTGCACCAGGTAATAGGGGAAAATT  
GTGTGACCTCCAGCAAACACATGAATGGTTATTTCTCTGGAGCCGGAAGCACTTGGGGGTC  
GTGGTAATTTCCAGTGTTTTCTGTGTCTAGTTTTTACCCTTTCTAAACACTGTCCTTTTT  
GAAAGTTTTGAATATATCCACATTCTATTGAAACCTTGAACTAAAAATTTAGACTCTTA  
TCGTCTCTTAAGTTCTTCATGCTACTCTTAACCTCCCAAAAAGCAGTATCTAAGTCACA  
TACATGATGTCTTGGGCATTTTCTGAGCCATGGAGAAGCTCTGAAAGGAAGAATCGCTGCT  
TTTCTCAAGCAAATCGGTTTCTTGATGTCTTTTGGTTCTCCTTGCCTGCTCCTGATGCTT

353/392

[illegible]

354/392

**FIGURE 340**

MAASAKKKKNGKGTISLTDFLAEDGGTGGGSTYVSKPVSWADETDDLEGDVSTTWHSNDD  
DVYRAPPIDRSILPTAPRAAREPNIDRSRLPKSPPYTAFLGNLPYDVTEESIKEFFRGLN  
ISAVRLPREPSNPERLKGFYAEFEDLDSLLSALSLSNEESLGNRRIRVDVADQAQDKORD  
DRSFGRDRNRDSKTDTDWRARPATDSFDDYPPRRGDDSFQDKYRDRYDSDRYRDGYRDG  
YRDGPRRDMDRYGGRDRYDDRGSRDYDRGYDSRIGSGRRAFGSGYRRDDDYRGGGDRYED  
RYDRRDDRWSRRDDYSRDDYRRDDRGPQRPKLNKPRSTPEEDDSSASTSQSTRAASI  
FGGAKPVDTAAREREVEERLQKEQEKLRQWNEPKLERRPRERHPSWRSEETQERERSRT  
GSESSQTGTSTTSSRNARRRESEKSLNETLNKEEDCHSPTSKPPKPDQPLKVMPPPPK  
ENAWVKRSSNPPARSQSSDTEQQSPTSGGGKVAPAPQSEEGPGRKDENVKVDGMNAPKGQT  
GNSSRGPGDGGNRDHWKESDRKDGKKDQDSRSAPEPKKPEENPASKFSSASKYAALSVDG  
EDENEGEDYAE

**Signal Sequence:**

None

**Transmembrane domain:**

None

**N-glycosylation site:**

120-123, 448-451, 542-545

**Glycosaminoglycan attachment site:**

507-510

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

439-442, 486-489

**Tyrosine kinase phosphorylation site:**

225-233, 264-270

**N-myristoylation site:**

25-30, 26-31, 28-33, 118-123, 421-426, 428-433, 538-543

**Amidation site:**

276-279, 522-525, 563-566

**Cell attachment sequence:**

215-217

**Eukaryotic putative RNA-binding region RNP-1 signature:**

137-144

**RNA recognition motif:**

98-168

355/392

**FIGURE 341**

GCGTGGACACCACCTCAGCCCACTGAGCAGGAGTCACAGCACGAAGACCAAGCGCAAAGC  
GACCCCTGCCCTCCATCCTGACTGCTCCTCCTAAGAGAGATGGCACCGGCCAGAGCAGGA  
TTCTGCCCCCTTCTGCTGCTTCTGCTGCTGGGGCTGTGGGTGGCAGAGATCCCAGTCAGT  
GCCAAGCCCAAGGGCATGACCTCATCACAGTGGTTTAAATTCAGCACATGCAGCCCAGC  
CCTCAAGCATGCAACTCAGCCATGAAAAACATTAACAAGCACACAAAACGGTGCAAAGAC  
CTCAACACCTTCCTGCACGAGCCTTCTCCAGTGTGGCCGCCACCTGCCAGACCCCCAAA  
ATAGCCTGCAAGAATGGCGATAAAAACTGCCACCAGAGCCACGGGCCCCGTGTCCCTGACC  
ATGTGTAAGCTCACCTCAGGGAAGTATCCGAAGTGCAGGTACAAAGAGAAGCGACAGAAC  
AAGTCTTACGTAGTGGCCTGTAAGCCTCCCCAGAAAAGGACTCTCAGCAATTCCACCTG  
GTTCTGTACACTTGGACAGAGTCCTTTAGGTTTCCAGACTGGCTTGCTCTTTGGCTGAC  
CTTCAATTCCCTCTCCAGGACTCCGCACCACTCCCCTACACCCAGAGCATTCTCTTCCCC  
TCATCTCTTGGGGCTGTTCTTGGTTCAGCCTCTGCTGGGAGGCTGAAGCTGACACTCTGG  
TGAGCTGAGCTCTAGAGGGATGGCTTTTCATCTTTTTTGTGTGCTGTTTTCCAGATGCTTA  
TCCCAAGAAACAGCAAGCTCAGGTCTGTGGGTTCCTGCTATGCCATTGCACATGTC  
TCCCCTGCCCCCTGGCATTAGGGCAGCATGACAAGGAGAGGAAATAAATGGAAAGGGGGC  
AA  
AAA

356/392

**FIGURE 342**

MAPARAGFCPLLLLLLLGLWVAEIPVSAKPKGMTSSQWFKIQHMQPSPQACNSAMKNINK  
HTKRCKDLNTFLHEPFSSVAATCQTPKIAKNGDKNCHQSHGPVSLTMCKLTSGKYPNCR  
YKEKRQNKSYVVACKPPQKKDSQQFHLVPVHLDRVL

**Important features of the protein****Signal peptide:**

1-22

**Transmembrane domain:**

none

**N-glycosylation site:**

127-131

**cAMP- and cGMP-dependent protein kinase phosphorylation  
site:**

139-143

**N-myristoylation site:**

18-24, 32-38

**Pancreatic ribonuclease family signature:**

65-72

**Pancreatic ribonuclease family proteins:**

49-93

357/392

## FIGURE 343

GCATTTGCCACTGGTTGCAGATCAGGCGGACGAGGAGCCGGGAAGGCAGAGCCATGTGGC  
TGCCCCCTGCTCTGCTCCTTCTCAGCCTCTCAGGCTGTTTCTCCATCCAAGGCCAGAGT  
CTGTGAGAGCCCCAGAGCAGGGGTCCCTGACGGTTCATGCCACTATAAGCAAGGATGGG  
AGACCTACATTAAGTGGTGGTGCCGAGGGGTGCGCTGGGATACATGCAAGATCCTCATTG  
AAACCAGAGGGTCCGAGCAAGGAGAGAAGAGTGACCGTGTGTCCATCAAGGACAATCAGA  
AAGACCGCACGTTCACTGTGACCATGGAGGGGCTCAGGCGAGATGACGCAGATGTTTACT  
GGTGTGGGATTGAAAGAAGAGGACCTGACCTTGGGACTCAAGTGAAAGTGATCGTTGACC  
CAGAGGGAGCGGCTTCCACAACAGCAAGCTCACCTACCAACAGCAATATGGCAGTGTTCA  
TCGGCTCCCAAGAGGAACCACTACATGCTCCTGGTATTTGTGAAGGTGCCCATCTTGC  
TCATCTTGGTCACTGCCATCCTCTGGTTGAAGGGTCTCAGAGGGTCCCTGAGGAGCCAG  
GGGAACAGCCTATCTACATGAACCTTCTCCGAACCTCTGACTAAAGACATGGCCACTTAGA  
GAGATGGATCTGCAGAGCCTTCTGCCCCTGGCCACGTTTCCAGAAGAGACTCGGGCTGTG  
GAAGGAACATCTACGAGTCTCGGGATGCAGTGACTGAGATAGGGGCCCTGGGCCCTCCGC  
CCTGGCCTTGGAGCTGGTGGGCACCTCCCTGTTCTGCACAGCTCAGGGACTTAGCCAGGT  
CCTCTCCTGAGCCACCATCACCTCCTGGGGTGCCAGCACCTGTTCTCTTGGTCAGGAGCT  
GTAGAGATGGAGCTCAAGCACTGGACGACTCTGTCCCCACTGCTGGAATAACTCGGGCAC  
AGAGCATGGGACCAAAAGTACAGAAAGAGGTTGGGGGAGACCCCCCAGCCCTAGACTTCC  
ATCATTCGGGAGACCAACTCAACACCGTCTTTGCCTGAGAACCTGATATATCCGTGTTTT  
TAAATTTTTTTTTTTTCTAGCAAAGTTGGGTTTTAATGACTTATGTTTATAGGAAACCTCT  
CTGATCCCACACACAAGGAGGGTGATTCTGGGATGAGTTCCTGGTTCTAGGGCATGAGGG  
GCTGGATGGACCCTGTCCCCAGGGAGGACATGGCTCTGAGTCCACAGGGCTGAGGAGGCA  
ATGGGAACCTCCCTGGCCCCGGCCCCGTGCTTGTCTCCCCCTCCACCTCTTCTCTCTCC  
TAGCTCCCCAAGCTCCCTGCCTATTCCCCCACCTCCGAGGGGCTGCAGCTTGGGAGCCTC  
CTCAGCATGACAGCTTGGGTCTCCTCCCCAAAAGAGCCTGTCAGGCCTCAAGAACCACCT  
CCAGGTGGGGAGGGCAGTAACGAAAACCATCGCAGGAAATGGCACCCCTCCCTTTTCGGTG  
ATGTTGAAATCATGTTACTAATGAAAACCTGTCTTAGGGAAGTGGTTCTGTCTCCTCACAG  
GCTTCACCCACGGCGATGAGGCCCTTGAATGTGGTCACTTTGTGCTGTATGGTTGAGGGA  
CCCTCACACCAAAGGGACCTTCCCATGTGAGATGTGCTCCCGCCCCACCTGCCACAAG  
CAAACACACCACACATGTTCGGCATGTTGCCCTTTGAACACCCATGAGGACGCCTCCAAC  
CTGCTCTTGGTTCTAATAGGGAGTACTGACTGTGAGCAGTGGATAAAGGAGAGGGGACCC  
TCTGGTCCCTAGCATGGCACCCAGAGCCTCCCTCTTCTTGTCTTTCAGCCAAAGAGAAA  
CTTTCTCTGACTTTGAACTGAATTTAGGTCTCTGGCCAATGATGGGCCTGAAAATTCCAT  
AATGGCCAGAGAGGAGAGTTCGAGCCCGGCTAAGATCCCCTGAGTCATTCTGTGAGGGAC  
CAAGACCCACAGTCCACCAGCCCCAGGGCCCTACCTCCTGGAATGCTTTCTTGGATCCAG  
CTTCCCGAAGATCCGACCAGACCCAGGGAGGACGGCACCGCTCCGCGGGAGGGAAAGCCA  
AAGCATGGTGCTTCACCAGCTGGACTCAGGGGCGAGGGGACATGGGCGCTTGTCAACGTG  
ATGTCATTCTTTTCCACCGTTTCTTCTCTGTTGATATTCAATGAATCCGTCAATCTCTCT  
GGGAAA



358/392

**FIGURE 344**

MWLPPALLLLSLSGCFSIQGPESVRAPEQGSITVQCHYKQGWETIYKWWCRGVRWDTCKI  
LIETRGSEQGEKSDRVSIKDNQKDRFTFTVMEGLRRDDADVWCGIERRGPDLTQVKVI  
VDPEGAASTTASSPTNSNMAVFIGSHKRNHYMLLVFVKVPILLILVTAILWLKGSQRVPE  
EPGEQPIYMNFSSEPLTKDMAT

**Important features of the protein:**

**Signal peptide:**

Amino acids 1-17

**Transmembrane domain:**

Amino acids 151-170

**N-glycosylation site:**

Amino acids 190-194

**Tyrosine kinase phosphorylation site:**

Amino acids 95-103

**N-myristoylation sites:**

Amino acids 66-72; 125-131

**Prokaryotic membrane lipoprotein lipid attachment site:**

Amino acids 5-16

359/392

## FIGURE 345

CTGAGCTCCCGGGCTCCGGCAGCGCGCTGGCGGGGCGCCGCATTGCACACTCTGGGGGCG  
CCGCAGTGTTCGTGGGATGGGGCAGCGGGCTGCAGCTGGCGGCCGGAATCCGCGCGCAGC  
CCGGGTGCAAGTTCTCTCCTGTTGCCCTGAGTGCCCACTCCCAGGCCCTCTGTATGAGTG  
ACACTTCAGTCTGCCATGGAACCTGGCCCTGCTCTGGCCTGGCTCCTGCTCCTGAGCCTG  
CTGGCGGATTGTCTGAAAGCTGCTCAGTCCCGAGACTTCACAGTGAAAGACATTATCTAC  
CTCCATCCTTCAACCACACCATATCCTGGTGGATTAAATGTTTCACCTGTGAAAAGGCA  
GCAGACAATTATGAGTGCAACCGATGGGCTCCAGACATCTACTGCCCTCGAGAGACCAGA  
TACTGCTACACTCAGCACACAATGGAAGTCACAGGAAACAGTATCTCAGTCACCAAACGC  
TGTGTCCCACTGGAAGAGTGCTTATCCACTGGCTGCAGAGACTCCGAGCATGAAGGCCAC  
AAGGTCTGCACTTCTTGTTGTGAAGGAAATATCTGTAACCTTGCCACTGCCCCGAAATGAA  
ACTGATGCCACATTTGCCACGACGTACCTATAAATCAGACAAATGGGCACCCACGCTGT  
ATGTCAGTGATAGTGTCTTGCTTGTGGTTGTGGTTAGGGCTCATGTTATAGTGGCTCAGT  
GGCTCCATGTGTTAATAGCGATCCATGGGGATCTCGATGGTCCACAGACCTGCATGAGTC  
ATTGGCCTGACAGTAATTACACATGTGAGACACAACACTCTTGAGGTCATCACAGCCAA  
GCATTGCCACTTACCATGAGGAATAAATGTTGCTTCATTGTAGCCATTTTGAGTCTAACC  
GAGACTCATCAAAGCCTTCTGTGAGTACAGCCCAAGTTCATACCATAAACGTTTGTGTTT  
CATTCGAAGAAGTAGTTCTGCATTTATCGAGATCTGGGGTTCTTAATTTGGAAGAATACA  
TGCATGAGATGCAGTAGGTCCTGAGACTGTAAGATATTAGGAGTATGTTATAGGGGCATG  
TATAGATGTGGGCTTTTTCAGGAGAAAAGTAACCATTTGGTTTAAATATAATCATGAGTTCA  
TTTGTAGCTTTAGAAATTTTAAAACATTGACTCCAAACTGAATGGACTATTTCTTTGGAAA  
TTCTGACTGAGTCCCTGGAAGAGTAGTAATTCACAACATTCAGCCATTTGTTCAATTAA  
TTTTCCCAACATTCTTCTCCAGTGCTGGGAATCACATTTCTCTGTTCTGTGCAGAAGA  
CAAAAAGGCAATCATAAAAGTTTGTTATATTGTGGGGGTGCCTGGAGGAGGATTTTCCT  
CAACTTAATGGAGCCACTGTCCATAAAGTGGCTGTTATCCCTTCATATAAATTGGTGAGAT  
CAGCCTTCTCCTTGACTTGGCACCTAATTATGCTTCATGAGATCCTAGATTCCACCTGAG  
TCAATTGTGTCCAGAGCCCCAAACCAGGATGGAGTTGTTTTCCCAGATATGGGGTTCTA  
TTCAGCCATAGATAATCTAGACAGAGGATTTCAGAAATGAAAGGAAAAATGTGTGGAGATT  
AGTCTAGTTTCAATTCTGAGGGCCGACTAAGTGGCTCAGCCAGCTTCTTACTCCATCTGCA  
GTTTCACTAGTCCAAAGAGCTCCCACTTCCAAATCCCCAGTGAATTTATGGAGAAGATTCT  
GCATTAAATTGTCTTTTGAATGATGGGGAAGCAAGGCATAATATGCGATGATGAGGAGAA  
AGTAGACCAGTGAGGTGATTGCAAGACTAACAAGGAGACTCAATGGGAAGTTTTTCTTTC  
TTTTAGATATTGCTTTTGAAGTAGATGGTAAATTTTTGTGTCATCTTCTTGATTTTTTG  
TACCCCAAGTTACAATTTTTCTTCTTCTTGTAAATAATTTAAACAGTATTTATTTTTGT  
AAGGCATAACTAGAACTAAAATATATTCTAAAAAATTCATTATTCTGAACAAAGTGATC  
AAATTAGAATACATATTTTTCAACAGTGGTAGAGCTTTTAAATATAATGTTTATTGAAAGTT  
ATCTATAATACTTGCACCAAGTGTGAAAAAAGTTAACATGTAGGCAAGAGCAATATGTTT  
GTCTCAAGGATTTTTCCATGGTTTTCTCAGTGATGGTGTCTGGAATTATTAGGTGGTG  
ACCATCACTGGTCTAAGTTTTGTGTGCAGGGTTTTTCAGACGTGTTTTGTGAAACTTGGTA  
GAACCATGGCTAATAAAGAGGACAGTGTGTGAGGGTCCATCTGCCCTCCATAGAAAAAT  
GTCTCTGGCTCATAAATGAGACTCCCTCAGGGACTAAATATGAACTGACAGCAGTAACT  
CTGATACAGAATAATCTAAATTGCATCAAATGGCCTTAATTCAGAGTTTGTAGGCTTAT  
CAGTATGTTGCTTTTAAATGGGGTGGGAAAGTAGAGGGAGAGAAAGCAAGACATTTATTA  
AGCACCTCGTATGTGCCAGGCACTATGCTAAGCACTTTACATAAGTTAGGATTAATCCCT  
GCAAGAATCCTATAAAGAATGTTACTAGCATTTACACTTCCCAATGAAGGTACCAAAGC  
TCAAACGCAATGTTGTGAAGCTGTTTCTTTCAGATTTAGGTTATGTGGGATGATGTGGGA  
TTGAAGAGGAAAGAAAGGTGGGATTATCCCCCTAGGAAGACTTTCAGGCCTGACTTCATA  
GGAATTCATCCATCTTATCATGTGGAGTTTATCTCACCTGCTGTTGCAGGATGCTATTT  
GCATGTGTCCCAGGTGATGTTTTTTCTTTGGGGAGTAGGGGTTTGGCTTCCTCATTCAT

360/392

CCCTCTTGCTAAAAGAGGACATAGTTGATGTTGCATCTAAAGATGCTATAAGACAATCAAAGTTTGATGTGTGAC  
ATACCTACAAGTACCATTTTTGTGTCATGATTACACTCCACTGACATCTTCCAAGTACTAC  
ATGTGATTGAATAAGAAACAAGAAAGTGACCACACCAAAGCCTCCCTGGCTGGTGTACAG  
GGATCAGGTCCACAGTGGTGCAGATTCAACCACCACCCAGGGAGTGCTTGCAGACTCTGC  
ATAGATGTTGCTGCATGCGTCCCATGTGCCTGTCAGAATGGCAGTGTTTAATTCTCTTGA  
AAGAAAGTTATTTGCTCACTATCCCCAGCCTCAAGGAGCCAAGGAAGAGTCATTACATG  
GAAGGTCCGGGACTGGTTCAGCCACTCTGACTTTTCTACCACATTAAATTCTCCATTACAT  
CTCACTATTGGTAATGGCTTAAGTGTAAGAGCCATGATGTGTATATTAAGCTATGTGCC  
ACATATTTATTTTTAGACTCTCCACAGCATTTCATGTCAATATGGGATTAATGCCTAAACT  
TTGTAAATATTGTACAGTTTGTAATCAATGAATAAAGGTTTTGAGTGTAAAAAAAAAA  
AAAAAA

361/392

## FIGURE 346

MEPGPALAWLLLLSLADCLKAAQSRDFTVKDIIYLHPSTTPYPGGFKCFTCEKAADNYE  
CNRWAPDIYCPRETRYCYTQHTMEVTGNSISVTKRCVPLEECLSTGCRDSEHEGHKVCTS  
CCEGNICNLPLPRNETDATFATTSPINQTNHGPRCMSVIVSCLWLWLGLML

Important features of the protein:

Signal peptide:

1-22

Transmembrane domain:

None

N-glycosylation site:

134-138, 147-151

N-myristoylation site:

45-51, 87-93, 106-112, 124-130

Ly-6 / u-PAR domain protein:

115-128

362/392

## FIGURE 347

GATCAAGCGCCTTCCTTTCCCTTCCTCTCCCTACTTGGCCTTTGCCCTAAGCCAAGACCT  
GGCCATCAGCCTGGCTGCAGGGGCCTGCAGAGCCAGCTGCACTTTTTCAGGTATGGGGGA  
GGGCCAGGCACCATGAAGCCAGTGTGGGTCGCCACCCCTTCTGTGGATGCTACTGCTGGTG  
CCCAGGCTGGGGGCCGCCGGAAGGGGTCCCAGAAGAGGCCTCCTTCTACTATGGAACC  
TTCCCTCTTGGCTTCTCCTGGGGCGTGGGCAGTTCTGCCTACCAGACGGAGGGGCGCTGG  
GACCAGGACGGGAAAGGGCCTAGCATCTGGGACGTCTTCACACACAGTGGGAAGGGGAAA  
GTGCTTGGGAATGAGACGGCAGATGTAGCCTGTGACGGCTACTACAAGGTCCAGGAGGAC  
ATCATTCTGCTGAGGGAACTGCACGTCAACCACTACCGATTCTCCCTGTCTTGGCCCCGG  
CTCCTGCCCACAGGCATCCGAGCCGAGCAGGTGAACAAGAAGGGAATCGAATTCTACAGT  
GATCTTATCGATGCCCTTCTGAGCAGCAACATCACTCCCATCGTGACCTTGCACCACTGG  
GATCTGCCACAGCTGCTCCAGGTCAAATACGGTGGGTGGCAGAATGTGAGCATGGCCAAC  
TACTTCAGAGACTACGCCAACCTGTGCTTTGAGGCCTTTGGGGACCGTGTGAAGCACTGG  
ATCACGTTCAGTGATCCTCGGGCAATGGCAGAAAAAGGCTATGAGACGGGGCCACCATGCG  
CCGGGCCTGAAGCTCCGCGGCACCGGCCTGTACAAGGCAGCACACCACATCATTAAGGCC  
CACGCCAAAACCTGGCATTCTTATAACACCACGTGGCGCAGCAAGCAGCAAGGTCTGGTG  
GGAATTTCACTGAACTGTGACTGGGGGGAACCTGTGGACATTAGTAACCCCAAGGACCTA  
GAGGCTGCCGAGAGATACCTACAGTTCTGTCTGGGCTGGTTTGCCAACCCCATTTATGCC  
GGTGACTACCCCAAGTCATGAAGGACTACATTGGAAGAAAGAGTGCAGAGCAAGGCCTG  
GAGATGTGAGGTTACCGGTGTTCTCACTCCAGGAGAAGAGCTACATTAAAGGCACATCC  
GATTTCTTGGGATTAGGTCAATTTTACTACTCGGTACATCACGGAAGGAACTACCCCTCC  
CGCCAGGGGCCAGCTACCAGAACGATCGTGACTTGATAGAGCTGGTTGACCCAAACTGG  
CCAGATCTGGGGTCTAAATGGCTATATTCTGTGCCATGGGGATTTAGGAGGCTCCTTAAC  
TTTGCTCAGACTCAATACGGTGATCCTCCCATATATGTGATGGAAAATGGAGCATCTCAA  
AAATTCCACTGTACTCAATTATGTGATGAGTGGAGAATTCAATACCTTAAAGGATACATA  
AATGAAATGCTAAAAGCTATAAAAGATGGTGCTAATATAAAGGGGTATACTTCCTGGTCT  
CTGTTGGATAAGTTTGAATGGGAGAAAGGATACTCAGATAGATATGGATTCTACTATGTT  
GAATTTAACGACAGAAATAAGCCTCGCTATCCAAAGGCTTCAGTTCAATATTACAAGAAG  
ATTATCATTGCCAATGGGTTTCCCAATCCAAGAGAGGTGGAAAGTTGGTACCTCAAAGCT  
TTGGAAACTTGCTCTATCAACAATCAGATGCTTGCTGCAGAGCCTTTGCTAAGTCACATG  
CAAATGGTTACGGAGATCGTGGTACCCACTGTCTGCTCCCTCTGTGTCCTCATCACTGCT  
GTTCTACTAATGCTCCTCCTGAGGAGGCAGAGCTGAGACAGGATTATCAATTTTGGAGCT  
TCATAAGAGAATCTTCAGGATCTTCTCCCTTTTCTGCTTTGAGGGTTTCCATACATTGC  
TGTTTTTCAGGTTCTACAATAATTACCTTTTTTTCTCTTTCTCTTTTGGCTTGTGCTGG  
ATTTAAGAATTAGAAAATAAAAATAAGCAGAAATTA

363/392

**FIGURE 348**

MKPVVWVATLLWMLLLVPRLLGAARKGSPEEASFYYGTFPLGFSWGVGSSAYQTEGAWDQDG  
KGPSIWDVFTHSGKGKVLGNETADVACDGYKQVEDIILLRELHVNHYRFSLSWPRLPT  
GIRAEQVNKKGIEFYSDLIDALLSSNITPIVTLHHWDLPQLLQVKYGGWQNVSMANYFRD  
YANLCFEAFGDRVKHWTFSDPRAAEKGYETGHHAPGLKLRGTGLYKAAHHIIKAHAKT  
WHSYNTTWRSKQOGLVGISLNCDWGEPVDISNPKDLEAAERYLQFCLGWGFANPIYAGDYP  
QVMKDYIGRKSAAEQGLEMSRLPVFSLQEKSYIKGTSDFLGLGHFTTRYITERNYPSRQGP  
SYQNDRLIELVDPNWPDLGSKWLYSVPWGFRLLNFAQTQYGDPPYYVMENGASQKFHC  
TQLCDEWRIQYLKGYINEMLKAIKDGANIKGYTSWSLLDKFEWEKGYSDRYGFYYVEFND  
RNKPRYPKASVQYYKKIIANGFPNPREVESWYLKALETCSINNQMLAAEPLLSHMQMVT  
EIVVPTVCSLCVLITAVLLMLLLRRQS

**Important features:****Signal peptide:**

amino acids 1-21

**Transmembrane domain:**

amino acids 541-558

**N-glycosylation sites:**

amino acids 80-84,171-175,245-249

**Glycosaminoglycan attachment site:**

amino acids 72-76

**cAMP- and cGMP-dependent protein kinase phosphorylation sites:**

amino acids 23-27,564-568

**Tyrosine kinase phosphorylation sites:**

amino acids 203-211,347-355,460-468,507-514

**N-myristoylation sites:**

amino acids 44-50,79-85,167-173,225-231,257-263,315-321

**Amidation site:**

amino acids 307-311

**Glycosyl hydrolases family 1 active site:**

amino acids 407-416

**Glycosyl hydrolases family 1 N-terminal signature:**

amino acids 41-56

**Motif name Glycosyl hydrolases family:**

amino acids 37- 67

364/392

**FIGURE 349**

CGCAAAGCCGCCCTCGGGGCGCTCATGGCGGGACGCCTCCTGGGAAAGGCTTTAGCCGCG  
GTGTCTCTCTCTCTGGCCTTGGCCTCTGTGACTATCAGGTCCTCGCGCTGCCGCGGCATC  
CAGGCGTTCAGAACTCGTTTTTCATCTTCTTGGTTTCATCTTAATACCAACGTCATGTCT  
GGTTCTAATGGTTCCAAAGAAAATTCTCACAATAAGGCTCGGACGTCTCCTTACCCAGGT  
TCAAAAGTTGAACGAAGCCAGGTTCTAATGAGAAAGTGGGCTGGCTTGTTGAGTGGCAA  
GACTATAAGCCTGTGGAATACACTGCAGTCTCTGTCTTGGCTGGACCCAGGTGGGCAGAT  
CCTCAGATCAGTGAAAGTAATTTTTCTCCCAAGTTTAAACGAAAAGGATGGGCATGTTGAG  
AGAAAGAGCAAGAATGGCCTGTATGAGATTGAAAATGGAAGACCGAGAAATCCTGCAGGA  
CGGACTGGACTGGTGGGCCGGGGGCTTTTGGGGCGATGGGGCCCAAATCACGCTGCAGAT  
CCCATTATAACCAGATGGAAAAGGGATAGCAGTGGAAAATAAAATCATGCATCCTGTTTCT  
GGGAAGCATATCTTACAATTTGTTGCAATAAAAAGGAAAGACTGTGGAGAATGGGCAATC  
CCAGGGGGGATGGTGGATCCAGGAGAGAAGATTAGTGCCACACTGAAAAGAGAATTTGGT  
GAGGAAGCTCTCAACTCCTTACAGAAAACCACTGCTGAGAAGAGAGAAATAGAGGAAAAG  
TTGCACAACTCTTCAGCCAAGACCACCTAGTGATATATAAGGGATATGTTGATGATCCT  
CGAAACACTGATAATGCATGGATGGAGACAGAAGCTGTGAACTACCATGACGAAACAGGT  
GAGATAATGGATAATCTTATGCTAGAAGCTGGAGATGATGCTGGAAAAGTGAAATGGGTG  
GACATCAATGATAAACTGAAGCTTTATGCCAGTCACTCTCAATTCATCAAACTTGTGGCT  
GAGAAACGAGATGCACACTGGAGCGAGGACTCTGAAGCTGACTGCCATGCGTTGTAGCTG  
ATGGTCTCCGTGTAAGCCAAAGGCCACAGAGGAGCATATACTGAAAAGAAGCAGTATC  
ACAGAATTTATACTATAAAAAGGGCAGGGTAGGCCACTTGGCCTATTTACTTTCAAACA  
ATTTGCATTTAGAGTGTTTCGCATCAGAATAACATGAGTAAGATGAACTGGAACACAAAA  
TTTTCAGCTCTTTGGTCAAAGGAATATAAGTAATCATATTTTGTATGTATTTCGATTTAA  
GCATGGCTTAAATTAAATTTAAACAATAATGCTCTTTGAAGAATCATAATCAGAATAAA  
GATAAATTCTTGATCAGCTATA

365/392

**FIGURE 350**

MAGRLLGKALAAVSLSLALASVTIRSSRCRGIQAFRNSFSSSWFHLNTNVMMSGSNNGSKEN  
SHNKARTSPYPGSKVERSQVPNEKVGWLVEWQDYKPVEYTAVSVLAGPRWADPQISESNF  
SPKFNEKDGHVERKSKNGLYEIEENGRPRNPAGRTGLVGRGLLGRWGPNHAADPIITRWKR  
DSSGNKIMHPVSGKHILQFVAIKRKDCGEWAI PGGMVDPGEKISATLKREFGEEALNSLQ  
KTSAEKREIEEKLHKLFSQDHLVIYKGYVDDPRNTDNAWMETEAVNYHDETGEIMDNLMML  
EAGDDAGKVKWVDINDKLKLYASHSQFIKLVAEKRDAHWESEADCHAL

**Important features of the protein:**

**Signal peptide:**

1-20

**Transmembrane domain:**

None

**N-glycosylation site:**

55-59

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

179-183

**N-myristoylation site:**

53-59, 56-62

**mutT domain signature:**

215-235



366/392

**FIGURE 351**

CCTCTGTCTGTGCTCCCATCCCAGGGAGTATAGGTGGAGCCTCCAGAGCCCATGGACAGG  
GCATGCTGGGGCTGGGCCAGCCCCAGCGGTGTCTCTAAGGCACCCCTGGGATCCCCACTG  
AGCTGGCCTACTTCAGACAGCCAGGGCCCCACCCCTCTGGCCCCCTTAGTGTCAGCTCGT  
GGCCCCCTTGGCATTTCACAAAGACGCCAAGATGGAGATTCCCATGGGGACCCAGGGCTGC  
TTCTCAAAGAGCCTCCTGCTCTCAGCCTCAATCCTGGTCCTCTGGATGCTCCAAGGCTCC  
CAGGCAGCTCTCTACATCCAGAAGATTCCAGAGCAGCCTCAAAAGAACCAGGACCTTCTC  
CTGTCAGTCCAGGGTGTCCCAGACACCTTCCAGGACTTCAACTGGTACCTGGGGGAGGAG  
ACGTACGGAGGCACGAGGCTATTTACCTACATCCCTGGGATACAACGGCCTCAGAGGGAT  
GGCAGTGCCATGGGACAGCGAGACATCGTGGGCTTCCCCAATGGTTCCATGCTGCTGCGC  
CGCGCCAGCCTACAGACAGTGGCACCTACCAAGTAGCCATTACCATCAACTCTGAATGG  
ACTATGAAGGCCAAGACTGAGGTCCAGGTAGCTGAAAAGAATAAGGAGCTGCCCAGTACA  
CACCTGCCCACCAACGCTGGGATCCTGGCGGCCACCATCATTGGATCTCTTGCTGCCGGG  
GCCCTTCTCATCAGCTGCATTGCCTATCTCCTGGTGACAAGGAAGTGGAGGGGCCAGAGC  
CACAGACTGCCTGCTCCGAGGGGCCAGGGATCTCTGTCCATCTTGTGCTCGGCTGTATCC  
CCAGTGCCCTCAGTGACGCCAGCACATGGATGGCGACCACAGAGAAGCCAGAATTGGGC  
CCTGCTCATGATGCTGGTGACAACAACATCTATGAAGTGATGCCCTCTCCAGTCTCCTG  
GTGTCCCCCATCAGTGACACAAGGTCCATAAACCCAGCCCGGCCCTGCCACACCCCCA  
CACCTGCAGGCGGAGCCAGAGAACCACCAAGTACCAGCAGGACCTGCTAAACCCGACCCT  
GCCCCCTACTGCCAGCTGGTGCCAACTTCCTGATGGGTCTTGGGCCAGGCCAGCCAGGGA  
GAAGACAAGGCCCCAGCCCTCCTCTGGGAGCCTCACACCTGAGACCAGCAGGACAAGGCC  
ATTGGGGGCTGTGGGGCCGATGAGGTGGACTCAGCCAAAGACTCAGCAGCACATGGGGCA  
GGTGTCTTGGCAGGGGGACAGGAGACTGTAACAGGCCCAGGTCTTGTGCAGCCCCTGAA  
TGCACGCCCCGCTTTCGGTCTGTTCCTTCAAGCAAGCTGGCCTGGGCCATGTGCCTGTGAA  
AGGCAGGCTCTGGCCCCCTTCCATGCCAAAGTCCCCCAAGATCTGGATATCTGGGGACAA  
GATGGTGGCCTCAGGCCTGCCTCCCAGGCAGTTGGCTGGGCTCCCAACTGTCTGTCTCA  
ATGCCCTACCCCAACTCCACTAGTGACCCTCAGAGTCTTCTCCCCTTAGGACAAGGCAGA  
CACCCACCATGCGGGCCTCAGGTGGCAGAGAGGCCAGCCTCACAGGCCTGTGGCCCCA  
CACACCAGTCCCAGCAAGGTGACCACGGCTGCTGGACCCCTTCCCTGTTTCAGGCAGGCCC  
AGCCCCCTCTCAGAACCTGCTGCCAGCTGCTGGTCTTGGCCCCCACCCTGAATCTTACTGA  
GTCCCTCTGGGCAGCAGCTCCCTTCTCCACCCACCCAGCACCCGTCCCAAATGTGGCC  
TCAGCTTGTCTCCTCCCCTTCCCCAAACTATGCATTCAATCAGCAATAAATGAGCCTTTGCT  
GCA

367/392

**FIGURE 352**

MEIPMGQTQGCFSKSLLLSASILVLWMLQGSQAALYIQKIPEQPQKNQDLLLSVQGVPDF  
QDFNWYLGEETYGGTRLFTYIPGIQRPQRDGSAMGQDIVGFNGSMLLRRAQPTDSGT  
QVAITINSEWTMKAKTEVQVAEKNKELPSTHLPTNAGILAATTIIGSLAAGALLISCIAYL  
LVTRNWRGQSHRLPAPRGQGSLSILCSAVSPVPSVTPSTWMATTEKPELGPAGHDAGDNNI  
YEVMPSPVLLVSPISDTRSINPARPLPTPHLQAEPEHQQDILLNPDPAFYCQLVPTS

**Important features of the protein:**

**Signal peptide:**

Amino acids 1-32

**Transmembrane domain:**

Amino acids 159-178

**N-glycosylation site:**

Amino acids 104-108

**N-myristoylation sites:**

Amino acids 6-12; 29-35; 55-61; 91-97; 157-163; 165-171

368/392

**FIGURE 353**

CTTCAGAACAGGTTCTCCTTCCCCAGTCACCAGTTGCTCGAGTTAGAATTGTCTGCAATG  
GCCGCCCTGCAGAAATCTGTGAGCTCTTTCCTTATGGGGACCCCTGGCCACCAGCTGCCTC  
CTTCTCTTGGCCCTCTTGGTACAGGGAGGAGCAGCTGCGCCCATCAGCTCCCACTGCAGG  
CTTGACAAGTCCAACTTCCAGCAGCCCTATATCACCAACCGCACCTTCATGCTGGCTAAG  
GAGGCTAGCTTGGCTGATAACAACACAGACGTTTCGTCTCATTGGGGAGAACTGTTCCAC  
GGAGTCAGTATGAGTGAGCGCTGCTATCTGATGAAGCAGGTGCTGAACTTCACCCTTGAA  
GAAGTGCTGTTCCCTCAATCTGATAGGTTCCAGCCTTATATGCAGGAGGTGGTGCCCTTC  
CTGGCCAGGCTCAGCAACAGGCTAAGCACATGTCATATTGAAGGTGATGACCTGCATATC  
CAGAGGAATGTGCAAAAGCTGAAGGACACAGTGAAAAAGCTTGGAGAGAGTGGAGAGATC  
AAAGCAATTGGAGAACTGGATTTGCTGTTTATGTCTCTGAGAAATGCCTGCATTTGACCA  
GAGCAAAGCTGAAAAATGAATAACTAACCCCTTTCCCTGCTAGAAATAACAATTAGATG  
CCCCAAAGCGATTTTTTTTAAACCAAAGGAAGATGGGAAGCCAACTCCATCATGATGGG  
TGGATTCCAAATGAACCCCTGCGTTAGTTACAAAGGAAACCAATGCCACTTTTGTTTATA  
AGACCAGAAGGTAGACTTTCTAAGCATAGATATTTATTGATAACATTTTCATTGTAAGTGG  
TGTTCTATACACAGAAAACAATTTATTTTTTAAATAATTGTCTTTTTTCCATAAAAAAGAT  
TACTTTCCATTTCCTTTAGGGGAAAAAACCCTAAATAGCTTCATGTTTCCATAATCAGTA  
CTTTATATTTATAAATGTATTTATTATTATTATAAGACTGCATTTTATTTATATCATTTT  
ATTAATATGGATTTATTTATAGAAACATCATTCGATATTGCTACTTGAGTGTAAGGCTAA  
TATTGATATTTATGACAATAATTATAGAGCTATAACATGTTTATTTGACCTCAATAACA  
CTTGATATCCC

369/392

**FIGURE 354**

MAALQKSVSSFLMGTLATSCLLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA  
KEASLADNNTDVRLLIGEKLFGVSMSERCYLMKQVLNFTLEEVLPQSDRFQPYMQEVVP  
FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI

**Important features of the protein:**

**Signal peptide:**

amino acids 1-33

**N-glycosylation sites:**

amino acids 54-58, 68-72, 97-101

**N-myristoylation sites:**

amino acids 14-20, 82-88

**Prokaryotic membrane lipoprotein lipid attachment site:**

amino acids 10-21

370/392

**FIGURE 355**

TGGCCTACTGGAAAAAAAAAAAAAAAAAAAAAGTCACCCGGGCCCCGCGGTGGCCACAA  
CATGGCTGCGGCGCCGGGGCTGCTCTTCTGGCTGTTTCGTGCTGGGGGCGCTCTGGTGGGT  
CCCGGGCCAGTCGGATCTCAGCCACGGACGGCGTTTCTCGGACCTCAAAGTGTGCGGGGA  
CGAAGAGTGCAGCATGTTAATGTACCGTGGGAAAGCTCTTGAAGACTTCACGGGCCCTGA  
TTGTCGTTTTGTGAATTTTAAAAAAGGTGACGATGTATATGTCTACTACAACTGGCAGG  
GGGATCCCTTGAACCTTGGGCTGGAAGTGTGTAACACAGTTTTTGGATATTTTCCAAAAGA  
TTTGATCAAGGTACTTCATAAATACACGGAAGAAGAGCTACATATTCAGCAGATGAGAC  
AGACTTTGTCTGCTTTGAAGGAGGAAGAGATGATTTTAATAGTTATAATGTAGAAGAGCT  
TTTAGGATCTTTGGAACCTGGAGGACTCTGTACCTGAAGAGTCGAAGAAAGCTGAAGAAGT  
TTCTCAGCACAGAGAGAAATCTCCTGAGGAGTCTCGGGGGCGTGAACCTTGACCCTGTGCC  
TGAGCCCGAGGCATTTCAGAGCTGATTTCAGAGGATGGAGAAGGTGCTTTCTCAGAGAGCAC  
CGAGGGGCTGCAGGGACAGCCCTCAGCTCAGGAGAGCCACCCTCACACCAGCGGTCTGTC  
GGCTAACGCTCAGGGAGTGCAGTCTTCGTTGGACACTTTTGAAGAAATTCCTGCACGATAA  
ATTGAAAGTGCCGGGAAGCGAAAGCAGAACTGGCAATAGTTCTCCTGCCTCGGTGGAGCG  
GGAGAAGACAGATGCTTACAAAGTCCTGAAAACAGAAATGAGTCAGAGAGGAAGTGGACA  
GTGCGTTATTTCATTACAGCAAAGGATTTTCGTTGGCATCAAATCTAAGTTTGTTTTACAA  
AGATTGTTTTTAGTACTAAGCTGCCTTGGCAGTTTGCATTTTTTGAGCCAAACAAAAATAT  
ATTATTTTCCCTTCTAAGTAAAAAAAAAAAAAAAAAAAAA

371/392

**FIGURE 356**

MAAAPGLLFWLFLVGLALWWVPGQSDLSHGRRFSDLKVCGDEEC SMLMYRGKALEDFTGPD  
CRFVNFKKGDDVYVYYKLAGGSLELWAGSVEHSFGYFPKDLIKVLHKEYTEELHIPADET  
DFVCFEGGRDDFNSYNVEELLGSLELEDSVPEESKKAEEVSQHREKSPPEESRGRELD PVP  
EPEAFRADSEEDGEAFSESTEGLOQQPSAQESH PHTSGPAANAQGVQSSLDTFEEILHDK  
LKVPGSESRTGNSSPASVEREKTDAYKVLKTEMSQ RSGQCVIHYSKGFWRWHQNL SLFYK  
DCF

**Important features of the protein:**

**Signal peptide:**

amino acids 1-22

**N-glycosylation site:**

amino acids 294-298

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 30-34

**Tyrosine kinase phosphorylation site:**

amino acids 67-76

**N-myristoylation sites:**

amino acids 205-211, 225-231, 277-283

**Amidation site:**

amino acids 28-32

**FIGURE 357**

[illegible]

373/392

**FIGURE 358**

MEAPGPRALRTALCGGCCCLLLCAQLAVAGKGARGFGRGALIRLNIWPAVQGACKQLEVC  
EHCVEGDRARNLSSCMWEQCRPEEPGHCVAQSEVVKEGCSIYNRSEACPAHHHPTYPEPK  
TVTTGSPVPVPEAHSPGFDGASFIGGVVLVLSLQAVAFFVLHFLKAKDSTYQTL

**Important features of the protein:**

**Signal peptide:**

1-29

**Transmembrane domain:**

141-160

**N-glycosylation site:**

71-75, 103-107

**Tyrosine kinase phosphorylation site:**

164-171

**N-myristoylation site:**

15-21



374/392

**FIGURE 359**

TTCCAGTCAGAGTTAAGTTAAAACAGAAAAAAGGAAGATGGCAAGAATATTGTTACTTTT  
CCTCCCGGGTCTTGTGGCTGTATGTGCTGTGCATGGAATATTTATGGACCGTCTAGCTTC  
CAAGAAGCTCTGTGCAGATGATGAGTGTGTCTATACTATTTCTCTGGCTAGTGCTCAAGA  
AGATTATAATGCCCCGACTGTAGATTCATTAACGTTAAAAAAGGGCAGCAGATCTATGT  
GTACTCAAAGCTGGTAAAAGAAAATGGAGCTGGAGAATTTTGGGCTGGCAGTGTTTATGG  
TGATGGCCAGGACGAGATGGGAGTCGTGGGTATTTCCCCAGGAACCTGGTCAAGGAACA  
GCGTGTGTACCAGGAAGCTACCAAGGAAGTTCCACCACGGATATTGACTTCTTCTGCGA  
GTAATAAATTAGTTAAAACGCAATAGAAAAGAAAACACCAAAAATAAAGAAAAGAGCAA  
AAGTGGCCAAAAAATGCATGTCTGTAATTTTGGACTGACGT

375/392

## FIGURE 360

MARILLFLPGLVAVCAVHGIFMDRLASKKLCADDECVTISLASAQEDYNAPDCRFINV  
KKGQQIYVYSKLVKENGAGEFWAGSVYGDGQDEMGVVGYPRLVKEQRVYQEATKEVPT  
TDIDFFCE

Important features of the protein:

Signal peptide:

1-14

Transmembrane domain:

None

N-myristoylation site:

84-90

376/392

## FIGURE 361

GGCACGAGCCACCACTTACAACCACACAGCCTATCCAGAAACATGAAGATAAGAAATGCT  
TGTGCTGTCCCTTATTGAAGTACTCCTGTTTATACTTGAAGGAGTTACAGGAGCTCGAAAA  
ATTTCAACTTTCTCAGGCCCTGGCTCATGGCCGTGCAATCCCAAGTGTGATGGCAGAACT  
TACAACCCCTCAGAGGAGTGTTGTGTTTCATGACACCATCCTGCCCTTTAAGCGGATTAAC  
CTCTGTGGCCCTAGCTGCACCTACAGGCCCTGCTTTGAGCTCTGCTGTCTGAGTCCCTAT  
AGCCCCAAGAAGAAATTTATTGTCAAGCTTAAAGTTCATGGAGAGAGATCCCATTGCAGT  
TCATCCCCTATCTCCAGGAAGTGTAAAAGCAACAAGATTTTTTCATGGAGAAGATATTGAA  
GACAACCAACTTTCTCTTAGGAAAAAAAGTGGTGACCAGCCTTGAGAGTCTGCTTTCCTTC  
CTGCAAGCACCAGTTCCTGAATGTTCTTACTTGAAGAATGGATACCTGAAGCATTGGGGT  
GCAGTGATATATGTGTCTCATTACAATGCTCCTTTGGATATTGTTTTCTAAGCATGTGT  
TGGAATGTTCCCCCATAACTTTCTAAAATTATCCTATTTCAATGCAACTAAAGATAAATG  
TATTCCAGCCAGAGTCCACAGAGAAGGCAAGTTATGCAAGGCAGGCATGGGGCCCTCACA  
AAATTTCAAGCTGTGCGACTTATGTAGTAATTTTCTACAAACAATCCCTCCTGGATATCC  
AGGAGGCTCCAGACCTGAATAAAAACCAATGTCTGTCTAGAAAAAGGGAATGAATCAAG  
ATCCACAGGACCTTTTCAAGATTTTAGAAGCAGCAAACCTATGGCTGAGAGAAAAGACTCT  
CTGACCAGGCAAATTGTTCTGCAGTATTCTCCGGGCGTGTAGCTCCCCTGAGTAGTCGCC  
AGGCTGGTCTTGGCTTTGTAATAATACAGCTGCCTTTGAGTCCTCCCTACCCCTGTTAGTA  
ACCCCTTGCCCTGCACTGTTGTCCTTACAACCGAAATAAACTGATTAGTTG

377/392

## FIGURE 362

MKIRNACAVLIEVLLFILEGVTGARKISTFSGPGSWPCNPKCDGRTYNPSEECCVHDTIL  
PFKRINLCGPSCTYRPCFELCCPESYSPKKKFIVKLKVHGERSHCSSSPISRNCKSNKIF  
HGEDIEDNQLSLRKKSGDQP

### Important features of the protein:

#### Signal peptide:

1-23

#### Transmembrane domain:

None

#### Glycosaminoglycan attachment site:

31-35

#### N-myristoylation site:

20-26, 34-40

378/392

**FIGURE 363**

ACACTGGCCAAACAAAAACGAAAGCACTCCGTGCTGGAAGTAGGAGGAGAGTCAGGACTC  
CCAGGACAGAGAGTGCACAACTACCCAGCACAGCCCCCTCCGCCCCCTCTGGAGGCTGA  
AGAGGGATTCCAGCCCCCTGCCACCCACAGACACGGGCTGACTGGGGTGTCTGCCCCCCTT  
GGGGGGGGGCGAGCACAGGGCCTCAGGCCTGGGTGCCACCTGGCACCTAGAAGATGCCTGT  
GCCCTGGTTCTTGCTGTCTTGGCACTGGGCCGAAGCCCAGTGGTCCTTTCTCTGGAGAG  
GCTTGTGGGGCCTCAGGACGCTACCCACTGCTCTCCGGGCCTCTCCTGCCGCTCTGGGA  
CAGTGACATACTCTGCCTGCCTGGGGACATCGTGCCTGCTCCGGGGCCCCGTGCTGGCGCC  
TACGCACCTGCAGACAGAGCTGGTGTCTGAGGTGCCAGAAGGAGACCGACTGTGACCTCTG  
TCTGCGTGTGGCTGTCCACTTGGCCGTGCATGGGCACTGGGAAGAGCCTGAAGATGAGGA  
AAAGTTTGGAGGAGCAGCTGACTCAGGGGTGGAGGAGCCTAGGAATGCCTCTCTCCAGGC  
CCAAGTCGTGCTCTCCTTCCAGGCCTACCTACTGCCCGCTGCGTCCTGCTGGAGGTGCA  
AGTGCCTGCTGCCCTTGTGCAGTTTGGTCAGTCTGTGGGCTCTGTGGTATATGACTGCTT  
CGAGGCTGCCCTAGGGAGTGAGGTACGAATCTGGTCTATACTCAGCCAGGTACGAGAA  
GGAACCTCAACCACACACAGCAGCTGCCTGCCCTGCCCTGGCTCAACGTGTCAGCAGATGG  
TGACAACGTGCATCTGGTTCTGAATGTCTCTGAGGAGCAGCACTTCGGCCTCTCCCTGTA  
CTGGAATCAGGTCCAGGGCCCCCCTAAACCCCGGTGGCACAACCTGACTGGACCGCA  
GATCATTACCTTGAACCACACAGACCTGGTTCCCTGCCTCTGTATTTCAGGTGTGGCCTCT  
GGAACCTGACTCCGTTAGGACGAACATCTGCCCTTCAGGGAGGACCCCCGCGCACACCA  
GAACCTCTGGCAAGCCGCCGACTGCGACTGCTGACCCTGCAGAGCTGGCTGCTGGACGC  
ACCGTGCTCGCTGCCCGCAGAAGCGGCACTGTGCTGGCGGGCTCCGGGTGGGGACCCCTG  
CCAGCCACTGGTCCCACCGCTTTCCTGGGAGAACGTCACTGTGGACAAGGTTCTCGAGTT  
CCCATTGCTGAAAGGCCACCCTAACCTCTGTGTTTCAGGTGAACAGCTCGGAGAAGCTGCA  
GCTGCAGGAGTGCTTGTGGGCTGACTCCCTGGGGCCTCTCAAAGACGATGTGCTACTGTT  
GGAGACACGAGGCCCCCAGGACAACAGATCCCTCTGTGCCTTGAACCCAGTGGCTGTAC  
TTCCTACCCAGCAAAGCCTCCACGAGGGCAGCTCGCCTTGGAGAGTACTTACTACAAGA  
CCTGCAGTCAGGCCAGTGTCTGCAGCTATGGGACGATGACTTGGGAGCGCTATGGGCCTG  
CCCCATGGACAAATACATCCACAAGCGCTGGGCCCTCGTGTGGCTGGCCTGCCTACTCTT  
TGCCGCTGCGCTTTCCCTCATCCTCCTTCTCAAAAAGGATCACGCGAAAGGGTGGCTGAG  
GCTCTTGAAACAGGACGTCCGCTCGGGGGCGGCCGCCAGGGGCCGCGCGGCTCTGCTCCT  
CTACTCAGCCGATGACTCGGGTTTCGAGCGCCTGGTGGGCGCCCTGGCGTTCGGCCCTGTG  
CCAGTGGCCGCTGCGCGTGGCCGTAGACCTGTGGAGCCGTCGTGAACTGAGCGCGCAGGG  
GCCCCTGGCTTGGTTTCACGCGCAGCGGCCAGACCTGCAGGAGGGCGGCGTGGTGGT  
CTTGCTCTTCTCTCCCGGTGCGGTGGCGCTGTGCAGCGAGTGGCTACAGGATGGGGTGTG  
CGGGCCCCGGGGCGCACGGCCCCGACGACGCTTCCGCGCCTCGCTCAGCTGCGTGCTGCC  
CGACTTCTTGAGGGCCGGGCGCCCCGCGAGCTACGTGGGGGCTGCTTTCGACAGGCTGCT  
CCACCCGGACGCCGTACCCGCCCTTTTCCGACCGTGCCCGTCTTCACACTGCCCTCCCA  
ACTGCCAGACTTCTTGGGGGCCCTGCAGCAGCCTCGCGCCCCGCGTTCCGGGCGGCTCCA  
AGAGAGAGCGGAGCAAGTGTCCCGGGCCCTTCAGCCAGCCCTGGATAGCTACTTCCATCC  
CCCGGGGACTCCCGCGCCGGGACGCGGGGTGGGACCAGGGGCGGGACCTGGGGCGGGGA  
CGGGACTTAAATAAAGGCAGACGCTGTTTTTCTAAAAAA

379/392

**FIGURE 364**

MPVPWFLLSLALGRSPVVLSELERLVGPQDATHCSPGLSCRLWSDIILCLPGDIVPAPGPV  
LAPTHLQTELVLRQCQKETDCDLCLRVAVHLAVHGHWEEDEEKFGGGAADSGVEEPRNAS  
LQAQVVLVSFQAYPTARCVLLEVVQVPAALVQFGQSVGSVVYDCFEAALGSEVRIWSYTQPR  
YEKELNHTQQLPALPWLNVVSADGDNVHLVLNVSEEQHFGLSLYWNQVQGPPKPRWHKNLT  
GPQIITLNTDLVPCLCIQVWPLEPDSVRTNICPFREDPRAHQNLWQAARLRLTLQSWL  
LDAPCSLPAAALCWRAPGGDPCQPLVPPLSWENVTVDKVLEFPLLKGHPNLCVQVNSSE  
KLQEQECLWADSLGPLKDDVLLLETRGPQDNRSCLCALEPSGCTSLPSKASTRAARLGEYL  
LQDLQSGQCLQLWDDDLGALWACPMCKYIHKRWALVWLACLLFAAALSLILLKKDHAKG  
WLRLLLKQDVRSGAAARGRAALLYSADDSGFERLVGALASALCQLPLRVAVDLWSRRELS  
AQGPVAFWFAQRRQTLQEGGVVLLFSPGAVALCSEWLQDGVSGPGAHPHDAFRASLSC  
VLPDFLQGRAPGSYVGACFDRLHPDAVPALFRTVPVFTLPSQLPDFLGALQQPRAPRSG  
RLQERAEQVSRAALQPALDSYFHPPGTPAPGRGVGPGAGPGAGDGT

**Signal sequence:**

amino acids 1-20

**Transmembrane domain:**

amino acids 453-475

**N-glycosylation sites:**amino acids 118-121, 186-189, 198-201, 211-214, 238-241,  
248-251, 334-337, 357-360, 391-394**Glycosaminoglycan attachment site:**

amino acids 583-586

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 552-555

**N-myristoylation sites:**amino acids 107-112, 152-157, 319-324, 438-443, 516-521,  
612-617, 692-697, 696-701, 700-705

380/392

**FIGURE 365**

AATAGAAGTCCTCAGGACGGAGCAGAGGTGGCCGGCGGGCCCGGCTGACTGCGCCTCTGC  
TTTCTTTCCATAACCTTTTCTTTCGGA CTGAATCACGGCTGCTGCGAAGGGTCTAGTTC  
CGGACACTAGGGTGCCCGAACGCGCTGATGCCCCGAGTGCTCGCAGGGCTTCCCGCTAAC  
CATGCTGCCGCCGCCGCGGGCCGCGAGCTGCCTTGGCGCTGCCTGTGCTCCTGCTACTGCT  
GGTGGTGCTGACGCCGCCCGGACCGGCGCAAGGCCATCCCCAGGCCCAGATTACCTGCG  
GCGCGGCTGGATGCGGCTGCTAGCGGAGGGCGAGGGCTGCGCTCCCTGCCGGCCAGAAGA  
GTGCGCCCGCGCCGCGGGGCTGCCTGGCGGGCAGGGTGCGCGACGCGTGCGGCTGCTGCTG  
GGAATGCGCCAACCTCGAGGGCCAGCTCTGCGACCTGGACCCCAGTGCTCACTTCTACGG  
GCACTGCGGCGAGCAGCTTGAGTGCCGGCTGGACACAGGCGGCGACCTGAGCCGCGGAGA  
GGTGCCCGGAACCTCTGTGTGCCTGTCTGTCGAGAGTCCGCTCTGCGGGTCCGACGGTCA  
CACCTACTCCAGATCTGCCGCTGCAGGAGGCGGCGCGCTCGGCCCCGATGCCAACCT  
CACTGTGGCACACCCGGGGCCCTGCGAATCGGGGCCCCAGATCGTGTCACATCCATATGA  
CACTTGGAATGTGACAGGGCAGGATGTGATCTTTGGCTGTGAAGTGTTTGCCTACCCCAT  
GGCCTCCATCGAGTGGAGGAAGGATGGCTTGACATCCAGCTGCCAGGGGATGACCCCCA  
CATCTCTGTGCAGTTTAGGGGTGGACCCCAGAGGTTTGAGGTGACTGGCTGGCTGCAGAT  
CCAGGCTGTGCGTCCCAGTGATGAGGGCACTTACCGCTGCCTTGGCCGCAATGCCCTGGG  
TCAAGTGGAGGCCCCCTGCTAGCTTGACAGTGCTCACACCTGACCAGCTGAACTCTACAGG  
CATCCCCCAGCTGCGATCACTAAACCTGGTTCCCTGAGGAGGAGGCTGAGAGTGAAGAGAA  
TGACGATTACTACTAGGTCCAGAGCTCTGGCCCATGGGGGTGGGTGAGCGGCTATAGTGT  
TCATCCCTGCTCTTGAAAAGACCTGGAAAGGGGAGCAGGGTCCCTTCATCGACTGCTTTC  
ATGCTGTCAGTAGGGATGATCATGGGAGGCCTATTTGACTCCAAGGTAGCAGTGTGGTAG  
GATAGAGACAAAAGCTGGAGGAGGGTAGGGAGAGAAGCTGAGACCAGGACCGGTGGGGTA  
CAAAGGGGGCCATGCAGGAGATGCCCTGGCCAGTAGGACCTCCAACAGGTTGTTTCCCAG  
GCTGGGGTGGGGGCTGAGCAGACACAGAGGTGCAGGCACCAGGATTCTCACTTCTTCC  
AGCCCTGCTGGGCCACAGTTCTAACTGCCCTTCCCTCCCAGGCCCTGGTTCTTGCTATTTT  
CTGGTCCCCAACGTTTATCTAGCTTGTTTGCCTTTCCCCAACTCATCTTCCAGAACTT  
TTCCCTCTCTCCTAAGCCCCAGTTGCACCTACTAACTGCAGTCCCTTTTGCTGTCTGCCG  
TCTTTTGTACAAGAGAGAGAAACAGCGGAGCATGACTTAGTTTCAGTGCAGAGAGATT

381/392

**FIGURE 366**

MLPPPRPAAALALPVLLLLLVLTTPPPTGARPSGPDYLRGWMRLLAEGEGCAPCRPEE  
CAAPRGCLAGVRDAGCCWEACANLEGQLCDLDPSAHFYGHCGEQLECRDLDGDLERGE  
VPEPLCACRSQSPLCGSDGHTYSQICRLQEAARAPDANLTVAHPGPCESGPQIVSHPYD  
TWNVTGQDVIFGCEVFAYPMASIEWRKDGLDIQLPGDDPHISVQFRGGPQRFVETGWLQI  
QAVRPSDEGTYRCLGRNALGQVEAPASLTVLTPDQLNSTGIPQLRSLNLVPEEEAESEEN  
DDYY

**Important features of the protein:**

**Signal peptide:**

1-30

**Transmembrane domain:**

None

**N-glycosylation site:**

159-163, 183-187, 277-281

**Tyrosine kinase phosphorylation site:**

244-252

**N-myristoylation site:**

52-58, 66-72, 113-119, 249-255

**Kazal-type serine protease inhibitor domain:**

121-168

**Immunoglobulin domain:**

186-255

**Insulin-like growth factor binding proteins:**

53-90



382/392

**FIGURE 367**

AGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTGCTGCCGCTGCTGCTGCTTCTG  
CGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGGCTACACGGCGGTCATC  
GAAGTGACCAGCGGGGTCCCTGGGGCGACTGGGCCTGGCCTGAGATGTGTCCCGATGGA  
TTCTTCGCCAGCGGGTTCTCGCTCAAGGTGGAGCCTCCCCAAGGCATTCCTGGCGACGAC  
ACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGGGAACGTCTAGGCAATACGCAC  
GTGGTAGAGTCCCAGTCTGGAAGCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTGCGCGC  
GGCGCCTACCTAGTGGCTTTCTCGCTTCGCGTGGAGGCACCCACGACCCTCGGTGACAAC  
ACAGCAGCGAACAACGTGCGCTTCCGCTGTTCAAGCGGCGAGGAACTGCAGGGGGCCTGGG  
CTGAGCTGGGGAGACTTTGGAGACTGGAGTGACCATTGCCCAAGGGCGCGTGCGGCCTG  
CAGACCAAGATCCAGGGACCTAGAGGCCTCGGCGATGACACTGCGCTGAACGACGCGCGC  
TTATTCTGCTGCCGCAGTTGAACGGCGCGCGCCGCCGCTCTCTCCGGGCCAGGAGGC  
TAGTCCACCTCTTGCTATTAAAGCTTCTCTGAGTTG

383/392

**FIGURE 368**

MERGAGAKLLPLLLLLLRATGFTCAQTDGRNGYTAVIEVTSGGPWGDWAWPEMCPDGFFAS  
GFSLKVEPPQGIPGDDTALNGIRLHCARGNVLGNTHVVESQSGSWGGEWSEPLWCRGGAYL  
VAFSLRVEAPTTLGDNNTAANNVRFRCSDGEELQGPGLSWGDFGDWSDHCPKGACGLQTKI  
QGPRGLGDDTALNDARLFCCRS

**Important features of the protein:**

**Signal peptide:**

1-24

**Transmembrane domain:**

None

**N-myristoylation site:**

41-47

89-95

156-162

**Growth factor and cytokines receptors family signature 2:**

103-110

384/392

**FIGURE 369**

GCCAACACTGGCCAAACCTCGGAGACCGTCCTGCGCTCTCTGGAGACGCGCTGTCCGCGC  
CCAGGGTGGTGCCATGTGGGGCGCTCGCCGCTCGTCCGTCTCCTCATCCTGGAACGCCGC  
TTCGCTCCTGCAGCTGCTGCTGGCTGCGCTGCTGGCGGCGGGGGCGAGGGCCAGCGGCGA  
GTACTGCCACGGCTGGCTGGACGCGCAGGGCGTCTGGCGCATCGGCTTCCAGTGTCCCGA  
GCGCTTCGACGGCGGCGACGCCACCATCTGCTGCGGCAGCTGCGCGTTGCGCTACTGCTG  
CTCCAGCGCCGAGGCGCGCCTGGACCAGGGCGGCTGCGACAATGACCGCCAGCAGGGCGC  
TGGCGAGCCTGGCCGGGCGGACAAAGACGGCCCCGACGGCTCGGCAGTGCCCATCTACGT  
GCCGTTCTCATTTGTTGGCTCCGTGTTTGTGCGCTTTATCATCTTGGGGTCCCTGGTGGC  
AGCCTGTTGCTGCAGATGTCTCCGGCCTAAGCAGGATCCCCAGCAGAGCCGAGCCCCAGG  
GGGTAAACCGCTTGATGGAGACCATCCCCATGATCCCCAGTGCCAGCACCTCCCGGGGGTC  
GTCCTCACGCCAGTCCAGCACAGCTGCCAGTTCAGCTCCAGCGCCAACCTCAGGGGCCCG  
GGCGCCCCCAACAAGGTCACAGACCAACTGTTGCTTGCCGGAAGGGACCATGAACAACGT  
GTATGTCAACATGCCCACGAATTTCTCTGTGCTGAACTGTCAGCAGGCCACCCAGATTGT  
GCCACATCAAGGGCAGTATCTGCATCCCCCATACTGGGGTACACGGTGCAGCACGACTC  
TGTGCCCATGACAGCTGTGCCACCTTTCATGGACGGCCTGCAGCCTGGCTACAGGCAGAT  
TCAGTCCCCCTTCCCTCACACCAACAGTGAACAGAAGATGTACCCAGCGGTGACTGTATA  
ACCGAGAGTCACTGGTGGGTTCTTTACTGAAGGGAGACGAAGGCAGGGGTGGATTTTCG  
AGGTGGAAGT

385/392

**FIGURE 370**

MWGARRSSVSSSWNAASLLQLLLAALLAAGARASGEYCHGWLDAQGVWRIGFQCPERFDG  
GDATICCGSCALRYCCSSAEARLDQGGCDNDRQQGAGEPGRADKDGPDGSAPVIYVPFLI  
VGSVFVAFIILGSLVAACCCRCLRPKQDPQQSRAPGGNRLMETIPMIPSASTSRGSSSRQ  
SSTAASSSSSANS GARAPPTRSQTNCCLP EGT MN NVY VNMPTN FSVLNCQQATQIVPHQG  
QYLHPPYVGYTVQHDSVPMTAVPPFMDGLQPGYRQIQSPFPHTNSEQKMYPAVTV

**Important features of the protein:****Signal peptide:**

1-33

**Transmembrane domain:**

54-78

**N-glycosylation site:**

223-226

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

5-8

**N-myristoylation site:**

3-8, 30-35, 60-65, 86-91, 132-137, 211-216, 268-273

**Prokaryotic membrane lipoprotein lipid attachment site:**

128-138

386/392

## FIGURE 371

CACCAGACAGCACTCCAGCACTCTGTTTGGGGGGCATTGAAACAGCAAAATCACTCATA  
AAAGGCAAAAATTGCAAAAAAATAGTAATAACCAGCATGGCACTAAATAGACCATGA  
AAAGACATGTGTGTGCAGTATGAAAATTGAGACAGGAAGGCAGAGTGTCTGCTGTGAA  
CCTCAGCTGGGAATGTGCATCAGGCAACTCAAGTTTTTACCACGGCATGTGTCTGTGAA  
TGTCCGCAAAACATTCTCTCTCCCCAGCCTTCATGTGTAACTGGGGATGATGTGGACC  
TGGGCACTGTGGATGCTCCCTTCACTCTGCAAATTCAGCCTGGCAGCTCTGCCAGCTAAG  
CCTGAGAACATTTCTGTGTCTACTACTATAGGAAAAATTTAACCTGCACCTGGAGTCCA  
GGAAAGGAAACCAGTTATACCCAGTACACAGTTAAGAGAACTTACGCTTTTGGAGAAAA  
CATGATAATTGTACAACCAATAGTTCTACAAGTGAAAATCGTGCTTCGTGCTCTTTTTTC  
CTTCCAAGAATAACGATCCCAGATAATTATACCATTGAGGTGGAAGCTGAAAATGGAGAT  
GGTGTAAATTAATCTCATATGACATACTGGAGATTAGAGAACATAGCGAAAACCTGAACCA  
CCTAAGATTTTCCGTGTGAAACCAGTTTTTGGGCATCAAACGAATGATTCAAATTGAATGG  
ATAAAGCCTGAGTTGGCGCCTGTTTCATCTGATTTAAAATACACACTTCGATTCAGGACA  
GTCAACAGTACCAGCTGGATGGAAGTCAACTTCGCTAAGAACCGTAAGGATAAAAACCAA  
ACGTACAACCTCACGGGGCTGCAGCCTTTTACAGAAATATGTCATAGCTCTGCGATGTGCG  
GTCAAGGAGTCAAAGTTCTGGAGTGACTGGAGCCAAGAAAAAATGGGAATGACTGAGGAA  
GAAGCTCCATGTGGCCTGGAAGTGTGGAGAGTCCTGAAACCAGCTGAGGCGGATGGAAGA  
AGGCCAGTGCGGTTGTTATGGAAGAAGGCAAGAGGAGCCCCAGTCCTAGAGAAAACACTT  
GGCTACAACATATGGTACTATCCAGAAAGCAACACTAACCTCACAGAAACAATGAACACT  
ACTAACCAGCAGCTTGAAGTGCATCTGGGAGGCGAGAGCTTTTGGGTGTCTATGATTTCT  
TATAATTCTCTTGGGAAGTCTCCAGTGGCCACCCTGAGGATTCCAGCTATTCAAGAAAAA  
TCATTTTCAGTGCATTGAGGTGCATGCAGGCCTGCGTTGCTGAGGACCAGCTAGTGGTGAAG  
TGGCAAAGCTCTGCTCTAGACGTGAACACTTGGATGATTGAATGGTTTCCGGATGTGGAC  
TCAGAGCCCCACCACCTTTTCTGGGAATCTGTGTCTCAGGCCACGAAGTGGACGATCCAG  
CAAGATAAATTAAACCTTTCTGGTGCTATAACATCTCTGTGTATCCAATGTTGCATGAC  
AAAGTTGGCGAGCCATATTCATCCAGGCTTATGCCAAAGAAGGCGTTCCATCAGAAGGT  
CCTGAGACCAAGGTGGAGAACATTGGCGTGAAGACGGTACGATCACATGGAAAGAGATT  
CCCAAGAGTGAGAGAAAGGGTATCATCTGCAACTACACCATCTTTTACCAAGCTGAAGGT  
GGAAAAGGATTCTGTAAGCACGCCCATAGCGAAGTGGAAGAAAAACCCCAAGCCCCAGATA  
GATGCTATGGATAGACCTGTTGTAGGCATGGCTCCCCCATCTCATTTGTGACTTGCAACCT  
GGCATGAATCACTTAGCTTCTTTAAATCTCTCTGAAAATGGGGCCAAGAGCACCCACCTT  
TTGGGGTTTTTGGGGGTAAATGAGAGTGAAGTGACAGTACCTGAGAGGAGAGTCTTGAGG  
AAATGGAAGGAGTTGTTATAATTTGTCTGTTAGGCCCTGAATTGACCTCCCGGGAGCT  
CCCCGACCATCATTCCCAGGAATGGCGTGCCTGGCTTAAAGAGTGAGGAGGAACAGACCC  
TGTCAACCATGACTTCTACTGCCCCTGCCAAATCATGCTTTTGTTTTTTCACTCCACCTTAT  
CTCCTGACATCTTAAATACTGGGCAAGGCTTGATTCTTGCTTAGGCTAAATAATTTTTT  
CTTATGGTAAATAACAGTAAATATTTTTCCAGTTTAAACATTTGAAAGTGTACAATTT  
AGTGGCATTAGAAGCATTCACAATATTGTGCAACCATCACCCTATTTCCAGAACTCTTC  
TATTTCTGCCCAAATAGAAGCCCTATACCCATTATTAGTCACTCCCCATTCCTCTCCTC  
CCACAGCCCCCTGGCAACTACCAAACTGCTTTGTGTCTCTATGGATTGCCTATTTTGGATA  
TTTCATATACATAGAATCATAAANTAAAAA

387/392

**FIGURE 372**

MCIRQLKFFTTACVCECPQNILSPQPSCVNLGMMWTWALWMLPSLCKFSLAALPAKPENI  
SCVYYYRKNLCTWSPGKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRI  
TIPDNYTIEVEAENG DGVKSHMTYWRL ENIAKTEPPKIFRVKPV LGIKRMIQIEWIKPE  
LAPVSSDLKYTLRFRTVNSTSWMEVNF AKNRKDKNQTYNLTGLQPFTEYVIALRCAVKES  
KFWSDWSQEKMGMT EEEAPCGLELWRVLKPAEADGRRPVRL LWKKARGAPVLEKTLGYNI  
WYYPESNTNLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQC  
IEVMQACVAEDQLVVKWQSSALDVNTWMI EWFPD V DSEPTTLSWESVSQATNWTIQQDKL  
KPFWCYNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKT V TITWKEIPKSE  
RKGII CNYTIFYQAEGGKGFC KHAHSEVEKNPKPQIDAMDRPVVGMAPP SHCDLQPGMNH  
LASLNLSENGAKSTHLLGFWGLNESEVTVPERRVLRKWKELL

**Important features of the protein:**

**Signal peptide:**

1-46

**Transmembrane domain:**

None

**N-glycosylation site:**

59-63, 69-73, 99-103, 103-107, 125-129, 198-202, 215-219, 219-223, 309-313, 315-319, 412-416, 427-431, 487-491, 545-549, 563-567

**N-myristoylation site:**

32-38, 137-143, 483-489, 550-556, 561-567

**Amidation site:**

274-278

**Growth factor and cytokines receptors family signature 1:**

62-75

**Fibronectin type III domain:**

54-144

154-247

388/392

## FIGURE 373

CCAGGTCCAACCTGCACCTCGGTTCTATCGATTGAATCCCCGGGGATCCTCTAGAGATCC  
CTCGACCTCGACCCACGCGTCCGCCAAGCTGGCCCTGCACGGCTGCAAGGGAGGCTCCTG  
TGGACAGGCCAGGCAGGTGGGCCTCAGGAGGTGCCTCCAGGCGGCCAGTGGGCCTGAGGC  
CCCAGCAAGGGCTAGGGTCCATCTCCAGTCCCAGGACACAGCAGCGGCCACCATGGCCAC  
GCCTGGGCTCCAGCAGCATCAGCAGCCCCCAGGACCGGGGGAGGCACAGGTGGCCCCCAC  
CACCCGGAGGAGCAGCTCCTGCCCCCTGTCCGGGGGATGACTGATTCTCCTCCGCCAGGCC  
ACCCAGAGGAGAAGGCCACCCCGCCTGGAGGACACAGGCCATGAGGGGCTCTCAGGAGGTG  
CTGCTGATGTGGCTTCTGGTGTTGGCAGTGGGCGGCACAGAGCACGCCTACCGGCCCGGC  
CGTTAGGGTGTGTGCTGTCCCGGGCTCACGGGGACCCTGTCTCCGAGTCGTTTCGTGCAGC  
GTGTGTACCAGCCCTTCCTCACCACCTGCGACGGGCACCGGGCCTGCAGCACCTACCGAA  
CCATTTATAGGACCGCCTACCGCCGCAGCCCTGGGCTGGCCCTGCCAGGCCTCGCTACG  
CGTGCTGCCCCGGCTGGAAGAGGACCAGCGGGCTTCCTGGGGCCTGTGGAGCAGCAATAT  
GCCAGCCGCCATGCCGGAACGGAGGGAGCTGTGTCCAGCCTGGCCGCTGCCGCTGCCCTG  
CAGGATGGCGGGGTGACACTTGCCAGTCAGATGTGGATGAATGCAGTGCTAGGAGGGGCG  
GCTGTCCCCAGCGCTGCATCAACACCGCCGCGAGTTACTGGTGCCAGTGTGGGAGGGGC  
ACAGCCTGTCTGCAGACGGTACACTCTGTGTGCCAAGGGAGGGCCCCCAGGGTGGCCC  
CCAACCCGACAGGAGTGGACAGTGCAATGAAGGAAGAAGTGCAGAGGCTGCAGTCCAGGG  
TGGACCTGCTGGAGGAGAAGCTGCAGCTGGTGCTGGCCCCACTGCACAGCCTGGCCTCGC  
AGGCACTGGAGCATGGGCTCCCGGACCCCGGCAGCCTCCTGGTGCACTCCTTCCAGCAGC  
TCGGCCGCATCGACTCCCTGAGCGAGCAGATTTCTTCTTCTGGAGGAGCAGCTGGGGTCCT  
GCTCCTGCAAGAAAGACTCGTGACTGCCAGCGCCCCAGGCTGGACTGAGCCCTCACGC  
CGCCCTGCAGCCCCCATGCCCTGCCCAACATGCTGGGGGTCCAGAAGCCACCTCGGGGT  
GACTGAGCGGAAGGCCAGGCAGGGCCTTCTCCTTTTCTCCTCCCCTTCCCTCGGGAGG  
GTCCCCAGACCCTGGCATGGGATGGGCTGGGATTTTTTTTGTGAATCCACCCCTGGCTAC  
CCCCACCCTGGTTACCCCAACGGCATCCCAAGGCCAGGTGGGCCCTCAGCTGAGGGAAGG  
TACGAGTTCCCTGCTGGAGCCTGGGACCCATGGCACAGGCCAGGCAGCCCGAGGCTGG  
GTGGGGCCTCAGTGGGGCTGCTGCCTGACCCCCAGCACATAAAATGAAACGTGAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGCGCCGCGACTCTAGAGTC  
GACCTGCAGAAGCTTGGCCGCCATGGCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAAT

389/392

**FIGURE 374**

MTDSPPPGHPEEKATPPGGTGHEGLSGGAADVASGVGSGRHRARLPARPLGCVLSRAHGD  
PVSESFVQRVYQPFLTTCDGHRACSTYRTIYRTAYRRSPGLAPARPRYACCPGWKRTSGL  
PGACGAATICQPPCRNGGSCVQPGRCRCPAGWRGDTQCSDVDECSARRGGCPQRCINTAGS  
YWCQCWEGHSLSADGTLCPKGGPPRVAPNPTGVDSAMKEEVQRLQSRVDLLEEKQLVL  
APLHSLASQALEHGLPDPGSLLVHSFQQLGRIDSLSEQISFLEEQLGSCSCKKDS



390/392

# FIGURE 375

Whollemount In Situ with PRO1449 Orthologue






FIGURE 376

PRO1449 is expressed in vasculature of many inflamed and diseased tissues

Human tumor tissue (DF)




Human tumor tissue (BF)



392/392

## FIGURE 377

Mouse orthologue of PRO1449 induces ectopic vessels in the eyes of chicken embryos



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
**WO 02/000690 A3**

(51) International Patent Classification?:	C07K 14/47, C12N 15/12, A61K 38/17, C07K 16/18	09/808,689	14 March 2001 (14.03.2001)	US
		09/816,744	22 March 2001 (22.03.2001)	US
		09/828,366	5 April 2001 (05.04.2001)	US
(21) International Application Number:	PCT/US01/19692	09/854,208	10 May 2001 (10.05.2001)	US
		09/854,280	10 May 2001 (10.05.2001)	US
(22) International Filing Date:	20 June 2001 (20.06.2001)	09/866,028	25 May 2001 (25.05.2001)	US
		09/866,034	25 May 2001 (25.05.2001)	US
(25) Filing Language:	English	PCT/US01/17092	25 May 2001 (25.05.2001)	US
		09/870,574	30 May 2001 (30.05.2001)	US
(26) Publication Language:	English	PCT/US01/17443	30 May 2001 (30.05.2001)	US
		PCT/US01/17800	1 June 2001 (01.06.2001)	US
(30) Priority Data:				
60/213,637	23 June 2000 (23.06.2000)	US		
60/219,556	20 July 2000 (20.07.2000)	US		
60/220,624	25 July 2000 (25.07.2000)	US		
60/220,664	25 July 2000 (25.07.2000)	US		
PCT/US00/20710	28 July 2000 (28.07.2000)	US		
60/222,695	2 August 2000 (02.08.2000)	US		
09/643,657	17 August 2000 (17.08.2000)	US		
PCT/US00/23522	23 August 2000 (23.08.2000)	US		
PCT/US00/23328	24 August 2000 (24.08.2000)	US		
60/230,978	7 September 2000 (07.09.2000)	US		
60/000,000	15 September 2000 (15.09.2000)	US		
09/664,610	18 September 2000 (18.09.2000)	US		
09/665,350	18 September 2000 (18.09.2000)	US		
60/242,922	24 October 2000 (24.10.2000)	US		
09/709,238	8 November 2000 (08.11.2000)	US		
PCT/US00/30952				
	8 November 2000 (08.11.2000)	US		
PCT/US00/30873				
	10 November 2000 (10.11.2000)	US		
PCT/US00/32678				
	1 December 2000 (01.12.2000)	US		
09/747,259	20 December 2000 (20.12.2000)	US		
PCT/US00/34956				
	20 December 2000 (20.12.2000)	US		
09/767,609	22 January 2001 (22.01.2001)	US		
09/796,498	28 February 2001 (28.02.2001)	US		
PCT/US01/06520				
	28 February 2001 (28.02.2001)	US		
PCT/US01/06666	1 March 2001 (01.03.2001)	US		
09/802,706	9 March 2001 (09.03.2001)	US		
(71) Applicant (for all designated States except US):	GENEN- TECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).			
(72) Inventors; and				
(75) Inventors/Applicants (for US only):	BAKER, Kevin, P. [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). FERRARA, Napoleone [US/US]; #704, 2090 Pacific Avenue, San Francisco, CA 94109 (US). GERBER, Hanspeter [CH/US]; #5, 1121 Tennessee Street, San Francisco, CA 94107 (US). GERRITSEN, Mary, E. [CA/US]; 541 Parrott Drive, San Mateo, CA 94402 (US). GODDARD, Audrey [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). GODOWSKI, Paul, J. [US/US]; 25 Orange Court, Hillsborough, CA 94010 (US). GURNEY, Austin, L. [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). HILLAN, Kenneth, J. [GB/US]; 64 Seward Street, San Francisco, CA 94114 (US). MARSTERS, Scot, A. [US/US]; 990 Cherry Street, San Carlos, CA 94070 (US). PAN, James [CA/US]; 2705 Coronet Boulevard, Belmont, CA 94002 (US). PAONI, Nicholas, F. [US/US]; 1756 Terrace Drive, Belmont, CA 94002 (US). STEPHAN, Jean-Philippe, F. [FR/US]; 320 C Lansdale Avenue, Millbrae, CA 94030 (US). WATAN- ABE, Colin, K. [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). WILLIAMS, P., Mickey [US/US]; 509 Alto Avenue, Half Moon Bay, CA 94019 (US). WOOD, William, I. [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US). YE, Weilan [CN/US]; 119 Barkentine Street, Foster City, CA 94404 (US).			

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISORDERS INVOLVING ANGIOGENESIS

(57) Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

WO 02/000690 A3



(74) Agents: AGARWAL, Atulya, R. et al.; c/o GENENTECH, INC., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

**Published:**

— with international search report

(88) Date of publication of the international search report:

13 March 2003

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/19692

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 A61K38/17 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,L	WO 99 46281 A (BAKER KEVIN P ;CHEN JIAN (US); GENENTECH INC (US); GURNEY AUSTIN () 16 September 1999 (1999-09-16) see PR0181	1-19
X,L	US 5 968 744 A (CORLEY-NEIL C ET AL) 19 October 1999 (1999-10-19) L: priority. the whole document	1-19
X	WO 99 50405 A (GENETICS INST) 7 October 1999 (1999-10-07) see pk65_4 and seq.ID's 11 and 12	1-19
X	WO 99 43802 A (KATO SEISHI ;KIMURA TOMOKO (JP); PROTEGENE INC (JP); SEKINE SHINGO) 2 September 1999 (1999-09-02) see clone HP02239.	1-19
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

21 August 2002

Date of mailing of the international search report

29. 11. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/19692

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 10363 A (WEI YING FEI ;HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A (US);) 4 March 1999 (1999-03-04) see secreted protein 24 ---	1-19
X	WO 99 33979 A (CHIRON CORP) 8 July 1999 (1999-07-08) the whole document ---	1-19
A	WO 95 29242 A (CHILDRENS MEDICAL CENTER) 2 November 1995 (1995-11-02) the whole document ---	
A	EP 0 335 243 A (HARVARD COLLEGE) 4 October 1989 (1989-10-04) the whole document ---	
A	FOLKMAN J: "CLINICAL APPLICATIONS OF RESEARCH ON ANGIOGENESIS" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 333, no. 26, 28 December 1995 (1995-12-28), pages 1757-1763, XP000654557 ISSN: 0028-4793 the whole document ---	
A	KLGSBRUN M: "REGULATORS OF ANGIOGENESIS: STIMULATORS, INHIBITORS, AND EXTRACELLULAR MATRIX" JOURNAL OF CELLULAR BIOCHEMISTRY, LISS, NEW YORK, NY, US, vol. 47, no. 3, 1 November 1991 (1991-11-01), pages 199-200, XP000616588 ISSN: 0730-2312 the whole document ---	
P,X, L	WO 00 53756 A (BOTSTEIN DAVID;BAKER KEVIN P ; GENENTECH INC (US); ASHKENAZI AVI J) 14 September 2000 (2000-09-14) see seq.ID.322; L: priority. ---	1-19
P,X, L	WO 00 53751 A (BAKER KEVIN P ;GENENTECH INC (US); NAPIER MARY A (US); ASHKENAZI A) 14 September 2000 (2000-09-14)  the whole document ---	1-21,23, 27-29, 31,32, 34,35
P,X	WO 01 00828 A (CORIXA CORP ;FANGER GARY R (US); RETTER MARC W (US); WANG TONGTONG) 4 January 2001 (2001-01-04)  see seq.ID.327 ---	1-21,23, 27-29, 31,32, 34,35

-/--

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/19692

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E, L	WO 02 08284 A (FERRARA NAPOLEONE ;STEPHAN JEAN PHILIPPE F (US); WILLIAMS P MICKEY) 31 January 2002 (2002-01-31) See seq.ID's 1 and 120. L: priority. -----	1-35,37, 41



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/19692

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 20-34, 37 and 41 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1-35, 37, 41 all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 20-28,31,34,35,37, and 41 relate to products defined by reference to a desirable characteristic or property, namely having (ant)agonistic activity towards the protein(s) of claim 1. The application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible. Consequently, the search of said claims, in as far as the (ant)agonists are concerned, has been carried out for those aspects which appear to be clear, supported and disclosed, namely those parts relating to antibodies directed against the protein(s) of claim 1.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: 1-35, 37, 41 all partially

Nucleic acid with at least 80% identity to seq.ID.1 and protein encoded thereby, vector, host cell, method for producing the protein, chimeric protein, antibody, and pharmaceutical compositions.

Inventions 2-187: 1-42, all partially,  
and as far as applicable

Subject matter as defined for invention 1. above, but limited to the respective nucleic acid sequences 3-373 (odd numbers) and the polypeptides encoded thereby (seq.ID's 4-374, even numbers).

For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No

PCT/US 01/19692

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9946281	A	16-09-1999	US 6391311 B1	21-05-2002
			AU 3072199 A	27-09-1999
			CA 2321677 A1	16-09-1999
			US 2002127584 A1	12-09-2002
			US 2002094416 A1	18-07-2002
			WO 9946281 A2	16-09-1999
			US 2002156006 A1	24-10-2002
			US 2002169284 A1	14-11-2002
			ZA 9901937 A	17-04-2000
			EP 1241187 A2	18-09-2002
			AU 3075099 A	11-10-1999
			CA 2322792 A1	23-09-1999
			EP 1064382 A2	03-01-2001
			WO 9947677 A2	23-09-1999
			US 6455283 B1	24-09-2002
			EP 1241183 A2	18-09-2002
			US 2002072496 A1	13-06-2002
			US 2002142961 A1	03-10-2002
			US 2002072067 A1	13-06-2002
			US 2002072092 A1	13-06-2002
			US 2002072497 A1	13-06-2002
			US 2002103125 A1	01-08-2002
			US 2002123463 A1	05-09-2002
			US 2002132252 A1	19-09-2002
			US 2002127576 A1	12-09-2002
			US 2002132253 A1	19-09-2002
			US 2002160384 A1	31-10-2002
			AU 735081 B2	28-06-2001
			AU 1532499 A	15-06-1999
			CA 2309358 A1	03-06-1999
			EP 1241180 A2	18-09-2002
			EP 1032667 A2	06-09-2000
			WO 9927098 A2	03-06-1999
			US 6410708 B1	25-06-2002
			EP 1241185 A2	18-09-2002
			EP 1249491 A2	16-10-2002
			EP 1251139 A2	23-10-2002
			US 2002161199 A1	31-10-2002
			EP 1241179 A2	18-09-2002
			EP 1241186 A2	18-09-2002
			AU 741133 B2	22-11-2001
			AU 3757099 A	08-11-1999
			CA 2324297 A1	28-10-1999
			EP 1071773 A1	31-01-2001
			JP 2002512032 T	23-04-2002
			WO 9954467 A1	28-10-1999
			US 2002147322 A1	10-10-2002
			EP 1241251 A2	18-09-2002
			US 2002119118 A1	29-08-2002
US 5968744	A	19-10-1999	US 2002103342 A1	01-08-2002
			US 6348576 B1	19-02-2002
WO 9950405	A	07-10-1999	AU 3457299 A	18-10-1999
			CA 2324492 A1	07-10-1999
			EP 1068307 A1	17-01-2001
			JP 2002509722 T	02-04-2002
			WO 9950405 A1	07-10-1999

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/19692

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9943802	A	02-09-1999	AU 2549399 A	15-09-1999
			CA 2322711 A1	02-09-1999
			EP 1056847 A2	06-12-2000
			WO 9943802 A2	02-09-1999
			JP 2002506615 T	05-03-2002
-----				
WO 9910363	A	04-03-1999	AU 8921598 A	16-03-1999
			CA 2302387 A1	04-03-1999
			EP 1017707 A1	12-07-2000
			JP 2002532054 T	02-10-2002
			WO 9910363 A1	04-03-1999
			US 6410709 B1	25-06-2002
			US 2001016647 A1	23-08-2001
-----				
WO 9933979	A	08-07-1999	AU 1929599 A	19-07-1999
			EP 1042470 A2	11-10-2000
			JP 2002511231 T	16-04-2002
			WO 9933979 A2	08-07-1999
			US 2002034800 A1	21-03-2002
-----				
WO 9529242	A	02-11-1995	US 5639725 A	17-06-1997
			US 5792845 A	11-08-1998
			AU 692865 B2	18-06-1998
			AU 2461795 A	16-11-1995
			BR 9507479 A	16-09-1997
			CA 2188813 A1	02-11-1995
			CN 1149319 A	07-05-1997
			CZ 9603122 A3	14-05-1997
			EP 0758390 A1	19-02-1997
			HU 76095 A2	30-06-1997
			JP 9512173 T	09-12-1997
			NZ 285501 A	26-02-1998
			WO 9529242 A1	02-11-1995
			US 5885795 A	23-03-1999
			US 5733876 A	31-03-1998
			US 5776704 A	07-07-1998
			ZA 9503419 A	11-01-1996
-----				
EP 0335243	A	04-10-1989	US 4900673 A	13-02-1990
			AT 96844 T	15-11-1993
			AU 621358 B2	12-03-1992
			AU 3433189 A	16-10-1989
			CA 1331356 A1	09-08-1994
			DE 68910354 D1	09-12-1993
			DE 68910354 T2	03-03-1994
			DK 233390 A	26-11-1990
			EP 0335243 A2	04-10-1989
			IE 890954 L	28-09-1989
			JP 3503641 T	15-08-1991
			PT 90129 A	10-11-1989
			WO 8909277 A1	05-10-1989
			ZA 8902270 A	24-12-1991
-----				
WO 0053756	A	14-09-2000	AU 1748200 A	19-06-2000
			AU 1749900 A	12-07-2000
			AU 2192800 A	12-07-2000
			AU 2224800 A	28-09-2000
			AU 2399300 A	28-09-2000

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/19692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 0053756	A	AU 2495200 A	28-09-2000	
		AU 2596700 A	28-09-2000	
		AU 2600800 A	28-09-2000	
		AU 2879400 A	31-07-2001	
		AU 2883600 A	28-09-2000	
		AU 3072199 A	27-09-1999	
		AU 3107700 A	28-09-2000	
		AU 3381600 A	28-09-2000	
		AU 3514400 A	28-09-2000	
		CA 2321677 A1	16-09-1999	
		EP 1173563 A1	23-01-2002	
		EP 1159419 A1	05-12-2001	
		EP 1220905 A2	10-07-2002	
		EP 1135485 A2	26-09-2001	
		EP 1141284 A2	10-10-2001	
		EP 1159422 A1	05-12-2001	
		EP 1141289 A2	10-10-2001	
		US 2002119130 A1	29-08-2002	
		WO 0053753 A2	14-09-2000	
		WO 0053754 A1	14-09-2000	
		WO 0053755 A2	14-09-2000	
		WO 0153486 A1	26-07-2001	
		WO 0053756 A2	14-09-2000	
		WO 0053757 A2	14-09-2000	
		WO 0053758 A2	14-09-2000	
		US 2002127584 A1	12-09-2002	
		US 2002094416 A1	18-07-2002	
		WO 0032221 A2	08-06-2000	
		WO 0053750 A1	14-09-2000	
		WO 0037638 A2	29-06-2000	
		WO 0037640 A2	29-06-2000	
		WO 0053751 A1	14-09-2000	
		WO 0053752 A2	14-09-2000	
		US 2002119118 A1	29-08-2002	
		US 2002161199 A1	31-10-2002	
		US 2002156006 A1	24-10-2002	
		US 2002169284 A1	14-11-2002	
		US 2002072496 A1	13-06-2002	
		US 2002142961 A1	03-10-2002	
		US 2002072067 A1	13-06-2002	
		US 2002072092 A1	13-06-2002	
		US 2002072497 A1	13-06-2002	
		US 2002103125 A1	01-08-2002	
WO 0053751	A	14-09-2000	AU 1748200 A	19-06-2000
			AU 1749900 A	12-07-2000
			AU 2192800 A	12-07-2000
			AU 2224800 A	28-09-2000
			AU 2399300 A	28-09-2000
			AU 2495200 A	28-09-2000
			AU 2596700 A	28-09-2000
			AU 2600800 A	28-09-2000
			AU 2879400 A	31-07-2001
			AU 2883600 A	28-09-2000
			AU 3072199 A	27-09-1999
			AU 3107700 A	28-09-2000
			AU 3381600 A	28-09-2000
			AU 3514400 A	28-09-2000

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No

PCT/US 01/19692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0053751	A	CA 2321677 A1	16-09-1999
		EP 1173563 A1	23-01-2002
		EP 1159419 A1	05-12-2001
		EP 1220905 A2	10-07-2002
		EP 1135485 A2	26-09-2001
		EP 1141284 A2	10-10-2001
		EP 1159422 A1	05-12-2001
		EP 1141289 A2	10-10-2001
		US 2002119130 A1	29-08-2002
		WO 0053753 A2	14-09-2000
		WO 0053754 A1	14-09-2000
		WO 0053755 A2	14-09-2000
		WO 0153486 A1	26-07-2001
		WO 0053756 A2	14-09-2000
		WO 0053757 A2	14-09-2000
		WO 0053758 A2	14-09-2000
		US 2002127584 A1	12-09-2002
		US 2002094416 A1	18-07-2002
		WO 0032221 A2	08-06-2000
		WO 0053750 A1	14-09-2000
		WO 0037638 A2	29-06-2000
		WO 0037640 A2	29-06-2000
		WO 0053751 A1	14-09-2000
		WO 0053752 A2	14-09-2000
		US 2002119118 A1-	29-08-2002
		US 2002161199 A1	31-10-2002
		US 2002156006 A1	24-10-2002
		US 2002169284 A1	14-11-2002
		US 2002072496 A1	13-06-2002
		US 2002142961 A1	03-10-2002
		US 2002072067 A1	13-06-2002
		US 2002072092 A1	13-06-2002
		US 2002072497 A1	13-06-2002
		US 2002103125 A1	01-08-2002
WO 0100828	A	04-01-2001	
		AU 5902700 A	31-01-2001
		BR 0012069 A	27-08-2002
		CN 1367829 T	04-09-2002
		EP 1196565 A2	17-04-2002
		HU 3201757 A2	28-09-2002
		NO 20016427 A	25-02-2002
		WO 0100828 A2	04-01-2001
WO 0208284	A	31-01-2002	
		US 2002042367 A1	11-04-2002
		US 2002010137 A1	24-01-2002
		US 2002106743 A1	08-08-2002
		US 2002052027 A1	02-05-2002
		US 2002058309 A1	16-05-2002
		US 2002102723 A1	01-08-2002
		AU 6531101 A	17-12-2001
		AU 7197301 A	05-02-2002
		AU 7315001 A	30-01-2002
		AU 7885201 A	08-01-2002
		WO 0193983 A1	13-12-2001
WO 0208288	A2	0200690 A2	03-01-2002
		0208288 A2	31-01-2002

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No

PCT/US 01/19692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0208284	A	WO 0208284 A2	31-01-2002
		AU 1916701 A	16-07-2001
		AU 2055401 A	12-06-2001
		AU 6391000 A	19-02-2001
		AU 6802801 A	24-09-2001
		AU 6901800 A	12-06-2001
		EP 1244784 A2	02-10-2002
		EP 1250426 A2	23-10-2002
		WO 0140464 A1	07-06-2001
		WO 0149715 A2	12-07-2001
		WO 0140466 A2	07-06-2001
		WO 0168848 A2	20-09-2001
		US 2002127584 A1	12-09-2002
		US 2002094416 A1	18-07-2002
		US 2002160374 A1	31-10-2002
		US 2002146709 A1	10-10-2002
		US 2002132240 A1	19-09-2002
		US 2002142958 A1	03-10-2002
		US 2002150976 A1	17-10-2002
		US 2002132981 A1	19-09-2002
		US 2002165143 A1	07-11-2002
		US 2002156004 A1	24-10-2002
		US 2002142419 A1	03-10-2002
		US 2002102647 A1	01-08-2002
		US 2002110859 A1	15-08-2002
		US 2002142959 A1	03-10-2002
		US 2002115145 A1	22-08-2002
		US 2002132768 A1	19-09-2002
		US 2002127643 A1	12-09-2002
		US 2002156006 A1	24-10-2002
		US 2002169284 A1	14-11-2002
		US 2002072496 A1	13-06-2002
		US 2002142961 A1	03-10-2002
		US 2002072067 A1	13-06-2002
		US 2002072092 A1	13-06-2002
		US 2002072497 A1	13-06-2002
		US 2002103125 A1	01-08-2002